<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-08-12T19:16:04.9118811+00:00 -->
<!-- Version            : 5.0.1.648 -->
<!-- Package ID         : ec50b0f05eb644fba5ac3b65e90cd380 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ibrx="http://www.immunitybio.com/20210630" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
ibrx-10q_20210630.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001326110_20210101_20210630">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001326110_20210101_20210630">2021</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001326110_20210101_20210630">Q2</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001326110_20210101_20210630">0001326110</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001326110_20210101_20210630">--12-31</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000891" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="C_0001326110_20200101_20201231" decimals="-3">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_ibrxTerm" id="F_001141" name="ibrx:OptionsToExtendNumberOfTerms" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210201_20210228" decimals="INF">1</ix:nonFraction>
			<ix:nonFraction unitRef="U_ibrxTerm" id="F_001150" name="ibrx:OptionsToExtendNumberOfTerms" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentForExpansionOfPremisesLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210501_20210531" decimals="INF">1</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlishares" id="F_001224" name="ibrx:IssuanceOfCommonStockUnderAtMarketOfferingShares" contextRef="C_0001326110_20210401_20210630" decimals="INF">6420441</ix:nonFraction>
			<ix:nonNumeric id="F_001255" name="ibrx:OptionExpirationDateExtendedPeriod" contextRef="C_0001326110_20210101_20210630">P30D</ix:nonNumeric>
			<ix:nonNumeric id="F_001258" name="ibrx:ModifiedOptionsExercisablePeriod" contextRef="C_0001326110_20210101_20210630">P90D</ix:nonNumeric>
			<ix:nonNumeric id="F_001316" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210630">P70M</ix:nonNumeric>
			<ix:nonNumeric id="F_001107" name="ibrx:PeriodOfExtendedLeaseTerm" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20160901_20160930">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001121" name="ibrx:PeriodOfExtendedLeaseTerm" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20170201_20170228">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001127" name="ibrx:PeriodOfExtendedLeaseTerm" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSeptemberTwentyNineteenLeaseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20190901_20190930">P5Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_ibrxTerm" id="F_001141_2" name="ibrx:OptionsToExtendNumberOfTerms" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210201_20210228" decimals="INF">1</ix:nonFraction>
			<ix:nonNumeric id="F_001142" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210228">P3Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_ibrxTerm" id="F_001150_2" name="ibrx:OptionsToExtendNumberOfTerms" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentForExpansionOfPremisesLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210501_20210531" decimals="INF">1</ix:nonFraction>
			<ix:nonNumeric id="F_001154" name="ibrx:PeriodOfExtendedLeaseTerm" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentForExpansionOfPremisesLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210501_20210531">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001155" name="ibrx:RentAbatementPeriod" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210201_20210228">P7M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlishares" id="F_001224_2" name="ibrx:IssuanceOfCommonStockUnderAtMarketOfferingShares" contextRef="C_0001326110_20210401_20210630" decimals="INF">6420441</ix:nonFraction>
			<ix:nonNumeric id="F_001315" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210630">P6M</ix:nonNumeric>
			<ix:nonNumeric id="F_001000" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_20210630">P10Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000999" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_20210630">P2Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001002" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_20210630">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001001" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_20210630">P1Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001128" name="ibrx:PeriodOfExtendedLeaseTerm" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxJulyTwentyNineteenLeaseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20190701_20190731">P5Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001326110_20210630" decimals="-3">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001326110_20201231" decimals="-3">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000075_2" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001326110_20210630" decimals="-3">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000076_2" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001326110_20201231" decimals="-3">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200401_20200630" decimals="-3">0</ix:nonFraction>
			<ix:nonNumeric id="F_000864" name="ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210101_20210630">P8M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_000865" name="ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210101_20210630">P5Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_001274" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P4Y8M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_001275" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630">P5Y8M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_001276" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630">P4Y3M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_001291" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630">P5Y10M24D</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="ibrx-20210630.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001326110_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_20210810">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-08-10</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapInvestmentTypeAxis_ibrxMarketableDebtAndEquitySecuritiesMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ibrx:MarketableDebtAndEquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_20210309_20210309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-09</xbrli:startDate>
					<xbrli:endDate>2021-03-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_20210309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtOwnershipAxis_ibrxNantKwestMember_20210309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NantKwestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtTitleOfIndividualAxis_ibrxExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember_20210309_20210309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibrx:ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-09</xbrli:startDate>
					<xbrli:endDate>2021-03-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20121231_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2012-12-31</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantKwestIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantKwestIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantKwestIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210430_20210430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-30</xbrli:startDate>
					<xbrli:endDate>2021-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidatedEntitiesAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_srtRangeAxis_srtMinimumMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidatedEntitiesAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_srtRangeAxis_srtMaximumMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxNantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember_20210309_20210309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-09</xbrli:startDate>
					<xbrli:endDate>2021-03-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapDebtSecuritiesMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapDebtSecuritiesMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapBusinessAcquisitionAxis_ibrxSunesisPharmaceuticalsIncMember_us-gaapEquityInterestIssuedOrIssuableByTypeAxis_us-gaapCommonStockMember_20210225_20210225">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:SunesisPharmaceuticalsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-25</xbrli:startDate>
					<xbrli:endDate>2021-02-25</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20180102_20180131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EtubicsCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-02</xbrli:startDate>
					<xbrli:endDate>2018-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EtubicsCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EtubicsCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxAmgenMember_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20180102_20180131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:AmgenMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-02</xbrli:startDate>
					<xbrli:endDate>2018-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxAmgenMember_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:AmgenMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxAmgenMember_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:AmgenMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210222_20210222">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-22</xbrli:startDate>
					<xbrli:endDate>2021-02-22</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapTypeOfArrangementAxis_ibrxInfectiousDiseaseResearchInstituteMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:InfectiousDiseaseResearchInstituteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapTypeOfArrangementAxis_ibrxInfectiousDiseaseResearchInstituteMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:InfectiousDiseaseResearchInstituteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtRangeAxis_srtMinimumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ibrxSponsoredResearchAgreementMember_us-gaapTypeOfArrangementAxis_ibrxInfectiousDiseaseResearchInstituteMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:InfectiousDiseaseResearchInstituteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:SponsoredResearchAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ibrxSponsoredResearchAgreementMember_us-gaapTypeOfArrangementAxis_ibrxInfectiousDiseaseResearchInstituteMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:InfectiousDiseaseResearchInstituteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:SponsoredResearchAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapTypeOfArrangementAxis_ibrxIosbioLtdExclusiveLicenseAgreementMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:IosbioLtdExclusiveLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapTypeOfArrangementAxis_ibrxIosbioLtdExclusiveLicenseAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:IosbioLtdExclusiveLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150410">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-04-10</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150410_20150410">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-04-10</xbrli:startDate>
					<xbrli:endDate>2015-04-10</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150615_20150615">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-06-15</xbrli:startDate>
					<xbrli:endDate>2015-06-15</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapContingentConsiderationByTypeAxis_ibrxContingentValueRightsPayableAtDecember312022Member_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsPayableAtDecember312022Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapContingentConsiderationByTypeAxis_ibrxContingentValueRightsPayableBeforeDecember312026Member_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsPayableBeforeDecember312026Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapContingentConsiderationByTypeAxis_ibrxContingentValueRightsPayableBeforeDecember312026Member_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsPayableBeforeDecember312026Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxDrSoonShiongAndPelatedPartyMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:DrSoonShiongAndPelatedPartyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceLLCMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceLLCMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtRangeAxis_srtMinimumMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtRangeAxis_srtMaximumMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantOmicsLLCMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantOmicsLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantOmicsLLCMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantOmicsLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVariousMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VariousMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVariousMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VariousMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_ibrxReimbursementsMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_ibrxReimbursementsMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20151130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20151101_20151130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-11-01</xbrli:startDate>
					<xbrli:endDate>2015-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentToExtendLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:AmendmentToExtendLeaseTermMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentToExtendLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200901_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:AmendmentToExtendLeaseTermMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-09-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190701_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20191001_20191031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2019-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20160301_20160331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-03-01</xbrli:startDate>
					<xbrli:endDate>2016-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioIncMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioIncMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioIncMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EmployeeBonusesPaymentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioIncMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EmployeeBonusesPaymentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVendorCostsPaymentsMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioIncMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VendorCostsPaymentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVendorCostsPaymentsMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioIncMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VendorCostsPaymentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantOmicsLLCMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantOmicsLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EmployeeBonusesPaymentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantOmicsLLCMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantOmicsLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EmployeeBonusesPaymentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20160930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20160901_20160930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-09-01</xbrli:startDate>
					<xbrli:endDate>2016-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20170228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20170201_20170228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-02-01</xbrli:startDate>
					<xbrli:endDate>2017-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByLiabilityClassAxis_ibrxDueToRelatedPartiesMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DueToRelatedPartiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByLiabilityClassAxis_ibrxDueToRelatedPartiesMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DueToRelatedPartiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ibrxTerm">
				<xbrli:measure>ibrx:Term</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSeptemberTwentyNineteenLeaseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SeptemberTwentyNineteenLeaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxJulyTwentyNineteenLeaseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:JulyTwentyNineteenLeaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSeptemberTwentyNineteenLeaseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20190901_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SeptemberTwentyNineteenLeaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-09-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxJulyTwentyNineteenLeaseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20190701_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:JulyTwentyNineteenLeaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialPremisesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210201_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialPremisesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-01</xbrli:startDate>
					<xbrli:endDate>2021-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialPremisesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialPremisesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialPremisesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentForExpansionOfPremisesLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:AmendmentForExpansionOfPremisesLeaseTermMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentForExpansionOfPremisesLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210501_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:AmendmentForExpansionOfPremisesLeaseTermMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-01</xbrli:startDate>
					<xbrli:endDate>2021-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapLeaseContractualTermAxis_ibrxAmendmentForExpansionOfPremisesLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:AmendmentForExpansionOfPremisesLeaseTermMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapLeaseContractualTermAxis_ibrxAmendmentForExpansionOfPremisesLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:AmendmentForExpansionOfPremisesLeaseTermMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_us-gaapLeaseContractualTermAxis_ibrxAmendmentForExpansionOfPremisesLeaseTermAndInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:AmendmentForExpansionOfPremisesLeaseTermAndInitialPremisesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalOneMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalTwoMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalOneMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalTwoMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalOneMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalTwoMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalTwoMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenShareRepurchasePlanMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenShareRepurchasePlanMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenShareRepurchasePlanMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandAndFifteenPlanMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20150701_20150731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-07-01</xbrli:startDate>
					<xbrli:endDate>2015-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtTitleOfIndividualAxis_ibrxNonEmployeeDirectorMember_us-gaapNatureOfExpenseAxis_ibrxModificationOfStockOptionsAssociatedWithResignationMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">ibrx:ModificationOfStockOptionsAssociatedWithResignationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibrx:NonEmployeeDirectorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapNatureOfExpenseAxis_ibrxModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember_20210318_20210318">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">ibrx:ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-18</xbrli:startDate>
					<xbrli:endDate>2021-03-18</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ibrxDirector">
				<xbrli:measure>ibrx:Director</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210329_20210329">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-29</xbrli:startDate>
					<xbrli:endDate>2021-03-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-05</xbrli:startDate>
					<xbrli:endDate>2021-02-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210503_20210503">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-03</xbrli:startDate>
					<xbrli:endDate>2021-05-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtTitleOfIndividualAxis_srtBoardOfDirectorsChairmanMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210610_20210610">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-06-10</xbrli:startDate>
					<xbrli:endDate>2021-06-10</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtTitleOfIndividualAxis_srtBoardOfDirectorsChairmanMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-05</xbrli:startDate>
					<xbrli:endDate>2021-02-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ibrxAward">
				<xbrli:measure>ibrx:Award</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-05</xbrli:startDate>
					<xbrli:endDate>2021-02-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxFirstRSUAwardMember_20210205_20210205">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:FirstRSUAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-05</xbrli:startDate>
					<xbrli:endDate>2021-02-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxSecondRSUAwardMember_20210205_20210205">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:SecondRSUAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-05</xbrli:startDate>
					<xbrli:endDate>2021-02-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210205_20210205">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-05</xbrli:startDate>
					<xbrli:endDate>2021-02-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210304_20210304">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-04</xbrli:startDate>
					<xbrli:endDate>2021-03-04</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210304_20210304">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-04</xbrli:startDate>
					<xbrli:endDate>2021-03-04</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_ibrxWarrantsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ibrx:WarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_countryUS_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_countryIT_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_countryKR_20210101_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="line-height:4pt;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:3pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001326110_20210101_20210630">10-Q</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:3pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One)</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:DocumentQuarterlyReport" contextRef="C_0001326110_20210101_20210630" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001326110_20210101_20210630" format="ixt:datemonthdayyearen">June&#160;30,&#160;2021</ix:nonNumeric></p>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:DocumentTransitionReport" contextRef="C_0001326110_20210101_20210630" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission file number: <ix:nonNumeric id="F_000018" name="dei:EntityFileNumber" contextRef="C_0001326110_20210101_20210630">001-37507</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:3pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0001326110_20210101_20210630">IMMUNITYBIO, INC.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter)</p>
<p style="text-align:center;margin-top:3pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001326110_20210101_20210630" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001326110_20210101_20210630">43-1979754</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:EntityAddressAddressLine1" contextRef="C_0001326110_20210101_20210630">3530 John Hopkins Court</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:EntityAddressCityOrTown" contextRef="C_0001326110_20210101_20210630">San Diego</ix:nonNumeric><span style="font-family:Times New Roman Bold;">, <ix:nonNumeric id="F_000023" name="dei:EntityAddressStateOrProvince" contextRef="C_0001326110_20210101_20210630" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></span></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000024" name="dei:EntityAddressPostalZipCode" contextRef="C_0001326110_20210101_20210630">92121</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <span style="font-size:9pt;">(<ix:nonNumeric id="F_000025" name="dei:CityAreaCode" contextRef="C_0001326110_20210101_20210630">858</ix:nonNumeric>)&#160;<ix:nonNumeric id="F_000026" name="dei:LocalPhoneNumber" contextRef="C_0001326110_20210101_20210630">633-0300</ix:nonNumeric></span></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:5.33%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title&#160;of each class </p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:Security12bTitle" contextRef="C_0001326110_20210101_20210630">Common Stock, par&#160;value&#160;$0.0001 per share</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001326110_20210101_20210630">IBRX</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:SecurityExchangeName" contextRef="C_0001326110_20210101_20210630" format="ixt-sec:exchnameen">The Nasdaq </ix:nonNumeric>Global Select Market</p></td>
</tr>
</table></div>
<p style="margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant&#160;(1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of&#160;1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and&#160;(2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;<span style="text-transform:uppercase;font-size:10pt;"><ix:nonNumeric id="F_000013" name="dei:EntityCurrentReportingStatus" contextRef="C_0001326110_20210101_20210630">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;<span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;<span style="text-transform:uppercase;font-size:10pt;"><ix:nonNumeric id="F_000014" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001326110_20210101_20210630">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;<span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top" style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:3.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:4.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:3.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:4.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityFilerCategory" contextRef="C_0001326110_20210101_20210630" format="ixt-sec:entityfilercategoryen">Non-accelerated&#160;filer</ix:nonNumeric></p></td>
<td valign="top" style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntitySmallBusiness" contextRef="C_0001326110_20210101_20210630" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:3.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:4.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:3.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:4.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging&#160;growth&#160;company</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001326110_20210101_20210630" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:3.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000015" name="dei:EntityShellCompany" contextRef="C_0001326110_20210101_20210630" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;<span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of the Registrant&#8217;s common stock outstanding as of August&#160;10,&#160;2021 was <ix:nonFraction unitRef="U_xbrlishares" id="F_000012" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001326110_20210810" decimals="INF" format="ixt:numdotdecimal">391,156,513</ix:nonFraction> (excluding 163,800&#160;shares held by a majority owned subsidiary of ours which are treated as treasury shares for accounting purposes).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="TABLE_CONTENTS">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:89.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:3.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:89.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:3.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:14.4pt;">
<td colspan="3" valign="top" style="width:95.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I_FINANCIAL_INFORMATION"><span style="text-decoration:underline;">Part I&#8212;FINANCIAL INFORMATION</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:89.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FINANCIAL_STATEMENTS"><span style="text-decoration:underline;">Financial Statements</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FS_BALANCE_SHEETS"><span style="text-decoration:underline;">Condensed Consolidated Balance Sheets &#8211; <br />&#160;&#160; As of June&#160;30, 2021 and December&#160;31, 2020</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FS_INCOME_STATEMENT"><span style="text-decoration:underline;">Condensed Consolidated Statements of Operations &#8211; <br />&#160;&#160; For the three and six months ended June&#160;30, 2021 and 2020</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.19%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FS_COMPREHENSIVE_INCOME"><span style="text-decoration:underline;">Condensed Consolidated Statements of Comprehensive Loss &#8211; <br />&#160;&#160; For the three and six months ended June&#160;30, 2021 and 2020</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.19%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FS_EQUITY"><span style="text-decoration:underline;">Condensed Consolidated Statements of Stockholders&#8217; (Deficit) Equity &#8211; <br />&#160;&#160; For the three and six months ended June&#160;30, 2021 and 2020</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:6.67%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FS_CASH_FLOWS"><span style="text-decoration:underline;">Condensed Consolidated Statements of Cash Flows &#8211; <br />&#160;&#160; For the six months ended June&#160;30, 2021 and 2020</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FS_FOOTNOTES"><span style="text-decoration:underline;">Notes to Unaudited Condensed Consolidated Financial Statements</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures about Market Risk</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td valign="top" style="width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:89.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:14.4pt;">
<td colspan="3" valign="top" style="width:95.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IIOR_INFORMATION"><span style="text-decoration:underline;">Part II&#8212;OTHER INFORMATION</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:89.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1A.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"><span style="text-decoration:underline;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES"><span style="text-decoration:underline;">Defaults Upon Senior Securities</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 5.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS"><span style="text-decoration:underline;">Exhibits</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
<tr style="height:14.4pt;">
<td colspan="3" valign="top" style="width:95.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">Signatures</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-i-</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I_FINANCIAL_INFORMATION">PART I&#8212;FINANCIAL INFORMATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FINANCIAL_STATEMENTS">ITEM 1. FINANCIAL STATEMENTS.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FS_BALANCE_SHEETS">Condensed Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000029" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">83,958</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000030" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000031" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000032" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related parties</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000033" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,047</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,003</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">7,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,649</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:AssetsCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">113,731</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:AssetsCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">111,713</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, noncurrent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:MarketableSecuritiesNoncurrent" contextRef="C_0001326110_20210630" decimals="-3" scale="3">822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:MarketableSecuritiesNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">950</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">89,023</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-marketable equity investment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,849</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible asset, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,445</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,463</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="ibrx:ConvertibleNoteReceivableNonCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,253</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="ibrx:ConvertibleNoteReceivableNonCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets, net (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">28,230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,797</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,598</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:Assets" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">246,301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:Assets" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">221,381</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,510</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">36,134</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,771</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related parties</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">16,711</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,838</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,430</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,015</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">74,428</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,134</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party notes payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">300,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">254,353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, less current portion (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">29,116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="C_0001326110_20210630" decimals="-3" scale="3">170</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="C_0001326110_20201231" decimals="-3" scale="3">170</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001326110_20210630" decimals="-3" scale="3">920</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,035</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:Liabilities" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">404,886</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:Liabilities" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">339,871</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 7)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000075">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000076">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; deficit:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000094" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000093" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_20210630" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000096" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001326110_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000095" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001326110_20210630" decimals="INF" format="ixt:numdotdecimal">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000097" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001326110_20210630" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000099" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_20210630" decimals="INF" format="ixt:numdotdecimal">390,347,740</ix:nonFraction></ix:nonFraction> and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; <ix:nonFraction unitRef="U_xbrlishares" id="F_000098" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001326110_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000100" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_20201231" decimals="INF" format="ixt:numdotdecimal">382,243,142</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June 30, 2021 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020, respectively&#59; excluding treasury stock, <ix:nonFraction unitRef="U_xbrlishares" id="F_000102" name="us-gaap:TreasuryStockShares" contextRef="C_0001326110_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000101" name="us-gaap:TreasuryStockShares" contextRef="C_0001326110_20210630" decimals="INF" format="ixt:numdotdecimal">163,800</ix:nonFraction></ix:nonFraction> shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; outstanding as of June 30, 2021 and December 31, 2020, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:CommonStockValue" contextRef="C_0001326110_20210630" decimals="-3" scale="3">39</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:CommonStockValue" contextRef="C_0001326110_20201231" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,625,018</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,495,163</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001326110_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,783,033</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001326110_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,615,131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20210630" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20201231" decimals="-3" scale="3">122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total ImmunityBio stockholders&#8217; deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:StockholdersEquity" contextRef="C_0001326110_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">157,939</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:StockholdersEquity" contextRef="C_0001326110_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">119,808</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling interests</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:MinorityInterest" contextRef="C_0001326110_20210630" decimals="-3" sign="-" scale="3">646</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:MinorityInterest" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">158,585</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">118,490</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">246,301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">221,381</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FS_INCOME_STATEMENT">Condensed Consolidated Statements of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:Revenues" contextRef="C_0001326110_20210401_20210630" decimals="-3" scale="3">339</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:Revenues" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">436</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:Revenues" contextRef="C_0001326110_20210101_20210630" decimals="-3" scale="3">478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:Revenues" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">601</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">53,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">33,005</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">94,928</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">60,379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">32,445</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">18,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">77,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">27,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:OperatingExpenses" contextRef="C_0001326110_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">86,245</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:OperatingExpenses" contextRef="C_0001326110_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">51,352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:OperatingExpenses" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">172,648</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:OperatingExpenses" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">88,219</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,906</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">50,916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">172,170</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">87,618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and investment (loss) income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:GainLossOnInvestments" contextRef="C_0001326110_20210401_20210630" decimals="-3" sign="-" scale="3">177</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:GainLossOnInvestments" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">986</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:GainLossOnInvestments" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,767</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:GainLossOnInvestments" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,064</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:InterestExpense" contextRef="C_0001326110_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,577</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:InterestExpense" contextRef="C_0001326110_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,123</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:InterestExpense" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,745</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:InterestExpense" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,012</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001326110_20210401_20210630" decimals="-3" scale="3">277</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">81</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001326110_20210101_20210630" decimals="-3" scale="3">290</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other (expense) income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,477</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,312</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,763</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes and noncontrolling interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001326110_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">89,383</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">51,972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">169,858</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">89,381</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_20210401_20210630" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_20210101_20210630" decimals="-3" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">63</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">89,385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">169,866</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">89,444</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to noncontrolling interests, net of tax</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_0001326110_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" scale="3">578</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" scale="3">967</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to ImmunityBio common stockholders</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:NetIncomeLoss" contextRef="C_0001326110_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">88,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:NetIncomeLoss" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">51,439</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:NetIncomeLoss" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">167,902</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:NetIncomeLoss" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">88,477</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per ImmunityBio common share &#8211; basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000159" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001326110_20210401_20210630" decimals="2" sign="-">0.23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000160" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001326110_20200401_20200630" decimals="2" sign="-">0.14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000161" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001326110_20210101_20210630" decimals="2" sign="-">0.44</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000162" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001326110_20200101_20200630" decimals="2" sign="-">0.24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of common shares used in computing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net loss per share &#8211; basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000163" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001326110_20210401_20210630" decimals="0" format="ixt:numdotdecimal">384,820,486</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000164" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001326110_20200401_20200630" decimals="0" format="ixt:numdotdecimal">372,286,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000165" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001326110_20210101_20210630" decimals="0" format="ixt:numdotdecimal">383,939,031</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000166" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001326110_20200101_20200630" decimals="0" format="ixt:numdotdecimal">372,137,752</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FS_COMPREHENSIVE_INCOME">Condensed Consolidated Statements of Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">89,385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">169,866</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">89,444</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income (loss), net of income taxes:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unrealized gains on available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" contextRef="C_0001326110_20210401_20210630" decimals="-3" scale="3">18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" contextRef="C_0001326110_20210101_20210630" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001326110_20210401_20210630" decimals="-3" scale="3">60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" scale="3">63</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" scale="3">102</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of net realized gains on</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; available-for-sale securities included in net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_0001326110_20210401_20210630" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other comprehensive income (loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20210401_20210630" decimals="-3" scale="3">75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" scale="3">85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">89,310</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,052</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">169,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">89,432</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Comprehensive loss attributable to noncontrolling interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" scale="3">578</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" scale="3">967</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss attributable to ImmunityBio </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; common stockholders</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001326110_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">88,213</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">51,474</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">167,987</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">88,465</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FS_EQUITY">Condensed Consolidated Statements of Stockholders&#8217; (Deficit) Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interests</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of March 31, 2021</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000199" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="INF" format="ixt:numdotdecimal">383,067,321</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,508,958</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,694,745</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331" decimals="-3" sign="-" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">185,787</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210331" decimals="-3" scale="3">451</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">185,336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; under &#8220;at-the market&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; offering net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; commissions and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; offering costs</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001326110_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,077</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000207" name="ibrx:IssuanceOfCommonStockUnderAtMarketOfferingShares" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="INF" format="ixt:numdotdecimal">6,420,441</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="ibrx:IssuanceOfCommonStockUnderAtMarketOffering" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="ibrx:IssuanceOfCommonStockUnderAtMarketOffering" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">94,886</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="ibrx:IssuanceOfCommonStockUnderAtMarketOffering" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="ibrx:IssuanceOfCommonStockUnderAtMarketOffering" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="ibrx:IssuanceOfCommonStockUnderAtMarketOffering" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">94,887</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="ibrx:IssuanceOfCommonStockUnderAtMarketOffering" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="ibrx:IssuanceOfCommonStockUnderAtMarketOffering" contextRef="C_0001326110_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">94,887</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; expense</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">17,863</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">17,863</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">17,863</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000223" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="INF" format="ixt:numdotdecimal">759,639</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,311</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,311</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,311</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of restricted stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; units (RSUs)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000231" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="INF" format="ixt:numdotdecimal">100,359</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net share settlement for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; RSUs vesting</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000239" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="INF">20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net of tax</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630" decimals="-3" scale="3">75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210401_20210630" decimals="-3" scale="3">75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20210401_20210630" decimals="-3" scale="3">75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">88,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">88,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">89,385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of June&#160;30, 2021</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000263" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630" decimals="INF" format="ixt:numdotdecimal">390,347,740</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630" decimals="-3" scale="3">39</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,625,018</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,783,033</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210630" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">157,939</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210630" decimals="-3" sign="-" scale="3">646</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">158,585</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interests</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000273" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">382,243,142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,495,163</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,615,131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" scale="3">122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">119,808</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">118,490</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; under &#8220;at-the market&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; offering net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; commissions and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; offering costs</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,077</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000281" name="ibrx:IssuanceOfCommonStockUnderAtMarketOfferingShares" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="INF" format="ixt:numdotdecimal">6,420,441</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="ibrx:IssuanceOfCommonStockUnderAtMarketOffering" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="ibrx:IssuanceOfCommonStockUnderAtMarketOffering" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">94,886</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="ibrx:IssuanceOfCommonStockUnderAtMarketOffering" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="ibrx:IssuanceOfCommonStockUnderAtMarketOffering" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="ibrx:IssuanceOfCommonStockUnderAtMarketOffering" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">94,887</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="ibrx:IssuanceOfCommonStockUnderAtMarketOffering" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="ibrx:IssuanceOfCommonStockUnderAtMarketOffering" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">94,887</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; expense</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">33,161</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">33,161</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">33,161</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000297" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="INF" format="ixt:numdotdecimal">1,450,104</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,432</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,432</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,432</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of RSUs</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000305" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="INF" format="ixt:numdotdecimal">336,084</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net share settlement for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; RSUs vesting</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000313" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="INF" format="ixt:numdotdecimal">102,031</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net of tax</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630" decimals="-3" sign="-" scale="3">85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210630" decimals="-3" sign="-" scale="3">85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" scale="3">85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">167,902</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">167,902</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">169,866</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of June 30, 2021</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000337" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630" decimals="INF" format="ixt:numdotdecimal">390,347,740</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630" decimals="-3" scale="3">39</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,625,018</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,783,033</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210630" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">157,939</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210630" decimals="-3" sign="-" scale="3">646</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">158,585</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Condensed Consolidated Statements of Stockholders&#8217; (Deficit) Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interests</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of March 31, 2020</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000345" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331" decimals="INF" format="ixt:numdotdecimal">372,015,023</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,406,359</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,430,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331" decimals="-3" sign="-" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">23,962</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,265</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">20,697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net of offering costs</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001326110_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,392</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000353" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="INF" format="ixt:numdotdecimal">8,521,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">86,281</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000358" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">86,282</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001326110_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">86,282</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;expense</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630" decimals="-3" scale="3">322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200401_20200630" decimals="-3" scale="3">322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000369" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="INF" format="ixt:numdotdecimal">259,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630" decimals="-3" scale="3">564</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000372" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200401_20200630" decimals="-3" scale="3">564</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000375" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">564</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of RSUs</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000377" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="INF" format="ixt:numdotdecimal">495,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000378" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000379" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net share settlement for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; RSUs vesting</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000385" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="INF" format="ixt:numdotdecimal">10,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200401_20200630" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net of tax</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630" decimals="-3" sign="-" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200401_20200630" decimals="-3" sign="-" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">51,439</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">51,439</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200401_20200630" decimals="-3" sign="-" scale="3">578</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of June&#160;30, 2020</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000409" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630" decimals="INF" format="ixt:numdotdecimal">381,280,749</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000410" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000411" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,493,486</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,481,757</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200630" decimals="-3" sign="-" scale="3">75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">11,692</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,687</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000416" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">14,379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000419" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">371,976,995</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000420" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,406,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,393,280</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" sign="-" scale="3">87</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,672</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000425" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,654</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,326</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net of offering costs</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,392</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000427" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="INF" format="ixt:numdotdecimal">8,521,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">86,281</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000431" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">86,282</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">86,282</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; expense</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630" decimals="-3" scale="3">802</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200630" decimals="-3" scale="3">802</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">802</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000443" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="INF" format="ixt:numdotdecimal">259,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630" decimals="-3" scale="3">564</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200630" decimals="-3" scale="3">564</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000450" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">564</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of RSUs</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000451" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="INF" format="ixt:numdotdecimal">558,976</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net share settlement for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; RSUs vesting</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000459" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="INF" format="ixt:numdotdecimal">35,739</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630" decimals="-3" scale="3">163</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200630" decimals="-3" scale="3">163</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">163</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net of tax</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200630" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">88,477</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">88,477</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200630" decimals="-3" sign="-" scale="3">967</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">89,444</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of June 30, 2020</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000483" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630" decimals="INF" format="ixt:numdotdecimal">381,280,749</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200630" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,493,486</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,481,757</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200630" decimals="-3" sign="-" scale="3">75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">11,692</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,687</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">14,379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FS_CASH_FLOWS">Condensed Consolidated Statements of Cash Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">169,866</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">89,444</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:ShareBasedCompensation" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">33,161</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:ShareBasedCompensation" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">802</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gains on equity securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">494</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,956</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,959</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash interest items, net (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="ibrx:NonCashInterestIncomeExpenseFromOperatingActivities" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">6,248</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="ibrx:NonCashInterestIncomeExpenseFromOperatingActivities" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,988</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash lease expense related to operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="ibrx:OperatingLeaseRightOfUseAssetNonCashLeaseExpense" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,269</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="ibrx:OperatingLeaseRightOfUseAssetNonCashLeaseExpense" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,034</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gains on sales of equity securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:DebtAndEquitySecuritiesRealizedGainLoss" contextRef="C_0001326110_20210101_20210630" decimals="-3" scale="3">173</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:DebtAndEquitySecuritiesRealizedGainLoss" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of net premiums and discounts on marketable debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">248</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">93</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="ibrx:ChangeInFairValueOfContingentConsiderationObligations" contextRef="C_0001326110_20210101_20210630" decimals="-3" scale="3">118</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="ibrx:ChangeInFairValueOfContingentConsiderationObligations" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">457</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,029</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">5,420</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,635</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,199</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,600</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000516" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,287</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000517" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,821</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000518" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">10,216</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related parties</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,579</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,740</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="ibrx:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,977</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="ibrx:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,823</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">130,064</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000524" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">77,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investing activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property, plant and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">15,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000526" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">324</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of marketable debt securities, available-for-sale</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000527" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001326110_20210101_20210630" decimals="-3" scale="3">266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000528" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">14,828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of marketable debt securities, available for sale</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">44,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">42,920</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sales of marketable debt and equity securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">13,569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000532" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000533" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">42,334</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">29,268</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financing activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from equity offering, net of issuance costs paid</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">95,026</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">86,816</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of related-party promissory notes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">40,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercises of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,432</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">564</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net share settlement for RSUs vesting</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">163</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">136,834</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">87,217</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" scale="3">61</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in cash, cash equivalents, and restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">49,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000548" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">39,361</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash, beginning of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000549" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,094</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000550" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">75,980</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash, end of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000551" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">84,137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">115,341</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">, Inc.</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> and Subsidiaries</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Condensed Consolidated Statements of Cash Flows (Continued)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of cash, cash equivalents, and restricted cash, end of period:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000553" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">83,958</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000554" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001326110_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">115,162</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (Note 3)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000555" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001326110_20210630" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000556" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001326110_20200630" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash, end of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000557" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">84,137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000558" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">115,341</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of cash flow information:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid during the period for:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="us-gaap:InterestPaidNet" contextRef="C_0001326110_20210101_20210630" decimals="-3" scale="3">842</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000560" name="us-gaap:InterestPaidNet" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000561" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001326110_20210101_20210630" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000562" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment purchases included in accounts payable, accrued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; expenses and due to related parties</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000563" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,368</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unpaid offering costs included in accounts payable and accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000565" name="ibrx:UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" contextRef="C_0001326110_20210101_20210630" decimals="-3" scale="3">140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000566" name="ibrx:UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">534</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for operating lease liabilities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000567" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">12,361</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000568" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gains on marketable debt securities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000569" name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="C_0001326110_20210101_20210630" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000570" name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FS_FOOTNOTES">Notes to Unaudited Condensed Consolidated Financial Statements</p><ix:nonNumeric id="F_000571" name="us-gaap:NatureOfOperations" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000571_cnt_1">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N1___DESCRIPTION_BUSINESS">1. &#160;&#160;&#160;&#160;Description of Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Organization</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We were </span>incorporated in Illinois on October&#160;7,&#160;2002 under the name ZelleRx Corporation. On January&#160;22,&#160;2010, we changed our name to Conkwest,&#160;Inc. In March&#160;2014, we formed Conkwest, Inc., our wholly-owned subsidiary in the state of Delaware, or Conkwest Delaware, for the purposes of changing the state of our incorporation to the state of Delaware. In March&#160;2014, we merged with and into Conkwest Delaware, with Conkwest Delaware surviving the merger. On July&#160;10,&#160;2015, we changed our name to NantKwest,&#160;Inc. On March&#160;9,&#160;2021, we completed a merger with NantCell,&#160;Inc. (formerly known as ImmunityBio, Inc., a private company) (&#8220;NantCell&#8221;), and we changed our name to ImmunityBio,&#160;Inc. Our principal executive offices are located in San&#160;Diego, California. In these notes to the unaudited condensed consolidated financial statements, the terms &#8220;ImmunityBio,&#8221; &#8220;the company,&#8221; &#8220;the combined company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to ImmunityBio and subsidiaries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We established ImmunityBio to advance next-generation immunotherapies and address unmet needs within oncology and infectious disease. Our platform is designed to overcome limitations of the current standards of T&#160;cell-based immunotherapies, including checkpoint inhibitors and CAR-T&#160;cells and is based on our four&#160;key modalities:&#160;(1)&#160;activating natural killer (&#8220;NK&#8221;), and T&#160;cells using antibody cytokine fusion proteins, (2)&#160;activating tumoricidal macrophages using low-dose synthetic immunomodulators, (3)&#160;generating memory T&#160;cells using vaccine candidates developed with our second-generation adenovirus, or hAd5, technology, and (4)&#160;off-the-shelf natural killer cells from the NK&#8209;92 cell line and memory-like cytokine-enhanced NK&#160;cells (&#8220;M&#8209;ceNK&#8221;) from allogenic and autologous donors.</span></p></ix:nonNumeric><ix:continuation id="F_000571_cnt_1" continuedAt="F_000571_dcnt_ef31e0af-89ae-4eb3-8b7e-d5838bcd06ee">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We own a broad, clinical-stage immunotherapy pipeline, including an antibody cytokine fusion protein&#160;(an IL&#8209;15 superagonist&#160;(N&#8209;803) known as Anktiva), an albumin-associated anthracycline synthetic immunomodulator (aldoxorubicin), second-generation adenovirus&#160;(&#8220;hAd5&#8221;) and yeast vaccine technologies (targeting tumor-associated antigens and neoepitopes), off-the-shelf genetically engineered natural killer cell lines inducing cancer and virally infected cell death through a variety of concurrent mechanisms (including innate killing, antibody-mediated killing, and CAR-directed killing), patient specific NK&#160;cell product for cancer (M-ceNK), macrophage polarizing peptides, and bi-specific fusion proteins targeting CD20, PD&#8209;L1, TGF&#8209;</span><span style="Background-color:#FFFFFF;font-family:'Times New Roman';"><span style="font-size:10pt;font-family:'Times New Roman'">b</span></span><span style="Background-color:#FFFFFF;"> and IL&#8209;12. Our immunotherapy clinical pipeline consists of over 40&#160;clinical trials in Phase&#160;1, 2, or 3&#160;development across 19&#160;indications in solid and liquid cancers and infectious diseases. We have an expansive clinical-stage pipeline and intellectual property portfolio with 17&#160;first-in-human assets in 25&#160;Phase&#160;II to III&#160;clinical trials.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2019, the </span>United States (&#8220;U.S.&#8221;) Food and Drug Administration<span style="Background-color:#FFFFFF;"> (&#8220;FDA&#8221;) granted Breakthrough Therapy designation to Anktiva for bacillus Calmette-Gu&#233;rin (&#8220;BCG&#8221;) unresponsive carcinoma in situ non-muscle invasive bladder cancer. Based on patient readout data that was submitted with our application to obtain our Breakthrough Therapy designation, Anktiva achieved its primary endpoint of complete response rate at any time in the ongoing registrational Phase&#160;II / III&#160;trial. Other indications currently with registration-potential studies include BCG unresponsive papillary bladder cancer, first- and second-line lung cancer, and metastatic pancreatic cancer.</span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000571_dcnt_ef31e0af-89ae-4eb3-8b7e-d5838bcd06ee" continuedAt="F_000571_dcnt_b18014c4-6f6d-46ee-866d-d43be1365e7a">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Merger</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On <ix:nonNumeric id="F_000615" name="us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210630" format="ixt:datemonthdayyearen">December&#160;21,&#160;2020</ix:nonNumeric>, we and NantCell entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), pursuant to which we and NantCell agreed to combine our businesses. The Merger Agreement provided that a wholly-owned subsidiary of the company would merge with and into NantCell (the&#160;&#8220;Merger&#8221;), with NantCell surviving the Merger as a wholly-owned subsidiary of the company.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On <ix:nonNumeric id="F_000619" name="us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1" contextRef="C_0001326110_20210101_20210630" format="ixt:datemonthdayyearen">March&#160;9,&#160;2021</ix:nonNumeric>, we completed the Merger pursuant to the terms of the Merger Agreement. Under the terms of the Merger Agreement, at the effective time of the Merger&#160;(the &#8220;Effective Time&#8221;), each share of NantCell common stock</span>, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000616" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210309" decimals="3">0.001</ix:nonFraction>&#160;per share, <span style="Background-color:#FFFFFF;">issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000617" name="ibrx:MergerExchangeRatio" contextRef="C_0001326110_20210309_20210309" decimals="4">0.8190</ix:nonFraction>&#160;(the &#8220;Exchange Ratio&#8221;) newly</span> issued shares of common stock, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000618" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_20210309" decimals="4">0.0001</ix:nonFraction>&#160;per share, of the company (&#8220;Company Common Stock&#8221;), with cash paid in lieu of any fractional shares.<span style="Background-color:#FFFFFF;"> At the Effective Time, each share of the company&#8217;s common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company. At the Effective Time, each outstanding option, warrant or restricted stock unit to purchase NantCell common stock was converted using the Exchange Ratio into an option, warrant or restricted stock unit, respectively, on the same terms and conditions immediately prior to the Effective Time, to purchase shares of Company Common Stock.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Immediately following the Effective Time, the former stockholders of NantCell held approximately&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000620" name="ibrx:OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210309" decimals="3" scale="-2">71.5</ix:nonFraction>% of the outstanding shares of Company Common Stock and the stockholders of the company as of immediately prior to the Merger held approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000621" name="ibrx:OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" contextRef="C_0001326110_srtOwnershipAxis_ibrxNantKwestMember_20210309" decimals="3" scale="-2">28.5</ix:nonFraction>%&#160;of the outstanding shares of Company Common Stock. As a result of the Merger and immediately following the Effective Time, Dr.&#160;Patrick Soon-Shiong, our Executive Chairman, and his affiliates beneficially owned, in the aggregate, approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000622" name="ibrx:OwnershipPercentageByKeyExecutives" contextRef="C_0001326110_srtTitleOfIndividualAxis_ibrxExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember_20210309_20210309" decimals="3" scale="-2">81.8</ix:nonFraction>%&#160;of the outstanding shares of Company Common Stock. Following the consummation of the Merger, shares of the company&#8217;s common stock were listed on the Nasdaq Global Select Market under the symbol &#8220;IBRX.&#8221;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We incurred costs totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000623" name="us-gaap:PaymentsForMergerRelatedCosts" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20121231_20210630" decimals="-5" scale="6">23.3</ix:nonFraction>&#160;million in connection with the Merger, consisting of financial advisory, legal and other professional fees, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000624" name="us-gaap:PaymentsForMergerRelatedCosts" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210630" decimals="-5" scale="6">13.0</ix:nonFraction>&#160;million was recorded during the six&#160;months ended June&#160;30,&#160;2021. Merger-related costs are</span><span style="Background-color:#FFFFFF;color:#000000;"> reported in </span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">selling, general and administrative expense</span><span style="Background-color:#FFFFFF;color:#000000;">, on the condensed consolidated statements of operations.</span></p><ix:nonNumeric id="F_000585" name="us-gaap:BusinessCombinationsPolicy" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000585_dcnt_106a8ee8-807f-4e78-908f-23c0f0bbcdf2">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Treatment of the Merger</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Merger represents a business combination pursuant to Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;805-50,&#160;<span style="font-style:italic;">Mergers</span>, which is accounted for as a transaction between entities under common control as Dr.&#160;Soon-Shiong and his affiliates were the controlling stockholders of both the company and NantCell for all of the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We have recast our prior period financial statements to reflect the conveyance of NantCell&#8217;s common shares as if the Merger had occurred as of the earliest date of the financial statements presented. All material intercompany accounts and transactions have been eliminated in consolidation.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000571_dcnt_b18014c4-6f6d-46ee-866d-d43be1365e7a" continuedAt="F_000571_dcnt_486bd8fb-1e1d-4d7d-aeed-256fcca0b1a6"><ix:continuation id="F_000585_dcnt_106a8ee8-807f-4e78-908f-23c0f0bbcdf2">
</ix:continuation><ix:nonNumeric id="F_000596" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables provide the impact of the change in reporting entity on our unaudited condensed consolidated statements of operations for the three&#160;months ended March&#160;31,&#160;2021 and the three and six&#160;months ended June&#160;30,&#160;2020, respectively (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantCell</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantKwest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intercompany</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Eliminations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inc.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000625" name="us-gaap:Revenues" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" scale="3">183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000626" name="us-gaap:Revenues" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000627" name="us-gaap:Revenues" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331" decimals="-3" sign="-" scale="3">44</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000628" name="us-gaap:Revenues" contextRef="C_0001326110_20210101_20210331" decimals="-3" scale="3">139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000629" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">21,509</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000630" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">19,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000631" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331" decimals="-3" sign="-" scale="3">106</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000632" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">41,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000633" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">24,382</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000634" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">20,903</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000635" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331" decimals="-3" sign="-" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000636" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">45,275</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000637" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">45,708</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000638" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">40,628</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000639" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331" decimals="-3" scale="3">72</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000640" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">86,264</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income, net (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000641" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" sign="-" scale="3">848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000642" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,637</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000643" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000644" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000645" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000646" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000647" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000648" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_20210101_20210331" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000649" name="us-gaap:ProfitLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000650" name="us-gaap:ProfitLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">33,997</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000651" name="us-gaap:ProfitLoss" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331" decimals="-3" scale="3">72</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000652" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">80,481</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantCell</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantKwest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intercompany</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Eliminations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inc.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000653" name="us-gaap:Revenues" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000654" name="us-gaap:Revenues" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000655" name="us-gaap:Revenues" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,090</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000656" name="us-gaap:Revenues" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">436</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000657" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,384</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000658" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">13,709</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000659" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200401_20200630" decimals="-3" sign="-" scale="3">88</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000660" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">33,005</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000661" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">11,828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000662" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,519</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000663" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000664" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">18,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000665" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">29,687</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000666" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">20,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">50,916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income, net (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630" decimals="-3" scale="3">139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000671" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200401_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000673" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630" decimals="-3" scale="3">41</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000674" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000675">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000676" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000677" name="us-gaap:ProfitLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">30,923</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000678" name="us-gaap:ProfitLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">20,092</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000679" name="us-gaap:ProfitLoss" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000680" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantCell</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantKwest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intercompany</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Eliminations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inc.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000681" name="us-gaap:Revenues" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,693</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="us-gaap:Revenues" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630" decimals="-3" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="us-gaap:Revenues" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000684" name="us-gaap:Revenues" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">601</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000685" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">33,636</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000686" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">26,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000687" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200630" decimals="-3" sign="-" scale="3">200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000688" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">60,379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000689" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">15,948</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000690" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">11,892</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000691" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000692" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">27,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000693" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">47,891</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000694" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">38,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000695" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200630" decimals="-3" sign="-" scale="3">914</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000696" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">87,618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income, net (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000697" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,105</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000698" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630" decimals="-3" scale="3">342</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000699" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000700" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,763</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000701" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630" decimals="-3" scale="3">59</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000702" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000703" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000704" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">63</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000705" name="us-gaap:ProfitLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">50,055</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000706" name="us-gaap:ProfitLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">38,475</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000707" name="us-gaap:ProfitLoss" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200630" decimals="-3" sign="-" scale="3">914</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000708" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">89,444</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000571_dcnt_486bd8fb-1e1d-4d7d-aeed-256fcca0b1a6">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000573" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000573_dcnt_9cd4c632-23ec-4a7f-a897-b540a0719c88">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N2___SUMMARY_SIGNIFICANT_ACCOUNTING_POLI">2. &#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no material changes to our significant accounting policies from those described in the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019&#160;(including NantCell,&#160;Inc.) filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Exhibit&#160;99.2</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Current Report on Form&#160;8&#8209;K/A filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on April&#160;22,&#160;2021.</span></p><ix:nonNumeric id="F_000586" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. The unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. The unaudited condensed consolidated financial statements do not include all information and notes required by U.S.&#160;GAAP for annual reports.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021, the company had an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000709" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001326110_20210630" decimals="-8" sign="-" format="ixt:numdotdecimal" scale="9">1.8</ix:nonFraction>&#160;billion. We also had negative cash flows from operations of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000710" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001326110_20210101_20210630" decimals="-5" sign="-" scale="6">130.1</ix:nonFraction>&#160;million for the six&#160;months ended June&#160;30,&#160;2021. The company will likely need additional capital to further fund the development of, and seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements are derived from NantKwest&#8217;s and NantCell&#8217;s respective historical consolidated financial statements for each period presented. Since the entities have been under common control for all periods presented, the condensed consolidated financial statements assume that the Merger took place at the beginning of the earliest period for which the condensed consolidated financial statements are presented. Accordingly, these financial statements should be read in conjunction with the audited Combined Consolidated Financial Statements and Notes thereto included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019&#160;(including NantCell,&#160;Inc.) filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Exhibit&#160;99.2</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Current Report on Form&#160;8&#8209;K/A filed with the SEC on April&#160;22,&#160;2021. Interim operating results are not necessarily indicative of operating results for the full year.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty of our ability to continue as a going concern. As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings (including but not limited to the offering, issuance and sale by us of up to a maximum aggregate offering of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000711" name="ibrx:AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210430_20210430" decimals="INF" scale="6">500.0</ix:nonFraction>&#160;million of our common stock that may be issued and sold under an &#8220;at-the-market&#8221; sales agreement with Jefferies LLC (the &#8220;ATM&#8221;)), and our potential ability to borrow from affiliated entities, will be sufficient to fund our operations through at least the next 12&#160;months following the issuance date of the financial statements based primarily upon our Executive Chairman&#8217;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of our product candidates in development, we may need additional funds to meet our needs sooner than planned.</p></ix:nonNumeric><ix:nonNumeric id="F_000587" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000587_dcnt_882a64cf-2c78-48a6-a562-43b3a5c11be0">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements include the accounts of the company and its subsidiaries. All intercompany amounts have been eliminated. For consolidated entities where we have less than 100% of ownership, we record net loss attributable to noncontrolling interest on the condensed consolidated statements of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We apply the variable interest model under ASC Topic&#160;810,&#160;<span style="font-style:italic;">Consolidation</span>, to any entity in which we hold an equity investment or to which we have the power to direct the entity&#8217;s most significant economic activities and the ability to participate in the entity&#8217;s economics. If the entity is within the scope of the variable interest model and meets the definition of a variable interest entity (&#8220;VIE&#8221;), we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000573_dcnt_9cd4c632-23ec-4a7f-a897-b540a0719c88" continuedAt="F_000573_dcnt_b112cf63-42d5-4a47-a77d-a4dd1a1a72aa"><ix:continuation id="F_000587_dcnt_882a64cf-2c78-48a6-a562-43b3a5c11be0">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For entities we hold as an equity investment that are not consolidated under the VIE </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">odel, we consider whether our investment constitutes ownership of a majority of the voting interests in the entity and therefore should be considered for consolidation under the voting interest model.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unconsolidated equity investments in the common stock or in-substance common stock of an entity under which we are able to exercise significant influence, but not control, are accounted for using the equity method. Our ability to exercise significant influence is generally indicated by ownership of <ix:nonFraction unitRef="U_xbrlipure" id="F_000712" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_srtRangeAxis_srtMinimumMember_20210630" decimals="2" scale="-2">20</ix:nonFraction>% to <ix:nonFraction unitRef="U_xbrlipure" id="F_000713" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_srtRangeAxis_srtMaximumMember_20210630" decimals="2" scale="-2">50</ix:nonFraction>% interest in the voting securities of the entity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other unconsolidated equity investments on which we are not able to exercise significant influence will be subsequently measured at fair value with unrealized holding gains and losses included in <span style="font-style:italic;">interest and investment income, net</span>, on the condensed consolidated statements of operations. In the instance the equity investment does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC Topic&#160;820, <span style="font-style:italic;">Fair Value Measurement</span> (&#8220;ASC&#160;820&#8221;), we will apply the measurement alternative under ASC Topic&#160;321, <span style="font-style:italic;">Investments&#8212;Equity Securities</span> (&#8220;ASC&#160;321&#8221;), pursuant to which we will measure the investment at its cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to March&#160;31,&#160;2021, we owned non-marketable equity securities that were accounted for using the measurement alternative under ASC&#160;321 because the preferred stock held by us was not considered in-substance common stock and such preferred stock did not have a readily determinable fair value. All investments are reviewed for possible impairment on a regular basis. If an investment&#8217;s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an impairment indicator is present include:&#160;the investees&#8217; earnings performance and clinical trial performance, change in the investees&#8217; industry and geographic area in which it operates, offers to purchase or sell the security for a price less than the cost of the investment, issues that raise concerns about the investee&#8217;s ability to continue as a going concern, and any other information that we may be aware of related to the investment. Factors considered in determining whether an observable price change has occurred include:&#160;the price at which the investee issues equity instruments similar to those of our investment and the rights and preferences of those equity instruments compared to ours.</p></ix:continuation><ix:nonNumeric id="F_000588" name="us-gaap:UseOfEstimates" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric id="F_000589" name="us-gaap:UnusualRisksAndUncertaintiesTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000589_dcnt_eeee890b-8af4-4664-a3bd-ff6e7d7ecb36">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2020, the World Health Organization declared the novel strain of coronavirus disease&#160;(SARS&#8209;CoV&#8209;2) a pandemic. To date, our operations have not been significantly disadvantaged by the pandemic. However, we cannot at this time predict the specific extent, duration, or full impact that this pandemic may have on our financial condition and results of operations, including ongoing and planned clinical trials. More specifically, the pandemic may result in prolonged impacts that we cannot predict at this time and we expect that such uncertainties will continue to exist for the foreseeable future. The impact of the pandemic on our financial performance will depend on future developments, including the duration and spread of the outbreak, impact of potential variants and the related governmental advisories and restrictions. These developments and the impact of the ongoing pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, our results may be adversely affected.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000573_dcnt_b112cf63-42d5-4a47-a77d-a4dd1a1a72aa" continuedAt="F_000573_dcnt_2cff46d2-2e5b-4997-81b3-9c51705bafe7"><ix:continuation id="F_000589_dcnt_eeee890b-8af4-4664-a3bd-ff6e7d7ecb36">
</ix:continuation><ix:nonNumeric id="F_000590" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</p></ix:nonNumeric><ix:nonNumeric id="F_000591" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, marketable securities, and a convertible note receivable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash and cash equivalents are held by one major financial institution in the U.S., one in South&#160;Korea and one in Italy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates developed by us will require approvals or clearances from the FDA or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</p></ix:nonNumeric><ix:nonNumeric id="F_000592" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for stock-based compensation under the provisions of FASB ASC Topic&#160;718, <span style="font-style:italic;">Compensation&#8212;Stock Compensation</span> (&#8220;ASC&#160;718&#8221;). We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.</p></ix:nonNumeric><ix:nonNumeric id="F_000593" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000593_dcnt_0fa10d94-7820-4925-93ad-053e92e0cc43">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basic and Diluted Net Loss per Share of Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. <ix:nonNumeric id="F_000597" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000597_cnt_1">The following table details those securities that have been excluded from the computation of potentially dilutive securities:</ix:nonNumeric></p><ix:continuation id="F_000597_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000714" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="0" format="ixt:numdotdecimal">4,330,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000715" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20200630" decimals="0" format="ixt:numdotdecimal">6,104,799</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding RSUs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000716" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210630" decimals="0" format="ixt:numdotdecimal">7,443,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000717" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200630" decimals="0" format="ixt:numdotdecimal">565,802</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding related-party warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000718" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20210630" decimals="0" format="ixt:numdotdecimal">1,638,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000719" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20200630" decimals="0" format="ixt:numdotdecimal">1,638,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000720" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_20210101_20210630" decimals="0" format="ixt:numdotdecimal">13,411,822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000721" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_20200101_20200630" decimals="0" format="ixt:numdotdecimal">8,308,601</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts in the table above reflect the common stock equivalents of the noted instruments, including awards issued under the NantKwest 2015&#160;Equity Incentive Plan&#160;(the &#8220;2015&#160;Plan&#8221;), the NantKwest 2014&#160;Equity Incentive Plan&#160;(the &#8220;2014&#160;Plan&#8221;), and awards issued under the NantCell,&#160;Inc. 2015&#160;Stock Incentive Plan&#160;(the &#8220;NC&#160;2015&#160;Plan&#8221;) that, in the case of June&#160;30,&#160;2021, were outstanding immediately prior to the Effective Time of the Merger and in the case of June&#160;30,&#160;2020 have been adjusted to include the combined NC&#160;2015&#160;Plan and NantCell warrants then outstanding (in both cases adjusted <span style="Background-color:#FFFFFF;color:#000000;">using the Exchange Ratio of&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000722" name="ibrx:MergerExchangeRatio" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxNantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember_20210309_20210309" decimals="4">0.8190</ix:nonFraction></span>). See <a href="#N11___STOCKBASED_COMPENSATION"><span style="text-decoration:underline;">Note&#160;10</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Stock-Based Compensation</span>, for further information.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000573_dcnt_2cff46d2-2e5b-4997-81b3-9c51705bafe7"><ix:continuation id="F_000593_dcnt_0fa10d94-7820-4925-93ad-053e92e0cc43">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000594" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Application of New or Revised Accounting Standards &#8211; Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016&#8209;13,&#160;<span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic&#160;326):&#160;Measurement of Credit Losses on Financial Instruments</span> (&#8220;ASU&#160;2016-13&#8221;). The FASB subsequently issued amendments to ASU&#160;2016&#8209;13, which have the same effective date and transition dates as described below. The new guidance supersedes existing U.S.&#160;GAAP for measuring and recording of credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. For public business entities that meet the definition of an SEC filer, except entities that are eligible to be a smaller reporting company as defined by the SEC, the standard is effective for annual periods beginning after December&#160;15,&#160;2019, and interim periods therein. For all other entities, including us, the standard is effective for annual periods beginning after December&#160;15,&#160;2022, and interim periods therein. Early adoption is permitted for all entities for annual periods beginning after December&#160;15,&#160;2018. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. We continue to evaluate the impact that this new standard and its related amendments will have on our consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC during the three&#160;months ended June&#160;30,&#160;2021 did not, or are not expected to, have a material effect on our consolidated financial statements.</p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000574" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000574_dcnt_e6289558-d4f6-4bf8-949e-7cd9af567521">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N3___FINANCIAL_STATEMENT_DETAILS">3. &#160;&#160;&#160;&#160;Financial Statement Details</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets </p><ix:nonNumeric id="F_000598" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000598_cnt_1">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, prepaid expenses and other current assets consist of the following (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:continuation id="F_000598_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid preclinical and clinical trial services &#8211; with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related party (Note 8)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000723" name="ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,760</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000724" name="ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,626</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid license fees</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000725" name="ibrx:PrepaidLicenseFees" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,579</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000726" name="ibrx:PrepaidLicenseFees" contextRef="C_0001326110_20201231" decimals="-3" scale="3">801</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid services</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000727" name="ibrx:PrepaidServices" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,356</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000728" name="ibrx:PrepaidServices" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000729" name="us-gaap:PrepaidInsurance" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,191</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000730" name="us-gaap:PrepaidInsurance" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,365</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid rent</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000731" name="us-gaap:PrepaidRent" contextRef="C_0001326110_20210630" decimals="-3" scale="3">659</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000732" name="us-gaap:PrepaidRent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">589</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance premium financing asset</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000733" name="ibrx:InsurancePremiumFinancingAsset" contextRef="C_0001326110_20210630" decimals="-3" scale="3">627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000734" name="ibrx:InsurancePremiumFinancingAsset" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,421</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid equipment maintenance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000735" name="ibrx:PrepaidEquipmentMaintenance" contextRef="C_0001326110_20210630" decimals="-3" scale="3">198</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000736" name="ibrx:PrepaidEquipmentMaintenance" contextRef="C_0001326110_20201231" decimals="-3" scale="3">243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid supplies &#8211; with related party (Note 8)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000737" name="ibrx:PrepaidSuppliesWithRelatedParty" contextRef="C_0001326110_20210630" decimals="-3" scale="3">103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000738" name="ibrx:PrepaidSuppliesWithRelatedParty" contextRef="C_0001326110_20201231" decimals="-3" scale="3">143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance claims receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000739" name="us-gaap:InsuranceSettlementsReceivableCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000740" name="us-gaap:InsuranceSettlementsReceivableCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,518</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment deposits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000741" name="ibrx:EquipmentDepositsCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000742" name="ibrx:EquipmentDepositsCurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">66</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable <span style="font-family:Calibri;">&#8211;</span> marketable debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000743" name="us-gaap:InterestReceivableCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000744" name="us-gaap:InterestReceivableCurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">473</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000745" name="us-gaap:OtherAssetsCurrent" contextRef="C_0001326110_20210630" decimals="-3" scale="3">283</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000746" name="us-gaap:OtherAssetsCurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000747" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">7,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000748" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,649</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have reflected our right to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund. <span style="color:#000000;">Our insurance claims receivable as of December&#160;31,&#160;2020 were the result of the recovery of legal costs, which had been previously charged in prior periods to s</span><span style="font-style:italic;color:#000000;">elling, general and administrative expense, </span><span style="color:#000000;">on the condensed consolidated statements of operations.</span></p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000574_dcnt_e6289558-d4f6-4bf8-949e-7cd9af567521" continuedAt="F_000574_dcnt_740c6472-cb51-4479-b016-d0e5690fa729">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property, </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">p</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">lant and </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">quipment, </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">et</span></p><ix:nonNumeric id="F_000599" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, property, plant and equipment, net, consist of the following&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000749" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">62,445</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000750" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,251</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000751" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">45,443</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000752" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,738</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000753" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">22,690</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000754" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,690</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000755" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,030</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000756" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000757" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,449</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000758" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &#38; fixtures</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000759" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,046</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000760" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,015</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross property, plant and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000761" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">137,103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000762" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">114,403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000763" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">48,080</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000764" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,862</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000765" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">89,023</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000766" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress at June&#160;30,&#160;2021 is related primarily to expansion of our pharmaceutical development and manufacturing facilities, including construction of a new filling suite at our leased facilities in El&#160;Segundo, California<span style="color:#1F497D;">. </span>For the three&#160;months ended June&#160;30,&#160;2021, costs totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000767" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" contextRef="C_0001326110_20210101_20210630" decimals="-5" scale="6">8.2</ix:nonFraction>&#160;million were transferred from construction in progress to leasehold improvements as the construction was complete and the asset was ready for its intended use.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense related to property, plant and equipment totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000768" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001326110_20210101_20210630" decimals="-5" scale="6">7.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000769" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001326110_20200101_20200630" decimals="-5" scale="6">7.0</ix:nonFraction>&#160;million for the six&#160;months ended June&#160;30,&#160;2021 and 2020, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other assets</p><ix:nonNumeric id="F_000600" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000600_cnt_1">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, other assets consist of the following&#160;(in&#160;thousands): </p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000600_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000770" name="ibrx:PrepaidInsuranceInOtherAssets" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,220</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000771" name="ibrx:PrepaidInsuranceInOtherAssets" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid preclinical and clinical trial services &#8211; with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related party (Note 8)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000772" name="ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" contextRef="C_0001326110_20210630" decimals="-3" scale="3">911</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000773" name="ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" contextRef="C_0001326110_20201231" decimals="-3" scale="3">92</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value-added tax (VAT) receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000774" name="us-gaap:ValueAddedTaxReceivableNoncurrent" contextRef="C_0001326110_20210630" decimals="-3" scale="3">877</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000775" name="us-gaap:ValueAddedTaxReceivableNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">864</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ERP system implementation costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000776" name="ibrx:ERPSystemImplementationCostsInOtherAssets" contextRef="C_0001326110_20210630" decimals="-3" scale="3">585</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000777" name="ibrx:ERPSystemImplementationCostsInOtherAssets" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security deposits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000778" name="us-gaap:SecurityDeposit" contextRef="C_0001326110_20210630" decimals="-3" scale="3">486</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000779" name="us-gaap:SecurityDeposit" contextRef="C_0001326110_20201231" decimals="-3" scale="3">634</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000780" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001326110_20210630" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000781" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid software license fees</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000782" name="ibrx:PrepaidSoftwareLicenseFeesInOtherAssets" contextRef="C_0001326110_20210630" decimals="-3" scale="3">110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000783" name="ibrx:PrepaidSoftwareLicenseFeesInOtherAssets" contextRef="C_0001326110_20201231" decimals="-3" scale="3">455</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related party</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000784" name="us-gaap:DueFromRelatedPartiesNoncurrent" contextRef="C_0001326110_20210630" decimals="-3" scale="3">55</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000785" name="us-gaap:DueFromRelatedPartiesNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">51</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000786" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" contextRef="C_0001326110_20210630" decimals="-3" scale="3">374</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000787" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000788" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,797</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000789" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,598</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance consists of policies required by and associated with the Merger. Restricted cash is comprised of a certificate of deposit that serves as collateral for a letter of credit required by our landlord as a security deposit related to our facility in San&#160;Diego, California.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000574_dcnt_740c6472-cb51-4479-b016-d0e5690fa729" continuedAt="F_000574_dcnt_f555acf1-08e5-4408-a1ce-91666ceed2f4">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">xpenses</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> and other liabilities</span></p><ix:nonNumeric id="F_000601" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, accrued expenses and other liabilities consist of the following&#160;(in&#160;thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued dissenting shares (Note 7)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000790" name="ibrx:AccruedDissentingShares" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,941</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000791" name="ibrx:AccruedDissentingShares" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,769</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and service fees</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000792" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,575</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000793" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,668</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued preclinical and clinical trial costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000794" name="ibrx:AccruedPreclinicalAndClinicalTrialCosts" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,866</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000795" name="ibrx:AccruedPreclinicalAndClinicalTrialCosts" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,339</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000796" name="us-gaap:AccruedSalariesCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,719</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000797" name="us-gaap:AccruedSalariesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,891</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000798" name="ibrx:AccruedResearchAndDevelopmentCosts" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,528</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000799" name="ibrx:AccruedResearchAndDevelopmentCosts" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000800" name="us-gaap:AccruedBonusesCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,377</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000801" name="us-gaap:AccruedBonusesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued construction costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000802" name="us-gaap:ConstructionPayableCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,894</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000803" name="us-gaap:ConstructionPayableCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued contingent consideration payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000804" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="C_0001326110_20210630" decimals="-3" scale="3">831</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000805" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">856</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued laboratory equipment, supplies and related services</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000806" name="ibrx:AccruedLaboratoryEquipmentSuppliesAndRelatedServices" contextRef="C_0001326110_20210630" decimals="-3" scale="3">779</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000807" name="ibrx:AccruedLaboratoryEquipmentSuppliesAndRelatedServices" contextRef="C_0001326110_20201231" decimals="-3" scale="3">641</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing obligation &#8211; current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000808" name="us-gaap:AccruedInsuranceCurrent" contextRef="C_0001326110_20210630" decimals="-3" scale="3">627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000809" name="us-gaap:AccruedInsuranceCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,421</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000810" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001326110_20210630" decimals="-3" scale="3">217</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000811" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001326110_20201231" decimals="-3" scale="3">270</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued franchise, sales, use and property taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000812" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" contextRef="C_0001326110_20210630" decimals="-3" scale="3">211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000813" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued capital expenditures</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000814" name="ibrx:AccruedCapitalExpenditures" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000815" name="ibrx:AccruedCapitalExpenditures" contextRef="C_0001326110_20201231" decimals="-3" scale="3">337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000816" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001326110_20210630" decimals="-3" scale="3">569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000817" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000818" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">36,134</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000819" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,771</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest and investment (loss) income, net</p><ix:nonNumeric id="F_000602" name="us-gaap:InterestAndOtherIncomeTableTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and investment (loss) income, net consists of the following&#160;(in&#160;thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized (losses) gains from equity securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000820" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" contextRef="C_0001326110_20210401_20210630" decimals="-3" sign="-" scale="3">442</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000821" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">692</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000822" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000823" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">494</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000824" name="us-gaap:InterestAndOtherIncome" contextRef="C_0001326110_20210401_20210630" decimals="-3" scale="3">112</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000825" name="us-gaap:InterestAndOtherIncome" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">341</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000826" name="us-gaap:InterestAndOtherIncome" contextRef="C_0001326110_20210101_20210630" decimals="-3" scale="3">451</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000827" name="us-gaap:InterestAndOtherIncome" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">663</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment amortization expense, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000828" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="C_0001326110_20210401_20210630" decimals="-3" sign="-" scale="3">23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000829" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="C_0001326110_20200401_20200630" decimals="-3" sign="-" scale="3">48</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000830" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="C_0001326110_20210101_20210630" decimals="-3" sign="-" scale="3">248</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000831" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="C_0001326110_20200101_20200630" decimals="-3" sign="-" scale="3">93</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gains on investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000832" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="C_0001326110_20210401_20210630" decimals="-3" scale="3">176</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000833" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000834" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="C_0001326110_20210101_20210630" decimals="-3" scale="3">173</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000835" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and investment (loss) income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000836" name="us-gaap:GainLossOnInvestments" contextRef="C_0001326110_20210401_20210630" decimals="-3" sign="-" scale="3">177</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000837" name="us-gaap:GainLossOnInvestments" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">986</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000838" name="us-gaap:GainLossOnInvestments" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,767</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000839" name="us-gaap:GainLossOnInvestments" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,064</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income includes interest from marketable securities, convertible notes receivable, other assets, and interest from bank deposits. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000574_dcnt_f555acf1-08e5-4408-a1ce-91666ceed2f4">
</ix:continuation><ix:nonNumeric id="F_000575" name="us-gaap:InvestmentTextBlock" contextRef="C_0001326110_us-gaapInvestmentTypeAxis_ibrxMarketableDebtAndEquitySecuritiesMember_20210101_20210630" escape="true" continuedAt="F_000575_dcnt_2b37af82-067c-4627-bb8f-a628eb9d4b08">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N5___FINANCIAL_INSTRUMENTS">4. &#160;&#160;&#160;&#160;Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments in Marketable Debt Securities</p><ix:nonNumeric id="F_000603" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000603_cnt_1">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="16" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="16" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000864">0.7</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000840" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" scale="3">244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000846" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000852" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000858" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" scale="3">244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000841" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20210630" decimals="-3" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000847" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20210630" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000853" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000859" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20210630" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000842" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20210630" decimals="-3" scale="3">279</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000848" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20210630" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000854" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000860" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20210630" decimals="-3" scale="3">282</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000865">5.4</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000843" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" scale="3">761</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000849" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" scale="3">61</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000855" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000861" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" scale="3">822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000844" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20210630" decimals="-3" scale="3">761</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000850" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20210630" decimals="-3" scale="3">61</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000856" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000862" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20210630" decimals="-3" scale="3">822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000845" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,040</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000851" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_20210630" decimals="-3" scale="3">64</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000857" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000863" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,104</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:continuation id="F_000603_cnt_1">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,&#160;2020, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000866" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000872" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000878" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" scale="3">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000884" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,772</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000867" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20201231" decimals="-3" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000873" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000879" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000885" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20201231" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000868" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,824</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000874" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000880" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20201231" decimals="-3" scale="3">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000886" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,809</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000869" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" scale="3">861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000875" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" scale="3">89</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000881" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000887" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" scale="3">950</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000870" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20201231" decimals="-3" scale="3">861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000876" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20201231" decimals="-3" scale="3">89</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000882" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000888" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20201231" decimals="-3" scale="3">950</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000871" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,685</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000877" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_20201231" decimals="-3" scale="3">93</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000883" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_20201231" decimals="-3" scale="3">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000889" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,759</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000604" name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000604_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do <ix:nonFraction unitRef="U_iso4217USD" id="F_000890" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction>t have debt securities classified as available-for-sale that were in an unrealized loss position as of June&#160;30,&#160;2021. Accumulated unrealized losses on debt securities that have been in a continuous loss position for less than 12&#160;months and more than 12&#160;months as of December&#160;31,&#160;2020 were as follows&#160;(in&#160;thousands): </p></ix:nonNumeric><ix:continuation id="F_000604_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 months</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than 12 months</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000892" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,762</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000894" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" scale="3">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000896" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000898" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000893" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,762</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000895" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="C_0001326110_20201231" decimals="-3" scale="3">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000897" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000899" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We evaluated our securities for other-than-temporary impairment, and we did <ix:nonFraction unitRef="U_iso4217USD" id="F_000900" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapDebtSecuritiesMember_20210101_20210630" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000901" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapDebtSecuritiesMember_20200101_20200630" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t recognize any other-than-temporary impairment losses for the six&#160;months ended June&#160;30,&#160;2021 and 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gains and losses on sales of available-for-sale debt securities were not significant for the six&#160;months ended June&#160;30,&#160;2021 and 2020.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000575_dcnt_2b37af82-067c-4627-bb8f-a628eb9d4b08">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Marketable E</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">quity</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> S</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ecurities</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We held investments in marketable equity securities with readily determinable fair values of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000902" name="us-gaap:AvailableForSaleSecuritiesEquitySecurities" contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630" decimals="-5" scale="6">19.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000903" name="us-gaap:AvailableForSaleSecuritiesEquitySecurities" contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-5" scale="6">6.3</ix:nonFraction>&#160;million as of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, respectively. Unrealized gains recorded on these securities totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000904" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210101_20210630" decimals="-5" scale="6">8.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000905" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20200101_20200630" decimals="-5" scale="6">0.5</ix:nonFraction>&#160;million in <span style="font-style:italic;">interest and investment (loss) income, net</span>, on the condensed consolidated statements of operations for the six&#160;months ended June&#160;30,&#160;2021 and 2020, respectively. We recorded a realized gain totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000906" name="us-gaap:DebtAndEquitySecuritiesRealizedGainLoss" contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210101_20210630" decimals="INF" scale="6">0.2</ix:nonFraction>&#160;million from sales of equity securities in <span style="font-style:italic;">interest and investment (loss) income, net</span>, on the condensed consolidated statements of operations for the six&#160;months ended June&#160;30,&#160;2021. </p></ix:continuation><ix:nonNumeric id="F_000576" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000576_dcnt_5d37ecc6-ab4b-422f-8749-9f95f880a04a">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N6___FAIR_VALUE_MEASUREMENTS">5. &#160;&#160;&#160;&#160;Fair Value Measurements</p><ix:nonNumeric id="F_000595" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The&#160;hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The three tiers are defined as follows:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level&#160;1&#8212;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level&#160;2&#8212;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities and corporate bonds, as well as foreign municipal securities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level&#160;3&#8212;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.</p></ix:nonNumeric>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recurring Valuations</p><ix:nonNumeric id="F_000605" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000605_dcnt_b72e59aa-f73d-400d-a049-691309073ca1">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities measured at fair value on a recurring basis are summarized below as of June&#160;30,&#160;2021 and December&#160;31,&#160;2020 (in&#160;thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="15" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="15" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000907" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">83,958</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000908" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">83,958</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000909" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000910" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000911" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,688</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000912" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,688</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000913" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000914" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000915" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" scale="3">244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000916" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" scale="3">244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000917" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000918" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000919" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210630" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000920" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210630" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000921" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000922" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000923" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" scale="3">822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000924" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" scale="3">822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000925" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000926" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000927" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">104,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000928" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">104,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000929" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000930" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000931" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" scale="3">854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000932" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000933" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000934" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" scale="3">854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000576_dcnt_5d37ecc6-ab4b-422f-8749-9f95f880a04a"><ix:continuation id="F_000605_dcnt_b72e59aa-f73d-400d-a049-691309073ca1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="15" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000935" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000936" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000937" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000938" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000939" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,772</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000940" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000941" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,772</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000942" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000943" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000944" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000945" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000946" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000947" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000948" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000949" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000950" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000951" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" scale="3">950</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000952" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" scale="3">950</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000953" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000954" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000955" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">97,011</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000956" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,239</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000957" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,772</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000958" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000959" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" scale="3">972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000960" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000961" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000962" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" scale="3">972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our equity securities include a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000963" name="us-gaap:AvailableForSaleSecuritiesEquitySecurities" contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210630" decimals="-5" scale="6">17.7</ix:nonFraction>&#160;million investment in Viracta Therapeutics,&#160;Inc. (&#8220;Viracta&#8221;), a clinical stage drug development company with whom we have an exclusive worldwide license to develop and commercialize one of their proprietary drug candidates. In February&#160;2021, Viracta merged with Sunesis Pharmaceuticals,&#160;Inc. (&#8220;Sunesis&#8221;), a public company. In connection with this transaction, our preferred stock investment in Viracta was converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000964" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapBusinessAcquisitionAxis_ibrxSunesisPharmaceuticalsIncMember_us-gaapEquityInterestIssuedOrIssuableByTypeAxis_us-gaapCommonStockMember_20210225_20210225" decimals="INF" format="ixt:numdotdecimal">1,562,604</ix:nonFraction>&#160;shares of Viracta common stock effective February&#160;25,&#160;2021.</span><span style="Background-color:#FFFFFF;color:#000000;"> Prior to the acquisition by Sunesis, we accounted for our investment in Viracta </span><span style="color:#000000;">by applying the measurement alternative under ASC&#160;321. As of December&#160;31,&#160;2020, the carrying value of our investment in Viracta, which was reflected in </span><span style="font-style:italic;color:#000000;">non-marketable equity investment</span><span style="color:#000000;">, on the condensed combined consolidated balance sheets, was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000965" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20201231" decimals="-5" scale="6">7.8</ix:nonFraction>&#160;million.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period until the related contingencies are resolved. The fair value measurements of these obligations are based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level&#160;3 measurement within the fair value hierarchy) and are reviewed periodically by management. See </span><a href="#N8___COMMITMENTS_CONTINGENCIES"><span style="text-decoration:underline;color:#000000;">Note&#160;7</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;color:#000000;">Commitments and Contingencies,</span><span style="color:#000000;"> for additional information.</span></p></td></tr></table></div></ix:continuation><ix:nonNumeric id="F_000606" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the carrying amount of contingent consideration obligations were as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value, beginning of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000966" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" sign="-" scale="3">972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000967" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in fair value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000968" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210101_20210630" decimals="-3" scale="3">118</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000969" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20200630" decimals="-3" scale="3">457</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.5pt;">
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value, end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000970" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630" decimals="-3" sign="-" scale="3">854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000971" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,268</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-recurring Valuations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-financial assets and liabilities are recognized at fair value subsequent to initial recognition when they are deemed to be other-than-temporarily impaired. There were no material non-financial assets and liabilities deemed to be other-than-temporarily impaired and measured at fair value on a non-recurring basis for the six&#160;months ended June&#160;30,&#160;2021 and 2020.</p></ix:continuation><ix:nonNumeric id="F_000577" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000577_dcnt_63f498ea-6b3c-4a4c-a286-3572b0989718">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N7___COLLABORATION_LICENSE_AGREEMENTS">6. &#160;&#160;&#160;&#160;Collaboration and License Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">National Cancer Institute</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2015, Etubics Corporation (&#8220;Etubics&#8221;) entered into a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) with the U.S. Department of Health and Human Services as represented by the National Cancer Institute (&#8220;NCI&#8221;) of the National Institutes of Health (&#8220;NIH&#8221;) to collaborate on the preclinical and clinical development of an adenovirus technology expressing tumor-associated antigens for cancer immunotherapy. In January&#160;2016, we acquired all of the outstanding equity interests in Etubics and Etubics became a wholly-owned subsidiary.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000577_dcnt_63f498ea-6b3c-4a4c-a286-3572b0989718" continuedAt="F_000577_dcnt_a0009937-4293-47bb-a702-334bd8657ff8">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 2018, we assumed the CRADA and it was amended to cover a collaboration for the preclinical and clinical development </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our proprietary yeast-based T</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">armogens expressing tumor-associated antigens and proprietary adenovirus technology expressing tumor-associated antigens for cancer immunotherapy. Pursuant to the CRADA, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IH</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> provides scientific staff and other support necessary to conduct research and related activities as described in the CRADA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of the CRADA, we are required to make annual payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000972" name="ibrx:AnnualPaymentForSupportOfResearchActivities" contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20180102_20180131" decimals="-5" scale="6">0.6</ix:nonFraction>&#160;million to the NIH for support of research activities. We made payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000973" name="ibrx:CashPaidToNIH" contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210101_20210630" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000974" name="ibrx:CashPaidToNIH" contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20200101_20200630" decimals="-5" scale="6">0.6</ix:nonFraction></ix:nonFraction>&#160;million in each of the six&#160;months ended June&#160;30,&#160;2021 and 2020, respectively, and recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000975" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210101_20210630" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000976" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20200101_20200630" decimals="-5" scale="6">0.3</ix:nonFraction></ix:nonFraction>&#160;million in <span style="font-style:italic;">research and development expense</span>, on the condensed consolidated statements of operations for the six&#160;months ended June&#160;30,&#160;2021 and 2020. The&#160;CRADA expires in May&#160;2023.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, we entered into an amendment to a CRADA with the NIH that was originally executed between the NIH and Amgen,&#160;Inc. (&#8220;Amgen&#8221;) in May&#160;2012 and subsequently assigned by Amgen to the company effective as of December&#160;17,&#160;2015. The research goal of this CRADA, as amended, is for the non-clinical and clinical development of ganitumab, our licensed monoclonal antibody targeting insulin-like growth factor&#160;one receptor, to evaluate its safety and efficacy in patients with hematological malignancies and solid tumors. The CRADA has a five-year term commencing on February&#160;20,&#160;2018 and expiring on February&#160;20,&#160;2023.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of the agreement, we are required to make minimum annual payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000977" name="ibrx:MinimumAnnualPaymentsForSupportOfResearchActivities" contextRef="C_0001326110_deiLegalEntityAxis_ibrxAmgenMember_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20180102_20180131" decimals="-5" scale="6">0.2</ix:nonFraction>&#160;million to the NIH for support of research activities and additional payments for the clinical trials based on the scope and phase of the clinical trials. Unpaid research and development expense was estimated at $<ix:nonFraction unitRef="U_iso4217USD" id="F_000978" name="ibrx:EstimatedUnpaidResearchAndDevelopmentExpense" contextRef="C_0001326110_deiLegalEntityAxis_ibrxAmgenMember_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210101_20210630" decimals="-5" scale="6">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000979" name="ibrx:EstimatedUnpaidResearchAndDevelopmentExpense" contextRef="C_0001326110_deiLegalEntityAxis_ibrxAmgenMember_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20200101_20201231" decimals="-5" scale="6">0.6</ix:nonFraction>&#160;million as of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2021, we entered into a CRADA with the NIH to conduct collaborative analysis of human clinical trial samples from clinical trials utilizing our proprietary recombinant NK&#160;cells and/or monoclonal antibodies (&#8220;mAbs&#8221;) for preclinical development in monotherapy and in combination immunotherapies. The CRADA has a two-year term commencing on February&#160;22,&#160;2021 and expiring on February&#160;22,&#160;2023. During the term of the agreement, we are required to provide $<ix:nonFraction unitRef="U_iso4217USD" id="F_000980" name="ibrx:AnnualPaymentForSupportOfResearchActivities" contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210222_20210222" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million per year to the NIH for support of the research activities. We made a payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000981" name="ibrx:CashPaidToNIH" contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210101_20210630" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million during the six&#160;months ended June&#160;30,&#160;2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All CRADA agreements may be terminated at any time upon the mutual written consent of the company and the NIH. Either party may unilaterally terminate either of the CRADAs at any time by providing written notice to the other party at least 60&#160;days before the desired termination date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the CRADAs, we have an option to elect to negotiate an exclusive or non-exclusive commercialization license to any inventions discovered in the performance of either of the CRADAs, whether solely by an NIH employee or jointly with a company employee for which a patent application has been filed. The parties jointly own any inventions and materials that are jointly produced by employees of both parties in the course of performing activities under the CRADAs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Infectious Disease Research Institute </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, we entered into license agreements with the Infectious Disease Research Institute (&#8220;IDRI&#8221;), pursuant to which we received licenses to certain of their platforms and formulations relevant to our product portfolio. Under the licenses, we were obligated to pay one-time, non-creditable, non-refundable upfront cash payments totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000982" name="ibrx:NonrefundableUpfrontPayment" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapTypeOfArrangementAxis_ibrxInfectiousDiseaseResearchInstituteMember_20210101_20210630" decimals="-5" scale="6">2.0</ix:nonFraction>&#160;million that we recorded in <span style="font-style:italic;">research and development expense</span>, on the condensed consolidated statements of operations for the six&#160;months ended June&#160;30,&#160;2021. In addition, we will owe IDRI milestone payments based on the achievement of certain development and regulatory milestones and royalties on net sales of licensed products. <ix:nonFraction unitRef="U_iso4217USD" id="F_000983" name="ibrx:MilestonePaymentAmount" contextRef="C_0001326110_us-gaapTypeOfArrangementAxis_ibrxInfectiousDiseaseResearchInstituteMember_20210101_20210630" decimals="INF" format="ixt-sec:numwordsen" scale="3">No</ix:nonFraction> milestone fees were incurred for the six&#160;months ended June&#160;30,&#160;2021. In connection with the license agreements, we also entered into a Sponsored Research Agreement (&#8220;SRA&#8221;) with IDRI pursuant to which we will fund continued research of at least $<ix:nonFraction unitRef="U_iso4217USD" id="F_000984" name="ibrx:MinimumAnnualPaymentsForSupportOfResearchActivities" contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ibrxSponsoredResearchAgreementMember_us-gaapTypeOfArrangementAxis_ibrxInfectiousDiseaseResearchInstituteMember_20210101_20210630" decimals="-6" scale="6">2</ix:nonFraction>&#160;million per year, payable in four&#160;equal quarterly installments each year until May&#160;2024, or such year of earlier termination. For the six&#160;months ended June&#160;30,&#160;2021, we recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000985" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ibrxSponsoredResearchAgreementMember_us-gaapTypeOfArrangementAxis_ibrxInfectiousDiseaseResearchInstituteMember_20210101_20210630" decimals="-5" scale="6">0.2</ix:nonFraction>&#160;million in <span style="font-style:italic;">research and development expense</span>, on the condensed consolidated statements of operations related to the SRA.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000577_dcnt_a0009937-4293-47bb-a702-334bd8657ff8">

<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">iosBio Ltd. Exclusive License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, we executed an exclusive license agreement with iosBio Ltd., formerly Stabilitech Biopharma Ltd. (&#8220;iosBio&#8221;), pursuant to which we and our affiliates will receive an exclusive, worldwide license to certain of iosBio&#8217;s intellectual property rights relating to the SARS-CoV-2 and successor vaccine candidates. In return, we are required to pay mid-to-high single-digit royalties on net sales of the resulting licensed products. Concurrently we entered into a non-exclusive license agreement with iosBio, which grants iosBio and its affiliates a non-exclusive, worldwide license for the intellectual property and technology relating to our adenovirus constructs for the prevention and treatment of shingles and other infectious disease targets to be mutually agreed by the parties in good faith. As of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, we accrued $<ix:nonFraction unitRef="U_iso4217USD" id="F_000986" name="ibrx:AccruedReimbursableCostsPayable" contextRef="C_0001326110_us-gaapTypeOfArrangementAxis_ibrxIosbioLtdExclusiveLicenseAgreementMember_20210630" decimals="-5" scale="6">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000987" name="ibrx:AccruedReimbursableCostsPayable" contextRef="C_0001326110_us-gaapTypeOfArrangementAxis_ibrxIosbioLtdExclusiveLicenseAgreementMember_20201231" decimals="-5" scale="6">0.5</ix:nonFraction>&#160;million payable, respectively, to iosBio for costs of supplies and reimbursable costs related to the clinical trial activities initiated by iosBio.</p></ix:continuation><ix:nonNumeric id="F_000578" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000578_dcnt_c71f1551-00b9-4305-b95f-21759a263ff0">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N8___COMMITMENTS_CONTINGENCIES">7. &#160;&#160;&#160;&#160;Commitments and Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingent Consideration Related to Business Combinations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">VivaBioCell, S.p.A.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;10, 2015, NantWorks,&#160;LLC (&#8220;NantWorks&#8221;), a related party, acquired a <ix:nonFraction unitRef="U_xbrlipure" id="F_000988" name="ibrx:PercentageOfWhollyOwnedSubsidiary" contextRef="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150410" decimals="INF" scale="-2">100</ix:nonFraction>%&#160;interest in VivaBioCell, S.p.A. (&#8220;VivaBioCell&#8221;) through its wholly-owned subsidiary, VBC&#160;Holdings, LLC, (&#8220;VBC&#160;Holdings&#8221;) for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000989" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150410_20150410" decimals="-5" scale="6">0.7</ix:nonFraction>&#160;million, less working capital adjustments. On June&#160;15,&#160;2015, NantWorks contributed its equity interest in VBC&#160;Holdings to the company, in exchange for cash consideration equal to its cost basis in the investment. VivaBioCell develops bioreactors and products based on cell culture and tissue engineering in Italy. In connection with this transaction, we are obligated to pay the former owners up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000990" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" contextRef="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150615_20150615" decimals="-5" scale="6">3.7</ix:nonFraction>&#160;million upon the achievement of certain sales milestones relating to scaffold technology and certain clinical and regulatory milestones relating to the GMP-in-a-Box technology. The fair value of the contingent consideration obligation decreased $<ix:nonFraction unitRef="U_iso4217USD" id="F_000991" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20210101_20210630" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million during the six&#160;months ended June&#160;30,&#160;2021 to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000992" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20210630" decimals="-5" scale="6">0.8</ix:nonFraction>&#160;million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Altor BioScience Corporation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our July&#160;2017 acquisition of Altor BioScience Corporation (&#8220;Altor&#8221;), we issued contingent value rights (&#8220;CVRs&#8221;) under which we agreed to pay the prior stockholders of Altor approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000993" name="ibrx:ContingentValueRightsPayable" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapContingentConsiderationByTypeAxis_ibrxContingentValueRightsPayableAtDecember312022Member_20210630" decimals="-5" scale="6">304.0</ix:nonFraction>&#160;million upon successful approval of the Biologics License Application (&#8220;BLA&#8221;) or foreign equivalent, for Anktiva by December&#160;31,&#160;2022 and approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000994" name="ibrx:ContingentValueRightsPayable" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapContingentConsiderationByTypeAxis_ibrxContingentValueRightsPayableBeforeDecember312026Member_20210630" decimals="-5" scale="6">304.0</ix:nonFraction>&#160;million upon the first calendar year before December&#160;31,&#160;2026 in which worldwide net sales of Anktiva exceed $<ix:nonFraction unitRef="U_iso4217USD" id="F_000995" name="ibrx:MinimumNetSalesMilestoneContingentValueRightsPayable" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapContingentConsiderationByTypeAxis_ibrxContingentValueRightsPayableBeforeDecember312026Member_20210101_20210630" decimals="-8" scale="9">1.0</ix:nonFraction>&#160;billion (with amounts payable in cash or shares of our common stock or a combination thereof). Dr.&#160;Soon-Shiong and his related party hold approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000996" name="ibrx:ContingentValueRightsPayable" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxDrSoonShiongAndPelatedPartyMember_20210630" decimals="-5" scale="6">279.5</ix:nonFraction>&#160;million in the aggregate of CVRs and they have both irrevocably agreed to receive shares of the company&#8217;s common stock in satisfaction of their CVRs. As the transaction was recorded as an asset acquisition, future CVR payments will be recorded when the corresponding events are probable of achievement or the consideration becomes payable.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Litigation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. We are aware of complaints that have been filed regarding the Merger, but we have not been served with any of such complaints. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Altor BioScience, LLC Litigation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, NantCell announced it had entered into a definitive merger agreement to acquire Altor BioScience Corporation. An action captioned Gray v.&#160;Soon-Shiong, et&#160;al. was filed in Delaware Chancery Court by plaintiffs Clayland Boyden Gray (&#8220;Gray&#8221;) and Adam R. Waldman. The plaintiffs, two&#160;minority stockholders, asserted claims against the company and other defendants for (1)&#160;breach of fiduciary duty and (2)&#160;aiding and abetting breach of fiduciary duty and filed a motion to enjoin the merger. The court denied the motion and permitted the merger to close. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsequent to the close of the merger, in&#160;2017 the plaintiffs (joined by two&#160;additional minority stockholders, Barbara Sturm Waldman and Douglas E. Henderson (&#8220;Henderson&#8221;)) filed a second&#160;amended complaint, asserting claims for (1)&#160;appraisal&#59; (2)&#160;quasi-appraisal&#59; (3)&#160;breach of fiduciary duty&#59; and (4)&#160;aiding and abetting breach of fiduciary duty. The defendants moved to dismiss the second&#160;amended complaint, raising grounds that included a &#8220;standstill&#8221; agreement under which defendants maintained that Gray and Adam R. Waldman and Barbara Strum Waldman (the &#8220;Waldmans&#8221;) agreed not to bring the lawsuit. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000578_dcnt_c71f1551-00b9-4305-b95f-21759a263ff0" continuedAt="F_000578_dcnt_939b3732-9f89-4a1d-b3c1-4bcc760caf29">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> second</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">action, Dyad Pharmaceutical Corporation, or Dyad, filed a petition </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in Delaware Chancery Court </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for appraisal in connection with the merger. Respondent moved to dismiss the appraisal petition </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018, arguing in part that the petition was barred by the same &#8220;standstill&#8221; agreement.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018, the court heard oral arguments on the motions to dismiss in both consolidated cases and converted the motions to dismiss into motions for summary judgment with regard to the &#8220;standstill&#8221; agreement argument, or the Converted Motions. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The court issued an oral ruling in 2019 that dismissed certain claims and dismissed Altor BioScience from the action. The following claims remain: (a)&#160;the appraisal claims by all plaintiffs and Dyad (against Altor BioScience,&#160;LLC), and (b)&#160;Henderson&#8217;s claims for breach of fiduciary duty and aiding and abetting breach of fiduciary duty. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, the court issued a written order implementing its ruling on the Converted Motions (the &#8220;Implementing Order&#8221;). In the Implementing Order, the court confirmed that all fiduciary duty claims brought by Gray, both individually and as trustee of the Gordon Gray Trust f/b/o C. Boyden Gray, were dismissed. Gray and the Waldmans filed answers denying the counterclaims and asserting defenses. The plaintiffs moved for leave to file a third&#160;amended complaint to add two&#160;former Altor stockholders as plaintiffs and a fiduciary duty claim on behalf of a purported class of former Altor stockholders, which the defendants opposed. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the court granted the plaintiffs&#8217; motion, and the plaintiffs filed a third&#160;amended complaint. In 2020, the defendants answered the third&#160;amended complaint and asserted counter claims against the plaintiffs. The defendants are seeking damages for attorneys&#8217; fees and costs incurred as a result of these breaches. The plaintiffs filed an answer denying the counterclaims and asserting defenses. The trial has been set to commence in October&#160;2021, but trial is likely to be continued until the second&#160;half of 2022.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The shares of these former Altor stockholders met the definition of dissenting shares under the merger agreement and were not entitled to receive any portion of the merger consideration at the closing date. However, these dissenting shares will automatically be converted to receive the portion of the merger consideration they were entitled to, on the later of the closing date or when the stockholder withdraws or loses the right to demand appraisal rights. Payment for dissenting shares will be on the same terms and conditions originally stated in the merger agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, we had accrued $<ix:nonFraction unitRef="U_iso4217USD" id="F_000997" name="ibrx:AccruedPaymentForDissentingShares" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceLLCMember_20210630" decimals="-5" scale="6">6.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000998" name="ibrx:AccruedPaymentForDissentingShares" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceLLCMember_20201231" decimals="-5" scale="6">6.8</ix:nonFraction>&#160;million related to these obligations, respectively. The accrued amount represents the estimated low-end of the range of currently estimated payout amounts in accordance with ASC Topic&#160;450, <span style="font-style:italic;">Contingencies</span>, after considering the reasonable outcomes for settling the dissenting stockholder dispute along with any accrued statutory interest. We cannot reasonably estimate a range of loss or likelihood of loss beyond the amounts recorded for dissenting shares as of June&#160;30,&#160;2021, as the dissenting stockholders have not yet provided a quantified value of their claim and, therefore, an upper end of the range of loss cannot be determined. Discovery is ongoing, and class certification motions relating to the putative class have not yet been filed or decided. We reassess the reasonableness of the recorded amount at each reporting period. We believe the claims lack merit and intend to continue defending the case vigorously.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sorrento Therapeutics, Inc. Litigation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;), derivatively on behalf of NANTibody, LLC (&#8220;NANTibody&#8221;), filed an action in the Superior Court of California, Los&#160;Angeles County (the &#8220;Superior Court&#8221;) against the company, Dr.&#160;Soon-Shiong and Charles&#160;Kim. The action alleged that the defendants improperly caused NANTibody to acquire IgDraSol,&#160;Inc. from our affiliate NantPharma,&#160;LLC (&#8220;NantPharma&#8221;) and sought to have the transaction undone and the purchase amount returned to NANTibody. In&#160;2019, we filed a demurrer to several causes of action alleged in the Superior Court action, and Sorrento filed an amended complaint, eliminating Mr.&#160;Kim as a defendant and dropping the causes of action we had challenged in our demurrer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sorrento filed a related arbitration proceeding, the Cynviloq arbitration, against Dr.&#160;Soon-Shiong and NantPharma&#59; the company is not named in the Cynviloq arbitration. In&#160;2020, the Superior Court granted Dr.&#160;Soon-Shiong&#8217;s request for a preliminary injunction barring Sorrento from pursuing claims against him in the Cynviloq arbitration. Sorrento then filed the claims it had previously asserted in arbitration against Dr.&#160;Soon-Shiong in the Superior Court, and at Sorrento&#8217;s request, the arbitrator entered an order dismissing Sorrento&#8217;s claims against Dr.&#160;Soon-Shiong in the Cynviloq arbitration. The hearing in the Cynviloq arbitration commenced in June&#160;2021, and is scheduled to continue with breaks until at least September&#160;2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also in 2019, the company and Dr.&#160;Soon-Shiong filed cross-claims in the Superior Court action against Sorrento and its Chief Executive Officer Henry&#160;Ji, asserting claims for fraud, breach of contract, breach of the covenant of good faith and fair dealing, tortious interference with contract, unjust enrichment, and declaratory relief. Our claims allege that Dr.&#160;Ji and Sorrento breached the terms of an exclusive license agreement between the company and Sorrento related to Sorrento&#8217;s antibody library and that Sorrento did not perform its obligations under the exclusive license agreement. The Superior Court ruled that the company&#8217;s claims should be pursued in arbitration and that Dr.&#160;Soon-Shiong&#8217;s claims could be pursued in Superior Court.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000578_dcnt_939b3732-9f89-4a1d-b3c1-4bcc760caf29" continuedAt="F_000578_dcnt_0877a95d-a364-4a80-b519-84000adfb729">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the company</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, along with NANTibody, filed an arbitration against Sorrento and Dr.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ji asserting </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> claims relating to the exclusive license agreement. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020, Sorrento sent letters purporting to terminate the exclusive license agreement with the company, and an exclusive license agreement with NANTibody and demanding the return of its confidential information and transfer of all regulatory filings and related materials. As required pursuant to the exclusive license agreements, both parties must engage in good-faith negotiations before attempting to invoke any termination provision contained in the agreement. Notwithstanding such negotiations, Sorrento sent a letter purporting to terminate the exclusive license agreements, maintaining the negotiations did not reach a successful resolution. We believe we have cured any perceived breaches during the 90-day contractual cure period provided under the agreements.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sorrento filed counterclaims against the company and NANTibody in the arbitration and requested leave to file a dispositive motion. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The hearings in the antibody arbitration commenced in April&#160;2021 and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">concluded in</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> early August&#160;2021.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Post-hearing briefing will be followed by concluding arguments on November&#160;10,&#160;2021.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to prosecute our claims, and to defend the claims asserted against us, vigorously. An estimate of the possible loss or range of loss cannot be made at this time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shenzhen Beike Biotechnology Corporation Litigation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration, served by Shenzhen Beike Biotechnology Corporation (&#8220;Beike&#8221;). The arbitration relates to a license, development, and commercialization agreement that Altor Bioscience Corporation (succeeded by our wholly-owned subsidiary Altor BioScience,&#160;LLC (&#8220;Altor&#8221;)) entered into with Beike in 2014, which agreement was amended and restated in 2017, pursuant to which Altor granted to Beike an exclusive license to use, research, develop and commercialize products based on Anktiva in China for human therapeutic uses. In the arbitration, Beike is asserting a claim for breach of contract under the license agreement. Among other things, Beike alleges that we failed to use commercially reasonable efforts to deliver to Beike materials and data related to Anktiva. Beike is seeking specific performance, or in the alternative, damages for the alleged breaches. On September&#160;25,&#160;2020, the parties entered into a standstill and tolling agreement under which, among other things, the parties affirmed they will perform certain of their obligations under the license agreement by specified dates and agreed that all deadlines in the arbitration are indefinitely extended. The standstill agreement may be terminated by any party on ten&#160;calendar days&#8217; notice, and upon termination, the parties will have the right to pursue claims arising from the license agreement in any appropriate tribunal. The parties have been asked to provide an update to the International Chamber of Commerce by August&#160;31,&#160;2021 of any further developments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given that this action remains at the pleading stage and no discovery has occurred, it remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the claims lack merit and intend to defend the case vigorously and that we may have counterclaims.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Fox Chase Litigation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;21,&#160;2020, ImmunityBio filed a declaratory judgment lawsuit in the Superior Court for San&#160;Diego County, California, naming Fox&#160;Chase Cancer Center Foundation and Institute for Cancer Research as the defendants&#160;(hereafter collectively &#8220;Fox&#160;Chase&#8221;). This litigation relates to the license with Fox&#160;Chase and includes various intellectual property rights (the&#160;&#8220;2004&#160;License&#8221;). Our initial court filing requested the Court to find that we have not breached material obligations under the 2004&#160;License and that Fox&#160;Chase has not and cannot terminate the 2004&#160;License. Fox&#160;Chase filed a Cross-Complaint raising a patent inventorship challenge and moved the case to federal court. On June&#160;4,&#160;2021, the federal court separated the parties&#8217; claims, and returned ImmunityBio&#8217;s declaratory judgment claims back to the San&#160;Diego County court while retaining the patent inventorship challenge. While the litigation is in the early stage, its outcome cannot be predicted. We do not consider the 2004&#160;License or the patent inventorship challenge to be material to our business.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Litigation Related to the Merger with ImmunityBio, Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Merger with <span style="letter-spacing:-0.05pt;">NantCell, Inc.&#160;(formerly known as ImmunityBio, Inc., a private company), a Delaware corporation, via a wholly-owned subsidiary of NantKwest&#160;(the &#8220;Merger&#160;Sub&#8221;), </span>seven&#160;complaints have been filed as individual actions in United States District Courts. Three&#160;complaints have been filed in the United States District Court for the District of Delaware against NantKwest and its directors and are captioned&#160;<span style="font-style:italic;">Hargett v. NantKwest, Inc., et al.</span>, 1:21&#8209;cv&#8209;00197&#160;(filed February&#160;11,&#160;2021) (the &#8220;Hargett Complaint&#8221;),&#160;<span style="font-style:italic;">Franchi v. NantKwest, Inc., et al.</span>, 1:21&#8209;cv&#8209;00218&#160;(filed February&#160;16,&#160;2021) (the&#160;&#8220;Franchi Complaint&#8221;), and <span style="font-style:italic;">Gross&#160;v.&#160;NantKwest,&#160;Inc., et al.</span>, 1:21&#8209;cv&#8209;00223&#160;(filed February&#160;17,&#160;2021) (the &#8220;Gross Complaint&#8221;). One&#160;complaint has been filed in the United States District Court for the Southern District of New York and is captioned <span style="font-style:italic;">Leaman&#160;v.&#160;NantKwest,&#160;Inc., et al.</span>, 1:21&#8209;cv&#8209;01351&#160;(filed February&#160;16,&#160;2021) (the&#160;&#8220;Leaman Complaint&#8221;). Two&#160;complaints have been filed in the United States District Court for the Southern District of California and are captioned <span style="font-style:italic;">Weiss&#160;v.&#160;NantKwest,&#160;Inc., et al.</span>, 3:21&#8209;cv&#8209;00280&#160;(filed February&#160;16,&#160;2021) (the&#160;&#8220;Weiss Complaint&#8221;) and <span style="font-style:italic;">Carlisle&#160;v.&#160;NantKwest,&#160;Inc., et al.</span>, 3:21&#8209;cv&#8209;00304&#160;(filed February&#160;19,&#160;2021) (the&#160;&#8220;Carlisle Complaint&#8221;). <span style="font-size:12pt;"><br /></span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000578_dcnt_0877a95d-a364-4a80-b519-84000adfb729" continuedAt="F_000578_dcnt_2f2b3d6e-991c-42d3-8278-13a83f01b1d6">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One&#160;complaint has been filed in the United States District Court for the Eastern District of New York and was captioned <span style="font-style:italic;">Shenk&#160;v.&#160;NantKwest,&#160;Inc., et al.</span>, 1:21&#8209;cv&#8209;00871&#160;(filed February&#160;18,&#160;2021) (the &#8220;Shenk Complaint,&#8221; and collectively with the Hargett Complaint, the &#8220;Franchi Complaint,&#8221; the Gross Complaint, the Leaman Complaint, the Weiss Complaint, and the Carlisle Complaint, the &#8220;Merger Actions&#8221;). The Shenk Complaint was voluntarily dismissed on March&#160;10,&#160;2021. The Franchi Complaint was voluntarily dismissed on May&#160;6,&#160;2021. The Leaman Complaint was voluntarily dismissed on May&#160;7,&#160;2021. The Hargett Complaint and the Gross Complaint were both voluntarily dismissed on May&#160;18,&#160;2021. The Hargett Complaint and the Gross Complaint also brought claims against ImmunityBio, and Merger&#160;Sub. The Merger Actions generally allege that the Definitive Proxy Statement filed with the SEC on February&#160;2,&#160;2021 misrepresents and/or omits certain purportedly material information relating to financial projections, analysis performed by the financial advisor to NantKwest&#8217;s Special Committee, alleged past engagements of the Special Committee&#8217;s financial advisor and industry consultant, and the terms of the engagement of such consultant. The Merger Actions assert violations of Sections&#160;14(a) of the Securities Exchange Act of&#160;1934, as amended (the&#160;&#8220;Exchange Act&#8221;), and Rule&#160;14a-9 promulgated thereunder against all defendants and violations of Section&#160;20(a) of the Exchange Act against NantKwest&#8217;s directors. The Merger Actions seek, among other things, an injunction enjoining the stockholder vote on the Merger and the consummation of the Merger unless and until certain additional information is disclosed to NantKwest&#8217;s stockholders, costs of the action, including plaintiffs&#8217; attorneys&#8217; fees and experts&#8217; fees, and other relief the Court may deem just and proper. Neither the stockholder vote on the Merger nor the Merger were enjoined and occurred on March&#160;8 and March&#160;9,&#160;2021, respectively. The company cannot predict the outcome of the Merger Actions. The company believes the Merger Actions are without merit and the company and the individual defendants intend to vigorously defend against the Merger Actions and any subsequently filed similar actions. If additional similar complaints are filed, absent new or significantly different allegations, the company will not necessarily disclose such additional filings.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. We have leases in multiple facilities across the U.S. and Italy, including El&#160;Segundo, California&#160;(general corporate and administrative activities, research and development and regulatory from related parties)&#59; San&#160;Diego, California&#160;(research facility and office space)&#59; Culver&#160;City, California&#160;(research and manufacturing space from a related party)&#59; Torrance, California&#160;(a research facility from a related party)&#59; Miramar, Florida&#160;(clinical development)&#59; Seattle, Washington&#160;(research and development)&#59; Louisville, Colorado&#160;(research and development and manufacturing)&#59; Woburn, Massachusetts&#160;(research facility)&#59; and Udine and Tavangnacco, Italy&#160;(GMP-in-a-Box, research facility and office space). See&#160;<a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;8</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Related-Party Agreements</span>, for further information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our leases generally have initial terms ranging from <span style="-sec-ix-hidden:F_000999">two to ten&#160;years</span> and often include one&#160;or more options to renew. These renewal terms can extend the lease term from <span style="-sec-ix-hidden:F_001001">one to five&#160;years</span>, and are included in the lease term when it is reasonably certain that we will exercise the option.</p><ix:nonNumeric id="F_000607" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000607_cnt_1">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information regarding our leases is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease term</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_001003" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001326110_20210630" format="ixt-sec:duryear">6.2</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_001004" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001326110_20201231" format="ixt-sec:duryear">3.9</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average discount rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001005" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001326110_20210630" decimals="2" scale="-2">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001006" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001326110_20201231" decimals="2" scale="-2">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric><ix:continuation id="F_000607_cnt_1" continuedAt="F_000607_cnt_2">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense consist of the following&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001007" name="us-gaap:OperatingLeaseCost" contextRef="C_0001326110_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,717</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001008" name="us-gaap:OperatingLeaseCost" contextRef="C_0001326110_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001009" name="us-gaap:OperatingLeaseCost" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,864</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001010" name="us-gaap:OperatingLeaseCost" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">3,406</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001011" name="us-gaap:VariableLeaseCost" contextRef="C_0001326110_20210401_20210630" decimals="-3" scale="3">517</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001012" name="us-gaap:VariableLeaseCost" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">726</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001013" name="us-gaap:VariableLeaseCost" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001014" name="us-gaap:VariableLeaseCost" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,574</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001015" name="us-gaap:LeaseCost" contextRef="C_0001326110_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,234</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001016" name="us-gaap:LeaseCost" contextRef="C_0001326110_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,350</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001017" name="us-gaap:LeaseCost" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,047</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001018" name="us-gaap:LeaseCost" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,980</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000578_dcnt_2f2b3d6e-991c-42d3-8278-13a83f01b1d6" continuedAt="F_000578_dcnt_a0defe66-31ef-498c-b48e-285bbdf08105">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000607_cnt_2">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities is as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows for operating leases</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001019" name="us-gaap:OperatingLeasePayments" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,004</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001020" name="us-gaap:OperatingLeasePayments" contextRef="C_0001326110_20200101_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,785</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000608" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments as of June&#160;30,&#160;2021, including $<ix:nonFraction unitRef="U_iso4217USD" id="F_001021" name="ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" contextRef="C_0001326110_20210101_20210630" decimals="-5" scale="6">12.6</ix:nonFraction>&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table&#160;(in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 (excluding the six months ended June 30, 2021)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001022" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="C_0001326110_20210630" decimals="-3" scale="3">834</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001023" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001024" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">7,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001025" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001026" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,467</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001027" name="ibrx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">15,729</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001028" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">44,110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001029" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">12,564</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001030" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">31,546</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In February 2021, but effective on January&#160;1,&#160;2021, we entered into a lease agreement with 605&#160;Nash, LLC, a related party, for a facility primarily used for pharmaceutical development and manufacturing purposes. </span>In May&#160;2021, but effective on April&#160;1,&#160;2021, we entered into an amendment to our lease agreement with 605&#160;Nash, LLC. See&#160;<a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;8</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;">Related-Party Agreements</span>, for further information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no other material changes related to our existing lease agreements from those disclosed in Note&#160;8 of the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019 (including NantCell,&#160;Inc.) filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Exhibit&#160;99.2</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Current Report on Form&#160;8&#8209;K/A filed with the SEC on April&#160;22,&#160;2021.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not enter into any significant contracts during the six&#160;months ended June&#160;30,&#160;2021, other than those disclosed in these condensed consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are also a party to various contracts with contract research organizations and contract manufacturers that generally provide for termination on notice, with the exact amounts in the event of termination to be based on the timing of the termination and the terms of the agreement. There have been no material changes in unconditional purchase commitments from those disclosed in Note&#160;8 of the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31, 2020 and December&#160;31,&#160;2019 (including NantCell,&#160;Inc.) filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Exhibit&#160;99.2</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Current Report on Form&#160;8&#8209;K/A filed with the SEC on April&#160;22,&#160;2021.</span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000578_dcnt_a0defe66-31ef-498c-b48e-285bbdf08105">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000579" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000579_dcnt_ba66e09d-f7fb-4d3d-99b7-2aa06294db7f">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N9___RELATED_PARTY_AGREEMENTS">8. &#160;&#160;&#160;&#160;Related-Party Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conduct business with several affiliates under written agreements and informal arrangements. <ix:nonNumeric id="F_000609" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000609_cnt_1">Below is a summary of outstanding balances and a description of significant relationships&#160;(in&#160;thousands):</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><ix:continuation id="F_000609_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related party&#8211;NantBio</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001031" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001032" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related party&#8211;NantOmics</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001033" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantOmicsLLCMember_20210630" decimals="-3" scale="3">591</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001034" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantOmicsLLCMember_20201231" decimals="-3" scale="3">591</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related parties&#8211;Various</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001035" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVariousMember_20210630" decimals="-3" scale="3">162</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001036" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVariousMember_20201231" decimals="-3" scale="3">118</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total due from related parties</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001037" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,047</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001038" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,003</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party&#8211;NantWorks</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001039" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">12,925</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001040" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,650</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party&#8211;Duley Road</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001041" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,427</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001042" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,787</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party&#8211;NantBio</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001043" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20210630" decimals="-3" scale="3">943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001044" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20201231" decimals="-3" scale="3">943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party&#8211;Immuno-Oncology Clinic</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001045" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicMember_20210630" decimals="-3" scale="3">229</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001046" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicMember_20201231" decimals="-3" scale="3">271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party&#8211;Various</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001047" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVariousMember_20210630" decimals="-3" scale="3">187</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001048" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVariousMember_20201231" decimals="-3" scale="3">187</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total due to related parties</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001049" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">16,711</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001050" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,838</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Executive Chairman, and principal stockholder, founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new genetically modified NK&#160;cells for our product pipeline. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NantWorks</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the NantWorks shared services agreement executed in November&#160;2015, but effective August&#160;2015, NantWorks, a related party, provides corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy, and other support services. We are charged for the services at cost plus reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the employees providing the services. For the three&#160;months ended June&#160;30,&#160;2021 and 2020, we recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_001051" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210401_20210630" decimals="-5" scale="6">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001052" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20200401_20200630" decimals="-5" scale="6">2.4</ix:nonFraction>&#160;million, respectively, in <span style="font-style:italic;">selling, general and administrative expense</span>, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001055" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210401_20210630" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001056" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20200401_20200630" decimals="-5" scale="6">0.2</ix:nonFraction>&#160;million, respectively, of expense reimbursements under this arrangement in <span style="font-style:italic;">research and development expense</span>, on the condensed consolidated statements of operations. For the six&#160;months ended June&#160;30,&#160;2021 and 2020, we recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_001053" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210101_20210630" decimals="-5" scale="6">3.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001054" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20200101_20200630" decimals="-5" scale="6">3.9</ix:nonFraction>&#160;million, respectively, in <span style="font-style:italic;">selling, general and administrative expense</span>, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001057" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210101_20210630" decimals="-5" scale="6">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001058" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20200101_20200630" decimals="-5" scale="6">1.2</ix:nonFraction>&#160;million, respectively, of expense reimbursements under this arrangement in <span style="font-style:italic;">research and development expense</span>, on the condensed consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third-party vendors directly for our benefit, which have been reimbursed to NantWorks based on those vendors&#8217; invoiced amounts without markup by NantWorks.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, we owed NantWorks a net amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001063" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_ibrxReimbursementsMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210630" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001059" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_ibrxReimbursementsMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210630" decimals="-5" scale="6">12.9</ix:nonFraction></ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001064" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_ibrxReimbursementsMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001060" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_ibrxReimbursementsMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20201231" decimals="-5" scale="6">10.7</ix:nonFraction></ix:nonFraction>&#160;million, respectively, for all agreements between the two&#160;affiliates, which is included in <span style="font-style:italic;">due to related parties,</span> on the condensed consolidated balance sheets. We also recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_001065" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210630" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001061" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210630" decimals="-5" scale="6">1.2</ix:nonFraction></ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001066" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001062" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20201231" decimals="-5" scale="6">1.1</ix:nonFraction></ix:nonFraction>&#160;million of prepaid expenses for services that have been passed through to the company from NantWorks as of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, respectively, which are included in <span style="font-style:italic;">prepaid expenses and other current assets</span>, on the condensed consolidated balance sheets.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000579_dcnt_ba66e09d-f7fb-4d3d-99b7-2aa06294db7f" continuedAt="F_000579_dcnt_86c0eba3-f91a-4e08-a97b-b2c1998285fd">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2015, we entered into a facility license agreement with NantWorks for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_001067" name="ibrx:NumberOfSquareFootOfFacilityLeased" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20151130" decimals="INF" format="ixt:numdotdecimal">9,500</ix:nonFraction>&#160;square feet of office space in Culver&#160;City, California, which has been converted to a research and development laboratory and a current Good Manufacturing Practice (&#8220;cGMP&#8221;) manufacturing facility. The initial license was effective from May&#160;2015 through December&#160;2020. The base rent for the initial lease term was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001068" name="ibrx:BaseMonthlyRent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20151101_20151130" decimals="0" format="ixt:numdotdecimal">47,000</ix:nonFraction> per month, with annual increases of 3% beginning in January&#160;2017. In September&#160;2020, we amended this agreement to extend the term of this lease through December&#160;31,&#160;2021. Commencing January&#160;1,&#160;2021, the base rent increased by 3% to approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001069" name="ibrx:BaseMonthlyRent" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentToExtendLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210101" decimals="0" format="ixt:numdotdecimal">54,500</ix:nonFraction> per month. Subsequent to December&#160;31,&#160;2021, the lease term will automatically renew on a month-to-month basis, terminable by either party with at least 30&#160;days&#8217; prior written notice to the other party. In addition, we have a one-time option to extend the lease term through December&#160;31,&#160;2022. If we exercise the option to extend the lease through December&#160;31,&#160;2022, or continue on a month-to-month basis, the base rent will increase by <ix:nonFraction unitRef="U_xbrlipure" id="F_001070" name="ibrx:AnnualPercentageIncreasesToBaseRent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20151101_20151130" decimals="2" scale="-2">3</ix:nonFraction>% annually commencing on January&#160;1 of each year. On the date of amendment, we recorded an increase of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001071" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentToExtendLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200901_20200930" decimals="-5" scale="6">1.2</ix:nonFraction>&#160;million in both <span style="font-style:italic;">operating lease right-of-use assets</span> and <span style="font-style:italic;">operating lease liabilities</span>, on the condensed consolidated balance sheets, reflecting our belief that we will extend the term of this lease through December&#160;31,&#160;2022. Lease expense for this facility totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_001072" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210630" decimals="-5" scale="6">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001073" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200101_20200630" decimals="-5" scale="6">0.3</ix:nonFraction>&#160;million for the six&#160;months ended June&#160;30,&#160;2021 and 2020, respectively, was recorded in <span style="font-style:italic;">research and development expense</span>, on the condensed consolidated statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Immuno-Oncology Clinic, Inc.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning in 2017, we entered into multiple agreements with Immuno-Oncology Clinic,&#160;Inc. (the&#160;&#8220;Clinic&#8221;) to conduct clinical trials related to certain of our product candidates. The&#160;Clinic is a related party as it is owned by an officer of the company and NantWorks manages the administrative operations of the&#160;Clinic. Prior to June&#160;30,&#160;2019, one of our officers was an investigator or sub-investigator for all of our trials conducted at the&#160;Clinic.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July&#160;2019, we entered into a new agreement with the&#160;Clinic (the&#160;&#8220;Clinic Agreement&#8221;), which became effective on July&#160;1,&#160;2019. The&#160;Clinic Agreement, as amended on March&#160;31,&#160;2020, covers clinical trial and research-related activities on a non-exclusive basis relating to our existing clinical trials, commenced prior to July&#160;1,&#160;2019, and prospective clinical trials and research projects. The&#160;Clinic Agreement also specifies certain services and related costs that are excluded from the&#160;Clinic Agreement. Prior to commencing any work under the&#160;Clinic Agreement, the parties have agreed to execute written work orders setting forth the terms and conditions related to specific services to be performed, including financial terms. For clinical trials that commenced prior to July&#160;1,&#160;2019, fees incurred for services performed after July&#160;1,&#160;2019 are covered under the&#160;Clinic Agreement and applied towards the below-mentioned prepayments. The&#160;Clinic Agreement allows for automatic renewal and additional extensions beyond the initial one-year term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of the services to be performed under the&#160;Clinic Agreement, as amended on March&#160;31,&#160;2020, we agreed to make payments of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_001074" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190701_20190731" decimals="-5" scale="6">7.5</ix:nonFraction>&#160;million to the&#160;Clinic, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_001075" name="ibrx:RelatedPartyInstallmentPayment" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190701_20190731" decimals="-4" scale="6">3.75</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001076" name="ibrx:RelatedPartyInstallmentPayment" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20191001_20191031" decimals="-4" scale="6">1.88</ix:nonFraction>&#160;million were paid in July&#160;2019 and October&#160;2019, respectively. As amended, a conditional payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001077" name="ibrx:RelatedPartyTransactionConditionalPayment" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190731" decimals="-4" scale="6">1.88</ix:nonFraction>&#160;million shall be due and payable at such time, if any, that the payments made in July&#160;2019 and October&#160;2019 have been earned by the&#160;Clinic through the performance of services. On a quarterly basis, our prepayment is increased by a nominal interest credit computed in accordance with terms specified in the&#160;Clinic Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent any portion of the prepayments remain unearned by the&#160;Clinic on the third anniversary of the&#160;Clinic Agreement, we may elect at our sole discretion either to (i)&#160;not extend the term of the&#160;Clinic Agreement and have the&#160;Clinic reimburse us for the total amount of any remaining unused portion of the prepayments, or (ii)&#160;extend the term of the&#160;Clinic Agreement for up to three&#160;additional one&#160;year periods, at which time the&#160;Clinic will reimburse us for the total amount of any remaining unused portion of the prepayments plus interest if reimbursement is not made within 60&#160;days of expiration. The&#160;Clinic may terminate this agreement upon each anniversary date upon 60&#160;days prior written notice and reimbursement in full to us of any outstanding unearned balance of the prepayments, provided that any such termination by the&#160;Clinic will not apply with respect to any work orders still in effect at the time of such termination.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We executed a clinical trial work order under the&#160;Clinic Agreement for an open-label, Phase&#160;I study of PD&#8209;L1.t&#8209;haNK for infusion in subjects with locally advanced or metastatic solid cancers. In July&#160;2020, but effective on June&#160;22,&#160;2020, we and NantCell executed a clinical trial work order under our existing master agreement with the&#160;Clinic for an open-label, randomized, comparative Phase&#160;II study of NantCell&#8217;s proprietary IL&#8209;15&#160;superagonist (&#8220;N&#8209;803&#8221;) and aldoxorubicin hydrochloride&#160;(&#8220;Aldoxorubicin&#8221;) and our PD&#8209;L1.t&#8209;haNK with standard-of-care chemotherapy versus standard-of-care chemotherapy for first and second-line treatment of locally or advanced metastatic pancreatic cancer.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000579_dcnt_86c0eba3-f91a-4e08-a97b-b2c1998285fd" continuedAt="F_000579_cnt_1">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April&#160;2021, ImmunityBio executed two&#160;work orders under an existing master agreement with </span><span style="Background-color:#FFFFFF;color:#000000;">the&#160;Clinic. Under these work orders, the parties agreed that the</span><span style="Background-color:#FFFFFF;color:#000000;">&#160;</span><span style="Background-color:#FFFFFF;color:#000000;">Clinic would serve as a site for the following multi-site clinical trials:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;">A Phase&#160;I study of the safety, reactogenicity, and immunogenicity of subcutaneously- and orally-administered supplemental spike &#38; nucleocapsid-targeted COVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="Background-color:#FFFFFF;">19 vaccine to enhance T&#160;cell-based immunogenicity in participants who have already received a vaccine authorized for emergency use&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;color:#000000;">A Phase&#160;I study of the safety, reactogenicity, and immunogenicity of a supplemental spike &#38; nucleocapsid-targeted COVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="Background-color:#FFFFFF;color:#000000;">19 vaccine to enhance T&#160;cell-based immunogenicity in participants who have already received a vaccine authorized for emergency use.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Based on a review of our updated clinical trial programs post-Merger, we updated our estimates of the investigator fees for the clinical trials currently underway or planned at the&#160;Clinic. As certain programs costs are excluded from and certain services are subject to credit adjustments under the&#160;Clinic Agreement, we determined the expected future fees for services to be performed are less than the carrying value of the prepaid asset on the condensed consolidated balance sheets. As a result, we partially wrote down the value of our prepayments under the&#160;Clinic Agreement and recorded approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001078" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210401_20210630" decimals="-5" scale="6">1.9</ix:nonFraction>&#160;million in </span><span style="font-style:italic;Background-color:#FFFFFF;">research and development expense</span><span style="Background-color:#FFFFFF;">, on the condensed consolidated statements of operations for the three&#160;months ended June&#160;30,&#160;2021. In addition</span><span style="color:#000000;">, we reclassified $<ix:nonFraction unitRef="U_iso4217USD" id="F_001079" name="ibrx:PrepaidExpensesAndOtherCurrentAssetsReclassified" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210630" decimals="-5" scale="6">0.9</ix:nonFraction>&#160;million of prepaid assets from </span><span style="font-style:italic;color:#000000;">prepaid expenses and other current assets</span><span style="color:#000000;"> to </span><span style="font-style:italic;color:#000000;">other assets,</span><span style="color:#000000;"> on the condensed consolidated balance sheets</span><span style="Background-color:#FFFFFF;"> as of June&#160;30,&#160;2021 based on the additional time expected for them to be realized than initially estimated</span><span style="color:#000000;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three&#160;months ended June&#160;30,&#160;2021 and 2020, we incurred $<ix:nonFraction unitRef="U_iso4217USD" id="F_001080" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210401_20210630" decimals="-5" scale="6">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001082" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20200401_20200630" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million in <span style="font-style:italic;">research and development expense</span>, on the condensed consolidated statements of operations related to the&#160;Clinic Agreement. For the six months ended June&#160;30, 2021 and 2020, we incurred $<ix:nonFraction unitRef="U_iso4217USD" id="F_001081" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210101_20210630" decimals="-5" scale="6">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001083" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20200101_20200630" decimals="-5" scale="6">0.2</ix:nonFraction> million in <span style="font-style:italic;">research and development expense</span>, on the condensed consolidated statements of operations related to the&#160;Clinic Agreement. As of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, we owed the&#160;Clinic $<ix:nonFraction unitRef="U_iso4217USD" id="F_001084" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210630" decimals="-5" scale="6">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001085" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20201231" decimals="-5" scale="6">0.3</ix:nonFraction>&#160;million, respectively, for services excluded from the&#160;Clinic Agreement. As of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, we had prepaid balances related to the&#160;Clinic Agreement of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001086" name="ibrx:PrepaidBalance" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210630" decimals="-5" scale="6">2.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001087" name="ibrx:PrepaidBalance" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20201231" decimals="-5" scale="6">4.7</ix:nonFraction>&#160;million, respectively. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NantBio, Inc.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2016, NantBio,&#160;Inc. (&#8220;NantBio&#8221;) and the NCI entered into a cooperative research and development agreement. The initial five-year agreement covered NantBio and its affiliates, including us. Under the agreement, the parties collaborated on the preclinical and clinical development of proprietary recombinant natural killer cells and monoclonal antibodies in monotherapy and combination immunotherapies. In each of the contractual years under the agreement we paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_001090" name="ibrx:PrepaymentOfFundingAmount" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20160301_20160331" decimals="-5" scale="6">0.6</ix:nonFraction>&#160;million to the NCI as a payment for services under the agreement. We recognize expense related to this agreement ratably over a 12-month period for each funding year. We accrued $<ix:nonFraction unitRef="U_iso4217USD" id="F_001088" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20210101_20210630" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001089" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20200101_20200630" decimals="-5" scale="6">0.2</ix:nonFraction></ix:nonFraction>&#160;million in <span style="font-style:italic;">research and development expense</span>, on the condensed consolidated statements of operations related to this agreement for the six&#160;months ended June&#160;30,&#160;2021 and 2020. As of December&#160;31,&#160;2020, we recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_001091" name="ibrx:PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20201231" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million in <span style="font-style:italic;">prepaid expenses and other current assets</span>, on the condensed consolidated balance sheets related to this agreement.</p></ix:continuation><ix:continuation id="F_000579_cnt_1" continuedAt="F_000579_dcnt_41e9a2f9-a72a-4c46-8134-4ec747b189ac">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, we entered into a supply agreement with NantCancerStemCell, LLC (&#8220;NCSC&#8221;), a 60% owned subsidiary of NantBio (with the other 40%&#160;owned by Sorrento). Under this agreement, we agreed to supply VivaBioCell&#8217;s proprietary GMP-in-a-Box bioreactors and related consumables, made according to specifications mutually agreed to with both companies. The agreement has an initial term of five&#160;years and renews automatically for successive one-year terms unless terminated by either party in the event of material default upon prior written notice of such default and the failure of the defaulting party to remedy the default within 30&#160;days of the delivery of such notice, or upon 90&#160;days&#8217; prior written notice by NCSC. We recognized revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001092" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210101_20210630" decimals="-5" scale="6">0.3</ix:nonFraction>&#160;million for the six&#160;months ended June&#160;30,&#160;2021. We recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_001093" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210630" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001095" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001094" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20200630" decimals="-5" scale="6">0.3</ix:nonFraction></ix:nonFraction>&#160;million of deferred revenue for bioreactors that were delivered but not installed as of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, respectively. As of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, we recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_001097" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001096" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210630" decimals="-5" scale="6">0.9</ix:nonFraction></ix:nonFraction>&#160;million in <span style="font-style:italic;">due to related parties</span>, on the condensed consolidated balance sheets related to this agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, we entered into a shared service agreement, pursuant to which, we are charged for services at cost, without mark-up or profit for NantBio, but including reasonable allocations of employee benefits that relate to the employees providing the services. In April&#160;2019, we agreed with NantBio to transfer certain NantBio employees and associated research and development projects, comprising the majority of NantBio&#8217;s business, to the company. After the transfer, NantBio continued to make payments on our behalf for certain employee benefits and vendor costs related to the research and development projects that were transferred to the company. In addition, we settled certain employee bonuses and benefits that were accrued by NantBio for 2018. As of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, we recorded a net receivable from NantBio of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001099" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioIncMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001098" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioIncMember_20210630" decimals="-5" scale="6">1.3</ix:nonFraction></ix:nonFraction>&#160;million, which included $<ix:nonFraction unitRef="U_iso4217USD" id="F_001101" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioIncMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001100" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioIncMember_20210630" decimals="-5" scale="6">1.0</ix:nonFraction></ix:nonFraction>&#160;million for employee bonuses and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001103" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVendorCostsPaymentsMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioIncMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001102" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVendorCostsPaymentsMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioIncMember_20210630" decimals="-5" scale="6">0.3</ix:nonFraction></ix:nonFraction>&#160;million for vendor costs we paid on behalf of NantBio.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000579_dcnt_41e9a2f9-a72a-4c46-8134-4ec747b189ac" continuedAt="F_000579_dcnt_b58216ce-cab7-484d-a41b-beee345ec923">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NantOmics</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, we made a strategic decision and transferred certain employees from NantOmics, LLC (&#8220;NantOmics&#8221;), a related party that is controlled by our Executive Chairman, to the company. After the transfer, we settled certain employee bonuses and benefits that were accrued by NantOmics for the year ended December&#160;31,&#160;2020 and recorded a $<ix:nonFraction unitRef="U_iso4217USD" id="F_001105" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantOmicsLLCMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001104" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantOmicsLLCMember_20210630" decimals="-5" scale="6">0.6</ix:nonFraction></ix:nonFraction>&#160;million receivable from NantOmics as of June&#160;30,&#160;2021 and December&#160;31,&#160;2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">605&#160;Doug&#160;St,&#160;LLC</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September&#160;2016, we entered into a lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Executive Chairman, for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_001106" name="ibrx:NumberOfSquareFootOfFacilityLeased" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20160930" decimals="0" format="ixt:numdotdecimal">24,250</ix:nonFraction>&#160;square feet in El&#160;Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease runs from July&#160;2016 through July&#160;2023. We have the option to extend the lease for an additional <span style="-sec-ix-hidden:F_001107">three-year</span> term through July&#160;2026. The base rent is approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001108" name="ibrx:BaseMonthlyRent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20160901_20160930" decimals="0" format="ixt:numdotdecimal">72,385</ix:nonFraction> per month, with annual increases of <ix:nonFraction unitRef="U_xbrlipure" id="F_001109" name="ibrx:AnnualPercentageIncreasesToBaseRent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20160901_20160930" decimals="2" scale="-2">3</ix:nonFraction>% that began in July&#160;2017. Lease expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001110" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210101_20210630" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001111" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20200101_20200630" decimals="-5" scale="6">0.4</ix:nonFraction></ix:nonFraction>&#160;million for this facility for the six&#160;months ended June&#160;30,&#160;2021 and 2020, respectively, was recorded in <span style="font-style:italic;">research and development expense</span>, on the condensed consolidated statements of operations. The prepaid rent for this lease was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001112" name="us-gaap:PrepaidRent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210630" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million, which was included in <span style="font-style:italic;">prepaid expenses and other current assets</span>, and the security deposit for this lease was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001113" name="us-gaap:SecurityDeposit" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210630" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million, which was included in <span style="font-style:italic;">other assets</span>, on the condensed consolidated balance sheets as of June&#160;30,&#160;2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Duley Road, LLC</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2017, Altor BioScience Corporation (succeeded by our wholly-owned subsidiary Altor BioScience,&#160;LLC), through its wholly-owned subsidiary, entered into a lease agreement with Duley Road,&#160;LLC (&#8220;Duley Road&#8221;), a related party that is indirectly controlled by our Executive Chairman, for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_001114" name="ibrx:NumberOfSquareFootOfFacilityLeased" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20170228" decimals="INF" format="ixt:numdotdecimal">12,000</ix:nonFraction>&#160;square feet of office and cGMP manufacturing facility space in El&#160;Segundo, California. The lease term is from February&#160;2017 through October&#160;2024. We have the option to extend the initial term for <ix:nonFraction unitRef="U_ibrxTerm" id="F_001122" name="ibrx:OptionsToExtendNumberOfTerms" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20170201_20170228" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction>&#160;consecutive <span style="-sec-ix-hidden:F_001121">five-year</span> periods through July&#160;2034. The base rent is approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001115" name="ibrx:BaseMonthlyRent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20170201_20170228" decimals="0" format="ixt:numdotdecimal">40,700</ix:nonFraction> per month, with annual increases of <ix:nonFraction unitRef="U_xbrlipure" id="F_001116" name="ibrx:AnnualPercentageIncreasesToBaseRent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20170201_20170228" decimals="2" scale="-2">3</ix:nonFraction>% that began in November&#160;2018. As of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, we recorded rent payable to Duley Road of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001117" name="us-gaap:AccruedRentCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapFairValueByLiabilityClassAxis_ibrxDueToRelatedPartiesMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20210630" decimals="-5" scale="6">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001118" name="us-gaap:AccruedRentCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapFairValueByLiabilityClassAxis_ibrxDueToRelatedPartiesMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20201231" decimals="-5" scale="6">1.0</ix:nonFraction>&#160;million, respectively. For the six&#160;months ended June&#160;30,&#160;2021 and 2020, we recorded rent expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001119" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20210101_20210630" decimals="-5" scale="6">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001120" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20200101_20200630" decimals="-5" scale="6">0.3</ix:nonFraction>&#160;million, respectively, which is reflected in <span style="font-style:italic;">research</span> <span style="font-style:italic;">and development expense</span>, on the condensed consolidated statements of operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective in January&#160;2019, we entered into two&#160;lease agreements with Duley Road for a second building located in El&#160;Segundo, California. The first lease is for the first floor of the building with approximately <ix:nonFraction unitRef="U_utrsqft" id="F_001123" name="ibrx:NumberOfSquareFootOfFacilityLeased" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSeptemberTwentyNineteenLeaseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20190930" decimals="0" format="ixt:numdotdecimal">5,650</ix:nonFraction>&#160;square feet. The lease has a seven-year&#160;term commencing in September&#160;2019. The second&#160;lease is for the second&#160;floor of the building with approximately <ix:nonFraction unitRef="U_utrsqft" id="F_001124" name="ibrx:NumberOfSquareFootOfFacilityLeased" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxJulyTwentyNineteenLeaseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20190731" decimals="0" format="ixt:numdotdecimal">6,488</ix:nonFraction>&#160;square feet. The lease has a seven-year term commencing in July&#160;2019. Both floors of the building are used for research and development and office space. We have options to extend the initial terms of both leases for <ix:nonFraction unitRef="U_ibrxTerm" id="F_001125" name="ibrx:OptionsToExtendNumberOfTerms" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSeptemberTwentyNineteenLeaseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20190901_20190930" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_ibrxTerm" id="F_001126" name="ibrx:OptionsToExtendNumberOfTerms" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxJulyTwentyNineteenLeaseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20190701_20190731" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></ix:nonFraction>&#160;consecutive <span style="-sec-ix-hidden:F_001127"><span style="-sec-ix-hidden:F_001128">five-year</span></span> periods through 2036. The base rent for the two&#160;leases is approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001129" name="ibrx:BaseMonthlyRent" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSeptemberTwentyNineteenLeaseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20190901_20190930" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_iso4217USD" id="F_001130" name="ibrx:BaseMonthlyRent" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxJulyTwentyNineteenLeaseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20190701_20190731" decimals="0" format="ixt:numdotdecimal">35,800</ix:nonFraction></ix:nonFraction> per month that increases at a rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_001131" name="ibrx:AnnualPercentageIncreasesToBaseRent" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSeptemberTwentyNineteenLeaseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20190901_20190930" decimals="2" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_001132" name="ibrx:AnnualPercentageIncreasesToBaseRent" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxJulyTwentyNineteenLeaseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20190701_20190731" decimals="2" scale="-2">3</ix:nonFraction></ix:nonFraction>%&#160;per year.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, we recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_001133" name="ibrx:LeaseholdImprovementPayables" contextRef="C_0001326110_us-gaapFairValueByLiabilityClassAxis_ibrxDueToRelatedPartiesMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20210630" decimals="-5" scale="6">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001134" name="ibrx:LeaseholdImprovementPayables" contextRef="C_0001326110_us-gaapFairValueByLiabilityClassAxis_ibrxDueToRelatedPartiesMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20201231" decimals="-5" scale="6">0.7</ix:nonFraction>&#160;million of leasehold improvement payables, respectively, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001135" name="ibrx:LeaseRelatedPayables" contextRef="C_0001326110_us-gaapFairValueByLiabilityClassAxis_ibrxDueToRelatedPartiesMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20210630" decimals="-5" scale="6">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001136" name="ibrx:LeaseRelatedPayables" contextRef="C_0001326110_us-gaapFairValueByLiabilityClassAxis_ibrxDueToRelatedPartiesMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20201231" decimals="-5" scale="6">1.1</ix:nonFraction>&#160;million of lease-related payables to Duley Road, which were included in <span style="font-style:italic;">due to related parties</span>, on the condensed consolidated balance sheets. For the six&#160;months ended June&#160;30,&#160;2021 and 2020, we recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_001137" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20210101_20210630" decimals="-5" scale="6">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001138" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20200101_20200630" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million of rent expense for the two&#160;leases, respectively, which was included in <span style="font-style:italic;">research and development expense</span>, on the condensed consolidated statements of operations. The security deposits for the leases totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_001139" name="us-gaap:SecurityDeposit" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxAltorBioScienceCorporationMember_20210630" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million as of June&#160;30,&#160;2021, which were included in <span style="font-style:italic;">other assets</span>, on the condensed consolidated balance sheets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">605 Nash, LLC</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In February 2021, but effective on January&#160;1,&#160;2021, we entered into a lease agreement with 605&#160;Nash, LLC, a related party, whereby we leased approximately <ix:nonFraction unitRef="U_utrsqft" id="F_001140" name="ibrx:NumberOfSquareFootOfFacilityLeased" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210228" decimals="INF" format="ixt:numdotdecimal">6,883</ix:nonFraction>&#160;square feet (the &#8220;Initial Premises&#8221;) in a two&#160;story mixed use building containing approximately 64,643&#160;rentable square feet on 605-607&#160;Nash Street in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease term commenced in January&#160;2021 and expires in December&#160;2027, and includes an option to extend the lease for <span style="-sec-ix-hidden:F_001141_2">an</span> additional <span style="-sec-ix-hidden:F_001142">three-year</span> term through December&#160;2030. The base rent is approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001143" name="ibrx:BaseMonthlyRent" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210201_20210228" decimals="0" format="ixt:numdotdecimal">20,300</ix:nonFraction>&#160;per month with an annual increase of&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_001144" name="ibrx:AnnualPercentageIncreasesToBaseRent" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210201_20210228" decimals="2" scale="-2">3</ix:nonFraction>% on January&#160;1 of each year during the initial term and, if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. We will receive a rent abatement for the first&#160;seven months, and a tenant improvement incentive of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001145" name="us-gaap:IncentiveFromLessor" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210228" decimals="-5" scale="6">0.3</ix:nonFraction>&#160;million from the landlord for </span>costs and expenses associated with the construction of tenant improvements for the Initial Premises. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000579_dcnt_b58216ce-cab7-484d-a41b-beee345ec923" continuedAt="F_000579_dcnt_d703ef85-2557-4aae-bcfd-0c393604d10d">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three&#160;months ended June&#160;30,&#160;2021, we completed the build out of certain facility space in connection with this lease and transferred costs totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_001146" name="us-gaap:LeaseholdImprovementsGross" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210630" decimals="-5" scale="6">8.2</ix:nonFraction>&#160;million from construction in progress to leasehold improvements. For<span style="Background-color:#FFFFFF;"> the three and six&#160;months ended June&#160;30,&#160;2021, we recorded rent expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001147" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210401_20210630" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001148" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapLeaseContractualTermAxis_ibrxInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210101_20210630" decimals="-5" scale="6">0.1</ix:nonFraction></ix:nonFraction>&#160;million, which is reflected in </span><span style="font-style:italic;Background-color:#FFFFFF;">research and development expense,</span><span style="Background-color:#FFFFFF;"> on the condensed consolidated statements of operations.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May&#160;2021, but effective on April&#160;1,&#160;2021, we entered into an amendment to our Initial Premises lease with 605&#160;Nash, LLC. The amendment expanded the leased square feet by approximately <ix:nonFraction unitRef="U_utrsqft" id="F_001149" name="ibrx:NumberOfSquareFootOfFacilityLeased" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentForExpansionOfPremisesLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210531" decimals="INF" format="ixt:numdotdecimal">57,760</ix:nonFraction>&#160;rentable square feet (the &#8220;Expansion Premises&#8221;). The lease term of the Expansion Premises commenced in April&#160;2021 and expires in March&#160;2028, whereby the company has the <span style="-sec-ix-hidden:F_001150_2">option</span> to extend the initial term for <span style="-sec-ix-hidden:F_001154">three&#160;years</span>. Per the terms of the amendment, the term of the Initial Premises lease was extended for an additional three&#160;months and now expires on March&#160;31,&#160;2028. Base rent for the Expansion Premises is approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001151" name="ibrx:BaseMonthlyRent" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentForExpansionOfPremisesLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210501_20210531" decimals="0" format="ixt:numdotdecimal">170,400</ix:nonFraction>&#160;per month with annual increases of&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_001152" name="ibrx:AnnualPercentageIncreasesToBaseRent" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentForExpansionOfPremisesLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210501_20210531" decimals="2" scale="-2">3</ix:nonFraction>% on April&#160;1 of each year. We are responsible for the build out of the facility space and associated costs. The amended lease provides for a rent abatement for the first <span style="-sec-ix-hidden:F_001155">seven&#160;month</span>s, and for a tenant improvement allowance of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001153" name="us-gaap:IncentiveFromLessor" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentForExpansionOfPremisesLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210531" decimals="-5" scale="6">2.6</ix:nonFraction>&#160;million for costs and expenses related to improvements made by us to the Expansion Premises. During the three and six&#160;months ended June&#160;30,&#160;2021, we incurred <span>$<ix:nonFraction unitRef="U_iso4217USD" id="F_001157" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapLeaseContractualTermAxis_ibrxAmendmentForExpansionOfPremisesLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210101_20210630" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001156" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapLeaseContractualTermAxis_ibrxAmendmentForExpansionOfPremisesLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210401_20210630" decimals="-5" scale="6">0.5</ix:nonFraction></ix:nonFraction></span>&#160;million of rent expense related to the Expansion Premises lease agreement. The security deposits for the leases total $<ix:nonFraction unitRef="U_iso4217USD" id="F_001158" name="us-gaap:SecurityDeposit" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapOtherAssetsMember_us-gaapLeaseContractualTermAxis_ibrxAmendmentForExpansionOfPremisesLeaseTermAndInitialPremisesMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210630" decimals="-5" scale="6">0.2</ix:nonFraction>&#160;million as of June&#160;30,&#160;2021, which are included in <span style="font-style:italic;">other assets</span>, on the condensed consolidated balance sheets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Related-Party Notes Payable</p><ix:nonNumeric id="F_000610" name="ibrx:ScheduleOfRelatedPartyNotesPayableTableTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000610_dcnt_e0f27f07-5002-478f-97cc-0b3ed3658373">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, related-party notes payable consist of the following (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="7" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Notes and Interest Payable</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Related-Party Notes Payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Advances</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nant Capital <span style="font-size:9pt;">(1)</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_001159" name="ibrx:RelatedPartyNotesPayableMaturity" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210101_20210630">2015</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001165" name="ibrx:RelatedPartyNotesPayable" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">55,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001172" name="us-gaap:RelatedPartyTransactionRate" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210101_20210630" decimals="INF" scale="-2">5.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001178" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">59,908</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001185" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">58,482</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nant Capital <span style="font-size:9pt;">(1)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_001160" name="ibrx:RelatedPartyNotesPayableMaturity" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalOneMember_20210101_20210630">2020</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001166" name="ibrx:RelatedPartyNotesPayable" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalOneMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">50,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001173" name="us-gaap:RelatedPartyTransactionRate" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalOneMember_20210101_20210630" decimals="INF" scale="-2">6.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001179" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalOneMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">52,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001186" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalOneMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">50,764</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nant Capital <span style="font-size:9pt;">(4)</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_001161" name="ibrx:RelatedPartyNotesPayableMaturity" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalTwoMember_20210101_20210630">2021</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001167" name="ibrx:RelatedPartyNotesPayable" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalTwoMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">40,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001174" name="us-gaap:RelatedPartyTransactionRate" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalTwoMember_20210101_20210630" decimals="INF" scale="-2">6.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001180" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalTwoMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">40,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001187" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalTwoMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NantMobile <span style="font-size:9pt;">(1)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_001162" name="ibrx:RelatedPartyNotesPayableMaturity" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210101_20210630">2019</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001168" name="ibrx:RelatedPartyNotesPayable" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">55,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001175" name="us-gaap:RelatedPartyTransactionRate" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210101_20210630" decimals="INF" scale="-2">3.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001181" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">57,502</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001188" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">56,660</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NantWorks <span style="font-size:9pt;">(1)</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_001163" name="ibrx:RelatedPartyNotesPayableMaturity" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210630">2017</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001169" name="ibrx:RelatedPartyNotesPayable" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">43,418</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001176" name="us-gaap:RelatedPartyTransactionRate" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210630" decimals="INF" scale="-2">5.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001182" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">52,791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001189" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,546</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NCSC <span style="font-size:9pt;">(1)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_001164" name="ibrx:RelatedPartyNotesPayableMaturity" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210101_20210630">2018</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001170" name="ibrx:RelatedPartyNotesPayable" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">33,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001177" name="us-gaap:RelatedPartyTransactionRate" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210101_20210630" decimals="INF" scale="-2">5.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001183" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">37,799</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001190" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,901</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total related-party notes payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001171" name="ibrx:RelatedPartyNotesPayable" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">276,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001184" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">300,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001191" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">254,353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">All outstanding advances and accrued and unpaid interest is due and payable on <ix:nonNumeric id="F_001192" name="ibrx:DateOutstandingAdvancesAndInterestPayableIsDue" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210101_20210630" format="ixt:datemonthdayyearen"><ix:nonNumeric id="F_001208" name="ibrx:DateOutstandingAdvancesAndInterestPayableIsDue" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210101_20210630" format="ixt:datemonthdayyearen">September&#160;30,&#160;2025</ix:nonNumeric></ix:nonNumeric>. Interest on related-party notes payable is compounded annually. We may prepay the outstanding principal at any time without premium, penalty or the prior consent of the issuer. All outstanding amounts under the notes become due and payable upon certain bankruptcy and insolvency-related events. There are no equity or equity-linked convertible rights related to these promissory notes.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Accrued and unpaid interest on this note totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_001193" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210630" decimals="-5" scale="6">4.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001194" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231" decimals="-5" scale="6">3.3</ix:nonFraction>&#160;million as of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, respectively.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Accrued and unpaid interest on this note totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_001195" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalOneMember_20210630" decimals="-5" scale="6">2.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001196" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalOneMember_20201231" decimals="-5" scale="6">0.8</ix:nonFraction>&#160;million as of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, respectively.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The outstanding principal is due and payable on <ix:nonNumeric id="F_001197" name="ibrx:DateOutstandingAdvancesAndInterestPayableIsDue" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalOneMember_20210101_20210630" format="ixt:datemonthdayyearen"><ix:nonNumeric id="F_001198" name="ibrx:DateOutstandingAdvancesAndInterestPayableIsDue" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalTwoMember_20210101_20210630" format="ixt:datemonthdayyearen"><ix:nonNumeric id="F_001202" name="ibrx:DateOutstandingAdvancesAndInterestPayableIsDue" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210101_20210630" format="ixt:datemonthdayyearen"><ix:nonNumeric id="F_001205" name="ibrx:DateOutstandingAdvancesAndInterestPayableIsDue" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210630" format="ixt:datemonthdayyearen">September&#160;30,&#160;2025</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>. Interest on this related-party note is compounded annually and payable quarterly commencing on June&#160;30,&#160;2021. We paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_001199" name="ibrx:CashPaidForInterestWithRelatedParty" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalTwoMember_20210401_20210630" decimals="-5" scale="6">0.8</ix:nonFraction>&#160;million in interest on this loan during the three&#160;months ended June&#160;30,&#160;2021. All outstanding amounts under the note become due and payable upon certain bankruptcy and insolvency-related events. There are no equity or equity-linked convertible rights related to this promissory note.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Accrued and unpaid interest on this note totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_001200" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210630" decimals="-5" scale="6">2.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001201" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20201231" decimals="-5" scale="6">1.7</ix:nonFraction>&#160;million as of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, respectively.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(6)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Accrued and unpaid interest on this note totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_001203" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210630" decimals="-5" scale="6">9.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001204" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20201231" decimals="-5" scale="6">8.1</ix:nonFraction>&#160;million as of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, respectively.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(7)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Accrued and unpaid interest on this note totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_001206" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210630" decimals="-5" scale="6">4.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001207" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20201231" decimals="-5" scale="6">3.9</ix:nonFraction>&#160;million as of June&#160;30,&#160;2021 and December&#160;31,&#160;2020, respectively.</span></p></td></tr></table></div></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000579_dcnt_d703ef85-2557-4aae-bcfd-0c393604d10d"><ix:continuation id="F_000610_dcnt_e0f27f07-5002-478f-97cc-0b3ed3658373">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.13%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div></ix:continuation></ix:continuation><ix:nonNumeric id="F_000581" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000581_dcnt_ec3c6d96-d11a-49b4-aa3f-efcafbe99141">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N10___STOCKHOLDERS_DEFICIT">9. &#160;&#160;&#160;&#160;Stockholders&#8217; Deficit</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Merger with NantCell</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Under the terms of the Merger Agreement, at the Effective Time of the Merger, each share of NantCell common stock</span>, par value $0.001&#160;per share, <span style="Background-color:#FFFFFF;">issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive <ix:nonFraction unitRef="U_xbrlipure" id="F_001209" name="ibrx:MergerExchangeRatio" contextRef="C_0001326110_20210309_20210309" decimals="4">0.8190</ix:nonFraction>&#160;newly issued shares of common stock</span>, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001210" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_20210309" decimals="INF">0.0001</ix:nonFraction>&#160;per share, resulting in the issuance of approximately <ix:nonFraction unitRef="U_xbrlishares" id="F_001211" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001326110_20210309_20210309" decimals="-5" scale="6">273.7</ix:nonFraction>&#160;million shares of Company Common Stock.<span style="Background-color:#FFFFFF;"> </span>From and after the Effective Time, all of such NantCell shares ceased to be outstanding, were canceled and ceased to exist. <span style="Background-color:#FFFFFF;">At the Effective Time, each share of our common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Merger has been accounted for as a transaction between entities under common control, the outstanding shares presented on the condensed consolidated financial statements assume that NantCell outstanding common stock was converted into shares of Company Common Stock for all periods presented, and in connection with the conversion, those shares of common stock have been recorded at the company&#8217;s par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001212" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_20210630" decimals="INF">0.0001</ix:nonFraction>&#160;per share. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Repurchases</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001214" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenShareRepurchasePlanMember_20210101_20210630" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_001215" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenShareRepurchasePlanMember_20200101_20200630" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction>&#160;shares of our common stock were repurchased during the six&#160;months ended June&#160;30, 2021 and 2020 under the company&#8217;s 2015&#160;Share Repurchase Program. As of June&#160;30,&#160;2021, $<ix:nonFraction unitRef="U_iso4217USD" id="F_001213" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenShareRepurchasePlanMember_20210630" decimals="-5" scale="6">18.3</ix:nonFraction>&#160;million remained authorized for repurchase under the program. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021, a total of approximately <ix:nonFraction unitRef="U_xbrlishares" id="F_001216" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandAndFifteenPlanMember_20210630" decimals="-5" scale="6">11.8</ix:nonFraction>&#160;million shares of common stock were reserved for issuance, <span style="Background-color:#FFFFFF;color:#000000;">including awards issued under the NC&#160;2015&#160;Plan that were outstanding immediately prior to the Effective Time of the Merger. </span>At the Effective Time, all outstanding equity awards granted under the NC&#160;2015&#160;Plan to purchase NantCell common stock were converted into equity awards to purchase shares of Company Common Stock (using the Exchange Ratio of <ix:nonFraction unitRef="U_xbrlipure" id="F_001217" name="ibrx:MergerExchangeRatio" contextRef="C_0001326110_20210309_20210309" decimals="4">0.8190</ix:nonFraction>), on the same terms and conditions as immediately prior to the Effective Time. As of June&#160;30,&#160;2021, there were approximately <ix:nonFraction unitRef="U_xbrlishares" id="F_001218" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210630" decimals="-5" scale="6">6.8</ix:nonFraction>&#160;million RSUs and <ix:nonFraction unitRef="U_xbrlishares" id="F_001219" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210630" decimals="-5" scale="6">0.7</ix:nonFraction>&#160;million stock options outstanding under the NC&#160;2015&#160;Plan, and there were <ix:nonFraction unitRef="U_xbrlishares" id="F_001220" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210630" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> additional shares available for future grant.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Open Market Sale Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;30,&#160;2021, we entered into an Open Market Sale Agreement (the &#8220;Sale Agreement&#8221;) with respect to an ATM&#160;offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_001221" name="ibrx:AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210430_20210430" decimals="INF" scale="6">500.0</ix:nonFraction>&#160;million through our sales agent. We pay our sales agent a commission of up to <ix:nonFraction unitRef="U_xbrlipure" id="F_001222" name="ibrx:PercentageOfSalesAgentCommission" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210430_20210430" decimals="3" scale="-2">3.0</ix:nonFraction>%&#160;of the gross sales proceeds of any shares of our common stock sold through them under the Sale Agreement, and also have provided them with customary indemnification and contribution rights.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three&#160;months ended June&#160;30,&#160;2021, we received net proceeds totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_001223" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001326110_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210401_20210630" decimals="-5" scale="6">94.9</ix:nonFraction>&#160;million from the issuance of <span style="-sec-ix-hidden:F_001224_2">6,420,441&#160;shares </span>under the ATM, which <span style="Background-color:#FFFFFF;color:#000000;">we expect to use for general corporate purposes, including to progress our clinical development programs, fund other research and development activities, for capital expenditures and to fund working capital. We may also use a portion of the net proceeds to license intellectual property or to make acquisitions or investments. </span>As of June&#160;30,&#160;2021, we had $<ix:nonFraction unitRef="U_iso4217USD" id="F_001225" name="ibrx:CommonStockValueAvailableForFutureStockIssuance" contextRef="C_0001326110_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210630" decimals="-5" scale="6">402.0</ix:nonFraction>&#160;million available for future stock issuances under the ATM.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not obligated to sell any shares and may at any time suspend solicitation and offers under the Sale Agreement. The Sale Agreement may be terminated by us at any time given written notice to the sales agent for any reason or by the sales agent at any time by giving written notice to us for any reason or immediately under certain circumstances, and shall automatically terminate upon the issuance and sale of all of the shares.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000581_dcnt_ec3c6d96-d11a-49b4-aa3f-efcafbe99141">
</ix:continuation><ix:nonNumeric id="F_000582" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000582_dcnt_6a196dbe-f088-4b93-a254-58145d57034f">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N11___STOCKBASED_COMPENSATION">10. &#160;&#160;&#160;&#160;Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2015 Equity Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July&#160;2015, the company&#8217;s board of directors adopted, and the company&#8217;s stockholders approved, the 2015&#160;Plan. Pursuant to the Merger, we assumed <ix:nonFraction unitRef="U_xbrlishares" id="F_001226" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20150701_20150731" decimals="INF" format="ixt:numdotdecimal">7,121,110</ix:nonFraction>&#160;RSUs (adjusted for the Exchange Ratio of <ix:nonFraction unitRef="U_xbrlipure" id="F_001227" name="ibrx:MergerExchangeRatio" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20150701_20150731" decimals="4">0.8190</ix:nonFraction>) issued under NantCell&#8217;s equity incentive plan. As of June&#160;30,&#160;2021, the 2015&#160;Plan is the only equity plan available for grant of equity awards to employees, directors and consultants of the company. As of June&#160;30,&#160;2021, a total of approximately <ix:nonFraction unitRef="U_xbrlishares" id="F_001228" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210630" decimals="INF" scale="6">5.9</ix:nonFraction>&#160;million shares were available for future grant under the 2015&#160;Plan.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-based Compensation</p><ix:nonNumeric id="F_000611" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents stock-based compensation included on the condensed consolidated statements of operations (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001229" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,610</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001230" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20200401_20200630" decimals="-3" scale="3">198</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001231" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">7,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001232" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20200101_20200630" decimals="-3" scale="3">328</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001233" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">16,253</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001234" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200401_20200630" decimals="-3" scale="3">124</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001235" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">25,196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001236" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200630" decimals="-3" scale="3">474</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001237" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">17,863</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001238" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001239" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">33,161</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001240" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">802</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense in operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001241" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">8,545</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001242" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200401_20200630" decimals="-3" sign="-" scale="3">53</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001243" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">11,433</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001244" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200630" decimals="-3" scale="3">108</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001245" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">9,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001246" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200401_20200630" decimals="-3" scale="3">375</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001247" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">21,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001248" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20200630" decimals="-3" scale="3">694</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001249" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">17,863</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001250" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_20200401_20200630" decimals="-3" scale="3">322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001251" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_20210101_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">33,161</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001252" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_20200101_20200630" decimals="-3" scale="3">802</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;18,&#160;2021, the Board of Directors approved to modify certain non-qualified stock options that were assumed in the Merger and otherwise would have expired during a period when the grantees were legally restricted from exercising these awards. The expiration date of these options was extended to thirty (30)&#160;days following the effective date of Post-Effective Amendment No.&#160;1 on Form&#160;S-3 to our Form&#160;S-4 Registration Statement. We recorded incremental stock-based compensation expense of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001254" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapNatureOfExpenseAxis_ibrxModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember_20210318_20210318" decimals="-5" scale="6">2.7</ix:nonFraction>&#160;million for this stock option modification.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;29,&#160;2021, in connection with the resignation of <ix:nonFraction unitRef="U_ibrxDirector" id="F_001256" name="ibrx:NumberOfBoardOfDirectors" contextRef="C_0001326110_20210101_20210630" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction>&#160;former independent directors, the Board of Directors approved the acceleration of vesting of <ix:nonFraction unitRef="U_xbrlishares" id="F_001257" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210329_20210329" decimals="INF" format="ixt:numdotdecimal">83,333</ix:nonFraction>&#160;shares of unvested stock options of the former directors on the date of their respective resignations. The modified options are exercisable for ninety (90)&#160;days after the date of the modification. We recorded incremental stock-based compensation expense of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001253" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_srtTitleOfIndividualAxis_ibrxNonEmployeeDirectorMember_us-gaapNatureOfExpenseAxis_ibrxModificationOfStockOptionsAssociatedWithResignationMember_20210101_20210630" decimals="-5" scale="6">2.3</ix:nonFraction>&#160;million for this stock option modification.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The stock option modifications were measured as the excess of the fair value of the modified awards over the fair value of the original awards immediately before the modifications. The incremental stock-based compensation was recorded in <span style="font-style:italic;">selling, general and administrative expense</span>, on the condensed consolidated statements of operations during the six&#160;months ended June&#160;30,&#160;2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p><ix:nonNumeric id="F_000612" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity and related information for the six&#160;months ended June&#160;30,&#160;2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001259" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="INF" format="ixt:numdotdecimal">4,996,284</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001265" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="2">9.96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001271" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,746</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001274">4.7</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001260" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="INF" format="ixt:numdotdecimal">1,069,940</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001266" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="2">21.38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_001261" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="INF" format="ixt:numdotdecimal">1,661,912</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001267" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="2">3.86</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired/forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_001262" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="INF" format="ixt:numdotdecimal">73,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001268" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="2">5.22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001263" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210630" decimals="INF" format="ixt:numdotdecimal">4,330,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001269" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210630" decimals="2">15.25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001272" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,012</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001275">5.7</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001264" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210630" decimals="INF" format="ixt:numdotdecimal">3,143,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001270" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210630" decimals="2">13.61</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001273" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">17,705</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001276">4.3</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000582_dcnt_6a196dbe-f088-4b93-a254-58145d57034f" continuedAt="F_000582_dcnt_6ec40b29-55b5-409d-a419-94899a76e290">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On<span style="letter-spacing:-0.2pt;"> </span>February<span style="letter-spacing:-0.15pt;">&#160;</span>5,&#160;2021, the<span style="letter-spacing:-0.2pt;"> </span>compensation<span style="letter-spacing:-0.15pt;"> </span>committee<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> the</span><span style="letter-spacing:-0.2pt;"> </span>board<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>directors<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> the c</span>ompany<span style="letter-spacing:-0.1pt;"> </span>granted<span style="letter-spacing:-0.15pt;"> </span>Richard<span style="letter-spacing:-0.15pt;"> </span>Adcock,<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.15pt;"> c</span>hief<span style="letter-spacing:-0.15pt;"> e</span>xecutive<span style="letter-spacing:-0.1pt;"> o</span><span style="letter-spacing:-0.05pt;">fficer, a stock option award</span><span style="letter-spacing:-0.15pt;"> </span>(the<span style="letter-spacing:-0.15pt;"> &#8220;</span>Option<span style="letter-spacing:-0.1pt;"> </span>Grant&#8221;)<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>purchase<span style="letter-spacing:-0.1pt;"> </span><ix:nonFraction unitRef="U_xbrlishares" id="F_001277" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205" decimals="INF" format="ixt:numdotdecimal">750,000</ix:nonFraction>&#160;shares<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:1.15pt;"> </span>common<span style="letter-spacing:-0.15pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>pursuant<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>2015&#160;Plan.<span style="letter-spacing:-0.15pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>Option<span style="letter-spacing:-0.15pt;"> </span>Grant<span style="letter-spacing:-0.1pt;"> </span>has<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>exercise<span style="letter-spacing:-0.15pt;"> </span>price<span style="letter-spacing:-0.15pt;"> </span>of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001278" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205" decimals="INF">23.72</ix:nonFraction>&#160;per share,<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>closing<span style="letter-spacing:-0.15pt;"> </span>price<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.1pt;"> </span>reported<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.1pt;"> the </span>Nasdaq<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>date<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>grant.<span style="letter-spacing:-0.15pt;"> </span>In<span style="letter-spacing:-0.1pt;"> </span>addition,<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Option<span style="letter-spacing:-0.1pt;"> </span>Grant<span style="letter-spacing:-0.15pt;"> </span>shall<span style="letter-spacing:-0.1pt;"> </span>vest<span style="letter-spacing:-0.1pt;"> </span>according<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>following<span style="letter-spacing:-0.15pt;"> </span>vesting<span style="letter-spacing:-0.1pt;"> </span>schedule:&#160;<ix:nonNumeric id="F_001279" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630">one-third<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Option<span style="letter-spacing:-0.1pt;"> </span>Grant <span style="letter-spacing:-0.05pt;">(i.e.,</span><span style="letter-spacing:-0.1pt;">&#160;</span>250,000&#160;options)<span style="letter-spacing:-0.15pt;"> </span>shall<span style="letter-spacing:-0.1pt;"> </span>vest<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>equal<span style="letter-spacing:-0.1pt;"> </span>installments<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>each<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>first,<span style="letter-spacing:-0.15pt;"> </span>second,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>anniversaries<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> date of </span>grant,<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>all<span style="letter-spacing:-0.15pt;"> </span>shares<span style="letter-spacing:-0.15pt;"> </span>shall<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>fully<span style="letter-spacing:-0.15pt;"> </span>vested<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>third&#160;anniversary<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> date of grant</span>,<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.6pt;">&#160;</span>Adcock<span style="letter-spacing:-0.1pt;"> </span>remaining<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> c</span>ontinuous<span style="letter-spacing:-0.1pt;"> s</span>ervice<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:1.05pt;"> </span>defined<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> 2015&#160;</span>Plan<span style="letter-spacing:-0.15pt;"> </span>through<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>applicable<span style="letter-spacing:-0.15pt;"> </span>vesting<span style="letter-spacing:-0.1pt;"> </span>dates.</ix:nonNumeric> This<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>equity<span style="letter-spacing:-0.1pt;"> </span>awards<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.55pt;">&#160;</span>Adcock<span style="letter-spacing:1.1pt;"> </span>was<span style="letter-spacing:-0.15pt;"> </span>made<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>connection<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>his<span style="letter-spacing:-0.15pt;"> </span>appointment<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.15pt;"> c</span>hief<span style="letter-spacing:-0.15pt;"> e</span>xecutive<span style="letter-spacing:-0.1pt;"> o</span><span style="letter-spacing:-0.05pt;">fficer</span><span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> c</span><span style="letter-spacing:-0.1pt;">ompany, </span>which<span style="letter-spacing:-0.15pt;"> </span>was<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">effective</span><span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>October<span style="letter-spacing:-0.1pt;">&#160;</span>26,&#160;2020,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>was<span style="letter-spacing:1.25pt;"> </span>modified<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>recommended<span style="letter-spacing:-0.15pt;"> </span>equity<span style="letter-spacing:-0.15pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>described<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.6pt;">&#160;</span><span style="letter-spacing:-0.1pt;">Adcock&#8217;s</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">offer</span><span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>employment<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;3,&#160;2021, the compensation committee of the board of directors of the company granted each of our newly-appointed independent directors a non-qualified stock option award to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_001280" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001326110_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210503_20210503" decimals="INF" format="ixt:numdotdecimal">21,873</ix:nonFraction>&#160;shares of our common stock pursuant to the 2015&#160;Plan at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001281" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001326110_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210503_20210503" decimals="INF">17.24</ix:nonFraction>&#160;per share, the closing price as reported on the Nasdaq on the date of grant. <ix:nonNumeric id="F_001282" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="C_0001326110_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630">The shares subject to the award will vest in three&#160;(3) equal installments on each of the first, second and third anniversary date of their appointment to the board of directors, such that the award will be fully vested on the third&#160;anniversary date in 2024, subject to the director continuing to be a service provider as defined in the 2015&#160;Plan through the applicable vesting dates.</ix:nonNumeric></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June&#160;10,&#160;2021, the compensation committee of the board of directors of the company granted our Chairman and each of the independent members of our board of directors a non-qualified stock option award to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_001283" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001326110_srtTitleOfIndividualAxis_srtBoardOfDirectorsChairmanMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210610_20210610" decimals="INF" format="ixt:numdotdecimal">26,064</ix:nonFraction>&#160;shares of our common stock pursuant to the 2015&#160;Plan at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001284" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001326110_srtTitleOfIndividualAxis_srtBoardOfDirectorsChairmanMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210610_20210610" decimals="INF">14.91</ix:nonFraction>&#160;per share, the closing price as reported on the Nasdaq on the date of grant. <ix:nonNumeric id="F_001285" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="C_0001326110_srtTitleOfIndividualAxis_srtBoardOfDirectorsChairmanMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630">The shares subject to the award will vest 100% on the earlier to occur of June&#160;10,&#160;2022 or the date immediately preceding the 2022&#160;annual meeting of stockholders, subject to the recipient continuing to be a service provider as defined in the 2015&#160;Plan through the applicable vesting date.</ix:nonNumeric> These grants were made in connection with the re-election of our Executive Chairman and independent directors to the company&#8217;s board of directors at the 2021 annual meeting of stockholders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021, the unrecognized compensation cost related to outstanding stock options was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001286" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210630" decimals="-5" scale="6">16.2</ix:nonFraction>&#160;million, which is expected to be recognized over a remaining weighted-average period of <ix:nonNumeric id="F_001287" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" format="ixt-sec:duryear">2.4</ix:nonNumeric>&#160;years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total intrinsic value of stock options exercised during the six&#160;months ended June&#160;30,&#160;2021 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001289" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="-5" scale="6">20.6</ix:nonFraction>&#160;million. Cash proceeds received from stock option exercises during the six&#160;months ended June&#160;30,&#160;2021 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001288" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="-5" scale="6">4.4</ix:nonFraction>&#160;million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,&#160;2020, a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_001290" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="INF" format="ixt:numdotdecimal">4,345,497</ix:nonFraction>&#160;vested and exercisable shares were outstanding.</p><ix:nonNumeric id="F_000613" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of stock options issued was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001291">5.9</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001292" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="3" scale="-2">0.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001293" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="3" scale="-2">101.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001294" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average grant date fair value</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001295" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210630" decimals="2">16.80</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expected term was estimated using the average of the contractual term and the weighted-average vesting term of the options. The risk-free interest rate was based on the U.S.&#160;Treasury&#8217;s rates for U.S.&#160;Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The expected volatility was estimated based on the historical volatility of our common stock. The assumed dividend yield was based on our expectation of not paying dividends in the foreseeable future.</p><ix:nonNumeric id="F_000614" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000614_dcnt_052a67d4-a5fb-41a5-a54e-e52d8cd06c9c"></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000582_dcnt_6ec40b29-55b5-409d-a419-94899a76e290" continuedAt="F_000582_dcnt_64475702-0cae-440a-868f-2377b6a40cb4"><ix:continuation id="F_000614_dcnt_052a67d4-a5fb-41a5-a54e-e52d8cd06c9c">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes RSU activity during the six&#160;months ended June&#160;30,&#160;2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested balance at December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001296" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="INF" format="ixt:numdotdecimal">466,842</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001301" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="2">2.52</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001297" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210630" decimals="INF" format="ixt:numdotdecimal">7,643,955</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001302" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210630" decimals="2">25.23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_001298" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210630" decimals="INF" format="ixt:numdotdecimal">336,084</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001303" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210630" decimals="2">11.78</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_001299" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210630" decimals="INF" format="ixt:numdotdecimal">331,209</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001304" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210630" decimals="2">23.91</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested balance at June&#160;30, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001300" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210630" decimals="INF" format="ixt:numdotdecimal">7,443,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001305" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210630" decimals="2">24.47</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001306" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210630" decimals="-5" scale="6">159.9</ix:nonFraction>&#160;million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of <ix:nonNumeric id="F_001307" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210630" format="ixt-sec:duryear">3.9</ix:nonNumeric>&#160;years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may grant RSUs to both employees and directors of the company and to employees of related parties that provide shared services to the company under our shared services agreement with NantWorks as discussed in <a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;8</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;">Related-Party Agreements</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On<span style="letter-spacing:-0.2pt;"> </span>February<span style="letter-spacing:-0.15pt;">&#160;</span>5,<span style="letter-spacing:-0.15pt;"> </span>2021, the<span style="letter-spacing:-0.2pt;"> </span>compensation<span style="letter-spacing:-0.15pt;"> </span>committee<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> the</span><span style="letter-spacing:-0.2pt;"> </span>board<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>directors<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> the c</span>ompany<span style="letter-spacing:-0.1pt;"> </span>granted<span style="letter-spacing:-0.15pt;"> </span>Mr.&#160;Adcock<span style="letter-spacing:-0.1pt;"> </span><ix:nonFraction unitRef="U_ibrxAward" id="F_001309" name="ibrx:NumberOfAwardsGranted" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction><span style="letter-spacing:-0.1pt;">&#160;</span>awards<span style="letter-spacing:-0.15pt;"> </span>totaling<span style="letter-spacing:-0.15pt;"> </span><ix:nonFraction unitRef="U_xbrlishares" id="F_001308" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205" decimals="INF" format="ixt:numdotdecimal">400,000</ix:nonFraction><span style="letter-spacing:-0.15pt;">&#160;</span>RSUs<span style="letter-spacing:-0.15pt;"> </span>(each<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>&#8220;RSU<span style="letter-spacing:-0.15pt;"> Award&#8221;</span><span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">collectively,</span><span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>&#8220;RSU<span style="letter-spacing:-0.15pt;"> Awards&#8221;) </span>of<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>common<span style="letter-spacing:-0.1pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>pursuant<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> 2015&#160;</span>Plan.<span style="letter-spacing:-0.1pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>RSU<span style="letter-spacing:-0.1pt;">&#160;</span><span style="letter-spacing:-0.15pt;">Awards </span>are<span style="letter-spacing:-0.1pt;"> </span>comprised<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>two&#160;separate<span style="letter-spacing:-0.15pt;"> </span>awards,<span style="letter-spacing:-0.1pt;"> </span>one<span style="letter-spacing:-0.15pt;"> </span>settled<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>issuing<span style="letter-spacing:-0.15pt;"> </span><ix:nonFraction unitRef="U_xbrlishares" id="F_001310" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxFirstRSUAwardMember_20210205_20210205" decimals="INF" format="ixt:numdotdecimal">150,000</ix:nonFraction><span style="letter-spacing:-0.1pt;">&#160;</span>shares<span style="letter-spacing:1.05pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>common<span style="letter-spacing:-0.1pt;"> </span>stock<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>settled<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>issuing<span style="letter-spacing:-0.1pt;"> </span><ix:nonFraction unitRef="U_xbrlishares" id="F_001311" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxSecondRSUAwardMember_20210205_20210205" decimals="INF" format="ixt:numdotdecimal">250,000</ix:nonFraction><span style="letter-spacing:-0.15pt;">&#160;</span>shares<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>common<span style="letter-spacing:-0.1pt;"> </span>stock<span style="letter-spacing:-0.1pt;"> </span>upon<span style="letter-spacing:-0.15pt;"> </span>vesting.<span style="letter-spacing:-0.1pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>first<span style="letter-spacing:-0.1pt;"> </span>RSU<span style="letter-spacing:-0.1pt;">&#160;</span><span style="letter-spacing:-0.2pt;">Aw</span><span style="letter-spacing:-0.25pt;">a</span><span style="letter-spacing:-0.2pt;">rd</span><span style="letter-spacing:-0.1pt;"> </span>vested<span style="letter-spacing:1.15pt;"> </span>immediately<span style="letter-spacing:1.15pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> date of grant </span>with<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> c</span>ompany<span style="letter-spacing:-0.15pt;"> </span>retaining<span style="letter-spacing:-0.1pt;"> </span>shares<span style="letter-spacing:-0.15pt;"> </span>equal<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>value<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> c</span><span style="letter-spacing:-0.1pt;">ompany&#8217;s</span><span style="letter-spacing:-0.15pt;"> </span>tax<span style="letter-spacing:-0.1pt;"> </span>withholding<span style="letter-spacing:-0.15pt;"> </span>obligations. The<span style="letter-spacing:-0.15pt;"> </span>second<span style="letter-spacing:-0.1pt;"> </span>RSU<span style="letter-spacing:-0.15pt;">&#160;</span><span style="letter-spacing:-0.2pt;">Aw</span><span style="letter-spacing:-0.25pt;">a</span><span style="letter-spacing:-0.2pt;">rd</span><span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>vest<span style="letter-spacing:1.1pt;"> </span>according<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>following<span style="letter-spacing:-0.15pt;"> </span>schedule:<span style="letter-spacing:-0.1pt;">&#160;</span>one-third<span style="letter-spacing:-0.15pt;"> </span>(i.e.<span style="letter-spacing:-0.1pt;">&#160;</span><ix:nonFraction unitRef="U_xbrlishares" id="F_001312" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210205_20210205" decimals="INF" format="ixt:numdotdecimal">83,333</ix:nonFraction>)<span style="letter-spacing:-0.15pt;">&#160;</span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>shares<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>RSU<span style="letter-spacing:-0.1pt;">&#160;</span><span style="letter-spacing:-0.2pt;">Aw</span><span style="letter-spacing:-0.25pt;">a</span><span style="letter-spacing:-0.2pt;">rd</span><span style="letter-spacing:-0.15pt;"> </span>shall<span style="letter-spacing:-0.1pt;"> </span>vest<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>equal<span style="letter-spacing:-0.15pt;"> </span>annual<span style="letter-spacing:-0.1pt;"> </span>installments<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>each<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>first,<span style="letter-spacing:-0.15pt;"> </span>second<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>third&#160;anniversaries<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> date of grant</span>,<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>shares<span style="letter-spacing:-0.1pt;"> </span>shall<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>fully<span style="letter-spacing:-0.15pt;"> </span>vested<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>third&#160;anniversary<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> date of g</span>rant,<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.1pt;"> </span>to <span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.6pt;">&#160;</span>Adcock<span style="letter-spacing:-0.1pt;"> </span>remaining<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> c</span>ontinuous<span style="letter-spacing:-0.1pt;"> s</span>ervice<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>defined<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> 2015&#160;</span>Plan<span style="letter-spacing:-0.1pt;"> </span>through<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>applicable<span style="letter-spacing:-0.1pt;"> </span>vesting<span style="letter-spacing:-0.15pt;"> </span>dates.<span style="letter-spacing:-0.15pt;"> </span>This<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>equity<span style="letter-spacing:-0.1pt;"> </span>awards<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.55pt;">&#160;</span>Adcock<span style="letter-spacing:1.1pt;"> </span>was<span style="letter-spacing:-0.15pt;"> </span>made<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>connection<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>his<span style="letter-spacing:-0.15pt;"> </span>appointment<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.15pt;"> c</span>hief<span style="letter-spacing:-0.15pt;"> e</span>xecutive<span style="letter-spacing:-0.1pt;"> o</span><span style="letter-spacing:-0.05pt;">fficer</span><span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> c</span><span style="letter-spacing:-0.1pt;">ompany, </span>which<span style="letter-spacing:-0.15pt;"> </span>was<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">effective</span><span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>October<span style="letter-spacing:-0.1pt;">&#160;</span>26,&#160;2020,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>was<span style="letter-spacing:1.25pt;"> </span>modified<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>recommended<span style="letter-spacing:-0.15pt;"> </span>equity<span style="letter-spacing:-0.15pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>described<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.6pt;">&#160;</span><span style="letter-spacing:-0.1pt;">Adcock&#8217;s</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">offer</span><span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>employment<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;4,&#160;2021, prior to the Merger, NantCell awarded <ix:nonFraction unitRef="U_xbrlishares" id="F_001313" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210304_20210304" decimals="INF" format="ixt:numdotdecimal">7,121,110</ix:nonFraction>&#160;RSUs (adjusted for the Exchange Ratio of <ix:nonFraction unitRef="U_xbrlipure" id="F_001314" name="ibrx:MergerExchangeRatio" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210304_20210304" decimals="4">0.8190</ix:nonFraction>) to employees and consultants of NantCell and its affiliated companies, pursuant to the NC&#160;2015&#160;Plan. These RSU awards were subject to a performance condition in connection with a &#8220;Liquidity Event&#8221;, defined as either (i)&#160;NantCell&#8217;s registration of shares for issuance on a securities offering or (ii)&#160;the closing of a corporate transaction. In addition, the vesting of certain performance-based RSU grants accelerates upon obtaining approval by the FDA of a BLA or equivalent application for approval of Anktiva for use in the treatment of non-muscle-invasive bladder cancer. These performance-based RSUs are also subject to service conditions and are scheduled to cliff vest on the last date of each tranche as defined by the individual grant agreements. On March&#160;9,&#160;2021, we completed the Merger with NantCell, and the performance condition related to the Liquidity Event was met.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the RSUs was estimated based on a third-party valuation as of the grant date of March&#160;4,&#160;2021 and was derived primarily from the estimated probabilities of the Merger close on March&#160;9,&#160;2021 and the other exit assumptions. Once the liquidity event related performance condition was met as of March&#160;9,&#160;2021 due to the Merger, compensation expense for these RSUs began to be recognized on a graded vesting attribution approach over the requisite service period for each participant, which ranges from <span style="-sec-ix-hidden:F_001315">six-month</span> to seventy&#160;(70)-month vesting periods. During the six&#160;months ended June&#160;30,&#160;2021, we recorded approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001317" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210630" decimals="-5" scale="6">21.1</ix:nonFraction>&#160;million of stock-based compensation expense related to these awards, of which approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001318" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210630" decimals="-5" scale="6">11.3</ix:nonFraction>&#160;million was recorded in <span style="font-style:italic;">research and development expense</span> and approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001319" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210630" decimals="-5" scale="6">9.8</ix:nonFraction>&#160;million was recorded in <span style="font-style:italic;">selling, general and administrative expense</span>, on the condensed consolidated statements of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RSUs awarded to employees and consultants of affiliated companies were accounted for as stock-based compensation in accordance with ASU&#160;2018-07, <span style="font-style:italic;">Compensation&#8212;Stock Compensation (Topic&#160;718)</span>, as the compensation was in exchange for continued support or services expected to be provided to the company over the vesting periods under the NantWorks shared services agreement discussed in <a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;8</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;">Related-Party Agreements</span>. We have evaluated the associated benefit of these awards to the affiliated companies under common control and determined that the benefit is limited to the retention of their employees. We estimated such benefit at the grant date fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001320" name="ibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" contextRef="C_0001326110_20210101_20210630" decimals="-5" scale="6">4.0</ix:nonFraction>&#160;million and recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_001321" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="C_0001326110_20210101_20210630" decimals="-5" scale="6">0.5</ix:nonFraction>&#160;million of deemed dividends for the six&#160;months ended June&#160;30,&#160;2021 in <span style="font-style:italic;">additional paid-in capital,</span> on the condensed consolidated balance sheets, with a corresponding credit to stock compensation expense.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000582_dcnt_64475702-0cae-440a-868f-2377b6a40cb4" continuedAt="F_000582_cnt_1">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Warrants</p></ix:continuation><ix:continuation id="F_000582_cnt_1">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Merger, warrants issued to NantWorks, a related party, in connection with NantCell&#8217;s acquisition of Altor were assumed by the company. After applying the Exchange Ratio at the Effective Time of the Merger, a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_001322" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001326110_us-gaapAwardTypeAxis_ibrxWarrantsMember_20210630" decimals="INF" format="ixt:numdotdecimal">1,638,000</ix:nonFraction>&#160;warrants with an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001323" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001326110_20210630" decimals="2">3.24</ix:nonFraction>&#160;per share were outstanding as of June&#160;30,&#160;2021. The fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001324" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" contextRef="C_0001326110_20210630" decimals="-5" scale="6">18.0</ix:nonFraction>&#160;million assigned to the warrants will be recognized in equity upon achievement of a performance-based vesting condition <span style="color:#000000;">pertaining to building manufacturing capacity to support supply requirements for one of our product candidates</span>. </p></ix:continuation><ix:nonNumeric id="F_000584" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001326110_20210101_20210630" escape="true" continuedAt="F_000584_dcnt_b26b9154-c7a9-495c-a819-8b631fbc8ece">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N12___INCOME_TAXES">11. &#160;&#160;&#160;&#160;Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;9,&#160;2021, the company completed the Merger with NantCell. The Merger is accounted for as a transaction between entities under common control, and is considered a nontaxable transaction for U.S. income tax purposes, as it is intended to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Internal Revenue Code of&#160;1986, as amended.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company is subject to taxation in the United States, various state, and foreign jurisdictions. Earnings from non-U.S.&#160;activities are subject to local country income tax. The company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. <ix:nonFraction unitRef="U_iso4217USD" id="F_001325" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtStatementGeographicalAxis_countryUS_20210101_20210630" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_001326" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtStatementGeographicalAxis_countryIT_20210101_20210630" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_001327" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtStatementGeographicalAxis_countryKR_20210101_20210630" decimals="INF" format="ixt-sec:numwordsen" scale="3">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> tax benefit was provided for losses incurred in the United States, Italy, and South Korea because those losses are offset by a full valuation allowance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The difference between the federal statutory tax rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_001328" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001326110_20210101_20210630" decimals="2" scale="-2">21</ix:nonFraction>% and the company&#8217;s <ix:nonFraction unitRef="U_xbrlipure" id="F_001329" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001326110_20210101_20210630" decimals="2" scale="-2">0</ix:nonFraction>% tax rate is due to losses from which the company cannot benefit.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company is no longer subject to income tax examination by the U.S.&#160;federal, state or local tax authorities for years ended December&#160;31,&#160;2015 or prior&#59; however, its tax attributes, such as net operating loss (&#8220;NOL&#8221;) carryforwards and tax credits, are still subject to examination in the year they are used.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000584_dcnt_b26b9154-c7a9-495c-a819-8b631fbc8ece">
</ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F">ITEM 2.  MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis should be read together with our condensed consolidated financial statements and the notes to those statements included elsewhere in this Quarterly Report on Form&#160;10-Q. This Quarterly Report on Form&#160;10-Q contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of&#160;1933, as amended (&#8220;Securities Act&#8221;) and Section&#160;21E of the Securities Exchange Act of&#160;1934, as amended (&#8220;Exchange Act&#8221;) that are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. The forward-looking statements are contained in this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. Forward-looking statements include, but are not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to pioneer immunotherapy, harness the power of the innate immune system, implement precision cancer medicine and change the current paradigm of cancer care&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to implement and support our COVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="color:#000000;">19 vaccine and therapeutic programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any impact of the coronavirus pandemic, or responses to the pandemic, on our business, clinical trials or personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding the potential benefits of our strategy and technology&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding the operation of our product candidates and related benefits&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to utilize multiple modes to induce cell death&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our beliefs regarding the benefits and perceived limitations of competing approaches, and the future of competing technologies and our industry&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">details regarding our strategic vision and planned product candidate pipeline, including that we eventually plan to advance therapies for virally induced infectious diseases&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our beliefs regarding the success, cost and timing of our product candidate development activities and current and future clinical trials and studies, including study design&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding our ability to utilize the Phase&#160;I and II&#160;aNK and haNK clinical trials data to support the development of our product candidates, including our haNK, taNK, t&#8209;haNK, MSC and M-ceNK product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding the development, application, commercialization, marketing, prospects and use generally of our product candidates, including Anktiva, hAd5 and aldoxorubicin&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing or likelihood of regulatory filings or other actions and related regulatory authority responses, including any planned investigational new drug (&#8220;IND&#8221;)&#59; Biologics License Application (&#8220;BLA&#8221;)&#59; or New Drug Application (&#8220;NDA&#8221;) filings or pursuit of accelerated regulatory approval pathways or orphan drug status and Breakthrough Therapy designations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to implement an integrated discovery ecosystem and the operation of that planned ecosystem, including being able to regularly add neoepitopes and subsequently formulate new product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability and willingness of strategic collaborators, including certain affiliates of NantWorks,&#160;LLC (&#8220;NantWorks&#8221;) to share our vision and effectively work with us to achieve our goals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability and willingness of various third parties to engage in research and development activities involving our product candidates, and our ability to leverage those activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to attract additional third-party collaborators&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding the ease of administration associated with our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding the patient compatibility associated with our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our beliefs regarding the potential markets for our product candidates and our ability to serve those markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to produce an &#8220;off-the-shelf&#8221; therapy&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our beliefs regarding the potential manufacturing and distribution benefits associated with our product candidates, and our ability to scale up the production of our product candidates&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">our plans regarding our manufacturing facilit</span><span style="color:#000000;">ies</span><span style="color:#000000;"> and our belief that our manufacturing is capable of being conducted in</span><span style="color:#000000;">&#8209;house&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our belief in the potential of our antibody cytokine fusion protein, vaccine technology and NK-92 and M-ceNK cell therapy technology, and the fact that our business is based upon the success individually and collectively of our platforms&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our antibody cytokine fusion protein, vaccine technology and NK-92 and M-ceNK cell therapy technology along with other product candidate families, will require significant additional clinical testing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">even if we successfully develop and commercialize specific product candidates like our Anktiva or haNK and t&#8209;hank, we may not be successful in developing and commercializing our other product candidates either alone or in combination with other therapeutic agents&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability to obtain and maintain regulatory approval of any of our product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product candidate&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to commercialize any approved products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the rate and degree of market acceptance of any approved products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to attract and retain key personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the accuracy of our estimates regarding our future revenue, as well as our future operating expenses, capital requirements and needs for additional financing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain funding for our operations, including funding necessary to complete further development and any commercialization of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain, maintain, protect and enforce intellectual property protection for our product candidates and technology and not infringe upon, misappropriate or otherwise violate the intellectual property of others&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the terms and conditions of licenses granted to us and our ability to license additional intellectual property relating to our product candidates and technology&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the impact on us, if any, if the contingent value rights (&#8220;CVRs&#8221;) held by former Altor BioScience Corporation (&#8220;Altor&#8221;) stockholders become due and payable in accordance with their terms&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory developments in the United States (&#8220;U.S.&#8221;) and foreign countries.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Forward-looking statements include statements that are not historical facts and can be identified by terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or similar expressions and the negatives of those terms. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form&#160;10-Q, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in Part&#160;II, Item&#160;1A. &#8220;Risk Factors&#8221; of this Quarterly Report <span style="color:#000000;">on Form&#160;10-Q</span>. Given these uncertainties, you should not place undue reliance on these forward-looking statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Quarterly Report <span style="color:#000000;">on Form&#160;10-Q</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You should read this Quarterly Report on Form&#160;10-Q completely and with the understanding that our actual future results may be materially different from what we expect.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">This </span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Quarterly Report</span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> on Form&#160;10-Q</span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this </span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Quarterly Report</span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> on Form&#160;10-Q</span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">, including logos, artwork and other visual displays, may appear without the </span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> or </span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us</span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">,</span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> by any other companies.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">In this Quarterly Report on Form&#160;10-Q, &#8220;ImmunityBio,&#8221; &#8220;the company,&#8221; &#8220;the combined company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to ImmunityBio,&#160;Inc. and its subsidiaries.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We established ImmunityBio to advance next-generation immunotherapies and address unmet needs within oncology and infectious disease. Our platform is designed to overcome limitations of the current standards of T&#160;cell-based immunotherapies, including checkpoint inhibitors and CAR-T&#160;cells and is based on our&#160;four key modalities:&#160;(1)&#160;activating natural killer (&#8220;NK&#8221;) and T&#160;cells using antibody cytokine fusion proteins, (2)&#160;activating tumoricidal macrophages using low-dose synthetic immunomodulators, (3)&#160;generating memory T&#160;cells using vaccine candidates developed with our second-generation adenovirus (&#8220;hAd5&#8221;) technology, and (4)&#160;off-the-shelf natural killer cells from the NK-92 cell line and memory-like cytokine-enhanced natural killer cells&#160;(&#8220;M-ceNK&#8221;) from allogenic and autologous donors.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g01jb3kt0hkn000001.jpg" title="" alt="" style="width:719px;height:313px;" /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We own a broad, clinical-stage immunotherapy pipeline, including an antibody cytokine fusion protein&#160;(an IL-15 superagonist (&#8220;N-803&#8221;) known as Anktiva), an albumin-associated anthracycline synthetic immunomodulator&#160;(aldoxorubicin), second-generation adenovirus&#160;(&#8220;hAd5&#8221;) and yeast vaccine technologies (targeting tumor-associated antigens and neoepitopes), off-the-shelf genetically engineered natural killer cell lines inducing cancer and virally infected cell death through a variety of concurrent mechanisms (including innate killing, antibody-mediated killing, and CAR-directed killing), </span><span style="Background-color:#FFFFFF;">patient specific NK&#160;cell product for cancer that is an autologous memory cytokine enhanced NK&#160;cells (&#8220;M-ceNK&#8221;), </span><span style="Background-color:#FFFFFF;">macrophage polarizing peptides, and bi-specific fusion proteins targeting CD20, PD-L1, TGF-</span><span style="Background-color:#FFFFFF;font-family:'Times New Roman';"><span style="font-size:10pt;font-family:'Times New Roman'">b</span></span><span style="Background-color:#FFFFFF;"> and IL-12. Our immunotherapy clinical pipeline consists of over 40&#160;clinical trials in Phase&#160;1, 2, or 3&#160;development across 19&#160;indications in solid and liquid cancers and infectious diseases. We have an expansive clinical-stage pipeline and intellectual property portfolio with 17&#160;first-in-human assets in 25&#160;Phase&#160;II to III&#160;clinical trials.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December&#160;2019, the </span><span style="color:#000000;">U.S.</span><span style="color:#000000;"> Food and Drug Administration</span><span style="Background-color:#FFFFFF;"> </span><span style="Background-color:#FFFFFF;">(&#8220;</span><span style="Background-color:#FFFFFF;">FDA</span><span style="Background-color:#FFFFFF;">&#8221;)</span><span style="Background-color:#FFFFFF;"> granted Breakthrough Therapy designation to Anktiva for bacillus Calmette-Gu&#233;rin </span><span style="Background-color:#FFFFFF;">(&#8220;</span><span style="Background-color:#FFFFFF;">BCG</span><span style="Background-color:#FFFFFF;">&#8221;)</span><span style="Background-color:#FFFFFF;"> unresponsive carcinoma in situ non-muscle invasive bladder cancer. </span><span style="Background-color:#FFFFFF;">Based on patient reado</span><span style="Background-color:#FFFFFF;">ut data that was submitted with </span><span style="Background-color:#FFFFFF;">our application to obtain our Breakthrough Therapy designation, Anktiva achieved its primary endpoint of complete response</span><span style="Background-color:#FFFFFF;"> </span><span style="Background-color:#FFFFFF;">rate at any time in the ongoing registrational Phase</span><span style="Background-color:#FFFFFF;">&#160;</span><span style="Background-color:#FFFFFF;">II / III</span><span style="Background-color:#FFFFFF;">&#160;</span><span style="Background-color:#FFFFFF;">trial</span><span style="Background-color:#FFFFFF;">. </span><span style="Background-color:#FFFFFF;">Other indications currently </span><span style="Background-color:#FFFFFF;">with</span><span style="Background-color:#FFFFFF;"> registration-</span><span style="Background-color:#FFFFFF;">potential</span><span style="Background-color:#FFFFFF;"> studies include BCG unresponsive papillary bladder cancer, first- and second-line lung cancer, and metastatic pancreatic cancer.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Merger</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On December&#160;21,&#160;2020, we and NantCell,&#160;Inc.&#160;(formerly known as ImmunityBio,&#160;Inc., a private company) (&#8220;NantCell&#8221;) entered into an Agreement and Plan of Merger&#160;(the &#8220;Merger Agreement&#8221;), pursuant to which we and NantCell agreed to combine our businesses. The Merger Agreement provided that a wholly-owned subsidiary of the company would merge with and into NantCell&#160;(the&#160;&#8220;Merger&#8221;), with NantCell surviving the Merger as a wholly-owned subsidiary of the company.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On March&#160;9,&#160;2021, we completed the Merger pursuant to the terms of the Merger Agreement. Under the terms of the Merger Agreement, at the effective time of the Merger&#160;(the &#8220;Effective Time&#8221;), each share of NantCell common stock</span>, par value <span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000616_2" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210309" decimals="3">0.001</ix:nonFraction></span>&#160;per share, <span style="Background-color:#FFFFFF;">issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive&#160;</span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000617_2" name="ibrx:MergerExchangeRatio" contextRef="C_0001326110_20210309_20210309" decimals="4">0.8190</ix:nonFraction></span><span style="Background-color:#FFFFFF;"> (the &#8220;Exchange Ratio&#8221;) newly</span> issued shares of common stock, par value <span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000618_2" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_20210309" decimals="4">0.0001</ix:nonFraction></span>&#160;per share, of the company&#160;(&#8220;Company Common Stock&#8221;), with cash paid in lieu of any fractional shares.<span style="Background-color:#FFFFFF;"> At the Effective Time, each share of the company&#8217;s common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company. At the Effective Time, each outstanding option, warrant or restricted stock unit to purchase NantCell common stock was converted using the Exchange Ratio into an option, warrant or restricted stock unit, respectively, on the same terms and conditions immediately prior to the Effective Time, to purchase shares of Company Common Stock.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Immediately following the Effective Time, the former stockholders of NantCell held approximately&#160;71.5% of the outstanding shares of Company Common Stock and the stockholders of the company as of immediately prior to the Merger held approximately 28.5%</span><span style="Background-color:#FFFFFF;">&#160;</span><span style="Background-color:#FFFFFF;">of the outstanding shares of Company Common Stock. As a result of the Merger and immediately following the Effective Time, Dr.&#160;Patrick Soon-Shiong, our Executive Chairman, and his affiliates beneficially owned, in the aggregate, approximately 81.8%&#160;of the outstanding shares of Company Common Stock. </span><span style="Background-color:#FFFFFF;">Following the consummation of the Merger, shares of the company&#8217;s common stock were listed on the Nasdaq Global Select Market under the symbol &#8220;IBRX.&#8221;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We incurred costs totaling $23.3&#160;million in connection with the Merger, consisting of financial advisory, legal and other professional fees, of which $13.0&#160;million was recorded during the six&#160;months ended June&#160;30,&#160;2021.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Treatment of the Merger</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Merger represents a business combination pursuant to Financial Accounting Standards Board Accounting Standards Codification Topic&#160;805-50,&#160;<span style="font-style:italic;">Mergers</span>, which is accounted for as a transaction between entities under common control as Dr.&#160;Soon&#8209;Shiong <span style="color:#000000;">and his affiliates were the controlling stockholders of both the company and </span>NantCell for all of the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We have recast our prior <span style="color:#000000;">period financial statements to reflect the conveyance of NantCell&#8217;s common shares as if the Merger had occurred as of the earliest date of the condensed consolidated financial statements presented in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q. All</span> material intercompany accounts and transactions have been eliminated in consolidation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Coronavirus Pandemic</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2020, the World Health Organization declared the novel strain of coronavirus disease (SARS&#8209;CoV&#8209;2) a pandemic. To date, our operations have not been significantly disadvantaged by the pandemic. However, we cannot at this time predict the specific extent, duration, or full impact that this pandemic may have on our financial condition and results of operations, including ongoing and planned clinical trials. More specifically, the pandemic may result in prolonged impacts that we cannot predict at this time and we expect that such uncertainties will continue to exist for the foreseeable future. The impact of the pandemic on our financial performance will depend on future developments, including the duration and spread of the outbreak, impact of potential variants and the related governmental advisories and restrictions. These developments and the impact of the ongoing pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, our results may be adversely affected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the unprecedented and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continuously </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">evolving nature of the pandemic, the future impact of these changes and potential changes on </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> company are unknown at this time. To date, we have seen no material adverse impact</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our business from the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pandemic. We anticipate, however, that enrollment of patients in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> studies will likely take longer than forecasted in prior </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities and Exchange Commission</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (&#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SEC</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> filings and that our clinical trials may require additional time to complete which would in turn impact the timeline in which we were previously forecasting </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BLA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> submissions of our product candidates and subsequent revenue generation. These factors have been accounted for in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">company&#8217;s </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">anticipated upcoming milestones. During any such delays in our clinical trials, we will continue to incur fixed costs such as selling, general and administrative expenses and operating expenses related to our laboratory, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Good Manufacturing Practice </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(&#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GMP</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> manufacturing, and office facilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our office-based employees have been working from home since mid-March&#160;2020. Essential staffing levels for our research and development operations remain in place, including maintaining key personnel in our laboratory and GMP&#160;manufacturing facilities. It is likely that the pandemic and resulting mitigation efforts could have an impact in the future on our third-party suppliers who manufacture laboratory supplies required for our in-house manufacturing process, which in turn could have an impact on having sufficient clinical product supply available for our clinical trials. We have addressed this in part by ensuring that we have sufficient supplies on hand to weather interruptions in our supply chain.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty about the progression and ultimate impact of the pandemic on our business and operations. While the pandemic did not materially impact our results during the periods presented in this Quarterly Report on Form&#160;10-Q, we anticipate that it could impact our business in the future due to factors such as fewer patients accessing treatment for cancer.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Results</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>generated<span style="letter-spacing:-0.35pt;"> minimal </span>revenue<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>non-exclusive<span style="letter-spacing:-0.45pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.1pt;">g</span>reements<span style="letter-spacing:-0.4pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>cell<span style="letter-spacing:-0.15pt;"> </span>li<span style="letter-spacing:-0.05pt;">n</span>es,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>sale<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>bioreactors<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>related consumables<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>programs. We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. We have incurred net losses in each year since our inception and, as of June&#160;30,&#160;2021, we had an accumulated deficit of $1.8&#160;billion. Our net losses attributable to ImmunityBio common stockholders were $167.9&#160;million and $88.5&#160;million for the six&#160;months ended June&#160;30,&#160;2021 and 2020, respectively. Substantially all of our net losses resulted principally from costs incurred in connection with our ongoing clinical trials and operations, our research and development programs, and from selling, general and administrative costs associated with our operations, including stock-based compensation expense.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021, we had 511&#160;employees. Personnel of related companies who provide corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy and other support services under our shared services agreement with NantWorks are not included in this number. For additional information, see <a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;8</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-style:italic;">&#160;Related-Party Agreements,</span> of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; <span style="color:#000000;">that appears</span> in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of this Quarterly Report<span style="color:#000000;"> on Form&#160;10-Q</span>. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, which may fluctuate significantly from quarter-to-quarter and year-to-year. See &#8220;&#8212;<span style="font-style:italic;">Future Funding Requirements</span>&#8221; below for a discussion of our anticipated expenditures and sources of capital we expect to access to fund these expenditures.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that strategic collaborations will become an integral part of our operations, providing opportunities to leverage our partners&#8217; expertise and capabilities to further expand the potential of our technologies and product candidates. We believe we are well positioned to become a leader in immunotherapy due to our broad and vertically integrated platform and through complementary strategic partnerships. We may also enter into supply arrangements for various investigational agents to be used in our clinical trials. See&#160;<a href="#N7___COLLABORATION_LICENSE_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;6</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Collaboration and License Agreements</span>, of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; <span style="color:#000000;">that appears </span>in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of <span style="color:#000000;">this Quarterly Report on Form&#160;10-Q</span> for a more detailed discussion regarding our existing collaboration and license agreements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Agreements with Related Parties</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conduct business with several affiliates under written and informal arrangements. Our Executive Chairman, and principal stockholder, founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. We have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new immunotherapies for our product pipeline. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021, we have outstanding promissory notes with certain entities affiliated with Dr.&#160;Soon-Shiong in an aggregate amount of $300.3&#160;million, including accrued interest. The notes bear interest at a per annum rate ranging from 3.0% to 6.0%. As of June&#160;30,&#160;2021, the notes provide that all outstanding principal is due and payable on September&#160;30,&#160;2025, and accrued and unpaid interest is payable on either the maturity date or, with respect to one of the notes, on a quarterly basis beginning June&#160;30,&#160;2021. We may prepay the outstanding amount of any advance under such notes, together with accrued and unpaid interest, at any time, in whole or in part, without premium or penalty.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May&#160;2021, but effective on April&#160;1,&#160;2021, we entered into an amendment to our existing lease with 605&#160;Nash,&#160;LLC. The amendment expanded the leased square feet by approximately 57,760&#160;rentable square feet (the &#8220;Expansion Premises&#8221;). The lease term of the Expansion Premises commenced in April&#160;2021 and expires in March&#160;2028, whereby the company has the option to extend the initial term for three&#160;years. Per the terms of the amendment, the term of the lease that commenced in January&#160;2021 was extended for an additional three&#160;months and now expires on March&#160;31,&#160;2028. Base rent for the Expansion Premises is approximately $170,400&#160;per month with annual increases of&#160;3% on April&#160;1 of each year. We are responsible for the build out of the facility space and associated costs. The amended lease provides for a rent abatement for the first seven&#160;months, and for a tenant improvement allowance of approximately $2.6&#160;million for costs and expenses related to improvements made by us to the Expansion Premises.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into multiple agreements with Immuno-Oncology Clinic,&#160;Inc.<span style="Background-color:#FFFFFF;color:#000000;"> (the&#160;&#8220;Clinic&#8221;) </span>to conduct clinical trials related to certain of our product candidates. The&#160;Clinic is a related party as it is owned by an officer of the company and NantWorks manages the administrative operations of the&#160;Clinic. B<span style="Background-color:#FFFFFF;color:#000000;">ased on a review of our updated clinical trial programs post-Merger, we updated our estimates of the investigator fees for the clinical trials currently underway or planned at the&#160;Clinic. As certain programs costs are excluded from and certain services are subject to credit adjustments under the&#160;Clinic Agreement, we determined the expected future fees for services to be performed are less than the carrying value of the prepaid asset on the condensed consolidated balance sheets. As a result, we partially wrote down the value of our prepayments under the&#160;Clinic Agreement and recorded approximately $1.9&#160;million in </span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">research and development expense</span><span style="Background-color:#FFFFFF;color:#000000;">, on the condensed consolidated statements of operations for the three&#160;months ended June&#160;30,&#160;2021. In addition, we reclassified $0.9&#160;million of prepaid assets from </span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">prepaid expenses and other current assets</span><span style="Background-color:#FFFFFF;color:#000000;"> to </span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">other current assets</span><span style="Background-color:#FFFFFF;color:#000000;">, on the condensed consolidated balance sheets as of June&#160;30,&#160;</span>2021 based on the additional time expected for them to be realized than initially estimated. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See&#160;<a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;8</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Related-Party Agreements</span>, of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; that appears in Item&#160;1. &#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q for a more detailed discussion regarding our related party agreements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Components of our Results of Operations</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>generated<span style="letter-spacing:-0.35pt;"> minimal </span>revenue<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>non-exclusive<span style="letter-spacing:-0.45pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.1pt;">g</span>reements<span style="letter-spacing:-0.4pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>cell<span style="letter-spacing:-0.15pt;"> </span>li<span style="letter-spacing:-0.05pt;">n</span>es,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>sale<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>bioreactors<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>related consumables<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>programs. We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. If we fail to complete the development of our product candidates in a timely manner or fail to obtain regulatory approval for them, we may never be able to generate substantial future revenue.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally classify our operating expenses into research and development, and selling, general and administrative expenses. Personnel costs, including salaries, benefits, bonuses, and stock-based compensation expense comprise a significant component of our research and development, and selling, general and administrative expense categories. We allocate expenses associated with our facilities and information technology costs between these two&#160;categories based on the nature of each cost.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense consists of expenses incurred while performing research and development activities to discover and develop our technology and product candidates. This includes conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for product candidates. We recognize research and development expenses as they are incurred. Our research and development expense primarily consists of:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical trial and regulatory-related costs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenses incurred under agreements with investigative sites and consultants that conduct our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenses incurred under collaborative agreements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacturing and testing costs and related supplies and materials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">employee-related expenses, including salaries, benefits, travel and stock-based compensation&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">facility expenses dedicated to research and development.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We typically use our employee, consultant and infrastructure resources across our development programs. We track outsourced development costs by product candidate or development program, but we do not allocate personnel costs, other internal costs or external consultant costs to specific product candidates or development programs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our research and development expenses to continue to increase significantly for the foreseeable future as we advance our product candidates through clinical development, including the conduct of our ongoing and any future clinical trials. The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. The successful development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required to complete the remaining development of any product candidates. This is due to the numerous risks and uncertainties associated with the development of product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The costs of clinical trials may vary significantly over the life of a project owing to, but not limited to, the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">per patient trial costs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number of sites included in the clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the countries in which the clinical trials are conducted&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the length of time required to enroll eligible patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number of patients that participate in the clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number of doses that patients receive&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of comparative agents used in clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the drop-out or discontinuation rates of patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential additional safety monitoring or other studies requested by regulatory agencies&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the duration of patient follow-up&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the efficacy and safety profile of the product candidate.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not expect any of our product candidates to be commercially available for the foreseeable future, if ever.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Selling, General and Administrative</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expense consists primarily of salaries and personnel-related costs, including employee benefits and any stock-based compensation, for employees performing functions other than research and development. This includes personnel in executive, finance, human resources, information technology, legal, and administrative support functions. Other selling, general and administrative expenses include facility-related costs not otherwise allocated to research and development expense, professional fees for auditing, tax and legal services, advertising costs, expenses associated with strategic business transactions and business development efforts, obtaining and maintaining patents, consulting costs, royalties and licensing costs, and costs of our information systems.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our selling, general and administrative expenses will increase for the foreseeable future as we expand operations, build out information systems and increase our headcount to support continued research activities and the development of our clinical programs. We have incurred and expect that we will continue to incur in the future, additional costs associated with operating as a public company, including costs to comply with stock exchange listing and SEC&#160;requirements, future funding efforts, corporate governance, internal controls, investor relations, disclosure and similar requirements applicable to public companies. Additionally, if and when we believe that a regulatory approval of a product candidate appears likely, we expect to incur significant increases in our selling, general and administrative expenses relating to the sales and marketing of the approved product candidate.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Income and Expense</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income and expense consists primarily of interest income, interest expense, unrealized gains and losses on investments in equity securities, realized gains and losses on both debt and equity securities, and gains and losses on foreign currency transactions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company is subject to taxation in the United States, various state, and foreign jurisdictions. Earnings from non-U.S. activities are subject to local country income tax. To date, we have not been required to pay U.S.&#160;federal income taxes or foreign income taxes because of our or our subsidiaries&#8217; current and accumulated net operating losses.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the three months ended June&#160;30, 2021 and 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$ Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited, $ in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">339</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(97</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,800</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,005</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,795</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,445</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,347</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,098</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,245</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,352</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,893</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,906</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,916</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,990</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and investment (expense) income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(177</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">986</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,163</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,577</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,123</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,454</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">196</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,477</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,056</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,421</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes and noncontrolling interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,383</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,972</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,411</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,385</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,017</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,368</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;" id="OLE_LINK1">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expense</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense increased $20.8&#160;million during the three&#160;months ended June&#160;30,&#160;2021, as compared to the three&#160;months ended June&#160;30,&#160;2020. The increase in research and development expense was primarily driven by an $11.2&#160;million increase in compensation expense, including an $8.6&#160;million increase in stock compensation expense due to new grants issued and a $2.6&#160;million increase in personnel costs due to higher headcount to support our continued research and development efforts, a $3.4&#160;million increase in clinical trial and regulatory expenses related to our Anktiva and COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19 programs, including a $1.9&#160;million expense associated with the write down of a prepaid asset with the&#160;Clinic, a $2.5&#160;million increase in license and research agreement costs, primarily driven by new license agreements entered into in the second&#160;quarter of 2021, a $1.9&#160;million increase in facilities expense, primarily related to the expansion of our manufacturing facility in El&#160;Segundo, California during 2021, and a $1.8&#160;million increase in laboratory supply expenses and other research and development costs, primarily driven by higher expenses related to our COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19 programs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our research and development expense to increase significantly for the foreseeable future as we advance our product candidates through clinical development and conduct our ongoing and planned clinical trials.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Selling, General and Administrative Expense</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expense increased $14.1&#160;million during the three&#160;months ended June&#160;30,&#160;2021, as compared to the three&#160;months ended June&#160;30,&#160;2020. <span style="Background-color:#FFFFFF;color:#000000;">The increase in selling, general and administrative expense was primarily attributable to $</span>9.8&#160;million increase in compensation expense, including an $8.9&#160;million increase in stock compensation expense driven by new grants and option modifications resulting in incremental stock-based compensation expense in 2021 and a $0.9&#160;million increase personnel-related expenses, and a $6.2&#160;million increase in legal expense, primarily due to ongoing litigation. These increases were partially offset by a $1.2&#160;million decrease in shared services and travel costs, and a $0.7&#160;million decrease in general liability insurance costs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expense</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense increased $2.4&#160;million during the three&#160;months ended June&#160;30,&#160;2021, as compared to the three&#160;months ended June&#160;30,&#160;2020. <span style="Background-color:#FFFFFF;color:#000000;">The increase in other expense was mainly due to a $1.4&#160;million increase in interest expense driven higher related-party borrowings and a reduction in net unrealized gains of $1.2&#160;million related to our equity securities, which were partially offset by a $0.2&#160;million increase in other income.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the six months ended June&#160;30, 2021 and 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.42%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$ Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited, $ in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">478</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">601</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(123</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,928</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,379</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,549</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,720</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,840</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,880</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,648</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,219</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,429</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(172,170</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87,618</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84,552</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and investment income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,767</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,064</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,703</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">724</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,745</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,012</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,733</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">290</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,185</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(895</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,312</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,763</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,075</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(231</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes and noncontrolling interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(169,858</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,381</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80,477</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(169,866</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,444</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80,422</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.24%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expense</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense increased $34.5&#160;million during the six&#160;months ended June&#160;30,&#160;2021, as compared to the six&#160;months ended June&#160;30,&#160;2020. The increase in research and development expense was primarily driven by a $15.3&#160;million increase in compensation expense, including an $11.3&#160;million increase in stock compensation expense due to new grants issued and a $4.0&#160;million increase in the personnel costs due to higher headcount in support of our continued research and development efforts, a $5.1&#160;million increase in clinical trial expenses and regulatory costs related to our Anktiva and COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19 programs, including a $1.9&#160;million expense associated with the write down of a prepaid asset with the&#160;Clinic, a $4.7&#160;million increase in laboratory supply expenses and other preclinical research and development costs, a $4.5&#160;million increase in manufacturing costs for contract manufacturing of clinical materials, a $2.8&#160;million increase in facilities expense, primarily related to the expansion of our manufacturing facility in El&#160;Segundo, California during 2021, and a $2.1&#160;million increase in license and collaboration costs, primarily driven by new license agreements entered in the second&#160;quarter of 2021.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our research and development expense to increase significantly for the foreseeable future as we advance our product candidates through clinical development and conduct our ongoing and planned clinical trials.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Selling, General and Administrative</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> Expense</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expense increased $49.9&#160;million during the six&#160;months ended June&#160;30,&#160;2021, as compared to the six&#160;months ended June&#160;30,&#160;2020. <span style="Background-color:#FFFFFF;color:#000000;">The increase in selling, general and administrative expense was primarily attributable to a </span>$22.4&#160;million increase in compensation expense, including a $21.0&#160;million increase in stock compensation expense driven by new grants issued and option modifications <span style="Background-color:#FFFFFF;color:#000000;">resulting in incremental stock-based compensation expense in 2021 </span>and a $1.4&#160;million increase in personnel-related expenses due to higher headcount needed to support our business activities, a $24.3&#160;million increase in financial advisory, legal, public company and other professional fees (including fees related to our Merger, which was announced in December&#160;2020 and closed in March&#160;2021), as well as higher costs associated with ongoing litigation, patent-related legal fees and other matters, and a $3.2&#160;million increase in insurance costs, primarily due to higher directors&#8217; and officers&#8217; insurance renewal rates and increased insurance coverage.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Income and Expense</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income increased $4.1&#160;million during the six&#160;months ended June&#160;30,&#160;2021, as compared to the six&#160;months ended June&#160;30,&#160;2020. <span style="Background-color:#FFFFFF;color:#000000;">The increase was mainly due a $7.7&#160;million increase in unrealized gains from our equity investments, which were partially offset by a $2.7&#160;million increase in interest expense driven primarily by higher related-party borrowings and a $0.9&#160;million decrease in other income.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sources of Liquidity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our principal sources of liquidity are our existing cash, cash equivalents, and marketable securities. We have historically invested our cash primarily in investment grade short- to intermediate-term corporate debt securities, commercial paper, government-sponsored securities, U.S.&#160;treasury securities, and foreign government bonds and classify these investments as available-for-sale. Certain of these investments are subject to general credit, liquidity and other market risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021, we had cash and cash equivalents, and marketable securities of $104.8&#160;million compared to $97.0&#160;million as of December&#160;31,&#160;2020. On April&#160;30,&#160;2021, we entered into an Open Market Sale Agreement (the &#8220;Sale Agreement&#8221;) with respect to an at-the-market (the &#8220;ATM&#8221;) offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $500.0&#160;million through our sales agent. For the three&#160;months ended June&#160;30,&#160;2021, we received net proceeds totaling $94.9&#160;million from the issuance of 6,420,441&#160;shares under the ATM, which <span style="Background-color:#FFFFFF;color:#000000;">we expect to use for general corporate purposes, including to progress our clinical development programs, fund other research and development activities, for capital expenditures and to fund working capital. We may also use a portion of the net proceeds to license intellectual property or to make acquisitions or investments. </span>As of June&#160;30,&#160;2021, we had $402.0&#160;million available for future stock issuances under the ATM. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to complete the development of our current product candidates, and implement our business plan, we will require substantial additional funding. Furthermore, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to raise even greater amounts of funds sooner if we choose to expand more rapidly than we presently anticipate. Moreover, our fixed expenses such as rent and other contractual commitments are substantial and are expected to increase in the future.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Uses of Liquidity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the cash used to fund our operating activities discussed in &#8220;<span style="font-style:italic;">&#8212;Future Funding Requirements</span>&#8221; below, we will require cash to settle the following obligations:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021, we had related-party notes payable together with accrued interest thereon of $300.3&#160;million compared to $254.4&#160;million as of December&#160;31,&#160;2020. During the six&#160;months ended June&#160;30,&#160;2021, we received a $40.0&#160;million advance pursuant to a related-party promissory note. Such notes bear interest at 3% to 6% per year and may be prepaid by us without penalty. The notes allow for additional advances as we may request with the consent of the applicable lender. With the exception of interest on the recent $40.0&#160;million advance, all outstanding principal and accrued and unpaid interest on these notes are due and payable on September&#160;30,&#160;2025.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our acquisition of Altor, we issued </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CVRs</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> under which we have agreed to pay the prior stockholders of Altor approximately </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$304.0&#160;million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> upon successful approval of the BLA or foreign equivalent for Anktiva by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,&#160;2022</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and approximately </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$304.0&#160;million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> upon the first calendar year prior to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,&#160;2026</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in which worldwide net sales of Anktiva exceed </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.0&#160;billion</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(with payments payable in cash or shares of our common stock or a combination thereof). Dr.&#160;Soon-Shiong and his related party hold approximately </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$279.5&#160;million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the aggregate of CVRs and they have both irrevocably agreed to receive shares of common stock in satisfaction of their CVRs. We may need to seek additional sources of capital to satisfy the CVR obligations if they are achieved.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth our primary sources and uses of cash for periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:2pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited, in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by (used in):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(130,064</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(77,129</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,334</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,268</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,834</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,217</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effects of exchange rate changes on cash, cash equivalents,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in cash, cash equivalents, and restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,043</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,361</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the six&#160;months ended June&#160;30,&#160;2021, net cash used in operating activities of $130.1&#160;million consisted of a<span style="letter-spacing:0.25pt;"> </span>net<span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:0.05pt;">l</span>oss<span style="letter-spacing:0.65pt;"> </span>of $169.9&#160;million and $0.4&#160;million<span style="letter-spacing:0.6pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>cash used in net working capital changes, part<span style="letter-spacing:0.05pt;">i</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">l</span>ly<span style="letter-spacing:1.25pt;"> </span>offset by<span style="letter-spacing:0.45pt;"> </span>$40.2&#160;million<span style="letter-spacing:0.45pt;"> </span>in<span style="letter-spacing:0.35pt;"> </span>ad<span style="letter-spacing:0.05pt;">j</span>us<span style="letter-spacing:0.05pt;">t</span>ments<span style="letter-spacing:1.7pt;"> </span>f<span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:0.5pt;"> </span>no<span style="letter-spacing:0.05pt;">n</span>-cash<span style="letter-spacing:1.4pt;"> </span>items.<span style="letter-spacing:1.3pt;"> </span>A<span style="letter-spacing:0.05pt;">d</span>justmen<span style="letter-spacing:0.05pt;">t</span>s<span style="letter-spacing:1.8pt;"> </span><span style="letter-spacing:0.05pt;">f</span>or non<span style="letter-spacing:0.05pt;">-</span>cash<span style="letter-spacing:1.35pt;"> </span><span style="letter-spacing:0.05pt;">i</span>tems<span style="letter-spacing:0.85pt;"> </span>pr<span style="letter-spacing:0.05pt;">i</span>mari<span style="letter-spacing:0.05pt;">l</span>y<span style="letter-spacing:1.35pt;"> </span>consisted<span style="letter-spacing:1.35pt;"> </span>of $33.2&#160;million<span style="letter-spacing:1.1pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>s<span style="letter-spacing:0.05pt;">t</span>ock<span style="letter-spacing:0.8pt;"> </span>compe<span style="letter-spacing:0.05pt;">n</span>sati<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:2pt;"> </span>expense, $7.0&#160;million<span style="letter-spacing:0.9pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>depreciati<span style="letter-spacing:0.1pt;">o</span>n<span style="letter-spacing:1.8pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>amo<span style="letter-spacing:0.05pt;">r</span>tizati<span style="letter-spacing:0.05pt;">o</span>n expense,<span style="letter-spacing:1.3pt;"> </span>$6.2&#160;million<span style="letter-spacing:1.1pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>non<span style="letter-spacing:0.05pt;">-</span>cash<span style="letter-spacing:1.35pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span>terest<span style="letter-spacing:1.1pt;"> </span>related primarily to related party loans, $2.3&#160;million<span style="letter-spacing:1.9pt;"> </span>in<span style="letter-spacing:0.45pt;"> </span>non<span style="letter-spacing:0.05pt;">-</span>cash<span style="letter-spacing:1.35pt;"> </span><span style="letter-spacing:0.05pt;">l</span><span style="letter-spacing:-0.05pt;">e</span>ase<span style="letter-spacing:0.8pt;"> </span>expense<span style="letter-spacing:1.2pt;"> </span>related<span style="letter-spacing:1pt;"> </span>to<span style="letter-spacing:0.4pt;"> </span>operat<span style="letter-spacing:0.05pt;">i</span>ng<span style="letter-spacing:1.4pt;"> </span>lease<span style="letter-spacing:0.85pt;"> </span>righ<span style="letter-spacing:0.05pt;">t</span>-of-use assets,<span style="letter-spacing:1pt;"> </span>and $0.2&#160;million<span style="letter-spacing:1.1pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>a<span style="letter-spacing:0.05pt;">m</span>or<span style="letter-spacing:0.05pt;">t</span>iza<span style="letter-spacing:0.05pt;">t</span>ion<span style="letter-spacing:1.8pt;"> </span>of<span style="letter-spacing:0.45pt;"> net </span>premiums and discounts on<span style="letter-spacing:0.5pt;"> </span>mar<span style="letter-spacing:0.05pt;">k</span>e<span style="letter-spacing:0.05pt;">t</span>a<span style="letter-spacing:0.05pt;">b</span>le<span style="letter-spacing:1.6pt;"> </span>debt<span style="letter-spacing:0.7pt;"> </span>securi<span style="letter-spacing:0.05pt;">t</span>ies, reduced<span style="letter-spacing:1.15pt;"> </span><span style="letter-spacing:0.05pt;">b</span>y<span style="letter-spacing:0.45pt;"> $8.4&#160;million in</span><span style="letter-spacing:0.35pt;"> </span>u<span style="letter-spacing:0.05pt;">n</span>realized<span style="letter-spacing:1.5pt;"> </span>gains<span style="letter-spacing:0.8pt;"> </span>on<span style="letter-spacing:0.5pt;"> </span>e<span style="letter-spacing:0.05pt;">q</span>u<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:0.95pt;"> </span>secur<span style="letter-spacing:0.05pt;">i</span>ties<span style="letter-spacing:1.4pt;"> </span>dri<span style="letter-spacing:0.05pt;">v</span>en pr<span style="letter-spacing:0.05pt;">i</span>mari<span style="letter-spacing:0.05pt;">l</span>y<span style="letter-spacing:0.35pt;"> </span>by<span style="letter-spacing:0.45pt;"> </span>an<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">i</span>ncrease<span style="letter-spacing:1.2pt;"> </span><span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:0.35pt;"> </span>the<span style="letter-spacing:0.5pt;"> </span>val<span style="letter-spacing:0.05pt;">u</span>e<span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.4pt;"> </span>our<span style="letter-spacing:0.55pt;"> </span>in<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>st<span style="letter-spacing:0.05pt;">m</span>ents, $0.2&#160;million in realized gains on sales of equity securities, and a $0.1&#160;million change in the fair value of contingent consideration.<span style="letter-spacing:1.45pt;"> </span>The<span style="letter-spacing:0.65pt;"> </span>change<span style="letter-spacing:1.05pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>net<span style="letter-spacing:0.5pt;"> </span>working<span style="letter-spacing:1.25pt;"> </span>capi<span style="letter-spacing:0.05pt;">t</span>al<span style="letter-spacing:1.05pt;"> </span>co<span style="letter-spacing:0.1pt;">n</span>sisted<span style="letter-spacing:1.35pt;"> </span>pr<span style="letter-spacing:0.05pt;">i</span>mari<span style="letter-spacing:0.05pt;">l</span>y<span style="letter-spacing:1.35pt;"> </span>of increases of $5.4&#160;million in prepaid and other current assets and<span style="letter-spacing:1.35pt;"> </span>$2.6&#160;million<span style="letter-spacing:0.05pt;"> in each of accounts payable and related parties.</span><span style="letter-spacing:1.25pt;"> </span>T<span style="letter-spacing:0.05pt;">h</span>e increases<span style="letter-spacing:1.35pt;"> </span><span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:0.35pt;"> </span>net<span style="letter-spacing:0.5pt;"> </span>wo<span style="letter-spacing:0.05pt;">r</span>king<span style="letter-spacing:1.3pt;"> </span>ca<span style="letter-spacing:0.05pt;">p</span>ital<span style="letter-spacing:1pt;"> </span>were<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">r</span>tially<span style="letter-spacing:1.3pt;"> </span>of<span style="letter-spacing:0.05pt;">f</span><span style="letter-spacing:-0.05pt;">s</span>et<span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:0.05pt;">b</span>y<span style="letter-spacing:0.45pt;"> de</span>creases<span style="letter-spacing:1.4pt;"> </span>of $4.2&#160;million in other assets,<span style="letter-spacing:0.4pt;"> </span>$3.8&#160;million in<span style="letter-spacing:0.05pt;"> accrued expenses</span> and other liabilities and $3.0&#160;million in o<span style="letter-spacing:0.05pt;">p</span>e<span style="letter-spacing:0.05pt;">r</span>ating<span style="letter-spacing:1.45pt;"> </span>lease<span style="letter-spacing:0.8pt;"> </span>liab<span style="letter-spacing:0.05pt;">i</span>lities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the six&#160;months ended June&#160;30,&#160;2020, net cash used in operating activities of $77.1&#160;million consisted of a<span style="letter-spacing:0.25pt;"> </span>net<span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:0.05pt;">l</span>oss<span style="letter-spacing:0.65pt;"> </span>of $89.4&#160;million, partially offset by $11.9&#160;million<span style="letter-spacing:1.1pt;"> </span><span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:0.35pt;"> </span>adjustmen<span style="letter-spacing:0.05pt;">t</span>s<span style="letter-spacing:1.7pt;"> </span><span style="letter-spacing:0.05pt;">f</span>or<span style="letter-spacing:0.55pt;"> </span>non-cash<span style="letter-spacing:1.35pt;"> </span>i<span style="letter-spacing:0.05pt;">t</span>e<span style="letter-spacing:0.05pt;">m</span>s and $0.4&#160;million<span style="letter-spacing:1.1pt;"> </span>of cash provided by net<span style="letter-spacing:0.5pt;"> </span>w<span style="letter-spacing:0.05pt;">o</span>rki<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:1.25pt;"> </span>capital<span style="letter-spacing:1pt;"> </span>changes.<span style="letter-spacing:1pt;"> </span>Adjust<span style="letter-spacing:0.05pt;">m</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span>ts<span style="letter-spacing:1.85pt;"> </span>for<span style="letter-spacing:0.5pt;"> </span>non-cash items<span style="letter-spacing:0.85pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>ima<span style="letter-spacing:0.05pt;">r</span>ily<span style="letter-spacing:1.35pt;"> </span>consisted of<span style="letter-spacing:0.4pt;"> </span>$7.0&#160;million<span style="letter-spacing:1.15pt;"> </span>in<span style="letter-spacing:0.35pt;"> </span>dep<span style="letter-spacing:0.05pt;">r</span>ec<span style="letter-spacing:0.05pt;">i</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">t</span>ion<span style="letter-spacing:1.8pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>a<span style="letter-spacing:0.05pt;">m</span>ort<span style="letter-spacing:0.05pt;">i</span>za<span style="letter-spacing:0.05pt;">t</span>ion,<span style="letter-spacing:1.9pt;"> </span><span style="letter-spacing:0.05pt;">$4.0&#160;million</span><span style="letter-spacing:1.15pt;"> </span>in<span style="letter-spacing:0.35pt;"> </span>n<span style="letter-spacing:0.05pt;">o</span>n-cash<span style="letter-spacing:1.35pt;"> </span>inte<span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span>st items, $2.0&#160;million<span style="letter-spacing:1.15pt;"> </span>in non-cash<span style="letter-spacing:1.35pt;"> </span>lease<span style="letter-spacing:0.8pt;"> </span>ex<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:1.2pt;"> </span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">l</span>ated<span style="letter-spacing:1pt;"> </span>to<span style="letter-spacing:0.3pt;"> </span>o<span style="letter-spacing:0.05pt;">p</span>e<span style="letter-spacing:0.05pt;">r</span>ating<span style="letter-spacing:1.45pt;"> </span>lease ri<span style="letter-spacing:0.05pt;">g</span>ht-<span style="letter-spacing:0.05pt;">o</span>f-<span style="letter-spacing:0.05pt;">u</span>se<span style="letter-spacing:1.7pt;"> </span>assets, and<span style="letter-spacing:1pt;"> </span>$0.8&#160;million<span style="letter-spacing:1.15pt;"> </span>in<span style="letter-spacing:0.35pt;"> </span>stock<span style="letter-spacing:0.8pt;"> </span>co<span style="letter-spacing:0.05pt;">m</span>pensa<span style="letter-spacing:0.05pt;">t</span>ion<span style="letter-spacing:2pt;"> </span>expense, partially offset by a $1.0&#160;million change in deferred tax liability, a $0.5&#160;million unrealized gain on equity securities and a $0.4&#160;million change in the fair value of contingent consideration obligation.<span style="letter-spacing:1.25pt;"> </span>The changes in net working capital consisted primarily of increases related to $10.2&#160;million in accrued expenses and other liabilities and $2.3&#160;million in accounts payable, partially offset by decreases related to $5.6&#160;million in prepaid<span style="letter-spacing:1.15pt;"> </span>expenses<span style="letter-spacing:1.35pt;"> </span>and<span style="letter-spacing:1.15pt;"> </span>other<span style="letter-spacing:0.8pt;"> </span>current<span style="letter-spacing:1.1pt;"> </span>assets, $4.7&#160;million in due<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.35pt;"> </span>related<span style="letter-spacing:1.05pt;"> </span>parties<span style="letter-spacing:1pt;"> </span>and<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">$1.8&#160;million</span> in ope<span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">t</span>ing<span style="letter-spacing:1.4pt;"> </span>lease liabi<span style="letter-spacing:0.05pt;">l</span>ities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the six&#160;months ended June&#160;30,&#160;2021, net cash provided by investing activities was $42.3&#160;million, which included cash inflows of $57.7&#160;million <span style="letter-spacing:0.05pt;">f</span>rom<span style="letter-spacing:0.8pt;"> </span>matu<span style="letter-spacing:0.05pt;">r</span>ities<span style="letter-spacing:1.45pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>sales<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">m</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">r</span>ketable<span style="letter-spacing:1.6pt;"> </span>sec<span style="letter-spacing:0.05pt;">u</span>rit<span style="letter-spacing:0.05pt;">i</span>es<span style="letter-spacing:0.05pt;">, partially offset</span><span style="letter-spacing:1.5pt;"> </span><span style="letter-spacing:0.05pt;">by $15.1&#160;million</span><span style="letter-spacing:1.1pt;"> </span><span style="letter-spacing:0.05pt;">of p</span>urchases<span style="letter-spacing:1.45pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>opert<span style="letter-spacing:0.05pt;">y</span>,<span style="letter-spacing:1.35pt;"> </span>plant<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>equip<span style="letter-spacing:0.05pt;">m</span>ent and $0.3&#160;million of purchases of marketable debt securities.<span style="letter-spacing:1.6pt;"> </span>Our<span style="letter-spacing:0.7pt;"> </span>invest<span style="letter-spacing:0.05pt;">m</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span>ts<span style="letter-spacing:1.75pt;"> </span>in<span style="letter-spacing:0.35pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>opert<span style="letter-spacing:0.05pt;">y</span>,<span style="letter-spacing:1.35pt;"> </span>plant<span style="letter-spacing:0.8pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:0.6pt;"> </span>equip<span style="letter-spacing:0.05pt;">m</span>ent<span style="letter-spacing:0.85pt;"> </span>related<span style="letter-spacing:1pt;"> </span><span style="letter-spacing:0.05pt;">p</span>ri<span style="letter-spacing:0.05pt;">m</span>a<span style="letter-spacing:0.05pt;">r</span>ily<span style="letter-spacing:1.35pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o<span style="letter-spacing:0.35pt;"> </span>acquisiti<span style="letter-spacing:0.05pt;">o</span>ns<span style="letter-spacing:1.75pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>equ<span style="letter-spacing:0.05pt;">i</span>pment<span style="letter-spacing:1.55pt;"> </span><span style="letter-spacing:0.05pt;">w</span>hich<span style="letter-spacing:0.95pt;"> </span>wi<span style="letter-spacing:0.05pt;">l</span>l<span style="letter-spacing:0.65pt;"> </span>be<span style="letter-spacing:0.4pt;"> </span>used<span style="letter-spacing:0.7pt;"> </span>f<span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:0.05pt;">m</span>anufactu<span style="letter-spacing:0.05pt;">r</span>ing<span style="letter-spacing:2.1pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.4pt;"> </span>our<span style="letter-spacing:0.6pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>oduct<span style="letter-spacing:1.15pt;"> </span>cand<span style="letter-spacing:0.05pt;">ida</span>te<span style="letter-spacing:-0.05pt;">s and expenditures related to the build out of our manufacturing facilities</span>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">six&#160;months ended June&#160;30,&#160;2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, net cash </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provided by</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> investing activities was </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$29.3&#160;million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which included cash </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inflows</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$44.4&#160;million</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.05pt;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rom</span><span style="letter-spacing:0.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">matu</span><span style="letter-spacing:0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ities</span><span style="letter-spacing:1.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sales</span><span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</span><span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">m</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ketable</span><span style="letter-spacing:1.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sec</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rit</span><span style="letter-spacing:0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:1.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">partially offset by</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$14.8&#160;million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of purchases of marketable debt securities</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.3&#160;million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of purchases of property, plant and equipment</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the six&#160;months ended June&#160;30,&#160;2021, net cash provided by financing activities was $136.8&#160;million, which consisted of $95.0&#160;million in net proceeds <span style="letter-spacing:0.05pt;">from the&#160;ATM offering</span>, $40.0&#160;million in proceeds from issuances of<span style="letter-spacing:0.4pt;"> </span>related<span style="letter-spacing:1pt;"> </span>party notes and $4.4&#160;million in proceeds from exercises of stock options. Net cash used in financing activities consisted of $2.6&#160;million<span style="letter-spacing:1.1pt;"> </span>related<span style="letter-spacing:1pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o<span style="letter-spacing:0.35pt;"> </span>net<span style="letter-spacing:0.5pt;"> </span>share<span style="letter-spacing:0.8pt;"> </span>settle<span style="letter-spacing:0.05pt;">m</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:1.5pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>ves<span style="letter-spacing:0.05pt;">t</span>ed<span style="letter-spacing:1pt;"> </span>RSUs<span style="letter-spacing:0.9pt;"> </span>for<span style="letter-spacing:0.55pt;"> </span>pay<span style="letter-spacing:0.05pt;">m</span>e<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>pay<span style="letter-spacing:0.05pt;">r</span>oll<span style="letter-spacing:1.05pt;"> </span><span style="letter-spacing:0.05pt;">t</span>a<span style="letter-spacing:0.05pt;">x withholding</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the six&#160;months ended June&#160;30,&#160;2020, net cash provided by financing activities was $87.2&#160;million, which consisted primarily of $86.8&#160;million in net proceeds from an equity offering.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future Funding Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have generated minimal revenue, and we have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. We do not expect to generate significant revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not know when, or if, this will occur. In addition, we expect our expenses to significantly increase in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our product candidates. We have also incurred and expect that we will continue to incur in the future additional costs associated with operating as a public company as well as costs related to future fundraising efforts. In addition, subject to obtaining regulatory approval of our product candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations. We expect that our expenses will increase substantially if and as we:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">continue research and development, including preclinical and clinical development of our existing product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potentially seek regulatory approval for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seek to discover and develop additional product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establish a commercialization infrastructure and scale up our manufacturing and distribution capabilities to commercialize any of our product candidates for which we may obtain regulatory approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seek to comply with regulatory standards and laws&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">maintain, leverage and expand our intellectual property portfolio&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">hire clinical, manufacturing, scientific and other personnel to support our product candidates&#8217; development and future commercialization efforts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">add operational, financial and management information systems and personnel&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">incur additional legal, accounting and other expenses in operating as a public company.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings (including the&#160;ATM) and our potential ability to borrow from affiliated entities, will be sufficient to fund our operations through at least the next 12&#160;months following the issuance date of the condensed consolidated financial statements based primarily upon our Executive Chairman&#8217;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we may need additional funds to meet our needs sooner than planned.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">need</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to obtain</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dditional</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financing</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to fund</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fut</span><span style="letter-spacing:-0.1pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:0.05pt;">p</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">erations,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">completing</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial</span><span style="letter-spacing:0.1pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">zation</span><span style="letter-spacing:-0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates.</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.3pt;">C</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hanging</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cir</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">umstances</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cause</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to increase</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">spending</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gnif</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ly</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">faster</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">th</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we curr</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ntly</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ic</span><span style="letter-spacing:-0.05pt;">ip</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ate</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.15pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eed</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">raise</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">funds</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sooner</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">presently</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">anticipate.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.35pt;">research and development and our operating costs and fixed</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rent</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contractual</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">co</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mitm</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uding those</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborat</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ons,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subs</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">xpec</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to </span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ncr</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">se</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">futur</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>funding<span style="letter-spacing:-0.35pt;"> </span>requ<span style="letter-spacing:-0.1pt;">i</span>rements<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>depend<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>many<span style="letter-spacing:-0.15pt;"> </span>factors,<span style="letter-spacing:-0.3pt;"> </span>including,<span style="letter-spacing:-0.35pt;"> </span>but<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>limited<span style="letter-spacing:-0.25pt;"> </span>to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">progr</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ming,</span><span style="letter-spacing:-0.25pt;color:#000000;"> number, </span><span style="color:#000000;">scope</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">os</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> researching and developing our product candidates </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;">g</span><span style="color:#000000;">oing,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">plan</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd po</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">lin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ria</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ime</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.1pt;color:#000000;"> of</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">successfully</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">commercialize</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approved and the costs of such commercialization activities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">revenue</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">oduct</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">commercialize,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">any,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">i</span><span style="letter-spacing:-0.1pt;color:#000000;">n</span><span style="color:#000000;">cluding</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">selling</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">prices</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">su</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">h potential</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">availabi</span><span style="letter-spacing:0.05pt;color:#000000;">l</span><span style="color:#000000;">ity</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">adequate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">third-party</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">cover</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">ge</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">building,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">staffing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">validating</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">own</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:-0.5pt;color:#000000;"> facilities</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Un</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ted</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">Sta</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">es, including having a product candidate successfully manufactured consistent with FDA and European Medicines Agency regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">erms,</span><span style="letter-spacing:-0.25pt;color:#000000;"> t</span><span style="color:#000000;">iming</span><span style="letter-spacing:-0.2pt;color:#000000;"> and costs </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">pote</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">tial</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">collaborations,</span><span style="letter-spacing:-0.5pt;color:#000000;"> business or product acquisitions, </span><span style="color:#000000;">CVRs,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">lestones,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">yalti</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">g or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">arrangements</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">established</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">establish&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ime</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">necessary</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to respond</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">technological,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">regulatory,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">po</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">itical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">developments&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">osts</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">filing,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">prosecuting,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">maintaining,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">defending</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">enforcing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">claims</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">rights.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>until<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>generate<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>suffic<span style="letter-spacing:0.05pt;">i</span>ent<span style="letter-spacing:-0.35pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>reve<span style="letter-spacing:0.05pt;">n</span>ues,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>m<span style="letter-spacing:-0.1pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>finance<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>uture<span style="letter-spacing:-0.2pt;"> </span>cash<span style="letter-spacing:-0.2pt;"> </span>needs<span style="letter-spacing:-0.25pt;"> </span>through<span style="letter-spacing:-0.35pt;"> </span>pu<span style="letter-spacing:0.05pt;">b</span>lic<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>private<span style="letter-spacing:-0.25pt;"> </span>equity<span style="letter-spacing:-0.15pt;"> </span>offerings,<span style="letter-spacing:-0.4pt;"> </span>license agreements,<span style="letter-spacing:-0.45pt;"> </span>debt<span style="letter-spacing:-0.15pt;"> </span>financings,<span style="letter-spacing:-0.4pt;"> </span>col<span style="letter-spacing:0.05pt;">l</span>abor<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">i</span>ons,<span style="letter-spacing:-0.4pt;"> </span>str<span style="letter-spacing:-0.05pt;">a</span>teg<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.25pt;"> </span>al<span style="letter-spacing:-0.05pt;">l</span>ian<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>dis<span style="letter-spacing:-0.1pt;">t</span>ribution<span style="letter-spacing:-0.35pt;"> </span>arrangements. <span style="letter-spacing:-0.05pt;">However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms, or at all, including but not limited to the offering, issuance and sale by us of up to a maximum aggregate amount of</span> $500.0&#160;million of our common stock that may be issued and sold under the ATM. See <a href="#N10___STOCKHOLDERS_DEFICIT"><span style="text-decoration:underline;">Note&#160;9</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;">Stockholders&#8217; Deficit</span>, of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; that appear in Item&#160;1. &#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>extent<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>raise<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:-0.1pt;">a</span>pital<span style="letter-spacing:-0.25pt;"> </span>through<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>sale<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>equity<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>conver<span style="letter-spacing:-0.05pt;">t</span>ible<span style="letter-spacing:-0.35pt;"> </span>debt<span style="letter-spacing:-0.2pt;"> </span>securitie<span style="letter-spacing:-0.05pt;">s including through the ATM or other offerings</span>,<span style="letter-spacing:-0.3pt;"> </span>your<span style="letter-spacing:-0.05pt;"> </span>ownership<span style="letter-spacing:0.05pt;"> </span>interest<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>diluted,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the terms<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>liquidation<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>preferences<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>your<span style="letter-spacing:-0.05pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>stockholder.<span style="letter-spacing:-0.4pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>incurrence<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>indebtedness<span style="letter-spacing:-0.3pt;"> </span>would result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>increased<span style="letter-spacing:-0.35pt;"> </span>fixed<span style="letter-spacing:-0.15pt;"> </span>payment<span style="letter-spacing:-0.25pt;"> </span>obligations<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>involve<span style="letter-spacing:-0.3pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:0.1pt;">e</span>strictive<span style="letter-spacing:-0.35pt;"> </span>covenants,<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>limitations<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>abil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>to incur<span style="letter-spacing:-0.15pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>debt, li<span style="letter-spacing:-0.05pt;">m</span>it<span style="letter-spacing:-0.05pt;">a</span>tions<span style="letter-spacing:-0.35pt;"> </span>on our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>to <span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">c</span>qu<span style="letter-spacing:-0.05pt;">i</span>re<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">e</span>nse<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">l</span>le<span style="letter-spacing:-0.05pt;">c</span>tu<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.3pt;"> </span>p<span style="letter-spacing:-0.15pt;">r</span>operty<span style="letter-spacing:-0.3pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>operating<span style="letter-spacing:-0.35pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>strictions<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>impact<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to conduct<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>raise<span style="letter-spacing:-0.2pt;"> </span>additional<span style="letter-spacing:-0.4pt;"> </span>funds<span style="letter-spacing:-0.05pt;"> </span>through<span style="letter-spacing:-0.25pt;"> </span>strategic<span style="letter-spacing:-0.3pt;"> </span>partnerships<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd alliances<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>licensing<span style="letter-spacing:-0.35pt;"> </span>arrangements<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parti<span style="letter-spacing:0.05pt;">e</span>s,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">w</span>e<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>y have<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>relinquish<span style="letter-spacing:-0.3pt;"> </span>valuable<span style="letter-spacing:-0.3pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>to our technologies<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>licenses<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>terms<span style="letter-spacing:-0.15pt;"> </span>unfavorable<span style="letter-spacing:-0.4pt;"> </span>to us. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to delay or reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts. Our current license and collaboration agreements may also be terminated if we are unable to meet the payment obligations under those agreements. As a result, we may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations, Commitments and Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See <a href="#N8___COMMITMENTS_CONTINGENCIES"><span style="text-decoration:underline;">Note&#160;7</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Commitments and Contingencies &#8211; Lease Arrangements</span>,<span style="font-style:italic;"> </span>and<span style="font-style:italic;"> </span><a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;8</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Related-Party Agreements</span>, of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; <span style="color:#000000;">that appear </span>in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of <span style="color:#000000;">this Quarterly Report on Form&#160;10-Q.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contingencies</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. <span style="Background-color:#FFFFFF;color:#000000;">We are aware of complaints that have been filed regarding the Merger, but we have not been served with any of such complaints. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. </span>Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019&#160;(including NantCell,&#160;Inc.) filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Exhibit&#160;99.2</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations of ImmunityBio,&#160;Inc. filed as </span><a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex993.htm"><span style="text-decoration:underline;">Exhibit&#160;99.3</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Current Report on Form&#160;8-K/A filed with the SEC on April&#160;22,&#160;2021, we have disclosed those accounting policies that we consider to be significant in determining our results of operations and financial condition. There have been no material changes to those policies that we consider to be significant since the filing of our Current Report on Form&#160;8-K/A on April&#160;22,&#160;2021. The accounting principles used in preparing our condensed consolidated financial statements conform in all material respects </span><span style="Background-color:#FFFFFF;color:#000000;">with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;)</span>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses for the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for stock-based compensation under the provisions of FASB ASC Topic&#160;718, <span style="font-style:italic;">Compensation&#8212;Stock Compensation</span> (&#8220;ASC&#160;718&#8221;). We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refer to <a href="#N2___SUMMARY_SIGNIFICANT_ACCOUNTING_POLI"><span style="text-decoration:underline;">Note&#160;2</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Summary of Significant Accounting Policies</span>, of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; <span style="color:#000000;">that appears </span>in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of <span style="color:#000000;">this Quarterly Report on Form&#160;10-Q</span> for a discussion of recent accounting pronouncements or changes in accounting pronouncements that are of significance, or potential significance, to us.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial market risks related to interest rates, equity investments, foreign currency exchange rates and inflation are described in the Combined Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations of ImmunityBio,&#160;Inc. filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex993.htm"><span style="text-decoration:underline;">Exhibit&#160;99.3</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to </span>our Current Report on Form&#160;8-K filed with the SEC on April&#160;22,&#160;2021, there have been no material changes to the financial market risks described at December&#160;31,&#160;2020. We do not currently anticipate any other near-term changes in the nature of our financial market risk exposures or in management&#8217;s objectives and strategies with respect to managing such exposures.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_CONTROLS_PROCEDURES">ITEM 4. CONTROLS AND PROCEDURES.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives of ensuring that information we are required to disclose in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer (&#8220;CEO&#8221;) and chief financial officer (&#8220;CFO&#8221;), as appropriate, to allow timely decisions regarding required disclosures, and is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. There is no assurance that our disclosure controls and procedures will operate effectively under all circumstances.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management, with the participation of our CEO and CFO, evaluated the effectiveness of our disclosure controls and procedures as of June&#160;30,&#160;2021. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rule&#160;13a-15(e) of the Exchange Act means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June&#160;30,&#160;2021, our CEO and CFO have concluded that, as of June&#160;30,&#160;2021, our disclosure controls and procedures were effective at the reasonable assurance level.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no changes in our internal control over financial reporting&#160;(as defined in Rules 13a-15(f) and 15d-15(f) of the&#160;Exchange Act) during the fiscal quarter ended June&#160;30,&#160;2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. However, as a result of the Merger, our internal control over financial reporting may change. Our process for evaluating controls and procedures is continuous and encompasses constant improvement of the design and effectiveness of established controls and procedures and the remediation of any deficiencies, which may be identified during this process.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inherent Limitations on Effectiveness of Controls</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management recognizes that a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions&#59; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IIOR_INFORMATION">PART II&#8212;OTHER INFORMATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_LEGAL_PROCEEDINGS">ITEM 1. LEGAL PROCEEDINGS.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. We are aware of complaints that have been filed regarding the Merger, but we have not been served with any of such complaints. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See <a href="#N8___COMMITMENTS_CONTINGENCIES"><span style="text-decoration:underline;">Note&#160;7</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Commitments and Contingencies&#8212;Litigation</span>, of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; included in Part&#160;I, Item&#160;1. &#8220;Financial Statements&#8221; of this Quarterly Report on Form 10-Q for a discussion of legal matters.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">ITEM 1A. RISK FACTORS.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, any of which may be relevant to decisions regarding an investment in or ownership of our stock. The occurrence of any of these risks could have a significant adverse effect on our reputation, business, financial condition, results of operations, growth and ability to accomplish our strategic objectives. We have organized the description of these risks into groupings in an effort to enhance readability, but many of the risks interrelate or could be grouped or ordered in other ways, so no special significance should be attributed to the groupings or order below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">On<span style="letter-spacing:-0.05pt;"> </span>March&#160;9,&#160;2021,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>completed<span style="letter-spacing:-0.3pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>merger<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>ImmunityBio,<span style="letter-spacing:-0.45pt;"> </span>Inc<span style="letter-spacing:0.05pt;">.</span>,<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>private<span style="letter-spacing:-0.2pt;"> </span>company<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>ferred<span style="letter-spacing:-0.15pt;"> </span>to below<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>&#8220;Imm<span style="letter-spacing:0.05pt;">u</span>nityBio.&#8221;<span style="letter-spacing:-0.4pt;"> </span>After<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">t</span>he<span style="letter-spacing:-0.15pt;"> </span>completion<span style="letter-spacing:-0.4pt;"> </span>of this<span style="letter-spacing:-0.1pt;"> </span>merger,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>(formerly<span style="letter-spacing:-0.3pt;"> </span>known<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>NantK<span style="letter-spacing:-0.05pt;">w</span>est,<span style="letter-spacing:-0.45pt;"> </span>Inc.)<span style="letter-spacing:-0.1pt;"> </span>changed<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>name<span style="letter-spacing:0.05pt;"> </span>to ImmunityBio,&#160;Inc.,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>references<span style="letter-spacing:-0.4pt;"> </span>below<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>&#8220;the<span style="letter-spacing:-0.2pt;"> c</span>ompan<span style="letter-spacing:0.1pt;">y</span>,&#8221;<span style="letter-spacing:0.05pt;"> &#8220;the combined company,&#8221; </span>&#8220;we,&#8221;<span style="letter-spacing:0.05pt;"> &#8220;us,&#8221; </span>and &#8220;our&#8221;<span style="letter-spacing:-0.05pt;"> </span>refer<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> ImmunityBio, Inc. and its subsidiaries</span>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk<span style="letter-spacing:0.05pt;"> </span>Factor<span style="letter-spacing:-0.2pt;"> </span>Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R<span style="letter-spacing:-0.05pt;">i</span>sks<span style="letter-spacing:-0.05pt;"> </span>Relat<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>to Our<span style="letter-spacing:-0.15pt;"> Limited Operating History, </span><span style="letter-spacing:-0.05pt;">F</span>inan<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.15pt;"> </span>Condition<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>Capital<span style="letter-spacing:-0.3pt;"> </span>R<span style="letter-spacing:-0.05pt;">e</span>qui<span style="letter-spacing:-0.05pt;">r</span>em<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span>ts</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">need</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">f</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nancing</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">fund</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">operations</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">complete</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">dev</span><span style="letter-spacing:0.1pt;color:#000000;">e</span><span style="color:#000000;">lopment</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">comme</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">cialization</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">various</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">pr</span><span style="letter-spacing:-0.05pt;color:#000000;">o</span><span style="color:#000000;">duct candidates,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">if we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">unable</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to obtain</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">financing when needed, or on acceptable terms,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">unable</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to complete</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">dev</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">lopment</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">commercialization</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">o</span><span style="color:#000000;">f</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates.</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">Raising</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">addit</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">onal</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">capital</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cause</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">dilution</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">stockholders,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">restrict</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">operat</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">ons</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">require</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">relinquish rights</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">technologies</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">debt</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">adversely</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">affect</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">cash</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">flows</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">limit</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">f</span><span style="letter-spacing:-0.1pt;color:#000000;">l</span><span style="color:#000000;">exib</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ra</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ddit</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">onal</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">pit</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">b</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">sinesses</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">integrated</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">succ</span><span style="letter-spacing:0.15pt;color:#000000;">e</span><span style="color:#000000;">ssfully,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">integration</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">d</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">fficult,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">time</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">consuming</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">costly</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">ex</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">ected. Operating</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">costs,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">customer</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">loss</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">disruption,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">difficult</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">es</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">n m</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">int</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ionsh</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ps</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ploye</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">u</span><span style="letter-spacing:-0.1pt;color:#000000;">s</span><span style="color:#000000;">tom</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">, suppliers</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">vendors,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">greater</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">expected</span><span style="letter-spacing:-0.3pt;color:#000000;"> for the combined company</span><span style="color:#000000;">.</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">Revenues</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">lower</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">expec</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ed for the combined company.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">history</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">operat</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">losses,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">expect</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to continue</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">incur</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">losses</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">never</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">profitable, which together with our limited operating history, makes it difficult to assess our future viability.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">We invest our cash on hand in various financial instruments, which are subject to risks that could adversely affect our business, results of operations, liquidity and financial condition</span><span style="color:#000000;">.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.05pt;">k</span>s Related<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>Our<span style="letter-spacing:-0.15pt;"> </span>Business and<span style="letter-spacing:-0.05pt;"> </span>I<span style="letter-spacing:-0.05pt;">n</span>d<span style="letter-spacing:-0.05pt;">u</span>stry<span style="letter-spacing:-0.05pt;"> </span>R<span style="letter-spacing:-0.05pt;">e</span>gulation</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We will be substantially dependent on the success of our product candidates and cannot guarantee that these product candidates will successfully complete development, receive regulatory approval or be successfully commercialized.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in combination</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">therapies,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">exposes us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">risks.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Due to the significant resources required for the development of our product candidates, and depending on our ability to access capital, we must prioritize among many different opportunities. We may expend our limited resources on programs that do not yield successful product candidates as opposed to indications that may be more profitable or for which there is a greater likelihood of success</span><span style="letter-spacing:-0.05pt;color:#000000;">.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trial</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">costs</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">higher</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">conventional</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">therapeutic</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">chnologies</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">drug</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">products.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">il</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">demonst</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">ate</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">adequately</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">sa</span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">ty</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">efficacy</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cand</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">dates,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">would</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">prevent</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">delay regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">co</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">mer</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">z</span><span style="color:#000000;">at</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">on.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Interim,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">initial,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">&#8220;top-line&#8221;</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">preliminary</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.1pt;color:#000000;">a</span><span style="color:#000000;">ls</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">announce</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">publi</span><span style="letter-spacing:-0.1pt;color:#000000;">s</span><span style="color:#000000;">h</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">time</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">time</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">c</span><span style="color:#000000;">hange</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">more patient</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">become</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">v</span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">lab</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">re</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">sub</span><span style="letter-spacing:-0.05pt;color:#000000;">j</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o audit</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">veri</span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="color:#000000;">ication</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">procedures</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ould</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">ult in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rial</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">hang</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">final</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">data.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">limited</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">experience</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">conducting</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">lied</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rely</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">rties</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">relat</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">parties</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to c</span><span style="letter-spacing:-0.05pt;color:#000000;">o</span><span style="color:#000000;">nduct</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">many</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">preclinical</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">studies</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">cal</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials and to manufacture products.</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">Any</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">failure</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">party,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">relat</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">party,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">conduct</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">according</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to Good</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">Clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">Practi</span><span style="letter-spacing:-0.1pt;color:#000000;">c</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">(&#8220;GCP&#8221;)</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">regulations,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a timely</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">manner</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">delay</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">prevent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">seek</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">btain</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">g</span><span style="color:#000000;">ulato</span><span style="letter-spacing:-0.1pt;color:#000000;">r</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">val for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> commercialization of our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">initiated</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">completed</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">when</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">expec</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.2pt;color:#000000;">or at all, they may take longer and cost more to complete than we project </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">required</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">conduct</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ls</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or modify</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">cli</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">ical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">based</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">feedback</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">receive</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.15pt;color:#000000;">United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;</span><span style="letter-spacing:0.05pt;color:#000000;">F</span><span style="color:#000000;">DA</span><span style="color:#000000;">&#8221;)</span><span style="color:#000000;">.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We will be unable to commercialize our product candidates if our trials are not successful.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Even if one of our product candidates is approved and commercialized, we may not become profitable.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">Immuno-Oncology</span><span style="letter-spacing:-0.75pt;color:#000000;"> </span><span style="color:#000000;">Clinic,&#160;Inc</span><span style="letter-spacing:0.15pt;color:#000000;">. (the&#160;&#8220;Clinic&#8221;)</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a related</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">party,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in some</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">expose</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">significant</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">regul</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">tory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">risks.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">If our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">this</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">site</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">sufficiently</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">robust</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">there</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">integrity</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">sues, we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">requ</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">red</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">repeat</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="color:#000000;">studies</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">required </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ontra</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">th o</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">her</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ni</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">developme</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">plans</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">significantly</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">delayed,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">inc</span><span style="letter-spacing:-0.1pt;color:#000000;">u</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">additional </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">s.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">encounter</span><span style="letter-spacing:-0.35pt;color:#000000;"> delays or </span><span style="color:#000000;">difficulties</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">enr</span><span style="letter-spacing:-0.05pt;color:#000000;">o</span><span style="color:#000000;">lling</span><span style="letter-spacing:-0.25pt;color:#000000;"> and/or maintaining </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">devel</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">pment</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">activities</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">receipt</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ne</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">essary</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">marketing approvals</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">delayed</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">otherwise</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">adversely</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">affected.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">prod</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">ct</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cause</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">undesirable</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">side</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">effects</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">h</span><span style="letter-spacing:-0.1pt;color:#000000;">a</span><span style="color:#000000;">ve</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">properties</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">halt</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">development,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">prev</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">heir regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">approval,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">limit</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">omm</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rc</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">pot</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nti</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or result</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">significant</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">negative</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">consequences.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">T</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">manufacture</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ndidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">complex,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">encounter</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">difficulties</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">duction,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">particularly</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">resp</span><span style="letter-spacing:0.1pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o process</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">development,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">quali</span><span style="letter-spacing:-0.1pt;color:#000000;">t</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">control,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">scaling-up</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">nufacturing</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">capabili</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ies.</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">If</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">related</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">parties,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">third-party manufacturers</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">encounter</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">fficulties,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to provide</span><span style="letter-spacing:-0.3pt;color:#000000;"> adequate </span><span style="color:#000000;">supply</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> p</span><span style="color:#000000;">roducts</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for patients,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approved,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">delayed</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">stoppe</span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">unable</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to maintain</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">commerc</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ally</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">viable</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">structure.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Cell-based therapies and biologics rely on the availability of reagents, specialized equipment and other specialty materials, which may not be available to us on acceptable terms or at all. For some of these reagents, equipment and materials, we rely or may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products, if approved.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">efforts</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to develop,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">manufacture</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">COVID&#8209;19</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">therapeutics</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">require</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">personnel</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">who</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">ll</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">require training,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may cause</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">some</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">employees</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">reallocate</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">me</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">from other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">duties</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in turn</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">cause</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">delays</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">supply</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">product candidates</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">trials.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to use</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">net</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">operating</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">losses</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">research</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">credits</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">offset</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">axable</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">income</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">subject</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rtain</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">im</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">tat</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ons.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Changes</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">tax</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">law</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">adv</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ly</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">affe</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">b</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">sin</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">ss</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and financial</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">co</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">dition. Negative or unexpected tax consequences could adversely affect our results of operations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">transfer</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">pricing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">poli</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">subject</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">challenge</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Internal Revenue Service (&#8220;IRS&#8221;) or other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">taxing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">thorities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We could be subje</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> additional income tax liabilities and to </span><span style="color:#000000;">examinations</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tax</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">returns by</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">h</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">IRS</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">domestic</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">d</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">foreign</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tax authorities.</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">An</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">adverse</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">out</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">ome</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">audit</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">examination</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">IRS</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tax</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">authority</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">cou</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">material</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">adver</span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">eff</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ct</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">on o</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">r op</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rating</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">results and finan</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ial</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">condit</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">on.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our projections regarding the market opportunities for our product candidates may not be accurate, and the actual market for our products, if approved, may be smaller than we estimate.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Because our current product candidates represent, and our other potential product candidates will represent novel approaches to the treatment of disease, there are many uncertainties regarding the development, market acceptance, third-party reimbursement coverage and the commercial potential of our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We will face significant competition from other biotechnology and pharmaceutical companies and from non-profit institutions.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Public opinion and scrutiny of immunotherapy approaches may impact public perception of us and our product candidates, which may adversely affect our ability to conduct our business and implement our business plans.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">We may seek orphan drug status or Fast Track or Breakthrough Therapy designations or other designation for one or more of our product candidates, but even if any such designation or status is granted, it may </span><span style="color:#000000;">not</span><span style="color:#000000;"> lead to faster development or a faster regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval and we may be unable to maintain any benefits associated with such designations or status, including market exclusivity.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">As a condition of approval, the FDA may require that we implement various post-marketing requirements and conduct post-marketing studies, any of which would require a substantial investment of time, effort, and money, and which may limit our commercial prospects.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">never</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">zed</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">before,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">lack</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">necessary</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">exper</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ise,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">personnel</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">resources</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to successfully</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">commercia</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ize</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:-0.1pt;color:#000000;">w</span><span style="color:#000000;">n</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">together</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">suitable</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">collaborators. We may be unable to establish effective marketing and sales capabilities or enter into agreements with third parties or related parties to market and sell our product candidates, if they are approved, and as a result, we may be unable generate product revenues.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We expect to rely on third parties to perform many essential services for any products that we commercialize, including services related to distribution, government price reporting, customer service, accounts receivable management, cash collection and adverse event reporting. If these third parties fail to perform as expected or to comply with legal and regulatory requirements, our ability to commercialize our current or future product candidates will be significantly impacted and we may be subject to regulatory sanctions.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If our product candidates do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">need</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to obtain</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">y proposed</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">branded</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">names,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">f</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">ilure</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">delay</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">associated</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">adversely affect</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">r </span><span style="letter-spacing:0.05pt;color:#000000;">b</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">i</span><span style="letter-spacing:-0.1pt;color:#000000;">n</span><span style="color:#000000;">te</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">omputer</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">y</span><span style="color:#000000;">s</span><span style="letter-spacing:0.1pt;color:#000000;">t</span><span style="color:#000000;">ems,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">those</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">used</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> contract research organizations (&#8220;</span><span style="color:#000000;">CROs&#8221;), contract manufacturing organizations (&#8220;C</span><span style="letter-spacing:0.05pt;color:#000000;">M</span><span style="color:#000000;">Os&#8221;), </span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">li</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">contractors</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">consultants,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">fail</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or suffer s</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">c</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">rity</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">b</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">ea</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">h</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our business could be adversely affected by the effects of health epidemics, pandemics or contagious diseases, including the recent COVID 19 pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have formed, and may in the future form or seek, strategic alliances or enter into collaborations with third parties or additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements. If we fail to enter into such strategic alliances, collaborations or licensing arrangement, or such strategic alliances, collaborations or licensing arrangements are not successful, we may not be able to capitalize on the market potential of our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We will be heavily dependent on our senior management, particularly Dr.&#160;Soon-Shiong, our Executive Chairman, and a loss of a member of our senior management team in the future, even if only temporary, could harm our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">b</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">come</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">v</span><span style="color:#000000;">olv</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">n securit</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">es</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">it</span><span style="letter-spacing:-0.15pt;color:#000000;">i</span><span style="color:#000000;">gation</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">stockholder</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">derivative</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">it</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">gation</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">n conn</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ion</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">wi</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">h</span><span style="letter-spacing:-0.1pt;color:#000000;"> our </span><span style="color:#000000;">recent</span><span style="letter-spacing:-0.1pt;color:#000000;"> merger, </span><span style="color:#000000;">and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">this</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">could divert</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">attention</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ma</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">agement</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">harm</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">bus</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and i</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">rance</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">ov</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">rage</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">ffi</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ie</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">cov</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">all</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ated</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">costs</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">and damages.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">A variety</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">risks</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">associated</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">mar</span><span style="letter-spacing:-0.1pt;color:#000000;">k</span><span style="color:#000000;">eting</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">int</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">rnationally</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">materially</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">adversely</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">affect</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">bus</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ness.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Related</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Government</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Regulation</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">We may be unable to obtain U.S. or foreign</span><span style="color:#000000;"> regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and,</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">as a result</span><span style="letter-spacing:-0.6pt;color:#000000;">, </span><span style="color:#000000;">be unable</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">to commercialize</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">our product</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.6pt;color:#000000;">. We are, </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> if </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> receive </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">app</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">oval</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates, will continue to be subject to ongoing extensive regulation, regulatory obligations and continued regulatory review, which may result in significant additional expense.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Results</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">patient</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">who</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">ceives</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">compassionate</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="color:#000000;">access</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">should</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">viewed</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">representative</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">how</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">perform</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">well-controlled</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trial,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cannot</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">used</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to establish</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">safety</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">efficacy</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">approval.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">GMP</span><span style="letter-spacing:-0.05pt;color:#000000;">-</span><span style="color:#000000;">in-a-Box</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">regulated</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">a medical</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">device,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">compliance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">dical</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">devices</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">expensive, complex</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">uncertain,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">failure</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">com</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">ly</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">lead</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to enf</span><span style="letter-spacing:-0.1pt;color:#000000;">o</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">tions</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">aga</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nst</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">us and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">negative</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">consequences</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="color:#000000;">our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We will be subject to governmental export and import controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">are subject</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">U.S.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and for</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ign</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">anti-corruption</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">anti-money</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">aundering </span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">aws with</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">sp</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">erations</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">non-compl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">an</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">such laws</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">can subj</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">riminal</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;">/</span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">civil</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">liabi</span><span style="letter-spacing:0.05pt;color:#000000;">l</span><span style="color:#000000;">ity</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and harm our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our failure to comply with state, national and/or international data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If we, or any third party contract manufacturers or suppliers that we engage, fail to comply with environmental, health, and safety laws and regulations, including regulations governing the handling, storage or disposal of hazardous materials, we could become subject to fines or penalties or incur costs that could harm our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Disruptions at the FDA, the Securities and Exchange Commission (&#8220;SEC&#8221;) and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If we</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">fail</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">comp</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">f</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">deral</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and s</span><span style="letter-spacing:-0.1pt;color:#000000;">t</span><span style="color:#000000;">ate</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">healthcare</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and promotional</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">laws,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">fraud</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">and ab</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">se</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">information</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">privacy</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">security</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">laws, we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">face</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">substantial</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">penalties</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:0.1pt;color:#000000;">u</span><span style="color:#000000;">r busines</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">, fi</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">an</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">ial</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">onditio</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">sults of operations,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">prospects</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">adversely</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">affe</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">ted.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may face difficulties from changes to current regulations and future legislation.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Go</span><span style="letter-spacing:-0.05pt;color:#000000;">v</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">ts</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">tside</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">h</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">Un</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ted</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">S</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ates</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tend</span><span style="letter-spacing:-0.05pt;color:#000000;"> t</span><span style="color:#000000;">o </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">mpose</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ct</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">pri</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">co</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">trols,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">whi</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">h</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">ad</span><span style="letter-spacing:0.05pt;color:#000000;">v</span><span style="color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">ly</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">aff</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">ct</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our r</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">v</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">n</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:0.05pt;color:#000000;">y</span><span style="color:#000000;">.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">employees,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">independent</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">contractors,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">consultants,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">partners, principal investigators, CROs, suppliers</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">vendors</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">engage</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">misconduct</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">improper</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">ac</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">v</span><span style="color:#000000;">it</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">es, in</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">luding</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">non</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">omp</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ian</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">gu</span><span style="letter-spacing:-0.05pt;color:#000000;">la</span><span style="color:#000000;">tory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">standards</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.1pt;color:#000000;">n</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">requirements.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">k</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">s R</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">lat</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">to I</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">te</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">le</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">tual</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">P</span><span style="letter-spacing:0.05pt;">r</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:-0.05pt;">p</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">er</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">y</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">unable</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to obtain,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">maintain,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ect</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">enforce</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.2pt;color:#000000;">a</span><span style="color:#000000;">tent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">protection</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">propri</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">tary</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">cand</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">dates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and technologies,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">able</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to compete</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">effectively</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">operate</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">profitably and our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">ab</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ty</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o pr</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">vent our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">competitors</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">comme</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">cializing</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">sim</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">lar</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">identical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">would</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">d</span><span style="letter-spacing:0.05pt;color:#000000;">v</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rsely</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">affected.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If any of our owned or in-licensed patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively. </span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> or our licensors, collaborators, or any future strategic partners may become subject to third party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation</span><span style="letter-spacing:-0.25pt;color:#000000;"> to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">protect</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">enforce</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">her</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">property of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">licenso</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.25pt;color:#000000;"> all of </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">uld</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">expensive,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">time-consuming</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">unsuccessful, may delay or prevent the development and commercialization of our product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates, or may put our patents and other proprietary rights at risk.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">T</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">oduct</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">potentially</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">conflict</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">others, and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">third-party</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">claims</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ll</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ctu</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">infringement,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">misa</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">iation</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">violation</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">against</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">us,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our licensors</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">collaborators</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">prevent</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">delay</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the development</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">commercialization</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">of our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidat</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">technologies.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Obtaining</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">maintaining</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">pro</span><span style="letter-spacing:-0.1pt;color:#000000;">t</span><span style="color:#000000;">ection</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">depends</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">compliance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">various</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">ocedural,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">document</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">submission,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">fee</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">payment,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">requirements</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">imposed</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">government</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">agencies,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">protection</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">duced</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">eliminated</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">non-compl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">an</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">e with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">ese</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">quirements.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Changes</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">United</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">States</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">law</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">diminish</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">value</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of patents</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in general,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">by</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">pairing</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">protect</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our product</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">comme</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">cialize</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">cand</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">dates</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">technologies</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">b</span><span style="letter-spacing:-0.05pt;color:#000000;">j</span><span style="color:#000000;">ec</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">part,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and condit</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:-0.1pt;color:#000000;">o</span><span style="color:#000000;">ns</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">es granted</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">others.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">fail</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">comp</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">obl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">gations</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">n t</span><span style="letter-spacing:-0.05pt;color:#000000;">h</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">agr</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">em</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">u</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">der</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">wh</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">h</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">tellectual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ghts</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">par</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ies</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or otherwise experience</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">disruptions</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">lat</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">ips</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">r lic</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">n</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">ors,</span><span style="letter-spacing:-0.15pt;color:#000000;"> we may be required to pay damages and </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">co</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">d lo</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ic</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">righ</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">h</span><span style="color:#000000;">at</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">important</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">b</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">mi</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ign</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">int</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ec</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">proper</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">y rights</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">able</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">protect</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">r intellectual</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">rights t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">roug</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">out</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">world.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">subject</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to claims</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our employees,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">consultants or i</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">depende</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">co</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">trac</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ors</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">h</span><span style="color:#000000;">ave</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">wro</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">gfully</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">used</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">disclosed</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">trade</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">cr</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">ts</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">oth</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">r confident</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">forma</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ion</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">parti</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">claims</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">asserti</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">g</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ownership</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">what</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">regard</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">own</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">property.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">able</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ense</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">acquire</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">necessary</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">i</span><span style="letter-spacing:-0.1pt;color:#000000;">n</span><span style="color:#000000;">tellectual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">chnology</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">pa</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">ti</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If we</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">do</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">ob</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ain</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">pa</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">rm</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">ext</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nsion</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">exclusivity</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product ca</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">didat</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">d</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">v</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">lop,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">m</span><span style="color:#000000;">at</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ally</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">harmed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">subject</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to claims</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">challenging</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">inv</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">orship</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">oth</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">int</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ll</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">propert</span><span style="letter-spacing:-0.05pt;color:#000000;">y</span><span style="color:#000000;">.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">unable</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to protect</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">confidentiality</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">r t</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">ade</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">c</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">ets,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">r business and</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="color:#000000;">co</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">pe</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">it</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ve</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">pos</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">on</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">wou</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">h</span><span style="color:#000000;">ar</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our trademarks</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">trade</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">names</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ad</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">quately</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">protected,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">h</span><span style="color:#000000;">en</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">able</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to build</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">name</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">recognition</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">marke</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">interest</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and o</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">r busi</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ss</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">adversely</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">affected.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Intellectual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">pr</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">perty</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">do</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">necessarily</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">address all</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">threats.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks<span style="letter-spacing:-0.05pt;"> </span>Related<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>Our<span style="letter-spacing:-0.1pt;"> </span>Common Stock</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Dr.</span><span style="letter-spacing:0.05pt;color:#000000;">&#160;Patrick </span><span style="color:#000000;">Soon-Shiong,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">ur</span><span style="letter-spacing:-0.05pt;color:#000000;"> E</span><span style="color:#000000;">xecutive</span><span style="letter-spacing:-0.35pt;color:#000000;"> C</span><span style="color:#000000;">hairman</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">principal</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">stockholder,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">has</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">significant</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">interests</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">companies</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">conflict wi</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">h</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our int</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rests.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Dr.</span><span style="letter-spacing:0.05pt;color:#000000;">&#160;</span><span style="color:#000000;">Soon-Shiong,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">gh</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">his</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">voting</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ontrol</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">company,</span><span style="letter-spacing:-0.4pt;color:#000000;"> has the ability </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">con</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">rol</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">actions</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.1pt;color:#000000;">q</span><span style="color:#000000;">uire stockholder</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">approval.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">T</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">price</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">common</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">stock</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">has</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">b</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">en</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">continue</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">volatile,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">inves</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">ors</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">difficulty</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">selling</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">shar</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">incurred</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">continue</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">incur</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">costs</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">result</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">operating</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">a public</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">company</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">management</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">has</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">been</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ll</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">be required</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">devote</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">substantial</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">time</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to compliance</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">initiatives</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">corporate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">governance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.1pt;color:#000000;">r</span><span style="color:#000000;">actices,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">maintaining</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">eff</span><span style="letter-spacing:-0.05pt;color:#000000;">ec</span><span style="color:#000000;">tive</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">sys</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">em of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">internal</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">control</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">over</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">financial</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">porting.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If a restatement of our financial statements were to occur, our stockholders&#8217; confidence in the company&#8217;s financial reporting in the future may be affected, which could in turn have a material adverse effect on our business and stock price.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have not paid cash dividends in the past and do not expect to pay dividends in the future. Any return on investment may be limited to the value of our common stock.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Because we are relying on the exemptions from corporate governance requirements as a result of being a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing standards, you do not have the same protections afforded to stockholders of companies that are subject to such requirements.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We are a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to smaller reporting companies could make our common stock less attractive to investors.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We are not subject to the provisions of Section&#160;203 of the Delaware General Corporation Law (&#8220;DGCL&#8221;), which could negatively affect your investment.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Limited Operating History, </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Condition and Capital Requirements</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>ad<span style="letter-spacing:0.05pt;">d</span>iti<span style="letter-spacing:0.05pt;">o</span>nal<span style="letter-spacing:-0.3pt;"> </span>financing<span style="letter-spacing:-0.3pt;"> </span>to fund<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>compl<span style="letter-spacing:-0.05pt;">e</span>te<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>de<span style="letter-spacing:-0.05pt;">v</span><span style="letter-spacing:0.05pt;">e</span>lop<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.45pt;"> </span>and com<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.05pt;">r</span>cialization<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>various<span style="letter-spacing:0.05pt;"> </span>pro<span style="letter-spacing:-0.05pt;">d</span>u<span style="letter-spacing:-0.05pt;">c</span>t candidat<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>, and<span style="letter-spacing:-0.05pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to obtain<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>financi<span style="letter-spacing:-0.1pt;">n</span>g when needed, or on acceptable terms,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>u<span style="letter-spacing:-0.05pt;">n</span>able<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o co<span style="letter-spacing:-0.05pt;">m</span>ple<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.3pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>dev<span style="letter-spacing:-0.1pt;">e</span>lopment<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>commercia<span style="letter-spacing:-0.05pt;">l</span>ization<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>produ<span style="letter-spacing:0.05pt;">c</span>t ca<span style="letter-spacing:0.05pt;">n</span>didat<span style="letter-spacing:0.05pt;">e</span>s.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development of biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>consumed<span style="letter-spacing:-0.4pt;"> </span>sub<span style="letter-spacing:0.05pt;">s</span>tantial<span style="letter-spacing:-0.2pt;"> </span>amounts<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>cash<span style="letter-spacing:-0.2pt;"> </span>since<span style="letter-spacing:-0.25pt;"> </span>inception.<span style="letter-spacing:-0.25pt;"> </span>A<span style="letter-spacing:0.05pt;"> </span>sign<span style="letter-spacing:-0.05pt;">i</span>fic<span style="letter-spacing:-0.05pt;">a</span>nt<span style="letter-spacing:-0.35pt;"> </span>p<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span>tion of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>funding<span style="letter-spacing:-0.25pt;"> </span>had<span style="letter-spacing:-0.1pt;"> </span>been<span style="letter-spacing:-0.2pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>form<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>promissory<span style="letter-spacing:-0.05pt;"> </span>notes<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>presenting<span style="letter-spacing:-0.4pt;"> $300.3&#160;million</span><span style="letter-spacing:-0.25pt;"> </span>in <span style="letter-spacing:-0.05pt;">i</span>ndebtedness, including interest thereon,<span style="letter-spacing:-0.4pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> June&#160;30,&#160;2021</span><span style="letter-spacing:-0.05pt;"> </span>held<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>entities<span style="letter-spacing:-0.3pt;"> </span>affiliated with<span style="letter-spacing:-0.2pt;"> </span>Dr.&#160;Soon-Shiong with<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>maturity<span style="letter-spacing:-0.25pt;"> </span>date<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>September&#160;30,&#160;2025.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30,&#160;2021, we<span style="letter-spacing:-0.45pt;"> held</span><span style="letter-spacing:-0.1pt;"> </span>cash,<span style="letter-spacing:-0.15pt;"> </span>cash<span style="letter-spacing:-0.1pt;"> </span>equiv<span style="letter-spacing:-0.05pt;">a</span>lents<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>ma<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">k</span>etable<span style="letter-spacing:-0.35pt;"> </span>securities<span style="letter-spacing:-0.3pt;"> totaling $104.8&#160;million</span>.<span style="letter-spacing:-0.25pt;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to obtain<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>dditional<span style="letter-spacing:-0.3pt;"> </span>financing<span style="letter-spacing:-0.3pt;"> </span>to fund<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>fut<span style="letter-spacing:-0.1pt;">u</span>re<span style="letter-spacing:-0.25pt;"> </span>o<span style="letter-spacing:0.05pt;">p</span>erations,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>completing<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>commercial<span style="letter-spacing:0.1pt;">i</span>zation<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product candidates.<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.3pt;">C</span>hanging<span style="letter-spacing:-0.35pt;"> </span>cir<span style="letter-spacing:-0.05pt;">c</span>umstances<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to increase<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>spending<span style="letter-spacing:-0.4pt;"> </span>s<span style="letter-spacing:-0.05pt;">i</span>gnif<span style="letter-spacing:-0.05pt;">i</span>can<span style="letter-spacing:-0.05pt;">t</span>ly<span style="letter-spacing:-0.4pt;"> </span>faster<span style="letter-spacing:-0.1pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>n<span style="letter-spacing:-0.05pt;"> </span>we curr<span style="letter-spacing:-0.05pt;">e</span>ntly<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.05pt;">t</span>ic<span style="letter-spacing:-0.05pt;">ip</span>ate<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> n</span>eed<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>raise<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>funds<span style="letter-spacing:0.05pt;"> </span>sooner<span style="letter-spacing:-0.05pt;"> </span>than<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>presently<span style="letter-spacing:-0.35pt;"> </span>anticipate.<span style="letter-spacing:-0.35pt;"> </span>Moreover,<span style="letter-spacing:-0.35pt;"> research and development and our operating costs and fixed</span><span style="letter-spacing:-0.15pt;"> </span>expenses<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>rent<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>contractual<span style="letter-spacing:-0.4pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>mitm<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">l</span>uding those<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:-0.25pt;"> </span>collaborat<span style="letter-spacing:-0.05pt;">i</span>ons,<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>subs<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>nt<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xpec<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.3pt;"> </span>to <span style="letter-spacing:-0.05pt;">i</span>ncr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">a</span>se<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>futur<span style="letter-spacing:-0.05pt;">e</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>funding<span style="letter-spacing:-0.35pt;"> </span>requ<span style="letter-spacing:-0.1pt;">i</span>rements<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>depend<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>many<span style="letter-spacing:-0.15pt;"> </span>factors,<span style="letter-spacing:-0.3pt;"> </span>including,<span style="letter-spacing:-0.35pt;"> </span>but<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>limited<span style="letter-spacing:-0.25pt;"> </span>to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">progr</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ming,</span><span style="letter-spacing:-0.25pt;color:#000000;"> number, </span><span style="color:#000000;">scope</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">os</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> researching and developing our product candidates </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;">g</span><span style="color:#000000;">oing,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">plan</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd po</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">lin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ria</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ime</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.1pt;color:#000000;"> of</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">successfully</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">commercialize</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approved and the costs of such commercialization activities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">revenue</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">oduct</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">commercialize,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">any,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">i</span><span style="letter-spacing:-0.1pt;color:#000000;">n</span><span style="color:#000000;">cluding</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">selling</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">prices</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">su</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">h potential</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">availabi</span><span style="letter-spacing:0.05pt;color:#000000;">l</span><span style="color:#000000;">ity</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">adequate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">third-party</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">cover</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">ge</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">building,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">staffing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">validating</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">own</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:-0.5pt;color:#000000;"> facilities</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Un</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ted</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">Sta</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">es, including having a product candidate successfully manufactured consistent with FDA and European Medicines Agency regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">erms,</span><span style="letter-spacing:-0.25pt;color:#000000;"> t</span><span style="color:#000000;">iming</span><span style="letter-spacing:-0.2pt;color:#000000;"> and costs </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">pote</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">tial</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">collaborations,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">business or product acquisitions</span><span style="letter-spacing:-0.5pt;color:#000000;">, </span><span style="color:#000000;">contingent</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">value</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">(&#8220;CVRs&#8221;),</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">lestones,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">yalti</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">g or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">arrangements</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">established</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">establish&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ime</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">necessary</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to respond</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">technological,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">regulatory,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">po</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">itical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">developments&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">osts</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">filing,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">prosecuting,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">maintaining,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">defending</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">enforcing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">claims</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">rights.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>until<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>generate<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>suffic<span style="letter-spacing:0.05pt;">i</span>ent<span style="letter-spacing:-0.35pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>reve<span style="letter-spacing:0.05pt;">n</span>ues,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>m<span style="letter-spacing:-0.1pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>finance<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>uture<span style="letter-spacing:-0.2pt;"> </span>cash<span style="letter-spacing:-0.2pt;"> </span>needs<span style="letter-spacing:-0.25pt;"> </span>through<span style="letter-spacing:-0.35pt;"> </span>pu<span style="letter-spacing:0.05pt;">b</span>lic<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>private<span style="letter-spacing:-0.25pt;"> </span>equity<span style="letter-spacing:-0.15pt;"> </span>offerings,<span style="letter-spacing:-0.4pt;"> </span>license agreements,<span style="letter-spacing:-0.45pt;"> </span>debt<span style="letter-spacing:-0.15pt;"> </span>financings,<span style="letter-spacing:-0.4pt;"> </span>col<span style="letter-spacing:0.05pt;">l</span>abor<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">i</span>ons,<span style="letter-spacing:-0.4pt;"> </span>str<span style="letter-spacing:-0.05pt;">a</span>teg<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.25pt;"> </span>al<span style="letter-spacing:-0.05pt;">l</span>ian<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>dis<span style="letter-spacing:-0.1pt;">t</span>ribution<span style="letter-spacing:-0.35pt;"> </span>arrangements.<span style="letter-spacing:-0.05pt;"> However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms, or at all, including but not limited to the offering, issuance and sale by us of up to a maximum aggregate amount of $500.0&#160;million of our common stock that may be issued and sold under an &#8220;at-the-market&#8221; sales agreement with Jefferies&#160;LLC (the &#8220;ATM&#8221;). </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>extent<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>raise<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:-0.1pt;">a</span>pital<span style="letter-spacing:-0.25pt;"> </span>through<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>sale<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>equity<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>conver<span style="letter-spacing:-0.05pt;">t</span>ible<span style="letter-spacing:-0.35pt;"> </span>debt<span style="letter-spacing:-0.2pt;"> </span>securitie<span style="letter-spacing:-0.05pt;">s including through the ATM or other offerings</span>,<span style="letter-spacing:-0.3pt;"> </span>your<span style="letter-spacing:-0.05pt;"> </span>ownership<span style="letter-spacing:0.05pt;"> </span>interest<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>diluted,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the terms<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>liquidation<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>preferences<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>your<span style="letter-spacing:-0.05pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>stockholder.<span style="letter-spacing:-0.4pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>incurrence<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>indebtedness<span style="letter-spacing:-0.3pt;"> </span>would result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>increased<span style="letter-spacing:-0.35pt;"> </span>fixed<span style="letter-spacing:-0.15pt;"> </span>payment<span style="letter-spacing:-0.25pt;"> </span>obligations<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>involve<span style="letter-spacing:-0.3pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:0.1pt;">e</span>strictive<span style="letter-spacing:-0.35pt;"> </span>covenants,<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>limitations<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>abil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>to incur<span style="letter-spacing:-0.15pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>debt, li<span style="letter-spacing:-0.05pt;">m</span>it<span style="letter-spacing:-0.05pt;">a</span>tions<span style="letter-spacing:-0.35pt;"> </span>on our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>to <span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">c</span>qu<span style="letter-spacing:-0.05pt;">i</span>re<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">e</span>nse<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">l</span>le<span style="letter-spacing:-0.05pt;">c</span>tu<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.3pt;"> </span>p<span style="letter-spacing:-0.15pt;">r</span>operty<span style="letter-spacing:-0.3pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>operating<span style="letter-spacing:-0.35pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>strictions<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>impact<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to conduct<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>raise<span style="letter-spacing:-0.2pt;"> </span>additional<span style="letter-spacing:-0.4pt;"> </span>funds<span style="letter-spacing:-0.05pt;"> </span>through<span style="letter-spacing:-0.25pt;"> </span>strategic<span style="letter-spacing:-0.3pt;"> </span>partnerships<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd alliances<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>licensing<span style="letter-spacing:-0.35pt;"> </span>arrangements<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parti<span style="letter-spacing:0.05pt;">e</span>s,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">w</span>e<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>y have<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>relinquish<span style="letter-spacing:-0.3pt;"> </span>valuable<span style="letter-spacing:-0.3pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>to our technologies<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>licenses<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>terms<span style="letter-spacing:-0.15pt;"> </span>unfavorable<span style="letter-spacing:-0.4pt;"> </span>to us. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to delay or reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts. Our current license and collaboration agreements may also be terminated if we are unable to meet the payment obligations under those agreements. As a result, we may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">debt</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">adversely</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">affect</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r cash</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">flows</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and limit</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our flexib</span><span style="letter-spacing:0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">li</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o raise addit</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">onal</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">apita</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a significant<span style="letter-spacing:-0.35pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>debt<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to incur<span style="letter-spacing:-0.15pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>debt<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>support<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>growth.<span style="letter-spacing:-0.05pt;"> </span>As<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> June&#160;30,&#160;2021</span>,<span style="letter-spacing:0.05pt;"> our in</span>debtedness<span style="letter-spacing:-0.4pt;"> </span>was $300.3&#160;million,<span style="letter-spacing:-0.1pt;"> </span>consisting<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>related<span style="letter-spacing:-0.2pt;">-</span>party<span style="letter-spacing:-0.15pt;"> </span>promissory<span style="letter-spacing:-0.4pt;"> </span>notes and interest thereon,<span style="letter-spacing:-0.15pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>held<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>ent<span style="letter-spacing:-0.05pt;">i</span>ties<span style="letter-spacing:-0.25pt;"> </span>affiliated<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">w</span>ith<span style="letter-spacing:-0.1pt;"> </span>Dr.&#160;Soon-Shiong, w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.05pt;"> </span>a <span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">t</span>urity<span style="letter-spacing:-0.25pt;"> </span>date of<span style="letter-spacing:0.05pt;"> </span>September&#160;30,&#160;2025.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>debt<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>important<span style="letter-spacing:-0.3pt;"> </span>consequences<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>could:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">require</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to dedicate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">substantial</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">portion</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">cash</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">sh</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">equivalents</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">make</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">interest</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">incipal</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">payments</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">d</span><span style="color:#000000;">ebt,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">reducing the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">availability</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">cash</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cash</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">equivalents</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">sh</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">flow</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">operations</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to fund</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">capital</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">expenditures,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">working</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.1pt;color:#000000;">a</span><span style="color:#000000;">pit</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l, execution</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">strategy</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">general</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">corporate</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ncrease</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">ur</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">borrowing</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">even</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">limit</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">access</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">debt</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to fund</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">growth&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ncrease</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">ur</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">vulnerability</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">general</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">adverse</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">economic</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">industry</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">conditions</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">adverse</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:0.1pt;color:#000000;">h</span><span style="color:#000000;">anges</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in governm</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">ntal</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">regulation</span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">imit</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">flexibility</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">planning</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or reacting</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">changes</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">industry,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">place</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">at a disadvantage compared</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">competitors&#59;</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">imit</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to borrow</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">fund</span><span style="letter-spacing:-0.1pt;color:#000000;">s</span><span style="color:#000000;">, even</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">when</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">necessary</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">intain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">adequate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">liquidity,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">h</span><span style="color:#000000;">ich</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">would</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">also</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">limit</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">a</span><span style="color:#000000;">bi</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ity</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to further</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">expand</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">business.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>occurrence<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>foregoing<span style="letter-spacing:-0.35pt;"> </span>facto<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>material<span style="letter-spacing:-0.3pt;"> </span>adverse<span style="letter-spacing:-0.1pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:-0.05pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>perations<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to refinance<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>portion<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>outstanding<span style="letter-spacing:-0.35pt;"> </span>debt<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>it mat<span style="letter-spacing:-0.05pt;">u</span>res.<span style="letter-spacing:-0.15pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to refina<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.4pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span>debt<span style="letter-spacing:-0.2pt;"> </span>or the<span style="letter-spacing:-0.05pt;"> </span>terms<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any refinanci<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">a</span>vorable<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>terms<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span>debt.<span style="letter-spacing:-0.25pt;"> </span>F<span style="letter-spacing:-0.05pt;">u</span>rthermore,<span style="letter-spacing:-0.35pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>prevailing<span style="letter-spacing:-0.3pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>rest<span style="letter-spacing:-0.2pt;"> </span>rates<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>fact<span style="letter-spacing:-0.05pt;">o</span>rs<span style="letter-spacing:-0.25pt;"> </span>at the<span style="letter-spacing:-0.05pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>refinancing result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>higher<span style="letter-spacing:-0.3pt;"> </span>interest<span style="letter-spacing:-0.25pt;"> </span>rates<span style="letter-spacing:-0.1pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>refinancing,<span style="letter-spacing:-0.45pt;"> </span>then<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>interest<span style="letter-spacing:-0.2pt;"> </span>expense<span style="letter-spacing:-0.3pt;"> </span>relating<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>refinanced<span style="letter-spacing:-0.4pt;"> </span>ind<span style="letter-spacing:-0.05pt;">e</span>btedness<span style="letter-spacing:-0.5pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>inc<span style="letter-spacing:0.05pt;">re</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">e</span>.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.1pt;"> </span>risks<span style="letter-spacing:-0.05pt;"> </span>could materially<span style="letter-spacing:-0.3pt;"> </span>adversely<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">a</span>ffect<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>condition,<span style="letter-spacing:-0.35pt;"> </span>cash<span style="letter-spacing:-0.2pt;"> </span>flows<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>ope<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>tions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">O<span style="letter-spacing:-0.05pt;">u</span>r b<span style="letter-spacing:-0.05pt;">u</span>s<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;">s</span>es<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.05pt;">e</span>gra<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.4pt;"> </span>s<span style="letter-spacing:-0.05pt;">u</span>c<span style="letter-spacing:-0.05pt;">c</span>essfu<span style="letter-spacing:-0.05pt;">l</span>ly,<span style="letter-spacing:-0.2pt;"> </span>or su<span style="letter-spacing:-0.05pt;">c</span>h integrat<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.3pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>difficult,<span style="letter-spacing:-0.25pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>consuming<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>cos<span style="letter-spacing:-0.1pt;">t</span>ly<span style="letter-spacing:-0.15pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>exp<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">t</span>ed.<span style="letter-spacing:-0.35pt;"> </span>Operat<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g costs,<span style="letter-spacing:-0.05pt;"> </span>customer<span style="letter-spacing:-0.4pt;"> </span>loss<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>busin<span style="letter-spacing:0.15pt;">e</span>ss<span style="letter-spacing:0.05pt;"> </span>disruption,<span style="letter-spacing:-0.05pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>d<span style="letter-spacing:-0.05pt;">i</span>ffi<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>in <span style="letter-spacing:-0.05pt;">m</span>aintaining<span style="letter-spacing:-0.35pt;"> </span>re<span style="letter-spacing:-0.05pt;">l</span>ationsh<span style="letter-spacing:-0.15pt;">i</span>ps<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>employe<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:0.05pt;">u</span>stom<span style="letter-spacing:0.05pt;">e</span>rs,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">s</span>uppliers<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>vendors, may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>greater<span style="letter-spacing:-0.25pt;"> </span>than<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">e</span>xp<span style="letter-spacing:0.05pt;">e</span>cted<span style="letter-spacing:-0.3pt;"> for the combined company</span>.<span style="letter-spacing:-0.1pt;"> </span>R<span style="letter-spacing:0.05pt;">ev</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">u</span>es<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>low<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>an<span style="letter-spacing:-0.05pt;"> </span>exp<span style="letter-spacing:-0.05pt;">e</span>ct<span style="letter-spacing:-0.05pt;">e</span>d for the combined company.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>bina<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.35pt;"> </span>of two<span style="letter-spacing:0.05pt;"> </span>busin<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>s<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>is <span style="letter-spacing:-0.05pt;">c</span>ompl<span style="letter-spacing:-0.1pt;">e</span>x,<span style="letter-spacing:-0.25pt;"> </span>costly<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>time-consuming<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>divert<span style="letter-spacing:-0.15pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>managem<span style="letter-spacing:-0.1pt;">e</span>nt<span style="letter-spacing:-0.5pt;"> </span>attention<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>re<span style="letter-spacing:0.05pt;">s</span>ources<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>mbining o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>prior<span style="letter-spacing:-0.2pt;"> </span>businesses.<span style="letter-spacing:-0.05pt;"> </span>This<span style="letter-spacing:-0.2pt;"> </span>process<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>dis<span style="letter-spacing:0.05pt;">r</span>upt<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>businesses.<span style="letter-spacing:-0.05pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>meet<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>challenges<span style="letter-spacing:-0.35pt;"> </span>involved<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>combining<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>two<span style="letter-spacing:0.05pt;"> </span>businesses<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>to rea<span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">z</span>e<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>ant<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">i</span>p<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.3pt;"> </span>b<span style="letter-spacing:-0.05pt;">e</span>nefi<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>merg<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ould<span style="letter-spacing:-0.2pt;"> </span>cause<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>i<span style="letter-spacing:-0.1pt;">n</span>terruption<span style="letter-spacing:-0.4pt;"> </span>of,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>loss<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>mom<span style="letter-spacing:0.05pt;">e</span>n<span style="letter-spacing:-0.05pt;">t</span>um<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n, the<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>tiv<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>of the<span style="letter-spacing:-0.15pt;"> </span>combined<span style="letter-spacing:-0.4pt;"> </span>company<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>could adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span>of operations<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>combined<span style="letter-spacing:-0.3pt;"> </span>comp<span style="letter-spacing:-0.05pt;">a</span>ny.<span style="letter-spacing:-0.3pt;"> </span>Our ability to realize the anticipated benefits of the merger will depend, to a large extent, on our ability to integrate our businesses in a manner that facilitates growth opportunities and achieves the projected synergies identified by each company without adversely affecting current revenues and investments in future growth. The<span style="letter-spacing:-0.15pt;"> </span>overall<span style="letter-spacing:-0.25pt;"> </span>combination<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our <span style="letter-spacing:0.05pt;">b</span>usines<span style="letter-spacing:0.05pt;">s</span>es may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">s</span>o<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>sult<span style="letter-spacing:-0.2pt;"> </span>in m<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>rial<span style="letter-spacing:-0.3pt;"> </span>un<span style="letter-spacing:-0.05pt;">a</span>nti<span style="letter-spacing:-0.05pt;">c</span>ipa<span style="letter-spacing:-0.05pt;">t</span>ed problems,<span style="letter-spacing:-0.3pt;"> </span>expenses,<span style="letter-spacing:-0.35pt;"> </span>li<span style="letter-spacing:-0.1pt;">a</span>bilities,<span style="letter-spacing:-0.35pt;"> </span>competitive<span style="letter-spacing:-0.4pt;"> </span>responses,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>loss<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>customer<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>relationships.<span style="letter-spacing:-0.5pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>difficulties<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>combining<span style="letter-spacing:-0.35pt;"> </span>the o<span style="letter-spacing:0.05pt;">p</span>erations<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>companies<span style="letter-spacing:-0.4pt;"> </span>include,<span style="letter-spacing:-0.25pt;"> </span>among<span style="letter-spacing:-0.3pt;"> </span>others:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">diversion</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">management</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">attention</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">integration</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">matters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">fficu</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ti</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">gra</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ing</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">operations</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">systems,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">communications</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">syste</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">dmin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ra</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ive</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">and information</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">infrastruc</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">ure</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">financial</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">reporting</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">internal</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">control</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">systems&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">hallenges</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">conforming</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">standards,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">controls,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">procedu</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">es</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">accounting</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">her</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">policies,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">cultures</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">compensation</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">struc</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ures between</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">two</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">companies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">integrating</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">employees</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">attracting</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">taining</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">key</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">personnel,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">talent&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">achiev</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">anticipated</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">savings,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">synergies,</span><span style="letter-spacing:-0.05pt;color:#000000;"> accretion targets, </span><span style="color:#000000;">business</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">opportunit</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">es,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">financing</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">plans</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">growth</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">prospects from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">combination&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">managing</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">exp</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">nded</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">operations</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">significantly</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">rger</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">complex</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">company&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">onting</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">bil</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ti</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">rger</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">exp</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ct</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d&#59;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">unknown</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">liabili</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ies,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">adverse</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cons</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">quences</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">unforeseen</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">increased</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">exp</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">nses</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">ass</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">ciated</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">merger.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>factors<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>outside<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ontrol,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>one<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>them<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in lower<span style="letter-spacing:-0.2pt;"> </span>revenues,<span style="letter-spacing:-0.35pt;"> </span>higher<span style="letter-spacing:-0.2pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>diversi<span style="letter-spacing:-0.05pt;">o</span>n<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>management<span style="letter-spacing:-0.4pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>and energy,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>materially<span style="letter-spacing:-0.35pt;"> </span>i<span style="letter-spacing:-0.05pt;">m</span>pact<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">b</span>usiness,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>cond<span style="letter-spacing:-0.1pt;">i</span>tion<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:-0.35pt;"> </span>of the<span style="letter-spacing:-0.1pt;"> </span>combined<span style="letter-spacing:-0.35pt;"> </span>company.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ddit<span style="letter-spacing:-0.05pt;">i</span>on,<span style="letter-spacing:-0.2pt;"> </span>even<span style="letter-spacing:-0.15pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>the o<span style="letter-spacing:0.05pt;">p</span>erations<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>businesses<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>integrated<span style="letter-spacing:-0.4pt;"> </span>su<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>sful<span style="letter-spacing:-0.05pt;">l</span>y,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>full<span style="letter-spacing:-0.15pt;"> </span>ben<span style="letter-spacing:-0.05pt;">e</span>fits<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">g</span>er<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>real<span style="letter-spacing:-0.1pt;">i</span>zed,<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>nc<span style="letter-spacing:-0.05pt;">l</span>ud<span style="letter-spacing:-0.05pt;">i</span>ng,<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;">m</span>ong<span style="letter-spacing:-0.15pt;"> </span>others,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>synergies<span style="letter-spacing:-0.4pt;"> </span>or growth<span style="letter-spacing:0.05pt;"> </span>opportunities<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>expected.<span style="letter-spacing:-0.35pt;"> </span>These<span style="letter-spacing:-0.15pt;"> </span>b<span style="letter-spacing:-0.1pt;">e</span>nefits<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>achieved<span style="letter-spacing:-0.25pt;"> </span>within<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>anticipated<span style="letter-spacing:-0.35pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>frame<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>all.<span style="letter-spacing:-0.1pt;"> </span>Furthe<span style="letter-spacing:0.05pt;">r</span>,<span style="letter-spacing:-0.2pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>unanticipated costs<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>incurred<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>integration<span style="letter-spacing:-0.4pt;"> </span>of our<span style="letter-spacing:-0.05pt;"> </span>businesses.<span style="letter-spacing:0.05pt;"> </span>All<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>factors<span style="letter-spacing:-0.3pt;"> </span>cou<span style="letter-spacing:0.1pt;">l</span>d<span style="letter-spacing:-0.2pt;"> </span>negatively<span style="letter-spacing:-0.3pt;"> </span>impact<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> company&#8217;s operations and/or the </span>price<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>company&#8217;s<span style="letter-spacing:-0.45pt;"> common stock</span>.<span style="letter-spacing:-0.35pt;"> </span>As a<span style="letter-spacing:-0.1pt;"> </span>result,<span style="letter-spacing:-0.15pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>cannot<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>assured<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>combination<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>businesses<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>re<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.05pt;">i</span>za<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>full ben<span style="letter-spacing:-0.05pt;">e</span>fits<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xpe<span style="letter-spacing:-0.05pt;">c</span>ted<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.05pt;">e</span>rger<span style="letter-spacing:-0.25pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>thin<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nti<span style="letter-spacing:-0.05pt;">c</span>ipa<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.35pt;"> </span>ti<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.15pt;"> </span>fram<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;"> </span>al<span style="letter-spacing:-0.05pt;">l</span>.<span style="letter-spacing:-0.1pt;"> </span>A<span style="letter-spacing:-0.05pt;">c</span>cord<span style="letter-spacing:-0.05pt;">i</span>ngly,<span style="letter-spacing:-0.35pt;"> </span>hold<span style="letter-spacing:-0.05pt;">e</span>rs<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> combined </span>comp<span style="letter-spacing:-0.2pt;">a</span>ny&#8217;s<span style="letter-spacing:-0.3pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>experie<span style="letter-spacing:0.05pt;">n</span>ce<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>loss <span style="letter-spacing:0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>res<span style="letter-spacing:0.05pt;">u</span>lt<span style="letter-spacing:-0.05pt;"> </span>of a<span style="letter-spacing:-0.05pt;"> </span>de<span style="letter-spacing:0.05pt;">c</span>line<span style="letter-spacing:-0.25pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>rket<span style="letter-spacing:-0.25pt;"> </span>pri<span style="letter-spacing:0.05pt;">c</span>e<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">s</span>uch<span style="letter-spacing:-0.1pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>sto<span style="letter-spacing:0.15pt;">c</span>k.<span style="letter-spacing:-0.1pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>a dec<span style="letter-spacing:-0.05pt;">l</span>ine<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>rket<span style="letter-spacing:-0.25pt;"> </span>pri<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> the combined company&#8217;s</span> com<span style="letter-spacing:-0.05pt;">m</span>on<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:-0.1pt;">o</span>mpany&#8217;s<span style="letter-spacing:-0.4pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to issue <span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">d</span>d<span style="letter-spacing:-0.05pt;">i</span>t<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.3pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>cur<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>obta<span style="letter-spacing:-0.1pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>additio<span style="letter-spacing:0.05pt;">n</span>al<span style="letter-spacing:-0.4pt;"> </span>financing<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>future.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. </span><span style="color:#000000;">We have a history of operating losses, and we expect to continue to incur losses and may never be profitable,</span><span style="font-weight:normal;font-style:normal;color:#000000;"> </span><span style="color:#000000;">which together with our limited operating history, makes it difficult to assess our future viability.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects, and now that the merger has been completed, we have a much broader portfolio of product candidates at various stages of development. None of our products have been approved for commercial sale and we have not generated any revenue from product sales, although we have generated revenues from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables and grant programs. <span style="color:#000000;">In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry, including in connection with </span>obtaining marketing approvals, manufacturing a commercial-scale product or arranging for a third party to do so on our behalf or conducting sales and marketing<span style="Background-color:#FFFFFF;color:#000000;"> </span>activities necessary for successful product commercialization<span style="color:#000000;">. </span>Because of the numerous risks and uncertainties associated with our product development efforts, we are unable to predict when we may become profitable, if at all.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.25pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the commencement of our operations, we have incurred significant losses in each year and, as of June&#160;30,&#160;2021 we had an accumulated deficit of $1.8&#160;billion. We expect to continue to<span style="letter-spacing:-0.1pt;"> </span>incur<span style="letter-spacing:-0.15pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>expenses as<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>seek to expand our business, including in connection with conducting research and development across multiple therapeutic areas, participating in clinical trial activities, continuing to acquire or in-license technologies, maintaining, protecting and expanding our intellectual property, seeking regulatory approvals, increasing our manufacturing capabilities and, upon successful receipt of FDA approval, commercializing our products. Moreover, we do not expect to have significant product sales or revenue for the foreseeable future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>resea<span style="letter-spacing:-0.05pt;">r</span>ch<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>efforts<span style="letter-spacing:-0.25pt;"> </span>are successful,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>face<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>risks<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">a</span>ssociated<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>shift<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>commercialization<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>new products based<span style="letter-spacing:-0.25pt;"> on innovative technologies</span>.<span style="letter-spacing:0.05pt;"> </span>Our ability to achieve profitability is dependent upon obtaining regulatory approvals for our product candidates and successfully commercializing our product candidates alone or with third parties. However, our operations may not be profitable even if one or more of our product candidates under development are successfully developed and produced and thereafter commercialized. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis. As a result, it may be more difficult for you to assess our future viability than it could be if we had a longer operating history.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.05pt;"> </span>inv<span style="letter-spacing:-0.05pt;">e</span>st<span style="letter-spacing:-0.2pt;"> </span>our cash on hand in<span style="letter-spacing:-0.1pt;"> </span>various<span style="letter-spacing:-0.05pt;"> </span>finan<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.15pt;"> </span>ins<span style="letter-spacing:-0.05pt;">t</span>rum<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>are sub<span style="letter-spacing:-0.05pt;">j</span>ect<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o ris<span style="letter-spacing:-0.1pt;">k</span>s<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>adversely<span style="letter-spacing:-0.2pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>busines<span style="letter-spacing:-0.1pt;">s</span>, r<span style="letter-spacing:-0.05pt;">e</span>sul<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.05pt;"> </span>of op<span style="letter-spacing:-0.05pt;">e</span>rations,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>iquidi<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.3pt;"> </span>and finan<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.35pt;"> </span>condi<span style="letter-spacing:-0.05pt;">t</span>ion.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>invest<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>cash<span style="letter-spacing:-0.2pt;"> </span>in a variety<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>financi<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.35pt;"> </span>instruments,<span style="letter-spacing:-0.5pt;"> </span>principally<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>mmercial<span style="letter-spacing:-0.4pt;"> </span>paper,<span style="letter-spacing:-0.2pt;"> </span>corporate<span style="letter-spacing:-0.35pt;"> </span>debt<span style="letter-spacing:-0.15pt;"> </span>securities<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">g</span>overnment<span style="letter-spacing:-0.35pt;"> </span>bonds.<span style="letter-spacing:-0.05pt;"> </span>All<span style="letter-spacing:-0.1pt;"> </span>of these<span style="letter-spacing:-0.2pt;"> </span>inv<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;">t</span>men<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>subj<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>cr<span style="letter-spacing:-0.05pt;">e</span>dit,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">li</span>quidity,<span style="letter-spacing:-0.35pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>interest<span style="letter-spacing:-0.25pt;"> </span>r<span style="letter-spacing:0.05pt;">a</span>te<span style="letter-spacing:-0.1pt;"> </span>ris<span style="letter-spacing:0.05pt;">k</span>. Such<span style="letter-spacing:0.05pt;"> </span>risks, in<span style="letter-spacing:0.05pt;">c</span>luding<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>severe<span style="letter-spacing:-0.35pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>distress<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>financial institutions<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>hold<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>cash,<span style="letter-spacing:-0.25pt;"> </span>cash<span style="letter-spacing:-0.2pt;"> </span>equiv<span style="letter-spacing:-0.05pt;">a</span>lents<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>investments,<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>loss<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>liquid<span style="letter-spacing:-0.05pt;">i</span>ty,<span style="letter-spacing:-0.4pt;"> </span>impairment<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>investments,<span style="letter-spacing:-0.5pt;"> </span>realization<span style="letter-spacing:-0.35pt;"> </span>of substantial future<span style="letter-spacing:-0.2pt;"> </span>losses,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>complete<span style="letter-spacing:-0.35pt;"> </span>l<span style="letter-spacing:-0.05pt;">o</span>ss<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>investments<span style="letter-spacing:-0.45pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>long-term,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a material<span style="letter-spacing:-0.3pt;"> </span>adverse<span style="letter-spacing:-0.3pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:-0.05pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>of o<span style="letter-spacing:0.05pt;">p</span>erations, liquidity<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>financi<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>condition.<span style="letter-spacing:-0.4pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>order<span style="letter-spacing:-0.15pt;"> </span>to manage<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>risk<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our investments,<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>maintain<span style="letter-spacing:-0.35pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>investment<span style="letter-spacing:-0.35pt;"> </span>policy<span style="letter-spacing:-0.2pt;"> </span>that,<span style="letter-spacing:-0.2pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>things,<span style="letter-spacing:-0.25pt;"> </span>limits<span style="letter-spacing:-0.15pt;"> </span>the amount<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>invest<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>one<span style="letter-spacing:-0.1pt;"> </span>issue<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>single<span style="letter-spacing:-0.25pt;"> </span>issuer<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>re<span style="letter-spacing:0.05pt;">q</span>uires<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>only<span style="letter-spacing:-0.15pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>st<span style="letter-spacing:-0.1pt;"> </span>in high<span style="letter-spacing:-0.1pt;"> </span>credit<span style="letter-spacing:-0.15pt;"> </span>quali<span style="letter-spacing:-0.1pt;">t</span>y<span style="letter-spacing:-0.2pt;"> </span>secur<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>preserve<span style="letter-spacing:-0.2pt;"> </span>liqu<span style="letter-spacing:-0.05pt;">i</span>d<span style="letter-spacing:-0.05pt;">i</span>ty.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">k</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">s R</span><span style="font-weight:bold;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">lated</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">O</span><span style="font-weight:bold;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">u</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Business a</span><span style="font-weight:bold;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">I</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;">u</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">st</span><span style="font-weight:bold;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">y</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will be substantially dependent on the success of our product candidates and cannot guarantee that these product candidates will successfully complete development, receive regulatory approval or be successfully commercialized.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than our proprietary GMP-in-a-Box bioreactors for which we have received nominal revenue to date, we currently have no products approved for commercial sale or for which regulatory approval to market has been sought. We have invested a significant portion of our efforts and financial resources in the development of our main product candidates, Anktiva, aldoxorubicin and human adenovirus serotype 5 (&#8220;hAd5&#8221;) vaccine candidates, some or all of which are used in combination with our natural killer cells. Our product candidates will require additional clinical and non-clinical development, regulatory approval, commercial manufacturing arrangements, establishment of a commercial organization, significant marketing efforts, and further investment before we can generate any revenues from product sales. We expect to invest heavily in these product candidates as well as in our other existing product candidates and in any future product candidates that we may develop. Our business and our ability to generate revenues in the future substantially depends on the successful development, regulatory approval and commercialization of such product candidates, each of which may never occur. Our product candidates will be susceptible to the risks of failure inherent at any stage of product development, including the appearance of unexpected adverse events or failure to achieve primary endpoints in clinical trials. Furthermore, we cannot assure you that we will meet our timelines for current or future clinical trials, which may be delayed or not completed for a number of reasons. Additionally, our ability to generate revenues from our combination therapy products will also depend on the availability of the other therapies with which our products are intended to be used. We currently generate no meaningful revenues from the sale of any product candidates, and we may never be able to develop or commercialize a product.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>can<span style="letter-spacing:0.05pt;">d</span>idates<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>combination<span style="letter-spacing:-0.5pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>therapies,<span style="letter-spacing:-0.4pt;"> </span>w<span style="letter-spacing:0.05pt;">h</span>ich<span style="letter-spacing:-0.05pt;"> </span>exposes<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to additional<span style="letter-spacing:-0.4pt;"> </span>risks.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may develop product candidates in combination with one or more other therapies. We are studying Anktiva therapy along with other product candidates, such as aldoxorubicin and hAd5 product candidates. The development of product candidates for use in combination with another product may present challenges. The FDA may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. To the extent that we do not have rights to already approved products, this may require us to work with another company to satisfy such a requirement. It is possible that the results of these trials could show that any positive results are attributable to the already approved product. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. Following product approval, the FDA may require that products used in conjunction with each other be cross labeled for combined use. If the therapies we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>evaluate<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candid<span style="letter-spacing:0.1pt;">a</span>tes<span style="letter-spacing:-0.35pt;"> </span>in combination<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;">r</span>a<span style="letter-spacing:0.05pt;">p</span>ies<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>yet<span style="letter-spacing:-0.05pt;"> </span>been<span style="letter-spacing:-0.2pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the FDA<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>comparable<span style="letter-spacing:-0.35pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities.<span style="letter-spacing:-0.45pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to market<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>sell<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candid<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.3pt;"> </span>in c<span style="letter-spacing:-0.05pt;">o</span>mb<span style="letter-spacing:-0.05pt;">i</span>nat<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>an u<span style="letter-spacing:0.05pt;">n</span>approved<span style="letter-spacing:-0.4pt;"> </span>therapy<span style="letter-spacing:-0.2pt;"> </span>if that<span style="letter-spacing:-0.15pt;"> </span>unapproved<span style="letter-spacing:-0.45pt;"> </span>therapy<span style="letter-spacing:-0.3pt;"> </span>does<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>ultimately<span style="letter-spacing:-0.3pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>approval.<span style="letter-spacing:-0.15pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>unapproved<span style="letter-spacing:-0.4pt;"> </span>therapies<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>ace<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>same<span style="letter-spacing:-0.25pt;"> </span>risks described<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>respect<span style="letter-spacing:-0.2pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>currently<span style="letter-spacing:-0.25pt;"> </span>in development<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials,<span style="letter-spacing:-0.15pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>serious<span style="letter-spacing:0.05pt;"> </span>adverse<span style="letter-spacing:-0.25pt;"> </span>effects,<span style="letter-spacing:-0.25pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ria<span style="letter-spacing:-0.05pt;">l</span>s<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>la<span style="letter-spacing:-0.05pt;">c</span>k<span style="letter-spacing:-0.05pt;"> o</span>f<span style="letter-spacing:-0.05pt;"> </span>FDA approval.<span style="letter-spacing:-0.4pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>or comparable<span style="letter-spacing:-0.35pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>approve<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>revoke<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>eir<span style="letter-spacing:-0.2pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>of these other therapies,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>safety,<span style="letter-spacing:-0.3pt;"> </span>efficacy,<span style="letter-spacing:-0.25pt;"> </span>quality,<span style="letter-spacing:-0.2pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>or supply<span style="letter-spacing:-0.3pt;"> </span>issues<span style="letter-spacing:0.05pt;"> </span>arise<span style="letter-spacing:-0.15pt;"> </span>with,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> therapies</span><span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>choo<span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>evaluate<span style="letter-spacing:-0.3pt;"> </span>in combination<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.2pt;"> any of </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to obtain<span style="letter-spacing:-0.2pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of or<span style="letter-spacing:0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>rket<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>comb<span style="letter-spacing:-0.05pt;">i</span>nat<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>herapy.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Due to the significant resources required for the development of our product candidates, and depending on our ability to access capital, we must prioritize among many different opportunities.</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> W</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e may expend our limited resources on programs that do not yield successful product candidates as opposed to indications that may be more profitable or for which there is a greater likelihood of success.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have sufficient resources to pursue development of all or even a substantial portion of the potential opportunities that we believe will be afforded to us by our product candidates. Because we have limited resources and access to capital to fund our operations, our management must make significant prioritization decisions as to which product candidates and indications to pursue and how much of our resources to allocate to each. Our management must also evaluate the benefits of developing in-licensed or jointly owned technologies, which in some circumstances we may be contractually obligated to pursue, relative to developing other product candidates, indications or programs. Our management has broad discretion to suspend, scale down, or discontinue any or all of these development efforts, or to initiate new programs to treat other diseases. If we select and commit resources to opportunities that we are unable to successfully develop, or we forego more promising opportunities, our business, financial condition and results of operations will be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>inical<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">i</span>al <span style="letter-spacing:-0.05pt;">c</span>osts may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>higher<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>an<span style="letter-spacing:-0.05pt;"> </span>for mo<span style="letter-spacing:0.05pt;">r</span>e<span style="letter-spacing:-0.2pt;"> </span>co<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">v</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">n</span>tional<span style="letter-spacing:-0.35pt;"> </span>therapeutic<span style="letter-spacing:-0.4pt;"> </span>techno<span style="letter-spacing:0.05pt;">l</span>ogies<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because our product candidates include, and we expect our future product candidates to include, candidates based on advanced therapy technologies, we expect that they will require extensive research and development and have substantial manufacturing costs. In addition, costs to treat patients and to treat potential side effects that may result from our product candidates can be significant. Some clinical trial sites may not bill, or obtain coverage from Medicare, Medicaid, or other third-party payors for some or all of these costs for patients enrolled in our clinical trials, and clinical trial sites outside of the United States may not reimburse for costs typically covered by third-party payors in the United States, and as a result we may be required by those trial sites to pay such costs. Accordingly, our clinical trial costs are likely to be significantly higher per patient than those of more conventional therapeutic technologies or drug products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our c<span style="letter-spacing:-0.05pt;">l</span>inical<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">i</span>als<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>fa<span style="letter-spacing:-0.05pt;">i</span>l<span style="letter-spacing:-0.15pt;"> </span>to d<span style="letter-spacing:-0.05pt;">e</span>mons<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">r</span>a<span style="letter-spacing:-0.1pt;">t</span>e<span style="letter-spacing:-0.4pt;"> </span>adequately<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>safety<span style="letter-spacing:-0.2pt;"> </span>and <span style="letter-spacing:-0.05pt;">e</span>fficacy<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>cand<span style="letter-spacing:-0.05pt;">i</span>dates,<span style="letter-spacing:-0.45pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>would<span style="letter-spacing:-0.25pt;"> </span>prevent<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:0.05pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>lay<span style="letter-spacing:-0.2pt;"> </span>regulatory a<span style="letter-spacing:0.05pt;">p</span>proval<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>com<span style="letter-spacing:-0.1pt;">m</span>ercia<span style="letter-spacing:-0.05pt;">l</span>ization.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical trials of our product candidates as well as the manufacturing and marketing of our product candidates will be subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective. Because most of our product candidates will be subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. The risk/benefit profile required for product licensure will vary depending on these factors and may include not only the ability to show tumor shrinkage, but also adequate duration of response, a delay in the progression of the disease, and/or an improvement in survival. For example, response rates from the use of our product candidates may not be sufficient to obtain regulatory approval unless we can also show an adequate duration of response. Regulatory authorities may ultimately disagree with our chosen endpoints or may find that our studies or study results do not support product approval. Preclinical studies may reveal unfavorable product candidate characteristics, including safety concerns. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. Moreover, should there be a flaw in a clinical trial or cross-site variation that are not properly addressed, it may not become apparent until the clinical trial is well advanced or until data from different sites become available. For example, our current clinical trials are, and we expect our clinical trials to be, conducted at multiple sites in different geographies, with different levels of experience and expertise by medical professionals, and these professionals may make mistakes or introduce site-specific variation that could have an impact on clinical trials by disqualifying patients or impacting patient ability to continue in a study or on the clinical data. Further, because we currently plan to test our product candidates for use with other oncology products, the design, implementation and interpretation of the clinical trials necessary for marketing approval may be more complex than if we were developing our product candidates alone.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, even if such trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have reported preliminary results for clinical trials of our product candidates, including Anktiva. These preliminary results, which include assessments of efficacy, are subject to substantial risk of change due to small sample sizes and may change as patients are evaluated or as additional patients are enrolled in these clinical trials. These outcomes may be unfavorable, deviate from our earlier reports, and/or delay or prevent regulatory approval or commercialization of our product candidates, including candidates for which we have reported preliminary efficacy results.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, certain of our hypotheses regarding the potential benefits of our product candidates compared to alternative therapies and treatments are based on cross-trial comparisons of results that were not derived from head-to-head clinical trials. Such clinical trial data may not be directly comparable due to differences in study protocols, conditions and patient populations. Accordingly, these cross-trial comparisons may not be reliable predictors of the relative efficacy or other benefits of our product candidates compared to other product candidates that may have been approved previously.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have data on possible harmful long-term effects of our product candidates and do not expect to have this data in the near future. As a result, our ability to generate clinical safety and effectiveness data sufficient to support submission of a marketing application or commercialization of our product candidates is uncertain and is subject to significant risk.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Int<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">i</span>m,<span style="letter-spacing:-0.3pt;"> </span>ini<span style="letter-spacing:-0.05pt;">t</span>ial,<span style="letter-spacing:-0.25pt;"> </span>&#8220;top-<span style="letter-spacing:-0.05pt;">l</span>in<span style="letter-spacing:-0.05pt;">e</span>&#8221;<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>preliminary<span style="letter-spacing:-0.4pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>from our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>ann<span style="letter-spacing:-0.05pt;">oun</span>ce<span style="letter-spacing:-0.1pt;"> </span>or p<span style="letter-spacing:-0.05pt;">u</span>blish<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.1pt;"> </span>ti<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.15pt;"> </span>to <span style="letter-spacing:-0.05pt;">t</span>ime<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">m</span>ay<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.1pt;">h</span>ange<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>patient d<span style="letter-spacing:0.05pt;">a</span>ta become<span style="letter-spacing:-0.25pt;"> </span>available<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>sub<span style="letter-spacing:-0.05pt;">j</span>ect<span style="letter-spacing:-0.15pt;"> </span>to audit<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>verification<span style="letter-spacing:-0.45pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>ocedures<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>mat<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">ch</span>anges<span style="letter-spacing:-0.1pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>final<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">d</span>ata.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publicly disclose preliminary, interim or top-line data from our preclinical studies and clinical trials, which are based on preliminary analyses of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. We also may make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We </span><span style="letter-spacing:-0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ave</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">mi</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">experi</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">co</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">du</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">cl</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">nical</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">trials</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">relied</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">rely</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">related</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to co</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">duct</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">many</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our pr</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">cal</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">stud</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">trials</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> and to manufacture products</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">failure</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a third</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">part</span><span style="letter-spacing:-0.05pt;">y</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.1pt;">a</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">part</span><span style="letter-spacing:-0.05pt;">y</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or by</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">us to </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">onduct</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;"> c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">lini</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">als</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ccording</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GCP regulations,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">timely</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">manner</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">delay</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or prevent</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ab</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">lity</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">seek</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">obtain</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">commercialization of</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large-scale clinical trials require significant financial and management resources. We expect to be heavily reliant on third and related parties, including medical institutions, academic institutions, clinical investigators or CROs to conduct, supervise or monitor some or all aspects of our clinical trials, and in some cases, CMOs to manufacture products. We have entered into agreements with the&#160;Clinic, a related party, to continue to conduct and oversee certain of our clinical trials. Our CROs, the&#160;Clinic and other third parties must communicate and coordinate with one another in order for our trials to be successful. We have a limited history of conducting clinical trials and have no experience as a company in filing and supporting the applications necessary to gain marketing approvals. Our relative lack of experience conducting clinical trials may contribute to our planned clinical trials not beginning or completing on time, if at all. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities and clinical trial sites by, applicable regulatory authorities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relying on third-party clinical investigators, CROs or CMOs may force us to encounter delays and challenges that are outside of our control. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable trial protocol and legal, regulatory and scientific standards, and our reliance on CROs, clinical trial sites, and other third parties does not relieve us of these responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial and for ensuring that our preclinical studies are conducted in accordance with Good Laboratory Practice (&#8220;GLP&#8221;) regulations, as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us and the third parties upon which we intend to rely for conducting our clinical trials to comply with GCP for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic inspections (including pre-approval inspections once a Biologics License Application (&#8220;BLA&#8221;) or New Drug Application (&#8220;NDA&#8221;) is filed with the FDA) of trial sponsors, clinical investigators, trial sites and certain third parties including CMOs. If we, our CROs, clinical trial sites, or other third parties fail to comply with applicable GCP or other regulatory requirements, we or they may be subject to enforcement or other legal actions, the clinical data generated in our clinical trials may be deemed unreliable and have to be repeated, and our submission of marketing applications may be delayed or the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clinical trials will need to be conducted with product candidates and materials that were produced under current Good Manufacturing Practices (&#8220;cGMP&#8221;) and/or Good Tissue Practice regulations, which are enforced by regulatory authorities. Our failure to comply or our CMOs&#8217; failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We may not be able to demonstrate sufficient comparability between products manufactured at different facilities to allow for inclusion of the clinical results from patients treated with products from these different facilities, in our product registrations. We also are required to register certain clinical trials and post the results of certain completed clinical trials on a government sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so could result in enforcement actions and adverse publicity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third parties to manufacture, package, label and ship some of our product candidates for the clinical trials that we conduct. Any performance failure on the part of these third parties could delay clinical development or marketing approval of our product candidates or commercialization of our product candidates, if approved, producing additional losses and depriving us of potential product revenues.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our CROs, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinic, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical trial sites and other third parties may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting clinical trials or other therapeutic development activities that could harm our competitive position. In addition, these third parties are not our employees, and except for remedies available to us under our agreements with them, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and preclinical programs. If these third parties</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> conducting our clinical trials</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do not successfully carry out their contractual duties, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do not </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meet expected deadlines</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, (iii)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">experience work stoppages, (iv)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do not</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> conduct our clinical trials in accordance with regulatory requirements or our stated protocols, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">need to be replaced</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, (vi)&#160;experience financial hardships</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or (vi)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terminate their agreements with us</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial protocols, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GCP or other </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory requirements or for other reasons, our trials may need to be repeated, extended, delayed or terminated, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates, we will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates or we or they may be subject to regulatory enforcement actions. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we may need to conduct additional clinical trials or enter into new arrangements with alternative CROs, clinical investigators or other third parties. We may be unable to enter into arrangements with alternative CROs on commercially reasonable terms, or at all.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Switching or adding additional contractors involves additional cost and time and requires management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays could occur, which could compromise our ability to meet our desired development timelines. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, if any of the third parties conducting our clinical trials experience any financial hardships due to difficulties relating to the operation of their business, if could damage our business, financial condition, results of operations and prospects. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if an agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> continued development of our product candidates utilizing the collaborator&#8217;s technology or intellectual property or require us to stop development of those product candidates completely.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. To the extent we are unable to successfully identify and manage the performance of third-party service providers in the future, our business may be materially and adversely affected.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on third and related parties can also present intellectual property-related risks. For example, collaborators may not properly obtain, maintain, enforce or defend intellectual property or proprietary rights relating to our product candidates or technology or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property-related proceedings, including proceedings challenging the scope, ownership, validity and enforceability of our intellectual property. Collaborators may also own or co-own intellectual property covering our product candidates or technology that results from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates or technology. Collaborators may also gain access to our trade secrets or formulations and impact our ability to commercialize proprietary technology. We may also need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also anticipate that part of our strategy for pursuing the wide range of indications potentially addressed by Anktiva will involve further investigator-initiated clinical trials. While these trials generally provide us with valuable clinical data that can inform our future development strategy, we generally have less control over not only the conduct but also the design of these clinical trials. Third-party investigators may design clinical trials involving our product candidates with clinical endpoints that are more difficult to achieve or in other ways that increase the risk of negative clinical trial results compared to clinical trials we may design on our own. Negative results from investigator-initiated clinical trials, regardless of how the clinical trial was designed or conducted, could have a material adverse effect on our business and the perception of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our c</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">inical</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">als</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">init</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ated</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ompl</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">w</span><span style="letter-spacing:0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">en we</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">xpect,</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.2pt;">or at all, they may take longer and cost more to complete than we project </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">required</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">conduct</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">addit</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">onal</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">lini</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.1pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">als</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or modify</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">current or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">trials</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">based</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">feedback</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">receive</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FDA.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot guarantee that any current or future clinical trials will be conducted as planned or completed on schedule, if at all, or that any of our product candidates will receive regulatory approval. A failure of one or more clinical trials can occur at any stage of the clinical trial process, other events may cause us to temporarily or permanently stop a clinical trial, and our future clinical trials may not be successful. We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulators</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Institutional</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">Review</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Boards</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">(&#8220;IRBs&#8221;) may</span><span style="letter-spacing:-0.1pt;color:#000000;"> (i)&#160;</span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">authorize</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our inv</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">iga</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ors</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">com</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ence</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> c</span><span style="color:#000000;">lin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">co</span><span style="letter-spacing:-0.15pt;color:#000000;">n</span><span style="color:#000000;">duct</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">lin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;"> a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">prosp</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ct</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ve</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">te,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or a</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">end</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">pro</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">oco</span><span style="letter-spacing:-0.15pt;color:#000000;">l</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> (ii)&#160;</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">quire</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">modify</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">amend</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al trial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">protocols&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in reaching, or a failure to reach,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a consensus</span><span style="letter-spacing:-0.05pt;color:#000000;"> with </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">authorities</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;"> t</span><span style="color:#000000;">rial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">design or e</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">igib</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">it</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ria</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">enro</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">lm</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nt&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">comparable</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">foreign</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">authorities</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> (i)&#160;</span><span style="color:#000000;">disagree</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">intended</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">indications, or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">ur</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">interpre</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">ation</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">data from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">preclinical</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">studies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials, (ii)&#160;find</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidate&#8217;s</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">benefits do not outweigh</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">its</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">safety</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">risks, (iii)&#160;not</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">cc</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">pt</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ia</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">cl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">tes</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in for</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ign</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">cou</span><span style="letter-spacing:-0.1pt;color:#000000;">n</span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s, (iv)&#160;fail to approve or subsequently find fault with the manufacturing processes or our manufacturing facilities for clinical and future commercial supplies or (v)&#160;take longer than we anticipate when making a decision on our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">FDA may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">allow</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to use</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">cli</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">ical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">research</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">institution</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to support</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">investigational</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">drug (&#8220;IN</span><span style="letter-spacing:0.05pt;color:#000000;">D</span><span style="color:#000000;">&#8221;)</span><span style="letter-spacing:-0.15pt;color:#000000;"> application </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we cannot</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">demonstrate</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">comparability</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidate</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">used</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the relevant</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">research</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">instit</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">tion</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in its </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">lin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">lays</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">in or fa</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">lure</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">h</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">agre</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">on a</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ptab</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">ter</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">prosp</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ct</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ve</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">CROs and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">tes,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">rms of which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">can</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">be subject</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">extensive</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">negotiation</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">vary</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">significantly</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">among</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">different</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">CROs and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">linical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">mposition</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">temporary</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">permanent</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">hold, such as the clinical hold on the Phase&#160;II/III clinical trial for our hAd5 COVID-19 vaccine candidate pending modifications to the protocol and FDA&#8217;s review of additional information, including of immunogenicity and safety data from the Phase&#160;I portion of the study&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in adding</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">investigators</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or w</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">thdr</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">sit</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l, including scheduling conflicts with participating clinicians and clinical institutions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties in identifying and enrolling patients who meet trial eligibility criteria and who remain in the study until its conclusion&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">f</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ilure</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">by our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">CROs, cl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ni</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patients,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">parties,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">us </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">dhere</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">requ</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">re</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">nts,</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">regulatory, contractual</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">pro</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ocol</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to perform</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in accordance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">GCP</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">requiremen</span><span style="letter-spacing:-0.2pt;color:#000000;">t</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">applicable</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">guidelines</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">occurrence</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">adverse</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">events</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">associated</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">can</span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="color:#000000;">idate</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">viewed</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">outweigh</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">its</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">benefits&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">hanges</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">requireme</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">guid</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nce</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">quire</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">amending</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">submitting</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">n</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">w</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">protocols</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">auth</span><span style="letter-spacing:-0.05pt;color:#000000;">o</span><span style="color:#000000;">ri</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ies</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and IRBs,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cause</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">delays</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">programs,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">chan</span><span style="letter-spacing:0.05pt;color:#000000;">g</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">review</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">times&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">here</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">qu</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">stions</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">disagreements</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">regarding</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">interpretations</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">resul</span><span style="letter-spacing:-0.1pt;color:#000000;">t</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">information</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">emerge regarding</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">duct</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">hanges</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">standard</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">care</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">plan</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">was</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">based,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">require</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">the availability of financial resources to commence and complete the planned trials</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ambiguous or negative interim results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials, or preclinical studies, or abandon product development programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">obtaining sufficient supply of therapies that may be used in combination with our molecular agents or as comparative agents in clinical trials or i</span><span style="color:#000000;">nterruption</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">delays</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">receiving,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">supplies</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">drugs</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or components</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">therapies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">due</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">staffing shortages,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">production</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">slowdowns or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">stoppages</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">disruptions</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">delivery</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">systems&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">arly</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">results</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">negatively</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">affected</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">changes</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">fficacy</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">measures</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">overall response</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">rate</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">duration</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">ponse</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">enrolled</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">as new</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">cohorts</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ria</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">sted, and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">overall</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">response</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">rate</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">duration</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">response</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">negat</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">vely</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="color:#000000;">fected</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">inclusion</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">unconfirmed</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">res</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">onses</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">pre</span><span style="letter-spacing:0.05pt;color:#000000;">l</span><span style="color:#000000;">iminary results</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">report</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">sponses are</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">later</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">confirmed&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">able</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to demonst</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">ate</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidate</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">provides</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="color:#000000;">vantage</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">over</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">standards</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">care</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">future competitive</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">therapies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">developme</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">t&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">here</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">changes</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">therapeutics</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;">t</span><span style="color:#000000;">atus</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">administering</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">combination</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">transfer</span><span style="letter-spacing:1.5pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.45pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.85pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:0.65pt;color:#000000;"> </span><span style="color:#000000;">processes</span><span style="letter-spacing:1.6pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:0.8pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.6pt;color:#000000;"> </span><span style="color:#000000;">CMOs</span><span style="letter-spacing:1.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.5pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:1.3pt;color:#000000;"> </span><span style="color:#000000;">larger-scale facilities</span><span style="letter-spacing:1.6pt;color:#000000;"> </span><span style="color:#000000;">operated</span><span style="letter-spacing:1.5pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.9pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.15pt;color:#000000;"> </span><span style="color:#000000;">CMO</span><span style="letter-spacing:1.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.45pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.45pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.8pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:0.65pt;color:#000000;"> </span><span style="color:#000000;">delays</span><span style="letter-spacing:1.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.45pt;color:#000000;"> </span><span style="color:#000000;">failure</span><span style="letter-spacing:1.5pt;color:#000000;"> </span><span style="color:#000000;">by our</span><span style="letter-spacing:0.6pt;color:#000000;"> </span><span style="color:#000000;">CMOs</span><span style="letter-spacing:1.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.45pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.65pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:0.25pt;color:#000000;"> </span><span style="color:#000000;">commence,</span><span style="letter-spacing:0.25pt;color:#000000;"> </span><span style="color:#000000;">make</span><span style="letter-spacing:1.45pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:0.6pt;color:#000000;"> </span><span style="color:#000000;">necessary</span><span style="letter-spacing:1.75pt;color:#000000;"> </span><span style="color:#000000;">changes</span><span style="letter-spacing:1.35pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:0.65pt;color:#000000;"> </span><span style="color:#000000;">or complete such</span><span style="letter-spacing:0.95pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:0.65pt;color:#000000;"> </span><span style="color:#000000;">process&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">different</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">manufactur</span><span style="letter-spacing:0.15pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">processes</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">within</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">eff</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">cts</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">result</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">diff</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">processes on the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ta</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we have</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">ported</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">report</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in manufacturing,</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">testing,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">releasing,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">validatin</span><span style="letter-spacing:0.05pt;color:#000000;">g</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">importing/exporting</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="color:#000000;">sufficient</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">sta</span><span style="letter-spacing:0.05pt;color:#000000;">b</span><span style="color:#000000;">le</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">quantities</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">ndidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">use in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clini</span><span style="letter-spacing:0.05pt;color:#000000;">ca</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">ls</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">bili</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">do any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">foregoing,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">a result</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of any</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">qua</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ity</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">issu</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s associ</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">wi</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">h</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">contract manufacturer&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">costs</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">associated</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">disruption</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">requirements,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">social</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">distancing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:-0.1pt;color:#000000;">s</span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">tions imposed</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">b</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">governmental</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">agenc</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">es</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">sites</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">due</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to the</span><span style="letter-spacing:-0.05pt;color:#000000;"> C</span><span style="color:#000000;">OVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="color:#000000;">19</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">pandemic,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">include</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">enroll</span><span style="letter-spacing:0.1pt;color:#000000;">m</span><span style="color:#000000;">ent d</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">lays</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">f</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ilur</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">follow</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">protoco</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">s.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations<span style="letter-spacing:-0.5pt;"> </span>with other entities<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to additional<span style="letter-spacing:-0.3pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>bec<span style="letter-spacing:-0.05pt;">a</span>use<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>management of the<span style="letter-spacing:-0.05pt;"> </span>trials,<span style="letter-spacing:-0.15pt;"> </span>contract<span style="letter-spacing:-0.3pt;"> </span>negotiations,<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to obtain<span style="letter-spacing:-0.25pt;"> </span>agreement<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>multiple<span style="letter-spacing:-0.3pt;"> </span>par<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>necessity<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>obtaining<span style="letter-spacing:-0.35pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>approvals<span style="letter-spacing:-0.4pt;"> </span>for ther<span style="letter-spacing:-0.05pt;">a</span>peut<span style="letter-spacing:-0.05pt;">i</span>cs<span style="letter-spacing:-0.25pt;"> </span>used in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>bina<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.4pt;"> </span>tri<span style="letter-spacing:-0.1pt;">a</span>ls.<span style="letter-spacing:-0.2pt;"> </span>Th<span style="letter-spacing:-0.05pt;">e</span>se<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>o<span style="letter-spacing:-0.05pt;">m</span>bin<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.35pt;"> </span>ther<span style="letter-spacing:-0.05pt;">a</span>pi<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>requ<span style="letter-spacing:-0.05pt;">i</span>re<span style="letter-spacing:-0.3pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>testing<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>FDA regulatory<span style="letter-spacing:-0.4pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>increase<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any inab<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o suc<span style="letter-spacing:-0.05pt;">c</span>essfu<span style="letter-spacing:-0.05pt;">l</span>ly<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>omp<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">e</span>te<span style="letter-spacing:-0.3pt;"> </span>pr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">i</span>ni<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>ni<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>addit<span style="letter-spacing:0.05pt;">i</span>onal<span style="letter-spacing:-0.3pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us, slow down our product development and approval process<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>impair<span style="letter-spacing:-0.2pt;"> </span>o<span style="letter-spacing:-0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> commence product sales and </span>generate revenues.<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.1pt;">a</span>ke<span style="letter-spacing:-0.15pt;"> </span>manufacturing<span style="letter-spacing:-0.45pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>to,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>elect<span style="letter-spacing:-0.15pt;"> </span>to,<span style="letter-spacing:-0.1pt;"> </span>conduct<span style="letter-spacing:-0.35pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>trials to bridge<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>modified<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>earlier<span style="letter-spacing:-0.2pt;"> </span>versions.<span style="letter-spacing:0.05pt;"> </span>These<span style="letter-spacing:-0.15pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.25pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>no<span style="letter-spacing:-0.1pt;">t</span>ification<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not have<span style="letter-spacing:-0.2pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>desired effect.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>acc<span style="letter-spacing:-0.1pt;">e</span>pt<span style="letter-spacing:-0.2pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>prior<span style="letter-spacing:-0.2pt;"> </span>versions<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>support<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>application,<span style="letter-spacing:-0.4pt;"> </span>delaying<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:0.05pt;">r</span>ials<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>programs<span style="letter-spacing:-0.4pt;"> </span>or nec<span style="letter-spacing:-0.05pt;">e</span>ssi<span style="letter-spacing:-0.05pt;">t</span>a<span style="letter-spacing:-0.05pt;">t</span>ing<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ddit<span style="letter-spacing:-0.05pt;">i</span>onal<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span>s<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>pr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">i</span>ni<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.4pt;"> </span>s<span style="letter-spacing:-0.05pt;">t</span>udi<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>.<span style="letter-spacing:-0.35pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>find<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>change<span style="letter-spacing:-0.25pt;"> </span>has<span style="letter-spacing:-0.1pt;"> </span>unintended<span style="letter-spacing:-0.35pt;"> </span>con<span style="letter-spacing:0.05pt;">s</span>equences<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>necessitates<span style="letter-spacing:-0.4pt;"> </span>additional development<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>work,<span style="letter-spacing:-0.05pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>precl<span style="letter-spacing:-0.1pt;">i</span>nical<span style="letter-spacing:-0.45pt;"> </span>studies,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>refusal<span style="letter-spacing:-0.2pt;"> </span>to file<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>non-app<span style="letter-spacing:-0.05pt;">r</span>oval<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a BLA<span style="letter-spacing:-0.05pt;"> </span>and/or<span style="letter-spacing:-0.2pt;"> </span>NDA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical<span style="letter-spacing:-0.25pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>shorten<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">e</span>riods<span style="letter-spacing:-0.05pt;"> </span>during<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>protecti<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>allow<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:0.1pt;">o</span>mpetitors<span style="letter-spacing:-0.4pt;"> </span>to bring products to market<span style="letter-spacing:-0.2pt;"> </span>before<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do,<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> c</span>ould<span style="letter-spacing:-0.15pt;"> </span>impair<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>successfully<span style="letter-spacing:-0.4pt;"> </span>commercialize<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>h<span style="letter-spacing:-0.05pt;">a</span>rm<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business and results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operati<span style="letter-spacing:0.05pt;">o</span>ns. If we fail to commence or complete, or experience delays in, any of our planned clinical trials, our stock price and our ability to conduct our business as currently planned could be harmed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We wi<span style="letter-spacing:-0.05pt;">l</span>l<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>u<span style="letter-spacing:-0.05pt;">n</span>able<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>merc<span style="letter-spacing:-0.05pt;">ia</span>lize<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidat<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.35pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>our trials<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.05pt;">r</span>e<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>s<span style="letter-spacing:0.05pt;">u</span>c<span style="letter-spacing:0.05pt;">ce</span>ssf<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development programs are each at an early stage and our current product candidates are in the early stages of development. We currently have ongoing clinical trials to evaluate our product candidates. We must demonstrate our product candidates&#8217; safety and efficacy in humans through extensive clinical testing. Success in early clinical trials does not ensure that large-scale clinical trials will be successful, nor does it predict final results. We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent commercialization of our product candidates, including but not limited to the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">fety</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">ffic</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">cy</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">ults</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in various</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">human</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">reported</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in scientific</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">medic</span><span style="letter-spacing:-0.1pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">literature</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">indicat</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ve</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of res</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">lts</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we obtain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">fter</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">v</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ewing</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">test</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">res</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">lts,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">collaborators</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">b</span><span style="color:#000000;">andon</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">projects</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">might</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">previously</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">believed</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">promising&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we, our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">collaborators</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">regulators</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">sus</span><span style="letter-spacing:0.1pt;color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ina</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">cl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ls</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">f </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he p</span><span style="letter-spacing:-0.15pt;color:#000000;">a</span><span style="color:#000000;">rticipating</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">subjects</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">exposed</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to unacceptable</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">health</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">risks&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">standard</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">care</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">change</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">result</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">tech</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">ology</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">therapies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">target</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ndicatio</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">precluding</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">gulatory approval</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">limited</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">effects</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">desired</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">effects</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">include</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">undesirab</span><span style="letter-spacing:0.1pt;color:#000000;">l</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">side</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">effects</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">chara</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">teristi</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">that precl</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">de</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">limit</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">if approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">anufacturers</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">meet</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the necessary</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">standa</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ds</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">production</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">oduct</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">able</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to supply</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">sufficient</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">quantity&#59;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">authorities</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">find</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trial</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">design</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">conduct</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">does</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">meet</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">applicable</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">requirements.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is very expensive, can take many years and the outcome is uncertain. It could take as much as 12&#160;months or more before we learn the results from any clinical trial using Anktiva, aldoxorubicin, adenovirus and yeast technologies or other therapy. The data collected from our clinical trials may not be sufficient to support approval by the FDA of our Anktiva product candidate for the treatment of bladder cancer or of other therapies, including our hAd5 COVID&#8209;19 vaccine candidate. Anktiva and many of our other product candidates have only been tested in a small number of patients. Results from these clinical trials may not necessarily be indicative of the safety and tolerability or efficacy of our product candidates as we expand into larger clinical trials. The clinical trials for our product candidates under development may not be completed on schedule and the FDA may not ultimately approve any of our product candidates for commercial sale. We may not ultimately be able to provide the FDA with substantial clinical evidence to support a claim of safety, purity and potency sufficient to enable the FDA to approve our product candidate for any indication. This may be because later clinical trials fail to reproduce favorable data obtained in earlier clinical trials, because the FDA disagrees with how we interpret the data from these clinical trials or because the FDA does not accept these therapeutic effects as valid endpoints in pivotal clinical trials necessary for market approval. If we fail to adequately demonstrate the safety and efficacy of any product candidate under development, we may not receive regulatory approval for those product candidates, which would prevent us from generating revenues or achieving profitability.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even<span style="letter-spacing:-0.15pt;"> </span>if one of our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>and commercialized,<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>become<span style="letter-spacing:-0.25pt;"> </span>profitable.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If approved for marketing by applicable regulatory authorities, our ability to generate revenues from our product candidates will depend on our ability to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">price our product candidates competitively such that third-party and government reimbursement leads to broad product adoption&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">prepare a broad network of clinical sites for administration of our product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">create market demand for our product candidates through our own marketing and sales activities, and any other arrangements to promote these product candidates that we may otherwise establish&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">receive regulatory approval for the targeted patient population(s) and claims that are necessary or desirable for successful marketing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacture product candidates through CMOs or in our own, or our affiliates&#8217;, manufacturing facilities in sufficient quantities and at acceptable quality and manufacturing cost to meet commercial demand at launch and thereafter&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establish and maintain agreements with wholesalers, distributors, pharmacies, and group purchasing organizations on commercially reasonable terms&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtain, maintain, protect and enforce patent and other intellectual property protection and regulatory exclusivity for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">successfully commercialize any of our product candidates that receive regulatory approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">maintain compliance with applicable laws, regulations, and guidance specific to commercialization including interactions with health care professionals, patient advocacy groups, and communication of health care economic information to payors and formularies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">achieve market acceptance of our product candidates by patients, the medical community, and third-party payors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">achieve appropriate reimbursement for our product candidates&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">maintain a distribution and logistics network capable of product storage within our specifications and regulatory guidelines, and further capable of timely product delivery to commercial clinical sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">effectively compete with other therapies or competitors&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">following launch, assure that our product will be used as directed and that additional unexpected safety risks will not arise.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the FDA approves Anktiva for certain indications, and even if we obtain significant market share for it, because the potential target population may be small, we may never achieve profitability without obtaining regulatory approval for additional indications. The FDA often approves new therapies initially only for use in patients with relapsed or refractory metastatic disease, which may limit our patient population.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we may not be able to obtain the labeling claims necessary or desirable for the promotion of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally,<span style="letter-spacing:-0.45pt;"> </span>in connection<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>merger<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>ImmunityBio,<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>assum<span style="letter-spacing:-0.1pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>obligation<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>issue<span style="letter-spacing:0.05pt;"> </span>CVRs<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>former<span style="letter-spacing:-0.2pt;"> </span>stockholde<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Al<span style="letter-spacing:-0.05pt;">t</span>or BioScience<span style="letter-spacing:-0.4pt;"> </span>Corporation<span style="letter-spacing:-0.45pt;"> </span>(succeeded<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>Altor<span style="letter-spacing:-0.15pt;"> </span>B<span style="letter-spacing:-0.05pt;">i</span>oScience&#160;LLC) (&#8220;Altor&#8221;)<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>connection<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>acquisit<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Altor.<span style="letter-spacing:-0.15pt;"> </span>These<span style="letter-spacing:-0.25pt;"> </span>CVRs<span style="letter-spacing:0.05pt;"> </span>b<span style="letter-spacing:-0.05pt;">e</span>come<span style="letter-spacing:-0.25pt;"> </span>payable<span style="letter-spacing:-0.3pt;"> </span>u<span style="letter-spacing:0.05pt;">p</span>on the<span style="letter-spacing:-0.1pt;"> </span>attainment<span style="letter-spacing:-0.35pt;"> </span>of certa<span style="letter-spacing:-0.1pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>milestones<span style="letter-spacing:-0.1pt;"> </span>related<span style="letter-spacing:-0.3pt;"> </span>to Anktiva.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>former<span style="letter-spacing:-0.3pt;"> </span>Altor<span style="letter-spacing:-0.25pt;"> </span>stockholders<span style="letter-spacing:-0.5pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>choose<span style="letter-spacing:-0.2pt;"> </span>to receive<span style="letter-spacing:-0.25pt;"> </span>these payments<span style="letter-spacing:-0.3pt;"> </span>either<span style="letter-spacing:-0.15pt;"> </span>in cas<span style="letter-spacing:0.05pt;">h</span>,<span style="letter-spacing:-0.1pt;"> </span>in an<span style="letter-spacing:-0.05pt;"> </span>equivalent<span style="letter-spacing:-0.5pt;"> </span>value<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>in a combination<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>both<span style="letter-spacing:-0.1pt;"> </span>cash<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>stock<span style="letter-spacing:-0.25pt;"> </span>at t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>payments<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>due, except<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>Dr.<span style="letter-spacing:-0.05pt;">&#160;</span>S<span style="letter-spacing:0.05pt;">o</span>on-Shiong<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>his<span style="letter-spacing:-0.05pt;"> </span>related<span style="letter-spacing:-0.25pt;"> </span>party,<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>prior<span style="letter-spacing:-0.2pt;"> </span>stockholders<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Altor,<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>irrevocably<span style="letter-spacing:-0.45pt;"> </span>elected<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>receive<span style="letter-spacing:-0.2pt;"> </span>all<span style="letter-spacing:-0.15pt;"> </span>pay<span style="letter-spacing:0.05pt;">m</span>ents<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:0.05pt;">s</span>pe<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.1pt;"> </span>of th<span style="letter-spacing:0.05pt;">e</span>ir CVRs<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>form<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:-0.3pt;"> </span>stock.<span style="letter-spacing:-0.15pt;"> </span>Such<span style="letter-spacing:-0.05pt;"> </span>CVR<span style="letter-spacing:-0.05pt;"> </span>payments<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>Dr.<span style="letter-spacing:0.05pt;">&#160;</span>Soon-Shiong<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>his<span style="letter-spacing:-0.05pt;"> </span>related<span style="letter-spacing:-0.25pt;"> </span>party<span style="letter-spacing:-0.1pt;"> </span>aggregate<span style="letter-spacing:-0.35pt;"> </span>to approximately $279.5&#160;million.<span style="letter-spacing:-0.25pt;"> We</span><span style="letter-spacing:-0.3pt;"> </span>may,<span style="letter-spacing:-0.25pt;"> </span>however,<span style="letter-spacing:-0.3pt;"> </span>still<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>requi<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>to pay<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>prior<span style="letter-spacing:-0.2pt;"> </span>Altor<span style="letter-spacing:-0.15pt;"> </span>stockholders<span style="letter-spacing:-0.5pt;"> </span>up<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> $164.2&#160;million </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>CVRs<span style="letter-spacing:-0.05pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>lating<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>regulatory milestone<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>up<span style="letter-spacing:0.05pt;"> </span>to $164.2&#160;million for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>CVRs relating<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>milestone<span style="letter-spacing:-0.3pt;"> </span>should<span style="letter-spacing:-0.3pt;"> </span>they<span style="letter-spacing:-0.1pt;"> </span>cho<span style="letter-spacing:0.05pt;">o</span>se<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>CVRs<span style="letter-spacing:0.05pt;"> </span>paid<span style="letter-spacing:-0.15pt;"> </span>in <span style="letter-spacing:-0.05pt;">c</span>ash instead<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>common stock.<span style="letter-spacing:-0.25pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>to occur,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to seek<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>sources<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>capital,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to a<span style="letter-spacing:0.05pt;">c</span>hieve<span style="letter-spacing:-0.25pt;"> </span>profitability<span style="letter-spacing:-0.45pt;"> </span>or p<span style="letter-spacing:0.05pt;">o</span>sitive<span style="letter-spacing:-0.15pt;"> </span>cash<span style="letter-spacing:-0.1pt;"> </span>flow.<span style="letter-spacing:0.05pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>plan<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>collaborate<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>governmen<span style="letter-spacing:0.05pt;">t</span>al,<span style="letter-spacing:-0.55pt;"> </span>academic<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>corporate<span style="letter-spacing:-0.3pt;"> </span>pa<span style="letter-spacing:-0.05pt;">r</span>tners,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>affili<span style="letter-spacing:-0.05pt;">a</span>tes,<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>improve<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>Anktiva, hAd5<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>therapies<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>indications<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>in combinat<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>therapies<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>imp<span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.35pt;"> </span>other prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">e</span>xpose<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>risks,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>we may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>realize<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>benefits<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>collaborations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We use the Clinic, a related party, in some of our clinical trials which may expose us to significant regulatory risks. If our data for this site is not sufficiently robust or if there are any data integrity issues, we may be required to repeat such studies or required to contract with other clinical trial sites, and our clinical development plans will be significantly delayed, and we will incur additional costs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Clinic has conducted, is currently conducting, and in the future may conduct, clinical trials involving our product candidates. The&#160;Clinic is a related party as it is owned by an officer of the company and additionally, NantWorks,&#160;LLC (&#8220;NantWorks&#8221;) manages the administrative operations of the&#160;Clinic. Prior to June&#160;30,&#160;2019, one of the company&#8217;s officers was an investigator or sub-investigator for certain of the company&#8217;s trials conducted at the&#160;Clinic. NantWorks, which is wholly owned by our Executive Chairman, Dr.&#160;Soon&#8209;Shiong, provides certain administrative services (and has loaned money) to the&#160;Clinic. Under certain circumstances, we may be required to report some of these relationships to the FDA. Relying on a related party clinical site to develop data that is used as the basis to support regulatory approval can expose us to significant regulatory risks. The FDA may conclude that a financial relationship between us, the&#160;Clinic and/or a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. If any data integrity, or regulatory non-compliance issues occur during the study, we may not be able to use the data for our regulatory approval. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of regulatory approval of one or more of our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we encounter </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">delays or </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">difficulties enrolling</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> and/or maintaining</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> patients in our clinical trials, our clinical development activities and receipt of necessary marketing approvals could be delayed or otherwise adversely affected.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We may experience difficulties or delays in patient enrollment and retention in our clinical trials for a variety of reasons, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the size and nature of the patient population&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the severity of the disease under investigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the patient eligibility criteria defined in the protocol&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the proximity of patients to trial sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to recruit clinical trial investigators with the appropriate competencies and experience&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the efforts to facilitate timely enrollment in clinical trials and the effectiveness of recruiting publicity&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the patient referral practices of physicians&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patients that enroll in our studies may misrepresent their eligibility or may otherwise not comply with the clinical trial protocol or clinical investigators may enroll patients who do not meet the enrollment criteria, resulting in the need to drop such patients from the study or clinical trial, increase the needed enrollment size for the study or clinical trial or extend the study&#8217;s or clinical trial&#8217;s duration&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">amendments to our clinical protocols, including amendments we have made to further define the patient population to be studied&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ability to obtain and maintain patient consents&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the impact of the current COVID&#8209;19 pandemic or other material adverse events, which may affect the conduct of a clinical trial, including by slowing potential enrollment or reducing the number of eligible patients for clinical trials&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the risk that patients enrolled in clinical trials will not complete a clinical trial, return for post-treatment follow-up, or follow the required study procedures.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we expect that our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Because the number of qualified clinical investigators is limited, we may need to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer and/or viral disease treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and approved immunotherapies that have established safety and efficacy profiles, rather than enroll patients in any future clinical trial. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we are able to enroll a sufficient number of patients in our clinical trials, delays in patient enrollment or small population size may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results of our trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. Combination immunotherapy that includes our current product candidates may be associated with more frequent adverse events or additional adverse events. Undesirable side effects or unacceptable toxicities caused by our product candidates could cause us, IRBs, Drug Safety Monitoring Boards, the FDA or comparable foreign regulatory authorities to interrupt, delay or halt clinical trials or order our clinical trials to be placed on clinical hold, and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities for any or all targeted indications. The FDA or comparable foreign regulatory authorities may also require additional data, clinical studies, or preclinical studies should unacceptable toxicities arise. We may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk/benefit perspective. Toxicities associated with our clinical trials and product candidates may also negatively impact our ability to conduct clinical trials using tumor-infiltrating lymphocyte therapy in larger patient populations, such as in patients that have not yet been treated with other therapies or have not yet progressed on other therapies. Even if we were to receive product approval, such approval could be contingent on inclusion of unfavorable information in our product labeling, such as limitations on the indicated uses for which the products may be marketed or distributed, a label with significant safety warnings, including boxed warnings, contraindications, and precautions, a label without statements necessary or desirable for successful commercialization, or requirements for costly post marketing testing and surveillance, or other requirements, including a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to monitor the safety or efficacy of the products, and in turn prevent us from commercializing and generating revenues from the sale of our current or future product candidates. In addition, these serious adverse effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from our product candidates are not normally encountered in the general patient population and by medical personnel. Any of these occurrences may materially harm our business, financial condition and prospects. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The manufacture of our product candidates is complex, and we may encounter difficulties in production, particularly with respect to process development, quality control, or scaling-up of our manufacturing capabilities. If we or our related parties, or any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacture of our product candidates involves complex processes, especially for our biologics, vectors and cell therapy product candidates, which are complex, highly regulated and subject to multiple risks. As a result of the complexities, the cost to manufacture biologics, vectors and cell therapies is generally higher than traditional small molecule chemical compounds, and the manufacturing process is less reliable and is more difficult to reproduce. The manufacture of cell therapy products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel and compliance with strictly enforced federal, state, local and foreign regulations. We may also find that the manufacture of our product candidates is more difficult than anticipated, resulting in an inability to produce a sufficient amount of our product candidates for our clinical trials or, if approved, commercial supply. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. Currently, our product candidates are manufactured using processes developed or modified by us, our affiliates or by our third-party research institution collaborators that we may not utilize for more advanced clinical trials or commercialization. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently we manufacture our product candidates or we may use third-party CMOs or some of our related parties to manufacture our product candidates. Our product candidates may compete with other products and product candidates for access to manufacturing facilities. Moreover, because of the complexity and novelty of our manufacturing process, there are only a limited number of manufacturers that operate under cGMP regulations and that are both capable of manufacturing our product candidates for us and willing to do so. If our CMOs should cease manufacturing for us, we would experience delays in obtaining sufficient quantities of our product candidates for clinical trials and, if approved, commercial supply. Further, our CMOs may breach, terminate, or not renew our agreements with them. If we were to need to find alternative manufacturing facilities it may take us significant time to find a replacement, if we are able to find a replacement at all and it would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. The commercial terms of any new arrangement could be less favorable than our existing arrangements and the expenses relating to the transfer of necessary technology and processes could be significant. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reliance on third-party manufacturers entails exposure to risks to which we would not be subject if we manufactured the product candidate ourselves, including:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">inability to negotiate manufacturing and quality agreements with third parties under commercially reasonable terms&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reduced day-to-day control over the manufacturing process for our product candidates as a result of using third-party manufacturers for all aspects of manufacturing activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reduced control over the protection of our trade secrets, know-how and other proprietary information from misappropriation or inadvertent disclosure or from being used in such a way as to expose us to potential litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that may be costly or damaging to us or result in delays in the development or commercialization of our product candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, any problems or delays we or our CMOs experience in preparing for commercial scale manufacturing of a product candidate may result in a delay in the FDA approval of the product candidate or may impair our ability to manufacture commercial quantities or such quantities at an acceptable cost, which could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates and could adversely affect our business. Furthermore, if we or our CMOs fail to deliver the required commercial quantities of our product candidates on a timely basis and at reasonable costs, we would likely be unable to meet demand for our products and we would lose potential revenues. We may ultimately be unable to reduce the cost of goods for our product candidates to levels that will allow for an attractive return on investment if and when those product candidates are commercialized.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the manufacturing process and facilities for any products that we may develop are subject to FDA and foreign regulatory authority approval processes, and we or our CMOs will need to meet all applicable FDA and foreign regulatory authority requirements, including cGMP, on an ongoing basis. The cGMP requirements include quality control, quality assurance and the maintenance of records and documentation. The FDA and other regulatory authorities enforce these requirements through facility inspections. Manufacturing facilities must submit to pre-approval inspections by the FDA that will be conducted after we submit our marketing applications, including our BLAs and NDAs, to the FDA. Manufacturers are also subject to continuing FDA and other regulatory authority inspections following marketing approval. Further, we and our third-party CMOs must supply all necessary chemistry, manufacturing and quality control documentation in support of a BLA or NDA on a timely basis. Our or our CMOs&#8217; manufacturing facilities may be unable to comply with our specifications, cGMP, and with other FDA, state, and foreign regulatory requirements, and there is no guarantee that we or our CMOs will be able to successfully pass all aspects of a pre-approval inspection by the FDA or other foreign regulatory authorities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of product candidates that may not be detectable in final product testing. If microbial, viral, environmental or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination which could delay clinical trials and adversely harm our business. If we or our CMOs are unable to reliably produce products to specifications acceptable to the FDA or other regulatory authorities, or in accordance with the strict regulatory requirements, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Deviations from manufacturing requirements may further require remedial measures that may be costly and/or time-consuming for us or a third party to implement and may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenues.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent we use CMOs, we are ultimately responsible for the manufacture of our products, if approved, and product candidates. A failure to comply with these requirements may result in regulatory enforcement actions against our manufacturers or us, including fines and civil and criminal penalties, which could result in imprisonment, suspension or restrictions of production, injunctions, delay or denial of product approval or supplements to approved products, clinical holds or termination of clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the biologic, refusal to permit the import or export of the products, product seizure, detention, or recall, operating restrictions, suits under the federal civil False Claims </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Act (&#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FCA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), co</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rporate integrity agreements, consent decrees, or withdrawal of product approval.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cell-based therapies and biologics rely on the availability of reagents, specialized equipment and other specialty materials, which may not be available to us on acceptable terms or at all. For some of these reagents, equipment and materials, we rely or may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products, if approved.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing our product candidates will require many reagents, which are substances used in our manufacturing processes to bring about chemical or biological reactions, and other specialty materials and equipment, some of which are manufactured or supplied by small companies with limited resources and experience to support commercial biologics production. For some of these reagents, equipment and materials used in the manufacture of our product candidates, we rely, and we may in the future rely, on sole source vendors or a limited number of vendors. Some of these suppliers may not have the capacity to support clinical trials and commercial products manufactured under cGMP by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. We also do not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key materials and equipment to support clinical or commercial manufacturing. An inability to continue to source product from any of these suppliers, which could be due to a number of issues, including regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we seek to develop and scale our manufacturing process, we expect that we will need to obtain rights to and supplies of certain materials and equipment to be used as part of that process. We may not be able to obtain rights to such materials on commercially reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect on our business. Even if we are able to alter our process so as to use other materials or equipment, such a change may lead to a delay in our clinical development and/or commercialization plans. If such a change occurs for a product candidate that is already in clinical testing, the change may require us to perform both ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>efforts<span style="letter-spacing:-0.05pt;"> </span>to develop,<span style="letter-spacing:-0.3pt;"> </span>manufacture<span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">n</span>d<span style="letter-spacing:-0.05pt;"> </span>market<span style="letter-spacing:-0.3pt;"> </span>COVID&#8209;19<span style="letter-spacing:0.05pt;"> </span>therapeutics<span style="letter-spacing:-0.5pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.05pt;"> </span>additional<span style="letter-spacing:-0.4pt;"> </span>personnel<span style="letter-spacing:0.05pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>w<span style="letter-spacing:-0.1pt;">i</span>ll<span style="letter-spacing:-0.15pt;"> </span>require training,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>may cause<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>employees<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>reallocate<span style="letter-spacing:-0.35pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;">i</span>r<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">i</span>me<span style="letter-spacing:-0.15pt;"> </span>from other<span style="letter-spacing:-0.25pt;"> </span>duties<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>in turn<span style="letter-spacing:0.05pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>in clinical<span style="letter-spacing:-0.25pt;"> </span>supply<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>product candidates<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>trials.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>been<span style="letter-spacing:-0.15pt;"> </span>planning<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19-related<span style="letter-spacing:-0.75pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oduct<span style="letter-spacing:-0.25pt;"> </span>candidates.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>repurposed<span style="letter-spacing:-0.1pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>personnel<span style="letter-spacing:-0.35pt;"> </span>overseeing<span style="letter-spacing:-0.45pt;"> </span>q<span style="letter-spacing:0.05pt;">u</span>ality, clinical<span style="letter-spacing:-0.25pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> our</span><span style="letter-spacing:-0.1pt;"> </span>oncology<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>cand<span style="letter-spacing:-0.1pt;">i</span>dates<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>support<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19 <span style="letter-spacing:0.05pt;">e</span>fforts and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>plan<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>hire<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ddit<span style="letter-spacing:-0.05pt;">i</span>onal<span style="letter-spacing:-0.35pt;"> </span>s<span style="letter-spacing:-0.05pt;">t</span>aff<span style="letter-spacing:-0.15pt;"> </span>to support<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:-0.05pt;"> </span>efforts,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>increase<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>expenses.<span style="letter-spacing:-0.4pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>personnel<span style="letter-spacing:-0.3pt;"> </span>fail<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>remain<span style="letter-spacing:-0.25pt;"> </span>focused<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">n</span>cology<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>oth<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>infectious<span style="letter-spacing:-0.3pt;"> </span>disease drug<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or, if<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>services<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>shifted<span style="letter-spacing:-0.3pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>COV<span style="letter-spacing:-0.1pt;">I</span>D<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:0.05pt;"> </span>efforts<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>adequately<span style="letter-spacing:-0.35pt;"> </span>covered<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.25pt;"> </span>em<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">l</span>oyees,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> if </span>new personnel<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>plan<span style="letter-spacing:-0.1pt;"> </span>to hire<span style="letter-spacing:-0.1pt;"> </span>to support<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:-0.05pt;"> </span>effor<span style="letter-spacing:-0.2pt;">t</span>s<span style="letter-spacing:-0.25pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>extensive<span style="letter-spacing:-0.3pt;"> </span>training,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:-0.25pt;"> </span>oncology<span style="letter-spacing:-0.3pt;"> </span>ope<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>tions<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>adversely<span style="letter-spacing:-0.35pt;"> </span>impacted.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to use<span style="letter-spacing:0.05pt;"> </span>net<span style="letter-spacing:-0.05pt;"> </span>operating<span style="letter-spacing:-0.4pt;"> </span>losses<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>credits<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>offset<span style="letter-spacing:-0.25pt;"> </span>future<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">t</span>axable<span style="letter-spacing:-0.2pt;"> </span>income<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">e</span>rtain<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>im<span style="letter-spacing:-0.05pt;">i</span>tat<span style="letter-spacing:-0.05pt;">i</span>ons</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>general,<span style="letter-spacing:-0.3pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>Sections<span style="letter-spacing:-0.35pt;">&#160;</span>382<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>383<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> Internal Revenue </span>Code<span style="letter-spacing:-0.25pt;"> (&#8220;Code&#8221;), </span>a<span style="letter-spacing:-0.1pt;"> </span>corporation<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>undergoes<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>&#8220;ow<span style="letter-spacing:-0.1pt;">n</span>ership<span style="letter-spacing:-0.15pt;"> </span>change&#8221;<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>to limitatio<span style="letter-spacing:-0.05pt;">n</span>s<span style="letter-spacing:-0.3pt;"> </span>on its<span style="letter-spacing:-0.05pt;"> a</span>bi<span style="letter-spacing:-0.05pt;">l</span>ity<span style="letter-spacing:-0.2pt;"> </span>to <span style="letter-spacing:-0.05pt;">utilize its</span><span style="letter-spacing:0.05pt;"> </span>pre-change<span style="letter-spacing:-0.4pt;"> </span>net<span style="letter-spacing:-0.1pt;"> </span>operating<span style="letter-spacing:-0.35pt;"> </span>losses<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>tax<span style="letter-spacing:-0.1pt;"> </span>credits<span style="letter-spacing:0.05pt;"> (&#8220;</span>NOLs&#8221;)<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>cr<span style="letter-spacing:-0.05pt;">e</span>dits,<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>offset<span style="letter-spacing:-0.2pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>xab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.25pt;"> </span>inco<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">a</span>xes.<span style="letter-spacing:-0.05pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span>pu<span style="letter-spacing:-0.05pt;">r</span>poses,<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>ownership<span style="letter-spacing:-0.05pt;"> </span>change generally<span style="letter-spacing:-0.35pt;"> </span>occurs<span style="letter-spacing:-0.3pt;"> </span>where<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>aggregate<span style="letter-spacing:-0.35pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>ownership<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>mo<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>s<span style="letter-spacing:0.05pt;">t</span>ockholders<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>groups<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>stockho<span style="letter-spacing:-0.05pt;">l</span>ders<span style="letter-spacing:-0.25pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>owns at least&#160;5%<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a corporation&#8217;s stock<span style="letter-spacing:-0.15pt;"> </span>increases<span style="letter-spacing:-0.3pt;"> </span>its<span style="letter-spacing:-0.05pt;"> </span>ownership<span style="letter-spacing:-0.05pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>mo<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>than<span style="letter-spacing:-0.15pt;"> </span>50&#160;percentage<span style="letter-spacing:-0.35pt;"> </span>points<span style="letter-spacing:-0.2pt;"> </span>over<span style="letter-spacing:-0.15pt;"> </span>its<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:-0.05pt;">o</span>west<span style="letter-spacing:-0.1pt;"> </span>ownership<span style="letter-spacing:0.05pt;"> </span>percentage<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>spe<span style="letter-spacing:-0.05pt;">c</span>ifi<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>sting<span style="letter-spacing:-0.35pt;"> </span>period.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>not conducted<span style="letter-spacing:-0.35pt;"> </span>a complete<span style="letter-spacing:-0.3pt;"> </span>study<span style="letter-spacing:-0.25pt;"> </span>to assess<span style="letter-spacing:0.05pt;"> </span>whether<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>change<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>control<span style="letter-spacing:-0.25pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>occurred<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>whether<span style="letter-spacing:-0.3pt;"> </span>there<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">a</span>ve<span style="letter-spacing:-0.15pt;"> </span>been<span style="letter-spacing:-0.1pt;"> </span>multiple<span style="letter-spacing:-0.3pt;"> </span>chan<span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>control<span style="letter-spacing:-0.2pt;"> </span>since<span style="letter-spacing:-0.25pt;"> </span>inception d<span style="letter-spacing:0.05pt;">u</span>e<span style="letter-spacing:0.05pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>significant<span style="letter-spacing:-0.45pt;"> </span>complexity<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>associated<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>study.<span style="letter-spacing:-0.25pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xperienced<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>change<span style="letter-spacing:-0.25pt;"> </span>of control,<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>defined<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>Section&#160;382,<span style="letter-spacing:-0.05pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>any time since<span style="letter-spacing:-0.2pt;"> </span>inception<span style="letter-spacing:-0.3pt;"> </span>(inc<span style="letter-spacing:-0.05pt;">l</span>udi<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>a result<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>merger),<span style="letter-spacing:-0.35pt;"> </span>utilization<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>net<span style="letter-spacing:-0.05pt;"> </span>operating<span style="letter-spacing:-0.3pt;"> </span>loss carryforwards<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>research<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>tax<span style="letter-spacing:-0.15pt;"> </span>credit carryforwards<span style="letter-spacing:-0.55pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nnual<span style="letter-spacing:-0.2pt;"> </span>limitation<span style="letter-spacing:-0.3pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>Section&#160;382. Any<span style="letter-spacing:0.05pt;"> </span>limitation<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>sult<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>expiration<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a portion<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>net<span style="letter-spacing:-0.05pt;"> </span>operating<span style="letter-spacing:-0.3pt;"> </span>loss carryforwards<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>credit<span style="letter-spacing:-0.25pt;"> </span>carryforwards<span style="letter-spacing:-0.45pt;"> </span>before<span style="letter-spacing:-0.3pt;"> </span>utilization.<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">I</span>n<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>NOLs<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>credits<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>impaired<span style="letter-spacing:-0.25pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>state law.<span style="letter-spacing:-0.15pt;"> </span>Acc<span style="letter-spacing:0.05pt;">o</span>rdingly,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:0.1pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to utilize<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>material<span style="letter-spacing:-0.35pt;"> </span>portion<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>NOLs<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>credits.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>raise<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">s</span>ubstantial<span style="letter-spacing:-0.3pt;"> </span>ad<span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:0.05pt;">o</span>nal<span style="letter-spacing:-0.35pt;"> </span>funding<span style="letter-spacing:-0.35pt;"> </span>to finance<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operations,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">e</span>xperience<span style="letter-spacing:-0.4pt;"> </span>further<span style="letter-spacing:-0.2pt;"> </span>ownership<span style="letter-spacing:-0.05pt;"> </span>chan<span style="letter-spacing:-0.05pt;">g</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>futur<span style="letter-spacing:0.05pt;">e</span>,<span style="letter-spacing:-0.2pt;"> </span>some<span style="letter-spacing:-0.2pt;"> </span>of which<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>outside<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>contr<span style="letter-spacing:0.05pt;">o</span>l.<span style="letter-spacing:-0.3pt;"> </span>L<span style="letter-spacing:-0.05pt;">i</span>mi<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our abi<span style="letter-spacing:-0.05pt;">l</span>ity<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>use our<span style="letter-spacing:-0.05pt;"> </span>pre-change<span style="letter-spacing:-0.35pt;"> </span>NOLs<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>credits<span style="letter-spacing:-0.2pt;"> </span>to offset<span style="letter-spacing:-0.25pt;"> </span>U.S.&#160;federal<span style="letter-spacing:-0.25pt;"> </span>taxable<span style="letter-spacing:-0.25pt;"> </span>income<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>potentially result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>increased<span style="letter-spacing:-0.35pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>liability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>earn<span style="letter-spacing:-0.1pt;"> </span>net<span style="letter-spacing:-0.05pt;"> </span>taxable<span style="letter-spacing:-0.25pt;"> </span>income<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>future.<span style="letter-spacing:-0.25pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.35pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>legislation<span style="letter-spacing:-0.4pt;"> </span>commonly<span style="letter-spacing:-0.35pt;"> </span>referred<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Tax Cuts<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>Jobs<span style="letter-spacing:-0.05pt;"> </span>Act<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>2017 (&#8220;TCJA&#8221;),<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>modified<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Co<span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">a</span>virus Aid,<span style="letter-spacing:0.05pt;"> </span>Relief,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>E<span style="letter-spacing:-0.1pt;">c</span>onomic<span style="letter-spacing:-0.3pt;"> </span>Security<span style="letter-spacing:-0.35pt;"> </span>Act<span style="letter-spacing:-0.1pt;"> (&#8220;</span>CARES<span style="letter-spacing:0.05pt;"> </span>Act&#8221;),<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>NOLs generated<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>taxable<span style="letter-spacing:-0.2pt;"> </span>periods<span style="letter-spacing:-0.2pt;"> </span>beginning<span style="letter-spacing:-0.35pt;"> </span>after<span style="letter-spacing:-0.1pt;"> </span>December&#160;31,&#160;2017,<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>permitted<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>deduct<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>taxable<span style="letter-spacing:-0.2pt;"> </span>year<span style="letter-spacing:-0.2pt;"> </span>beginning<span style="letter-spacing:-0.3pt;"> </span>after<span style="letter-spacing:-0.2pt;"> </span>December&#160;31,&#160;2020 is<span style="letter-spacing:0.05pt;"> </span>limited<span style="letter-spacing:-0.25pt;"> </span>to 80%&#160;of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>taxable<span style="letter-spacing:-0.2pt;"> </span>income<span style="letter-spacing:-0.2pt;"> </span>in such<span style="letter-spacing:-0.05pt;"> </span>year,<span style="letter-spacing:-0.25pt;"> </span>where<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">a</span>xable<span style="letter-spacing:-0.2pt;"> </span>income<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>determined<span style="letter-spacing:-0.35pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>hout<span style="letter-spacing:-0.2pt;"> </span>regard<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>NOL<span style="letter-spacing:0.05pt;"> </span>deduction<span style="letter-spacing:-0.3pt;"> </span>it<span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">e</span>lf.<span style="letter-spacing:-0.1pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>TCJA <span style="letter-spacing:0.05pt;">a</span>llo<span style="letter-spacing:0.05pt;">w</span>s p<span style="letter-spacing:0.05pt;">o</span>st-2017<span style="letter-spacing:0.05pt;"> </span>unused<span style="letter-spacing:-0.05pt;"> </span>NOLs<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>car<span style="letter-spacing:-0.05pt;">r</span>ied<span style="letter-spacing:-0.3pt;"> </span>forward<span style="letter-spacing:0.05pt;"> </span>indefi<span style="letter-spacing:0.15pt;">n</span>itely.<span style="letter-spacing:-0.45pt;"> </span>Similar<span style="letter-spacing:-0.25pt;"> </span>rul<span style="letter-spacing:-0.1pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>apply<span style="letter-spacing:-0.15pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>state<span style="letter-spacing:-0.2pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>laws.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>tax<span style="letter-spacing:-0.15pt;"> </span>law<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adv<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">e</span>ly<span style="letter-spacing:-0.25pt;"> </span>affe<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>b<span style="letter-spacing:0.05pt;">u</span>sin<span style="letter-spacing:0.05pt;">e</span>ss<span style="letter-spacing:-0.1pt;"> </span>and financial<span style="letter-spacing:-0.35pt;"> </span>co<span style="letter-spacing:0.05pt;">n</span>dition. Negative or unexpected tax consequences could adversely affect our results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our domestic and international business operations, and our business and financial performance. The rules dealing with U.S.&#160;federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S.&#160;Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us and our stockholders. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, the TCJA significantly reformed the Code. We have generally accounted for such changes in accordance with our understanding of the TCJA and guidance available as of the date of this filing as described in more detail in our condensed consolidated financial statements. Additionally, on March&#160;27,&#160;2020, the CARES Act was enacted, which, among other things, suspends the&#160;80% limitation on the deduction for net operating losses in taxable years beginning before January&#160;1,&#160;2021, permits a 5-year carryback of net operating losses arising in taxable years beginning after December&#160;31,&#160;2017 and before January&#160;1,&#160;2021, and generally caps the limitation on the deduction for net interest expense at&#160;50% of adjusted taxable income for taxable years beginning in 2019 and 2020. It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof. In addition, adverse changes in the financial outlook of our operations or further changes in tax laws or regulations could lead to changes in our valuation allowances against deferred tax assets on our consolidated balance sheets, which could materially affect our results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>transfer<span style="letter-spacing:-0.05pt;"> </span>pricing<span style="letter-spacing:-0.25pt;"> </span>poli<span style="letter-spacing:-0.05pt;">c</span>ies<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>challenge<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>IRS or other<span style="letter-spacing:-0.25pt;"> </span>taxing<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">u</span>thorities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>intercompany<span style="letter-spacing:-0.45pt;"> </span>relationships<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to complex<span style="letter-spacing:-0.25pt;"> </span>trans<span style="letter-spacing:-0.1pt;">f</span>er<span style="letter-spacing:-0.3pt;"> </span>pricing<span style="letter-spacing:-0.2pt;"> </span>regulations<span style="letter-spacing:-0.35pt;"> </span>administered<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>taxing<span style="letter-spacing:-0.2pt;"> </span>authorities<span style="letter-spacing:-0.35pt;"> </span>in vario<span style="letter-spacing:-0.05pt;">u</span>s<span style="letter-spacing:-0.25pt;"> </span>juri<span style="letter-spacing:0.05pt;">s</span>di<span style="letter-spacing:0.05pt;">c</span>tions.<span style="letter-spacing:-0.15pt;"> </span>The relevant taxing<span style="letter-spacing:-0.2pt;"> </span>authorities<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>disa<span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">r</span>ee<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>deter<span style="letter-spacing:-0.05pt;">m</span>ina<span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>va<span style="letter-spacing:-0.05pt;">l</span>ue<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span>se<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.25pt;"> </span>sold<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>acquired<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>income<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>expe<span style="letter-spacing:-0.05pt;">n</span>ses<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ttr<span style="letter-spacing:-0.05pt;">i</span>butab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>sp<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>if<span style="letter-spacing:-0.05pt;">i</span>c jurisdictions.<span style="letter-spacing:-0.45pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>disagreement<span style="letter-spacing:-0.5pt;"> </span>were<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>occur,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>position<span style="letter-spacing:-0.25pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>sustain<span style="letter-spacing:0.05pt;">e</span>d,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>pay<span style="letter-spacing:-0.2pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>taxes,<span style="letter-spacing:-0.15pt;"> </span>interest<span style="letter-spacing:-0.2pt;"> </span>and penalties,<span style="letter-spacing:-0.3pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>one-time<span style="letter-spacing:-0.25pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>charges,<span style="letter-spacing:-0.25pt;"> </span>high<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>effective<span style="letter-spacing:-0.25pt;"> </span>tax<span style="letter-spacing:-0.15pt;"> </span>rates,<span style="letter-spacing:-0.15pt;"> </span>reduced<span style="letter-spacing:-0.25pt;"> </span>cash<span style="letter-spacing:-0.05pt;"> </span>flows,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>lower<span style="letter-spacing:-0.2pt;"> </span>overall<span style="letter-spacing:-0.25pt;"> </span>profitability<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operations.<span style="letter-spacing:-0.4pt;"> </span>We bel<span style="letter-spacing:-0.05pt;">i</span>eve<span style="letter-spacing:-0.25pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>fin<span style="letter-spacing:-0.05pt;">a</span>nc<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.3pt;"> </span>s<span style="letter-spacing:-0.05pt;">t</span>a<span style="letter-spacing:-0.05pt;">t</span>em<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.35pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>fle<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>ad<span style="letter-spacing:-0.05pt;">e</span>quate<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;">e</span>rves<span style="letter-spacing:-0.15pt;"> </span>to cover<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>contingency,<span style="letter-spacing:-0.45pt;"> </span>but<span style="letter-spacing:-0.15pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>assurances<span style="letter-spacing:-0.35pt;"> </span>in that<span style="letter-spacing:-0.2pt;"> </span>regard.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">could be </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">subje</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.1pt;">additional income tax liabilities and to </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">examinations</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">tax</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">returns by</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">IRS</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">domestic</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">foreign</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">tax authorities.</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">An</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">adverse</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">out</span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ome</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">audit</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">examination</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">IRS</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">tax</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">authority</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">cou</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">material</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">adver</span><span style="letter-spacing:-0.05pt;">s</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">eff</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ct</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">on o</span><span style="letter-spacing:-0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r op</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">rating</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">results and finan</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ial</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">condit</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">on.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a U.S.-based company subject to tax in the U.S. and certain foreign tax jurisdictions. Significant judgment is required in determining our global provision for income taxes, deferred tax assets or liabilities, and in evaluating our tax positions on a worldwide basis. We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>become<span style="letter-spacing:-0.25pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>regular<span style="letter-spacing:-0.25pt;"> </span>review<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>audit<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>IRS<span style="letter-spacing:0.05pt;"> a</span>nd<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>various<span style="letter-spacing:-0.2pt;"> </span>domestic<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>jurisdi<span style="letter-spacing:-0.05pt;">c</span>tions.<span style="letter-spacing:-0.45pt;"> </span>As a<span style="letter-spacing:-0.05pt;"> </span>resul<span style="letter-spacing:-0.05pt;">t</span>,<span style="letter-spacing:-0.2pt;"> </span>we may in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>ce<span style="letter-spacing:-0.05pt;">i</span>ve<span style="letter-spacing:-0.25pt;"> </span>ass<span style="letter-spacing:-0.05pt;">e</span>ssm<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.05pt;"> i</span>n <span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span>t<span style="letter-spacing:-0.05pt;">i</span>ple<span style="letter-spacing:-0.2pt;"> </span>jurisdi<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.05pt;">i</span>ons<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>various<span style="letter-spacing:-0.2pt;"> </span>tax-related<span style="letter-spacing:-0.35pt;"> </span>assert<span style="letter-spacing:-0.05pt;">i</span>ons.<span style="letter-spacing:-0.3pt;"> </span>Taxing<span style="letter-spacing:-0.2pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>challenge<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>tax p<span style="letter-spacing:0.05pt;">o</span>sitions<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>methodologies<span style="letter-spacing:-0.5pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>var<span style="letter-spacing:-0.1pt;">i</span>ous<span style="letter-spacing:-0.2pt;"> </span>matters,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>posit<span style="letter-spacing:0.1pt;">i</span>ons<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>garding<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>collection<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>taxes,<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>termination<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>payment<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>value<span style="letter-spacing:-0.25pt;"> </span>added<span style="letter-spacing:-0.25pt;"> </span>taxes<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>jurisdictions<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:0.05pt;">a</span>xes, which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xpose us<span style="letter-spacing:-0.05pt;"> </span>to additional<span style="letter-spacing:-0.35pt;"> </span>taxes.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>regularly<span style="letter-spacing:-0.25pt;"> </span>assess<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>likelihood<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>outcomes<span style="letter-spacing:-0.3pt;"> </span>result<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>e<span style="letter-spacing:0.05pt;">x</span>aminations<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>determine<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:0.05pt;">d</span>equacy<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>provision<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>income<span style="letter-spacing:-0.2pt;"> </span>taxes.<span style="letter-spacing:-0.25pt;"> </span>These<span style="letter-spacing:-0.15pt;"> </span>assessments<span style="letter-spacing:-0.1pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>require considerable<span style="letter-spacing:-0.4pt;"> </span>estimates<span style="letter-spacing:-0.3pt;"> </span>and judgments.<span style="letter-spacing:-0.35pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>calculation<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our tax<span style="letter-spacing:-0.05pt;"> </span>liabilities<span style="letter-spacing:-0.35pt;"> </span>involv<span style="letter-spacing:-0.1pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>dealing<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>uncertainties<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>applic<span style="letter-spacing:0.05pt;">a</span>tion<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>complex<span style="letter-spacing:-0.3pt;"> </span>tax<span style="letter-spacing:-0.15pt;"> </span>laws and<span style="letter-spacing:-0.1pt;"> </span>regulations<span style="letter-spacing:-0.35pt;"> </span>in a variety<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>jurisdictions.<span style="letter-spacing:-0.4pt;"> While we believe our tax positions are consistent with the tax laws in the jurisdictions in which we conduct our business, there</span><span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>assurance<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>positions<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.1pt;">e</span>thodologies<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>calculati<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>tax<span style="letter-spacing:-0.15pt;"> </span>liabilities<span style="letter-spacing:-0.35pt;"> </span>are accurate<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>outcomes<span style="letter-spacing:-0.3pt;"> </span>f<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>m<span style="letter-spacing:-0.05pt;"> </span>ongoing<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>examinations<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>adverse<span style="letter-spacing:-0.25pt;"> </span>eff<span style="letter-spacing:-0.1pt;">e</span>ct<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operati<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>projections<span style="letter-spacing:-0.35pt;"> </span>regarding<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>opportu<span style="letter-spacing:-0.1pt;">n</span>ities<span style="letter-spacing:-0.1pt;"> </span>for our product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>accurate,<span style="letter-spacing:-0.3pt;"> </span>and the<span style="letter-spacing:-0.05pt;"> </span>actual<span style="letter-spacing:-0.2pt;"> </span>market<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>products, if a<span style="letter-spacing:0.05pt;">p</span>proved,<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>small<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">a</span>n<span style="letter-spacing:-0.05pt;"> w</span>e<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">t</span>ima<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>verifia<span style="letter-spacing:-0.1pt;">b</span>le<span style="letter-spacing:-0.3pt;"> data regarding </span>the<span style="letter-spacing:-0.05pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>size<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>ma<span style="letter-spacing:-0.05pt;">r</span>kets<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.15pt;">c</span>andidates<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>future prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates.<span style="letter-spacing:-0.45pt;"> </span>Since<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:0.1pt;">u</span>rrent<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.25pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>represent<span style="letter-spacing:-0.4pt;"> </span>novel<span style="letter-spacing:-0.25pt;"> </span>approaches<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">t</span>reating<span style="letter-spacing:-0.25pt;"> </span>various conditions,<span style="letter-spacing:-0.4pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>difficult,<span style="letter-spacing:-0.3pt;"> </span>in any<span style="letter-spacing:-0.1pt;"> </span>eve<span style="letter-spacing:-0.1pt;">n</span>t,<span style="letter-spacing:-0.15pt;"> </span>to accurately<span style="letter-spacing:-0.35pt;"> </span>estimate<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>potential<span style="letter-spacing:-0.35pt;"> </span>revenues<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>Ac<span style="letter-spacing:-0.1pt;">c</span>ordingly,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>spend sig<span style="letter-spacing:0.05pt;">n</span>ificant<span style="letter-spacing:-0.4pt;"> </span>capital<span style="letter-spacing:-0.25pt;"> </span>trying<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>uncertain<span style="letter-spacing:-0.3pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>market.<span style="letter-spacing:-0.2pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>projections<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> addressable patient populations that may </span>benefit<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>treatme<span style="letter-spacing:-0.15pt;">n</span>t<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>cand<span style="letter-spacing:-0.05pt;">i</span>dates<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>based<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>beliefs<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>estimates. These<span style="letter-spacing:-0.25pt;"> </span>estimates<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>been<span style="letter-spacing:-0.2pt;"> </span>derived<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>a v<span style="letter-spacing:0.05pt;">a</span>riety<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>sources,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>scientific<span style="letter-spacing:-0.35pt;"> </span>lite<span style="letter-spacing:0.05pt;">r</span>ature,<span style="letter-spacing:-0.3pt;"> </span>surve<span style="letter-spacing:0.05pt;">y</span>s<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>clinics,<span style="letter-spacing:-0.25pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>foun<span style="letter-spacing:-0.05pt;">d</span>ations,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>mar<span style="letter-spacing:-0.05pt;">k</span>et<span style="letter-spacing:-0.25pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;">e</span>ar<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span>by third<span style="letter-spacing:-0.15pt;"> </span>parties,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>prove<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>incorrec<span style="letter-spacing:0.05pt;">t</span>.<span style="letter-spacing:-0.3pt;"> </span>Further,<span style="letter-spacing:-0.25pt;"> </span>new studies<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> a</span>pprovals<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>therapeutics<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>change<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he <span style="letter-spacing:-0.05pt;">e</span>sti<span style="letter-spacing:-0.05pt;">m</span>at<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">in</span>cidence<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>prevalence<span style="letter-spacing:-0.35pt;"> </span>of these<span style="letter-spacing:-0.2pt;"> </span>diseases.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>number<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>turn<span style="letter-spacing:-0.1pt;"> </span>out<span style="letter-spacing:-0.05pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>lower<span style="letter-spacing:-0.25pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>expected.<span style="letter-spacing:-0.3pt;"> </span>Add<span style="letter-spacing:-0.1pt;">i</span>tionally,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>potentia<span style="letter-spacing:0.05pt;">l</span>ly<span style="letter-spacing:-0.35pt;"> </span>addressable<span style="letter-spacing:-0.4pt;"> </span>patie<span style="letter-spacing:-0.1pt;">n</span>t<span style="letter-spacing:-0.2pt;"> </span>population<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>limited<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>amenable<span style="letter-spacing:-0.3pt;"> </span>to treatment<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">d</span>uct<span style="letter-spacing:-0.15pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>limited<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>cost<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our tre<span style="letter-spacing:-0.05pt;">a</span>tm<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd <span style="letter-spacing:-0.05pt;">t</span>he r<span style="letter-spacing:-0.05pt;">e</span>i<span style="letter-spacing:-0.05pt;">m</span>burs<span style="letter-spacing:-0.05pt;">e</span>ment<span style="letter-spacing:-0.35pt;"> </span>of those<span style="letter-spacing:-0.2pt;"> </span>tre<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.35pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>by thi<span style="letter-spacing:-0.1pt;">r</span>d-party<span style="letter-spacing:-0.4pt;"> </span>payors.<span style="letter-spacing:-0.05pt;"> </span>Even<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>share<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our product<span style="letter-spacing:-0.2pt;"> </span>candidat<span style="letter-spacing:-0.1pt;">e</span>s,<span style="letter-spacing:-0.35pt;"> </span>because<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">p</span>o<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">nt</span>i<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">rg</span><span style="letter-spacing:0.05pt;">e</span>t p<span style="letter-spacing:0.05pt;">o</span>pulations<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">m</span>all,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>never<span style="letter-spacing:-0.15pt;"> </span>achie<span style="letter-spacing:-0.05pt;">v</span>e<span style="letter-spacing:-0.3pt;"> </span>profitability<span style="letter-spacing:-0.45pt;"> </span>without<span style="letter-spacing:-0.2pt;"> </span>obtaining<span style="letter-spacing:-0.35pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>f<span style="letter-spacing:-0.05pt;">o</span>r<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>indications.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>present,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">u</span>r other<span style="letter-spacing:-0.25pt;"> </span>potential<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>ll<span style="letter-spacing:-0.15pt;"> </span>represent<span style="letter-spacing:-0.05pt;"> </span>novel<span style="letter-spacing:-0.2pt;"> </span>approaches<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>treat<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.35pt;"> </span>of dis<span style="letter-spacing:0.05pt;">e</span>ase,<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>ere<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>many<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">un</span>certa<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>gard<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>dev<span style="letter-spacing:-0.05pt;">e</span>lop<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.05pt;">n</span>t,<span style="letter-spacing:-0.15pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>acceptance,<span style="letter-spacing:-0.45pt;"> </span>third-party<span style="letter-spacing:-0.45pt;"> </span>reimbursement<span style="letter-spacing:-0.5pt;"> </span>coverage<span style="letter-spacing:-0.4pt;"> </span>and t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>merc<span style="letter-spacing:-0.05pt;">i</span>al p<span style="letter-spacing:0.05pt;">o</span>tential<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human<span style="letter-spacing:-0.2pt;"> </span>immunotherapy<span style="letter-spacing:-0.5pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>new<span style="letter-spacing:-0.05pt;"> </span>category<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>therapeutics.<span style="letter-spacing:-0.45pt;"> </span>B<span style="letter-spacing:-0.05pt;">e</span>cause<span style="letter-spacing:-0.3pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>relatively<span style="letter-spacing:-0.35pt;"> </span>new<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>expanding<span style="letter-spacing:-0.3pt;"> </span>area<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>novel<span style="letter-spacing:-0.25pt;"> </span>therapeutic int<span style="letter-spacing:-0.05pt;">e</span>rv<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.25pt;"> </span>th<span style="letter-spacing:0.05pt;">e</span>re<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>ny<span style="letter-spacing:-0.15pt;"> </span>un<span style="letter-spacing:0.05pt;">ce</span>rt<span style="letter-spacing:0.05pt;">a</span>inti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.4pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>l<span style="letter-spacing:0.05pt;">a</span>ted<span style="letter-spacing:-0.2pt;"> </span>to de<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>lopment,<span style="letter-spacing:-0.45pt;"> </span>marke<span style="letter-spacing:-0.15pt;">t</span>ing,<span style="letter-spacing:-0.35pt;"> </span>reimbursement<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>me<span style="letter-spacing:-0.05pt;">r</span>ci<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.4pt;"> </span>poten<span style="letter-spacing:-0.05pt;">t</span>ial<span style="letter-spacing:-0.3pt;"> </span>for <span style="letter-spacing:-0.05pt;">o</span>ur<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates. There<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>assurance<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>length<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>period,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>number<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>FDA will<span style="letter-spacing:-0.15pt;"> </span>requ<span style="letter-spacing:-0.05pt;">i</span>re<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> e</span>nrol<span style="letter-spacing:-0.05pt;">l</span>ed<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n <span style="letter-spacing:-0.15pt;">t</span>he<span style="letter-spacing:-0.1pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n order<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>est<span style="letter-spacing:-0.05pt;">a</span>blish the<span style="letter-spacing:-0.1pt;"> </span>safety,<span style="letter-spacing:-0.25pt;"> </span>efficacy,<span style="letter-spacing:-0.3pt;"> </span>purity<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>potency<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>immunotherapy<span style="letter-spacing:-0.5pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>ducts,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>g<span style="letter-spacing:0.05pt;">e</span>nerated<span style="letter-spacing:-0.3pt;"> </span>in these<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>accepta<span style="letter-spacing:-0.15pt;">b</span>le<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>to support marketing<span style="letter-spacing:-0.35pt;"> </span>approval.<span style="letter-spacing:-0.3pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">a</span>ke<span style="letter-spacing:-0.2pt;"> </span>longer<span style="letter-spacing:-0.3pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>usual<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>come<span style="letter-spacing:-0.15pt;"> </span>to a decision<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>BLA<span style="letter-spacing:-0.05pt;"> </span>and/<span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.25pt;"> </span>NDA<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>submit<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>ultimately<span style="letter-spacing:-0.3pt;"> </span>det<span style="letter-spacing:-0.05pt;">e</span>rmine that<span style="letter-spacing:-0.1pt;"> </span>there<span style="letter-spacing:-0.25pt;"> </span>is not<span style="letter-spacing:-0.05pt;"> </span>en<span style="letter-spacing:0.05pt;">o</span>ugh<span style="letter-spacing:-0.2pt;"> </span>data,<span style="letter-spacing:-0.2pt;"> </span>information,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>exper<span style="letter-spacing:-0.05pt;">i</span>ence<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>support<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>decision.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we conduct<span style="letter-spacing:-0.25pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>post-marketing<span style="letter-spacing:-0.5pt;"> </span>studies<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>implement<span style="letter-spacing:-0.4pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>management<span style="letter-spacing:-0.4pt;"> </span>programs,<span style="letter-spacing:-0.4pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>REMS,<span style="letter-spacing:0.05pt;"> </span>until<span style="letter-spacing:-0.2pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>experience<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">p</span>roduct<span style="letter-spacing:-0.3pt;"> </span>candidates is obtained.<span style="letter-spacing:-0.3pt;"> </span>Finall<span style="letter-spacing:0.05pt;">y</span>,<span style="letter-spacing:-0.25pt;"> </span>after<span style="letter-spacing:-0.1pt;"> </span>i<span style="letter-spacing:-0.1pt;">n</span>creased<span style="letter-spacing:-0.3pt;"> </span>usage,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>find<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>i<span style="letter-spacing:0.15pt;">n</span>tended<span style="letter-spacing:-0.25pt;"> </span>effect,<span style="letter-spacing:-0.3pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>w<span style="letter-spacing:-0.05pt;">o</span>rk<span style="letter-spacing:0.05pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>combinati<span style="letter-spacing:0.05pt;">o</span>n therapies<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>unanticipated<span style="letter-spacing:-0.5pt;"> </span>side<span style="letter-spacing:-0.2pt;"> </span>eff<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">t</span>s,<span style="letter-spacing:-0.2pt;"> </span>pot<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>j<span style="letter-spacing:-0.05pt;">e</span>opard<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">z</span>ing<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>continuing<span style="letter-spacing:-0.4pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>commercial<span style="letter-spacing:-0.45pt;"> </span>prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assurance</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approaches</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">offered</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gain</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">broad</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acceptance</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">among</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">docto</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">governmental agencies</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third-party</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">medical</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">insurers</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">willing</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to provide</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reimbursement</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">coverage</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.05pt;">our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">oposed</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ma</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ket</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prod</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cts</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successfully</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">depend</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product.</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">yet</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sufficient</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ably</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">est</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ma</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wh</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t it</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.05pt;">will cost to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercially</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manu</span><span style="letter-spacing:-0.05pt;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acture</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">current</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">produ</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">actual</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacture</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">materially</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adversely</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affect</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the commercial</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">viability</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">goal</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is to reduce</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturing</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">providing</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapies.</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, u</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">less we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduce</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">those</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acceptable</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amount,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">never</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">able</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a commercial</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">viable</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">succes</span><span style="letter-spacing:-0.1pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fully</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and commercialize</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">based</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approach</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">find</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suit</span><span style="letter-spacing:-0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ble</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">economical</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sources</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">materials</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">used</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">production</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products, we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">become</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">profitable,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">materially</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adver</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ely</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affect</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">value</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">com</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock.</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anktiva</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapies</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">her therapies</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provided</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pat</span><span style="letter-spacing:0.15pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ents</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">combination</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agents</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provided</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affiliates.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of such</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">co</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bina</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">her</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">py may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inc</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ease</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ov</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rall</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ost</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapy</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issues</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regarding</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">allocation</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reimbursements</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thera</span><span style="letter-spacing:-0.1pt;">p</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agents, all</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affect</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ability</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:0.1pt;">b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tain</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reimbursement</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">coverage</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">combi</span><span style="letter-spacing:-0.1pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ation</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapy</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">governmental</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">private</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hird-party</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">medical insu</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rs.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>liability<span style="letter-spacing:-0.25pt;"> </span>law<span style="letter-spacing:-0.05pt;">s</span>uits<span style="letter-spacing:-0.35pt;"> </span>are brought<span style="letter-spacing:-0.05pt;"> </span>against<span style="letter-spacing:-0.25pt;"> </span>u<span style="letter-spacing:0.1pt;">s</span>,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>incur<span style="letter-spacing:-0.05pt;"> </span>substanti<span style="letter-spacing:-0.1pt;">a</span>l liabilities<span style="letter-spacing:-0.3pt;"> </span>and may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>quired<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>limit<span style="letter-spacing:-0.15pt;"> </span>commer<span style="letter-spacing:0.05pt;">c</span>ialization<span style="letter-spacing:-0.75pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:-0.25pt;"> </span>candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>face<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>inherent<span style="letter-spacing:-0.3pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>liability<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a result<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> development, </span>testing<span style="letter-spacing:-0.25pt;"> and manufacturing </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>face<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>e<span style="letter-spacing:0.05pt;">v</span>en<span style="letter-spacing:-0.15pt;"> </span>gre<span style="letter-spacing:-0.05pt;">a</span>ter<span style="letter-spacing:-0.25pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>f we commercialize<span style="letter-spacing:-0.5pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>products.<span style="letter-spacing:-0.4pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>example,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>sued<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>perceived<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>cause<span style="letter-spacing:-0.25pt;"> </span>injury<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>found<span style="letter-spacing:0.05pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>otherwise u<span style="letter-spacing:0.05pt;">n</span>suitable<span style="letter-spacing:-0.25pt;"> </span>during<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>tes<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:0.05pt;">n</span>g,<span style="letter-spacing:-0.15pt;"> </span>manufacturing,<span style="letter-spacing:-0.6pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>or sale.<span style="letter-spacing:-0.1pt;"> </span>Any<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>liability<span style="letter-spacing:-0.2pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>allegations<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>defects<span style="letter-spacing:-0.2pt;"> </span>in manufacturing,<span style="letter-spacing:-0.55pt;"> </span>defects<span style="letter-spacing:-0.25pt;"> </span>in design,<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>warn<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>dange<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.25pt;"> </span>inherent<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>product,<span style="letter-spacing:-0.25pt;"> </span>negligence,<span style="letter-spacing:-0.4pt;"> </span>strict<span style="letter-spacing:-0.15pt;"> </span>lia<span style="letter-spacing:0.05pt;">b</span>ility<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>brea<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>warranties.<span style="letter-spacing:-0.45pt;"> </span>Claims<span style="letter-spacing:-0.3pt;"> </span>could also<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>asse<span style="letter-spacing:-0.05pt;">r</span>ted<span style="letter-spacing:-0.15pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>consumer<span style="letter-spacing:-0.4pt;"> </span>pro<span style="letter-spacing:0.05pt;">t</span>ection<span style="letter-spacing:-0.3pt;"> </span>acts.<span style="letter-spacing:-0.2pt;"> </span>Large<span style="letter-spacing:-0.2pt;"> </span>judgements<span style="letter-spacing:-0.4pt;"> </span>have<span style="letter-spacing:-0.2pt;"> b</span>een<span style="letter-spacing:-0.1pt;"> </span>awarded<span style="letter-spacing:-0.35pt;"> </span>in c<span style="letter-spacing:0.05pt;">l</span>ass<span style="letter-spacing:-0.05pt;"> </span>action<span style="letter-spacing:-0.15pt;"> </span>lawsuits<span style="letter-spacing:-0.25pt;"> </span>based<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>n ther<span style="letter-spacing:-0.05pt;">a</span>peu<span style="letter-spacing:-0.05pt;">t</span>ics<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>h<span style="letter-spacing:-0.05pt;">a</span>d u<span style="letter-spacing:0.05pt;">n</span>anticipated<span style="letter-spacing:-0.35pt;"> </span>side<span style="letter-spacing:-0.2pt;"> </span>effec<span style="letter-spacing:-0.05pt;">t</span>s.<span style="letter-spacing:-0.15pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:-0.2pt;"> </span>successfu<span style="letter-spacing:-0.1pt;">l</span>ly<span style="letter-spacing:-0.4pt;"> </span>defend<span style="letter-spacing:-0.3pt;"> </span>ourselves<span style="letter-spacing:-0.4pt;"> </span>against<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>lia<span style="letter-spacing:-0.05pt;">b</span>ility<span style="letter-spacing:-0.35pt;"> </span>claims,<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>incur<span style="letter-spacing:-0.15pt;"> </span>substant<span style="letter-spacing:0.05pt;">i</span>al<span style="letter-spacing:-0.4pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>ab<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>required to limit<span style="letter-spacing:-0.15pt;"> </span>commercia<span style="letter-spacing:-0.1pt;">l</span>ization<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>Even<span style="letter-spacing:-0.15pt;"> </span>successful<span style="letter-spacing:-0.3pt;"> </span>defense<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">w</span>ould<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>significant<span style="letter-spacing:-0.45pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>management<span style="letter-spacing:-0.45pt;"> </span>resources.<span style="letter-spacing:-0.4pt;"> </span>Regardless of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>merits<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>eventual<span style="letter-spacing:-0.3pt;"> </span>ou<span style="letter-spacing:-0.05pt;">t</span>com<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.3pt;"> </span>li<span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.3pt;"> </span>cl<span style="letter-spacing:-0.05pt;">a</span>ims<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in <span style="Background-color:#FFFFFF;color:#000000;">a regulatory investigation of the safety and effectiveness of our products, our third-party manufacturer&#8217;s manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, including limitations on the approved indications for which our product candidates may be used or suspension or withdrawal of approvals, decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>inability<span style="letter-spacing:-0.25pt;"> </span>to obtain<span style="letter-spacing:-0.2pt;"> </span>sufficient<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>l<span style="letter-spacing:-0.1pt;">i</span>ability<span style="letter-spacing:-0.3pt;"> </span>insurance<span style="letter-spacing:-0.35pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>acceptable<span style="letter-spacing:-0.35pt;"> </span>cost<span style="letter-spacing:-0.05pt;"> </span>to protect<span style="letter-spacing:-0.2pt;"> </span>again<span style="letter-spacing:-0.1pt;">s</span>t<span style="letter-spacing:-0.25pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>liab<span style="letter-spacing:-0.05pt;">i</span>lity<span style="letter-spacing:-0.3pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>prevent<span style="letter-spacing:-0.25pt;"> </span>or inhibit<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>commercialization<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>develop,<span style="letter-spacing:-0.25pt;"> </span>alone<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>corporate<span style="letter-spacing:-0.3pt;"> </span>c<span style="letter-spacing:-0.05pt;">o</span>llaborators.<span style="letter-spacing:-0.45pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>insurance<span style="letter-spacing:-0.3pt;"> </span>policies<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>various exclusions,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to product<span style="letter-spacing:-0.25pt;"> </span>liability<span style="letter-spacing:-0.25pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>cove<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>ge.<span style="letter-spacing:-0.3pt;"> </span>While<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>obta<span style="letter-spacing:-0.1pt;">i</span>ned<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">t</span>rial<span style="letter-spacing:-0.1pt;"> </span>insurance<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our cl<span style="letter-spacing:-0.05pt;">i</span>ni<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.2pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>ls,<span style="letter-spacing:-0.2pt;"> </span>we may<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>pay<span style="letter-spacing:-0.15pt;"> </span>am<span style="letter-spacing:0.05pt;">o</span>unts<span style="letter-spacing:-0.35pt;"> </span>awarded<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>court<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>negotiated<span style="letter-spacing:-0.3pt;"> </span>in a<span style="letter-spacing:-0.05pt;"> </span>set<span style="letter-spacing:-0.05pt;">t</span>l<span style="letter-spacing:-0.05pt;">e</span>ment<span style="letter-spacing:-0.35pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.2pt;"> </span>exceed<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>coverage<span style="letter-spacing:-0.35pt;"> </span>li<span style="letter-spacing:-0.05pt;">m</span>it<span style="letter-spacing:-0.05pt;">a</span>tions<span style="letter-spacing:-0.35pt;"> </span>or th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>not covered<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>insurance,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>have,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>ob<span style="letter-spacing:-0.05pt;">t</span>ain,<span style="letter-spacing:-0.25pt;"> </span>sufficient<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>pital<span style="letter-spacing:-0.25pt;"> </span>to pay<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>amounts.<span style="letter-spacing:-0.35pt;"> </span>Even<span style="letter-spacing:-0.25pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>agreem<span style="letter-spacing:0.05pt;">e</span>nts<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">w</span><span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">a</span>ny<span style="letter-spacing:-0.05pt;"> </span>future corporate<span style="letter-spacing:-0.35pt;"> </span>collaborators<span style="letter-spacing:-0.4pt;"> </span>entitle<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>indem<span style="letter-spacing:0.1pt;">n</span>ifi<span style="letter-spacing:-0.05pt;">c</span>a<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ga<span style="letter-spacing:-0.05pt;">i</span>nst<span style="letter-spacing:-0.2pt;"> </span>losses, such<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>ndemn<span style="letter-spacing:-0.05pt;">i</span>fi<span style="letter-spacing:-0.05pt;">c</span>a<span style="letter-spacing:-0.1pt;">t</span>ion<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;">v</span>ail<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>adequate<span style="letter-spacing:-0.25pt;"> </span>should<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>claim<span style="letter-spacing:-0.2pt;"> </span>arise.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We wi</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">face</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">signifi</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ant</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ompe</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">it</span><span style="letter-spacing:-0.1pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">biotech</span><span style="letter-spacing:0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ology</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">pharmaceutical</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">companies</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">non-prof</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t ins</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">itut</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ons.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competition in the field of cancer and viral infectious disease therapy is intense and is accentuated by the rapid pace of technological development. Based on the breadth and depth of our platforms, we believe our competitors include large pharmaceutical and biotechnology companies, and specialized pharmaceutical and biotechnology firms acting either independently or together with other such companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research in the U.S. and Europe are also potential competitors and may seek patent protection or may establish collaborative arrangements for competitive products or programs. These competitors have developed, may develop and are developing product candidates and processes competitive with our product candidates. Research and discoveries by others may result in breakthroughs which may render our product candidates obsolete even before they generate any revenues. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are developing product candidates. Many of our competitors have several therapeutic products that have already been developed, approved and successfully commercialized, or are in the process of obtaining regulatory approval for their therapeutic products in the United States and internationally. Many of our potential competitors have substantially greater research and development capabilities and scientific, regulatory, manufacturing, marketing, sales, financial, managerial, and human resources and experience than we do. Our competitors may be more successful than us in obtaining regulatory approval for their treatments and products, often more rapidly than we may obtain approval for ours, and achieving widespread market acceptance and a strong market position, rendering our treatments obsolete or non-competitive, possibly even before we are able to enter the market. Accelerated merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. Early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.<span style="letter-spacing:0.05pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>may:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">safe</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">convenient</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or more</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">effective</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">immunothe</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">pies</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">therapeutic</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">therapies</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">less</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">expensive</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">better</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">private</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">public</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">payors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reach</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">rapid</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">y,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">reducing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">stablish</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">superior</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">proprietary</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">positions.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for our product candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our therapies. The level of generic competition and the availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A large<span style="letter-spacing:-0.25pt;"> </span>number<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>compa<span style="letter-spacing:-0.05pt;">n</span>ies,<span style="letter-spacing:-0.35pt;"> </span>government<span style="letter-spacing:-0.4pt;"> </span>agenc<span style="letter-spacing:-0.1pt;">i</span>es<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>academic<span style="letter-spacing:-0.3pt;"> </span>centers<span style="letter-spacing:-0.2pt;"> </span>around<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>world<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>developing<span style="letter-spacing:-0.35pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span><span style="letter-spacing:0.05pt;">1</span>9<span style="letter-spacing:-0.05pt;"> </span>vaccines,<span style="letter-spacing:-0.35pt;"> </span>and many<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hese<span style="letter-spacing:-0.05pt;"> </span>ent<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n more<span style="letter-spacing:-0.25pt;"> </span>advanced<span style="letter-spacing:-0.3pt;"> </span>stages<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>than<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>started<span style="letter-spacing:-0.3pt;"> P</span>hase&#160;II<span style="letter-spacing:-0.05pt;"> </span>and/or<span style="letter-spacing:-0.2pt;"> </span>III<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>or have already<span style="letter-spacing:-0.25pt;"> obtained</span><span style="letter-spacing:-0.2pt;"> </span>emergency<span style="letter-spacing:-0.35pt;"> </span>regulato<span style="letter-spacing:0.05pt;">r</span>y<span style="letter-spacing:-0.25pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> the United States and internationally</span>.<span style="letter-spacing:-0.25pt;"> </span>Even<span style="letter-spacing:-0.15pt;"> </span>if our<span style="letter-spacing:-0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:0.05pt;"> </span>vaccine<span style="letter-spacing:-0.25pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>ultimately<span style="letter-spacing:-0.35pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">m</span>arketing,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>value of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>op<span style="letter-spacing:0.05pt;">p</span>o<span style="letter-spacing:-0.05pt;">r</span>tunity<span style="letter-spacing:-0.25pt;"> will be</span><span style="letter-spacing:-0.05pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>impacted<span style="letter-spacing:-0.35pt;"> by</span><span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:-0.05pt;"> </span>vaccines<span style="letter-spacing:-0.35pt;"> that have obtained emergency regulatory approval, obtain full regulatory approval, </span>or<span style="letter-spacing:0.05pt;"> demonstrate</span><span style="letter-spacing:-0.15pt;"> better </span>efficacy<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>sa<span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">e</span>ty<span style="letter-spacing:-0.1pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>our COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19 vaccine<span style="letter-spacing:-0.2pt;"> </span>candidate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from other methods of treatment to our product, or if physicians switch to other new therapies, drugs or biologic products or choose to reserve our product candidates for use in limited circumstances. We may be adversely impacted if any of these competitors gain market share as a result of new technologies, commercialization strategies or otherwise.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pu</span><span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ic</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">opinion</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.1pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">rutiny</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">immunotherapy</span><span style="letter-spacing:-0.65pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">app</span><span style="letter-spacing:0.05pt;">r</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">oaches</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">impact</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">public</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">per</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">eption</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.05pt;">us</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> product</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candi</span><span style="letter-spacing:0.05pt;">d</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ates,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.35pt;">which</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may ad</span><span style="letter-spacing:-0.05pt;">v</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">rsely</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">aff</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ct</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our abil</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ty</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">condu</span><span style="letter-spacing:-0.1pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">business</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.1pt;"> </span><span style="letter-spacing:0.1pt;">implement </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">business</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">plans.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>latively<span style="letter-spacing:-0.3pt;"> </span>novel<span style="letter-spacing:-0.2pt;"> </span>technologies<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:0.05pt;">v</span>olving<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Anktiva,<span style="letter-spacing:-0.35pt;"> a</span>ldoxorubicin,<span style="letter-spacing:-0.45pt;"> </span>hAd5<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>yeast<span style="letter-spacing:-0.25pt;"> </span>technologies<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>cell-based<span style="letter-spacing:-0.35pt;"> </span>therapies<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>natural<span style="letter-spacing:-0.2pt;"> </span>killer cell<span style="letter-spacing:-0.15pt;"> </span>platform<span style="letter-spacing:-0.25pt;"> </span>utilizes<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>relatively<span style="letter-spacing:-0.35pt;"> </span>novel<span style="letter-spacing:-0.15pt;"> </span>technology<span style="letter-spacing:-0.35pt;"> </span>involv<span style="letter-spacing:0.05pt;">i</span>ng<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>genetic<span style="letter-spacing:-0.2pt;"> </span>modification<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>human<span style="letter-spacing:-0.35pt;"> </span>cells<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>util<span style="letter-spacing:-0.05pt;">i</span>zation<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>modified<span style="letter-spacing:-0.25pt;"> </span>cells<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>other individuals.<span style="letter-spacing:-0.4pt;"> </span>Public<span style="letter-spacing:-0.2pt;"> </span>pe<span style="letter-spacing:-0.05pt;">r</span>ception<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>influ<span style="letter-spacing:-0.05pt;">e</span>nced<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>claims,<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>technologies<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>unsafe,<span style="letter-spacing:-0.25pt;"> </span>unethical<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>immo<span style="letter-spacing:-0.05pt;">r</span>al<span style="letter-spacing:-0.3pt;"> </span>and,<span style="letter-spacing:-0.1pt;"> </span>consequently,<span style="letter-spacing:-0.5pt;"> </span>our approach<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>gain<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>acceptance<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>public<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>medical<span style="letter-spacing:-0.25pt;"> </span>community.<span style="letter-spacing:-0.4pt;"> </span>Negative<span style="letter-spacing:-0.25pt;"> </span>public<span style="letter-spacing:-0.25pt;"> </span>react<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>cell-based<span style="letter-spacing:-0.3pt;"> </span>immunotherapy<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>general<span style="letter-spacing:-0.2pt;"> </span>could result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>greater<span style="letter-spacing:-0.25pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>regulation<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nd<span style="letter-spacing:-0.1pt;"> </span>stricter<span style="letter-spacing:-0.2pt;"> </span>labeling<span style="letter-spacing:-0.25pt;"> </span>requirem<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>immunotherapy<span style="letter-spacing:-0.55pt;"> </span>products,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.05pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>and could<span style="letter-spacing:-0.25pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>decrease<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>demand<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>any products<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>develop. Adverse<span style="letter-spacing:0.05pt;"> </span>public<span style="letter-spacing:-0.2pt;"> </span>attitudes<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.4pt;"> </span>impact<span style="letter-spacing:-0.2pt;"> </span>our ability<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>enro<span style="letter-spacing:-0.05pt;">l</span>l<span style="letter-spacing:-0.15pt;"> patients in </span><span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l trials.<span style="letter-spacing:-0.2pt;"> </span>Moreover,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>success<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>depend<span style="letter-spacing:-0.25pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>physicians<span style="letter-spacing:-0.45pt;"> </span>specializing<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>treatment<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:-0.15pt;"> </span>dis<span style="letter-spacing:-0.1pt;">e</span>ases<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>duct<span style="letter-spacing:-0.2pt;"> </span>can<span style="letter-spacing:-0.05pt;">d</span>ida<span style="letter-spacing:-0.05pt;">t</span>es<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>rget<span style="letter-spacing:-0.2pt;"> </span>pr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">c</span>ribing, and<span style="letter-spacing:-0.1pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>being<span style="letter-spacing:-0.15pt;"> </span>willing<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>receive<span style="letter-spacing:-0.3pt;"> </span>treatments<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>involve<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>lieu<span style="letter-spacing:-0.1pt;"> </span>of,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>addit<span style="letter-spacing:0.1pt;">i</span>on<span style="letter-spacing:-0.2pt;"> </span>to,<span style="letter-spacing:-0.1pt;"> </span>ex<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">t</span>ing<span style="letter-spacing:-0.15pt;"> </span>tre<span style="letter-spacing:-0.05pt;">a</span>tm<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hey are<span style="letter-spacing:-0.1pt;"> </span>already<span style="letter-spacing:-0.2pt;"> </span>familiar<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>or<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>greater<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>available.<span style="letter-spacing:-0.35pt;"> </span>More<span style="letter-spacing:0.05pt;"> </span>restrictive<span style="letter-spacing:-0.35pt;"> </span>gove<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">n</span>ment<span style="letter-spacing:-0.35pt;"> </span>reg<span style="letter-spacing:0.05pt;">u</span>lations<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>negative<span style="letter-spacing:-0.35pt;"> </span>public<span style="letter-spacing:-0.25pt;"> </span>o<span style="letter-spacing:0.05pt;">p</span>inion<span style="letter-spacing:-0.25pt;"> </span>could have<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>or financial<span style="letter-spacing:-0.3pt;"> </span>condition<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>del<span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>impair<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>de<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>lopme<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>commercialization<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates or<span style="letter-spacing:0.05pt;"> </span>demand<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>develop.<span style="letter-spacing:-0.3pt;"> </span>Adverse<span style="letter-spacing:-0.05pt;"> </span>events<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trial<span style="letter-spacing:-0.05pt;">s</span>,<span style="letter-spacing:-0.15pt;"> </span>even<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>ultimately<span style="letter-spacing:-0.35pt;"> </span>attributable<span style="letter-spacing:-0.35pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oduct<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the resulting<span style="letter-spacing:-0.25pt;"> </span>publicity<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>increas<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.35pt;"> </span>governmental<span style="letter-spacing:-0.5pt;"> </span>regulation,<span style="letter-spacing:-0.35pt;"> </span>unfavorable<span style="letter-spacing:-0.4pt;"> </span>pub<span style="letter-spacing:-0.05pt;">l</span>ic<span style="letter-spacing:-0.15pt;"> </span>perception,<span style="letter-spacing:-0.4pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>del<span style="letter-spacing:-0.1pt;">a</span>ys<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>testing<span style="letter-spacing:-0.25pt;"> </span>or approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>stricter<span style="letter-spacing:-0.2pt;"> </span>labeling<span style="letter-spacing:-0.35pt;"> </span>requirements<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>a decrease<span style="letter-spacing:-0.25pt;"> </span>in demand<span style="letter-spacing:-0.35pt;"> </span>for any<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may seek orphan drug status or Fast Track or Breakthrough Therapy designations or other designation for one or more of our product candidates, but even if any such designation or status is granted, it may not lead to faster development or a faster regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval and we may be unable to maintain any benefits associated with such designations or status, including market exclusivity.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2012, the FDA established a Breakthrough Therapy designation, which is intended to expedite the development and review of products that treat serious or life-threatening conditions. We have received, and may seek in the future, Fast Track or Breakthrough Therapy designation for current or future product candidates. Receipt of a designation to facilitate product candidate development is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for a designation, the FDA may disagree. In any event, the receipt of such a designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and does not assure ultimate marketing approval by the FDA. In addition, the FDA may later decide that the product candidates no longer meet the designation conditions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition or for which there is no reasonable expectation that the cost of developing and making available the drug or biologic will be recovered from sales in the U.S. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA to market the same drug or biologic for the same indication for seven years, except in limited circumstances. We may seek orphan drug status for one or more of our product candidates, but exclusive marketing rights in the U.S. may be lost if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As<span style="letter-spacing:-0.05pt;"> </span>a condition<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>approval,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA m<span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span>re<span style="letter-spacing:0.05pt;">q</span><span style="letter-spacing:0.1pt;">u</span>ire<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>implement<span style="letter-spacing:-0.35pt;"> </span>var<span style="letter-spacing:0.05pt;">i</span>ous<span style="letter-spacing:-0.1pt;"> </span>post-marketing<span style="letter-spacing:-0.6pt;"> </span>requirements<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>conduct<span style="letter-spacing:-0.35pt;"> </span>post-marketi<span style="letter-spacing:0.1pt;">n</span>g<span style="letter-spacing:-0.55pt;"> </span>studies,<span style="letter-spacing:-0.35pt;"> </span>any of<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>would<span style="letter-spacing:-0.25pt;"> </span>require<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>substantial<span style="letter-spacing:-0.35pt;"> </span>investment<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>time,<span style="letter-spacing:-0.15pt;"> </span>effort,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>money,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>im<span style="letter-spacing:-0.05pt;">i</span>t<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>omm<span style="letter-spacing:-0.05pt;">e</span>rcial<span style="letter-spacing:-0.35pt;"> </span>prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a condition of biologic licensing, the FDA is authorized to require that sponsors of approved BLAs implement various post-market requirements, including REMS and Phase IV trials. For example, in connection with FDA approval of another company&#8217;s drug, the FDA required significant post-marketing commitments, including a Phase IV trial, revalidation of a test method, and a substantial REMS program that included, among other requirements, the certification of hospitals and their associated clinics that dispensed the drug, including the implementation of a training program and limited distribution only to certified hospitals and their associated clinics. If we receive approval of our product candidates, the FDA may determine that similar or additional or more burdensome post-approval requirements are necessary to ensure that our product candidates are safe, pure and potent. To the extent that we are required to establish and implement any post-approval requirements, we will likely need to invest a significant amount of time, effort and money. Such post-approval requirements may also limit the commercial prospects of our product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have never commercialized a product candidate before, and we may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be unable to establish effective marketing and sales capabilities or enter into agreements with third parties or related parties to market and sell our product candidates, if they are approved, and as a result, we may be unable to generate product revenues.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have little to no prior experience in, and currently do not have a commercial infrastructure for, the marketing, sale and distribution of biopharmaceutical products. To achieve commercial success for the product candidates, which we may license to others, we will rely on the assistance and guidance of those collaborators. For product candidates for which we retain commercialization rights and marketing approval, if approved, in order to commercialize our product candidates, we must build our marketing, sales and distribution capabilities, including a comprehensive healthcare compliance program, or arrange with third parties to perform these services, which will take time and require significant financial expenditures and could delay any product launch and we may not be successful in doing so. There are significant risks involved with building and managing a commercial infrastructure. We, or our collaborators, will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train, manage and retain medical affairs, marketing, sales and commercial support personnel. Recruiting, training and retaining a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have incurred these commercialization expenses prematurely or unnecessarily. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In the event we are unable to develop a commercial infrastructure, we may not be able to commercialize our current or future product candidates, which would limit our ability to generate product revenues. Even if we are able to effectively establish a sales force and develop a marketing and sales infrastructure, our sales force and marketing teams may not be successful in commercializing our current or future product candidates. To the extent we rely on third parties to commercialize any products for which we obtain regulatory approval, we would have less control over their sales efforts and could be held liable if they failed to comply with applicable legal or regulatory requirements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors that may inhibit our efforts to commercialize our current or future product candidates and generate product revenues include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">if the COVID&#8209;19 pandemic continues or reoccurs it may negatively impact our ability to establish commercial operations, educate and interact with healthcare professionals, and successfully launch our product on a timely basis&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe our current or future product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our inability to effectively oversee a geographically dispersed sales and marketing team&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs and time associated with the initial and ongoing training of sales and marketing personnel on legal and regulatory compliance matters and monitoring their actions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an inability to secure adequate coverage and reimbursement by government and private health plans&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the clinical indications for which the products are approved and the claims that we may make for the products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">limitations or warnings, including distribution or use restrictions, contained in the products&#8217; approved labeling&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any distribution and use restrictions imposed by the FDA or to which we agree as part of a mandatory REMS or voluntary risk management plan&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">liability for sales or marketing personnel who fail to comply with the applicable legal and regulatory requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unforeseen costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales organization.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We expect to rely on third parties to perform many essential services for any products that we commercialize, including services related to distribution, government price reporting, customer service, accounts receivable management, cash collection and adverse event reporting. If these third parties fail to perform as expected or to comply with legal and regulatory requirements, our ability to commercialize our current or future product candidates will be significantly impacted and we may be subject to regulatory sanctions.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to retain third-party service providers to perform a variety of functions related to the sale of our current or future product candidates, key aspects of which will be out of our direct control. These service providers may provide key services related to distribution, customer service, accounts receivable management, and cash collection. If we retain a service provider, we would substantially rely on it as well as other third-party providers that perform services for us, including entrusting our inventories of products to their care and handling. If these third-party service providers fail to comply with applicable laws and regulations, fail to meet expected deadlines or otherwise do not carry out their contractual duties to us, or encounter physical or natural damage at their facilities, our ability to deliver product to meet commercial demand would be significantly impaired and we may be subject to regulatory enforcement action.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may engage in the future with third parties to perform various other services for us relating to adverse event reporting, safety database management, fulfillment of requests for medical information regarding our product candidates and related services. If the quality or accuracy of the data maintained by these service providers is insufficient, or these third parties otherwise fail to comply with regulatory requirements related to adverse event reporting, we could be subject to regulatory sanctions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we may contract in the future with a third party to calculate and report pricing information mandated by various government programs. If a third party fails to timely report or adjust prices as required or errs in calculating government pricing information from transactional data in our financial records, it could impact our discount and rebate liability, and potentially subject us to regulatory sanctions or FCA lawsuits.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.05pt;"> </span>our product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>achieve<span style="letter-spacing:-0.25pt;"> </span>b<span style="letter-spacing:0.05pt;">r</span>oad<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:-0.3pt;"> </span>acceptance,<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>rev<span style="letter-spacing:0.1pt;">e</span>nues<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>generate<span style="letter-spacing:-0.25pt;"> </span>from their<span style="letter-spacing:-0.2pt;"> </span>sales<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>limit<span style="letter-spacing:0.05pt;">e</span>d.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not commercialized a product candidate for any indication. Even if our product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors and others in the medical community. If any product candidate for which we obtain regulatory approval does not gain an adequate level of market acceptance, we may not generate significant product revenues or become profitable. Market acceptance of our product candidates by the medical community, patients and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians are often reluctant to switch their patients, and patients may be reluctant to switch from, existing therapies even when new and potentially more effective or safer treatments enter the market. Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. Even if the medical community accepts that our product candidates are safe and effective for their approved indications, physicians and patients may not immediately be receptive to such product candidates and may be slow to adopt them as an accepted treatment of the approved indications. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market acceptance of any of our product candidates will depend on a number of factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the continued safety and efficacy of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the prevalence and severity of adverse events associated with such product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the clinical indications for which the products are approved and the approved claims that we may make for the products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">limitations or warnings contained in the product&#8217;s FDA-approved labeling, including potential limitations or warnings for such products that may be more restrictive than other competitive products or distribution and use restrictions imposed by the FDA with respect to such product candidates or to which we agree as part of a mandatory REMS or voluntary risk management plan&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the standard of care for the targeted indications for such product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the relative difficulty of administration of such product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to offer such product candidates for sale at competitive prices, including the cost of treatment versus economic and clinical benefit in relation to alternative treatments or therapies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the availability of adequate coverage or reimbursement by third parties, such as insurance companies and other healthcare payors, and by government healthcare programs, including Medicare and Medicaid&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">the extent and strength of our marketing and distribution of such product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the safety, efficacy and other potential advantages over, and availability of, alternative treatments already used or that may later be approved for any of our intended indications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing of market introduction of such product candidates, as well as competitive products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the extent and strength of our third-party manufacturer and supplier support&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse publicity about the product or favorable publicity about competitive products&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential product liability claims.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any product candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>face<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.05pt;">o</span>mpetition<span style="letter-spacing:-0.45pt;"> </span>sooner<span style="letter-spacing:0.05pt;"> </span>than<span style="letter-spacing:-0.05pt;"> </span>anticipated.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>enactment<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Biologics<span style="letter-spacing:-0.4pt;"> </span>Price<span style="letter-spacing:-0.25pt;"> </span>Competition<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>Innovation<span style="letter-spacing:-0.4pt;"> </span>A<span style="letter-spacing:-0.1pt;">c</span>t<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>2009<span style="letter-spacing:0.05pt;"> </span>(&#8220;BPCIA&#8221;)<span style="letter-spacing:0.05pt;"> </span>created<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>abbre<span style="letter-spacing:0.05pt;">v</span>iated<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">a</span>thway<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;">p</span>proval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>biosimilar and<span style="letter-spacing:-0.1pt;"> </span>inte<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">c</span>hangeable<span style="letter-spacing:-0.5pt;"> </span>biological<span style="letter-spacing:-0.3pt;"> </span>products.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>abbreviated<span style="letter-spacing:-0.4pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>pathway<span style="letter-spacing:-0.3pt;"> </span>establi<span style="letter-spacing:-0.05pt;">s</span>hes<span style="letter-spacing:-0.3pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>authority<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>review<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>approve<span style="letter-spacing:-0.25pt;"> </span>biosimilar biologics,<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>possible<span style="letter-spacing:-0.3pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>signation<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>biosimilar<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>&#8220;in<span style="letter-spacing:0.05pt;">t</span>erchangeable&#8221;<span style="letter-spacing:-0.65pt;"> </span>based<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>its<span style="letter-spacing:-0.1pt;"> </span>sim<span style="letter-spacing:-0.1pt;">i</span>lar<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.35pt;"> </span>to <span style="letter-spacing:-0.05pt;">a</span>n <span style="letter-spacing:-0.05pt;">e</span>xisting<span style="letter-spacing:-0.25pt;"> </span>brand<span style="letter-spacing:-0.25pt;"> </span>product.<span style="letter-spacing:-0.25pt;"> </span>Under<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>BPCIA, the<span style="letter-spacing:-0.15pt;"> </span>FDA cannot<span style="letter-spacing:-0.3pt;"> </span>make<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">a</span>pplication<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a biosimilar<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>effective<span style="letter-spacing:-0.25pt;"> </span>until<span style="letter-spacing:-0.2pt;"> </span>12&#160;years<span style="letter-spacing:-0.15pt;"> </span>after<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>original<span style="letter-spacing:-0.25pt;"> </span>branded<span style="letter-spacing:-0.35pt;"> </span>product was approved under a BLA.<span style="letter-spacing:0.05pt;"> </span>Certain<span style="letter-spacing:-0.2pt;"> </span>changes,<span style="letter-spacing:-0.25pt;"> </span>ho<span style="letter-spacing:-0.05pt;">w</span>ever,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>supplements<span style="letter-spacing:-0.4pt;"> </span>to an<span style="letter-spacing:-0.05pt;"> </span>app<span style="letter-spacing:-0.1pt;">r</span>oved<span style="letter-spacing:-0.3pt;"> </span>BLA,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>subsequent applications<span style="letter-spacing:-0.5pt;"> </span>fil<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>same<span style="letter-spacing:-0.25pt;"> </span>spons<span style="letter-spacing:0.05pt;">o</span>r,<span style="letter-spacing:-0.05pt;"> </span>manufacturer, li<span style="letter-spacing:-0.05pt;">c</span>ensor,<span style="letter-spacing:-0.1pt;"> </span>pred<span style="letter-spacing:-0.05pt;">e</span>cessor<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">e</span>st<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>entity<span style="letter-spacing:-0.15pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>qualify<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>12-year<span style="letter-spacing:-0.2pt;"> </span>exclusivity<span style="letter-spacing:-0.4pt;"> </span>period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>qualify<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>BPCIA&#8217;s<span style="letter-spacing:-0.05pt;"> </span>12-year<span style="letter-spacing:-0.3pt;"> </span>period<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>exclusivity.<span style="letter-spacing:-0.35pt;"> </span>Howev<span style="letter-spacing:0.05pt;">e</span>r,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>n<span style="letter-spacing:0.05pt;">o</span>t consider<span style="letter-spacing:-0.35pt;"> </span>our <span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>od<span style="letter-spacing:0.05pt;">u</span>ct candidates<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>reference<span style="letter-spacing:-0.3pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>competing<span style="letter-spacing:-0.35pt;"> </span>products,<span style="letter-spacing:-0.4pt;"> </span>p<span style="letter-spacing:0.05pt;">o</span>ten<span style="letter-spacing:-0.1pt;">t</span>ially<span style="letter-spacing:-0.35pt;"> </span>creating<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>opport<span style="letter-spacing:0.05pt;">u</span>nity<span style="letter-spacing:-0.45pt;"> </span>f<span style="letter-spacing:0.05pt;">o</span>r bi<span style="letter-spacing:0.05pt;">o</span>similar<span style="letter-spacing:-0.3pt;"> </span>competition<span style="letter-spacing:-0.4pt;"> </span>sooner<span style="letter-spacing:-0.1pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>n<span style="letter-spacing:-0.05pt;"> a</span>nti<span style="letter-spacing:-0.05pt;">c</span>ipa<span style="letter-spacing:-0.05pt;">t</span>ed. Additionally,<span style="letter-spacing:-0.45pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>pe<span style="letter-spacing:-0.05pt;">r</span>iod<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>exclusivity<span style="letter-spacing:-0.35pt;"> </span>does<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">l</span>ock<span style="letter-spacing:-0.2pt;"> </span>companies<span style="letter-spacing:-0.4pt;"> </span>pursu<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>via<span style="letter-spacing:-0.05pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>own<span style="letter-spacing:-0.05pt;"> </span>tradit<span style="letter-spacing:-0.05pt;">i</span>onal<span style="letter-spacing:-0.4pt;"> </span>BLA,<span style="letter-spacing:0.05pt;"> </span>rather<span style="letter-spacing:-0.2pt;"> </span>than<span style="letter-spacing:-0.2pt;"> </span>via the<span style="letter-spacing:-0.15pt;"> </span>abbreviated<span style="letter-spacing:-0.4pt;"> </span>pathway.<span style="letter-spacing:-0.3pt;"> </span>Changes<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.05pt;"> </span>made<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>this<span style="letter-spacing:-0.2pt;"> </span>exclusivity<span style="letter-spacing:-0.35pt;"> </span>period<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>legis<span style="letter-spacing:0.05pt;">l</span>ation<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>there<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>b<span style="letter-spacing:-0.05pt;">e</span>en<span style="letter-spacing:-0.1pt;"> </span>ongoing<span style="letter-spacing:-0.25pt;"> </span>efforts<span style="letter-spacing:-0.2pt;"> </span>to reduce<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>period<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>exclusivity.<span style="letter-spacing:-0.35pt;"> </span>Even<span style="letter-spacing:-0.15pt;"> </span>if<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>receive<span style="letter-spacing:-0.2pt;"> </span>a period<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>BPCIA<span style="letter-spacing:-0.05pt;"> </span>exclusivity<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>first<span style="letter-spacing:-0.1pt;"> </span>licensed<span style="letter-spacing:-0.3pt;"> </span>product,<span style="letter-spacing:-0.35pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>subse<span style="letter-spacing:0.05pt;">q</span>ue<span style="letter-spacing:0.1pt;">n</span>t<span style="letter-spacing:-0.2pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>include<span style="letter-spacing:-0.25pt;"> </span>a modification<span style="letter-spacing:-0.45pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>structure<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>produ<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>impacts<span style="letter-spacing:-0.3pt;"> </span>safety,<span style="letter-spacing:-0.3pt;"> </span>purity,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>potency,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>receive<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">a</span>dditional<span style="letter-spacing:-0.35pt;"> </span>periods<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>exclusivity<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>those prod<span style="letter-spacing:0.05pt;">u</span>cts.<span style="letter-spacing:-0.05pt;"> </span>Moreover,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>extent<span style="letter-spacing:-0.2pt;"> </span>to which<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>biosimilar,<span style="letter-spacing:-0.35pt;"> </span>once<span style="letter-spacing:-0.1pt;"> </span>approv<span style="letter-spacing:0.05pt;">e</span>d,<span style="letter-spacing:-0.25pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>substituted<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>ny one<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>refere<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>in a way<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>is similar<span style="letter-spacing:-0.2pt;"> </span>to traditional<span style="letter-spacing:-0.3pt;"> </span>generic<span style="letter-spacing:-0.25pt;"> </span>substitution<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>non-biological<span style="letter-spacing:-0.45pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>is not<span style="letter-spacing:-0.05pt;"> </span>y<span style="letter-spacing:-0.05pt;">e</span>t<span style="letter-spacing:-0.05pt;"> </span>clear,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>dep<span style="letter-spacing:-0.1pt;">e</span>nd<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>number<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>marke<span style="letter-spacing:0.05pt;">t</span>place<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>factors that<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>still<span style="letter-spacing:-0.15pt;"> </span>developing.<span style="letter-spacing:-0.45pt;"> </span>Medicare<span style="letter-spacing:-0.4pt;"> </span>Part<span style="letter-spacing:-0.2pt;"> </span>B encourages<span style="letter-spacing:-0.45pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>biosimilars<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>paying<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>provider<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>sa<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.2pt;"> </span>perc<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.05pt;">a</span>ge<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>f<span style="letter-spacing:-0.05pt;">e</span>rence<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>average sale<span style="letter-spacing:-0.2pt;"> </span>price<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a mark-up,<span style="letter-spacing:-0.4pt;"> </span>regardless<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>whi<span style="letter-spacing:0.1pt;">c</span>h<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>is reimbursed.<span style="letter-spacing:-0.45pt;"> </span>It is<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>possible<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>payors<span style="letter-spacing:-0.05pt;"> w</span>ill give<span style="letter-spacing:-0.1pt;"> </span>rei<span style="letter-spacing:-0.05pt;">m</span>bursement<span style="letter-spacing:-0.5pt;"> </span>pr<span style="letter-spacing:-0.05pt;">e</span>feren<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>biosim<span style="letter-spacing:-0.05pt;">i</span>lars<span style="letter-spacing:-0.35pt;"> </span>even o<span style="letter-spacing:0.05pt;">v</span>er<span style="letter-spacing:-0.05pt;"> </span>reference<span style="letter-spacing:-0.3pt;"> </span>biologics<span style="letter-spacing:-0.35pt;"> </span>abs<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>de<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rm<span style="letter-spacing:-0.05pt;">i</span>na<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>interchangeability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For<span style="letter-spacing:0.95pt;"> </span>our<span style="letter-spacing:0.5pt;"> </span>small<span style="letter-spacing:1.25pt;"> </span>molecular<span style="letter-spacing:1.9pt;"> </span>product<span style="letter-spacing:1.65pt;"> </span>candidates,<span style="letter-spacing:1.85pt;"> </span>if<span style="letter-spacing:0.25pt;"> </span>qualified,<span style="letter-spacing:1.75pt;"> </span>the<span style="letter-spacing:0.4pt;"> </span>regulatory exclusivity<span style="letter-spacing:1.9pt;"> </span>period<span style="letter-spacing:1.7pt;"> </span>is less<span style="letter-spacing:0.6pt;"> </span>than<span style="letter-spacing:0.95pt;"> </span>for<span style="letter-spacing:1pt;"> </span>our<span style="letter-spacing:0.55pt;"> </span>biologic<span style="letter-spacing:1.9pt;"> </span>product<span style="letter-spacing:1.15pt;"> </span>candidates. The<span style="letter-spacing:0.55pt;"> </span>Federal Food,<span style="letter-spacing:1.35pt;"> </span>Drug,<span style="letter-spacing:1.4pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>Cosmetic<span style="letter-spacing:1.7pt;"> </span>Act<span style="letter-spacing:0.65pt;"> </span>(&#8220;FDCA&#8221;) provides<span style="letter-spacing:1.6pt;"> </span>a<span style="letter-spacing:0.15pt;"> </span>five-year<span style="letter-spacing:1.75pt;"> </span>period<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>non-patent<span style="letter-spacing:1.75pt;"> </span>marketing<span style="letter-spacing:2.05pt;"> </span>exclusivity<span style="letter-spacing:1.8pt;"> </span>within<span style="letter-spacing:1.2pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>United<span style="letter-spacing:1.45pt;"> </span>States<span style="letter-spacing:1pt;"> </span>to<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.85pt;"> </span>first<span style="letter-spacing:0.65pt;"> </span>applicant to<span style="letter-spacing:0.8pt;"> </span>gain<span style="letter-spacing:0.75pt;"> </span>approval<span style="letter-spacing:1.9pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>an<span style="letter-spacing:0.25pt;"> </span>NDA<span style="letter-spacing:0.9pt;"> </span>for<span style="letter-spacing:1pt;"> </span>a drug<span style="letter-spacing:1.1pt;"> </span>where the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>has<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>previously<span style="letter-spacing:-0.45pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>new<span style="letter-spacing:-0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>containing<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>same<span style="letter-spacing:-0.25pt;"> </span>active<span style="letter-spacing:-0.15pt;"> </span>molecule<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>ion<span style="letter-spacing:-0.15pt;"> </span>respons<span style="letter-spacing:-0.05pt;">i</span>ble<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>action<span style="letter-spacing:-0.2pt;"> </span>of the<span style="letter-spacing:-0.1pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>substance.<span style="letter-spacing:-0.3pt;"> </span>During the<span style="letter-spacing:-0.1pt;"> </span>e<span style="letter-spacing:-0.05pt;">x</span>clusivity<span style="letter-spacing:-0.35pt;"> </span>period,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>cept<span style="letter-spacing:-0.25pt;"> </span>for rev<span style="letter-spacing:-0.05pt;">i</span>ew<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>n abbr<span style="letter-spacing:-0.05pt;">e</span>vi<span style="letter-spacing:-0.1pt;">a</span>ted<span style="letter-spacing:-0.4pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>drug<span style="letter-spacing:-0.05pt;"> </span>application<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>a 505(b)(2)<span style="letter-spacing:-0.05pt;">&#160;</span>NDA submitted<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>another<span style="letter-spacing:-0.25pt;"> </span>company<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>generic<span style="letter-spacing:-0.25pt;"> </span>version<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>where<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>applica<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.3pt;"> </span>does<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>own<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a legal<span style="letter-spacing:-0.15pt;"> </span>right<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>refe<span style="letter-spacing:-0.05pt;">re</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">a</span>ll<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">th</span>e<span style="letter-spacing:-0.05pt;"> da</span>ta required<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>approval.<span style="letter-spacing:-0.4pt;"> </span>However,<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>application<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>submitted<span style="letter-spacing:-0.3pt;"> </span>after<span style="letter-spacing:-0.2pt;"> </span>four<span style="letter-spacing:0.05pt;"> </span>years<span style="letter-spacing:-0.15pt;"> </span>if it <span style="letter-spacing:-0.15pt;">c</span>ontains<span style="letter-spacing:-0.25pt;"> </span>a certification<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>inva<span style="letter-spacing:-0.1pt;">l</span>idity<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>non-infringement. The<span style="letter-spacing:-0.2pt;"> </span>FDCA<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>provides<span style="letter-spacing:-0.25pt;"> </span>three<span style="letter-spacing:-0.2pt;"> </span>years<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>mar<span style="letter-spacing:-0.1pt;">k</span>eting<span style="letter-spacing:-0.4pt;"> </span>exclu<span style="letter-spacing:0.05pt;">s</span>ivity<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>an NDA, 505(b<span style="letter-spacing:-0.05pt;">)</span>(2)<span style="letter-spacing:0.05pt;">&#160;</span>N<span style="letter-spacing:0.05pt;">D</span>A<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>supplement<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>exi<span style="letter-spacing:0.05pt;">s</span>ting<span style="letter-spacing:-0.3pt;"> </span>NDA if<span style="letter-spacing:-0.1pt;"> </span>new c<span style="letter-spacing:0.15pt;">l</span><span style="letter-spacing:-0.05pt;">in</span>i<span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">al </span>investigations,<span style="letter-spacing:-0.45pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>than<span style="letter-spacing:-0.2pt;"> </span>bioav<span style="letter-spacing:0.05pt;">a</span>ilability<span style="letter-spacing:-0.5pt;"> </span>studies,<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>were<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">c</span>onducted<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>sponsored<span style="letter-spacing:-0.05pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>appli<span style="letter-spacing:-0.05pt;">c</span>ant<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.05pt;"> </span>deemed<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">b</span>y<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> e</span>ss<span style="letter-spacing:-0.05pt;">e</span>nti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>to <span style="letter-spacing:-0.05pt;">t</span>he approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>applicatio<span style="letter-spacing:0.05pt;">n</span>,<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>or<span style="letter-spacing:0.05pt;"> </span>example,<span style="letter-spacing:-0.35pt;"> </span>n<span style="letter-spacing:0.05pt;">e</span>w<span style="letter-spacing:-0.15pt;"> </span>indications,<span style="letter-spacing:-0.35pt;"> </span>dosages<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>strengths<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span>drug.<span style="letter-spacing:0.05pt;"> </span>As su<span style="letter-spacing:0.05pt;">c</span>h, we m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>f<span style="letter-spacing:0.05pt;">a</span>ce<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">c</span>omp<span style="letter-spacing:0.05pt;">e</span>tition<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>gene<span style="letter-spacing:-0.05pt;">r</span>ic versions<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>small<span style="letter-spacing:-0.2pt;"> </span>molecule<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndidates,<span style="letter-spacing:-0.45pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>negative<span style="letter-spacing:0.05pt;">l</span>y<span style="letter-spacing:-0.3pt;"> </span>impact<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>long-term<span style="letter-spacing:-0.3pt;"> </span>busi<span style="letter-spacing:-0.05pt;">n</span>ess<span style="letter-spacing:-0.2pt;"> </span>prospects<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>opportunities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">need</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to obtain</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FDA</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">y proposed</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">branded</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">names,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">f</span><span style="letter-spacing:0.05pt;">a</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ilure</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">delay</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">associated</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">adversely affect</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:-0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r </span><span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">u</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">s</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any name<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>intend<span style="letter-spacing:-0.15pt;"> </span>to use<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:0.05pt;">a</span>ndidates<span style="letter-spacing:-0.4pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>regardless<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>whether<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>secured<span style="letter-spacing:-0.2pt;"> </span>a formal<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ademark<span style="letter-spacing:-0.35pt;"> </span>registration<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>U.S.<span style="letter-spacing:-0.05pt;">&#160;</span>Patent<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>Trademark<span style="letter-spacing:-0.4pt;"> </span>Office (&#8220;USPTO&#8221;).<span style="letter-spacing:0.05pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>typically<span style="letter-spacing:-0.35pt;"> </span>conducts<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>review<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>prop<span style="letter-spacing:0.05pt;">o</span>sed<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>names,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>e<span style="letter-spacing:0.05pt;">v</span>aluation<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>pote<span style="letter-spacing:-0.1pt;">n</span>tial<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>confusion<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>names.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>object<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>a product<span style="letter-spacing:-0.3pt;"> </span>n<span style="letter-spacing:0.1pt;">a</span>me<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>it beli<span style="letter-spacing:-0.05pt;">e</span>v<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>name<span style="letter-spacing:0.05pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span>appropriately<span style="letter-spacing:-0.5pt;"> </span>implies<span style="letter-spacing:-0.2pt;"> </span>medical<span style="letter-spacing:-0.35pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>contributes<span style="letter-spacing:-0.35pt;"> </span>to an<span style="letter-spacing:-0.15pt;"> </span>overstatement<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.05pt;"> e</span>fficacy.<span style="letter-spacing:-0.3pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>objects<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>proposed<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>names,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>adopt<span style="letter-spacing:-0.15pt;"> </span>alternative<span style="letter-spacing:-0.4pt;"> </span>names<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>adopt<span style="letter-spacing:-0.25pt;"> </span>alternative<span style="letter-spacing:-0.35pt;"> </span>names,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.1pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>lose<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>benefit<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>existing<span style="letter-spacing:-0.3pt;"> </span>tradema<span style="letter-spacing:-0.05pt;">r</span>k<span style="letter-spacing:0.05pt;"> </span>applications<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>cand<span style="letter-spacing:0.05pt;">i</span>date<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>expend<span style="letter-spacing:-0.3pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>dditional<span style="letter-spacing:-0.35pt;"> </span>resources<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>effort<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o iden<span style="letter-spacing:-0.05pt;">t</span>ify<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>sui<span style="letter-spacing:-0.05pt;">t</span>ab<span style="letter-spacing:-0.05pt;">l</span>e prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>name<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>qualify<span style="letter-spacing:-0.2pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>applicable<span style="letter-spacing:-0.3pt;"> </span>trademark<span style="letter-spacing:-0.35pt;"> </span>laws,<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>infringe<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.1pt;">w</span>ise<span style="letter-spacing:-0.3pt;"> </span>violate<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span>ri<span style="letter-spacing:0.05pt;">g</span>hts<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>ac<span style="letter-spacing:-0.05pt;">c</span>ep<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>ble to the<span style="letter-spacing:-0.1pt;"> </span>FDA.<span style="letter-spacing:-0.05pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>build<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>successful<span style="letter-spacing:-0.2pt;"> </span>brand<span style="letter-spacing:-0.25pt;"> </span>identity<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a new<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>name<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>a timely<span style="letter-spacing:-0.25pt;"> </span>manner<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>at all,<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>w<span style="letter-spacing:-0.05pt;">o</span>uld<span style="letter-spacing:-0.1pt;"> </span>li<span style="letter-spacing:-0.05pt;">m</span>it<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>to commercialize<span style="letter-spacing:-0.5pt;"> </span>our product<span style="letter-spacing:-0.25pt;"> </span>candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>i<span style="letter-spacing:-0.1pt;">n</span>te<span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">n</span>al<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">c</span>omputer<span style="letter-spacing:-0.3pt;"> </span>s<span style="letter-spacing:0.05pt;">y</span>s<span style="letter-spacing:0.1pt;">t</span>ems,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>those<span style="letter-spacing:-0.2pt;"> </span>used<span style="letter-spacing:0.05pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>CROs, C<span style="letter-spacing:0.05pt;">M</span>Os, <span style="letter-spacing:0.05pt;">c</span>li<span style="letter-spacing:0.05pt;">n</span>i<span style="letter-spacing:0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">i</span>t<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.1pt;"> </span>or other<span style="letter-spacing:-0.15pt;"> </span>contractors<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>consultants,<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span>fail<span style="letter-spacing:-0.15pt;"> </span>or suffer s<span style="letter-spacing:0.05pt;">e</span>c<span style="letter-spacing:0.05pt;">u</span>rity<span style="letter-spacing:-0.15pt;"> </span>b<span style="letter-spacing:0.05pt;">r</span>ea<span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">h</span><span style="letter-spacing:0.05pt;">e</span>s.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>dependent<span style="letter-spacing:-0.3pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>inform<span style="letter-spacing:-0.1pt;">a</span>tion<span style="letter-spacing:-0.4pt;"> </span>technology<span style="letter-spacing:-0.4pt;"> </span>systems,<span style="letter-spacing:-0.35pt;"> </span>infrastruc<span style="letter-spacing:0.05pt;">t</span>ure<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>data.<span style="letter-spacing:-0.1pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>ordinary<span style="letter-spacing:-0.2pt;"> </span>course<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.05pt;"> </span>directly<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>indirectly col<span style="letter-spacing:-0.05pt;">l</span>ec<span style="letter-spacing:-0.05pt;">t</span>,<span style="letter-spacing:-0.25pt;"> </span>s<span style="letter-spacing:-0.05pt;">t</span>ore<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>transm<span style="letter-spacing:-0.05pt;">i</span>t<span style="letter-spacing:-0.3pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>ns<span style="letter-spacing:-0.05pt;">i</span>tive<span style="letter-spacing:-0.25pt;"> </span>d<span style="letter-spacing:-0.05pt;">a</span>ta,<span style="letter-spacing:-0.2pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property,<span style="letter-spacing:-0.3pt;"> </span>confidential<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>nforma<span style="letter-spacing:-0.05pt;">t</span>ion,<span style="letter-spacing:-0.4pt;"> </span>pre<span style="letter-spacing:-0.1pt;">c</span>l<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>dat<span style="letter-spacing:-0.05pt;">a</span>,<span style="letter-spacing:-0.15pt;"> </span>proprie<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>ry<span style="letter-spacing:-0.3pt;"> </span>bus<span style="letter-spacing:-0.05pt;">i</span>ness information,<span style="letter-spacing:-0.4pt;"> </span>personal<span style="letter-spacing:-0.3pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>personally<span style="letter-spacing:-0.4pt;"> </span>identifiable<span style="letter-spacing:-0.35pt;"> </span>health<span style="letter-spacing:-0.15pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>sub<span style="letter-spacing:-0.05pt;">j</span>ec<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>employees,<span style="letter-spacing:-0.35pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>centers<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our networks,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>those<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties.<span style="letter-spacing:-0.2pt;"> </span>T<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.2pt;"> </span>secure<span style="letter-spacing:-0.2pt;"> </span>processing,<span style="letter-spacing:-0.45pt;"> </span>ma<span style="letter-spacing:-0.05pt;">i</span>nten<span style="letter-spacing:-0.05pt;">a</span>nce<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd tr<span style="letter-spacing:-0.05pt;">a</span>ns<span style="letter-spacing:-0.05pt;">m</span>iss<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>of this<span style="letter-spacing:-0.15pt;"> </span>inform<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.4pt;"> </span>is <span style="letter-spacing:-0.05pt;">c</span>rit<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operations.<span style="letter-spacing:-0.45pt;"> </span>The multitude<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>complexity<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>computer<span style="letter-spacing:-0.35pt;"> </span>systems<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>CROs, CMOs, clinical<span style="letter-spacing:-0.2pt;"> </span>sites<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>con<span style="letter-spacing:-0.05pt;">t</span>ractors<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>consultan<span style="letter-spacing:0.05pt;">t</span>s<span style="letter-spacing:-0.35pt;"> </span>make<span style="letter-spacing:-0.25pt;"> </span>them inherently<span style="letter-spacing:-0.35pt;"> </span>vulnerable<span style="letter-spacing:-0.35pt;"> </span>to service<span style="letter-spacing:-0.25pt;"> </span>interruption<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>destruction,<span style="letter-spacing:-0.35pt;"> </span>mal<span style="letter-spacing:-0.1pt;">i</span>cious<span style="letter-spacing:-0.3pt;"> </span>intrusion<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>ndom<span style="letter-spacing:-0.3pt;"> </span>attack.<span style="letter-spacing:-0.25pt;"> </span>Data<span style="letter-spacing:-0.1pt;"> </span>privacy<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>security<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">b</span>reaches<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties, employees,<span style="letter-spacing:-0.35pt;"> </span>contractors<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>others<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>pose<span style="letter-spacing:0.05pt;"> </span>a risk<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>sensiti<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:-0.25pt;"> </span>data,<span style="letter-spacing:-0.1pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property,<span style="letter-spacing:-0.4pt;"> </span>trade<span style="letter-spacing:-0.15pt;"> </span>secrets<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>personal<span style="letter-spacing:-0.3pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our employees,<span style="letter-spacing:-0.35pt;"> </span>patients,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>partn<span style="letter-spacing:-0.05pt;">e</span>rs<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>exposed<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>unaut<span style="letter-spacing:0.05pt;">h</span>o<span style="letter-spacing:-0.05pt;">r</span>ized<span style="letter-spacing:-0.3pt;"> </span>persons<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>public.<span style="letter-spacing:-0.2pt;"> </span>Despite<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>implement<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>security measures,<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>internal<span style="letter-spacing:-0.2pt;"> </span>computer<span style="letter-spacing:-0.35pt;"> </span>systems<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>those<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our CROs,<span style="letter-spacing:-0.05pt;"> </span>C<span style="letter-spacing:-0.05pt;">M</span>Os, c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>sit<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>oth<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ontractors<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>consultants<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>vulnerable<span style="letter-spacing:-0.35pt;"> </span>to failure<span style="letter-spacing:-0.2pt;"> </span>or damage<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>computer<span style="letter-spacing:-0.3pt;"> </span>viruses<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>mal<span style="letter-spacing:-0.05pt;">w</span>are,<span style="letter-spacing:-0.4pt;"> </span>employee<span style="letter-spacing:-0.3pt;"> </span>error,<span style="letter-spacing:-0.15pt;"> </span>unauthorized<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>authori<span style="letter-spacing:0.05pt;">z</span>ed<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:0.05pt;">c</span>c<span style="letter-spacing:0.05pt;">e</span>ss<span style="letter-spacing:-0.15pt;"> </span>or oth<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.2pt;"> </span>cybe<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>ecurity<span style="letter-spacing:-0.4pt;"> </span>attacks,<span style="letter-spacing:-0.2pt;"> </span>natural<span style="letter-spacing:-0.25pt;"> </span>disasters, terrorism,<span style="letter-spacing:-0.35pt;"> </span>war,<span style="letter-spacing:-0.05pt;"> </span>fire<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>telecommunication<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>electrical<span style="letter-spacing:-0.35pt;"> </span>failures.<span style="letter-spacing:-0.25pt;"> </span>Cyberattacks<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>increasing<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>f<span style="letter-spacing:-0.05pt;">r</span>equency,<span style="letter-spacing:-0.35pt;"> </span>sophistica<span style="letter-spacing:0.05pt;">t</span>ion<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>intensity.<span style="letter-spacing:-0.3pt;"> </span>The techniques<span style="letter-spacing:-0.4pt;"> </span>used<span style="letter-spacing:0.05pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>cyber<span style="letter-spacing:-0.25pt;"> </span>crimina<span style="letter-spacing:0.05pt;">l</span>s<span style="letter-spacing:-0.25pt;"> </span>change<span style="letter-spacing:-0.2pt;"> </span>frequently,<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>recognized<span style="letter-spacing:-0.45pt;"> </span>until<span style="letter-spacing:-0.1pt;"> </span>launched<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>originate<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>wide<span style="letter-spacing:-0.2pt;"> </span>variety<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>sources,<span style="letter-spacing:0.05pt;"> </span>including o<span style="letter-spacing:0.05pt;">u</span>tside<span style="letter-spacing:-0.2pt;"> </span>groups<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>external<span style="letter-spacing:-0.25pt;"> </span>service<span style="letter-spacing:-0.2pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oviders,<span style="letter-spacing:-0.3pt;"> </span>organized<span style="letter-spacing:-0.35pt;"> </span>crime<span style="letter-spacing:-0.2pt;"> </span>aff<span style="letter-spacing:-0.1pt;">i</span>liates,<span style="letter-spacing:-0.3pt;"> </span>terrorist<span style="letter-spacing:-0.35pt;"> </span>organizations<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>ho<span style="letter-spacing:0.05pt;">s</span>tile<span style="letter-spacing:-0.05pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>gove<span style="letter-spacing:-0.05pt;">r</span>nments<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">a</span>gen<span style="letter-spacing:0.05pt;">c</span>ie<span style="letter-spacing:0.05pt;">s</span>. Cy<span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">e</span>rattacks<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>deployment<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>h<span style="letter-spacing:-0.05pt;">a</span>rmful<span style="letter-spacing:-0.3pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>lwar<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.3pt;"> </span>deni<span style="letter-spacing:-0.05pt;">a</span>l-of-serv<span style="letter-spacing:-0.05pt;">i</span>ce,<span style="letter-spacing:-0.45pt;"> </span>soc<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.25pt;"> </span>engineering<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>means<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">s</span>ervice<span style="letter-spacing:-0.2pt;"> </span>reliability<span style="letter-spacing:-0.3pt;"> </span>and thre<span style="letter-spacing:-0.05pt;">a</span>ten<span style="letter-spacing:-0.3pt;"> </span>da<span style="letter-spacing:-0.05pt;">t</span>a<span style="letter-spacing:-0.15pt;"> </span>confid<span style="letter-spacing:-0.05pt;">e</span>nti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.05pt;">i</span>ty,<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>gri<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd av<span style="letter-spacing:-0.05pt;">a</span>i<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>bi<span style="letter-spacing:-0.05pt;">l</span>ity.<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">W</span>hile<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>shared<span style="letter-spacing:-0.2pt;"> </span>services<span style="letter-spacing:-0.35pt;"> </span>partner,<span style="letter-spacing:-0.15pt;"> </span>NantWorks,<span style="letter-spacing:-0.5pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>invested,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>continue<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>invest,<span style="letter-spacing:-0.2pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>protection<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> our</span><span style="letter-spacing:-0.1pt;"> </span>data<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>information<span style="letter-spacing:-0.3pt;"> </span>technolo<span style="letter-spacing:0.05pt;">g</span>y<span style="letter-spacing:-0.4pt;"> </span>infrastruc<span style="letter-spacing:-0.05pt;">t</span>ure,<span style="letter-spacing:-0.45pt;"> </span>there<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>assurance<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> our </span>efforts,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>e<span style="letter-spacing:-0.05pt;">f</span>forts of<span style="letter-spacing:-0.05pt;"> our</span><span style="letter-spacing:-0.1pt;"> </span>partners, vendors,<span style="letter-spacing:-0.05pt;"> </span>CROs,<span style="letter-spacing:-0.05pt;"> </span>CMOs,<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>sites<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>ntractors<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>co<span style="letter-spacing:0.05pt;">n</span>sultants<span style="letter-spacing:-0.3pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>prevent<span style="letter-spacing:-0.25pt;"> </span>service<span style="letter-spacing:-0.2pt;"> </span>inte<span style="letter-spacing:-0.05pt;">r</span>ruptions,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>identify<span style="letter-spacing:-0.25pt;"> </span>brea<span style="letter-spacing:-0.1pt;">c</span>hes<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>their systems,<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ffect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>operations<span style="letter-spacing:-0.35pt;"> </span>and/or<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>of cr<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>nsi<span style="letter-spacing:-0.05pt;">t</span>ive<span style="letter-spacing:-0.25pt;"> </span>infor<span style="letter-spacing:-0.05pt;">m</span>a<span style="letter-spacing:-0.05pt;">t</span>io<span style="letter-spacing:-0.05pt;">n</span>,<span style="letter-spacing:-0.45pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in financial,<span style="letter-spacing:-0.35pt;"> </span>legal,<span style="letter-spacing:-0.15pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>reputational<span style="letter-spacing:-0.4pt;"> </span>harm<span style="letter-spacing:-0.15pt;"> </span>to us.<span style="letter-spacing:-0.05pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addit<span style="letter-spacing:-0.15pt;">i</span>on,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>liability<span style="letter-spacing:-0.25pt;"> </span>insurance<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>suf<span style="letter-spacing:-0.05pt;">f</span>icient<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>type<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.15pt;">m</span>ount<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>cover<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>against<span style="letter-spacing:-0.25pt;"> </span>claims rel<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>cur<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.15pt;"> </span>b<span style="letter-spacing:-0.05pt;">r</span>ea<span style="letter-spacing:-0.05pt;">c</span>hes,<span style="letter-spacing:-0.1pt;"> </span>cyb<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">a</span>ttacks<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>breaches.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>event<span style="letter-spacing:-0.15pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>to occur<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>cause<span style="letter-spacing:-0.25pt;"> </span>interruptions<span style="letter-spacing:-0.5pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span>operations,<span style="letter-spacing:-0.35pt;"> </span>it could<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>sult<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>a dis<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">u</span>ption<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> product</span><span style="letter-spacing:0.05pt;"> </span>develop<span style="letter-spacing:-0.1pt;">m</span>ent<span style="letter-spacing:-0.45pt;"> </span>progra<span style="letter-spacing:-0.05pt;">m</span>s.<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">F</span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xa<span style="letter-spacing:-0.05pt;">m</span>p<span style="letter-spacing:-0.05pt;">l</span>e, the<span style="letter-spacing:-0.15pt;"> </span>loss<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>completed<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>ongoing<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a product<span style="letter-spacing:-0.2pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>sult<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>delays<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>efforts and<span style="letter-spacing:-0.1pt;"> </span>significantly<span style="letter-spacing:-0.4pt;"> </span>increase<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>to r<span style="letter-spacing:-0.1pt;">e</span>cover<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>produce<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>data,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>limit<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to effec<span style="letter-spacing:-0.15pt;">t</span>ively<span style="letter-spacing:-0.35pt;"> </span>execute<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>recall,<span style="letter-spacing:-0.25pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>required.<span style="letter-spacing:-0.25pt;"> </span>To<span style="letter-spacing:-0.15pt;"> </span>the extent<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:-0.15pt;"> </span>disruption<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>security<span style="letter-spacing:-0.25pt;"> </span>breach<span style="letter-spacing:-0.2pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in a<span style="letter-spacing:-0.1pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>damage<span style="letter-spacing:-0.4pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>applications,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>inappropriate<span style="letter-spacing:-0.45pt;"> </span>disclosure<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>personal, confid<span style="letter-spacing:-0.05pt;">e</span>nti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>propri<span style="letter-spacing:-0.05pt;">e</span>t<span style="letter-spacing:-0.05pt;">a</span>ry<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>nforma<span style="letter-spacing:-0.05pt;">t</span>ion,<span style="letter-spacing:-0.4pt;"> </span>we could<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;">c</span>ur<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>abi<span style="letter-spacing:-0.05pt;">l</span>ity<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>further<span style="letter-spacing:-0.2pt;"> </span>development<span style="letter-spacing:-0.4pt;"> and commercialization </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>od<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.05pt;"> </span>dela<span style="letter-spacing:0.05pt;">y</span><span style="letter-spacing:-0.05pt;">e</span>d.<span style="letter-spacing:-0.3pt;"> </span>Any such<span style="letter-spacing:-0.05pt;"> </span>event could<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>proceedings,<span style="letter-spacing:-0.4pt;"> </span>liability<span style="letter-spacing:-0.25pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>otect<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.15pt;"> </span>privacy<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>personal<span style="letter-spacing:-0.25pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>si<span style="letter-spacing:0.05pt;">g</span>nificant<span style="letter-spacing:-0.4pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>penalties, and<span style="letter-spacing:-0.1pt;"> </span>damage<span style="letter-spacing:-0.25pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>reputation<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>confidence<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to conduct<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">O</span><span style="letter-spacing:-0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r </span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">b</span><span style="letter-spacing:-0.05pt;">u</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;"> c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">u</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be adversely affected by </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">eff</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </span><span style="letter-spacing:-0.05pt;">h</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">th</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ep</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">de</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.1pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">pandemics</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or contagious diseases, including the </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">cent</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#8209;</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">19</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> pandemic</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in regio</span><span style="letter-spacing:0.1pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">w</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">h</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;"> w</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">o</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">h</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ly</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ha</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">v</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">signif</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ant man</span><span style="letter-spacing:-0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">fa</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">tu</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">g</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">faci</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">it</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">es,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">co</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ra</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ions</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">lini</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">business</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">operations</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outbreaks of epidemic, pandemic or contagious diseases, such as the COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19 pandemic, may significantly disrupt our operations and adversely affect our business, financial condition and results of operations. In March&#160;2020, the World Health Organization<span style="letter-spacing:-0.15pt;"> </span>declared the outbreak of COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19 as a pandemic as the novel coronavirus continues to spread throughout the world. The spread of this pandemic has caused significant volatility and uncertainty in the U.S. and international markets and has resulted in increased risks to our operations. The<span style="letter-spacing:-0.2pt;"> </span>COVI<span style="letter-spacing:0.05pt;">D</span><span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:0.05pt;"> </span>pandemic and any actions we have taken in response,<span style="letter-spacing:-0.35pt;"> </span>could materially<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operations,<span style="letter-spacing:-0.4pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>at<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>headquarters<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>at<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:-0.45pt;"> </span>facilities,<span style="letter-spacing:-0.35pt;"> </span>which have been and may in the future be subject to state executive orders and shelter-in-place orders, and at our clinical trial sites, as well as the business or operations of our CROs, CMOs, clinical sites or other third parties with whom we conduct business. Any such epidemic or pandemic may heighten the risk that a significant portion of our workforce could suffer illness or otherwise not be permitted or be unable to work, and may require that certain of our employees work remotely, which heightens certain risks, including those related to cybersecurity and internal controls.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are monitoring<span style="letter-spacing:-0.35pt;"> </span>a number<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>risks<span style="letter-spacing:-0.05pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>to this<span style="letter-spacing:-0.1pt;"> </span>pandemic,<span style="letter-spacing:-0.35pt;"> </span>includi<span style="letter-spacing:-0.05pt;">n</span>g<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Financial</span><span style="color:#000000;">: We anticipate that the pandemic could have an adverse financial impact in the short-term and potentially beyond. We expect to continue spending on research and development during the ye</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">r-ended December</span><span style="letter-spacing:-0.35pt;color:#000000;">&#160;</span><span style="color:#000000;">31,&#160;2021 and beyond, and we could also have unexpected expenses related to the pandemic. The short-term continued expenses, as well as the overall uncertainty and disruption caused by the pandemic, will likely cause a delay in our ability to commercialize a product and adversely impact our financial results.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Manufacturing</span><span style="color:#000000;">: The pandemic has impacted, and may continue to impact, our manufacturing locations, including through the effects of facility closures, reductions in operating hours and other social distancing efforts. For example, if even a small number of our employees in our working clusters related to manufacturing, analytical, process development, or translational research, tested positive for COVID&#8209;19, it would require us to temporarily close a number of our offices or manufacturing facilities and temporarily suspend operations in order to conduct a deep clean of the facilities in order to ensure the safety of our employees. Additionally, we cannot predict whether these conditions and concerns will continue or whether we will experience more significant or frequent disruptions in the future, including the complete closure of one or more of our facilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;font-size:10pt;color:#000000;">Supply Chain</span><span style="font-size:10pt;color:#000000;">: An extended duration of this pandemic could result in significant disruptions in our respective supply chains and distribution channels in the future. For example, quarantines, shelter-in-place and similar government orders, travel restrictions and health impacts of the COVID</span><span style="Background-color:#FFFFFF;font-size:10pt;">&#8209;</span><span style="font-size:10pt;color:#000000;">19 pandemic, could impact the availability or productivity of personnel at third-party laboratory supply manufacturers, distributors, freight carriers and other necessary components of our supply chain. In addition, there may be unfavorable changes in the availability or cost of raw materials, intermediates and other materials necessary for production, which may result in disruptions in our supply chain and adversely affect our ability to have</span><span style="font-size:10pt;letter-spacing:-0.1pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">manufactured certain product candidates for clinical supply.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;font-size:10pt;color:#000000;">Clinical Trials</span><span style="font-size:10pt;color:#000000;">: This pandemic may adversely affect certain of our clinical trials, including our ability to initiate and complete our clinical trials within the anticipated timelines. Due to site and participant availability during the pandemic, new subject enrollment is expected to slow,</span><span style="font-size:10pt;letter-spacing:-0.05pt;color:#000000;"> a</span><span style="font-size:10pt;color:#000000;">t</span><span style="font-size:10pt;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">l</span><span style="font-size:10pt;letter-spacing:-0.05pt;color:#000000;">e</span><span style="font-size:10pt;color:#000000;">ast in the short-term, for most of our clinical trials. For ongoing trials, we have seen an increasing number of clinical trial sites imposing restrictions on patient visits to limit risks of possible COVID</span><span style="Background-color:#FFFFFF;font-size:10pt;">&#8209;</span><span style="font-size:10pt;color:#000000;">19 exposure, and we may experience issues with participant compliance with clinical trial protocols as a result of quarantines, travel restrictions and interruptions to healthcare services. The current pressures on medical systems and the prioritization of healthcare resources toward the COVID</span><span style="Background-color:#FFFFFF;font-size:10pt;">&#8209;</span><span style="font-size:10pt;color:#000000;">19 pandemic have also resulted in interruptions in data collection and submissions for certain clinical trials and delayed starts for certain planned studies. As a result, our anticipated filing and marketing timelines may be adversely impacted.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;font-size:10pt;color:#000000;">Overall Economic and Capital</span><span style="text-decoration:underline;font-size:10pt;letter-spacing:-0.2pt;color:#000000;"> </span><span style="text-decoration:underline;font-size:10pt;color:#000000;">Markets</span><span style="text-decoration:underline;font-size:10pt;letter-spacing:-0.25pt;color:#000000;"> </span><span style="text-decoration:underline;font-size:10pt;color:#000000;">Environmen</span><span style="text-decoration:underline;font-size:10pt;letter-spacing:-0.05pt;color:#000000;">t</span><span style="font-size:10pt;color:#000000;">: The impact of the COVID</span><span style="Background-color:#FFFFFF;font-size:10pt;">&#8209;</span><span style="font-size:10pt;color:#000000;">19 pandemic could result in a prolonged recession or depression in the United</span><span style="font-size:10pt;letter-spacing:-0.2pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">States or globally that could harm the banking system, limit demand for all products and services and cause other seen and unforeseen events and circumstances, all of which could negatively impact us. The continued spread of COVID</span><span style="Background-color:#FFFFFF;font-size:10pt;">&#8209;</span><span style="font-size:10pt;color:#000000;">19 has led to and could continue to lead to severe disruption and volatility in the United</span><span style="font-size:10pt;letter-spacing:-0.2pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">States and global capital markets, which could result in a decline in stock price, increase our cost of capital and adversely affect our ability to access the capital markets in the future. In addition, trading prices on the public stock market have been highly volatile as a result of the COVID</span><span style="Background-color:#FFFFFF;font-size:10pt;">&#8209;</span><span style="font-size:10pt;color:#000000;">19 pandemic.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;font-size:10pt;color:#000000;">Regulatory Reviews</span><span style="font-size:10pt;color:#000000;">: The operations of the FDA or other regulatory agencies may be adversely affected. In response to COVID</span><span style="Background-color:#FFFFFF;font-size:10pt;">&#8209;</span><span style="font-size:10pt;color:#000000;">19, federal, state and local governments are issuing new rules, regulations, orders and advisories on a regular basis. These government actions can impact us, our members and our suppliers. There is also the possibility that we may experience delays with obtaining approvals for our IND applications,</span><span style="font-size:10pt;letter-spacing:-0.45pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">BLA</span><span style="font-size:10pt;letter-spacing:0.05pt;color:#000000;">s</span><span style="font-size:10pt;color:#000000;">, and/or</span><span style="font-size:10pt;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">NDA</span><span style="font-size:10pt;letter-spacing:0.05pt;color:#000000;">s</span><span style="font-size:10pt;color:#000000;">.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have formed, and may in the future form or seek, strategic alliances or enter into collaborations with third parties or additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements. <span style="Background-color:#FFFFFF;color:#000000;">If we fail to enter into such strategic alliances, collaborations or licensing arrangement, or such strategic alliances, collaborations or licensing arrangements are not successful, we may not be able to capitalize on the market potential of our product candidates.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have formed, and may in the future form or seek, strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third and related parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. For example, we have entered into an agreement whereby Viracta Therapeutics,&#160;Inc. (&#8220;Viracta&#8221;) granted to us exclusive world-wide rights to Viracta&#8217;s Phase&#160;II drug candidate, VRx-3996, for use in combination with our platform of NK&#160;cell therapies. However, if Viracta fails to raise sufficient capital to complete their pivotal Phase&#160;II trial, if their trial is unsuccessful, or if our future clinical trial of NK&#160;cell therapy in combination with VRx-3996 fails, the value of the Viracta license would be adversely affected. We plan to collaborate with governmental, academic and corporate partners, including affiliates, to improve and develop Anktiva, hAd5 and other therapies for new indications for use in combination with other therapies and to improve and develop other product candidates, which may expose us to additional risks, or we may not realize the benefits of such collaborations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because some of our collaborations are conducted at outside laboratories, and we do not have complete control over how the studies are conducted or reported or over the manufacturing methods used to manufacture our Anktiva product candidate, the results of such studies, which we may use as the basis for our conclusions, projections or decisions with respect to our current or future product candidates, may be incorrect or unreliable, or may have a negative impact on us if the results of such studies are imputed to our product candidates or proposed indications, even if such imputation is improper. Additionally, we may use third-party data to analyze, reach conclusions or make predictions or decisions with respect to our product candidates that may be incomplete, inaccurate or otherwise unreliable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, collaborations involving our product candidates will be subject to numerous risks, which may include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators, including their related or affiliated companies, may be entitled to receive exclusive rights for or involving our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization of our product candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators may not properly maintain, defend or enforce our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">if an agreement with any collaborator terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaborator&#8217;s technology or intellectual property or require us to stop development of those product candidates completely&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators may own or co-own intellectual property covering our product candidates or technology that results from our collaborating with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, if we enter into collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. Additionally, exclusive rights that we may grant in connection with collaboration agreements may limit our ability to enter into new or additional collaboration agreements or strategic partnerships if we experience issues with existing collaborations. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenues or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If conflicts arise between our corporate or academic collaborators or strategic partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Some of our existing academic collaborators and strategic partners are conducting multiple product development efforts. Such current or future collaborators or strategic partners could become our competitors in the future and could develop competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the development and commercialization of our product candidates. Competing product candidates, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of our collaborator&#8217;s or partner&#8217;s support for our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in May&#160;2019, Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;) with which we jointly established a new entity called Immunotherapy NANTibody, LLC (&#8220;NANTibody&#8221;) as a stand-alone biotechnology company, commenced litigation against us and certain of our officers and directors, alleging that we improperly caused NANTibody to acquire IgDraSol, Inc. and in January&#160;2020 and April&#160;2020, Sorrento sent letters purporting to terminate an exclusive license agreement with us and an exclusive license agreement with NANTibody. Additionally, in July&#160;2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration, served by Shenzhen Beike Biotechnology Co.&#160;Ltd. asserting breach of contract under our subsidiary Altor&#8217;s license agreement with them. For more information regarding these disputes, see <a href="#N8___COMMITMENTS_CONTINGENCIES"><span style="text-decoration:underline;">Note&#160;7</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;">Commitments and Contingencies&#8212;Litigation</span>, of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; that appear in Part&#160;1. Item&#160;1. &#8220;Financial Statements&#8221; of this Quarterly Report on Form 10&#8209;Q. Any of these developments could harm our product development efforts. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">heavily</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">dependent</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">on our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">senior</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">management,</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">particularly</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dr.</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Soon-Shiong,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.05pt;">E</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">xecutive</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.3pt;">C</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">hairman,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">loss</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">member</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our senior</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">manageme</span><span style="letter-spacing:0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">fu</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">u</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ven</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">only</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">temporary,</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ould</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">harm</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r busines</span><span style="letter-spacing:0.05pt;">s</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations will be dependent upon the services of our executives and our employees who are engaged in research and development. If we lose the services of members of our senior management, particularly Dr.&#160;Soon-Shiong, for a short or an extended time, for any reason, we may not be able to find appropriate replacements on a timely basis, and our business, financial condition and results of operations could be materially adversely affected. Our existing operations and our future development depend to a significant extent upon the performance and active participation of certain key individuals, particularly Dr.&#160;Soon-Shiong, our Executive Chairman. Although Dr.&#160;Soon-Shiong focuses heavily on our matters and is highly active in our management, he does devote a significant amount of his time to a number of different endeavors and companies, including NantHealth,&#160;Inc., NantMedia Holdings,&#160;LLC (which operates the Los Angeles Times and the San Diego Union-Tribune) and NantWorks, which is a collection of multiple companies in the healthcare and technology space. The risks related to our dependence upon Dr.&#160;Soon-Shiong are particularly acute given his ownership percentage, the commercial and other relationships that we have with entities affiliated with him, his role in our company and his public reputation. We may also be dependent on additional funding from Dr.&#160;Soon-Shiong and his affiliates, which may not be available when needed and which he is under no obligation to provide. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided, and plan to continue providing, equity incentive awards that vest over time. The value to employees of equity incentive awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. We do not have employment agreements with our key employees and all of our employees are hired on an &#8220;at-will&#8221; basis, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>to grow<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>size<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>capabili<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>organization,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>experie<span style="letter-spacing:-0.05pt;">n</span>ce<span style="letter-spacing:-0.45pt;"> </span>difficulties<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>managing<span style="letter-spacing:-0.15pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>growth.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of their attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. In order to develop our business in accordance with our business plan, we will have to hire additional qualified personnel, including in the areas of research, manufacturing, clinical trials management, regulatory affairs, and sales and marketing. We are continuing our efforts to recruit and hire the necessary employees to support our planned operations in the near term. However, competition for qualified personnel in the biotechnology and pharmaceuticals industry is intense due to the limited number of individuals who possess the skills and experience required, and no assurance can be given that we will be able attract, hire, retain and motivate the highly skilled employees that we need, on acceptable terms or at all. Future growth will impose significant added responsibilities on members of management, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">dentifying,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">recruiting,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">integrating,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">mai</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ng,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">otiv</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ting</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">employees&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">anaging</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">internal</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">efforts</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">effectively,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">FDA rev</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ew</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">process</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidat</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">wh</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">e complying</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">contractual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">obligations</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">contractors</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">parties&#59;</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">mproving</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">operational,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">financial</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">management</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">controls,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ting</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">systems,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">procedures.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>currently<span style="letter-spacing:-0.3pt;"> </span>rely,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>foreseeable<span style="letter-spacing:-0.35pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>we exp<span style="letter-spacing:-0.05pt;">e</span>ct<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:-0.05pt;">l</span>y,<span style="letter-spacing:-0.1pt;"> </span>in substan<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.45pt;"> </span>part<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>independent<span style="letter-spacing:-0.45pt;"> </span>organizations,<span style="letter-spacing:-0.55pt;"> </span>advisors<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>onsultants<span style="letter-spacing:-0.4pt;"> </span>to provide<span style="letter-spacing:-0.3pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>services.<span style="letter-spacing:-0.25pt;"> </span>There<span style="letter-spacing:-0.2pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">s</span>surance<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>services<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>indep<span style="letter-spacing:0.1pt;">e</span>ndent<span style="letter-spacing:-0.5pt;"> </span>organizations,<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">a</span>dvisors and<span style="letter-spacing:-0.2pt;"> </span>consult<span style="letter-spacing:0.05pt;">a</span>nts<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>continue<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e ava<span style="letter-spacing:-0.05pt;">i</span>lab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">i</span>me<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.15pt;"> </span>b<span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.15pt;"> </span>when<span style="letter-spacing:0.05pt;"> </span>n<span style="letter-spacing:-0.05pt;">e</span>e<span style="letter-spacing:-0.1pt;">d</span>ed,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>find<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">q</span>ualified<span style="letter-spacing:-0.25pt;"> </span>replacemen<span style="letter-spacing:-0.05pt;">t</span>s on economically reasonable terms, or at all.<span style="letter-spacing:-0.5pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>ef<span style="letter-spacing:0.05pt;">f</span>ectively<span style="letter-spacing:-0.35pt;"> </span>manage<span style="letter-spacing:-0.25pt;"> </span>our o<span style="letter-spacing:0.05pt;">u</span>tsourced<span style="letter-spacing:-0.3pt;"> </span>activities<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>if the<span style="letter-spacing:-0.25pt;"> </span>quality,<span style="letter-spacing:-0.25pt;"> </span>compliance<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>accuracy<span style="letter-spacing:-0.25pt;"> </span>of the<span style="letter-spacing:-0.15pt;"> </span>services<span style="letter-spacing:-0.25pt;"> </span>provided<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>nsultants<span style="letter-spacing:-0.4pt;"> </span>is compromised<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.25pt;"> </span>reason,<span style="letter-spacing:-0.25pt;"> </span>our cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>extended,<span style="letter-spacing:-0.3pt;"> </span>delayed,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>terminated,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>regulato<span style="letter-spacing:-0.05pt;">r</span>y<span style="letter-spacing:-0.25pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>otherwise<span style="letter-spacing:-0.15pt;"> </span>advance<span style="letter-spacing:-0.3pt;"> </span>our b<span style="letter-spacing:0.05pt;">u</span>siness.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to effectively<span style="letter-spacing:-0.4pt;"> </span>expand<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>organization<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>hiring<span style="letter-spacing:-0.25pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>expanding<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>groups<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>consultants<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>contractors,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>su<span style="letter-spacing:0.05pt;">cc</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>sfully<span style="letter-spacing:-0.2pt;"> </span>implem<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:0.05pt;">a</span>sks necessary<span style="letter-spacing:-0.4pt;"> </span>to further<span style="letter-spacing:-0.3pt;"> </span>develop<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>commercialize<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oduct<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and,<span style="letter-spacing:-0.2pt;"> </span>accordi<span style="letter-spacing:0.05pt;">n</span>gl<span style="letter-spacing:0.05pt;">y</span>,<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>achieve our<span style="letter-spacing:-0.05pt;"> </span>res<span style="letter-spacing:-0.05pt;">e</span>arch,<span style="letter-spacing:-0.2pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>ve<span style="letter-spacing:-0.05pt;">l</span>opmen<span style="letter-spacing:-0.05pt;">t</span>,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>om<span style="letter-spacing:-0.05pt;">m</span>erc<span style="letter-spacing:-0.05pt;">i</span>a<span style="letter-spacing:-0.05pt;">l</span>iz<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.65pt;"> </span>goals<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>a timely<span style="letter-spacing:-0.2pt;"> </span>b<span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;">i</span>s,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>at<span style="letter-spacing:-0.05pt;"> a</span>ll.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">engage</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">acquis</span><span style="letter-spacing:0.1pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">tions</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">strate</span><span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">partne</span><span style="letter-spacing:0.05pt;">r</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ships,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">this</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">increase</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our capital</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">requirements,</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">dilute</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">stockhol</span><span style="letter-spacing:-0.05pt;">de</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">s</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">u</span><span style="letter-spacing:0.05pt;">s</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r debt</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">assume</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">contingent</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">liabilities,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">us to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">oth</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">risk</span><span style="letter-spacing:0.05pt;">s</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>evaluate<span style="letter-spacing:-0.3pt;"> </span>various<span style="letter-spacing:-0.3pt;"> </span>acqui<span style="letter-spacing:0.05pt;">s</span>itions<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>strategic<span style="letter-spacing:-0.25pt;"> </span>par<span style="letter-spacing:0.05pt;">t</span>nerships,<span style="letter-spacing:-0.1pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>licensing<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>acqu<span style="letter-spacing:-0.05pt;">i</span>ring<span style="letter-spacing:-0.3pt;"> </span>complementary<span style="letter-spacing:-0.55pt;"> </span>products,<span style="letter-spacing:-0.3pt;"> </span>inte<span style="letter-spacing:-0.05pt;">l</span>lectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights, technologies,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.1pt;">e</span>s.<span style="letter-spacing:-0.05pt;"> </span>Any<span style="letter-spacing:-0.05pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>acquisition<span style="letter-spacing:-0.4pt;"> </span>or strategic<span style="letter-spacing:-0.3pt;"> </span>partnership<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>ent<span style="letter-spacing:-0.1pt;">a</span>il<span style="letter-spacing:-0.15pt;"> </span>numerous<span style="letter-spacing:-0.4pt;"> </span>risks,<span style="letter-spacing:-0.05pt;"> </span>including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ssimilati</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">operation</span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">acquired</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">compa</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">oduct,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">fficulties</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">associ</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ted</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">with integrating</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">diversion</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">managem</span><span style="letter-spacing:0.1pt;color:#000000;">e</span><span style="color:#000000;">nt&#8217;s</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">attention</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">existing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">programs</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">nd initiatives</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in pursuing</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">strategic</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">rger</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or acquisition&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">retention</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">key</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">employees,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">loss</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">k</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">personnel,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">uncert</span><span style="letter-spacing:-0.1pt;color:#000000;">a</span><span style="color:#000000;">inties</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">mai</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">tain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">key</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">relationship</span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">ks </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd un</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">er</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ies</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">asso</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ia</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ed</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">h</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">pa</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ty</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">transaction,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">inc</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">uding</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">prospects</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">party</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">existing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">products or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">approvals&#59;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">inability</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to generate</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">revenues</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">acquired</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and/or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">sufficient</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to meet</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">objectives</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">undertaking</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">t</span><span style="color:#000000;">he acquisition</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">even</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to offset the associated</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">acquisition</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">maintenance</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">costs.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending<span style="letter-spacing:-0.45pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>size<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>nat<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>strategic<span style="letter-spacing:-0.3pt;"> </span>acquisitions,<span style="letter-spacing:-0.4pt;"> </span>we may<span style="letter-spacing:-0.1pt;"> </span>acquire<span style="letter-spacing:-0.2pt;"> </span>assets<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>busine<span style="letter-spacing:0.05pt;">s</span>ses<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.3pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>raise<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ddit<span style="letter-spacing:-0.05pt;">i</span>onal<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>pit<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>to o<span style="letter-spacing:0.05pt;">p</span>erate<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>manage<span style="letter-spacing:-0.25pt;"> </span>businesses<span style="letter-spacing:0.05pt;"> </span>in which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>limited<span style="letter-spacing:-0.25pt;"> </span>experience.<span style="letter-spacing:-0.35pt;"> </span>Mak<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.15pt;"> </span>larger<span style="letter-spacing:-0.2pt;"> </span>acquisitions<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>raise<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.4pt;"> </span>capital<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>fund<span style="letter-spacing:0.05pt;"> </span>the acquisition<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>expo<span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>risks<span style="letter-spacing:0.05pt;"> </span>associated<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>capital<span style="letter-spacing:-0.2pt;"> </span>raising<span style="letter-spacing:-0.2pt;"> </span>activities.<span style="letter-spacing:-0.3pt;"> </span>Acquiring<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>ere<span style="letter-spacing:-0.05pt;">a</span>fter<span style="letter-spacing:-0.3pt;"> </span>operating<span style="letter-spacing:-0.3pt;"> </span>larger<span style="letter-spacing:-0.25pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>busin<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>s<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>so increase<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>management,<span style="letter-spacing:-0.5pt;"> </span>operat<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>reporting<span style="letter-spacing:-0.3pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>burdens (including increased cash requirements).<span style="letter-spacing:-0.05pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.4pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>undertake<span style="letter-spacing:-0.3pt;"> </span>acquisitions,<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>issue<span style="letter-spacing:0.05pt;"> </span>di<span style="letter-spacing:-0.05pt;">l</span>utive<span style="letter-spacing:-0.2pt;"> equity </span>s<span style="letter-spacing:0.05pt;">e</span>curiti<span style="letter-spacing:0.05pt;">e</span>s,<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">a</span>ssume or<span style="letter-spacing:0.05pt;"> </span>incur<span style="letter-spacing:-0.15pt;"> additional </span>debt<span style="letter-spacing:-0.2pt;"> </span>o<span style="letter-spacing:0.05pt;">b</span>ligations or contingent liabilities,<span style="letter-spacing:-0.35pt;"> </span>incur<span style="letter-spacing:-0.15pt;"> </span>large<span style="letter-spacing:-0.2pt;"> </span>one-<span style="letter-spacing:-0.1pt;">t</span>ime<span style="letter-spacing:-0.25pt;"> </span>expenses<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>acquire<span style="letter-spacing:-0.2pt;"> </span>int<span style="letter-spacing:-0.05pt;">a</span>ngible<span style="letter-spacing:-0.35pt;"> </span>assets<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>co<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span>d<span style="letter-spacing:-0.1pt;"> </span>res<span style="letter-spacing:-0.05pt;">u</span>lt<span style="letter-spacing:-0.1pt;"> </span>in significant<span style="letter-spacing:-0.4pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;">m</span>ort<span style="letter-spacing:-0.05pt;">i</span>za<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.45pt;"> </span>expense. Moreover,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to locate<span style="letter-spacing:-0.15pt;"> </span>suitable<span style="letter-spacing:-0.15pt;"> </span>acquisition<span style="letter-spacing:-0.4pt;"> </span>opportunities<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>inability<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>impair<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>grow<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.1pt;">o</span>r<span style="letter-spacing:0.05pt;"> </span>ob<span style="letter-spacing:-0.05pt;">t</span>ain<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>c<span style="letter-spacing:-0.05pt;">e</span>ss<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o technology<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:0.1pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>important<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may<span style="letter-spacing:-0.15pt;"> </span>b<span style="letter-spacing:-0.05pt;">e</span>come<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">v</span>olv<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n securit<span style="letter-spacing:-0.05pt;">i</span>es<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>it<span style="letter-spacing:-0.15pt;">i</span>gation<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>stockholder<span style="letter-spacing:-0.4pt;"> </span>derivative<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>it<span style="letter-spacing:-0.05pt;">i</span>gation<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n conn<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.05pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.1pt;"> our recent merger, </span>and<span style="letter-spacing:0.05pt;"> </span>this<span style="letter-spacing:-0.2pt;"> </span>could divert<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>attention<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ma<span style="letter-spacing:-0.05pt;">n</span>agement<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>bus<span style="letter-spacing:-0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.05pt;"> </span>and i<span style="letter-spacing:0.05pt;">n</span>s<span style="letter-spacing:0.05pt;">u</span>rance<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ov<span style="letter-spacing:0.05pt;">e</span>rage<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">u</span>ffi<span style="letter-spacing:-0.05pt;">c</span>ie<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>cov<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">l</span>ated<span style="letter-spacing:-0.25pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>and damages.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities<span style="letter-spacing:-0.35pt;"> </span>litigation<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>stockho<span style="letter-spacing:-0.05pt;">l</span>der<span style="letter-spacing:-0.45pt;"> </span>derivative<span style="letter-spacing:-0.3pt;"> </span>litigation<span style="letter-spacing:-0.2pt;"> </span>frequently<span style="letter-spacing:-0.3pt;"> </span>follows<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>annou<span style="letter-spacing:0.05pt;">n</span>cement<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:-0.3pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>rans<span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">c</span>tions,<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>as the<span style="letter-spacing:-0.1pt;"> </span>s<span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span>e of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>division<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>announcement<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>bu<span style="letter-spacing:-0.1pt;">s</span>iness<span style="letter-spacing:0.05pt;"> </span>combination<span style="letter-spacing:-0.45pt;"> </span>transaction.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>involved<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>this<span style="letter-spacing:-0.2pt;"> </span>type<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>litigation<span style="letter-spacing:-0.25pt;"> </span>in c<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">n</span>nection<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> our recent</span><span style="letter-spacing:-0.15pt;"> </span>merger,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>become<span style="letter-spacing:-0.35pt;"> </span>involved<span style="letter-spacing:-0.25pt;"> </span>in this<span style="letter-spacing:-0.2pt;"> </span>type<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>litigation<span style="letter-spacing:-0.3pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>future.<span style="letter-spacing:-0.2pt;"> </span>Litigation<span style="letter-spacing:-0.3pt;"> </span>often<span style="letter-spacing:-0.2pt;"> </span>is expensive<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>dive<span style="letter-spacing:-0.05pt;">rt</span>s<span style="letter-spacing:-0.2pt;"> </span>management&#8217;s<span style="letter-spacing:-0.5pt;"> </span>attention and<span style="letter-spacing:-0.1pt;"> </span>reso<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>ces,<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.35pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>combined<span style="letter-spacing:-0.35pt;"> </span>company.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">v</span>ariety<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">s</span>ks associat<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>ma<span style="letter-spacing:0.05pt;">r</span>keti<span style="letter-spacing:0.1pt;">n</span>g<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>internationally<span style="letter-spacing:-0.55pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>materially<span style="letter-spacing:-0.35pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>busi<span style="letter-spacing:-0.1pt;">n</span><span style="letter-spacing:0.05pt;">e</span>ss.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>plan<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>seek<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>outside<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.25pt;"> </span>and,<span style="letter-spacing:-0.1pt;"> </span>accordingly,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>expect<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>subj<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>to additional<span style="letter-spacing:-0.3pt;"> </span>risks related<span style="letter-spacing:-0.3pt;"> </span>to operating<span style="letter-spacing:-0.35pt;"> </span>in foreign<span style="letter-spacing:-0.3pt;"> </span>countries<span style="letter-spacing:-0.3pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>ob<span style="letter-spacing:-0.05pt;">t</span>ain<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>necessary<span style="letter-spacing:-0.3pt;"> </span>approvals,<span style="letter-spacing:-0.4pt;"> </span>including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">differing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">regulato</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">requirem</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">nts</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in foreign</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unexpected</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">changes</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">tariffs,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">trade</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">b</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">rriers,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">price</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and exchange</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">controls</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:-0.1pt;color:#000000;">t</span><span style="color:#000000;">her</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">conomic</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">weakness,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">inflation,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">political</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">instability</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">in particular</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">fore</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">gn</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">economies</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ompliance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">tax,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">employment,</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">immigration</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">labor</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">laws</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">employees</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">living</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">traveling</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">abroad&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">foreign</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">taxes,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">wi</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">hholding</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">payroll</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">taxes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">foreign</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">currency</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">fluctuations,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">ult</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in in</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">op</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">expenses</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">reduced</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">revenues,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">oth</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">obligations</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">incident</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to doing</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">in an</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">her</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">count</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">y&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">sta</span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="color:#000000;">fing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">managing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">foreign</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">workforce</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">uncertainty</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">countries</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">where</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">labor</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">unrest</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">is more</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">common</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">United</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">States&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">differing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">payor</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">regimes,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">governm</span><span style="letter-spacing:0.1pt;color:#000000;">e</span><span style="color:#000000;">ntal</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">payors</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patient</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">self-pay</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">systems,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">price</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">controls&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">liability</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">under</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Foreign</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">C</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">rrupt</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">Practices</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">Act</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">1977</span><span style="letter-spacing:-0.05pt;color:#000000;"> (&#8220;</span><span style="color:#000000;">FCP</span><span style="letter-spacing:-0.05pt;color:#000000;">A&#8221;) </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">comparable</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">foreign</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">hallenges</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">enforcing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">contrac</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">ual</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">rights,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">especially</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">those</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">ign</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">countries</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">do</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">resp</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ct</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">protect </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nte</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">le</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">tu</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">op</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rty</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">me</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">ex</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">Un</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d </span><span style="letter-spacing:-0.05pt;color:#000000;">S</span><span style="color:#000000;">ta</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">es&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">production</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">tages</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">resulting</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">events</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">affecting</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">raw</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">mat</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">rial</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">supply</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">manufact</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">ring</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">capabilities</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">abroad&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">impact</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">public</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">health</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">epidemics</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">global</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">economy,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">coronavirus</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">pandemic</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">currently</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">hav</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">impact</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">throughout</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">the world&#59;</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">business</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">interruptions</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">resulting</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">geo-po</span><span style="letter-spacing:-0.1pt;color:#000000;">l</span><span style="color:#000000;">itical</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">actions,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">war</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">terrorism.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>oth<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>risks <span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span>soc<span style="letter-spacing:-0.05pt;">i</span>at<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.05pt;"> i</span>nter<span style="letter-spacing:-0.05pt;">n</span>ational<span style="letter-spacing:-0.4pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>material<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>adv<span style="letter-spacing:-0.05pt;">e</span>rsely<span style="letter-spacing:-0.35pt;"> </span>aff<span style="letter-spacing:-0.05pt;">e</span>ct<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>bi<span style="letter-spacing:-0.05pt;">l</span>ity<span style="letter-spacing:-0.2pt;"> </span>to <span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>in<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.15pt;">i</span>n<span style="letter-spacing:-0.2pt;"> </span>profitable<span style="letter-spacing:-0.3pt;"> </span>operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.05pt;">k</span>s R<span style="letter-spacing:0.05pt;">e</span>lat<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>to Government<span style="letter-spacing:-0.25pt;"> </span>Regulation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates. We are, and if we receive regulatory approval of our product candidates, will continue to be subject to ongoing extensive regulation, regulatory obligations and continued regulatory review, which may result in significant additional expense.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates are subject to extensive governmental regulations relating to, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs and therapeutic biologics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the United States and in many foreign jurisdictions before a new drug or therapeutic biologic can be marketed. Satisfaction of these and other regulatory requirements is costly, lengthy, time-consuming, uncertain and subject to unanticipated delays and can vary substantially based upon the type, complexity and novelty of the products involved. We will not be permitted to market or promote any of our product candidates without receiving regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates or regulatory approval that will allow us to successfully commercialize our product candidates. In addition, regulatory agencies may lack experience with our technologies and products, which may lengthen the regulatory review process, increase our development costs and delay or prevent their commercialization. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not previously submitted a BLA or NDA or similar marketing or drug approval application to the FDA or comparable foreign authorities, for any product candidate, which may impede our ability to obtain timely FDA approvals, if at all, and we cannot be certain that any of our current product candidates or any future product candidates will be successful in clinical trials or receive regulatory approval. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical studies, clinical trials or other research. The number and types of preclinical studies and clinical trials that will be required for regulatory approval also vary depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. Approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any delay in completing development or obtaining, or failing to obtain, required approvals would have a material and adverse effect on our ability to generate revenue from the particular product candidate for which we are developing and seeking approval. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, be subject to other regulatory enforcement action, and we may not achieve or sustain profitability.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, however a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval policies, procedures and requirements may vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our product candidates is also subject to approval. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. If we fail to comply with the regulatory requirements in international markets and/or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approvals<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>receive<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>requi<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.2pt;"> </span>surveillance<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>monitor<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>safety<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>efficacy<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>ca<span style="letter-spacing:0.05pt;">n</span>didate. The<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>a REMS<span style="letter-spacing:0.05pt;"> </span>to app<span style="letter-spacing:-0.1pt;">r</span>ove<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>entail<span style="letter-spacing:-0.2pt;"> </span>requirements<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a medication<span style="letter-spacing:-0.35pt;"> </span>guide,<span style="letter-spacing:-0.15pt;"> </span>phy<span style="letter-spacing:-0.05pt;">s</span>i<span style="letter-spacing:-0.05pt;">c</span>ian<span style="letter-spacing:-0.2pt;"> </span>communication plans<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>addit<span style="letter-spacing:-0.15pt;">i</span>onal<span style="letter-spacing:-0.35pt;"> </span>elements<span style="letter-spacing:-0.25pt;"> </span>to ensure<span style="letter-spacing:-0.2pt;"> </span>safe<span style="letter-spacing:-0.1pt;"> </span>use,<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as restricted<span style="letter-spacing:-0.35pt;"> </span>distribution<span style="letter-spacing:-0.35pt;"> </span>methods,<span style="letter-spacing:-0.3pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>regist<span style="letter-spacing:-0.05pt;">r</span>ies<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>minimization<span style="letter-spacing:-0.5pt;"> </span>tools.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>requi<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.2pt;"> </span>post-approv<span style="letter-spacing:0.1pt;">a</span>l<span style="letter-spacing:-0.45pt;"> P</span>hase&#160;IV<span style="letter-spacing:-0.05pt;"> </span>trials.<span style="letter-spacing:-0.15pt;"> </span>Moreover,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">F</span>DA and<span style="letter-spacing:-0.15pt;"> </span>comp<span style="letter-spacing:0.05pt;">a</span>rable<span style="letter-spacing:-0.35pt;"> </span>foreign<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>authorities<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>continue<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>closely<span style="letter-spacing:-0.2pt;"> </span>monitor<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>safety<span style="letter-spacing:0.05pt;"> </span>profile<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>even<span style="letter-spacing:-0.2pt;"> </span>after<span style="letter-spacing:-0.15pt;"> </span>approval.<span style="letter-spacing:-0.35pt;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>we,<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>contractors,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>collab<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span>ators<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>remain<span style="letter-spacing:-0.25pt;"> </span>responsible<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>compliance,<span style="letter-spacing:-0.45pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>requirem<span style="letter-spacing:-0.1pt;">e</span>nts<span style="letter-spacing:-0.4pt;"> </span>related<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>product design,<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;">t</span>ing, clinical trials and preclinical studies approval,<span style="letter-spacing:-0.3pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>processes<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>quality,<span style="letter-spacing:-0.25pt;"> </span>lab<span style="letter-spacing:-0.05pt;">e</span>ling,<span style="letter-spacing:-0.35pt;"> </span>packaging,<span style="letter-spacing:-0.35pt;"> </span>d<span style="letter-spacing:-0.05pt;">i</span>stribution,<span style="letter-spacing:-0.45pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>event<span style="letter-spacing:-0.2pt;"> </span>and deviation<span style="letter-spacing:-0.35pt;"> </span>reporting,<span style="letter-spacing:-0.35pt;"> </span>storage,<span style="letter-spacing:-0.25pt;"> </span>advertising,<span style="letter-spacing:-0.35pt;"> </span>marketing,<span style="letter-spacing:-0.4pt;"> </span>promotion,<span style="letter-spacing:-0.35pt;"> </span>sale,<span style="letter-spacing:-0.15pt;"> </span>imp<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span>t,<span style="letter-spacing:-0.25pt;"> </span>export,<span style="letter-spacing:-0.25pt;"> </span>sub<span style="letter-spacing:-0.1pt;">m</span>issions<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>safety<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>post-ma<span style="letter-spacing:0.05pt;">r</span>keting<span style="letter-spacing:-0.5pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>and reports<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>deviation<span style="letter-spacing:-0.35pt;"> </span>reports,<span style="letter-spacing:-0.2pt;"> </span>registration,<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>listing,<span style="letter-spacing:-0.3pt;"> </span>annual<span style="letter-spacing:-0.2pt;"> </span>user<span style="letter-spacing:-0.05pt;"> </span>fees,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>reco<span style="letter-spacing:0.05pt;">r</span>dkeeping<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidat<span style="letter-spacing:0.1pt;">e</span>s.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r collaborators,<span style="letter-spacing:-0.45pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>con<span style="letter-spacing:-0.05pt;">t</span>ract<span style="letter-spacing:-0.25pt;"> </span>manufacturers,<span style="letter-spacing:-0.5pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.05pt;"> s</span>ubject<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>periodic<span style="letter-spacing:-0.35pt;"> </span>unannounced<span style="letter-spacing:-0.55pt;"> </span>ins<span style="letter-spacing:0.05pt;">p</span>ections<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>to monitor<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>ensure compliance<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>requ<span style="letter-spacing:0.1pt;">i</span>rements.<span style="letter-spacing:-0.45pt;"> </span>Application<span style="letter-spacing:-0.4pt;"> </span>holders<span style="letter-spacing:-0.15pt;"> </span>must<span style="letter-spacing:-0.2pt;"> </span>further<span style="letter-spacing:-0.3pt;"> </span>notify<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>depending<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>nature<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:-0.1pt;">h</span>ange,<span style="letter-spacing:-0.25pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>FDA pre-approval<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>changes.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>compl<span style="letter-spacing:-0.05pt;">i</span>ance<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>post-approval<span style="letter-spacing:-0.5pt;"> </span>regulat<span style="letter-spacing:-0.1pt;">i</span>ons<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a negative<span style="letter-spacing:-0.35pt;"> </span>effe<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operating results<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA or comparable foreign regulatory authorities become aware of new safety information or previously unknown problems after approval of any of our product candidates, including: (i)&#160;adverse events of unanticipated severity or frequency, (ii)&#160;that the product is less effective than previously thought, (iii)&#160;problems with our third-party manufacturers or manufacturing processes, or (iv)&#160;failure to comply with regulatory requirements, or if we violate regulatory requirements at any stage, whether before or after marketing approval is obtained, we may face a number of regulatory consequences, including refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, modification of promotional materials or labeling (including required additional warnings), provision of corrective information, imposition of post-market requirements, including the need for additional testing or costly post-approval studies or post-market surveillance, imposition of distribution, manufacturing or other restrictions under a REMS, imposition of restrictions on a product&#8217;s indicated uses, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, FDA debarment, injunctions, fines, consent decrees, corporate integrity agreements, debarment from receiving government contracts, exclusion from participation in federal and state healthcare programs, issuance of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information, restitution, disgorgement, or civil or criminal penalties, including fines and imprisonment, reputational harm and adverse publicity, among other adverse consequences. Any such restrictions could limit sales of the product. Any of these events could further have other material and adverse effects on our operations and business and could adversely impact our stock price and could significantly harm our business, financial condition, results of operations, and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Results for any patient who receives compassionate use access to our product candidates should not be viewed as representative of how the product candidate will perform in a well-controlled clinical trial, and cannot be used to establish safety or efficacy for regulatory approval.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We often receive requests for compassionate use access to our investigational drugs by patients that do not meet the entry criteria for enrollment into our clinical trials. Generally, patients requesting compassionate use have no other treatment alternatives for life threatening conditions. We evaluate each compassionate use request on an individual basis, and in some cases grant access to our investigational product candidates outside of our sponsored clinical trials if a physician certifies that the patient receiving treatment is critically ill and does not meet the entry criteria for one of our open clinical trials. Individual patient results from compassionate use access may not be used to support submission of a regulatory application, may not support approval of a product candidate and should not be considered to be indicative of results from any on-going or future well-controlled clinical trial. Before we can seek regulatory approval for any of our product candidates, we must demonstrate in well-controlled clinical trials statistically significant evidence that the product candidate is both safe and effective for the indication we are seeking approval. The results of our compassionate use program may not be used to establish safety or efficacy or regulatory approval.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>GMP-in-a-Box<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>regulated<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>device,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.45pt;"> </span>com<span style="letter-spacing:0.05pt;">p</span>liance<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>devices<span style="letter-spacing:-0.25pt;"> </span>is expensive,<span style="letter-spacing:-0.55pt;"> </span>complex<span style="letter-spacing:-0.25pt;"> </span>and uncertain,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>failure<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>com<span style="letter-spacing:0.1pt;">p</span>ly<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>lead<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>enforcement<span style="letter-spacing:-0.4pt;"> </span>actions<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.3pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>o<span style="letter-spacing:-0.1pt;">t</span>her<span style="letter-spacing:-0.05pt;"> </span>negative<span style="letter-spacing:-0.25pt;"> </span>consequen<span style="letter-spacing:0.1pt;">c</span>es for our busine<span style="letter-spacing:-0.05pt;">s</span>s.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd si<span style="letter-spacing:-0.05pt;">m</span>il<span style="letter-spacing:-0.05pt;">a</span>r<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>genc<span style="letter-spacing:-0.05pt;">i</span>es<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>gula<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.3pt;"> </span>med<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>devices. All of our potential medical device products and material modifications will be subject to extensive regulation and clearance or approval from the FDA and non-U.S.&#160;regulatory agencies prior to commercial sale and distribution as well as after clearance or approval. Complying<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>ese<span style="letter-spacing:-0.15pt;"> </span>regulations<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>costly,<span style="letter-spacing:-0.3pt;"> </span>time-consuming,<span style="letter-spacing:-0.6pt;"> </span>complex<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">u</span>ncertain.<span style="letter-spacing:-0.2pt;"> </span>For instance,<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.05pt;">f</span>ore<span style="letter-spacing:-0.15pt;"> </span>a new<span style="letter-spacing:-0.05pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>device,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>intended<span style="letter-spacing:-0.25pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>existing<span style="letter-spacing:-0.35pt;"> </span>dev<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">ce</span>,<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:0.05pt;">a</span>n<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>rketed<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Unit<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.05pt;"> </span>State<span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:0.1pt;">o</span>mpany<span style="letter-spacing:-0.4pt;"> </span>must<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>irst submit and<span style="letter-spacing:-0.1pt;"> </span>receive<span style="letter-spacing:-0.25pt;"> </span>either<span style="letter-spacing:-0.2pt;"> </span>510(k)&#160;clearance<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>pre-marketing<span style="letter-spacing:-0.45pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>F<span style="letter-spacing:-0.05pt;">D</span>A,<span style="letter-spacing:-0.05pt;"> </span>unless<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>exe<span style="letter-spacing:-0.05pt;">m</span>ption<span style="letter-spacing:-0.4pt;"> </span>applies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA<span style="letter-spacing:0.05pt;"> </span>regulations<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulations<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>similar<span style="letter-spacing:-0.2pt;"> </span>agencies<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>wide-ranging<span style="letter-spacing:-0.5pt;"> </span>and include,<span style="letter-spacing:-0.3pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>things,<span style="letter-spacing:-0.3pt;"> </span>oversight<span style="letter-spacing:-0.4pt;"> </span>of:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">design,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">development,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">manufacture</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">(including</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">su</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">plie</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">s)</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">testing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">aboratory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">preclinical</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;">t</span><span style="color:#000000;">udi</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">cl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">safety</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">effectiveness&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">labeling&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">storage</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">shipping&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">record</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">kee</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">ing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">pre-market</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">clearance</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">arketing,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">adverti</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">ing</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">promotion&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and distribution&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">changes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">recalls&#59;</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">post-market</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">surveillance</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">porting</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">deaths</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">serious</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">injuries</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">certain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">malfunctions.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical<span style="letter-spacing:-0.3pt;"> </span>devices<span style="letter-spacing:-0.2pt;"> </span>regulated<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>subj<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>gen<span style="letter-spacing:-0.05pt;">e</span>ral<span style="letter-spacing:-0.25pt;"> </span>con<span style="letter-spacing:-0.05pt;">t</span>rols<span style="letter-spacing:-0.1pt;"> </span>whi<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;">c</span>lud<span style="letter-spacing:-0.05pt;">e:</span><span style="letter-spacing:-0.25pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>gistr<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.4pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA&#59; list<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>omm<span style="letter-spacing:-0.05pt;">e</span>rc<span style="letter-spacing:-0.05pt;">i</span>ally<span style="letter-spacing:-0.4pt;"> </span>distributed prod<span style="letter-spacing:0.05pt;">u</span>cts<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA&#59; complying<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>cGMP<span style="letter-spacing:-0.1pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>Quality<span style="letter-spacing:-0.2pt;"> </span>Systems<span style="letter-spacing:-0.35pt;"> </span>Regulations&#59;<span style="letter-spacing:-0.4pt;"> </span>filing<span style="letter-spacing:-0.25pt;"> </span>reports<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>keeping<span style="letter-spacing:-0.25pt;"> </span>recor<span style="letter-spacing:0.05pt;">d</span>s<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">a</span>tive<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o certain<span style="letter-spacing:-0.2pt;"> </span>types<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>adverse<span style="letter-spacing:-0.3pt;"> </span>events<span style="letter-spacing:-0.2pt;"> </span>associated<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>devices<span style="letter-spacing:-0.25pt;"> </span>under<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>device<span style="letter-spacing:-0.25pt;"> </span>repo<span style="letter-spacing:-0.1pt;">r</span>ting<span style="letter-spacing:-0.3pt;"> </span>regulation&#59;<span style="letter-spacing:-0.35pt;"> </span>assuring<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>device<span style="letter-spacing:-0.2pt;"> </span>la<span style="letter-spacing:-0.05pt;">b</span>eling<span style="letter-spacing:-0.3pt;"> </span>complies<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>device labeling<span style="letter-spacing:-0.3pt;"> </span>requirements&#59;<span style="letter-spacing:-0.5pt;"> </span>reporting<span style="letter-spacing:-0.3pt;"> </span>c<span style="letter-spacing:0.1pt;">e</span>rtain<span style="letter-spacing:-0.25pt;"> </span>device<span style="letter-spacing:-0.25pt;"> </span>field<span style="letter-spacing:-0.1pt;"> </span>removals<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>corrections<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA&#59;<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>obtaining<span style="letter-spacing:-0.35pt;"> </span>pre-market<span style="letter-spacing:-0.35pt;"> </span>notification<span style="letter-spacing:-0.3pt;"> </span>510(k)&#160;clearance<span style="letter-spacing:-0.3pt;"> </span>for devices<span style="letter-spacing:-0.2pt;"> </span>prior<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>marketing.<span style="letter-spacing:-0.4pt;"> </span>Some<span style="letter-spacing:-0.15pt;"> </span>devices<span style="letter-spacing:-0.2pt;"> </span>known as<span style="letter-spacing:0.05pt;"> </span>510(k)-exempt<span style="letter-spacing:-0.5pt;"> </span>d<span style="letter-spacing:0.05pt;">e</span>vices<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.1pt;">a</span>rketed<span style="letter-spacing:-0.3pt;"> </span>without<span style="letter-spacing:-0.3pt;"> </span>prior<span style="letter-spacing:-0.15pt;"> </span>marketing-clearance<span style="letter-spacing:-0.75pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">p</span>proval<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the FDA.<span style="letter-spacing:-0.05pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>general<span style="letter-spacing:-0.2pt;"> </span>controls,<span style="letter-spacing:-0.3pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>Class&#160;II<span style="letter-spacing:-0.05pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>devices<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.15pt;"> </span>sub<span style="letter-spacing:-0.05pt;">j</span>ect<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o spe<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.1pt;"> </span>controls,<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>adherence<span style="letter-spacing:-0.3pt;"> </span>to a particular<span style="letter-spacing:-0.35pt;"> </span>guidance d<span style="letter-spacing:0.05pt;">o</span>cument<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>compliance<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>performa<span style="letter-spacing:-0.1pt;">n</span>ce<span style="letter-spacing:-0.4pt;"> </span>standard.<span style="letter-spacing:-0.35pt;"> </span>Instead<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>obtaining<span style="letter-spacing:-0.35pt;"> </span>510(k)&#160;cle<span style="letter-spacing:-0.1pt;">a</span>rance,<span style="letter-spacing:-0.3pt;"> </span>most<span style="letter-spacing:-0.2pt;"> </span>Class&#160;<span style="letter-spacing:-0.05pt;">I</span>II<span style="letter-spacing:0.05pt;"> </span>devices<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>subje<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>pre-m<span style="letter-spacing:-0.05pt;">a</span>rket approval<span style="letter-spacing:0.05pt;"> (&#8220;</span>PMA&#8221;).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refuse</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to clear</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approve</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pre-market</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applications</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">medical</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">device</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to obtain the necessary clearances or approvals or may be unduly delayed in doing so, for any medical device products we develop, which could harm our business.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Furthermore, even if we are granted regulatory clearances or approvals for any medical device products, they may include significant limitations on the indicated uses for the product, which may limit the market for the product.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any<span style="letter-spacing:-0.05pt;"> </span>enforcement<span style="letter-spacing:-0.45pt;"> </span>action<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other comparable<span style="letter-spacing:-0.35pt;"> </span>non-U.S.<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>agencies<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ould<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a material<span style="letter-spacing:-0.25pt;"> </span>adver<span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:-0.3pt;"> </span>effect<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business,<span style="letter-spacing:-0.05pt;"> </span>f<span style="letter-spacing:0.05pt;">i</span>nancial<span style="letter-spacing:-0.25pt;"> </span>condit<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations.<span style="letter-spacing:-0.4pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>failure to comply<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>applicable<span style="letter-spacing:-0.35pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>requirements<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>enforcement<span style="letter-spacing:-0.45pt;"> </span>action<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>state<span style="letter-spacing:-0.15pt;"> </span>agencies,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span>clude<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the following<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>tions:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">un</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">it</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ed</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">le</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ters,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">warn</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">tt</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rs,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">fines,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">j</span><span style="color:#000000;">unctions,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">consent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">dec</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ees</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">civil</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">penalties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">un</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nti</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ip</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ted</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">exp</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nditur</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">address</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">defend</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">actions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ustomer</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">notificatio</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">repair,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">replacement</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">refunds&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">recall,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">detention</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">seizure</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">operating</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">restrictions</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">partial</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">suspension</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">total</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">sh</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">down</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">duction&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">delaying</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">requests</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">510(k)</span><span style="letter-spacing:0.05pt;color:#000000;">&#160;</span><span style="color:#000000;">clearance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">PMA</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">modified</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">operating</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ri</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">tions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">withdrawing</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">510(k)&#160;clearances</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">PMA approvals</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">h</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ve</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">already</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">been</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">granted&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">grant</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">export</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">products&#59;</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">riminal</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">prosecution.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>events<span style="letter-spacing:-0.2pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>to occur,<span style="letter-spacing:-0.25pt;"> </span>it<span style="letter-spacing:-0.15pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>material<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business, financial<span style="letter-spacing:-0.3pt;"> </span>condition<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>res<span style="letter-spacing:-0.05pt;">u</span>lts<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operatio<span style="letter-spacing:0.05pt;">n</span>s.<span style="letter-spacing:-0.3pt;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also regulates the advertising and promotion of medical devices to ensure that the claims are consistent with their regulatory clearances or approvals, that there are adequate and reasonable data to substantiate the claims and that the promotional labeling and advertising is neither false nor misleading in any respect. If the FDA determines that any of our advertising or promotional claims are misleading, not substantiated or not permissible, we may be subject to enforcement actions, including warning letters, and we may be required to revise our promotional claims and make other corrections or restitutions. Failure to comply with applicable U.S.&#160;requirements regarding, for example, promoting, manufacturing, or labeling our medical device products, may subject us to a variety of administrative or judicial actions and sanctions, such as Form&#160;483 observations, warning letters, untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. If any of our medical device products cause or contribute to a death or a serious injury or malfunction in certain ways, we will be required to report under applicable medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>governmental<span style="letter-spacing:-0.45pt;"> </span>export<span style="letter-spacing:-0.25pt;"> </span>and import<span style="letter-spacing:-0.2pt;"> </span>controls<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>impair<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>compete<span style="letter-spacing:-0.3pt;"> </span>in international<span style="letter-spacing:-0.45pt;"> </span>markets<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">du</span>e to <span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g requirements<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">u</span>s<span style="letter-spacing:-0.05pt;"> </span>to liability<span style="letter-spacing:-0.3pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>are <span style="letter-spacing:0.05pt;">n</span>ot in<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">c</span>omplian<span style="letter-spacing:0.05pt;">c</span>e<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>applicable<span style="letter-spacing:-0.35pt;"> </span>laws.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>export<span style="letter-spacing:-0.2pt;"> </span>control<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>import<span style="letter-spacing:-0.2pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulations,<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>U.S.&#160;Export<span style="letter-spacing:-0.2pt;"> </span>Administration<span style="letter-spacing:-0.6pt;"> </span>Regulations,<span style="letter-spacing:-0.4pt;"> </span>U.S.&#160;Cust<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">m</span>s<span style="letter-spacing:-0.35pt;"> </span>regulations<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>v<span style="letter-spacing:0.05pt;">a</span>rious<span style="letter-spacing:-0.15pt;"> </span>economic<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>trade<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:-0.1pt;">a</span>nctions<span style="letter-spacing:-0.2pt;"> </span>regulations<span style="letter-spacing:-0.35pt;"> </span>administered<span style="letter-spacing:-0.45pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>U.S.&#160;Treasury<span style="letter-spacing:-0.35pt;"> </span>Department&#8217;s<span style="letter-spacing:-0.55pt;"> </span>Office<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Foreign<span style="letter-spacing:-0.35pt;"> </span>Assets Co<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>rols.<span style="letter-spacing:-0.2pt;"> </span>Exports<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and solutions<span style="letter-spacing:-0.25pt;"> </span>outside<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span>States<span style="letter-spacing:-0.25pt;"> </span>must<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>made<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>compliance<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>laws<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulations.<span style="letter-spacing:-0.35pt;"> </span>If we f<span style="letter-spacing:-0.05pt;">a</span>il<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>ws<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>regu<span style="letter-spacing:-0.1pt;">l</span>ations,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>civil<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>criminal<span style="letter-spacing:-0.25pt;"> </span>penalties,<span style="letter-spacing:-0.35pt;"> </span>including the<span style="letter-spacing:-0.1pt;"> </span>possible<span style="letter-spacing:-0.3pt;"> </span>loss of<span style="letter-spacing:0.05pt;"> </span>export<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>import<span style="letter-spacing:-0.25pt;"> </span>privi<span style="letter-spacing:-0.15pt;">l</span>eges&#59;<span style="letter-spacing:-0.45pt;"> </span>fines,<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>i<span style="letter-spacing:-0.05pt;">m</span>posed<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>responsible<span style="letter-spacing:-0.4pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>managers&#59;<span style="letter-spacing:-0.3pt;"> </span>and,<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n <span style="letter-spacing:-0.05pt;">e</span>x<span style="letter-spacing:0.05pt;">tre</span><span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he incarceration<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>responsible<span style="letter-spacing:-0.4pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>managers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidat<span style="letter-spacing:-0.1pt;">e</span>s<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>solutions<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>changes<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>applicable<span style="letter-spacing:-0.35pt;"> </span>export<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>import<span style="letter-spacing:-0.2pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>regulations<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>cr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.2pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">a</span>ys<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the introduction,<span style="letter-spacing:-0.4pt;"> </span>provision,<span style="letter-spacing:-0.4pt;"> </span>or sale<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>solutions<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>international<span style="letter-spacing:-0.4pt;"> </span>markets,<span style="letter-spacing:-0.25pt;"> </span>prevent<span style="letter-spacing:-0.3pt;"> </span>customers<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>using<span style="letter-spacing:-0.2pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates and<span style="letter-spacing:-0.1pt;"> </span>solutions<span style="letter-spacing:-0.25pt;"> </span>or,<span style="letter-spacing:0.05pt;"> </span>in some<span style="letter-spacing:-0.25pt;"> </span>cases,<span style="letter-spacing:-0.15pt;"> </span>preve<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>export<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>import<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>solutions<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>countries,<span style="letter-spacing:-0.3pt;"> </span>governments<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>persons altogether.<span style="letter-spacing:-0.4pt;"> </span>Any<span style="letter-spacing:-0.05pt;"> </span>limitations<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>export,<span style="letter-spacing:-0.3pt;"> </span>provide,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>sell<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>produ<span style="letter-spacing:0.15pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>solutions<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.4pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business, financial condition<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">are subject</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S.</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and for</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ign</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">anti-corruption</span><span style="letter-spacing:-0.6pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">anti-money</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">aundering </span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">aws with</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">sp</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:0.05pt;">p</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">erations</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">non-compl</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">an</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">such laws</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">can subj</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">riminal</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">an</span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">/</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">civil</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">liabi</span><span style="letter-spacing:0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ity</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and harm our business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FCPA,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>U<span style="letter-spacing:0.1pt;">.</span>S.<span style="letter-spacing:-0.05pt;"> </span>domestic<span style="letter-spacing:-0.35pt;"> </span>bribery<span style="letter-spacing:-0.2pt;"> </span>sta<span style="letter-spacing:0.05pt;">t</span>ute<span style="letter-spacing:-0.2pt;"> </span>contained<span style="letter-spacing:-0.35pt;"> </span>in 18&#160;U.S.C.&#160;&#167;201,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>U.S.<span style="letter-spacing:0.05pt;">&#160;</span>T<span style="letter-spacing:-0.05pt;">r</span>avel<span style="letter-spacing:-0.2pt;"> </span>Act,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>USA<span style="letter-spacing:0.05pt;">&#160;</span>PATRIOT<span style="letter-spacing:-0.05pt;"> </span>Act<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>possibly other<span style="letter-spacing:-0.2pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>nation<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.35pt;"> </span>anti-bribery<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>anti-money<span style="letter-spacing:-0.35pt;"> </span>laund<span style="letter-spacing:-0.05pt;">e</span>ring<span style="letter-spacing:-0.35pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>countries<span style="letter-spacing:-0.3pt;"> </span>in which<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>conduct<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:0.1pt;">c</span>tivities.<span style="letter-spacing:-0.35pt;"> </span>Anti-corruption<span style="letter-spacing:-0.5pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>interpreted broadly<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>prohibit<span style="letter-spacing:-0.25pt;"> </span>companies<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>their<span style="letter-spacing:-0.2pt;"> </span>e<span style="letter-spacing:0.05pt;">m</span>ployees,<span style="letter-spacing:-0.35pt;"> </span>agents,<span style="letter-spacing:-0.2pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rm<span style="letter-spacing:-0.05pt;">e</span>di<span style="letter-spacing:-0.05pt;">a</span>ries,<span style="letter-spacing:-0.5pt;"> </span>jo<span style="letter-spacing:-0.05pt;">i</span>nt<span style="letter-spacing:-0.1pt;"> </span>ventu<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.2pt;"> </span>partners<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>collaborato<span style="letter-spacing:0.05pt;">r</span>s<span style="letter-spacing:-0.45pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>authorizing, promising,<span style="letter-spacing:-0.35pt;"> </span>offering<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>providing,<span style="letter-spacing:-0.4pt;"> </span>directly<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>indirectly,<span style="letter-spacing:-0.35pt;"> </span>improper<span style="letter-spacing:-0.3pt;"> </span>payments<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>benefits<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>recipients<span style="letter-spacing:-0.35pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>public<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>private<span style="letter-spacing:-0.3pt;"> </span>sector.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>use CROs abroad<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">r</span>ials.<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">I</span>n<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>engage<span style="letter-spacing:-0.3pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>intermediaries<span style="letter-spacing:-0.45pt;"> </span>to sell<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>solu<span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.25pt;"> </span>abroad<span style="letter-spacing:-0.3pt;"> </span>once<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>enter<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>commercialization<span style="letter-spacing:-0.65pt;"> </span>phase<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>cand<span style="letter-spacing:0.05pt;">i</span>dates<span style="letter-spacing:-0.45pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>nec<span style="letter-spacing:0.05pt;">e</span>ssary<span style="letter-spacing:-0.2pt;"> </span>permits,<span style="letter-spacing:-0.35pt;"> </span>licenses,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>approvals.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>third-party intermediaries<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>direct<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">i</span>rect<span style="letter-spacing:-0.3pt;"> </span>interactions<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>fficials<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>agencies<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>state-owned<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">a</span>ffi<span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">a</span>ted<span style="letter-spacing:-0.3pt;"> </span>en<span style="letter-spacing:-0.05pt;">t</span>it<span style="letter-spacing:-0.05pt;">i</span>es.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>n be<span style="letter-spacing:-0.05pt;"> </span>h<span style="letter-spacing:-0.05pt;">e</span>ld<span style="letter-spacing:-0.15pt;"> </span>li<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.2pt;"> </span>for the<span style="letter-spacing:-0.1pt;"> </span>corrupt<span style="letter-spacing:-0.25pt;"> </span>or other<span style="letter-spacing:-0.2pt;"> </span>i<span style="letter-spacing:-0.05pt;">l</span>leg<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>ac<span style="letter-spacing:-0.05pt;">t</span>ivi<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>intermediarie<span style="letter-spacing:-0.05pt;">s</span>,<span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>employees,<span style="letter-spacing:-0.4pt;"> </span>representatives,<span style="letter-spacing:-0.6pt;"> </span>contractors,<span style="letter-spacing:-0.4pt;"> </span>partners<span style="letter-spacing:-0.25pt;"> </span>and agents,<span style="letter-spacing:-0.2pt;"> </span>even<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>explicitly<span style="letter-spacing:-0.3pt;"> </span>authori<span style="letter-spacing:-0.05pt;">z</span>e<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>actual<span style="letter-spacing:-0.15pt;"> </span>knowledge<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>activities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> have </span>adopted<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>anti-corruption<span style="letter-spacing:-0.5pt;"> </span>policy<span style="letter-spacing:-0.2pt;">, which </span>mandates<span style="letter-spacing:-0.35pt;"> </span>compliance<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FCPA<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>anti<span style="letter-spacing:-0.05pt;">-</span>corruption<span style="letter-spacing:-0.5pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>applicable<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>throughout<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>world.<span style="letter-spacing:-0.05pt;"> </span>However,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:0.05pt;">r</span>e<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>no assurance<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>third-par<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rm<span style="letter-spacing:-0.05pt;">e</span>di<span style="letter-spacing:-0.05pt;">a</span>ries<span style="letter-spacing:-0.45pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>ply<span style="letter-spacing:-0.15pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.05pt;"> t</span>his<span style="letter-spacing:-0.05pt;"> </span>po<span style="letter-spacing:-0.1pt;">l</span>icy<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>anti-corruption<span style="letter-spacing:-0.5pt;"> </span>laws.<span style="letter-spacing:0.05pt;"> </span>Non-compl<span style="letter-spacing:-0.05pt;">i</span>ance<span style="letter-spacing:-0.6pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.05pt;"> a</span>nti-corruption<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>anti-money<span style="letter-spacing:-0.35pt;"> </span>laundering<span style="letter-spacing:-0.4pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>us to<span style="letter-spacing:-0.1pt;"> </span>whistleblower<span style="letter-spacing:-0.45pt;"> </span>compl<span style="letter-spacing:0.1pt;">a</span>ints,<span style="letter-spacing:-0.35pt;"> </span>investigations,<span style="letter-spacing:-0.45pt;"> </span>sanctions,<span style="letter-spacing:-0.4pt;"> </span>settlements,<span style="letter-spacing:-0.45pt;"> </span>prosecution,<span style="letter-spacing:-0.4pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>investigations,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>en<span style="letter-spacing:-0.05pt;">f</span>orcement<span style="letter-spacing:-0.4pt;"> </span>actions.<span style="letter-spacing:-0.2pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>actions<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>launched,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>governm<span style="letter-spacing:0.05pt;">e</span>ntal<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.2pt;"> </span>sanctions<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.05pt;"> </span>imposed,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>prevail<span style="letter-spacing:-0.2pt;"> </span>in any p<span style="letter-spacing:0.05pt;">o</span>ssible<span style="letter-spacing:-0.15pt;"> </span>civil<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>criminal<span style="letter-spacing:-0.35pt;"> </span>liti<span style="letter-spacing:0.1pt;">g</span>ation,<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>mat<span style="letter-spacing:0.05pt;">e</span>rially<span style="letter-spacing:-0.3pt;"> </span>harmed.<span style="letter-spacing:-0.4pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>res<span style="letter-spacing:0.05pt;">p</span>onding<span style="letter-spacing:-0.2pt;"> </span>to any ac<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.2pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>lik<span style="letter-spacing:-0.05pt;">e</span>ly<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>ma<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>sign<span style="letter-spacing:-0.05pt;">i</span>ficant<span style="letter-spacing:-0.35pt;"> </span>diversion<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>manag<span style="letter-spacing:-0.1pt;">e</span>me<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>&#8217;s<span style="letter-spacing:-0.4pt;"> </span>attention<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>resources<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>significant<span style="letter-spacing:-0.4pt;"> </span>defense<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>compliance<span style="letter-spacing:-0.35pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>and other<span style="letter-spacing:-0.25pt;"> </span>professional<span style="letter-spacing:-0.4pt;"> </span>fees.<span style="letter-spacing:-0.2pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>certa<span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:-0.25pt;"> </span>cases,<span style="letter-spacing:-0.2pt;"> </span>enforcement<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:0.05pt;">u</span>tho<span style="letter-spacing:0.05pt;">r</span>ities<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>even<span style="letter-spacing:-0.2pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to appoint<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>inde<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">e</span>ndent<span style="letter-spacing:-0.4pt;"> </span>compliance<span style="letter-spacing:-0.35pt;"> </span>monitor,<span style="letter-spacing:-0.2pt;"> </span>whi<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span>n<span style="letter-spacing:-0.1pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in added<span style="letter-spacing:-0.25pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>administrative<span style="letter-spacing:-0.5pt;"> </span>burdens.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our failure to comply with state, national and/or international data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are numerous laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns, and some state privacy laws apply more broadly than the Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;) and associated regulations. For example, California recently enacted legislation&#8212;the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;)&#8212;which went into effect on January&#160;1,&#160;2020. The CCPA, among other things, creates new data privacy and security obligations for covered companies and provides new privacy rights to California consumers, including the right to opt out of certain disclosures of their information. The CCPA also provides for civil penalties as well as a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Although the law includes limited exceptions, including for certain information collected as part of clinical trials as specified in the law, it may regulate or impact our processing of personal information depending on the context. Additionally, a new privacy law, the California Privacy Rights Act (&#8220;CPRA&#8221;), was approved by California voters in November&#160;2020. The CPRA significantly modified the CCPA, which may require us to modify our practices and policies and may further increase our compliance costs and potential liability. To the extent these state laws as well as other federal and state privacy laws, including new laws and changes in existing laws, apply to our business and operations, our compliance costs and potential liability with respect to personal information we collect could expose us to great liability and increase compliance costs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are also various laws and regulations in other jurisdictions relating to privacy and security. For example, European Union (&#8220;EU&#8221;) member states and other foreign jurisdictions, including Switzerland, have adopted data protection laws and regulations which impose significant compliance obligations on us. The collection and use of health data in the EU is governed by the EU&#160;General Data Protection Regulation (&#8220;GDPR&#8221;). The GDPR, which is wide-ranging in scope and applies extraterritorially, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to such individuals, the security and confidentiality of the personal data, data breach notification, the adoption of appropriate privacy governance, including policies, procedures, training and audits, and the use of third-party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EU, including to the United States, provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20&#160;million or up to 4%&#160;of the total worldwide annual global revenues of the noncompliant entity, whichever is greater. The GDPR requirements apply not only to third-party transactions, but also to transfers of information between us and our subsidiaries, including employee information. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Complying with these numerous, complex and often changing regulations is expensive and difficult, and failure to comply with any privacy laws or data security laws or any security incident or breach involving the misappropriation, loss or other unauthorized processing, use or disclosure of sensitive or confidential patient, consumer or other personal information, whether by us, one of our CROs or business associates or another third party, could adversely affect our business, financial condition and results of operations, including but not limited to: investigation costs&#59; material fines and penalties&#59; compensatory, special, punitive and statutory damages&#59; litigation&#59; consent orders regarding our privacy and security practices&#59; requirements that we provide notices, credit monitoring services and/or credit restoration services or other relevant services to impacted individuals&#59; adverse actions against our licenses to do business&#59; reputational damage&#59; and injunctive relief. The recent implementation of the CCPA and GDPR has increased our responsibility and liability in relation to personal data that we process, including in clinical trials, and we may in the future be required to put in place additional mechanisms to ensure compliance with the CCPA, GDPR and other applicable laws and regulations, which could divert management&#8217;s attention and increase our cost of doing business. In addition, new regulation or legislative actions regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the EU and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot assure you that our CROs or other third-party service providers with access to our or our customers&#8217;, suppliers&#8217;, trial patients&#8217; and employees&#8217; personally identifiable and other sensitive or confidential information in relation to which we are responsible will not breach contractual obligations imposed by us, or that they will not experience data security breaches, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations and/or which could in turn adversely affect our business, results of operations and financial condition. We cannot assure you that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, use, storage and transmission of such information. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we, or any third party contract manufacturers or suppliers that we engage, fail to comply with environmental, health, and safety laws and regulations, including regulations governing the handling, storage or disposal of hazardous materials, we could become subject to fines or penalties or incur costs that could harm our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and any of our third-party manufacturers or suppliers will be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, manufacture, storage, treatment and disposal of hazardous materials and wastes. Our operations and research and development activities involve the controlled use of medical and hazardous materials, including chemicals, biological materials and infectious agents. Our operations also may produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. Although we believe that our procedures for using, storing and disposing of these materials comply with legally prescribed standards, we will not be able to eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we will maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain comprehensive insurance coverage for liabilities arising from medical or hazardous materials, environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. These current or future laws and regulations may impair our research, development, or production efforts, which could harm our business, prospects, financial condition or results of operations. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Disruptions at </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the FDA, the</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> SEC and other government agencies</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> caused by funding shortages or global health concerns </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the FDA, SEC, and other government agencies on which our operations may rely is inherently fluid and unpredictable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S.&#160;government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. In response to the COVID&#8209;19 pandemic, in 2020, the FDA announced that it would postpone domestic and foreign routine surveillance inspections. Based on updated guidance issued in May 2021, the FDA continues to conduct &#8220;mission-critical&#8221; inspections on a case-by-case basis, or, where possible to do so safely, has resumed prioritized domestic inspections, such as pre-approval and surveillance inspections. While the FDA indicated that it will consider alternative methods for inspections and exercise discretion on a case-by-case basis to approve products based on a desk review, if a prolonged government shutdown occurs, or if the government experiences a protracted backlog of inspections and regulatory review, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns, delays, or prioritization policies could potentially impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we<span style="letter-spacing:-0.1pt;"> </span>fail<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>f<span style="letter-spacing:-0.05pt;">e</span>deral<span style="letter-spacing:-0.25pt;"> </span>and s<span style="letter-spacing:-0.1pt;">t</span>ate<span style="letter-spacing:-0.1pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span>and promotional<span style="letter-spacing:-0.45pt;"> </span>laws,<span style="letter-spacing:-0.2pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>fraud<span style="letter-spacing:0.05pt;"> </span>and ab<span style="letter-spacing:-0.05pt;">u</span>se<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>privacy<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>security<span style="letter-spacing:-0.25pt;"> </span>laws, we<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>face<span style="letter-spacing:-0.2pt;"> </span>substantial<span style="letter-spacing:-0.35pt;"> </span>penalties<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.1pt;">u</span>r busines<span style="letter-spacing:0.05pt;">s</span>, fi<span style="letter-spacing:0.05pt;">n</span>an<span style="letter-spacing:0.05pt;">c</span>ial<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">c</span>onditio<span style="letter-spacing:0.05pt;">n</span>,<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>sults of operations,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>prospects<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>adversely<span style="letter-spacing:-0.1pt;"> </span>affe<span style="letter-spacing:0.05pt;">c</span>ted.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a biopharmaceutical<span style="letter-spacing:-0.65pt;"> </span>company,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>sub<span style="letter-spacing:0.05pt;">j</span>ect<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>many<span style="letter-spacing:-0.2pt;"> </span>federal<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>sta<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.1pt;"> </span>healthcare<span style="letter-spacing:-0.4pt;"> </span>laws,<span style="letter-spacing:-0.05pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>federal<span style="letter-spacing:-0.2pt;"> </span>Anti<span style="letter-spacing:-0.05pt;">-</span>Kickback<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">S</span>t<span style="letter-spacing:-0.05pt;">a</span>tut<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;"> (&#8220;</span>AKS&#8221;), <span style="letter-spacing:-0.05pt;">t</span>he FCA, the civil monetary pen<span style="letter-spacing:-0.05pt;">a</span>lt<span style="letter-spacing:-0.05pt;">i</span>es<span style="letter-spacing:-0.2pt;"> </span>st<span style="letter-spacing:-0.05pt;">a</span>tut<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Medicaid<span style="letter-spacing:-0.3pt;"> </span>Drug Rebate<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:0.05pt;">t</span>atute<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>price<span style="letter-spacing:-0.15pt;"> </span>reporting<span style="letter-spacing:-0.3pt;"> </span>requirements,<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>federal<span style="letter-spacing:-0.2pt;"> </span>Physician<span style="letter-spacing:-0.4pt;"> </span>Payment Sunshine<span style="letter-spacing:-0.3pt;"> </span>Act,<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Veter<span style="letter-spacing:-0.05pt;">a</span>ns<span style="letter-spacing:-0.25pt;"> </span>Health<span style="letter-spacing:-0.3pt;"> </span>Care<span style="letter-spacing:-0.1pt;"> </span>Act<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>1992,<span style="letter-spacing:-0.05pt;"> </span>HIP<span style="letter-spacing:0.05pt;">A</span>A (as<span style="letter-spacing:0.05pt;"> </span>amended<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">b</span>y<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Health<span style="letter-spacing:-0.3pt;"> </span>Inf<span style="letter-spacing:0.05pt;">o</span>rmation<span style="letter-spacing:-0.3pt;"> </span>Technology<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>Economics<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>C<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.3pt;"> </span>He<span style="letter-spacing:-0.05pt;">a</span>lth Act),<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FCPA, the<span style="letter-spacing:-0.1pt;"> </span>Patient<span style="letter-spacing:-0.2pt;"> </span>Pro<span style="letter-spacing:0.1pt;">t</span>ection<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>Affordable<span style="letter-spacing:-0.45pt;"> </span>Care<span style="letter-spacing:-0.1pt;"> </span>Act<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;">&#160;</span>2010 (as<span style="letter-spacing:-0.05pt;"> </span>amended<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Health<span style="letter-spacing:-0.3pt;"> </span>Care<span style="letter-spacing:-0.1pt;"> </span>and Education<span style="letter-spacing:-0.35pt;"> </span>Reconcilia<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.45pt;"> </span>Act)<span style="letter-spacing:-0.2pt;"> (</span>the &#8220;ACA&#8221;)<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>similar<span style="letter-spacing:-0.25pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>laws. Even<span style="letter-spacing:-0.25pt;"> </span>though<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>make<span style="letter-spacing:-0.15pt;"> </span>referrals<span style="letter-spacing:-0.3pt;"> </span>of healthcare<span style="letter-spacing:-0.35pt;"> </span>services<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>bill<span style="letter-spacing:-0.1pt;"> </span>directly<span style="letter-spacing:-0.3pt;"> </span>to M<span style="letter-spacing:0.05pt;">e</span>dicare,<span style="letter-spacing:-0.2pt;"> </span>Medicaid,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>third-party payors,<span style="letter-spacing:-0.05pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>fe<span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">e</span>ral<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>sta<span style="letter-spacing:0.05pt;">t</span>e<span style="letter-spacing:-0.15pt;"> </span>healthcare<span style="letter-spacing:-0.3pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>regulations<span style="letter-spacing:-0.3pt;"> </span>pertaining<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>fraud<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>abuse<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>patients&#8217;<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>w<span style="letter-spacing:-0.15pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>applicable<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>our b<span style="letter-spacing:0.05pt;">u</span>siness.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>comply<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>app<span style="letter-spacing:-0.05pt;">l</span>icable<span style="letter-spacing:-0.35pt;"> </span>fraud<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>abuse<span style="letter-spacing:-0.2pt;"> </span>laws,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>sub<span style="letter-spacing:-0.05pt;">j</span>ect<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>healthcare<span style="letter-spacing:-0.3pt;"> </span>fraud<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>abuse<span style="letter-spacing:-0.15pt;"> </span>enforc<span style="letter-spacing:0.05pt;">e</span>ment<span style="letter-spacing:-0.5pt;"> </span>by both<span style="letter-spacing:-0.15pt;"> </span>the federal<span style="letter-spacing:-0.25pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>states<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>conduct<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>re<span style="letter-spacing:0.05pt;">g</span>ulations<span style="letter-spacing:-0.3pt;"> </span>re<span style="letter-spacing:0.05pt;">q</span>uire<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.15pt;">a</span>lculation<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>reporting<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>compl<span style="letter-spacing:-0.1pt;">e</span>x<span style="letter-spacing:-0.2pt;"> </span>pricing<span style="letter-spacing:-0.25pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>presc<span style="letter-spacing:-0.05pt;">r</span>iption<span style="letter-spacing:-0.5pt;"> </span>drugs,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>compliance<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to invest<span style="letter-spacing:-0.15pt;"> </span>in sig<span style="letter-spacing:0.05pt;">n</span>ificant<span style="letter-spacing:-0.4pt;"> </span>resources<span style="letter-spacing:-0.3pt;"> to </span>develop<span style="letter-spacing:-0.35pt;"> </span>a price<span style="letter-spacing:-0.15pt;"> </span>reporting<span style="letter-spacing:-0.4pt;"> </span>infrastructure<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>depend<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>compute<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>report<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>drug <span style="letter-spacing:-0.05pt;">p</span>ricing.<span style="letter-spacing:-0.25pt;"> </span>Pricing<span style="letter-spacing:-0.2pt;"> </span>reported<span style="letter-spacing:-0.3pt;"> </span>to the Centers<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>Medicare<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>Med<span style="letter-spacing:0.05pt;">i</span>caid<span style="letter-spacing:-0.35pt;"> </span>Services<span style="letter-spacing:0.05pt;"> (&#8220;</span>CMS&#8221;) must<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>certified.<span style="letter-spacing:-0.25pt;"> </span>Non<span style="letter-spacing:-0.1pt;">-</span>compliant<span style="letter-spacing:-0.35pt;"> </span>activiti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>expose<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>FCA<span style="letter-spacing:-0.05pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>if t<span style="letter-spacing:-0.05pt;">he</span>y<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">re</span><span style="letter-spacing:0.05pt;">s</span>u<span style="letter-spacing:-0.05pt;">l</span>t<span style="letter-spacing:-0.05pt;"> </span>in o<span style="letter-spacing:0.05pt;">v</span>ercharging agencies,<span style="letter-spacing:-0.3pt;"> </span>underpaying<span style="letter-spacing:-0.45pt;"> </span>rebates<span style="letter-spacing:-0.25pt;"> </span>to age<span style="letter-spacing:-0.05pt;">n</span>cies,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>causing<span style="letter-spacing:-0.3pt;"> </span>agencies<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>overpay<span style="letter-spacing:-0.25pt;"> </span>providers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>found<span style="letter-spacing:0.05pt;"> </span>to be<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>violation<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>fed<span style="letter-spacing:-0.05pt;">e</span>ral<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>state<span style="letter-spacing:-0.15pt;"> </span>healthcare<span style="letter-spacing:-0.4pt;"> </span>law,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>gove<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">n</span>mental<span style="letter-spacing:-0.45pt;"> </span>regulations<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>apply<span style="letter-spacing:-0.25pt;"> </span>to us,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>penalties,<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.4pt;"> </span>civ<span style="letter-spacing:-0.05pt;">i</span>l,<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">r</span>im<span style="letter-spacing:-0.05pt;">i</span>nal,<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd <span style="letter-spacing:-0.05pt;">a</span>dministrative<span style="letter-spacing:-0.45pt;"> </span>pen<span style="letter-spacing:0.05pt;">a</span>lties,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">a</span>mag<span style="letter-spacing:0.05pt;">e</span>s,<span style="letter-spacing:-0.25pt;"> </span>fin<span style="letter-spacing:0.05pt;">e</span>s,<span style="letter-spacing:-0.15pt;"> </span>d<span style="letter-spacing:0.05pt;">i</span>sgorgement,<span style="letter-spacing:-0.55pt;"> </span>debarment<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>contracts, refusal<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>orders<span style="letter-spacing:0.05pt;"> </span>under<span style="letter-spacing:-0.2pt;"> </span>existing<span style="letter-spacing:-0.3pt;"> </span>contracts,<span style="letter-spacing:-0.4pt;"> </span>exclusion<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>participation<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>U.S.&#160;federal<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>state<span style="letter-spacing:-0.15pt;"> </span>hea<span style="letter-spacing:0.05pt;">l</span>th<span style="letter-spacing:-0.15pt;"> </span>care<span style="letter-spacing:-0.2pt;"> </span>programs,<span style="letter-spacing:-0.3pt;"> </span>corpor<span style="letter-spacing:0.05pt;">a</span>te<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>ntegr<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>agre<span style="letter-spacing:-0.05pt;">e</span>m<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd the<span style="letter-spacing:-0.05pt;"> </span>curtailment<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>restructuring<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>op<span style="letter-spacing:0.05pt;">e</span>rations,<span style="letter-spacing:-0.45pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>materially<span style="letter-spacing:-0.35pt;"> </span>adv<span style="letter-spacing:-0.05pt;">e</span>rsely<span style="letter-spacing:-0.4pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to operate<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>financial results.<span style="letter-spacing:-0.3pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>physicians<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">v</span>iders<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>entities<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>whom<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>expect<span style="letter-spacing:-0.2pt;"> </span>to do<span style="letter-spacing:-0.05pt;"> </span>bu<span style="letter-spacing:-0.05pt;">s</span>iness,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>collaborators,<span style="letter-spacing:-0.5pt;"> </span>is found<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>to be<span style="letter-spacing:0.65pt;"> </span>in<span style="letter-spacing:0.55pt;"> </span>compliance<span style="letter-spacing:1.65pt;"> </span>with<span style="letter-spacing:1.2pt;"> </span>applicable<span style="letter-spacing:2pt;"> </span>laws,<span style="letter-spacing:0.65pt;"> </span>they<span style="letter-spacing:1.15pt;"> </span>may<span style="letter-spacing:0.85pt;"> </span>be<span style="letter-spacing:0.55pt;"> </span>subject<span style="letter-spacing:1.4pt;"> </span>to<span style="letter-spacing:0.4pt;"> </span>criminal,<span style="letter-spacing:1.75pt;"> </span>civil,<span style="letter-spacing:0.95pt;"> </span>or<span style="letter-spacing:0.5pt;"> </span>administrative<span style="letter-spacing:0.4pt;"> </span>sanctions,<span style="letter-spacing:2pt;"> </span>including<span style="letter-spacing:1.55pt;"> </span>but<span style="letter-spacing:1pt;"> </span>not<span style="letter-spacing:0.8pt;"> </span>limited<span style="letter-spacing:1.2pt;"> </span>to,<span style="letter-spacing:0.6pt;"> </span>exclusions<span style="letter-spacing:1.9pt;"> </span>from participation in<span style="letter-spacing:0.6pt;"> </span>government<span style="letter-spacing:2.05pt;"> </span>healt<span style="letter-spacing:0.35pt;">h</span>care<span style="letter-spacing:1.8pt;"> </span>programs,<span style="letter-spacing:1.55pt;"> </span>which<span style="letter-spacing:1.25pt;"> </span>could<span style="letter-spacing:1.1pt;"> </span>also<span style="letter-spacing:0.5pt;"> </span>materially<span style="letter-spacing:0.05pt;"> </span>affect<span style="letter-spacing:1.05pt;"> </span>our<span style="letter-spacing:0.95pt;"> </span>business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:0.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">particular,</span><span style="letter-spacing:1.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:0.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">found</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impermissibly</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">promoted</span><span style="letter-spacing:1.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:0.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:1.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates,</span><span style="letter-spacing:1.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:0.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">become</span><span style="letter-spacing:1.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:1.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">liability</span><span style="letter-spacing:1.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government fines.</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We,</span><span style="letter-spacing:0.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:0.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborators,</span><span style="letter-spacing:2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">must</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comply</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements</span><span style="letter-spacing:0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">concerning</span><span style="letter-spacing:1.85pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advertising</span><span style="letter-spacing:1.9pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">promotion</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">they</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pro</span><span style="letter-spacing:0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">otional</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">communications</span><span style="letter-spacing:-0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respe</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">her</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">peut</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cs are</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to a variety</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">legal</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restrictions</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continuing</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">review</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Department</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Justice,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Department</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Health</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human Services&#8217;</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inspector</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">state</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">attorneys</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">general,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">members</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Congress,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">public.</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comparable</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">foreign</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory authorities</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issue</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulato</span><span style="letter-spacing:0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limited</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hose</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">specific</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uses</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dications</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product is approved.</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">able</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">desired</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uses</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">indications</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">produ</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arket</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">promote</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our prod</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ct</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">those</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">indic</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tions</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uses,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refe</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">red</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to as off-label</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uses,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">busin</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ss</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adversely</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affected.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While<span style="letter-spacing:-0.25pt;"> </span>physicians<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:0.05pt;">h</span>oose<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>prescribe<span style="letter-spacing:-0.4pt;"> </span>produ<span style="letter-spacing:0.1pt;">c</span>ts<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>uses<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>described<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>product&#8217;s<span style="letter-spacing:-0.35pt;"> </span>labeling<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>uses<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">d</span>iffer<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>those<span style="letter-spacing:-0.15pt;"> </span>tested<span style="letter-spacing:-0.15pt;"> </span>in clinical trials<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>regula<span style="letter-spacing:-0.05pt;">t</span>ory<span style="letter-spacing:-0.2pt;"> </span>authorities,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>prohibited<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>rketing<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>promoting<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>indications<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>uses<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>are n<span style="letter-spacing:0.05pt;">o</span>t specifically<span style="letter-spacing:-0.4pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA.<span style="letter-spacing:-0.05pt;"> </span>These<span style="letter-spacing:-0.2pt;"> </span>off-label<span style="letter-spacing:-0.3pt;"> </span>uses<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>across<span style="letter-spacing:-0.05pt;"> </span>medical<span style="letter-spacing:-0.35pt;"> </span>specialties<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>onstitute<span style="letter-spacing:-0.35pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>appropriate<span style="letter-spacing:-0.4pt;"> </span>tr<span style="letter-spacing:0.05pt;">ea</span><span style="letter-spacing:-0.05pt;">t</span>m<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:0.05pt;">o</span>me pat<span style="letter-spacing:-0.05pt;">i</span>ents<span style="letter-spacing:-0.35pt;"> </span>in v<span style="letter-spacing:-0.05pt;">a</span>ri<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:-0.05pt;">i</span>rcu<span style="letter-spacing:-0.05pt;">m</span>s<span style="letter-spacing:-0.05pt;">t</span>anc<span style="letter-spacing:-0.1pt;">e</span>s.<span style="letter-spacing:-0.4pt;"> </span>Regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span>States<span style="letter-spacing:-0.15pt;"> </span>generally<span style="letter-spacing:-0.45pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>restrict<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>regulate<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>behavi<span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>physicians<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>their choice<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>treatment<span style="letter-spacing:-0.3pt;"> </span>within<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>practice<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>medicine.<span style="letter-spacing:-0.3pt;"> </span>Regulatory<span style="letter-spacing:-0.35pt;"> </span>au<span style="letter-spacing:-0.05pt;">t</span>horities<span style="letter-spacing:-0.45pt;"> </span>do,<span style="letter-spacing:-0.05pt;"> </span>however,<span style="letter-spacing:-0.3pt;"> </span>restrict<span style="letter-spacing:-0.2pt;"> </span>communications<span style="letter-spacing:-0.6pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>biopharmace<span style="letter-spacing:-0.05pt;">u</span>t<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.05pt;">co</span>mp<span style="letter-spacing:0.05pt;">a</span>n<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">e</span>s concerning<span style="letter-spacing:-0.4pt;"> </span>off-label<span style="letter-spacing:-0.3pt;"> </span>use. We further must be able to sufficiently substantiate any claims that we make for our product candidates including claims comparing our product candidates to other companies&#8217; products and must abide by the FDA&#8217;s strict requirements regarding the content of promotion and advertising. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.2pt;"> </span>FDA and<span style="letter-spacing:-0.1pt;"> </span>ot<span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>agencies<span style="letter-spacing:-0.35pt;"> </span>actively<span style="letter-spacing:-0.25pt;"> </span>enforce<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulations<span style="letter-spacing:-0.45pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>garding<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>promotion,<span style="letter-spacing:-0.4pt;"> </span>p<span style="letter-spacing:0.05pt;">a</span>rticularly<span style="letter-spacing:-0.4pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>prohibiting<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>promotion<span style="letter-spacing:-0.35pt;"> </span>of off-label<span style="letter-spacing:-0.35pt;"> </span>uses,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>a company<span style="letter-spacing:-0.4pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>at<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>found<span style="letter-spacing:0.05pt;"> </span>to ha<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:-0.15pt;"> </span>imprope<span style="letter-spacing:-0.05pt;">r</span>ly<span style="letter-spacing:-0.3pt;"> </span>promoted<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>produ<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>s<span style="letter-spacing:-0.05pt;">i</span>gnificant<span style="letter-spacing:-0.4pt;"> </span>sanctions.<span style="letter-spacing:-0.4pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>fe<span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">e</span>ral<span style="letter-spacing:-0.2pt;"> </span>government<span style="letter-spacing:-0.4pt;"> </span>has lev<span style="letter-spacing:-0.05pt;">i</span>ed<span style="letter-spacing:-0.2pt;"> </span>large<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ivil<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd cr<span style="letter-spacing:-0.05pt;">i</span>min<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.3pt;"> </span>fines<span style="letter-spacing:-0.2pt;"> </span>aga<span style="letter-spacing:-0.05pt;">i</span>nst<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ompan<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>for a<span style="letter-spacing:-0.05pt;">l</span>leged<span style="letter-spacing:-0.2pt;"> </span>improper<span style="letter-spacing:-0.35pt;"> </span>promotion<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>has<span style="letter-spacing:-0.1pt;"> </span>en<span style="letter-spacing:-0.05pt;">j</span>oined<span style="letter-spacing:-0.25pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>ver<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>comp<span style="letter-spacing:-0.05pt;">a</span>nies<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>engaging<span style="letter-spacing:-0.3pt;"> </span>in off-label promotio<span style="letter-spacing:0.05pt;">n</span>.<span style="letter-spacing:-0.4pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>has<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>requested<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>companies<span style="letter-spacing:-0.35pt;"> </span>enter<span style="letter-spacing:-0.25pt;"> </span>into<span style="letter-spacing:-0.2pt;"> </span>consent<span style="letter-spacing:-0.2pt;"> </span>decrees<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>permanent<span style="letter-spacing:-0.35pt;"> </span>injunctions<span style="letter-spacing:-0.35pt;"> </span>under<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>specified<span style="letter-spacing:-0.3pt;"> </span>promotional<span style="letter-spacing:-0.4pt;"> </span>conduct is changed<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>curtailed.<span style="letter-spacing:-0.35pt;"> </span>Thus,<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>collaborators<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>promote<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>indicat<span style="letter-spacing:0.05pt;">i</span>ons<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>uses<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>they<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>approved.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States,<span style="letter-spacing:-0.2pt;"> </span>engaging<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>imp<span style="letter-spacing:0.1pt;">e</span>rmissible<span style="letter-spacing:-0.5pt;"> </span>promotion<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>products,<span style="letter-spacing:-0.4pt;"> </span>follow<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.3pt;"> </span>approval,<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>off-label<span style="letter-spacing:-0.25pt;"> </span>uses<span style="letter-spacing:-0.05pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.15pt;"> </span>subje<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>us to<span style="letter-spacing:-0.05pt;"> </span>false<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ai<span style="letter-spacing:-0.05pt;">m</span>s and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>litigation<span style="letter-spacing:-0.3pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">e</span>deral<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>statutes,<span style="letter-spacing:-0.25pt;"> </span>inc<span style="letter-spacing:0.05pt;">l</span>uding<span style="letter-spacing:-0.3pt;"> </span>fraud<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>abuse<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>consumer<span style="letter-spacing:-0.3pt;"> </span>protection<span style="letter-spacing:-0.3pt;"> </span>laws,<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.1pt;"> </span>lead to civil and criminal penalties and<span style="letter-spacing:-0.15pt;"> </span>fines,<span style="letter-spacing:-0.15pt;"> </span>agreements<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>governmental<span style="letter-spacing:-0.45pt;"> </span>authori<span style="letter-spacing:-0.1pt;">t</span>ies<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>materially<span style="letter-spacing:-0.35pt;"> </span>restrict<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>manner<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>whi<span style="letter-spacing:0.1pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>promote<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>distr<span style="letter-spacing:-0.05pt;">i</span>bute<span style="letter-spacing:-0.3pt;"> </span>therapeutic<span style="letter-spacing:-0.35pt;"> </span>products and<span style="letter-spacing:-0.1pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>through,<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>example,<span style="letter-spacing:-0.35pt;"> </span>corporate<span style="letter-spacing:-0.35pt;"> </span>integrity<span style="letter-spacing:-0.25pt;"> </span>agreements,<span style="letter-spacing:-0.45pt;"> </span>sus<span style="letter-spacing:0.05pt;">p</span>ension<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>exclusion<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>rom participation<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>fede<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:-0.05pt;">t</span>ate<span style="letter-spacing:-0.15pt;"> </span>h<span style="letter-spacing:-0.05pt;">e</span>a<span style="letter-spacing:-0.05pt;">l</span>thc<span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.4pt;"> </span>programs,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>debarment<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>gove<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.1pt;">n</span>ment<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>ntracts<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>refusal<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>orders<span style="letter-spacing:-0.05pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span>contracts.<span style="letter-spacing:-0.4pt;"> </span>These<span style="letter-spacing:-0.15pt;"> </span>false<span style="letter-spacing:-0.2pt;"> </span>claims<span style="letter-spacing:-0.3pt;"> </span>st<span style="letter-spacing:0.1pt;">a</span>tut<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:0.05pt;">c</span>lude<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">F</span>CA,<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>allows<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>individual<span style="letter-spacing:-0.3pt;"> </span>to bring<span style="letter-spacing:-0.15pt;"> </span>a l<span style="letter-spacing:-0.1pt;">a</span>wsuit<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>biopharmaceut<span style="letter-spacing:0.05pt;">i</span>cal<span style="letter-spacing:-0.65pt;"> </span>company<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>behalf<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>fe<span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">e</span>ral<span style="letter-spacing:-0.2pt;"> </span>government<span style="letter-spacing:-0.4pt;"> </span>alleging<span style="letter-spacing:-0.25pt;"> </span>submission<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>false<span style="letter-spacing:-0.15pt;"> </span>or fraudulent claims<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>causing<span style="letter-spacing:-0.2pt;"> </span>others<span style="letter-spacing:-0.15pt;"> </span>to pre<span style="letter-spacing:-0.05pt;">s</span>ent<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>false<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>fraudulent<span style="letter-spacing:-0.4pt;"> </span>claims,<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:0.05pt;">a</span>yment<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>a federal<span style="letter-spacing:-0.2pt;"> </span>program<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>Medic<span style="letter-spacing:0.05pt;">a</span>re<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>Medicaid.<span style="letter-spacing:-0.3pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>g<span style="letter-spacing:0.05pt;">o</span>vernment<span style="letter-spacing:0.05pt;"> </span>decides<span style="letter-spacing:-0.2pt;"> </span>to intervene<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd pr<span style="letter-spacing:-0.05pt;">e</span>va<span style="letter-spacing:-0.05pt;">i</span>ls<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:-0.05pt;">a</span>wsu<span style="letter-spacing:-0.05pt;">i</span>t,<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>individual<span style="letter-spacing:-0.3pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>share<span style="letter-spacing:-0.25pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>proceeds<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>fines<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>settl<span style="letter-spacing:-0.1pt;">e</span>me<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.35pt;"> </span>funds. If the<span style="letter-spacing:-0.15pt;"> </span>g<span style="letter-spacing:0.05pt;">o</span>vernment<span style="letter-spacing:-0.3pt;"> </span>declines<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>inte<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">v</span>ene,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>individ<span style="letter-spacing:0.05pt;">u</span>al<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>pursue<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>case<span style="letter-spacing:-0.1pt;"> </span>alone.<span style="letter-spacing:-0.15pt;"> </span>The<span style="letter-spacing:-0.15pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>FCA lawsuits<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ga<span style="letter-spacing:-0.05pt;">i</span>nst<span style="letter-spacing:-0.2pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>nufacture<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>drugs<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd biologics<span style="letter-spacing:-0.4pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>increased<span style="letter-spacing:-0.35pt;"> </span>significantly<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>volume<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>breadt<span style="letter-spacing:-0.05pt;">h</span>,<span style="letter-spacing:-0.25pt;"> </span>l<span style="letter-spacing:-0.05pt;">e</span>ading<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>ver<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>substan<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ivil<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>nd criminal<span style="letter-spacing:-0.3pt;"> </span>settlements,<span style="letter-spacing:-0.4pt;"> </span>up<span style="letter-spacing:-0.05pt;"> </span>to $3.0&#160;billi<span style="letter-spacing:-0.05pt;">o</span>n,<span style="letter-spacing:-0.2pt;"> </span>pertaining<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">e</span>rta<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>s<span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.1pt;"> </span>practices<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>promoting<span style="letter-spacing:0.05pt;"> </span>off<span style="letter-spacing:-0.05pt;">-</span>label<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">u</span>ses.<span style="letter-spacing:0.05pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>FCA<span style="letter-spacing:-0.05pt;"> </span>lawsuits<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>e<span style="letter-spacing:0.05pt;">x</span>pose<span style="letter-spacing:-0.1pt;"> </span>manufacturers<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>fol<span style="letter-spacing:0.1pt;">l</span>ow-on<span style="letter-spacing:-0.1pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>private<span style="letter-spacing:-0.25pt;"> </span>payo<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.15pt;"> </span>based<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>fraudulent<span style="letter-spacing:-0.4pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>practices.<span style="letter-spacing:-0.35pt;"> </span>This growth in litigation<span style="letter-spacing:-0.25pt;"> </span>has<span style="letter-spacing:-0.05pt;"> </span>increased<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>risk<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>a biopharmaceutical<span style="letter-spacing:-0.65pt;"> </span>company<span style="letter-spacing:-0.3pt;"> </span>will have<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>defend<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>f<span style="letter-spacing:0.05pt;">a</span>lse<span style="letter-spacing:-0.1pt;"> </span>claim<span style="letter-spacing:-0.2pt;"> </span>action,<span style="letter-spacing:-0.2pt;"> </span>pay<span style="letter-spacing:-0.15pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>tt<span style="letter-spacing:-0.05pt;">l</span>em<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.25pt;"> </span>fines<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;">t</span>itu<span style="letter-spacing:-0.05pt;">t</span>ion,<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>w<span style="letter-spacing:-0.05pt;">e</span>ll<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>rim<span style="letter-spacing:-0.05pt;">i</span>nal<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:-0.05pt;">i</span>vil<span style="letter-spacing:-0.25pt;"> </span>pen<span style="letter-spacing:-0.05pt;">a</span>lt<span style="letter-spacing:-0.05pt;">i</span>es,<span style="letter-spacing:-0.25pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>e<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">c</span>omply<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>burdensome<span style="letter-spacing:-0.5pt;"> </span>reporting<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>compliance<span style="letter-spacing:-0.4pt;"> </span>obligations,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>exc<span style="letter-spacing:-0.05pt;">l</span>uded<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>M<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">a</span>re,<span style="letter-spacing:-0.3pt;"> </span>M<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.05pt;">i</span>ca<span style="letter-spacing:-0.05pt;">i</span>d,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>ot<span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>federal<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>hea<span style="letter-spacing:-0.05pt;">l</span>thcare<span style="letter-spacing:-0.3pt;"> </span>programs.<span style="letter-spacing:-0.4pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our future<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>oll<span style="letter-spacing:-0.05pt;">a</span>bora<span style="letter-spacing:-0.1pt;">t</span>ors<span style="letter-spacing:-0.35pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>law<span style="letter-spacing:-0.05pt;">f</span>ully<span style="letter-spacing:-0.35pt;"> </span>promote<span style="letter-spacing:-0.25pt;"> </span>our approved<span style="letter-spacing:-0.4pt;"> </span>products,<span style="letter-spacing:-0.3pt;"> </span>if any,<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>become<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">s</span>ubject<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>litigation<span style="letter-spacing:-0.25pt;"> </span>and,<span style="letter-spacing:-0.15pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>successfully<span style="letter-spacing:-0.5pt;"> </span>defend<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>actions,<span style="letter-spacing:-0.25pt;"> </span>those<span style="letter-spacing:-0.15pt;"> </span>actions<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>material<span style="letter-spacing:-0.3pt;"> </span>adve<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>bu<span style="letter-spacing:-0.05pt;">s</span>iness,<span style="letter-spacing:-0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition,<span style="letter-spacing:-0.3pt;"> </span>resul<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>perations<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>effective<span style="letter-spacing:-0.25pt;"> </span>compliance<span style="letter-spacing:-0.35pt;"> </span>program<span style="letter-spacing:-0.35pt;"> </span>can<span style="letter-spacing:-0.1pt;"> </span>mitigate<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>risk<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>investigation<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>pro<span style="letter-spacing:0.05pt;">s</span>ecution<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>violations<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>laws,<span style="letter-spacing:-0.05pt;"> t</span>he<span style="letter-spacing:-0.15pt;"> </span>risks cannot<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>entirely eliminated.<span style="letter-spacing:-0.35pt;"> </span>Moreo<span style="letter-spacing:0.05pt;">v</span>er,<span style="letter-spacing:-0.15pt;"> </span>achieving<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>sustaining<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ompl<span style="letter-spacing:-0.05pt;">i</span>an<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.35pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th <span style="letter-spacing:-0.05pt;">a</span>ppli<span style="letter-spacing:-0.05pt;">c</span>ab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.35pt;"> </span>feder<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd<span style="letter-spacing:-0.1pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>fraud<span style="letter-spacing:-0.15pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>prove<span style="letter-spacing:-0.25pt;"> </span>costly. Any action<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">u</span>s<span style="letter-spacing:-0.05pt;"> </span>for violation<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>laws,<span style="letter-spacing:-0.05pt;"> </span>even<span style="letter-spacing:-0.1pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>succ<span style="letter-spacing:-0.1pt;">e</span>ssfully<span style="letter-spacing:-0.5pt;"> </span>defend<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.3pt;"> </span>it,<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to incur<span style="letter-spacing:-0.15pt;"> </span>significant<span style="letter-spacing:-0.4pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>expenses<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>div<span style="letter-spacing:0.05pt;">e</span>rt<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ma<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">a</span>gement&#8217;s<span style="letter-spacing:-0.55pt;"> </span>attention<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>oper<span style="letter-spacing:0.05pt;">a</span>tion<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Coverage</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">reimbursement may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">limited</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">unavai</span><span style="letter-spacing:-0.1pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">able</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in certain</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">market</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">segments</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ma</span><span style="letter-spacing:0.05pt;">k</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">it difficult</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">for us to sell</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our product</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">pro</span><span style="letter-spacing:-0.05pt;">f</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">itably.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In both domestic and foreign markets, sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. Regulatory authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability or that of our collaborators to sell our product candidates profitably. In addition, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Patients are unlikely to use our product candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Such third-party payors include government health programs such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. Obtaining coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenues from our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities and third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers, or those of our collaborators, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. If reimbursement is not available, or is available only to limited levels, our product candidates may be competitively disadvantaged, and we, or our collaborators, may not be able to successfully commercialize our product candidates. Alternatively, securing favorable reimbursement terms may require us to compromise pricing and prevent us from realizing an adequate margin over cost. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a covered benefit under its health plan&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">safe, effective and medically necessary&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">appropriate for the specific patient&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">cost-effective&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">neither experimental nor investigational.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Moreover, the factors noted above have continued to be the focus of policy and regulatory debate that has, thus far, shown the potential for movement towards permanent policy changes&#59; this trend is likely to continue, and may result in more or less favorable impacts on pricing. The recent and ongoing series of congressional hearings relating to drug pricing has presented heightened attention to the biopharmaceutical industry, creating the potential for political and public pressure, while the potential for resulting legislative or policy changes presents uncertainty.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prices paid for a drug also vary depending on the class of trade. Prices charged to government customers are subject to price controls, including ceilings, and private institutions obtain discounts through group purchasing organizations. Net prices for drugs may be further reduced by mandatory discounts or rebates required by government healthcare programs and demanded by private payors. It is also not uncommon for market conditions to warrant multiple discounts to different customers on the same unit, such as purchase discounts to institutional care providers and rebates to the health plans that pay them, which reduces the net realization on the original sale.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, federal programs impose penalties on manufacturers of drugs marketed under a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> BLA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NDA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, in the form of mandatory additional rebates and/or discounts if commercial prices increase at a rate greater than the Consumer Price Index-Urban, and these rebates and/or discounts, which can be substantial, may impact our ability to raise commercial prices. Cost control initiatives could cause us, or our collaborators, to decrease, discount, or rebate a portion of the price we, or they, might establish for products, which could result in lower than anticipated product revenues. If the realized prices for our product candidates, if any, decrease or if governmental and other third-party payors do not provide adequate coverage or reimbursement, our prospects for revenues and profitability will suffer.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain coverage for a given product, the resulting approved reimbursement payment rates might not be high enough to allow us to establish or maintain a market share sufficient to realize a sufficient return on our or their investments or achieve or sustain profitability or may require co-payments that patients find unacceptably high. If payors subject our product candidates to maximum payment amounts or impose limitations that make it difficult to obtain reimbursement, providers may choose to use therapies which are less expensive when compared to our product candidates. Additionally, if payors require high copayments, beneficiaries may decline prescriptions and seek alternative therapies. We may need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any future products to the satisfaction of hospitals and other target customers and their third-party payors. Such studies might require us to commit a significant amount of management time and financial and other resources. Our future products might not ultimately be considered cost-effective. Adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, and our collaborators, cannot be sure that coverage will be available for any product candidate that we, or they, commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products, and our overall financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been, and likely will continue to be, legislative and regulatory proposals at the federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the demand for our product candidates, if we obtain regulatory approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to set a price that we believe is fair for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to generate revenues and achieve or maintain profitability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the level of taxes that we are required to pay&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the availability of capital.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. A particular challenge for our product candidates arises from the fact that they will primarily be used in an inpatient setting. Inpatient reimbursement generally relies on stringent packaging rules that may mean that there is no separate payment for our product candidates. Additionally, data used to set the payment rates for inpatient admissions is usually several years old and would not take into account all of the additional therapy costs associated with the administration of our product candidates. If special rules are not created for reimbursement for immunotherapy treatments such as our product candidates, hospitals might not receive enough reimbursement to cover their costs of treatment, which will have a negative effect on their adoption of our product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may face difficulties from changes to current regulations and future legislation.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability, or the ability of our collaborators, to profitably sell any products for which we obtain marketing approval. We expect that current laws, as well as other federal and state healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria, increased regulatory burdens and operating costs, decreased revenues from our biopharmaceutical product candidates, decreased potential returns from our development efforts, and additional downward pressure on the price that we, or our collaborators, may receive for any approved products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since enactment of the ACA in 2010, in both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our product candidates profitably. These changes included aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, effective April&#160;1,&#160;2013, which, due to subsequent legislative amendments, will stay in effect through 2030, with the exception of a temporary suspension implemented under various COVID&#8209;19 relief legislation from May&#160;1,&#160;2020 through the end of 2021, unless additional Congressional action is taken. In January&#160;2013, the American Taxpayer Relief Act of 2012 (&#8220;ATRA&#8221;) was approved which, among other things, reduced Medicare payments to several providers, with primary focus on the hospital outpatient setting and ancillary services, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our product candidates, if approved, and accordingly, our financial operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, various portions of the ACA have been subject to judicial and constitutional challenges. Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts to repeal or replace certain aspects of the ACA. It is unclear how judicial decisions, future litigation, and healthcare measures promulgated by the Biden administration will impact the ACA and our business, financial condition and results of operations. Complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenues, attain profitability or commercialize our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legislative<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>proposals<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>made<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>expand<span style="letter-spacing:-0.3pt;"> </span>post-approval<span style="letter-spacing:-0.55pt;"> </span>requirements<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>restrict<span style="letter-spacing:-0.3pt;"> </span>s<span style="letter-spacing:0.05pt;">a</span>les<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>promotional<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ctivities<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>drugs.<span style="letter-spacing:0.05pt;"> </span>We cannot<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>sure<span style="letter-spacing:-0.05pt;"> </span>whether<span style="letter-spacing:-0.25pt;"> </span>add<span style="letter-spacing:-0.05pt;">i</span>tional<span style="letter-spacing:-0.35pt;"> </span>legislati<span style="letter-spacing:-0.05pt;">v</span>e<span style="letter-spacing:-0.4pt;"> </span>changes<span style="letter-spacing:-0.25pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>enacted,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>whether<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>regulations,<span style="letter-spacing:-0.35pt;"> </span>guid<span style="letter-spacing:0.05pt;">a</span>nce,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>interpretations<span style="letter-spacing:-0.55pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>changed,<span style="letter-spacing:-0.3pt;"> </span>or what<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>impact<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>c<span style="letter-spacing:0.05pt;">h</span>anges<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.1pt;">a</span>rketing<span style="letter-spacing:-0.35pt;"> </span>approvals<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>produ<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>any,<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">e</span>.<span style="letter-spacing:-0.1pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>increased<span style="letter-spacing:-0.35pt;"> </span>s<span style="letter-spacing:0.05pt;">c</span>rutiny<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>Congress<span style="letter-spacing:-0.05pt;"> </span>of the<span style="letter-spacing:-0.05pt;"> </span>FDA&#8217;s<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>process<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>si<span style="letter-spacing:0.05pt;">g</span>nificantly<span style="letter-spacing:-0.4pt;"> </span>delay<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>prevent<span style="letter-spacing:-0.2pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>approval,<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>w<span style="letter-spacing:-0.05pt;">e</span>ll as<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>stringent<span style="letter-spacing:-0.25pt;"> </span>prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>labeling<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>post-marketing<span style="letter-spacing:-0.35pt;"> </span>testing<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>requirements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>ha<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:-0.15pt;"> </span>been<span style="letter-spacing:-0.2pt;"> increasing legislative efforts and enforcement interest in the United States with respect to drug pricing practices, including Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, in 2020, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives, some of which resulted in lawsuits against the U.S&#160;Department of Health and Human Services challenging various aspects of the rules. In January&#160;2021, the Biden administration issued a &#8220;regulatory freeze&#8221; memorandum that directs department and agency heads to review new or pending rules of the prior administration. The impact of these lawsuits as well as legislative, executive, and administrative actions of the Biden administration on us and the pharmaceutical industry as a whole remains unclear. </span>At<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>sta<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.1pt;"> </span>level,<span style="letter-spacing:-0.25pt;"> </span>legislatures<span style="letter-spacing:-0.35pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>increasingly<span style="letter-spacing:-0.4pt;"> </span>passed<span style="letter-spacing:-0.05pt;"> </span>legislation<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>implemented<span style="letter-spacing:-0.45pt;"> </span>regulations<span style="letter-spacing:-0.45pt;"> </span>designed<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>control p<span style="letter-spacing:0.05pt;">h</span>armaceutical<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>biological<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>pricing,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>price<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>patient<span style="letter-spacing:-0.2pt;"> </span>reimbursem<span style="letter-spacing:0.1pt;">e</span>nt<span style="letter-spacing:-0.6pt;"> </span>constraints,<span style="letter-spacing:-0.35pt;"> </span>dis<span style="letter-spacing:0.05pt;">c</span>ounts,<span style="letter-spacing:-0.3pt;"> </span>restrictions<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>access<span style="letter-spacing:-0.2pt;"> </span>and marketing<span style="letter-spacing:-0.4pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>discl<span style="letter-spacing:0.05pt;">o</span>sure<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>transparency<span style="letter-spacing:-0.4pt;"> </span>measures,<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:0.05pt;">d</span>,<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span>cases,<span style="letter-spacing:-0.25pt;"> </span>designed<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>encou<span style="letter-spacing:0.05pt;">r</span>age<span style="letter-spacing:-0.3pt;"> </span>importation<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>countries<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>bulk<span style="letter-spacing:-0.1pt;"> </span>purc<span style="letter-spacing:0.05pt;">h</span>asing<span style="font-weight:bold;font-style:italic;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>predict<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>course<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>federal<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>healthcare<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">e</span>g<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.05pt;">l</span>at<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Uni<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.25pt;"> </span>States<span style="letter-spacing:-0.25pt;"> </span>directed<span style="letter-spacing:-0.25pt;"> </span>at broaden<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>availability<span style="letter-spacing:-0.35pt;"> </span>of healthcare<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>containing<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>lowering<span style="letter-spacing:-0.35pt;"> </span>the cost of<span style="letter-spacing:0.05pt;"> </span>h<span style="letter-spacing:-0.05pt;">e</span>a<span style="letter-spacing:-0.05pt;">l</span>thc<span style="letter-spacing:-0.05pt;">a</span>re.<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">T</span>he<span style="letter-spacing:-0.05pt;"> </span>ACA and<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>further<span style="letter-spacing:-0.2pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>law<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>framewo<span style="letter-spacing:-0.1pt;">r</span>k<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>reduce<span style="letter-spacing:-0.2pt;"> </span>our revenues<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>increase<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a material<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.05pt;">d</span>verse<span style="letter-spacing:-0.3pt;"> </span>effect<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>con<span style="letter-spacing:0.05pt;">d</span>ition<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>f<span style="letter-spacing:0.05pt;"> </span>operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Go</span><span style="letter-spacing:-0.05pt;">v</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ts</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:-0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">tside</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Un</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ted</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">S</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ates</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">tend</span><span style="letter-spacing:-0.05pt;"> t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o </span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">mpose</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ct</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">pri</span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">co</span><span style="letter-spacing:0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">trols,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">whi</span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">h</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ad</span><span style="letter-spacing:0.05pt;">v</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:0.05pt;">r</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ly</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">aff</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ct</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our r</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">v</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">an</span><span style="letter-spacing:0.05pt;">y</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>international<span style="letter-spacing:-0.4pt;"> </span>markets,<span style="letter-spacing:-0.35pt;"> </span>reimbu<span style="letter-spacing:-0.05pt;">r</span>sement<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>health<span style="letter-spacing:-0.15pt;"> </span>care<span style="letter-spacing:-0.25pt;"> </span>pa<span style="letter-spacing:0.05pt;">y</span><span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.25pt;"> </span>systems<span style="letter-spacing:-0.35pt;"> </span>vary<span style="letter-spacing:-0.2pt;"> </span>significantly<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>country,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>many<span style="letter-spacing:-0.15pt;"> </span>countries<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>ns<span style="letter-spacing:-0.05pt;">t</span>itu<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span>price<span style="letter-spacing:-0.2pt;"> </span>ceilings <span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.05pt;"> </span>specific<span style="letter-spacing:-0.25pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>therapies.<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">I</span>n<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>countries,<span style="letter-spacing:-0.3pt;"> </span>p<span style="letter-spacing:0.05pt;">a</span>rticularly<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>countries<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>EU,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>pricing<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>prescript<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:-0.3pt;"> </span>pharmaceuticals<span style="letter-spacing:-0.6pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>governmental<span style="letter-spacing:-0.45pt;"> </span>contr<span style="letter-spacing:-0.05pt;">o</span>l.<span style="letter-spacing:-0.25pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>countries,<span style="letter-spacing:-0.3pt;"> </span>pricing<span style="letter-spacing:-0.25pt;"> </span>negotiations<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>governmental<span style="letter-spacing:-0.5pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>take<span style="letter-spacing:-0.15pt;"> </span>considerable<span style="letter-spacing:-0.4pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>aft<span style="letter-spacing:-0.15pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">e</span>ipt<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>rk<span style="letter-spacing:-0.05pt;">e</span>ting approval<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>product. To obtain coverage<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>reimbursement<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>pricing<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>in s<span style="letter-spacing:-0.05pt;">o</span>me<span style="letter-spacing:-0.05pt;"> </span>countries,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>to conduct<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t compares<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>cost-effectiveness<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>to other<span style="letter-spacing:-0.2pt;"> </span>avail<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.35pt;"> </span>therapies.<span style="letter-spacing:-0.35pt;"> </span>There<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>assurance<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>prod<span style="letter-spacing:-0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be considered<span style="letter-spacing:-0.35pt;"> </span>cost-effective<span style="letter-spacing:-0.5pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>payors,<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>adequate<span style="letter-spacing:-0.25pt;"> </span>level<span style="letter-spacing:-0.15pt;"> </span>of reimbursement<span style="letter-spacing:-0.5pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>ava<span style="letter-spacing:-0.05pt;">i</span>lable,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>third-<span style="letter-spacing:-0.05pt;">p</span>arty<span style="letter-spacing:-0.35pt;"> </span>payors&#8217;<span style="letter-spacing:0.05pt;"> </span>reimbursement p<span style="letter-spacing:0.05pt;">o</span>licies<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to sell<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndidates<span style="letter-spacing:-0.35pt;"> </span>pro<span style="letter-spacing:-0.05pt;">f</span>itably.<span style="letter-spacing:-0.25pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>imbu<span style="letter-spacing:0.05pt;">r</span>sement<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>cand<span style="letter-spacing:-0.1pt;">i</span>dates<span style="letter-spacing:-0.4pt;"> </span>is unavailable<span style="letter-spacing:-0.4pt;"> </span>or limited in scope or amount,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>pricing<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>set<span style="letter-spacing:-0.15pt;"> </span>at unsatis<span style="letter-spacing:-0.05pt;">f</span>actory<span style="letter-spacing:-0.45pt;"> </span>l<span style="letter-spacing:0.05pt;">e</span>vels,<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business <span style="letter-spacing:0.05pt;">c</span>ould<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>harmed,<span style="letter-spacing:-0.25pt;"> </span>possibly<span style="letter-spacing:-0.25pt;"> </span>materially.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>employees,<span style="letter-spacing:-0.4pt;"> </span>independent<span style="letter-spacing:-0.4pt;"> </span>contractors,<span style="letter-spacing:-0.2pt;"> </span>consultants,<span style="letter-spacing:-0.05pt;"> </span>commercial<span style="letter-spacing:-0.45pt;"> </span>partners, principal investigators, CROs, suppliers<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>vendors<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>engage<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>misconduct<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>improper<span style="letter-spacing:-0.3pt;"> </span>ac<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">v</span>it<span style="letter-spacing:-0.05pt;">i</span>es, in<span style="letter-spacing:-0.05pt;">c</span>luding<span style="letter-spacing:-0.1pt;"> </span>non<span style="letter-spacing:-0.05pt;">c</span>omp<span style="letter-spacing:-0.05pt;">l</span>ian<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>gu<span style="letter-spacing:-0.05pt;">la</span>tory<span style="letter-spacing:-0.3pt;"> </span>standards<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.1pt;">n</span>d<span style="letter-spacing:-0.05pt;"> </span>requirements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>exposed<span style="letter-spacing:-0.25pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>risk<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>employee<span style="letter-spacing:-0.35pt;"> </span>fraud<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>illegal<span style="letter-spacing:-0.15pt;"> </span>activity<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>employee<span style="letter-spacing:0.1pt;">s</span>,<span style="letter-spacing:-0.35pt;"> </span>independent<span style="letter-spacing:-0.45pt;"> </span>contractors,<span style="letter-spacing:-0.25pt;"> </span>consultants,<span style="letter-spacing:-0.45pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>partners, principal investigators, CROs, suppliers<span style="letter-spacing:-0.25pt;"> </span>and vendors.<span style="letter-spacing:-0.05pt;"> </span>Misconduct<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>inc<span style="letter-spacing:-0.05pt;">l</span>ude<span style="letter-spacing:-0.3pt;"> </span>intentional,<span style="letter-spacing:-0.4pt;"> </span>reckless<span style="letter-spacing:-0.25pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>negli<span style="letter-spacing:0.1pt;">g</span>ent<span style="letter-spacing:-0.35pt;"> </span>conduct<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>fails<span style="letter-spacing:-0.2pt;"> </span>to:<span style="letter-spacing:-0.1pt;"> </span>comply<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>laws of the<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">F</span>DA and other similar<span style="letter-spacing:-0.25pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>bodies,<span style="letter-spacing:-0.2pt;"> </span>provide<span style="letter-spacing:-0.3pt;"> </span>true,<span style="letter-spacing:-0.1pt;"> </span>complete<span style="letter-spacing:-0.3pt;"> </span>and accurate<span style="letter-spacing:-0.25pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>to the<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>similar<span style="letter-spacing:-0.25pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">r</span>egulatory<span style="letter-spacing:-0.3pt;"> </span>bodies,<span style="letter-spacing:-0.3pt;"> </span>comply with<span style="letter-spacing:-0.1pt;"> </span>manufacturing<span style="letter-spacing:-0.45pt;"> </span>standards<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>established,<span style="letter-spacing:-0.4pt;"> </span>comply<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>h<span style="letter-spacing:-0.05pt;">e</span>alt<span style="letter-spacing:0.05pt;">h</span>care<span style="letter-spacing:-0.3pt;"> </span>fraud<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>abuse<span style="letter-spacing:-0.2pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Un<span style="letter-spacing:-0.05pt;">i</span>t<span style="letter-spacing:-0.05pt;">e</span>d <span style="letter-spacing:-0.05pt;">S</span>ta<span style="letter-spacing:-0.05pt;">t</span>es<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd si<span style="letter-spacing:-0.05pt;">m</span>il<span style="letter-spacing:-0.05pt;">a</span>r<span style="letter-spacing:-0.2pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>f<span style="letter-spacing:-0.05pt;">r</span>audulent misconduct<span style="letter-spacing:-0.35pt;"> </span>laws,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>report<span style="letter-spacing:-0.15pt;"> </span>f<span style="letter-spacing:-0.1pt;">i</span>nancial<span style="letter-spacing:-0.25pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">f</span>ormation<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>accu<span style="letter-spacing:0.1pt;">r</span>ately<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>to disclose<span style="letter-spacing:-0.3pt;"> </span>unauthorized<span style="letter-spacing:-0.55pt;"> </span>activities<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us.<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">I</span>f<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>begin<span style="letter-spacing:-0.15pt;"> </span>comm<span style="letter-spacing:-0.05pt;">e</span>rcializing<span style="letter-spacing:-0.6pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States, our<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:-0.35pt;"> </span>exposure<span style="letter-spacing:-0.3pt;"> </span>under<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>aws will<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;">c</span>re<span style="letter-spacing:-0.05pt;">a</span>se sig<span style="letter-spacing:0.05pt;">n</span>ificantly,<span style="letter-spacing:-0.45pt;"> </span>and o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>associated<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>compliance<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>likely<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>increase.<span style="letter-spacing:-0.25pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>particular,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>promotion,<span style="letter-spacing:-0.4pt;"> </span>sales and<span style="letter-spacing:-0.1pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span>items<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>services,<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>well<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">r</span>rangements<span style="letter-spacing:-0.5pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span>industry,<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>subje<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">extensive laws designed to prevent </span>fraud,<span style="letter-spacing:-0.25pt;"> </span>kickb<span style="letter-spacing:0.05pt;">a</span>cks,<span style="letter-spacing:-0.3pt;"> </span>self-dealing<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>abusive<span style="letter-spacing:-0.1pt;"> </span>pra<span style="letter-spacing:-0.05pt;">c</span>ti<span style="letter-spacing:-0.05pt;">c</span>es.<span style="letter-spacing:-0.25pt;"> </span>Th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>ws<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>regulations<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>restrict<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>prohibit<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>wide<span style="letter-spacing:-0.15pt;"> </span>range<span style="letter-spacing:-0.15pt;"> </span>of pricing, discounting,<span style="letter-spacing:-0.45pt;"> </span>mar<span style="letter-spacing:0.05pt;">k</span>eting<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>promotion,<span style="letter-spacing:-0.4pt;"> </span>structuring<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>commission(s),<span style="letter-spacing:-0.5pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>customer<span style="letter-spacing:-0.25pt;"> </span>incentive<span style="letter-spacing:-0.35pt;"> </span>programs<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>bu<span style="letter-spacing:-0.1pt;">s</span>iness<span style="letter-spacing:0.05pt;"> </span>arrangements generally.<span style="letter-spacing:-0.3pt;"> </span>Activities<span style="letter-spacing:-0.35pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>to these<span style="letter-spacing:-0.25pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>involve<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>improper<span style="letter-spacing:-0.35pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>obta<span style="letter-spacing:0.05pt;">i</span>ned<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>course<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>rec<span style="letter-spacing:0.05pt;">r</span>uit<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>always<span style="letter-spacing:-0.3pt;"> </span>possible<span style="letter-spacing:-0.35pt;"> </span>to identify<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd deter<span style="letter-spacing:-0.2pt;"> </span>misconduct<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>imp<span style="letter-spacing:-0.05pt;">r</span>oper<span style="letter-spacing:-0.3pt;"> </span>activities<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>employ<span style="letter-spacing:-0.1pt;">e</span>es<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>engage<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business o<span style="letter-spacing:0.05pt;">p</span>erations and<span style="letter-spacing:-0.1pt;"> </span>the precautions<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>take<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>detect<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>prevent<span style="letter-spacing:-0.3pt;"> </span>inappropriate<span style="letter-spacing:-0.45pt;"> </span>conduct<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.1pt;">e</span>ffective<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>cont<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>lli<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.35pt;"> </span>unknown<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>unmanaged<span style="letter-spacing:-0.4pt;"> </span>risks or<span style="letter-spacing:0.05pt;"> </span>losses<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in protecting<span style="letter-spacing:-0.35pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>governmental<span style="letter-spacing:-0.5pt;"> </span>investigations<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>actions<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>lawsuits<span style="letter-spacing:-0.35pt;"> </span>stemming<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>a failure<span style="letter-spacing:-0.25pt;"> </span>to comply<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>or regulations.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>any such<span style="letter-spacing:0.05pt;"> </span>actions<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>instituted<span style="letter-spacing:-0.3pt;"> </span>against<span style="letter-spacing:-0.25pt;"> </span>us,<span style="letter-spacing:-0.05pt;"> a</span>nd we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>successful<span style="letter-spacing:-0.3pt;"> </span>in defending<span style="letter-spacing:-0.4pt;"> </span>oursel<span style="letter-spacing:-0.15pt;">v</span>es<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>asserting<span style="letter-spacing:-0.35pt;"> </span>our rights,<span style="letter-spacing:-0.3pt;"> </span>those<span style="letter-spacing:-0.15pt;"> </span>actions<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a si<span style="letter-spacing:0.05pt;">g</span>nificant impact<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business,<span style="letter-spacing:-0.05pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>imposit<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>of civil,<span style="letter-spacing:-0.15pt;"> </span>criminal<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>administrative<span style="letter-spacing:-0.5pt;"> </span>penalties,<span style="letter-spacing:-0.3pt;"> </span>d<span style="letter-spacing:-0.05pt;">a</span>mages,<span style="letter-spacing:-0.3pt;"> </span>disgorgement,<span style="letter-spacing:-0.3pt;"> </span>monetary<span style="letter-spacing:-0.3pt;"> </span>fines,<span style="letter-spacing:-0.15pt;"> </span>possible exclusion<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>participation<span style="letter-spacing:-0.4pt;"> </span>in Medicare,<span style="letter-spacing:-0.25pt;"> </span>Medicaid<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>fed<span style="letter-spacing:-0.05pt;">e</span>ral<span style="letter-spacing:-0.2pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span>programs,<span style="letter-spacing:-0.3pt;"> </span>contr<span style="letter-spacing:0.05pt;">a</span>ctual<span style="letter-spacing:-0.35pt;"> </span>damages,<span style="letter-spacing:-0.35pt;"> </span>reputational<span style="letter-spacing:-0.45pt;"> </span>ha<span style="letter-spacing:-0.05pt;">r</span>m,<span style="letter-spacing:-0.15pt;"> </span>diminished<span style="letter-spacing:-0.35pt;"> </span>profits and<span style="letter-spacing:-0.1pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>earnings,<span style="letter-spacing:-0.4pt;"> </span>compliance<span style="letter-spacing:-0.4pt;"> </span>agreeme<span style="letter-spacing:0.05pt;">n</span>ts,<span style="letter-spacing:-0.5pt;"> </span>withdrawal<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>approvals,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:-0.05pt;">u</span>rtailme<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our oper<span style="letter-spacing:0.05pt;">a</span>tions,<span style="letter-spacing:-0.35pt;"> </span>among<span style="letter-spacing:-0.3pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>th<span style="letter-spacing:-0.05pt;">i</span>ngs,<span style="letter-spacing:-0.1pt;"> </span>any of which could adversely affect<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to oper<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations.<span style="letter-spacing:-0.2pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>commer<span style="letter-spacing:0.05pt;">c</span>ialization<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>outside<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>likely<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>equivalents<span style="letter-spacing:-0.4pt;"> </span>of the<span style="letter-spacing:-0.05pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>mention<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.3pt;"> </span>above,<span style="letter-spacing:-0.2pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>other foreign<span style="letter-spacing:-0.25pt;"> </span>laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">k</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">s R</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">lat</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">to I</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">te</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">le</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">tual</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">P</span><span style="letter-spacing:0.05pt;">r</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:-0.05pt;">p</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">er</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">y</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to obtain,<span style="letter-spacing:-0.3pt;"> </span>mai<span style="letter-spacing:0.05pt;">n</span>tain,<span style="letter-spacing:-0.3pt;"> </span>protect<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>enfor<span style="letter-spacing:0.05pt;">c</span>e<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>proprietary<span style="letter-spacing:-0.35pt;"> </span>rights for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candi<span style="letter-spacing:0.05pt;">d</span>ates<span style="letter-spacing:-0.35pt;"> </span>and technologies, we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">n</span>ot be<span style="letter-spacing:-0.1pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">c</span>omp<span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>ffectively<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>oper<span style="letter-spacing:0.05pt;">a</span>te profitably and our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success is dependent in large part on our obtaining, maintaining, protecting and enforcing patents and other proprietary rights in the United States and other countries with respect to our product candidates and technology and on our ability to avoid infringing the intellectual property and other proprietary rights of others. Certain of our intellectual property rights are licensed from other entities, and as such the preparation and prosecution of any such patents and patent applications was not performed by us or under our control. Furthermore, patent law relating to the scope of claims in the biotechnology field in which we operate is still evolving and, consequently, patent positions in our industry may not be as strong as in other more well-established fields. The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved and has been the subject of much litigation in recent years. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. As a result, the issuance, scope, validity, enforceability, or commercial value of our patent rights remain highly uncertain. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing therapeutics and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, any of our issued or granted patents will not later be found to be invalid or unenforceable, or any issued or granted patents will include claims sufficiently broad to cover our product candidates and technology, or to provide meaningful protection from our competitors. Our owned or in-licensed pending and future patent applications may not result in patents being issued which protect our Anktiva, hAd5, aldoxorubicin or other product candidates or other technologies or which effectively prevent others from commercializing competitive technologies and product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or in-license may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether our Anktiva, hAd5 or other product candidates or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and growth prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and it is uncertain how much protection, if any, will be provided by our patents, including if they are challenged in the courts or patent offices or in other proceedings, such as re-examinations or oppositions, which may be brought in the United States or foreign jurisdictions to challenge the validity of a patent. A third party may challenge the validity or enforceability of a patent after its issuance. It is possible that a competitor may successfully challenge our patents or that a challenge will result in limiting their coverage. Moreover, it is possible that competitors may infringe our patents or successfully avoid the patented technology through design innovation. To stop these activities, we may need to file a lawsuit.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our licensors may be subject to a third-party preissuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant and <span style="font-style:italic;">inter partes</span> review, or interference proceedings or other similar proceedings challenging our owned or licensed patent rights. Should third parties file patent applications, or be issued patents claiming technology also used or claimed by our licensor(s) or by us in any future patent application, we, or one of our licensors, may be required to participate in interference proceedings in the USPTO to determine priority of invention for those patents or patent applications that are subject to the first-to-invent law in the United States, or may be required to participate in derivation proceedings in the USPTO for those patents or patent applications that are subject to the first-inventor-to-file law in the United States. We may be required to participate in such interference or derivation proceedings involving our issued patents and pending applications. We may also be required to participate in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or our licensor&#8217;s priority of invention or other features of patentability with respect to our owned or in-licensed patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our Anktiva, hAd5 or other product candidates and other technologies. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our owned or in-licensed patent rights, allow third parties to commercialize our Anktiva, hAd5 or other product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our collaborators are unsuccessful in any such proceeding or other priority or inventorship dispute, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">w</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e may be required to cease using the technology or to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain and maintain </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">license rights from prevailing third parties</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including parties involved in any such interference proceedings or other priority or inventorship disputes. A prevailing party in that case may not offer us a license on commercially acceptable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. In addition, certain of our licensors co-own the patents and patent applications we in-license with other third parties with whom we do not have a direct relationship. Our exclusive rights to certain of these patents and patent applications are dependent, in part, on inter-institutional or other operating agreements between the joint owners of such patents and patent applications, who are not parties to our license agreements. If our licensors do not have exclusive control of the grant of licenses under any such third-party co-owners&#8217; interest in such patents or patent applications or we are otherwise unable to secure such exclusive rights, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and growth prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.05pt;"> </span>any of<span style="letter-spacing:-0.05pt;"> </span>our owned<span style="letter-spacing:-0.25pt;"> </span>or in-lice<span style="letter-spacing:0.15pt;">n</span>sed<span style="letter-spacing:-0.35pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>applications<span style="letter-spacing:-0.4pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not issue<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>in any<span style="letter-spacing:-0.05pt;"> </span>jurisdi<span style="letter-spacing:-0.05pt;">c</span>tion,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>compete<span style="letter-spacing:-0.3pt;"> </span>e<span style="letter-spacing:-0.05pt;">f</span>fec<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">v</span>el<span style="letter-spacing:-0.05pt;">y</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties. The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in any of our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> or our licensors, collaborators, or any future strategic partners</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> may be</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">come subject to third </span><span style="Background-color:#FFFFFF;color:#231F20;">party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to protect or enforce our patents or other intellectual property or the patents or other intellectual property of our licensors, </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">all of </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">which could be expensive, time-consuming and unsuccessful</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">, may delay or prevent the development and commercialization of our product candidates, or may put our patents and other proprietary rights at risk </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors and other third parties may infringe, misappropriate or otherwise violate our patents or other intellectual property or the patents or other intellectual property of our licensors. In addition, our patents or the patents of our licensors also may become involved in inventorship, priority or validity disputes. To counter infringement or other unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming, even if we were successful in stopping the violation of our patent rights. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or one of our licensors initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or other technologies, the defendant could counterclaim that the patent is invalid and/or unenforceable or that we infringe their patents. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or other applicable body, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, <span style="font-style:italic;">inter partes</span> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our licensor, our or our licensor&#8217;s patent counsel and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources, including our scientists and management, from our business. &#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An adverse result in any litigation or defense proceeding could put one or more of our owned or licensed patents at risk of being invalidated, held unenforceable, or interpreted narrowly, and could put our patent applications at risk of not issuing. Such proceedings could result in revocation or cancellation of, or amendment to, our patents in such a way that they no longer cover our product candidates or technologies. If the outcome of litigation is adverse to us, third parties may be able to use our patented invention without payment to us. In addition, in an infringement proceeding, there is a risk that a court may decide that one or more of our patents is not valid or is unenforceable and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of our patents were upheld, a court would refuse to stop the other party on the grounds that its activities are not covered by, that is, do not infringe, our patents. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be better able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">T</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">se</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:-0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r t</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">no</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ogy</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">pote</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ia</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ly</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">confli</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">rights of</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">others,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">third-party</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">claims</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">property in</span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">r</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ingement,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">misappropriat</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.6pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">violation</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">against</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">us,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">licensors</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">collaborators</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">prevent</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">delay</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">deve</span><span style="letter-spacing:0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">opment</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and com</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ercia</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ization</span><span style="letter-spacing:-0.65pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">technologies.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our com<span style="letter-spacing:-0.05pt;">m</span>er<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.4pt;"> </span>suc<span style="letter-spacing:-0.05pt;">c</span>ess<span style="letter-spacing:-0.1pt;"> </span>dep<span style="letter-spacing:-0.05pt;">e</span>nds<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>part<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>ou<span style="letter-spacing:-0.05pt;">r</span>,<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>lice<span style="letter-spacing:0.05pt;">n</span>sors&#8217;<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>collaborators&#8217;<span style="letter-spacing:-0.45pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to avoid<span style="letter-spacing:-0.25pt;"> </span>infringing,<span style="letter-spacing:-0.45pt;"> </span>misappropriating<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>otherwise<span style="letter-spacing:-0.35pt;"> </span>violating the<span style="letter-spacing:-0.1pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>intellectu<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.45pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties.<span style="letter-spacing:-0.25pt;"> </span>There<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>substantial<span style="letter-spacing:-0.35pt;"> </span>amount<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>complex<span style="letter-spacing:-0.25pt;"> </span>litiga<span style="letter-spacing:0.05pt;">t</span>ion<span style="letter-spacing:-0.25pt;"> </span>involving<span style="letter-spacing:-0.3pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>biopharmaceutic<span style="letter-spacing:-0.1pt;">a</span>l<span style="letter-spacing:-0.7pt;"> </span>industry.<span style="letter-spacing:-0.35pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>or other<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>have,<span style="letter-spacing:-0.2pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>or acquire<span style="letter-spacing:-0.25pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>they<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>assert<span style="letter-spacing:-0.25pt;"> </span>again<span style="letter-spacing:-0.05pt;">s</span>t<span style="letter-spacing:-0.3pt;"> </span>us.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>they<span style="letter-spacing:-0.2pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>so,<span style="letter-spacing:0.05pt;"> </span>then<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>alter<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>pay<span style="letter-spacing:-0.1pt;"> </span>lic<span style="letter-spacing:-0.1pt;">e</span>nsing<span style="letter-spacing:-0.25pt;"> </span>fees<span style="letter-spacing:-0.1pt;"> </span>or cease<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>comme<span style="letter-spacing:-0.05pt;">r</span>cialization<span style="letter-spacing:-0.65pt;"> </span>activiti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>respect<span style="letter-spacing:-0.25pt;"> </span>to the<span style="letter-spacing:-0.1pt;"> </span>applicable<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>technologies.<span style="letter-spacing:-0.5pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates conflict<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>others,<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>parti<span style="letter-spacing:-0.1pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>bring<span style="letter-spacing:-0.15pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>act<span style="letter-spacing:-0.05pt;">i</span>ons<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>collaborators,<span style="letter-spacing:-0.45pt;"> </span>licensees,<span style="letter-spacing:-0.35pt;"> </span>suppliers<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>customers,<span style="letter-spacing:-0.45pt;"> </span>claim<span style="letter-spacing:0.05pt;">i</span>ng<span style="letter-spacing:-0.15pt;"> </span>damages<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>seeking<span style="letter-spacing:-0.2pt;"> </span>to enjoin<span style="letter-spacing:-0.25pt;"> </span>manufacturing,<span style="letter-spacing:-0.55pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>of the<span style="letter-spacing:-0.05pt;"> </span>affected<span style="letter-spacing:-0.25pt;"> </span>products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>conducted<span style="letter-spacing:-0.3pt;"> </span>fr<span style="letter-spacing:-0.05pt;">e</span>edom<span style="letter-spacing:-0.05pt;">-</span>to-operate<span style="letter-spacing:-0.05pt;"> (&#8220;</span>FTO&#8221;)<span style="letter-spacing:0.05pt;"> </span>analyses<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>landscape<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>respect<span style="letter-spacing:-0.25pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>lead<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candi<span style="letter-spacing:0.05pt;">d</span>ates<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>continue<span style="letter-spacing:-0.25pt;"> </span>to u<span style="letter-spacing:0.05pt;">n</span>dertake<span style="letter-spacing:-0.25pt;"> </span>FTO<span style="letter-spacing:-0.05pt;"> </span>analyses<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:-0.6pt;"> </span>processes,<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>Anktiva<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>contemplated<span style="letter-spacing:-0.5pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>processes<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>pr<span style="letter-spacing:-0.05pt;">o</span>ducts,<span style="letter-spacing:-0.15pt;"> </span>because<span style="letter-spacing:-0.3pt;"> </span>patent applications<span style="letter-spacing:-0.4pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">p</span>ublish<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>18&#160;months,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>because<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>applicat<span style="letter-spacing:-0.05pt;">i</span>ons<span style="letter-spacing:-0.35pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>change<span style="letter-spacing:-0.3pt;"> </span>ov<span style="letter-spacing:0.1pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>ti<span style="letter-spacing:-0.05pt;">m</span>e,<span style="letter-spacing:-0.2pt;"> </span>no F<span style="letter-spacing:-0.05pt;">T</span>O<span style="letter-spacing:-0.1pt;"> </span>analysis<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>considered<span style="letter-spacing:0.05pt;"> </span>exhaustive.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>aware<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.3pt;"> </span>already<span style="letter-spacing:-0.25pt;"> </span>been<span style="letter-spacing:-0.1pt;"> </span>issued<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>competitor<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>party<span style="letter-spacing:-0.25pt;"> </span>m<span style="letter-spacing:-0.05pt;">i</span>ght<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:0.05pt;">s</span>sert<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>infringed<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>c<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>rent<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.1pt;">a</span>ndidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>technologies.<span style="letter-spacing:-0.5pt;"> </span>It<span style="letter-spacing:-0.05pt;"> </span>is also<span style="letter-spacing:-0.2pt;"> </span>possible<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>found<span style="letter-spacing:-0.05pt;"> </span>to have<span style="letter-spacing:-0.2pt;"> </span>infringed<span style="letter-spacing:-0.3pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>owned<span style="letter-spacing:-0.05pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>aware,<span style="letter-spacing:-0.3pt;"> </span>but<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>believe<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>relevant<span style="letter-spacing:-0.25pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>technologies.<span style="letter-spacing:-0.5pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.35pt;"> </span>because<span style="letter-spacing:-0.3pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>applications<span style="letter-spacing:-0.4pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>take<span style="letter-spacing:-0.1pt;"> </span>many<span style="letter-spacing:0.05pt;"> </span>years<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>i<span style="letter-spacing:0.05pt;">s</span>su<span style="letter-spacing:0.05pt;">e</span>,<span style="letter-spacing:-0.05pt;"> </span>th<span style="letter-spacing:0.05pt;">e</span>re<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>curr<span style="letter-spacing:0.05pt;">e</span>ntly<span style="letter-spacing:-0.25pt;"> </span>pending<span style="letter-spacing:-0.25pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>ppli<span style="letter-spacing:-0.05pt;">c</span>a<span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.4pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>l<span style="letter-spacing:-0.05pt;">a</span>ter<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n issued <span style="letter-spacing:-0.1pt;">p</span>atents<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product candidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>technologies<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span>f<span style="letter-spacing:-0.05pt;">r</span>inge.<span style="letter-spacing:-0.2pt;"> </span>Furthermore,<span style="letter-spacing:-0.4pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>intellectu<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>biotechnology<span style="letter-spacing:-0.5pt;"> </span>remains<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>evolving<span style="letter-spacing:-0.25pt;"> </span>area<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>many risks<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>uncertainties.<span style="letter-spacing:-0.45pt;"> </span>As<span style="letter-spacing:0.05pt;"> </span>such,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to ensure<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>without<span style="letter-spacing:-0.3pt;"> </span>conflict<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>others.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property-related<span style="letter-spacing:-0.65pt;"> </span>leg<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>ac<span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span>s<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.2pt;"> </span>aga<span style="letter-spacing:-0.05pt;">i</span>nst<span style="letter-spacing:-0.25pt;"> </span>us <span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>su<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>sful,<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n <span style="letter-spacing:-0.05pt;">a</span>ddit<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>pot<span style="letter-spacing:-0.05pt;">e</span>nti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>for <span style="letter-spacing:-0.05pt;">d</span>amages<span style="letter-spacing:-0.25pt;"> </span>(including<span style="letter-spacing:-0.35pt;"> </span>treble<span style="letter-spacing:-0.25pt;"> </span>damages<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>attorneys&#8217;<span style="letter-spacing:-0.4pt;"> </span>fees<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>willful<span style="letter-spacing:-0.3pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span>fringement),<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>enjoined<span style="letter-spacing:-0.3pt;"> </span>from,<span style="letter-spacing:-0.15pt;"> </span>or required<span style="letter-spacing:-0.25pt;"> </span>to obtain<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>continue,<span style="letter-spacing:-0.3pt;"> </span>manufacturing,<span style="letter-spacing:-0.5pt;"> </span>promoting<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>affected<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.1pt;">d</span>ucts.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">n</span>ot prevail<span style="letter-spacing:-0.2pt;"> </span>in any<span style="letter-spacing:-0.1pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.1pt;">c</span>tion<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>applicable<span style="letter-spacing:-0.4pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>ll<span style="letter-spacing:-0.05pt;">e</span>ctu<span style="letter-spacing:-0.05pt;">a</span>l proper<span style="letter-spacing:-0.05pt;">t</span>y m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>available<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>acceptable<span style="letter-spacing:-0.35pt;"> </span>terms<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>at<span style="letter-spacing:-0.05pt;"> a</span>ll.<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">E</span>ven<span style="letter-spacing:-0.15pt;"> </span>if we were<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>obta<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">e</span>ns<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.15pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>cou<span style="letter-spacing:-0.05pt;">l</span>d<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>non-exclusive,<span style="letter-spacing:-0.6pt;"> </span>thereby<span style="letter-spacing:-0.3pt;"> </span>giving<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>ird<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>access<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>same<span style="letter-spacing:-0.15pt;"> </span>technologies<span style="letter-spacing:-0.45pt;"> </span>licensed<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>it could<span style="letter-spacing:-0.25pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to make<span style="letter-spacing:-0.35pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>licensing<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>royalty<span style="letter-spacing:0.05pt;"> </span>payments.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>cou<span style="letter-spacing:0.1pt;">l</span>d<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>to redesign<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>infringing<span style="letter-spacing:-0.3pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>ducts,<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>impossible<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>require<span style="letter-spacing:-0.3pt;"> </span>substantial<span style="letter-spacing:-0.35pt;"> </span>time<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>monetary<span style="letter-spacing:-0.35pt;"> </span>expenditure.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Defense<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">f</span>ringement<span style="letter-spacing:-0.4pt;"> </span>claims,<span style="letter-spacing:-0.2pt;"> </span>regardless<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>merit,<span style="letter-spacing:-0.15pt;"> </span>wou<span style="letter-spacing:-0.05pt;">l</span>d<span style="letter-spacing:-0.05pt;"> </span>involve<span style="letter-spacing:-0.2pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>litigation<span style="letter-spacing:-0.25pt;"> </span>expense<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>substan<span style="letter-spacing:0.05pt;">t</span>ial<span style="letter-spacing:-0.4pt;"> </span>diversion<span style="letter-spacing:-0.3pt;"> </span>of management<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>employee<span style="letter-spacing:-0.3pt;"> </span>re<span style="letter-spacing:0.05pt;">s</span>ources<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business, and<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>i<span style="letter-spacing:0.1pt;">m</span>pact<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>reputation.<span style="letter-spacing:-0.35pt;"> </span>Some<span style="letter-spacing:-0.25pt;"> </span>of our<span style="letter-spacing:-0.05pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>su<span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">c</span>osts of<span style="letter-spacing:0.05pt;"> </span>litigation<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>administrative<span style="letter-spacing:-0.55pt;"> </span>proceedings<span style="letter-spacing:-0.5pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>effectively<span style="letter-spacing:-0.35pt;"> </span>than<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>because<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>greater<span style="letter-spacing:-0.3pt;"> </span>fin<span style="letter-spacing:0.05pt;">a</span>ncial<span style="letter-spacing:-0.3pt;"> </span>resources.<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>here<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>public announcements<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>hearings,<span style="letter-spacing:-0.35pt;"> </span>m<span style="letter-spacing:-0.05pt;">o</span>tions,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>interim<span style="letter-spacing:-0.25pt;"> </span>proceedings<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>dev<span style="letter-spacing:-0.1pt;">e</span>lopments,<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>if securities<span style="letter-spacing:-0.35pt;"> </span>analysts<span style="letter-spacing:-0.3pt;"> </span>or investors<span style="letter-spacing:-0.3pt;"> </span>per<span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">e</span>i<span style="letter-spacing:-0.05pt;">v</span>e<span style="letter-spacing:-0.3pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e results<span style="letter-spacing:-0.2pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>negative,<span style="letter-spacing:-0.3pt;"> </span>it<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>adve<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.25pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>price<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>s<span style="letter-spacing:-0.05pt;">t</span>ock.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>occurrence<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.15pt;"> </span>foregoing<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a material<span style="letter-spacing:-0.3pt;"> </span>adve<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>bu<span style="letter-spacing:-0.05pt;">s</span>iness,<span style="letter-spacing:-0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition,<span style="letter-spacing:-0.3pt;"> </span>resul<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>perations<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>maintaining<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>prote<span style="letter-spacing:-0.1pt;">c</span>tion<span style="letter-spacing:-0.35pt;"> </span>depends<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>compliance<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>various<span style="letter-spacing:0.05pt;"> </span>procedural,<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;">c</span>ument<span style="letter-spacing:-0.4pt;"> </span>submission,<span style="letter-spacing:-0.05pt;"> </span>fee<span style="letter-spacing:-0.05pt;"> </span>paymen<span style="letter-spacing:0.05pt;">t</span>,<span style="letter-spacing:-0.25pt;"> </span>and other requirements<span style="letter-spacing:-0.45pt;"> </span>imposed<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.15pt;"> </span>govern<span style="letter-spacing:0.05pt;">m</span>ent<span style="letter-spacing:-0.5pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>agencies,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>red<span style="letter-spacing:-0.05pt;">u</span>ced<span style="letter-spacing:-0.05pt;"> </span>or eliminated<span style="letter-spacing:-0.35pt;"> </span>for non-compliance<span style="letter-spacing:-0.65pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span>se <span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">qu</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span>m<span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.05pt;">t</span>s.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic<span style="letter-spacing:-0.25pt;"> </span>maintenance<span style="letter-spacing:-0.45pt;"> </span>fees,<span style="letter-spacing:-0.1pt;"> </span>renewal<span style="letter-spacing:-0.25pt;"> </span>fees,<span style="letter-spacing:-0.2pt;"> </span>annuity<span style="letter-spacing:-0.2pt;"> </span>fees,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>various<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>fees<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>pat<span style="letter-spacing:0.05pt;">e</span>nts<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>applications<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>due<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>id<span style="letter-spacing:-0.15pt;"> </span>to <span style="letter-spacing:-0.05pt;">t</span>he USPTO and<span style="letter-spacing:-0.2pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>agencies<span style="letter-spacing:-0.25pt;"> </span>in several<span style="letter-spacing:-0.25pt;"> </span>stages<span style="letter-spacing:-0.25pt;"> </span>over<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>lifetime<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>patent.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>USPTO<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>various<span style="letter-spacing:-0.25pt;"> </span>fore<span style="letter-spacing:0.05pt;">i</span>gn<span style="letter-spacing:-0.2pt;"> </span>governmental<span style="letter-spacing:-0.5pt;"> </span>pat<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span>agen<span style="letter-spacing:-0.05pt;">c</span>i<span style="letter-spacing:-0.05pt;">e</span>s require<span style="letter-spacing:-0.2pt;"> </span>compliance<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>sever<span style="letter-spacing:-0.1pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>procedural,<span style="letter-spacing:-0.4pt;"> </span>documentary,<span style="letter-spacing:-0.5pt;"> </span>fee<span style="letter-spacing:-0.1pt;"> </span>payment<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>similar<span style="letter-spacing:-0.25pt;"> </span>provisions<span style="letter-spacing:-0.4pt;"> </span>during<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>pat<span style="letter-spacing:-0.1pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span>application<span style="letter-spacing:-0.4pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>ocess.<span style="letter-spacing:-0.05pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>certain circumstances,<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>rely<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors<span style="letter-spacing:-0.25pt;"> </span>to pay<span style="letter-spacing:-0.2pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>fees<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>take<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>ne<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>ss<span style="letter-spacing:0.05pt;">a</span>ry<span style="letter-spacing:-0.2pt;"> </span>ac<span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o co<span style="letter-spacing:-0.05pt;">m</span>ply<span style="letter-spacing:-0.2pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th <span style="letter-spacing:-0.05pt;">t</span>hese<span style="letter-spacing:-0.05pt;"> </span>requi<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>m<span style="letter-spacing:-0.05pt;">e</span>nts.<span style="letter-spacing:-0.45pt;"> </span>Wh<span style="letter-spacing:-0.05pt;">i</span>le<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>inadvertent<span style="letter-spacing:-0.35pt;"> </span>lapse can<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>many<span style="letter-spacing:-0.2pt;"> </span>cases<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>cured<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>payment<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a late<span style="letter-spacing:-0.15pt;"> </span>f<span style="letter-spacing:-0.05pt;">e</span>e<span style="letter-spacing:-0.05pt;"> </span>or by<span style="letter-spacing:0.05pt;"> </span>o<span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.2pt;"> </span>me<span style="letter-spacing:-0.05pt;">a</span>ns<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>cord<span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>app<span style="letter-spacing:-0.05pt;">l</span>ic<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.3pt;"> </span>rul<span style="letter-spacing:-0.05pt;">e</span>s,<span style="letter-spacing:-0.15pt;"> </span>there<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>s<span style="letter-spacing:-0.05pt;">i</span>tua<span style="letter-spacing:-0.15pt;">t</span>ions<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>which n<span style="letter-spacing:0.05pt;">o</span>ncompliance<span style="letter-spacing:-0.45pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in ab<span style="letter-spacing:-0.05pt;">a</span>ndonment<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>lapse<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>applica<span style="letter-spacing:-0.1pt;">t</span>ion,<span style="letter-spacing:-0.35pt;"> </span>resulting<span style="letter-spacing:-0.35pt;"> </span>in partial<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>complete<span style="letter-spacing:-0.3pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>relevant jurisdiction.<span style="letter-spacing:-0.4pt;"> </span>Noncompliance<span style="letter-spacing:-0.5pt;"> </span>e<span style="letter-spacing:0.05pt;">v</span>ents<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>cou<span style="letter-spacing:-0.05pt;">l</span>d<span style="letter-spacing:-0.1pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in abandonment<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>lapse<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>applica<span style="letter-spacing:-0.1pt;">t</span>ion<span style="letter-spacing:-0.35pt;"> </span>inclu<span style="letter-spacing:0.05pt;">d</span>e,<span style="letter-spacing:-0.35pt;"> </span>but<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>limited<span style="letter-spacing:-0.2pt;"> </span>to,<span style="letter-spacing:-0.1pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>to respond<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>official<span style="letter-spacing:-0.2pt;"> </span>actions<span style="letter-spacing:-0.3pt;"> </span>within<span style="letter-spacing:-0.2pt;"> </span>prescribed<span style="letter-spacing:-0.4pt;"> </span>time<span style="letter-spacing:-0.2pt;"> </span>limits,<span style="letter-spacing:-0.2pt;"> </span>non-payment<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>fees<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>to properly<span style="letter-spacing:-0.25pt;"> </span>legalize<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>submit<span style="letter-spacing:-0.25pt;"> </span>formal<span style="letter-spacing:-0.3pt;"> </span>documents.<span style="letter-spacing:-0.4pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>an event,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>might<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to e<span style="letter-spacing:0.05pt;">n</span>ter<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>similar<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>identical<span style="letter-spacing:-0.4pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>technology,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a mat<span style="letter-spacing:-0.05pt;">e</span>rial<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>dverse<span style="letter-spacing:-0.1pt;"> </span>imp<span style="letter-spacing:-0.05pt;">a</span>ct on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business, financial<span style="letter-spacing:-0.35pt;"> </span>condition,<span style="letter-spacing:-0.3pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">States</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">law</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">diminish</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">value</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of patents</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in general,</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">pairing</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ability</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">protect</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our product</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>case<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>i<span style="letter-spacing:0.05pt;">m</span>munotherapy<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.65pt;"> </span>companies,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>success<span style="letter-spacing:-0.05pt;"> </span>is dependent<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>intellec<span style="letter-spacing:-0.1pt;">t</span>ual<span style="letter-spacing:-0.4pt;"> </span>property,<span style="letter-spacing:-0.35pt;"> </span>particularly<span style="letter-spacing:-0.4pt;"> </span>patents. Obtaining<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>enforcing<span style="letter-spacing:-0.4pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>b<span style="letter-spacing:-0.05pt;">i</span>opharmaceutical<span style="letter-spacing:-0.6pt;"> </span>industry<span style="letter-spacing:-0.35pt;"> </span>invol<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:-0.3pt;"> </span>both<span style="letter-spacing:-0.1pt;"> </span>technological<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>complexity,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>is ther<span style="letter-spacing:-0.05pt;">e</span>fore<span style="letter-spacing:-0.25pt;"> </span>costly,<span style="letter-spacing:-0.25pt;"> </span>time-consuming<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>inherently<span style="letter-spacing:-0.35pt;"> </span>uncertain.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ddit<span style="letter-spacing:-0.05pt;">i</span>on,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Unit<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">S</span>t<span style="letter-spacing:-0.05pt;">a</span>tes<span style="letter-spacing:-0.15pt;"> </span>h<span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>cen<span style="letter-spacing:-0.05pt;">t</span>ly<span style="letter-spacing:-0.25pt;"> </span>ena<span style="letter-spacing:-0.1pt;">c</span>ted<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>is currently<span style="letter-spacing:-0.3pt;"> </span>implementing<span style="letter-spacing:-0.5pt;"> </span>wide-ranging<span style="letter-spacing:-0.45pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>reform legislation.<span style="letter-spacing:-0.4pt;"> </span>Assuming<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>requir<span style="letter-spacing:-0.05pt;">e</span>m<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.4pt;"> </span>for pat<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.05pt;">e</span>t,<span style="letter-spacing:-0.15pt;"> </span>prior<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>M<span style="letter-spacing:-0.05pt;">a</span>rch&#160;2013, <span style="letter-spacing:-0.05pt;">i</span>n <span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>Un<span style="letter-spacing:-0.05pt;">i</span>ted<span style="letter-spacing:-0.1pt;"> </span>S<span style="letter-spacing:-0.05pt;">t</span>at<span style="letter-spacing:-0.05pt;">e</span>s,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>first <span style="letter-spacing:-0.05pt;">t</span>o<span style="letter-spacing:-0.05pt;"> </span>invent<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>claimed<span style="letter-spacing:-0.3pt;"> </span>invention<span style="letter-spacing:0.05pt;"> </span>was<span style="letter-spacing:-0.05pt;"> </span>entitled<span style="letter-spacing:-0.2pt;"> </span>to t<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>nt,<span style="letter-spacing:-0.25pt;"> </span>while<span style="letter-spacing:-0.2pt;"> </span>outside<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>Un<span style="letter-spacing:-0.05pt;">i</span>ted<span style="letter-spacing:-0.1pt;"> </span>S<span style="letter-spacing:-0.05pt;">t</span>a<span style="letter-spacing:-0.05pt;">t</span>es,<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>first<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>file<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>tent<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ppli<span style="letter-spacing:-0.05pt;">c</span>at<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>was<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.05pt;">i</span>tl<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.15pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>patent.<span style="letter-spacing:-0.25pt;"> </span>After<span style="letter-spacing:-0.2pt;"> </span>March&#160;2013, u<span style="letter-spacing:0.05pt;">n</span>der<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Leahy-Smith<span style="letter-spacing:-0.4pt;"> </span>America<span style="letter-spacing:-0.25pt;"> </span>Inv<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.2pt;"> </span>Act<span style="letter-spacing:-0.05pt;"> (</span>the<span style="letter-spacing:-0.05pt;"> &#8220;</span>America<span style="letter-spacing:-0.25pt;"> </span>Invents<span style="letter-spacing:-0.2pt;"> </span>Act&#8221;)<span style="letter-spacing:-0.2pt;"> </span>enacted<span style="letter-spacing:-0.2pt;"> </span>in September&#160;2011,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.25pt;"> </span>transitioned<span style="letter-spacing:-0.35pt;"> </span>to a<span style="letter-spacing:-0.1pt;"> </span>first-to-file<span style="letter-spacing:-0.4pt;"> </span>system<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>which,<span style="letter-spacing:-0.3pt;"> </span>assuming<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>requir<span style="letter-spacing:-0.1pt;">e</span>men<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>ntab<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.05pt;"> m</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">t</span>,<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>first<span style="letter-spacing:-0.2pt;"> </span>inventor<span style="letter-spacing:-0.25pt;"> </span>to file<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>application<span style="letter-spacing:-0.4pt;"> </span>w<span style="letter-spacing:-0.1pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>en<span style="letter-spacing:-0.05pt;">t</span>it<span style="letter-spacing:-0.05pt;">l</span>ed<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span>on an<span style="letter-spacing:0.05pt;"> </span>invention<span style="letter-spacing:-0.3pt;"> </span>regardless<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>whether<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>third<span style="letter-spacing:-0.25pt;"> </span>party<span style="letter-spacing:-0.15pt;"> </span>was<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>first<span style="letter-spacing:-0.1pt;"> </span>to invent<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>claimed<span style="letter-spacing:-0.35pt;"> </span>inve<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>ion.<span style="letter-spacing:-0.3pt;"> </span>A<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>party<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>files<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>pat<span style="letter-spacing:-0.1pt;">e</span>nt<span style="letter-spacing:-0.25pt;"> </span>application<span style="letter-spacing:-0.4pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>USPTO after<span style="letter-spacing:-0.1pt;"> </span>March&#160;2013,<span style="letter-spacing:0.05pt;"> </span>but<span style="letter-spacing:-0.05pt;"> </span>before<span style="letter-spacing:-0.3pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;">r</span>efore<span style="letter-spacing:-0.35pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>awarded<span style="letter-spacing:-0.25pt;"> </span>a patent<span style="letter-spacing:-0.15pt;"> </span>covering<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>invention<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>ours even<span style="letter-spacing:-0.2pt;"> </span>if we<span style="letter-spacing:0.05pt;"> </span>had<span style="letter-spacing:-0.2pt;"> </span>made<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>inve<span style="letter-spacing:-0.05pt;">n</span>tion<span style="letter-spacing:-0.35pt;"> </span>before<span style="letter-spacing:-0.2pt;"> </span>it was<span style="letter-spacing:-0.05pt;"> </span>made by<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>party.<span style="letter-spacing:-0.15pt;"> </span>This<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:0.05pt;">g</span>nizant<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>invention<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>filing<span style="letter-spacing:-0.15pt;"> </span>of a<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>application.<span style="letter-spacing:-0.35pt;"> </span>Since<span style="letter-spacing:-0.15pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>appli<span style="letter-spacing:0.05pt;">ca</span><span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>most<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>countries<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:0.05pt;">r</span>e<span style="letter-spacing:-0.05pt;"> </span>con<span style="letter-spacing:-0.05pt;">f</span>idential<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>period<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>after<span style="letter-spacing:-0.2pt;"> </span>filing<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>until<span style="letter-spacing:-0.2pt;"> </span>issuance,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>cert<span style="letter-spacing:0.05pt;">a</span>in<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>licensors were the<span style="letter-spacing:-0.1pt;"> </span>first<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>either<span style="letter-spacing:-0.2pt;"> </span>file<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>ap<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">l</span>ication<span style="letter-spacing:-0.35pt;"> </span>r<span style="letter-spacing:-0.1pt;">e</span>lated<span style="letter-spacing:-0.25pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>technologies<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>invent<span style="letter-spacing:-0.2pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>inventions<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:-0.1pt;">l</span>aimed<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>or o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>licensor&#8217;s<span style="letter-spacing:-0.3pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>applications.<span style="letter-spacing:-0.45pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>Ame<span style="letter-spacing:-0.05pt;">r</span>ica<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">I</span>nvents<span style="letter-spacing:-0.2pt;"> </span>Act<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>includes<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>n<span style="letter-spacing:0.05pt;">u</span>mber<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>significant<span style="letter-spacing:-0.4pt;"> </span>changes<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>way patent applications<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>pro<span style="letter-spacing:-0.1pt;">s</span>e<span style="letter-spacing:-0.05pt;">c</span>ut<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>so<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> a</span>ffect<span style="letter-spacing:-0.25pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>litig<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">i</span>on.<span style="letter-spacing:-0.25pt;"> </span>These<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;">c</span>lude<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>lowing<span style="letter-spacing:-0.3pt;"> </span>thi<span style="letter-spacing:-0.05pt;">r</span>d-party<span style="letter-spacing:-0.45pt;"> </span>submission<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>ior<span style="letter-spacing:-0.05pt;"> </span>art<span style="letter-spacing:-0.15pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>USPTO during patent<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>osecution<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>proced<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>es<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>attack<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>validity<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a p<span style="letter-spacing:-0.1pt;">a</span>tent<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>USPTO-administered<span style="letter-spacing:-0.75pt;"> </span>post<span style="letter-spacing:-0.05pt;">-</span><span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">r</span>ant<span style="letter-spacing:-0.1pt;"> </span>proceedings,<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">i</span>ncluding<span style="letter-spacing:-0.4pt;"> </span>post-grant review,<span style="letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">int</span><span style="font-style:italic;letter-spacing:0.05pt;">e</span><span style="font-style:italic;">r</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">pa</span><span style="font-style:italic;letter-spacing:0.05pt;">r</span><span style="font-style:italic;">t</span><span style="font-style:italic;letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;"> </span>review,<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>derivation<span style="letter-spacing:-0.3pt;"> </span>proceedings.<span style="letter-spacing:-0.5pt;"> </span>There<span style="letter-spacing:0.05pt;">f</span>ore,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>America<span style="letter-spacing:-0.35pt;"> </span>Invents<span style="letter-spacing:-0.3pt;"> </span>Act<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>its<span style="letter-spacing:-0.05pt;"> </span>imp<span style="letter-spacing:-0.05pt;">l</span>ementation<span style="letter-spacing:-0.5pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>increase<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>uncertainties<span style="letter-spacing:-0.4pt;"> </span>and costs<span style="letter-spacing:0.05pt;"> </span>surrounding<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>prosecution<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>owned<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>in-licensed<span style="letter-spacing:-0.4pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>appli<span style="letter-spacing:0.05pt;">c</span>ations<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>enforcement<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>defense<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>owned<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>in-licensed<span style="letter-spacing:-0.35pt;"> </span>issued patents,<span style="letter-spacing:-0.35pt;"> </span>all<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">c</span>ould<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a material<span style="letter-spacing:-0.25pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>condition,<span style="letter-spacing:-0.4pt;"> </span>res<span style="letter-spacing:0.1pt;">u</span>lts<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>prosp<span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">c</span>ts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally,<span style="letter-spacing:-0.45pt;"> </span>recent<span style="letter-spacing:-0.15pt;"> </span>U<span style="letter-spacing:-0.05pt;">.</span>S.<span style="letter-spacing:0.05pt;">&#160;</span>Supreme<span style="letter-spacing:-0.25pt;"> </span>Court<span style="letter-spacing:-0.15pt;"> </span>rulings<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>narr<span style="letter-spacing:-0.1pt;">o</span>wed<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>scope<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>pro<span style="letter-spacing:-0.05pt;">t</span>ec<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.35pt;"> </span>ava<span style="letter-spacing:-0.05pt;">i</span>lab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>cer<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>in<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">i</span>rcu<span style="letter-spacing:-0.05pt;">m</span>s<span style="letter-spacing:-0.05pt;">t</span>anc<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>weak<span style="letter-spacing:-0.05pt;">e</span>ned<span style="letter-spacing:-0.3pt;"> </span>the rights<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>owners<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>cer<span style="letter-spacing:0.1pt;">t</span>ain<span style="letter-spacing:-0.2pt;"> </span>situations.<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">I</span>n<span style="letter-spacing:0.05pt;"> </span>addition<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span>creasing<span style="letter-spacing:-0.35pt;"> </span>uncertainty<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>regard<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to obtain<span style="letter-spacing:-0.25pt;"> </span>pate<span style="letter-spacing:-0.05pt;">n</span>ts<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>futur<span style="letter-spacing:0.05pt;">e</span>,<span style="letter-spacing:-0.2pt;"> </span>this comb<span style="letter-spacing:-0.05pt;">i</span>nat<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>of even<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>has<span style="letter-spacing:-0.05pt;"> </span>cre<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>unc<span style="letter-spacing:-0.05pt;">e</span>rt<span style="letter-spacing:-0.05pt;">a</span>inty<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>respe<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.05pt;"> t</span>o the<span style="letter-spacing:-0.15pt;"> </span>value<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patents,<span style="letter-spacing:-0.35pt;"> </span>once<span style="letter-spacing:-0.1pt;"> </span>ob<span style="letter-spacing:0.05pt;">t</span>ained. Depending<span style="letter-spacing:-0.45pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>decisio<span style="letter-spacing:0.05pt;">n</span>s<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>Congress,<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>federal courts,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>USPTO,<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulations<span style="letter-spacing:-0.35pt;"> </span>governing<span style="letter-spacing:-0.3pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>change<span style="letter-spacing:-0.25pt;"> </span>in unpredictable<span style="letter-spacing:-0.5pt;"> </span>ways<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>weaken<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>abi<span style="letter-spacing:0.05pt;">l</span>ity<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>new patents<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>enforce<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>exist<span style="letter-spacing:0.15pt;">i</span>ng<span style="letter-spacing:-0.15pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>patents<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:0.05pt;">i</span>ght<span style="letter-spacing:-0.15pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>fut<span style="letter-spacing:-0.05pt;">u</span>re.<span style="letter-spacing:-0.25pt;"> </span>While<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>believe<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.3pt;"> </span>ow<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">e</span>d or licensed<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>found<span style="letter-spacing:-0.05pt;"> </span>invalid<span style="letter-spacing:-0.25pt;"> </span>based<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>foregoing,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>cannot<span style="letter-spacing:-0.2pt;"> </span>predict<span style="letter-spacing:-0.2pt;"> </span>how<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span>decisions<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>Congress,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>federal<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.1pt;">o</span>urts<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>USPTO<span style="letter-spacing:-0.05pt;"> </span>may impact<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>value<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>patents.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>comme<span style="letter-spacing:0.05pt;">r</span>cialize<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>cand<span style="letter-spacing:-0.05pt;">i</span>dates<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>technologies<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:0.05pt;">u</span>b<span style="letter-spacing:-0.05pt;">j</span>ec<span style="letter-spacing:-0.05pt;">t</span>,<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>part,<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">m</span>s<span style="letter-spacing:-0.15pt;"> </span>and condit<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:-0.1pt;">o</span>ns<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.05pt;">s</span>es granted<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>others.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>rely<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>licenses<span style="letter-spacing:-0.3pt;"> </span>to cer<span style="letter-spacing:-0.15pt;">t</span>ain<span style="letter-spacing:-0.25pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>proprietary<span style="letter-spacing:-0.45pt;"> </span>technology<span style="letter-spacing:-0.45pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>at<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>important<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>necessary<span style="letter-spacing:-0.35pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>developme<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.4pt;"> </span>of aldoxorubicin<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>enabled<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>yeast,<span style="letter-spacing:-0.15pt;"> </span>inclu<span style="letter-spacing:0.05pt;">d</span>ing<span style="letter-spacing:-0.3pt;"> T</span>armogen,<span style="letter-spacing:-0.45pt;"> </span>technologies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License<span style="letter-spacing:-0.3pt;"> </span>agreements<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>prov<span style="letter-spacing:-0.1pt;">i</span>de<span style="letter-spacing:-0.2pt;"> </span>exclusive<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">r</span>ights<span style="letter-spacing:-0.15pt;"> </span>to use<span style="letter-spacing:-0.05pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>licensed<span style="letter-spacing:-0.25pt;"> </span>i<span style="letter-spacing:-0.1pt;">n</span>tellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>technology<span style="letter-spacing:-0.4pt;"> </span>in all<span style="letter-spacing:-0.1pt;"> </span>releva<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.25pt;"> </span>fiel<span style="letter-spacing:0.05pt;">d</span>s<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>in all territories<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>wish<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>dev<span style="letter-spacing:0.15pt;">e</span>lop<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>commercialize<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>technology<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>produ<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> f</span>uture.<span style="letter-spacing:-0.1pt;"> </span>As<span style="letter-spacing:0.05pt;"> </span>a result,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to prevent<span style="letter-spacing:-0.2pt;"> </span>competitors<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>developi<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>commercializing<span style="letter-spacing:-0.55pt;"> </span>competitive<span style="letter-spacing:-0.4pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;">l</span>so utilizes<span style="letter-spacing:-0.25pt;"> </span>technology<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have in-l<span style="letter-spacing:-0.05pt;">i</span>cens<span style="letter-spacing:0.05pt;">e</span>d.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>terms<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:0.05pt;">u</span>ch<span style="letter-spacing:-0.05pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>agreements,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">n</span>ot have<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>right<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>control<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>preparation,<span style="letter-spacing:-0.45pt;"> </span>filing,<span style="letter-spacing:-0.25pt;"> </span>prosecution<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>maintenance, and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>right<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>control<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>enforcement,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>defense<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>appli<span style="letter-spacing:-0.05pt;">c</span>ations<span style="letter-spacing:-0.45pt;"> </span>covering<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>technology<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we l<span style="letter-spacing:-0.05pt;">i</span>cense<span style="letter-spacing:-0.25pt;"> </span>from third<span style="letter-spacing:-0.15pt;"> </span>parties.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>cannot<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>cer<span style="letter-spacing:0.05pt;">t</span>ain<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>in-licensed<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>out<span style="letter-spacing:-0.05pt;">-</span>licensed<span style="letter-spacing:-0.45pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>applications<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>controlled<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>licensors<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>licensees will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>prepa<span style="letter-spacing:-0.05pt;">r</span>ed,<span style="letter-spacing:-0.4pt;"> </span>filed,<span style="letter-spacing:-0.15pt;"> </span>prosecuted,<span style="letter-spacing:-0.35pt;"> </span>maintained,<span style="letter-spacing:-0.45pt;"> </span>enforced,<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>defended<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>a manner<span style="letter-spacing:-0.2pt;"> </span>con<span style="letter-spacing:0.05pt;">s</span>istent<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>best<span style="letter-spacing:-0.2pt;"> </span>interests<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">b</span>usiness.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>licensors<span style="letter-spacing:-0.35pt;"> </span>or li<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>ns<span style="letter-spacing:0.05pt;">e</span>es<span style="letter-spacing:-0.15pt;"> </span>f<span style="letter-spacing:0.05pt;">a</span>il<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>pros<span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">c</span>ut<span style="letter-spacing:0.05pt;">e</span>,<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>int<span style="letter-spacing:0.05pt;">a</span>in,<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">e</span>nforce,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>defend<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>patents,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>lose<span style="letter-spacing:-0.1pt;"> </span>rig<span style="letter-spacing:0.05pt;">h</span>ts<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>application<span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>licensed may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>reduced<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>eliminated,<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>right<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>develop<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>commercialize<span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.05pt;">A</span>nktiva<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>licensed<span style="letter-spacing:-0.25pt;"> </span>rights could<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affec<span style="letter-spacing:0.1pt;">t</span>ed,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to prevent<span style="letter-spacing:-0.2pt;"> </span>competitors<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>making,<span style="letter-spacing:-0.25pt;"> </span>using<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:-0.1pt;">e</span>lling<span style="letter-spacing:-0.1pt;"> </span>competing<span style="letter-spacing:-0.35pt;"> </span>products.<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">I</span>n<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.35pt;"> </span>even<span style="letter-spacing:-0.1pt;"> </span>where we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>right<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>control<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>prosecution<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>applications<span style="letter-spacing:-0.45pt;"> </span>we have<span style="letter-spacing:-0.2pt;"> </span>licensed<span style="letter-spacing:-0.35pt;"> </span>to and<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>still<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>adversely affected<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>prejudiced<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>actions<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>inact<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">o</span>ns<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensees,<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:0.05pt;">i</span>r<span style="letter-spacing:-0.2pt;"> </span>counsel<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>took<span style="letter-spacing:-0.1pt;"> </span>place<span style="letter-spacing:-0.15pt;"> </span>prior<span style="letter-spacing:-0.15pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>date<span style="letter-spacing:-0.05pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>assumed control<span style="letter-spacing:-0.2pt;"> </span>over<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>prosecution.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">owned</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in-li</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ensed</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">su</span><span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">j</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ect</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a reservation</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties.</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">example,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our in-licensed</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">funded</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in part</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government.</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">res</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lt,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="letter-spacing:0.05pt;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:-0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">rig</span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">u</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">in</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tu</span><span style="letter-spacing:-0.05pt;">al </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technologies</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deve</span><span style="letter-spacing:0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">oped</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.05pt;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unding,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="letter-spacing:-0.05pt;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gover</span><span style="letter-spacing:0.1pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ment</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generally</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtains</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">righ</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resulting patents,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a non-exclusive</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">license</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">au</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">horizing</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="letter-spacing:-0.05pt;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gover</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ment</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">invention</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">others</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">invention</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">behalf.</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S.</span><span style="letter-spacing:0.05pt;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government&#8217;s</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">righ</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">permit</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disclose</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">funded</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inventions</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technology</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to third</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to exercise</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arch-in</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or allow</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to use</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technology</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensed</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">developed</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">using</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">funding.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="letter-spacing:-0.05pt;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ex</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rcise</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s march-in</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if it determines</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">action</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">necessary</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">because</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we fail</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to achieve</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">practical</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pplication</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government-funded</span><span style="letter-spacing:-0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technology,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">because ac</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is ne</span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ssary</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ll</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vi</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">te</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lth</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">saf</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ty</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ne</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ds,</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o m</span><span style="letter-spacing:-0.2pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">et</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fed</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ral</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulations,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">give</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preference</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">industry.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our rights</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in such</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inventions</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufact</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">embodying</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ch</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inventions</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unit</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stat</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in c</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rt</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in circumstances</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if this</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requir</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ment</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">waived.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exercise</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="letter-spacing:-0.05pt;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reserved</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could have</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">material</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competitive</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">positi</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cond</span><span style="letter-spacing:-0.1pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tion,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operations</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">growth</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prosp</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>fail<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>obl<span style="letter-spacing:-0.05pt;">i</span>gations<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>em<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>u<span style="letter-spacing:-0.05pt;">n</span>der<span style="letter-spacing:-0.05pt;"> </span>wh<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span>tellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:-0.05pt;">i</span>ghts<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:-0.25pt;"> </span>par<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.25pt;"> </span>or otherwise experience<span style="letter-spacing:-0.4pt;"> </span>disruptions<span style="letter-spacing:-0.25pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>r<span style="letter-spacing:-0.1pt;">e</span>lat<span style="letter-spacing:-0.05pt;">i</span>o<span style="letter-spacing:0.05pt;">n</span>s<span style="letter-spacing:0.05pt;">h</span>ips<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r lic<span style="letter-spacing:0.05pt;">e</span>n<span style="letter-spacing:0.05pt;">s</span>ors,<span style="letter-spacing:-0.15pt;"> we may be required to pay damages and </span>we<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span>d lo<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>ic<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span>righ<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>at<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>important<span style="letter-spacing:-0.3pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">u</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">s</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>en<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span>o<span style="letter-spacing:-0.05pt;"> l</span>ic<span style="letter-spacing:-0.05pt;">e</span>nse<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>gre<span style="letter-spacing:-0.05pt;">e</span>men<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>par<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>lice<span style="letter-spacing:0.05pt;">n</span>ses<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>others<span style="letter-spacing:-0.25pt;"> </span>to advance<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>research<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>allow commercialization<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:0.05pt;">a</span>ndidates.<span style="letter-spacing:-0.35pt;"> </span>It<span style="letter-spacing:-0.1pt;"> </span>is possible<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>licen<span style="letter-spacing:0.05pt;">s</span>es<span style="letter-spacing:-0.15pt;"> </span>at a reasonable<span style="letter-spacing:-0.45pt;"> </span>cost<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>reasonable terms,<span style="letter-spacing:-0.15pt;"> </span>if at all.<span style="letter-spacing:-0.1pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>event,<span style="letter-spacing:-0.2pt;"> </span>we may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> r</span><span style="letter-spacing:0.05pt;">e</span>quired<span style="letter-spacing:-0.2pt;"> </span>to expend<span style="letter-spacing:-0.2pt;"> </span>sign<span style="letter-spacing:-0.1pt;">i</span>ficant<span style="letter-spacing:-0.4pt;"> </span>time<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>resources<span style="letter-spacing:-0.4pt;"> </span>to redesign<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>technology,<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the methods<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:-0.45pt;"> </span>them<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>deve<span style="letter-spacing:0.05pt;">l</span>op<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>replace<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.45pt;"> </span>technology,<span style="letter-spacing:-0.35pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>feasible<span style="letter-spacing:-0.4pt;"> </span>on a<span style="letter-spacing:-0.05pt;"> </span>technical<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>basis. If<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>so,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>com<span style="letter-spacing:0.05pt;">m</span>ercialize<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>aff<span style="letter-spacing:-0.05pt;">e</span>cted<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>continue<span style="letter-spacing:-0.35pt;"> </span>to utilize<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span>technology, which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>harm<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business, financial<span style="letter-spacing:-0.3pt;"> </span>condition,<span style="letter-spacing:-0.3pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>growth<span style="letter-spacing:-0.05pt;"> </span>prospects<span style="letter-spacing:-0.35pt;"> </span>significan<span style="letter-spacing:-0.05pt;">t</span>ly.<span style="letter-spacing:-0.45pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>cannot<span style="letter-spacing:-0.25pt;"> </span>provide<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>assurances<span style="letter-spacing:-0.35pt;"> </span>that third-party<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">a</span>tents<span style="letter-spacing:-0.15pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>exist<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>might<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>enforced<span style="letter-spacing:-0.3pt;"> </span>aga<span style="letter-spacing:0.05pt;">i</span>nst<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>current<span style="letter-spacing:-0.3pt;"> </span>technology,<span style="letter-spacing:-0.35pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>methods,<span style="letter-spacing:-0.3pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>duct<span style="letter-spacing:-0.2pt;"> </span>candid<span style="letter-spacing:0.05pt;">a</span>tes,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>methods or<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>resulting<span style="letter-spacing:-0.35pt;"> </span>in either<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>injunct<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.2pt;"> </span>prohibiting<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>man<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">f</span>acture<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>fut<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>sales,<span style="letter-spacing:-0.25pt;"> </span>or,<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>respect<span style="letter-spacing:-0.25pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>sale<span style="letter-spacing:-0.05pt;">s</span>,<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>obligation<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>part<span style="letter-spacing:-0.1pt;"> </span>to pay<span style="letter-spacing:-0.1pt;"> </span>royalties<span style="letter-spacing:-0.25pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>forms<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>compensation<span style="letter-spacing:-0.45pt;"> </span>to third<span style="letter-spacing:-0.1pt;"> </span>parti<span style="letter-spacing:-0.1pt;">e</span>s,<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>significant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>each<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>agreements,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>expect<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>agreements,<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>im<span style="letter-spacing:0.05pt;">p</span>ose<span style="letter-spacing:-0.1pt;"> </span>various<span style="letter-spacing:-0.3pt;"> </span>development,<span style="letter-spacing:-0.45pt;"> </span>diligence,<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">c</span>ommercialization,<span style="letter-spacing:-0.65pt;"> </span>and other<span style="letter-spacing:-0.25pt;"> </span>obligatio<span style="letter-spacing:0.05pt;">n</span>s<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>us.<span style="letter-spacing:-0.05pt;"> </span>Certain<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>agreements<span style="letter-spacing:-0.35pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.1pt;">e</span>quire<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>meet<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>ti<span style="letter-spacing:-0.1pt;">m</span>el<span style="letter-spacing:-0.05pt;">i</span>nes,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">e</span>xerc<span style="letter-spacing:-0.05pt;">i</span>se<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>omm<span style="letter-spacing:-0.05pt;">er</span>cially<span style="letter-spacing:-0.35pt;"> </span>reasonable efforts to develop<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>commercialize<span style="letter-spacing:-0.55pt;"> </span>licensed<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.1pt;">s</span>,<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>order<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>maintain<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>licenses.<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>spite<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>efforts,<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors<span style="letter-spacing:-0.35pt;"> </span>mig<span style="letter-spacing:0.05pt;">h</span>t<span style="letter-spacing:-0.2pt;"> </span>conclude<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have ma<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>ri<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>bre<span style="letter-spacing:-0.05pt;">a</span>ch<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span>our oblig<span style="letter-spacing:-0.05pt;">a</span>tions<span style="letter-spacing:-0.45pt;"> </span>und<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">e</span>nse<span style="letter-spacing:-0.15pt;"> </span>ag<span style="letter-spacing:-0.05pt;">r</span>ee<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.05pt;">n</span>ts<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nd<span style="letter-spacing:-0.05pt;"> </span>might<span style="letter-spacing:-0.2pt;"> </span>ther<span style="letter-spacing:0.05pt;">e</span>fore<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>rmin<span style="letter-spacing:0.05pt;">a</span>te<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>lic<span style="letter-spacing:0.05pt;">e</span>nse<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">a</span>gr<span style="letter-spacing:0.05pt;">e</span>ements,<span style="letter-spacing:-0.35pt;"> </span>th<span style="letter-spacing:0.05pt;">e</span>reby<span style="letter-spacing:-0.15pt;"> </span>removing or limiting our ability to develop<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>com<span style="letter-spacing:-0.1pt;">m</span>ercialize<span style="letter-spacing:-0.5pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>chnology<span style="letter-spacing:-0.35pt;"> </span>covered<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>ements.<span style="letter-spacing:-0.45pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>in-licenses<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>rmin<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>d,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>the u<span style="letter-spacing:0.05pt;">n</span>derlying<span style="letter-spacing:-0.25pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>fail<span style="letter-spacing:-0.05pt;"> </span>to provide<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>int<span style="letter-spacing:-0.2pt;">e</span>nded<span style="letter-spacing:-0.35pt;"> </span>exclusivity,<span style="letter-spacing:-0.35pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.25pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>freedom<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>seek<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>of, and to market,<span style="letter-spacing:-0.25pt;"> </span>products<span style="letter-spacing:-0.3pt;"> </span>identical<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>ours and<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>cease<span style="letter-spacing:-0.2pt;"> </span>our development<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>commerciali<span style="letter-spacing:-0.05pt;">z</span>ation<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>of Anktiva.<span style="letter-spacing:-0.25pt;"> </span>Any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>foregoing<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>material<span style="letter-spacing:-0.25pt;"> </span>adver<span style="letter-spacing:-0.1pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:0.05pt;">e</span>titive<span style="letter-spacing:-0.4pt;"> </span>position,<span style="letter-spacing:-0.3pt;"> </span>business,<span style="letter-spacing:-0.05pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>conditions,<span style="letter-spacing:-0.4pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">p</span>erations<span style="letter-spacing:-0.25pt;"> </span>and growth<span style="letter-spacing:0.05pt;"> </span>prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disputes</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arise</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regar</span><span style="letter-spacing:-0.05pt;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ing</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a licensing</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agr</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ement,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">scope</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">granted</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">un</span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="color:#000000;">er the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">license</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">g</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">em</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">her</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">int</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rpre</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">on-re</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">sues&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">extent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">ocesses</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">infringe</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">licensor</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">is not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">subject</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">censing agr</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">em</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">nt&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">sublicensing</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">a</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">under</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">collaborative</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">relationships&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">diligence</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">obligations</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">under</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">license</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">agreement</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">what</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">activ</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ties</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">satisfy</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">those</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diligence</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">obligations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">inventorship</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">ownership</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">inventions</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">know-how</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">resulting</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">joint</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">eati</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or use of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">intellect</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">by our licensors</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">pa</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">tners&#59;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">priority</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">invent</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">on</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patented</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">technology.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>agreements<span style="letter-spacing:-0.35pt;"> </span>und<span style="letter-spacing:-0.15pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>curre<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>ly<span style="letter-spacing:-0.35pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span>tellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>technology<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>complex,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>certain<span style="letter-spacing:-0.3pt;"> </span>provisions in such agr<span style="letter-spacing:-0.05pt;">e</span>e<span style="letter-spacing:-0.05pt;">m</span>ents<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>susc<span style="letter-spacing:-0.05pt;">e</span>ptib<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.15pt;"> </span>to <span style="letter-spacing:-0.05pt;">m</span>ult<span style="letter-spacing:-0.05pt;">i</span>ple<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rpr<span style="letter-spacing:-0.05pt;">e</span>ta<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:-0.1pt;">i</span>ons.<span style="letter-spacing:-0.45pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>resolution<span style="letter-spacing:-0.3pt;"> </span>of any<span style="letter-spacing:-0.15pt;"> </span>contract<span style="letter-spacing:-0.35pt;"> </span>interpretation<span style="letter-spacing:-0.5pt;"> </span>disagreement<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>arise<span style="letter-spacing:-0.2pt;"> </span>could narrow what<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>believe<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>scope<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>relevant<span style="letter-spacing:-0.25pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span>tellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>technology,<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>increase<span style="letter-spacing:-0.35pt;"> </span>what<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">b</span>elieve<span style="letter-spacing:-0.15pt;"> </span>to be<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>financial or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>obligations<span style="letter-spacing:-0.35pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>relevant<span style="letter-spacing:-0.3pt;"> </span>agreement,<span style="letter-spacing:-0.35pt;"> </span>either<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a material<span style="letter-spacing:-0.25pt;"> </span>adverse<span style="letter-spacing:-0.3pt;"> </span>eff<span style="letter-spacing:-0.05pt;">e</span>ct<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>condition,<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of o<span style="letter-spacing:0.05pt;">p</span>erations<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>growth<span style="letter-spacing:-0.05pt;"> </span>prospects.<span style="letter-spacing:-0.35pt;"> </span>Moreover,<span style="letter-spacing:-0.45pt;"> </span>if disputes<span style="letter-spacing:-0.25pt;"> </span>over<span style="letter-spacing:-0.1pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>censed<span style="letter-spacing:-0.25pt;"> </span>prevent<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>impair<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> a</span>b<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>int<span style="letter-spacing:-0.05pt;">a</span>in<span style="letter-spacing:-0.3pt;"> </span>our current<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>ic<span style="letter-spacing:-0.05pt;">e</span>ns<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.2pt;"> </span>arrangements<span style="letter-spacing:-0.5pt;"> </span>on com<span style="letter-spacing:-0.05pt;">m</span>erc<span style="letter-spacing:-0.05pt;">i</span>a<span style="letter-spacing:-0.05pt;">l</span>ly<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>pt<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.35pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>rms,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to successfully<span style="letter-spacing:-0.4pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>commerci<span style="letter-spacing:-0.05pt;">a</span>li<span style="letter-spacing:-0.05pt;">z</span>e<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>aff<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.25pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>odu<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndida<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>s,<span style="letter-spacing:-0.35pt;"> </span>wh<span style="letter-spacing:-0.05pt;">i</span>ch<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a material<span style="letter-spacing:-0.3pt;"> </span>adve<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>busi<span style="letter-spacing:-0.05pt;">n</span>ess,<span style="letter-spacing:-0.25pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>conditions,<span style="letter-spacing:-0.4pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>of operations<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>growth<span style="letter-spacing:0.05pt;"> </span>prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have<span style="letter-spacing:-0.15pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>mi<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;">e</span>ign<span style="letter-spacing:-0.05pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">l</span>ec<span style="letter-spacing:-0.05pt;">t</span>ual<span style="letter-spacing:-0.4pt;"> </span>proper<span style="letter-spacing:-0.05pt;">t</span>y rights<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>protect<span style="letter-spacing:-0.3pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.05pt;"> </span>rights t<span style="letter-spacing:0.05pt;">h</span>roug<span style="letter-spacing:0.05pt;">h</span>out<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>world.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>limited<span style="letter-spacing:-0.25pt;"> </span>int<span style="letter-spacing:-0.1pt;">e</span>llectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>outside<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>United<span style="letter-spacing:-0.25pt;"> </span>States.<span style="letter-spacing:-0.25pt;"> </span>Filing,<span style="letter-spacing:-0.25pt;"> </span>prosecuting<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>def<span style="letter-spacing:-0.05pt;">e</span>nding<span style="letter-spacing:-0.3pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndidates<span style="letter-spacing:-0.35pt;"> </span>in all<span style="letter-spacing:-0.15pt;"> </span>countries throughout<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>world<span style="letter-spacing:0.05pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>prohibitively<span style="letter-spacing:-0.4pt;"> </span>expensive,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>in some<span style="letter-spacing:-0.3pt;"> </span>countries<span style="letter-spacing:-0.4pt;"> </span>outside<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Unit<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">S</span>t<span style="letter-spacing:-0.05pt;">a</span>tes<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:-0.05pt;">e</span>ss extensive<span style="letter-spacing:-0.35pt;"> </span>than<span style="letter-spacing:-0.15pt;"> </span>those<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Uni<span style="letter-spacing:0.05pt;">t</span>ed<span style="letter-spacing:-0.2pt;"> </span>States.<span style="letter-spacing:-0.25pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>countries<span style="letter-spacing:-0.35pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>protect<span style="letter-spacing:-0.2pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>llectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">a</span>me<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">e</span>xt<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">a</span>s feder<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>s<span style="letter-spacing:-0.05pt;">t</span>ate<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>ws<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Unit<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>St<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.1pt;">s</span>.<span style="letter-spacing:-0.2pt;"> </span>Consequently,<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to p<span style="letter-spacing:0.05pt;">r</span>event<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>acticing<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>inv<span style="letter-spacing:0.05pt;">e</span>ntions<span style="letter-spacing:-0.35pt;"> </span>in all<span style="letter-spacing:-0.15pt;"> </span>countries o<span style="letter-spacing:0.05pt;">u</span>tside<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span>States,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>selling<span style="letter-spacing:-0.2pt;"> </span>or importing<span style="letter-spacing:-0.3pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>made<span style="letter-spacing:-0.25pt;"> </span>using<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>inventions<span style="letter-spacing:-0.35pt;"> </span>in and<span style="letter-spacing:-0.1pt;"> </span>into<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.25pt;"> </span>or other jurisdictions. Competitors may<span style="letter-spacing:-0.2pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>technologies<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>jurisdictions<span style="letter-spacing:-0.45pt;"> </span>where<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>obtained<span style="letter-spacing:-0.3pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>own<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>further,<span style="letter-spacing:-0.3pt;"> may export </span>otherwise<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;">f</span>ringing<span style="letter-spacing:-0.35pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>to territories<span style="letter-spacing:-0.35pt;"> </span>w<span style="letter-spacing:0.05pt;">h</span>ere<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>protection,<span style="letter-spacing:-0.4pt;"> </span>but<span style="letter-spacing:-0.05pt;"> </span>enforcement<span style="letter-spacing:-0.4pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>strong<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Unit<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.05pt;"> </span>Stat<span style="letter-spacing:0.05pt;">e</span>s.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:0.05pt;">s</span>e prod<span style="letter-spacing:0.05pt;">u</span>cts<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>compete<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candid<span style="letter-spacing:0.05pt;">a</span>tes<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>effective<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>suff<span style="letter-spacing:-0.05pt;">i</span>ci<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span>to pr<span style="letter-spacing:-0.05pt;">e</span>vent<span style="letter-spacing:-0.2pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span>m from<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>omp<span style="letter-spacing:-0.05pt;">e</span>ting.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many<span style="letter-spacing:0.05pt;"> </span>companies<span style="letter-spacing:-0.35pt;"> </span>ha<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:-0.15pt;"> </span>encountered<span style="letter-spacing:-0.5pt;"> </span>significant<span style="letter-spacing:-0.3pt;"> </span>problems<span style="letter-spacing:-0.3pt;"> </span>in protecting<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>defending<span style="letter-spacing:-0.3pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>in foreign<span style="letter-spacing:-0.3pt;"> </span>juris<span style="letter-spacing:-0.05pt;">d</span>ictions.<span style="letter-spacing:-0.5pt;"> </span>The legal systems<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>countries,<span style="letter-spacing:-0.3pt;"> </span>particularly<span style="letter-spacing:-0.35pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>developing<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ount<span style="letter-spacing:-0.05pt;">r</span>ies,<span style="letter-spacing:-0.3pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>favor<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>enforcement<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patents,<span style="letter-spacing:-0.35pt;"> </span>trade<span style="letter-spacing:-0.25pt;"> </span>secrets<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.05pt;"> </span>protection,<span style="letter-spacing:-0.4pt;"> </span>parti<span style="letter-spacing:0.1pt;">c</span>ularly<span style="letter-spacing:-0.4pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>relating<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>biopharma<span style="letter-spacing:-0.05pt;">c</span>eutical<span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">d</span>ucts,<span style="letter-spacing:-0.15pt;"> </span>whi<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>make<span style="letter-spacing:-0.2pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>diffic<span style="letter-spacing:-0.05pt;">u</span>lt<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>stop<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>infringement<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>competing<span style="letter-spacing:-0.35pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>vio<span style="letter-spacing:-0.05pt;">l</span>ation<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>proprietary<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.1pt;"> </span>generally.<span style="letter-spacing:-0.35pt;"> </span>Proceedings<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>enforce<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">i</span>n foreign<span style="letter-spacing:-0.2pt;"> </span>jurisdictions could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>divert<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>efforts<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>attention<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>aspects<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>put<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.15pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>being<span style="letter-spacing:-0.25pt;"> </span>invalidated or<span style="letter-spacing:0.05pt;"> </span>interpreted<span style="letter-spacing:-0.4pt;"> </span>narrowly<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>appli<span style="letter-spacing:-0.15pt;">c</span>ations<span style="letter-spacing:-0.5pt;"> </span>at risk<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>issuing<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>provoke<span style="letter-spacing:-0.25pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>to assert<span style="letter-spacing:-0.15pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>ag<span style="letter-spacing:-0.1pt;">a</span>inst<span style="letter-spacing:-0.3pt;"> </span>us.<span style="letter-spacing:0.05pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>prevail in <span style="letter-spacing:-0.05pt;">a</span>ny <span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>wsu<span style="letter-spacing:-0.05pt;">i</span>ts<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.1pt;"> </span>we <span style="letter-spacing:-0.05pt;">i</span>nit<span style="letter-spacing:-0.05pt;">i</span>at<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>damages<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>medies<span style="letter-spacing:-0.3pt;"> </span>awa<span style="letter-spacing:-0.05pt;">r</span>ded,<span style="letter-spacing:-0.4pt;"> </span>if any,<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>m<span style="letter-spacing:-0.05pt;">m</span>er<span style="letter-spacing:-0.05pt;">c</span>ia<span style="letter-spacing:-0.05pt;">l</span>ly<span style="letter-spacing:-0.5pt;"> </span>me<span style="letter-spacing:-0.05pt;">a</span>ningful.<span style="letter-spacing:-0.4pt;"> </span>A<span style="letter-spacing:-0.05pt;">c</span>cordingly,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>e<span style="letter-spacing:-0.05pt;">f</span>forts to enforce<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>around<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>world<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>inadequate<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>a significant<span style="letter-spacing:-0.35pt;"> </span>commercial<span style="letter-spacing:-0.45pt;"> </span>advantage<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>license.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many<span style="letter-spacing:0.05pt;"> </span>countries<span style="letter-spacing:-0.4pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>compulsory<span style="letter-spacing:-0.4pt;"> </span>licensing<span style="letter-spacing:-0.25pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>owner<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>compelled<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.05pt;"> </span>licenses<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties.<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">I</span>n<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>many countries<span style="letter-spacing:-0.3pt;"> </span>limit<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>enforceabili<span style="letter-spacing:-0.15pt;">t</span>y<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.3pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>agencies<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>gov<span style="letter-spacing:0.05pt;">e</span>rnment<span style="letter-spacing:-0.45pt;"> </span>contractors.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>countries,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>owner<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have li<span style="letter-spacing:-0.05pt;">m</span>it<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:0.05pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>med<span style="letter-spacing:-0.05pt;">i</span>es,<span style="letter-spacing:-0.25pt;"> </span>wh<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span>h<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>materially<span style="letter-spacing:-0.3pt;"> </span>diminish<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>value<span style="letter-spacing:-0.25pt;"> </span>of such<span style="letter-spacing:-0.05pt;"> </span>patent.<span style="letter-spacing:-0.2pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>forced<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">e</span>nse<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>th<span style="letter-spacing:-0.05pt;">i</span>rd<span style="letter-spacing:-0.05pt;"> </span>pa<span style="letter-spacing:-0.05pt;">r</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th respect<span style="letter-spacing:-0.2pt;"> </span>to any<span style="letter-spacing:-0.1pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>relevant<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>competi<span style="letter-spacing:-0.1pt;">t</span>ive<span style="letter-spacing:-0.4pt;"> </span>position<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>impaired,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>conditi<span style="letter-spacing:-0.1pt;">o</span>n,<span style="letter-spacing:-0.25pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>and prospects<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">a</span>dversely<span style="letter-spacing:-0.3pt;"> </span>affected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to claims</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our employees,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">consultants or i</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">depende</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">co</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">trac</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ors</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ave</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">wro</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">gfully</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">used</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">disclosed</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">trade</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">cr</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ts</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">oth</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r confident</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">forma</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ion</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">parti</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">claims</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">asserti</span><span style="letter-spacing:0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">g</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ownership</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">what</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">regard</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">own</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">property.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">e</span>ived<span style="letter-spacing:-0.3pt;"> </span>conf<span style="letter-spacing:-0.05pt;">i</span>dent<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>proprietary<span style="letter-spacing:-0.4pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>con<span style="letter-spacing:-0.05pt;">t</span>ractors.<span style="letter-spacing:-0.45pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>plan<span style="letter-spacing:-0.15pt;"> </span>to employ<span style="letter-spacing:-0.25pt;"> </span>and contract<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>individuals<span style="letter-spacing:-0.3pt;"> </span>who<span style="letter-spacing:-0.05pt;"> </span>were<span style="letter-spacing:-0.2pt;"> </span>previously<span style="letter-spacing:-0.35pt;"> </span>e<span style="letter-spacing:0.05pt;">m</span>ployed<span style="letter-spacing:-0.3pt;"> </span>at other<span style="letter-spacing:-0.25pt;"> </span>biotechnology<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>pharmaceutical<span style="letter-spacing:-0.6pt;"> </span>companies.<span style="letter-spacing:-0.35pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to <span style="letter-spacing:-0.05pt;">c</span>la<span style="letter-spacing:-0.05pt;">i</span>ms<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hat<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>employees,<span style="letter-spacing:-0.4pt;"> </span>consultants<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>ind<span style="letter-spacing:0.05pt;">e</span>pendent<span style="letter-spacing:-0.4pt;"> </span>contractors<span style="letter-spacing:-0.35pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>inadver<span style="letter-spacing:-0.05pt;">t</span>ently<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>otherwise<span style="letter-spacing:-0.3pt;"> </span>used<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>disclosed<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>trade<span style="letter-spacing:-0.25pt;"> </span>secrets<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">t</span>her<span style="letter-spacing:-0.25pt;"> </span>confidential information<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>emp<span style="letter-spacing:-0.05pt;">l</span>oyees&#8217;<span style="letter-spacing:-0.4pt;"> </span>former<span style="letter-spacing:-0.25pt;"> </span>e<span style="letter-spacing:-0.05pt;">m</span>ployers.<span style="letter-spacing:-0.35pt;"> </span>Litigation<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>necessary<span style="letter-spacing:-0.4pt;"> </span>to defend<span style="letter-spacing:-0.25pt;"> </span>against<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>pursue<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ai<span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">s</span>.<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">E</span>ven<span style="letter-spacing:-0.15pt;"> </span>if we are<span style="letter-spacing:-0.1pt;"> </span>succ<span style="letter-spacing:-0.05pt;">e</span>ssful<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>resolv<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.2pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">a</span>ims,<span style="letter-spacing:-0.25pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>tig<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.3pt;"> </span>cou<span style="letter-spacing:-0.05pt;">l</span>d<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>sub<span style="letter-spacing:0.05pt;">s</span>t<span style="letter-spacing:0.05pt;">a</span>nti<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ost<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>distraction<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>management<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>employees.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>while<span style="letter-spacing:-0.2pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>is our poli<span style="letter-spacing:-0.15pt;">c</span>y<span style="letter-spacing:-0.15pt;"> </span>to require<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>empl<span style="letter-spacing:0.05pt;">o</span>yees,<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>onsultants<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>independ<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.45pt;"> </span>contractors<span style="letter-spacing:-0.4pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>involved<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>conception<span style="letter-spacing:-0.35pt;"> </span>or development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>prop<span style="letter-spacing:0.05pt;">e</span>rty<span style="letter-spacing:-0.25pt;"> </span>to execute<span style="letter-spacing:-0.2pt;"> </span>agreements<span style="letter-spacing:-0.35pt;"> </span>assigning<span style="letter-spacing:-0.4pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>intell<span style="letter-spacing:-0.2pt;">e</span>ctual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>unsuccessful<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:-0.05pt;"> </span>executing<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>an agreement<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>each<span style="letter-spacing:-0.15pt;"> </span>party<span style="letter-spacing:-0.15pt;"> </span>who,<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>fact,<span style="letter-spacing:-0.15pt;"> </span>conceives<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>develops<span style="letter-spacing:-0.35pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>regard<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>own.<span style="letter-spacing:-0.05pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>assignment<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.15pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property rights<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>self-executing,<span style="letter-spacing:-0.6pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> a</span><span style="letter-spacing:0.05pt;">s</span>s<span style="letter-spacing:-0.05pt;">i</span>gn<span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.35pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>e<span style="letter-spacing:-0.05pt;">m</span>ents<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>bre<span style="letter-spacing:-0.05pt;">a</span>ched,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>forced<span style="letter-spacing:-0.2pt;"> </span>to bring<span style="letter-spacing:-0.15pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.3pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>ird<span style="letter-spacing:-0.2pt;"> </span>parties,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>defend claims<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>they<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>bring<span style="letter-spacing:-0.15pt;"> </span>against<span style="letter-spacing:-0.2pt;"> </span>us,<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>determine<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>ownership<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>wh<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;"> </span>we r<span style="letter-spacing:-0.05pt;">e</span>gard<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>our int<span style="letter-spacing:-0.05pt;">e</span>ll<span style="letter-spacing:-0.1pt;">e</span>ctual<span style="letter-spacing:-0.4pt;"> </span>property.<span style="letter-spacing:-0.35pt;"> </span>Any<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> f</span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>going<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a material<span style="letter-spacing:-0.3pt;"> </span>adve<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>bu<span style="letter-spacing:-0.05pt;">s</span>iness,<span style="letter-spacing:-0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition,<span style="letter-spacing:-0.3pt;"> </span>resul<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>perations,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>li<span style="letter-spacing:-0.05pt;">c</span>ense<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>acquire<span style="letter-spacing:-0.25pt;"> </span>new<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>necessary<span style="letter-spacing:-0.05pt;"> </span>i<span style="letter-spacing:-0.1pt;">n</span>tellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>rights<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.1pt;">e</span>chnology<span style="letter-spacing:-0.45pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>i<span style="letter-spacing:0.05pt;">r</span>d<span style="letter-spacing:-0.2pt;"> </span>pa<span style="letter-spacing:0.05pt;">r</span>ti<span style="letter-spacing:0.05pt;">e</span>s.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An<span style="letter-spacing:-0.05pt;"> </span>element<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>s<span style="letter-spacing:0.05pt;">t</span>rategy<span style="letter-spacing:-0.3pt;"> </span>is to<span style="letter-spacing:-0.1pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>intel<span style="letter-spacing:-0.1pt;">l</span>ectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>echnologies<span style="letter-spacing:-0.45pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">f</span>filiates.<span style="letter-spacing:-0.3pt;"> </span>Other parties,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>affiliates,<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.1pt;">a</span>tents<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>filed<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.1pt;">i</span>kely<span style="letter-spacing:-0.25pt;"> </span>filing<span style="letter-spacing:-0.15pt;"> </span>pat<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span>applications<span style="letter-spacing:-0.45pt;"> </span>potentially<span style="letter-spacing:-0.35pt;"> </span>relevant<span style="letter-spacing:-0.3pt;"> </span>to our b<span style="letter-spacing:0.05pt;">u</span>siness.<span style="letter-spacing:0.05pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>order<span style="letter-spacing:-0.25pt;"> </span>to avoid<span style="letter-spacing:-0.25pt;"> </span>infringing<span style="letter-spacing:-0.3pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>patents,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>find<span style="letter-spacing:-0.1pt;"> </span>it<span style="letter-spacing:-0.1pt;"> </span>necessary<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>prud<span style="letter-spacing:0.1pt;">e</span>nt<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>licenses<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>f<span style="letter-spacing:0.05pt;">r</span>om<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>parties.<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition, w<span style="letter-spacing:-0.05pt;">i</span>th r<span style="letter-spacing:-0.05pt;">e</span>sp<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>pa<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>nts<span style="letter-spacing:-0.3pt;"> </span>we <span style="letter-spacing:-0.05pt;">c</span>o-own<span style="letter-spacing:-0.05pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>parties, including<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>affiliates, we<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>nses<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>co-owners&#8217;<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">in</span>terest<span style="letter-spacing:-0.15pt;"> </span>to such<span style="letter-spacing:-0.05pt;"> </span>patents. The<span style="letter-spacing:-0.15pt;"> </span>licensing<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>acquisition<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:-0.5pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>competitive<span style="letter-spacing:-0.4pt;"> </span>area,<span style="letter-spacing:-0.1pt;"> </span>and other<span style="letter-spacing:-0.2pt;"> </span>mo<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>established<span style="letter-spacing:-0.35pt;"> </span>companies<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>pursue<span style="letter-spacing:0.05pt;"> </span>strategies<span style="letter-spacing:-0.3pt;"> </span>to license or<span style="letter-spacing:0.05pt;"> </span>acquire<span style="letter-spacing:-0.2pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>intellect<span style="letter-spacing:-0.1pt;">u</span>al<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>consider<span style="letter-spacing:-0.25pt;"> </span>attract<span style="letter-spacing:-0.1pt;">i</span>ve<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>necessary.<span style="letter-spacing:-0.3pt;"> </span>These<span style="letter-spacing:-0.25pt;"> </span>established<span style="letter-spacing:-0.4pt;"> </span>companies<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a competitive advantage<span style="letter-spacing:-0.35pt;"> </span>over<span style="letter-spacing:-0.15pt;"> </span>us due<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">t</span>heir<span style="letter-spacing:-0.1pt;"> </span>siz<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>pit<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:-0.05pt;">es</span>ources<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>greater<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>commercial<span style="letter-spacing:-0.05pt;">i</span>z<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.65pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>p<span style="letter-spacing:-0.05pt;">a</span>bi<span style="letter-spacing:-0.05pt;">l</span>it<span style="letter-spacing:-0.05pt;">i</span>es.<span style="letter-spacing:-0.35pt;"> </span>In addition,<span style="letter-spacing:-0.3pt;"> </span>companies<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>perceive<span style="letter-spacing:-0.3pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>a competitor<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>unwilling<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>assign<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>license<span style="letter-spacing:-0.3pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>to us.<span style="letter-spacing:0.05pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be unable<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>acquire<span style="letter-spacing:-0.3pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>party<span style="letter-spacing:-0.15pt;"> </span>intelle<span style="letter-spacing:-0.05pt;">c</span>tual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>on terms that<span style="letter-spacing:-0.1pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>allow<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to make<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>approp<span style="letter-spacing:-0.05pt;">r</span>iate<span style="letter-spacing:-0.35pt;"> </span>return<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>inv<span style="letter-spacing:-0.1pt;">e</span>stment<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>at all.<span style="letter-spacing:-0.15pt;"> </span>No<span style="letter-spacing:-0.05pt;"> </span>assurance<span style="letter-spacing:-0.3pt;"> </span>can<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>given<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>succ<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:0.05pt;">s</span>ful<span style="letter-spacing:-0.2pt;"> in licensing any additional </span>rights<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>technologies<span style="letter-spacing:-0.45pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>ird<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>af<span style="letter-spacing:0.05pt;">f</span>iliates.<span style="letter-spacing:-0.35pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>inability<span style="letter-spacing:-0.25pt;"> </span>to l<span style="letter-spacing:-0.05pt;">i</span>cense<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>techno<span style="letter-spacing:-0.05pt;">l</span>ogies<span style="letter-spacing:-0.5pt;"> </span>that we have identified, or<span style="letter-spacing:0.05pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>we <span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> i</span>n <span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span>id<span style="letter-spacing:-0.05pt;">e</span>ntify,<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.15pt;">c</span>ould<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>material<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">a</span>dverse<span style="letter-spacing:-0.2pt;"> </span>impact<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:0.1pt;">o</span>mplete<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>to develop<span style="letter-spacing:-0.25pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndidates.<span style="letter-spacing:-0.4pt;"> </span>Even<span style="letter-spacing:-0.15pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>were<span style="letter-spacing:-0.2pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to obtain<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>lice<span style="letter-spacing:-0.05pt;">n</span>se,<span style="letter-spacing:-0.15pt;"> </span>it could<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>non-exclu<span style="letter-spacing:0.05pt;">s</span>ive,<span style="letter-spacing:-0.5pt;"> </span>thereby<span style="letter-spacing:-0.25pt;"> </span>giving<span style="letter-spacing:-0.25pt;"> </span>our competitors<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>third parties<span style="letter-spacing:-0.2pt;"> </span>access<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>same<span style="letter-spacing:-0.15pt;"> </span>technologies<span style="letter-spacing:-0.45pt;"> </span>licensed<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>it could<span style="letter-spacing:-0.15pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to make<span style="letter-spacing:-0.2pt;"> </span>substantial<span style="letter-spacing:-0.45pt;"> </span>licensing<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>royalty<span style="letter-spacing:-0.2pt;"> </span>payments.<span style="letter-spacing:-0.3pt;"> </span>Failure<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>necessary<span style="letter-spacing:-0.4pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>licenses<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>detriment<span style="letter-spacing:-0.1pt;">a</span>lly<span style="letter-spacing:-0.45pt;"> </span>af<span style="letter-spacing:-0.05pt;">f</span>ect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>planned<span style="letter-spacing:-0.25pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>current<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>increase<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>cost,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>extend<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>timelines<span style="letter-spacing:-0.3pt;"> </span>associated<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>development,<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>products,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>to abandon<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>relevant program<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidate.<span style="letter-spacing:-0.3pt;"> </span>Any<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:-0.05pt;"> </span>foregoing<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>material<span style="letter-spacing:-0.25pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>ffect<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>co<span style="letter-spacing:0.05pt;">n</span>dition,<span style="letter-spacing:-0.3pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of o<span style="letter-spacing:0.05pt;">p</span>erations<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we<span style="letter-spacing:-0.1pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>ob<span style="letter-spacing:-0.05pt;">t</span>ain<span style="letter-spacing:-0.15pt;"> </span>pa<span style="letter-spacing:-0.05pt;">t</span>ent<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rm<span style="letter-spacing:-0.15pt;"> </span>ext<span style="letter-spacing:-0.05pt;">e</span>nsion<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>exclusivity<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.05pt;"> </span>product ca<span style="letter-spacing:0.05pt;">n</span>didat<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>d<span style="letter-spacing:0.05pt;">e</span>v<span style="letter-spacing:0.05pt;">e</span>lop,<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">m</span>at<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">i</span>ally<span style="letter-spacing:-0.3pt;"> </span>harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending<span style="letter-spacing:-0.45pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>timing,<span style="letter-spacing:-0.25pt;"> </span>duration<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>specifi<span style="letter-spacing:-0.05pt;">c</span>s<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>we may<span style="letter-spacing:-0.15pt;"> </span>develop,<span style="letter-spacing:-0.3pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our owned<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>in-licensed<span style="letter-spacing:-0.35pt;"> </span>U.S.&#160;patents<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>eligible<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>limited<span style="letter-spacing:-0.25pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>term<span style="letter-spacing:-0.1pt;"> </span>extension<span style="letter-spacing:-0.35pt;"> </span>under<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>D<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">u</span>g<span style="letter-spacing:-0.05pt;"> </span>Price<span style="letter-spacing:-0.15pt;"> </span>Competition<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>Patent<span style="letter-spacing:-0.15pt;"> </span>Term<span style="letter-spacing:-0.2pt;"> </span>Restoration<span style="letter-spacing:-0.35pt;"> </span>Act of&#160;1984<span style="letter-spacing:-0.05pt;"> (</span>the<span style="letter-spacing:-0.1pt;"> &#8220;</span>Hatch-Wa<span style="letter-spacing:0.05pt;">x</span><span style="letter-spacing:-0.05pt;">m</span>an<span style="letter-spacing:-0.55pt;"> </span>Act&#8221;).<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>Hatch-Waxman<span style="letter-spacing:-0.5pt;"> </span>Act<span style="letter-spacing:-0.1pt;"> </span>permits<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>term<span style="letter-spacing:-0.2pt;"> </span>extension<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>up<span style="letter-spacing:0.05pt;"> </span>to five&#160;years<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>compensation<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>te<span style="letter-spacing:-0.05pt;">r</span>m<span style="letter-spacing:-0.1pt;"> </span>lost d<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>ing the<span style="letter-spacing:-0.15pt;"> </span>FDA reg<span style="letter-spacing:0.05pt;">u</span>latory<span style="letter-spacing:-0.3pt;"> </span>review<span style="letter-spacing:-0.2pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">c</span>ess.<span style="letter-spacing:-0.15pt;"> </span>A<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>term<span style="letter-spacing:-0.1pt;"> </span>extension<span style="letter-spacing:-0.3pt;"> </span>cannot<span style="letter-spacing:-0.3pt;"> </span>extend<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>remaining<span style="letter-spacing:-0.35pt;"> </span>term<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>beyond<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>total<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>f<span style="letter-spacing:0.05pt;"> </span>14&#160;years<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>date<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>approval,<span style="letter-spacing:-0.3pt;"> </span>only<span style="letter-spacing:-0.15pt;"> </span>one<span style="letter-spacing:-0.15pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>extended<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>only<span style="letter-spacing:-0.15pt;"> </span>tho<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>covering<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>approved<span style="letter-spacing:-0.35pt;"> </span>drug,<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>method<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>using<span style="letter-spacing:-0.15pt;"> </span>it,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>a method<span style="letter-spacing:-0.25pt;"> </span>for manufacturing<span style="letter-spacing:-0.45pt;"> </span>it may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>extended.<span style="letter-spacing:-0.3pt;"> </span>Similar<span style="letter-spacing:-0.25pt;"> </span>e<span style="letter-spacing:-0.05pt;">x</span>tensions<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>compensation<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>term<span style="letter-spacing:-0.1pt;"> </span>lost<span style="letter-spacing:-0.1pt;"> </span>during<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>gulatory<span style="letter-spacing:-0.3pt;"> </span>re<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">i</span>ew<span style="letter-spacing:-0.15pt;"> </span>processes are<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.05pt;"> a</span>va<span style="letter-spacing:-0.05pt;">i</span>lab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.3pt;"> </span>in certain<span style="letter-spacing:-0.2pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>countries<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>territories,<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>Europe<span style="letter-spacing:-0.25pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>Supplementary<span style="letter-spacing:-0.5pt;"> </span>Patent<span style="letter-spacing:-0.2pt;"> </span>Certificate.<span style="letter-spacing:-0.4pt;"> </span>Howev<span style="letter-spacing:0.05pt;">e</span>r,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">g</span>ranted<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>extension<span style="letter-spacing:-0.35pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span>States<span style="letter-spacing:-0.15pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>countries<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>territories<span style="letter-spacing:-0.35pt;"> </span>because<span style="letter-spacing:-0.3pt;"> </span>of,<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>example,<span style="letter-spacing:-0.35pt;"> </span>failing<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>exercise<span style="letter-spacing:-0.25pt;"> </span>due<span style="letter-spacing:-0.2pt;"> </span>diligence<span style="letter-spacing:-0.35pt;"> </span>during<span style="letter-spacing:-0.3pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>testing<span style="letter-spacing:-0.2pt;"> </span>phase<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>regulatory review<span style="letter-spacing:-0.3pt;"> </span>process,<span style="letter-spacing:0.05pt;"> </span>failing<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>apply<span style="letter-spacing:-0.15pt;"> </span>within<span style="letter-spacing:-0.2pt;"> </span>applicable<span style="letter-spacing:-0.3pt;"> </span>d<span style="letter-spacing:-0.1pt;">e</span>adlines,<span style="letter-spacing:-0.35pt;"> </span>failing<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>apply<span style="letter-spacing:-0.2pt;"> </span>prior<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">e</span>xpiration<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>relevant<span style="letter-spacing:-0.3pt;"> </span>patents,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>otherwise<span style="letter-spacing:-0.15pt;"> </span>fa<span style="letter-spacing:-0.05pt;">i</span>ling<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">a</span>tisfy applicable<span style="letter-spacing:-0.35pt;"> </span>requirements.<span style="letter-spacing:-0.5pt;"> </span>Mor<span style="letter-spacing:-0.05pt;">e</span>over,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ppli<span style="letter-spacing:-0.05pt;">c</span>ab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.35pt;"> </span>ti<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.15pt;"> </span>period<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>scope<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>protect<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:-0.2pt;"> </span>afforded<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>less<span style="letter-spacing:0.05pt;"> </span>than<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.1pt;"> </span>request.<span style="letter-spacing:-0.25pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>unable to obtain<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>term<span style="letter-spacing:-0.1pt;"> </span>extension<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>term<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>extension<span style="letter-spacing:-0.3pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>shorter<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>an<span style="letter-spacing:-0.2pt;"> </span>what<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>request,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>competing prod<span style="letter-spacing:0.05pt;">u</span>cts<span style="letter-spacing:-0.05pt;"> </span>following<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>e<span style="letter-spacing:0.05pt;">x</span>piration,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>busine<span style="letter-spacing:0.05pt;">s</span>s,<span style="letter-spacing:-0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition,<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>growth<span style="letter-spacing:-0.05pt;"> </span>prospects<span style="letter-spacing:-0.4pt;"> </span>co<span style="letter-spacing:0.05pt;">u</span>ld<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:0.05pt;">e</span>ri<span style="letter-spacing:0.05pt;">a</span>lly<span style="letter-spacing:-0.35pt;"> </span>harm<span style="letter-spacing:0.05pt;">e</span>d.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to claims</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">challenging</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">inv</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">orship</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">oth</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">int</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ll</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ual</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">propert</span><span style="letter-spacing:-0.05pt;">y</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>fo<span style="letter-spacing:-0.05pt;">r</span>mer<span style="letter-spacing:-0.2pt;"> </span>employees,<span style="letter-spacing:-0.35pt;"> </span>collaborators<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>o<span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>par<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.2pt;"> </span>h<span style="letter-spacing:-0.05pt;">a</span>ve<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>rest<span style="letter-spacing:-0.25pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span>owned<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in-licensed patents,<span style="letter-spacing:-0.35pt;"> </span>trade<span style="letter-spacing:-0.15pt;"> </span>secrets,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>inventor<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>co-inv<span style="letter-spacing:-0.15pt;">e</span>ntor.<span style="letter-spacing:-0.25pt;"> </span>For example,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>ha<span style="letter-spacing:-0.05pt;">v</span>e<span style="letter-spacing:-0.15pt;"> </span>inventorship<span style="letter-spacing:-0.4pt;"> </span>disputes<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.05pt;">r</span>ise from<span style="letter-spacing:-0.15pt;"> </span>conflicting<span style="letter-spacing:-0.35pt;"> </span>obligations<span style="letter-spacing:-0.4pt;"> </span>of emplo<span style="letter-spacing:0.05pt;">y</span>ees,<span style="letter-spacing:-0.45pt;"> </span>consult<span style="letter-spacing:0.05pt;">a</span>nts<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>others<span style="letter-spacing:-0.15pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>involved<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>developing<span style="letter-spacing:-0.4pt;"> our </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates. Litigation<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>necessary<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>defend<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.3pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:0.05pt;">l</span>aims<span style="letter-spacing:-0.2pt;"> </span>challenging<span style="letter-spacing:-0.35pt;"> </span>inventorship<span style="letter-spacing:-0.5pt;"> </span>or our<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors&#8217;<span style="letter-spacing:-0.3pt;"> </span>ownership<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>owned<span style="letter-spacing:0.05pt;"> </span>or in-licensed<span style="letter-spacing:-0.4pt;"> </span>patents,<span style="letter-spacing:-0.25pt;"> </span>trade<span style="letter-spacing:-0.2pt;"> </span>secrets<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>oth<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>licensors<span style="letter-spacing:-0.35pt;"> </span>fail<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>defending<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>claims,<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>addition<span style="letter-spacing:-0.25pt;"> </span>to p<span style="letter-spacing:-0.05pt;">a</span>ying<span style="letter-spacing:-0.2pt;"> </span>monetary dam<span style="letter-spacing:-0.05pt;">a</span>ges,<span style="letter-spacing:-0.2pt;"> </span>we <span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>lose<span style="letter-spacing:-0.1pt;"> </span>v<span style="letter-spacing:-0.05pt;">a</span>lu<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">l</span>ec<span style="letter-spacing:-0.05pt;">t</span>ual<span style="letter-spacing:-0.5pt;"> </span>prope<span style="letter-spacing:-0.05pt;">r</span>ty<span style="letter-spacing:-0.2pt;"> </span>rights,<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>exclusive<span style="letter-spacing:-0.35pt;"> </span>ownership<span style="letter-spacing:0.05pt;"> </span>of,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>right<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>use,<span style="letter-spacing:-0.05pt;"> valuable </span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.05pt;">c</span>tual property.<span style="letter-spacing:-0.45pt;"> </span>Even<span style="letter-spacing:-0.25pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>successful<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>defending<span style="letter-spacing:-0.3pt;"> </span>against<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>claims,<span style="letter-spacing:-0.25pt;"> </span>litigation<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>sult<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>sub<span style="letter-spacing:0.05pt;">s</span>t<span style="letter-spacing:0.05pt;">a</span>nti<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">c</span>osts and<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>a distraction<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>management<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>employees.<span style="letter-spacing:-0.35pt;"> </span>Any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>foregoing<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a material<span style="letter-spacing:-0.3pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">e</span>ffect<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">b</span>usin<span style="letter-spacing:0.05pt;">e</span>ss,<span style="letter-spacing:-0.1pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition, results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operati<span style="letter-spacing:0.05pt;">o</span>ns<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>growth<span style="letter-spacing:0.05pt;"> </span>prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September&#160;10,&#160;2020, a legal complaint was filed in a California court where Institute for Cancer Research (d/b/a Fox Chase Cancer Center) argued that it has a co-ownership interest in U.S.&#160;Patent No.&#160;10,456,420 and its underlying U.S. Patent Application No.&#160;15/529,848, as well as in certain related patent applications or issued patents that include claimed subject matter allegedly invented by one of the claimant&#8217;s employees. On September&#160;30,&#160;2020, we filed motion with the court asking that the complaint be dismissed. We disagree that this claim for co-ownership has merit and intend to vigorously defend our position. All of the existing named inventors have assigned their rights in this patent to us. We will continue to have an undivided interest in the entire patent even if claimant succeeds in this suit. However, litigating this matter could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to protect<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.15pt;"> </span>confidentiality<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r t<span style="letter-spacing:0.05pt;">r</span>ade<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:0.05pt;">e</span>c<span style="letter-spacing:0.05pt;">r</span>ets,<span style="letter-spacing:-0.1pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r business and<span style="letter-spacing:0.1pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>pe<span style="letter-spacing:-0.05pt;">t</span>it<span style="letter-spacing:-0.05pt;">i</span>ve<span style="letter-spacing:-0.35pt;"> </span>pos<span style="letter-spacing:-0.05pt;">i</span>t<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.2pt;"> </span>wou<span style="letter-spacing:-0.05pt;">l</span>d<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">h</span>ar<span style="letter-spacing:-0.05pt;">m</span>ed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>seeking<span style="letter-spacing:-0.2pt;"> </span>patents<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>Anktiva,<span style="letter-spacing:-0.35pt;"> hAd5</span><span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>yeast<span style="letter-spacing:-0.15pt;"> </span>te<span style="letter-spacing:-0.05pt;">c</span>hn<span style="letter-spacing:0.05pt;">o</span>logies<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>oduct<span style="letter-spacing:-0.15pt;"> </span>candidates<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>technologies,<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>lso<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>ly<span style="letter-spacing:-0.1pt;"> </span>on tr<span style="letter-spacing:-0.05pt;">a</span>de<span style="letter-spacing:-0.15pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>cr<span style="letter-spacing:-0.05pt;">e</span>ts and<span style="letter-spacing:-0.1pt;"> </span>confidentiality<span style="letter-spacing:-0.45pt;"> </span>agreements<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>otect<span style="letter-spacing:-0.15pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>unpatented<span style="letter-spacing:-0.35pt;"> </span>know-how,<span style="letter-spacing:-0.05pt;"> </span>technology,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>proprietary<span style="letter-spacing:-0.4pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>to mainta<span style="letter-spacing:-0.1pt;">i</span>n<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>omp<span style="letter-spacing:-0.05pt;">e</span>ti<span style="letter-spacing:-0.05pt;">t</span>ive p<span style="letter-spacing:0.05pt;">o</span>sition.<span style="letter-spacing:-0.15pt;"> </span>Trade<span style="letter-spacing:-0.25pt;"> </span>secrets<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>know-how<span style="letter-spacing:-0.05pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>difficult<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>protect.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>expect<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>trade<span style="letter-spacing:-0.25pt;"> </span>secrets<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>know-how<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>over<span style="letter-spacing:-0.15pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>dis<span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:-0.05pt;">m</span>ina<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.35pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>thin<span style="letter-spacing:-0.15pt;"> </span>the industry<span style="letter-spacing:-0.25pt;"> </span>through<span style="letter-spacing:-0.25pt;"> </span>independent<span style="letter-spacing:-0.4pt;"> </span>deve<span style="letter-spacing:-0.05pt;">l</span>opment,<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>publication<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>journ<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>articles<span style="letter-spacing:-0.2pt;"> </span>des<span style="letter-spacing:-0.1pt;">c</span>ribing<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>methodology,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>movement<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">p</span>ersonnel<span style="letter-spacing:-0.3pt;"> </span>from academic<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>industry<span style="letter-spacing:-0.25pt;"> </span>s<span style="letter-spacing:0.05pt;">c</span>ientific<span style="letter-spacing:-0.2pt;"> </span>positions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>seek<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>protect<span style="letter-spacing:-0.25pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>trade<span style="letter-spacing:-0.2pt;"> </span>secrets<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nd other<span style="letter-spacing:-0.15pt;"> </span>proprietary<span style="letter-spacing:-0.35pt;"> </span>technology,<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>part,<span style="letter-spacing:-0.1pt;"> </span>by entering<span style="letter-spacing:-0.3pt;"> </span>into<span style="letter-spacing:-0.1pt;"> </span>nondisclosure<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>confidentia<span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.5pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>e<span style="letter-spacing:-0.05pt;">m</span>ents<span style="letter-spacing:-0.45pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.1pt;"> </span>parties<span style="letter-spacing:0.05pt;"> </span>who have<span style="letter-spacing:-0.2pt;"> </span>access<span style="letter-spacing:-0.2pt;"> </span>to them,<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>employees,<span style="letter-spacing:-0.35pt;"> </span>corporate<span style="letter-spacing:-0.3pt;"> </span>collaborators,<span style="letter-spacing:-0.45pt;"> </span>outs<span style="letter-spacing:-0.05pt;">i</span>de<span style="letter-spacing:-0.25pt;"> </span>s<span style="letter-spacing:-0.05pt;">c</span>ien<span style="letter-spacing:-0.05pt;">t</span>ific<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>oll<span style="letter-spacing:-0.05pt;">a</span>borators,<span style="letter-spacing:-0.3pt;"> </span>CROs,<span style="letter-spacing:-0.05pt;"> </span>CMOs,<span style="letter-spacing:-0.5pt;"> </span>consultants, advisors,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>th<span style="letter-spacing:-0.05pt;">i</span>rd<span style="letter-spacing:-0.05pt;"> </span>par<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">e</span>s.<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">W</span>e<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.15pt;"> </span>ent<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>nto<span style="letter-spacing:-0.05pt;"> c</span>onfid<span style="letter-spacing:-0.05pt;">e</span>nti<span style="letter-spacing:-0.05pt;">a</span>li<span style="letter-spacing:-0.1pt;">t</span>y<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>invention<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>pat<span style="letter-spacing:-0.1pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span>sign<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.35pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>e<span style="letter-spacing:-0.05pt;">m</span>ents<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>employees<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>consultants<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>well<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">r</span>ain<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>employees<span style="letter-spacing:-0.45pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>to bring<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>proprietary<span style="letter-spacing:-0.35pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.1pt;">e</span>chnology<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>former<span style="letter-spacing:-0.2pt;"> </span>employers<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in their<span style="letter-spacing:-0.15pt;"> </span>w<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span>k,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>remind<span style="letter-spacing:-0.2pt;"> </span>former<span style="letter-spacing:0.05pt;"> </span>empl<span style="letter-spacing:0.05pt;">o</span>yees<span style="letter-spacing:-0.35pt;"> </span>when they<span style="letter-spacing:-0.1pt;"> </span>leave<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>eir<span style="letter-spacing:-0.15pt;"> </span>employment<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>confidentiality<span style="letter-spacing:-0.45pt;"> </span>obli<span style="letter-spacing:-0.05pt;">g</span>ations.<span style="letter-spacing:-0.45pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>cannot<span style="letter-spacing:-0.25pt;"> </span>guarantee<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:0.05pt;">e</span>red<span style="letter-spacing:-0.15pt;"> </span>into<span style="letter-spacing:-0.1pt;"> </span>su<span style="letter-spacing:0.05pt;">c</span>h agreements<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>each<span style="letter-spacing:-0.15pt;"> </span>party<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>had<span style="letter-spacing:-0.2pt;"> </span>access<span style="letter-spacing:-0.2pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>trade<span style="letter-spacing:-0.15pt;"> </span>secrets<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>proprietary<span style="letter-spacing:-0.35pt;"> </span>technology<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>processes.<span style="letter-spacing:0.05pt;"> </span>Despite<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>efforts,<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of these<span style="letter-spacing:-0.2pt;"> </span>par<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.3pt;"> </span>may bre<span style="letter-spacing:-0.05pt;">a</span>ch<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>em<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>nd disclose<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>proprietary<span style="letter-spacing:-0.35pt;"> </span>i<span style="letter-spacing:-0.1pt;">n</span>formation,<span style="letter-spacing:-0.45pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>trade<span style="letter-spacing:-0.25pt;"> </span>secrets,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be able<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>adequate<span style="letter-spacing:-0.35pt;"> </span>rem<span style="letter-spacing:-0.05pt;">e</span>dies<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>such bre<span style="letter-spacing:-0.05pt;">a</span>ches.<span style="letter-spacing:-0.3pt;"> </span>Enfor<span style="letter-spacing:-0.05pt;">c</span>ing<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>cl<span style="letter-spacing:-0.05pt;">a</span>im<span style="letter-spacing:-0.2pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>a p<span style="letter-spacing:-0.05pt;">a</span>rty<span style="letter-spacing:-0.2pt;"> </span>il<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.05pt;">g</span>ally<span style="letter-spacing:-0.35pt;"> </span>disclosed<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>misappropriated<span style="letter-spacing:-0.5pt;"> </span>a<span style="letter-spacing:-0.05pt;"> t</span>rade<span style="letter-spacing:-0.15pt;"> </span>secr<span style="letter-spacing:-0.05pt;">e</span>t<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>d<span style="letter-spacing:-0.05pt;">i</span>fficu<span style="letter-spacing:-0.05pt;">l</span>t,<span style="letter-spacing:-0.35pt;"> </span>expensive,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>time-consuming,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>outcome<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>unpredictable.<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">c</span>ourts inside<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>outside<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Uni<span style="letter-spacing:-0.1pt;">t</span>ed<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>less<span style="letter-spacing:0.05pt;"> </span>willing<span style="letter-spacing:-0.3pt;"> </span>or u<span style="letter-spacing:0.05pt;">n</span>willing<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>protect<span style="letter-spacing:-0.25pt;"> </span>trade<span style="letter-spacing:-0.25pt;"> </span>secrets.<span style="letter-spacing:-0.3pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>trade<span style="letter-spacing:-0.25pt;"> </span>secrets<span style="letter-spacing:-0.2pt;"> </span>w<span style="letter-spacing:0.05pt;">e</span>re to be<span style="letter-spacing:-0.15pt;"> </span>lawfully<span style="letter-spacing:-0.35pt;"> </span>obtained<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>independently<span style="letter-spacing:-0.5pt;"> </span>developed<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>a c<span style="letter-spacing:0.05pt;">o</span>mpetitor<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>third party,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>rig<span style="letter-spacing:0.05pt;">h</span>t<span style="letter-spacing:-0.1pt;"> </span>to prevent<span style="letter-spacing:-0.3pt;"> </span>them<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>using<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>technology<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>information<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>compete<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>us.<span style="letter-spacing:-0.05pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ade<span style="letter-spacing:-0.25pt;"> </span>secr<span style="letter-spacing:-0.05pt;">e</span>ts<span style="letter-spacing:-0.15pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o be disclosed<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>independently<span style="letter-spacing:-0.5pt;"> </span>developed<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>a competitor<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>party,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>com<span style="letter-spacing:-0.05pt;">p</span>etitive<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">p</span>osition<span style="letter-spacing:-0.25pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>materially<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>harmed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.05pt;"> </span>our trademarks<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>trade<span style="letter-spacing:-0.25pt;"> </span>names<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>ad<span style="letter-spacing:0.05pt;">e</span>quately<span style="letter-spacing:-0.35pt;"> </span>protected,<span style="letter-spacing:-0.35pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>en<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to build<span style="letter-spacing:-0.2pt;"> </span>name<span style="letter-spacing:-0.2pt;"> </span>recognition<span style="letter-spacing:-0.4pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span>marke<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>interest<span style="letter-spacing:-0.25pt;"> </span>and o<span style="letter-spacing:0.05pt;">u</span>r busi<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">e</span>ss<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>adversely<span style="letter-spacing:-0.4pt;"> </span>affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>registered<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>unregistered<span style="letter-spacing:-0.4pt;"> </span>trademarks<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ade<span style="letter-spacing:-0.25pt;"> </span>names<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>challenged,<span style="letter-spacing:-0.4pt;"> </span>infringed,<span style="letter-spacing:-0.4pt;"> </span>circumvented<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>dec<span style="letter-spacing:-0.05pt;">l</span>ared<span style="letter-spacing:-0.3pt;"> </span>generic<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>det<span style="letter-spacing:-0.05pt;">e</span>rmined<span style="letter-spacing:-0.35pt;"> </span>to be<span style="letter-spacing:-0.15pt;"> </span>infringing on<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>marks.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to pro<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>our righ<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>tr<span style="letter-spacing:-0.05pt;">a</span>dem<span style="letter-spacing:-0.05pt;">a</span>rks<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd<span style="letter-spacing:-0.05pt;"> </span>tr<span style="letter-spacing:-0.05pt;">a</span>de<span style="letter-spacing:-0.25pt;"> </span>names,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to build<span style="letter-spacing:-0.15pt;"> </span>name<span style="letter-spacing:-0.25pt;"> </span>reco<span style="letter-spacing:-0.1pt;">g</span>nition<span style="letter-spacing:-0.35pt;"> </span>among p<span style="letter-spacing:0.05pt;">o</span>tential<span style="letter-spacing:-0.15pt;"> </span>partners<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>customers<span style="letter-spacing:-0.3pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span>markets<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>interest.<span style="letter-spacing:-0.25pt;"> </span>At<span style="letter-spacing:-0.05pt;"> </span>times,<span style="letter-spacing:-0.15pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>ird<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>adopt<span style="letter-spacing:-0.2pt;"> </span>trade<span style="letter-spacing:-0.15pt;"> </span>names<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>tr<span style="letter-spacing:-0.05pt;">a</span>de<span style="letter-spacing:-0.05pt;">m</span>arks<span style="letter-spacing:-0.15pt;"> </span>sim<span style="letter-spacing:-0.05pt;">i</span>l<span style="letter-spacing:-0.05pt;">a</span>r<span style="letter-spacing:-0.15pt;"> </span>to o<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>ereby<span style="letter-spacing:-0.3pt;"> </span>im<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">e</span>ding<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to build<span style="letter-spacing:-0.25pt;"> </span>brand<span style="letter-spacing:-0.15pt;"> </span>identity<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>possibly<span style="letter-spacing:-0.35pt;"> </span>leading<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>mar<span style="letter-spacing:0.05pt;">k</span>et<span style="letter-spacing:-0.3pt;"> </span>confusion.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>there<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>trade<span style="letter-spacing:-0.15pt;"> </span>name<span style="letter-spacing:-0.25pt;"> </span>or tradema<span style="letter-spacing:-0.05pt;">r</span>k<span style="letter-spacing:-0.25pt;"> </span>infringement<span style="letter-spacing:-0.45pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>brought<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>owners of<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>registered<span style="letter-spacing:-0.3pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ademarks<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>trademarks<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>incorporate<span style="letter-spacing:-0.4pt;"> </span>variations<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>registered<span style="letter-spacing:-0.3pt;"> </span>or u<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>gistered<span style="letter-spacing:-0.3pt;"> </span>trademarks<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>trade<span style="letter-spacing:-0.2pt;"> </span>names.<span style="letter-spacing:-0.25pt;"> </span>Over<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>long<span style="letter-spacing:-0.1pt;"> </span>term,<span style="letter-spacing:-0.25pt;"> </span>if we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>e<span style="letter-spacing:-0.1pt;">s</span>tablish<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">a</span>me<span style="letter-spacing:-0.1pt;"> </span>recognition<span style="letter-spacing:-0.35pt;"> </span>based<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>tradem<span style="letter-spacing:-0.05pt;">a</span>rks<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>trade<span style="letter-spacing:-0.15pt;"> </span>names, th<span style="letter-spacing:0.05pt;">e</span>n<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">w</span>e<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">c</span>om<span style="letter-spacing:0.05pt;">p</span>ete<span style="letter-spacing:-0.25pt;"> </span>eff<span style="letter-spacing:0.05pt;">e</span>ctively<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>adversely<span style="letter-spacing:-0.4pt;"> </span>aff<span style="letter-spacing:-0.05pt;">e</span>cted.<span style="letter-spacing:-0.35pt;"> </span>Our efforts<span style="letter-spacing:-0.2pt;"> </span>to enforce<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>protect<span style="letter-spacing:-0.2pt;"> </span>o<span style="letter-spacing:-0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>proprietary<span style="letter-spacing:-0.4pt;"> </span>rights related<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>trademarks,<span style="letter-spacing:-0.35pt;"> </span>trade<span style="letter-spacing:-0.15pt;"> </span>sec<span style="letter-spacing:0.1pt;">r</span>ets,<span style="letter-spacing:-0.2pt;"> </span>domain<span style="letter-spacing:-0.25pt;"> </span>names,<span style="letter-spacing:-0.2pt;"> </span>copyrights<span style="letter-spacing:-0.45pt;"> </span>or other<span style="letter-spacing:-0.15pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>ineffective<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>resu<span style="letter-spacing:-0.05pt;">l</span>t<span style="letter-spacing:-0.05pt;"> </span>in substan<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>os<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.1pt;"> </span>and diversion<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>resources<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business, financial<span style="letter-spacing:-0.25pt;"> </span>condition,<span style="letter-spacing:-0.35pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>sults<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>growth<span style="letter-spacing:0.05pt;"> </span>prospect<span style="letter-spacing:-0.1pt;">s</span>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">pr</span><span style="letter-spacing:0.05pt;">o</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">perty</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">rights</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">do</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">necessarily</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">address all</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">potential</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">threats.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>degree<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>afforded<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>uncertain<span style="letter-spacing:-0.3pt;"> </span>because<span style="letter-spacing:-0.25pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>limitations<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not adequately<span style="letter-spacing:-0.35pt;"> </span>protect<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>permit<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> m</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">i</span>nta<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>our comp<span style="letter-spacing:-0.05pt;">e</span>ti<span style="letter-spacing:-0.05pt;">t</span>ive<span style="letter-spacing:-0.45pt;"> </span>advantage.<span style="letter-spacing:-0.4pt;"> </span>For<span style="letter-spacing:0.05pt;"> </span>example:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">others</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">able</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">make</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">ducts</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">h</span><span style="color:#000000;">at</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">similar</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or utilize</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">similar</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">but</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">covered</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the claims</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">license</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">own&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we, or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">licensors</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">collaborators,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">might</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">been</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">first</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">make</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">inven</span><span style="letter-spacing:-0.1pt;color:#000000;">t</span><span style="color:#000000;">ions</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">covered</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">ssued patent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or pending</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">appl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">cation</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">license</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">own</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">now</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">in the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we, or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">licensors</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">collaborators,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">might</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">been</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">first</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">file</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">tent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.1pt;color:#000000;">a</span><span style="color:#000000;">pplications</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">covering</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">rtain</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or their</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">inventions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">others</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">independently</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">deve</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">op</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">similar</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">alternati</span><span style="letter-spacing:-0.05pt;color:#000000;">v</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">technologies</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">duplicate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">technologies</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">without</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">infringing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ow</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d or </span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">en</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">in</span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">tual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">t is</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">possible</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">pending</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">owned</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">licensed</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">applications</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">le</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;"> t</span><span style="color:#000000;">o issued pat</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ssued</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">hold</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ights</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">held</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">invalid</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">unenforceable,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">result</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">legal</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">challenges</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> c</span><span style="color:#000000;">ompetitors</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">parties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">competitors</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">pa</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ties</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ght</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">conduct</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">research</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">activities</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in countries</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">where</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">do not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">pa</span><span style="letter-spacing:0.1pt;color:#000000;">t</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rights and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">then</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">information</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">learned</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">ch</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">activities</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">competitive</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">sale</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">major</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">mark</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">s&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">proprietary</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">technologies</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">patenta</span><span style="letter-spacing:0.05pt;color:#000000;">b</span><span style="color:#000000;">le&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">others</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:0.1pt;color:#000000;">a</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">harm</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">business&#59;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">choose</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">file</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a patent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in order</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">maintain</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">certain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trade</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">secrets</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">know-how,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">party</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">subsequently</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">file</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">tent covering</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">property.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>events<span style="letter-spacing:-0.25pt;"> </span>occur,<span style="letter-spacing:-0.2pt;"> </span>they<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a material<span style="letter-spacing:-0.3pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>ef<span style="letter-spacing:-0.05pt;">f</span>ect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:-0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition,<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>growth prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks<span style="letter-spacing:-0.05pt;"> </span>Related<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>Our<span style="letter-spacing:-0.1pt;"> </span>Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dr. Soon-Shiong,<span style="letter-spacing:0.05pt;"> </span>o<span style="letter-spacing:-0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> E</span>xecutive<span style="letter-spacing:-0.35pt;"> C</span>hairman and our principal stockholder, h<span style="letter-spacing:0.05pt;">a</span>s signifi<span style="letter-spacing:0.05pt;">c</span>ant interests<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>oth<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ompanies<span style="letter-spacing:-0.35pt;"> </span>w<span style="letter-spacing:0.05pt;">h</span>i<span style="letter-spacing:0.05pt;">c</span>h<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">c</span>onfli<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.1pt;"> </span>our i<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:0.05pt;">e</span>sts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Executive<span style="letter-spacing:-0.35pt;"> C</span>hairma<span style="letter-spacing:0.05pt;">n</span>, Dr.&#160;Soon-Shiong, is the founder of NantWorks. The various NantWorks companies are currently exploring opportunities in the immunotherapy,<span style="letter-spacing:-0.55pt;"> </span>oncology, infectious disease and inflammatory disease fields. In particular, we have agreements with a number of related parties that provide services, technology and equipment for use in their efforts to develop their product pipelines. Dr.&#160;Soon-Shiong holds a controlling interest, either directly or indirectly, in these entities. Consequently, Dr.&#160;Soon-Shiong&#8217;s interests may not be aligned with our other stockholders and he may from time to time be incentivized to take certain actions that benefit his other interests and that our other stockholders do not view as being in their interest as investors in our company. In addition, other companies affiliated with Dr.&#160;Soon-Shiong may compete with us for business opportunities or, in the future, develop products that are competitive with ours (including products in other therapeutic fields which we may target in the future). Moreover, even if they do not directly relate to us, actions taken by Dr.&#160;Soon-Shiong and the companies with which he is involved could impact us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also pursuing supply arrangements for various investigational agents controlled by affiliates to be used in their clinical trials. If Dr.&#160;Soon-Shiong w<span style="letter-spacing:-0.05pt;">e</span>re to cease his affiliation with us or NantWorks, these entities may be unwilling to continue these relationships with us on commercially reasonable terms, or at all, and as a result may impede our ability to control the supply chain for our combination therapies. These collaboration agreements do not typically specify how sales will be apportioned between the parties upon successful commercialization of the product. As a result, we cannot guarantee that we will receive a percentage of the revenues that is at least proportional to the costs that we will incur in commercializing the product candidate.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> entered into </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sh</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">red</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rvic</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agr</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ents </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with NantWorks, pursuant to which NantWorks and its affiliates provide corporate, general and administrative and other support services to us</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> If Dr.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soon-Shiong was to cease his affiliation with us or with NantWorks, we may be unable to establish or maintain this relationship with NantWorks on a commercially reasonable basis, if at all. As a result, we could experience a lack of business continuity due to loss of historical and institutional knowledge and a lack of familiarity of new employees and/or new service providers with business processes, operating requirements, policies and procedures, and we may incur additional costs as new employees and/or service providers gain necessary experience. In addition, the loss of the services of NantWorks might significantly delay or prevent the development of our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ca</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">didates </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or achievement of other business objectives by diverting management&#8217;s attention to transition matters and identification of suitable replacements, if any, and could have a material adverse effect on our business and results of operations.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dr.<span style="letter-spacing:-0.05pt;"> </span>Soon-Shiong,<span style="letter-spacing:-0.05pt;"> </span>through<span style="letter-spacing:0.05pt;"> </span>his<span style="letter-spacing:-0.05pt;"> </span>voti<span style="letter-spacing:-0.05pt;">n</span>g<span style="letter-spacing:-0.15pt;"> </span>co<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">r</span>ol<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>compan<span style="letter-spacing:0.05pt;">y</span>,<span style="letter-spacing:-0.15pt;"> has the ability</span><span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>control<span style="letter-spacing:-0.3pt;"> </span>actions<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>req<span style="letter-spacing:-0.05pt;">u</span>ire<span style="letter-spacing:-0.1pt;"> </span>stockholder a<span style="letter-spacing:0.05pt;">p</span>proval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr.&#160;Soon-Shiong,<span style="letter-spacing:-0.05pt;"> </span>through<span style="letter-spacing:-0.35pt;"> </span>his<span style="letter-spacing:-0.05pt;"> </span>direct<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>indi<span style="letter-spacing:0.05pt;">r</span>ect<span style="letter-spacing:-0.2pt;"> </span>ownership<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>company&#8217;s<span style="letter-spacing:-0.5pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock,<span style="letter-spacing:-0.25pt;"> has</span><span style="letter-spacing:-0.1pt;"> </span>voting<span style="letter-spacing:-0.2pt;"> </span>control<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>company.<span style="letter-spacing:-0.4pt;"> As of</span><span style="letter-spacing:-0.3pt;"> June&#160;30,&#160;2021</span>,<span style="letter-spacing:-0.25pt;"> </span>Dr.&#160;So<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.05pt;">-</span><span style="letter-spacing:0.05pt;">S</span>hiong<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>his<span style="letter-spacing:-0.05pt;"> </span>af<span style="letter-spacing:0.05pt;">f</span>iliates<span style="letter-spacing:-0.25pt;"> </span>beneficially<span style="letter-spacing:-0.4pt;"> </span>own<span style="letter-spacing:0.05pt;"> </span>approximately&#160;80.3%<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>company&#8217;s<span style="letter-spacing:-0.35pt;"> </span>common<span style="letter-spacing:-0.3pt;"> </span>stock<span style="letter-spacing:-0.25pt;"> </span>outstanding.<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">A</span>dditionally,<span style="letter-spacing:-0.35pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>affilia<span style="letter-spacing:-0.1pt;">t</span>e<span style="letter-spacing:-0.25pt;"> </span>of Dr.&#160;Soon-Shiong holds<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>warrant<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>pur<span style="letter-spacing:0.05pt;">c</span>ha<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>additional 1,638,000&#160;shares<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> the</span><span style="letter-spacing:-0.35pt;"> </span>comp<span style="letter-spacing:0.05pt;">a</span>ny&#8217;s<span style="letter-spacing:-0.2pt;"> </span>common<span style="letter-spacing:-0.35pt;"> </span>stock<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>become<span style="letter-spacing:-0.3pt;"> </span>exercisable<span style="letter-spacing:-0.35pt;"> </span>if certain<span style="letter-spacing:-0.25pt;"> </span>perfor<span style="letter-spacing:-0.1pt;">m</span>ance<span style="letter-spacing:-0.4pt;"> </span>conditions<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>satisfie<span style="letter-spacing:0.05pt;">d</span>.<span style="letter-spacing:-0.3pt;"> </span>Dr.&#160;Soon-Shiong and his related party also <span style="letter-spacing:0.05pt;">h</span>old<span style="letter-spacing:-0.15pt;"> approximately $279.5&#160;million in the aggregate of </span>C<span style="letter-spacing:0.1pt;">V</span>Rs<span style="letter-spacing:-0.05pt;"> </span>iss<span style="letter-spacing:0.05pt;">u</span>ed<span style="letter-spacing:-0.05pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>fo<span style="letter-spacing:-0.05pt;">r</span>mer<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:-0.1pt;">t</span>ockholders<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Altor<span style="letter-spacing:-0.15pt;"> </span>in connection<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> NantCell</span>&#8217;s<span style="letter-spacing:-0.6pt;"> </span>acquisition<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Altor.<span style="letter-spacing:-0.25pt;"> I</span>f the<span style="letter-spacing:-0.15pt;"> </span>u<span style="letter-spacing:0.05pt;">n</span>derlying<span style="letter-spacing:-0.25pt;"> </span>conditions<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>payment<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>met,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>CVRs<span style="letter-spacing:-0.05pt;"> </span>become<span style="letter-spacing:-0.3pt;"> </span>paya<span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>cash<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>shares<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> the company&#8217;s</span><span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>combination<span style="letter-spacing:-0.4pt;"> </span>as the<span style="letter-spacing:-0.05pt;"> </span>holder<span style="letter-spacing:-0.2pt;"> </span>elects. Dr.&#160;Soon-Shiong<span style="letter-spacing:0.05pt;"> and his related party </span>have<span style="letter-spacing:-0.05pt;"> irrevocably agreed</span><span style="letter-spacing:-0.25pt;"> </span>to receive<span style="letter-spacing:-0.2pt;"> </span>shares<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> the company&#8217;s</span><span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> in satisfaction</span><span style="letter-spacing:-0.05pt;"> </span>of their<span style="letter-spacing:-0.1pt;"> </span>CVRs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr.&#160;Soon-Shiong is<span style="letter-spacing:-0.05pt;"> </span>in a position<span style="letter-spacing:-0.25pt;"> </span>to con<span style="letter-spacing:-0.1pt;">t</span>rol<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>outcome<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>corporate<span style="letter-spacing:-0.3pt;"> </span>actions<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>require,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>accomplished<span style="letter-spacing:-0.45pt;"> </span>by,<span style="letter-spacing:0.05pt;"> </span>sto<span style="letter-spacing:-0.05pt;">c</span>kholder<span style="letter-spacing:-0.45pt;"> </span>approval, including<span style="letter-spacing:-0.3pt;"> </span>amending<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>bylaws<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>company,<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>elect<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>removal<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>directors<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>transactions<span style="letter-spacing:-0.5pt;"> </span>involving<span style="letter-spacing:-0.3pt;"> </span>a change<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>control.<span style="letter-spacing:-0.25pt;"> </span>Dr.&#160;Soon-Shiong&#8217;s<span style="letter-spacing:-0.05pt;"> controlling</span><span style="letter-spacing:-0.45pt;"> </span>ownership<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>limit<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;">b</span>ility<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>remaining<span style="letter-spacing:-0.25pt;"> </span>stockholders<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>company<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>influence<span style="letter-spacing:-0.3pt;"> </span>corporate<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">t</span>ers,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the interests<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Dr.&#160;Soon-Shiong<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>coincide<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>company&#8217;s<span style="letter-spacing:-0.35pt;"> </span>interests<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>int<span style="letter-spacing:-0.1pt;">e</span>rests<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>its<span style="letter-spacing:-0.15pt;"> </span>remaining<span style="letter-spacing:-0.3pt;"> </span>stockholders.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ddit<span style="letter-spacing:-0.05pt;">i</span>on,<span style="letter-spacing:-0.2pt;"> </span>ent<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span>s affiliated<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>Dr.&#160;Soon-Shiong<span style="letter-spacing:0.05pt;"> </span>hold<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">m</span>issory<span style="letter-spacing:-0.1pt;"> notes </span>representing<span style="letter-spacing:-0.4pt;"> $300.3&#160;million</span><span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>indebtedness, including interest thereon,<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> the company</span><span style="letter-spacing:-0.45pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> June&#160;30,&#160;2021</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, pursuant to the Nominating Agreement between us and Cambridge Equities, LP (&#8220;Cambridge&#8221;), an entity that Dr.&#160;Soon-Shiong controls, Cambridge has the ability to designate one director to be nominated for election to our board of directors for as long as Cambridge continues to hold at least 20% of the issued and outstanding shares of our common stock. Dr.&#160;Soon-Shiong was selected by Cambridge to hold this board seat. Dr.&#160;Soon-Shiong and his affiliates will therefore have significant influence over management and significant control over matters requiring stockholder approval, including the annual election of directors and significant corporate transactions, such as a merger or other sale of our company or its assets, for the foreseeable future. This control will limit stockholders&#8217; ability to influence corporate matters and, as a result, we may take actions that our stockholders do not view as beneficial. As a result, the market price of our common stock could be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market price of our common stock has been and may continue to be volatile, and investors may have difficulty selling their shares.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although our common stock is listed on the Nasdaq Global Select Market, the market for our shares has demonstrated varying levels of trading activity. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price of our common stock has been and may continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the commencement, enrollment or results of the planned clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse results or delays in clinical trials&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our failure to commercialize our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">additions or departures of key scientific or management personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unanticipated serious safety concerns related to the use of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to effectively manage our growth&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">variations in our quarterly operating results&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our liquidity position and the amount and nature of any debt we may incur&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements that our revenue or income are below or that costs or losses are greater than analysts&#8217; expectations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the market valuations of similar companies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sales of large blocks of our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fluctuations in stock market prices and volumes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">significant lawsuits, including patent or stockholder litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the perception of our clinical trial results by retail investors, which investors may be subject to the influence of information provided by third party investor websites and independent authors distributing information on the internet&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">general economic slowdowns&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">coordinated actions by independent third-party actors to affect the price of certain stocks, coordinated via the Internet and otherwise&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">other factors described in this &#8220;</span><span style="font-style:italic;color:#000000;">Risk Factors</span><span style="color:#000000;">&#8221; section.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. In addition, our Executive<span style="letter-spacing:-0.3pt;"> </span>Chairman, Dr.&#160;Soon-Shiong, and his affiliates cur<span style="letter-spacing:-0.05pt;">r</span>ently<span style="letter-spacing:-0.25pt;"> </span>beneficially own approximately&#160;80.3% of our outstanding shares of common stock as of June&#160;30,&#160;2021. Sales of stock by Dr.&#160;Soon-Shiong and his affiliates could have an adverse effect on the trading price of our common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of our common stock are entitled to certain rights with respect to the registration of their shares under the Securities Act of&#160;1933, as amended (&#8220;Securities Act&#8221;). Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by our affiliates as defined in Rule&#160;144 under the Securities Act. Any sales of securities by these stockholders could have an adverse effect on the market price of our common stock.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we expect that additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a public company. To raise capital, we may sell common stock, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including as part of t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he ATM</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including through the ATM, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">convertible securities or other equity securities, investors may be materially diluted and new investors could gain rights, preferences and privileges senior to the holders of our</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> common</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred and will continue to incur costs as a result of operating as a public company and our management has been and will be required to devote substantial time to compliance initiatives and corporate governance practices, including maintaining an effective system of internal control over financial reporting.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company listed in the U.S., and increasingly after we no longer qual<span style="letter-spacing:-0.05pt;">i</span>fy<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>&#8220;smaller<span style="letter-spacing:-0.25pt;"> </span>reporting company,&#8221; we have incurred and will continue to incur significant additional legal, accounting and other expenses as a result of operating as a public company. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002 (&#8220;Sarbanes Oxley&#8221;) and regulations implemented by the SEC and Nasdaq, may increase legal and financial compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to create a larger finance function with additional personnel to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If, notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us, and our business may be harmed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company in the U.S., we are required, pursuant to Section&#160;404 of Sarbanes-Oxley (&#8220;Section&#160;404&#8221;) to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. The controls and other procedures are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is disclosed accurately and is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>to disclose<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>material<span style="letter-spacing:-0.25pt;"> </span>weakn<span style="letter-spacing:-0.05pt;">e</span>sses<span style="letter-spacing:-0.25pt;"> </span>identified<span style="letter-spacing:-0.3pt;"> </span>by our management<span style="letter-spacing:-0.45pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span>internal<span style="letter-spacing:-0.2pt;"> </span>control<span style="letter-spacing:-0.25pt;"> </span>over<span style="letter-spacing:-0.2pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>reporting,<span style="letter-spacing:-0.35pt;"> </span>and,<span style="letter-spacing:-0.1pt;"> since</span><span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>longer<span style="letter-spacing:-0.3pt;"> </span>qualify<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a &#8220;<span style="letter-spacing:0.05pt;">s</span>maller<span style="letter-spacing:-0.25pt;"> </span>reporting<span style="letter-spacing:-0.3pt;"> </span>company&#8221;<span style="letter-spacing:-0.4pt;"> as of</span> fiscal year end&#160;2021, we are required to provide a statement that our independent registered public accounting firm has issued an opinion on our internal control over financial reporting in our Annual Report on Form&#160;10-K. We have initiated the process of engaging and coordinating with our independent registered public accounting firm to perform an audit of, and give an opinion on, our internal control over financial reporting for the annual period ending December&#160;31,&#160;2021. There can be no assurance that we will not discover deficiencies or a material weakness in our internal control over financial reporting or that our independent registered public accounting firm will agree with management&#8217;s assessment of our internal control over financial reporting when they conduct such audit and deliver an opinion.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business our controls and procedures may become inadequate because of changes in conditions or the degree of compliance with these policies or procedures may deteriorate and material weaknesses in our internal control over financial reporting may be discovered. We may err in the design or operation of our controls, and all internal control systems, no matter how well designed and operated, can provide only reasonable assurance that the objectives of the control system are met. Because there are inherent limitations in all control systems, there can be no absolute assurance that all control issues have been or will be detected. If we are unable, or are perceived as unable, to produce reliable financial reports due to internal control deficiencies, investors could lose confidence in our reported financial information and operating results, which could result in a negative market reaction.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To fully comply with Section 404, we will need to retain additional employees to supplement our current finance staff, and we may not be able to do so in a timely manner, or at all. In addition, in the process of evaluating our internal control over financial reporting, we expect that certain of our internal control practices will need to be updated to comply with the requirements of Section&#160;404 and the regulations promulgated thereunder, and we may not be able to do so on a timely basis, or at all. In the event that we are not able to demonstrate compliance with Section&#160;404 in a timely manner, or are unable to produce timely or accurate financial statements, we may be subject to sanctions or investigations by regulatory authorities, such as the SEC or Nasdaq, and investors may lose confidence in our operating results and the price of our common stock could decline. Furthermore, if we are unable to certify that our internal control over financial reporting is effective and in compliance with Section&#160;404, we may be subject to sanctions or investigations by regulatory authorities, such as the SEC or stock exchanges, and investors could lose confidence in the accuracy and completeness of our financial reports, which could hurt our business, the price of our common stock and our ability to access the capital markets.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating as </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a public company make</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> it more expensive for us to obtain director</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s&#8217;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and officer</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s&#8217;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or as members of senior management.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If a restatement of our financial statements were to occur, our stockholders&#8217; confidence in the company&#8217;s financial reporting in the future may be affected, which could in turn have a material adverse effect on our business and stock price.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any material weaknesses in our internal control over financial reporting are discovered or occur in the future, our consolidated financial statements may contain material misstatements, and we could be required to restate our financial results. In addition, if we are unable to successfully remediate any future material weaknesses in our internal controls or if we are unable to produce accurate and timely financial statements, our stock price may be adversely affected, and we may be unable to maintain compliance with applicable stock exchange listing requirements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have not paid cash dividends in the past and do not expect to pay dividends in the future. Any return on investment may be limited to the value of our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never paid cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future. The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting us at such time as the board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if our stock price appreciates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we are relying on the exemptions from corporate governance requirements as a result of being a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing standards, you do not have the same protections afforded to stockholders of companies that are subject to such requirements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Executive<span style="letter-spacing:-0.35pt;"> </span>Chairman, Dr.&#160;Patrick Soon-Shiong, and entities affiliated with him, control a majority of our common stock. As a result, we are a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing standards. Under these rules, a company of which more than 50%&#160;of the voting power is held by an individual, a group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain Nasdaq corporate governance requirements, including (1)&#160;the requirement that a majority of the board of directors consist of independent directors, and (2)&#160;the requirement that we have a nominating and corporate governance committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities. Accordingly, you do not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq corporate governance requirements. However, our board of directors is currently comprised of a majority of independent directors and we currently have a nominating and corporate governance committee and the majority of the members of such committee are independent directors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to smaller reporting companies could make our common stock less attractive to investors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>longer<span style="letter-spacing:-0.3pt;"> </span>qualify<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>emerging<span style="letter-spacing:-0.35pt;"> </span>g<span style="letter-spacing:0.05pt;">r</span>owth<span style="letter-spacing:0.05pt;"> </span>company,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>qualify<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a &#8220;smaller<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>porting<span style="letter-spacing:-0.25pt;"> </span>company&#8221;<span style="letter-spacing:-0.3pt;"> </span>during<span style="letter-spacing:-0.3pt;"> </span>fiscal<span style="letter-spacing:-0.2pt;"> </span>year<span style="letter-spacing:-0.2pt;">&#160;</span>2021,<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>allows<span style="letter-spacing:-0.3pt;"> </span>us to take<span style="letter-spacing:-0.1pt;"> </span>advantage<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>many<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>same<span style="letter-spacing:-0.15pt;"> </span>e<span style="letter-spacing:-0.05pt;">x</span>emptions<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>disclosu<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.3pt;"> </span>requirements,<span style="letter-spacing:-0.45pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>reduced<span style="letter-spacing:-0.25pt;"> </span>dis<span style="letter-spacing:0.05pt;">c</span>losure<span style="letter-spacing:-0.3pt;"> </span>obligations<span style="letter-spacing:-0.35pt;"> </span>regard<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.3pt;"> </span>executive compensation<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>periodic<span style="letter-spacing:-0.25pt;"> </span>reports<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>proxy<span style="letter-spacing:-0.05pt;"> </span>statements.<span style="letter-spacing:-0.35pt;"> </span>These<span style="letter-spacing:-0.25pt;"> </span>exemptions<span style="letter-spacing:-0.45pt;"> </span>include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">being permitted to provide only two&#160;years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8221; disclosure&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reduced disclosure obligations regarding executive compensation.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>find<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>less<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">t</span><span style="letter-spacing:-0.05pt;">t</span>ra<span style="letter-spacing:-0.05pt;">c</span>tive<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>result<span style="letter-spacing:-0.05pt;"> </span>of our<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">a</span>nce<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">th</span>ese<span style="letter-spacing:-0.2pt;"> </span>exemptio<span style="letter-spacing:0.05pt;">n</span>s.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>investors<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>ind our<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>less at<span style="letter-spacing:-0.05pt;">t</span>ra<span style="letter-spacing:-0.05pt;">c</span>tive<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>result,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>here<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">e</span>ss<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>tive<span style="letter-spacing:-0.2pt;"> </span>tr<span style="letter-spacing:-0.05pt;">a</span>ding<span style="letter-spacing:-0.2pt;"> </span>mark<span style="letter-spacing:-0.05pt;">e</span>t<span style="letter-spacing:-0.35pt;"> </span>for our<span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:0.1pt;">a</span>rket<span style="letter-spacing:-0.2pt;"> </span>price<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.35pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>reduced<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>more v<span style="letter-spacing:0.05pt;">o</span>l<span style="letter-spacing:0.05pt;">a</span>til<span style="letter-spacing:-0.05pt;">e</span>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will depend on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts&#8217; cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are not subject to the provisions of Section&#160;203 of the DGCL, which could negatively affect your investment.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We elected in our amended and restated certificate of incorporation to not be subject to the provisions of Section&#160;203 of the DGCL. In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns (or, in certain cases, within three years prior, did own) 15%&#160;or more of the corporation&#8217;s voting stock. Our decision not to be subject to Section&#160;203 will allow, for example, our Executive<span style="letter-spacing:-0.35pt;"> C</span>hairman (who, with members of his immediate family and entities affiliated with him, currently beneficially own, in the aggregate, approximately&#160;80.3% of our common stock as of June&#160;30,&#160;2021) to transfer shares in excess of 15%&#160;of our voting stock to a third-party free of the restrictions imposed by Section&#160;203. This may make us more vulnerable to takeovers that are completed without the approval of our board of directors and/or without giving us the ability to prohibit or delay such takeovers as effectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders. These provisions include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a requirement that special meetings of stockholders be called only by the board of directors, the president or the chief executive officer&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">advance notice requirements for stockholder proposals and nominations for election to our board of directors&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. In addition, as permitted by Section&#160;145 of the DGCL, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We are not obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that a claim for indemnification is brought by any of our directors or officers, it would reduce the amount of funds available for use in our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(a)&#160;Recent Sales of Unregistered Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(b)&#160;Issuer Purchases of Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES">ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">ITEM 4. MINE SAFETY DISCLOSURES.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_OR_INFORMATION">ITEM 5. OTHER INFORMATION.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_EXHIBITS">ITEM 6. EXHIBITS.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The documents listed below are incorporated by reference or are filed with this Quarterly Report, in each case as indicated therein (numbered in accordance with Item&#160;601 of Regulation&#160;S&#8209;K).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:7.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="bottom" style="width:92.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Exhibit</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;2.1</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312520323766/d21044dex21.htm"><span style="text-decoration:underline;">Agreement and Plan of Merger, dated as of December&#160;21,&#160;2020, by and among ImmunityBio, Inc. (f/k/a NantKwest, Inc.), NantCell, Inc. (f/k/a ImmunityBio, Inc.) and Nectarine Merger Sub, Inc. (filed as Exhibit&#160;2.1 to the company&#8217;s Current Report on Form&#160;8-K filed with the SEC on December&#160;22,&#160;2020).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:23.05pt;">
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521075243/d307217dex31.htm"><span style="text-decoration:underline;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of ImmunityBio, Inc. (f/k/a NantKwest, Inc.) dated March&#160;9,&#160;2021 (filed as Exhibit&#160;3.1 to the company&#8217;s Form&#160;8-K filed with the SEC on March&#160;10,&#160;2021).</span></a></p></td>
</tr>
<tr style="height:5.05pt;">
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:13.05pt;">
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.2*</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ibrx-ex32_717.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws of ImmunityBio, Inc., effective as of March&#160;10,&#160;2021.</span></a></p></td>
</tr>
<tr style="height:5.05pt;">
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:23.05pt;">
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.1*</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ibrx-ex101_955.htm"><span style="text-decoration:underline;">First Amendment to Lease made and entered into as of May&#160;28,&#160;2021, but made effective as of April&#160;1,&#160;2021, by and between 605 Nash,&#160;LLC and ImmunityBio,&#160;Inc.</span></a></p></td>
</tr>
<tr style="height:5.05pt;">
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.1*</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ibrx-ex311_9.htm"><span style="text-decoration:underline;"> Rule 13a-14(a) / 15(d)-14(a) Certification of Principal Executive Officer.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.2*</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ibrx-ex312_8.htm"><span style="text-decoration:underline;"> Rule 13a-14(a) / 15(d)-14(a) Certification of Principal Financial Officer.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;32.1**</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ibrx-ex321_6.htm"><span style="text-decoration:underline;"> Section 1350 Certification of Chief Executive Officer.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;32.2**</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ibrx-ex322_7.htm"><span style="text-decoration:underline;"> Section 1350 Certification of Chief Financial Officer.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;99.2</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Combined Consolidated Financial Statements of ImmunityBio, Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019 (including NantCell, Inc.) (filed as Exhibit&#160;99.2 to the company&#8217;s Current Report on Form&#160;8-K/A filed with the SEC on April&#160;22,&#160;2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:23.05pt;">
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Labels Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form&#160;10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of ImmunityBio,&#160;Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report, irrespective of any general incorporation language contained in such filing.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">IMMUNITYBIO, INC.</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 12, 2021</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Adcock</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Adcock</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 12, 2021</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David C. Sachs</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David C. Sachs</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></body>
</html>
{"company-data": {"conformed-name": "ImmunityBio, Inc.", "cik": "0001326110", "assigned-sic": "2836", "irs-number": "431979754", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "10-Q", "act": "34", "file-number": "001-37507", "film-number": "211168009"}, "business-address": {"street1": "3530 JOHN HOPKINS COURT", "city": "SAN DIEGO", "state": "CA", "zip": "92121", "phone": "(858) 633-0300"}, "mail-address": {"street1": "3530 JOHN HOPKINS COURT", "city": "SAN DIEGO", "state": "CA", "zip": "92121"}, "former-company": [{"former-conformed-name": "NantKwest, Inc.", "date-changed": "20150713"}, {"former-conformed-name": "Conkwest, Inc.", "date-changed": "20140416"}, {"former-conformed-name": "ZelleRx Corp", "date-changed": "20050504"}]}
ibrx-10q_20210630.htm
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
10-Q
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended
June 30, 2021
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM                      TO
Commission file number:
001-37507
IMMUNITYBIO, INC.
(Exact name of Registrant as specified in its Charter)
Delaware
43-1979754
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
3530 John Hopkins Court
San Diego
,
California
92121
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(
858
)
633-0300
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
IBRX
The Nasdaq
Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes
☒
No
☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes
☒
No
☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
☐
No
☒
The number of shares of the Registrant's common stock outstanding as of August 10, 2021 was
391,156,513
(excluding 163,800 shares held by a majority owned subsidiary of ours which are treated as treasury shares for accounting purposes).
TABLE OF CONTENTS
Page
Part I—FINANCIAL INFORMATION
Item 1.
Financial Statements
1
Condensed Consolidated Balance Sheets –
As of June 30, 2021 and December 31, 2020
1
Condensed Consolidated Statements of Operations –
For the three and six months ended June 30, 2021 and 2020
2
Condensed Consolidated Statements of Comprehensive Loss –
For the three and six months ended June 30, 2021 and 2020
3
Condensed Consolidated Statements of Stockholders' (Deficit) Equity –
For the three and six months ended June 30, 2021 and 2020
4
Condensed Consolidated Statements of Cash Flows –
For the six months ended June 30, 2021 and 2020
6
Notes to Unaudited Condensed Consolidated Financial Statements
8
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
36
Item 3.
Quantitative and Qualitative Disclosures about Market Risk
51
Item 4.
Controls and Procedures
51
Part II—OTHER INFORMATION
Item 1.
Legal Proceedings
52
Item 1A.
Risk Factors
53
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
116
Item 3.
Defaults Upon Senior Securities
116
Item 4.
Mine Safety Disclosures
116
Item 5.
Other Information
116
Item 6.
Exhibits
117
Signatures
118
-i-
Table of Contents
PART I—FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS.
ImmunityBio, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
June 30,
2021
December 31,
2020
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$
83,958
$
34,915
Marketable securities
19,970
61,146
Due from related parties
2,047
2,003
Prepaid expenses and other current assets (including amounts with related parties)
7,756
13,649
Total current assets
113,731
111,713
Marketable securities, noncurrent
822
950
Property, plant and equipment, net
89,023
72,541
Non-marketable equity investment
—
7,849
Intangible asset, net
1,445
1,463
Convertible note receivable
6,253
6,129
Operating lease right-of-use assets, net (including amounts with related parties)
28,230
18,138
Other assets (including amounts with related parties)
6,797
2,598
Total assets
$
246,301
$
221,381
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable
$
19,153
$
11,510
Accrued expenses and other liabilities
36,134
36,771
Due to related parties
16,711
14,838
Operating lease liabilities (including amounts with related parties)
2,430
5,015
Total current liabilities
74,428
68,134
Related-party notes payable
300,252
254,353
Operating lease liabilities, less current portion (including amounts with related parties)
29,116
16,179
Deferred income tax liability
170
170
Other liabilities
920
1,035
Total liabilities
404,886
339,871
Commitments and contingencies (Note 7)
Stockholders' deficit:
Common stock, $
0.0001
par value;
500,000,000
shares authorized;
390,347,740
and
382,243,142
shares issued and outstanding as of June 30, 2021 and
December 31, 2020, respectively; excluding treasury stock,
163,800
shares
outstanding as of June 30, 2021 and December 31, 2020, respectively
39
38
Additional paid-in capital
1,625,018
1,495,163
Accumulated deficit
(
1,783,033
)
(
1,615,131
)
Accumulated other comprehensive income
37
122
Total ImmunityBio stockholders' deficit
(
157,939
)
(
119,808
)
Noncontrolling interests
(
646
)
1,318
Total stockholders' deficit
(
158,585
)
(
118,490
)
Total liabilities and stockholders' deficit
$
246,301
$
221,381
The accompanying notes are an integral part of these condensed consolidated financial statements.
1
Table of Contents
ImmunityBio, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(Unaudited)
Three Months Ended
June 30,
Six Months Ended
June 30,
2021
2020
2021
2020
Revenue
$
339
$
436
$
478
$
601
Operating expenses:
Research and development (including amounts
with related parties)
53,800
33,005
94,928
60,379
Selling, general and administrative (including amounts
with related parties)
32,445
18,347
77,720
27,840
Total operating expenses
86,245
51,352
172,648
88,219
Loss from operations
(
85,906
)
(
50,916
)
(
172,170
)
(
87,618
)
Other (expense) income:
Interest and investment (loss) income, net
(
177
)
986
8,767
1,064
Interest expense (including amounts with related parties)
(
3,577
)
(
2,123
)
(
6,745
)
(
4,012
)
Other income, net (including amounts with related parties)
277
81
290
1,185
Total other (expense) income
(
3,477
)
(
1,056
)
2,312
(
1,763
)
Loss before income taxes and noncontrolling interests
(
89,383
)
(
51,972
)
(
169,858
)
(
89,381
)
Income tax expense
(
2
)
(
45
)
(
8
)
(
63
)
Net loss
(
89,385
)
(
52,017
)
(
169,866
)
(
89,444
)
Net loss attributable to noncontrolling interests, net of tax
(
1,097
)
(
578
)
(
1,964
)
(
967
)
Net loss attributable to ImmunityBio common stockholders
$
(
88,288
)
$
(
51,439
)
$
(
167,902
)
$
(
88,477
)
Net loss per ImmunityBio common share – basic and diluted
$
(
0.23
)
$
(
0.14
)
$
(
0.44
)
$
(
0.24
)
Weighted-average number of common shares used in computing
net loss per share – basic and diluted
384,820,486
372,286,278
383,939,031
372,137,752
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
Table of Contents
ImmunityBio, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Loss
(in thousands)
(Unaudited)
Three Months Ended
June 30,
Six Months Ended
June 30,
2021
2020
2021
2020
Net loss
$
(
89,385
)
$
(
52,017
)
$
(
169,866
)
$
(
89,444
)
Other comprehensive income (loss), net of income taxes:
Net unrealized gains on available-for-sale securities
18
29
17
5
Foreign currency translation adjustments
60
(
63
)
(
102
)
7
Reclassification of net realized gains on
available-for-sale securities included in net loss
(
3
)
(
1
)
—
—
Total other comprehensive income (loss)
75
(
35
)
(
85
)
12
Comprehensive loss
(
89,310
)
(
52,052
)
(
169,951
)
(
89,432
)
Less: Comprehensive loss attributable to noncontrolling interests
(
1,097
)
(
578
)
(
1,964
)
(
967
)
Comprehensive loss attributable to ImmunityBio
common stockholders
$
(
88,213
)
$
(
51,474
)
$
(
167,987
)
$
(
88,465
)
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
Table of Contents
ImmunityBio, Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders' (Deficit) Equity
(in thousands, except share amounts)
(Unaudited)
Common Stock
Additional
Paid-in
Accumulated
Accumulated
Other
Comprehensive
(Loss)
Total
ImmunityBio
Stockholders'
Noncontrolling
Total
Stockholders'
Three Months Ended June 30, 2021
Shares
Amount
Capital
Deficit
Income
Deficit
Interests
Deficit
Balance as of March 31, 2021
383,067,321
$
38
$
1,508,958
$
(
1,694,745
)
$
(
38
)
$
(
185,787
)
$
451
$
(
185,336
)
Issuance of common stock
under "at-the market"
offering net of
commissions and
offering costs
of $
3,077
6,420,441
1
94,886
—
—
94,887
—
94,887
Stock-based compensation
expense
—
—
17,863
—
—
17,863
—
17,863
Exercise of stock options
759,639
—
3,311
—
—
3,311
—
3,311
Vesting of restricted stock
units (RSUs)
100,359
—
—
—
—
—
—
—
Net share settlement for
RSUs vesting
(
20
)
—
—
—
—
—
—
—
Other comprehensive income,
net of tax
—
—
—
—
75
75
—
75
Net loss
—
—
—
(
88,288
)
—
(
88,288
)
(
1,097
)
(
89,385
)
Balance as of June 30, 2021
390,347,740
$
39
$
1,625,018
$
(
1,783,033
)
$
37
$
(
157,939
)
$
(
646
)
$
(
158,585
)
Common Stock
Additional
Paid-in
Accumulated
Accumulated
Other
Comprehensive
Total
ImmunityBio
Stockholders'
Noncontrolling
Total
Stockholders'
Six Months Ended June 30, 2021
Shares
Amount
Capital
Deficit
Income
Deficit
Interests
Deficit
Balance as of December 31, 2020
382,243,142
$
38
$
1,495,163
$
(
1,615,131
)
$
122
$
(
119,808
)
$
1,318
$
(
118,490
)
Issuance of common stock
under "at-the market"
offering net of
commissions and
offering costs
of $
3,077
6,420,441
1
94,886
—
—
94,887
—
94,887
Stock-based compensation
expense
—
—
33,161
—
—
33,161
—
33,161
Exercise of stock options
1,450,104
—
4,432
—
—
4,432
—
4,432
Vesting of RSUs
336,084
—
—
—
—
—
—
—
Net share settlement for
RSUs vesting
(
102,031
)
—
(
2,624
)
—
—
(
2,624
)
—
(
2,624
)
Other comprehensive loss,
net of tax
—
—
—
—
(
85
)
(
85
)
—
(
85
)
Net loss
—
—
—
(
167,902
)
—
(
167,902
)
(
1,964
)
(
169,866
)
Balance as of June 30, 2021
390,347,740
$
39
$
1,625,018
$
(
1,783,033
)
$
37
$
(
157,939
)
$
(
646
)
$
(
158,585
)
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
Table of Contents
ImmunityBio, Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders' (Deficit) Equity
(in thousands, except share amounts)
(Unaudited)
Common Stock
Additional
Paid-in
Accumulated
Accumulated
Other
Comprehensive
Total
ImmunityBio
Stockholders'
(Deficit)
Noncontrolling
Total
Stockholders'
(Deficit)
Three Months Ended June 30, 2020
Shares
Amount
Capital
Deficit
Loss
Equity
Interests
Equity
Balance as of March 31, 2020
372,015,023
$
37
$
1,406,359
$
(
1,430,318
)
$
(
40
)
$
(
23,962
)
$
3,265
$
(
20,697
)
Issuance of common stock,
net of offering costs
of $
4,392
8,521,500
1
86,281
—
—
86,282
—
86,282
Stock-based compensation
expense
—
—
322
—
—
322
—
322
Exercise of stock options
259,017
—
564
—
—
564
—
564
Vesting of RSUs
495,226
—
—
—
—
—
—
—
Net share settlement for
RSUs vesting
(
10,017
)
—
(
40
)
—
—
(
40
)
—
(
40
)
Other comprehensive loss,
net of tax
—
—
—
—
(
35
)
(
35
)
—
(
35
)
Net loss
—
—
—
(
51,439
)
—
(
51,439
)
(
578
)
(
52,017
)
Balance as of June 30, 2020
381,280,749
$
38
$
1,493,486
$
(
1,481,757
)
$
(
75
)
$
11,692
$
2,687
$
14,379
Common Stock
Additional
Paid-in
Accumulated
Accumulated
Other
Comprehensive
Total
ImmunityBio
Stockholders'
Noncontrolling
Total
Stockholders'
Six Months Ended June 30, 2020
Shares
Amount
Capital
Deficit
Loss
Equity
Interests
Equity
Balance as of December 31, 2019
371,976,995
$
37
$
1,406,002
$
(
1,393,280
)
$
(
87
)
$
12,672
$
3,654
$
16,326
Issuance of common stock,
net of offering costs
of $
4,392
8,521,500
1
86,281
—
—
86,282
—
86,282
Stock-based compensation
expense
—
—
802
—
—
802
—
802
Exercise of stock options
259,017
—
564
—
—
564
—
564
Vesting of RSUs
558,976
—
—
—
—
—
—
—
Net share settlement for
RSUs vesting
(
35,739
)
—
(
163
)
—
—
(
163
)
—
(
163
)
Other comprehensive income,
net of tax
—
—
—
—
12
12
—
12
Net loss
—
—
—
(
88,477
)
—
(
88,477
)
(
967
)
(
89,444
)
Balance as of June 30, 2020
381,280,749
$
38
$
1,493,486
$
(
1,481,757
)
$
(
75
)
$
11,692
$
2,687
$
14,379
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
Table of Contents
ImmunityBio, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in thousands)
(Unaudited)
Six Months Ended
June 30,
2021
2020
Operating activities:
Net loss
$
(
169,866
)
$
(
89,444
)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
33,161
802
Unrealized gains on equity securities
(
8,391
)
(
494
)
Depreciation and amortization
6,956
6,959
Non-cash interest items, net (including amounts with related parties)
6,248
3,988
Non-cash lease expense related to operating lease right-of-use assets
2,269
2,034
Realized gains on sales of equity securities
(
173
)
—
Amortization of net premiums and discounts on marketable debt securities
248
93
Change in fair value of contingent consideration obligations
(
118
)
(
457
)
Deferred tax
—
(
1,029
)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
5,420
(
5,635
)
Other assets
(
4,199
)
114
Accounts payable
2,600
2,287
Accrued expenses and other liabilities
(
3,821
)
10,216
Related parties
2,579
(
4,740
)
Operating lease liabilities
(
2,977
)
(
1,823
)
Net cash used in operating activities
(
130,064
)
(
77,129
)
Investing activities:
Purchases of property, plant and equipment
(
15,128
)
(
324
)
Purchases of marketable debt securities, available-for-sale
(
266
)
(
14,828
)
Maturities of marketable debt securities, available for sale
44,159
42,920
Proceeds from sales of marketable debt and equity securities
13,569
1,500
Net cash provided by investing activities
42,334
29,268
Financing activities:
Proceeds from equity offering, net of issuance costs paid
95,026
86,816
Proceeds from issuance of related-party promissory notes
40,000
—
Proceeds from exercises of stock options
4,432
564
Net share settlement for RSUs vesting
(
2,624
)
(
163
)
Net cash provided by financing activities
136,834
87,217
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
(
61
)
5
Net change in cash, cash equivalents, and restricted cash
49,043
39,361
Cash, cash equivalents, and restricted cash, beginning of period
35,094
75,980
Cash, cash equivalents, and restricted cash, end of period
$
84,137
$
115,341
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
Table of Contents
ImmunityBio
, Inc.
and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Continued)
(in thousands)
(Unaudited)
Six Months Ended
June 30,
2021
2020
Reconciliation of cash, cash equivalents, and restricted cash, end of period:
Cash and cash equivalents
$
83,958
$
115,162
Restricted cash (Note 3)
179
179
Cash, cash equivalents, and restricted cash, end of period
$
84,137
$
115,341
Supplemental disclosure of cash flow information:
Cash paid during the period for:
Interest
$
842
$
10
Income taxes
10
6
Supplemental disclosure of non-cash activities:
Property and equipment purchases included in accounts payable, accrued
expenses and due to related parties
$
8,347
$
2,368
Unpaid offering costs included in accounts payable and accrued expenses
140
534
Right-of-use assets obtained in exchange for operating lease liabilities
12,361
—
Unrealized gains on marketable debt securities
17
5
The accompanying notes are an integral part of these condensed consolidated financial statements.
7
Table of Contents
ImmunityBio, Inc. and Subsidiaries
Notes to Unaudited Condensed Consolidated Financial Statements
1.     Description of Business
Organization
We were
incorporated in Illinois on October 7, 2002 under the name ZelleRx Corporation. On January 22, 2010, we changed our name to Conkwest, Inc. In March 2014, we formed Conkwest, Inc., our wholly-owned subsidiary in the state of Delaware, or Conkwest Delaware, for the purposes of changing the state of our incorporation to the state of Delaware. In March 2014, we merged with and into Conkwest Delaware, with Conkwest Delaware surviving the merger. On July 10, 2015, we changed our name to NantKwest, Inc. On March 9, 2021, we completed a merger with NantCell, Inc. (formerly known as ImmunityBio, Inc., a private company) ("NantCell"), and we changed our name to ImmunityBio, Inc. Our principal executive offices are located in San Diego, California. In these notes to the unaudited condensed consolidated financial statements, the terms "ImmunityBio," "the company," "the combined company," "we," "us," and "our" refer to ImmunityBio and subsidiaries.
We established ImmunityBio to advance next-generation immunotherapies and address unmet needs within oncology and infectious disease. Our platform is designed to overcome limitations of the current standards of T cell-based immunotherapies, including checkpoint inhibitors and CAR-T cells and is based on our four key modalities: (1) activating natural killer ("NK"), and T cells using antibody cytokine fusion proteins, (2) activating tumoricidal macrophages using low-dose synthetic immunomodulators, (3) generating memory T cells using vaccine candidates developed with our second-generation adenovirus, or hAd5, technology, and (4) off-the-shelf natural killer cells from the NK‑92 cell line and memory-like cytokine-enhanced NK cells ("M‑ceNK") from allogenic and autologous donors.
We own a broad, clinical-stage immunotherapy pipeline, including an antibody cytokine fusion protein (an IL‑15 superagonist (N‑803) known as Anktiva), an albumin-associated anthracycline synthetic immunomodulator (aldoxorubicin), second-generation adenovirus ("hAd5") and yeast vaccine technologies (targeting tumor-associated antigens and neoepitopes), off-the-shelf genetically engineered natural killer cell lines inducing cancer and virally infected cell death through a variety of concurrent mechanisms (including innate killing, antibody-mediated killing, and CAR-directed killing), patient specific NK cell product for cancer (M-ceNK), macrophage polarizing peptides, and bi-specific fusion proteins targeting CD20, PD‑L1, TGF‑
b
and IL‑12. Our immunotherapy clinical pipeline consists of over 40 clinical trials in Phase 1, 2, or 3 development across 19 indications in solid and liquid cancers and infectious diseases. We have an expansive clinical-stage pipeline and intellectual property portfolio with 17 first-in-human assets in 25 Phase II to III clinical trials.
In December 2019, the
United States ("U.S.") Food and Drug Administration
("FDA") granted Breakthrough Therapy designation to Anktiva for bacillus Calmette-Guérin ("BCG") unresponsive carcinoma in situ non-muscle invasive bladder cancer. Based on patient readout data that was submitted with our application to obtain our Breakthrough Therapy designation, Anktiva achieved its primary endpoint of complete response rate at any time in the ongoing registrational Phase II / III trial. Other indications currently with registration-potential studies include BCG unresponsive papillary bladder cancer, first- and second-line lung cancer, and metastatic pancreatic cancer.
8
Table of Contents
The Merger
On
December 21, 2020
, we and NantCell entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which we and NantCell agreed to combine our businesses. The Merger Agreement provided that a wholly-owned subsidiary of the company would merge with and into NantCell (the "Merger"), with NantCell surviving the Merger as a wholly-owned subsidiary of the company.
On
March 9, 2021
, we completed the Merger pursuant to the terms of the Merger Agreement. Under the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of NantCell common stock
, par value $
0.001
per share,
issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive
0.8190
(the "Exchange Ratio") newly
issued shares of common stock, par value $
0.0001
per share, of the company ("Company Common Stock"), with cash paid in lieu of any fractional shares.
At the Effective Time, each share of the company's common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company. At the Effective Time, each outstanding option, warrant or restricted stock unit to purchase NantCell common stock was converted using the Exchange Ratio into an option, warrant or restricted stock unit, respectively, on the same terms and conditions immediately prior to the Effective Time, to purchase shares of Company Common Stock.
Immediately following the Effective Time, the former stockholders of NantCell held approximately
71.5
% of the outstanding shares of Company Common Stock and the stockholders of the company as of immediately prior to the Merger held approximately
28.5
% of the outstanding shares of Company Common Stock. As a result of the Merger and immediately following the Effective Time, Dr. Patrick Soon-Shiong, our Executive Chairman, and his affiliates beneficially owned, in the aggregate, approximately
81.8
% of the outstanding shares of Company Common Stock. Following the consummation of the Merger, shares of the company's common stock were listed on the Nasdaq Global Select Market under the symbol "IBRX."
We incurred costs totaling $
23.3
million in connection with the Merger, consisting of financial advisory, legal and other professional fees, of which $
13.0
million was recorded during the six months ended June 30, 2021. Merger-related costs are
reported in
selling, general and administrative expense
, on the condensed consolidated statements of operations.
Accounting Treatment of the Merger
The Merger represents a business combination pursuant to Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 805-50,
Mergers
, which is accounted for as a transaction between entities under common control as Dr. Soon-Shiong and his affiliates were the controlling stockholders of both the company and NantCell for all of the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We have recast our prior period financial statements to reflect the conveyance of NantCell's common shares as if the Merger had occurred as of the earliest date of the financial statements presented. All material intercompany accounts and transactions have been eliminated in consolidation.
9
Table of Contents
The following tables provide the impact of the change in reporting entity on our unaudited condensed consolidated statements of operations for the three months ended March 31, 2021 and the three and six months ended June 30, 2020, respectively (in thousands):
Three Months Ended
March 31, 2021
(Unaudited)
NantCell
NantKwest
Intercompany
Eliminations
ImmunityBio,
Inc.
Revenue
$
183
$
—
$
(
44
)
$
139
Operating expenses:
Research and development (including amounts
with related parties)
21,509
19,725
(
106
)
41,128
Selling, general and administrative (including amounts
with related parties)
24,382
20,903
(
10
)
45,275
Loss from operations
(
45,708
)
(
40,628
)
72
(
86,264
)
Other (expense) income, net (including amounts
with related parties)
(
848
)
6,637
—
5,789
Income tax expense
—
(
6
)
—
(
6
)
Net loss
$
(
46,556
)
$
(
33,997
)
$
72
$
(
80,481
)
Three Months Ended
June 30, 2020
(Unaudited)
NantCell
NantKwest
Intercompany
Eliminations
ImmunityBio,
Inc.
Revenue
$
1,525
$
1
$
(
1,090
)
$
436
Operating expenses:
Research and development (including amounts
with related parties)
19,384
13,709
(
88
)
33,005
Selling, general and administrative (including amounts
with related parties)
11,828
6,519
—
18,347
Loss from operations
(
29,687
)
(
20,227
)
(
1,002
)
(
50,916
)
Other (expense) income, net (including amounts
with related parties)
(
1,195
)
139
—
(
1,056
)
Income tax expense
(
41
)
(
4
)
(
45
)
Net loss
$
(
30,923
)
$
(
20,092
)
$
(
1,002
)
$
(
52,017
)
Six Months Ended
June 30, 2020
(Unaudited)
NantCell
NantKwest
Intercompany
Eliminations
ImmunityBio,
Inc.
Revenue
$
1,693
$
22
$
(
1,114
)
$
601
Operating expenses:
Research and development (including amounts
with related parties)
33,636
26,943
(
200
)
60,379
Selling, general and administrative (including amounts
with related parties)
15,948
11,892
—
27,840
Loss from operations
(
47,891
)
(
38,813
)
(
914
)
(
87,618
)
Other (expense) income, net (including amounts
with related parties)
(
2,105
)
342
—
(
1,763
)
Income tax expense
(
59
)
(
4
)
—
(
63
)
Net loss
$
(
50,055
)
$
(
38,475
)
$
(
914
)
$
(
89,444
)
10
Table of Contents
2.     Summary of Significant Accounting Policies
There have been no material changes to our significant accounting policies from those described in the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio, Inc. as of December 31, 2020 and December 31, 2019 (including NantCell, Inc.) filed as
Exhibit 99.2
to our Current Report on Form 8‑K/A filed with the Securities and Exchange Commission ("SEC") on April 22, 2021.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the rules and regulations of the SEC. The unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. The unaudited condensed consolidated financial statements do not include all information and notes required by U.S. GAAP for annual reports.
As of June 30, 2021, the company had an accumulated deficit of $
1.8
billion. We also had negative cash flows from operations of $
130.1
million for the six months ended June 30, 2021. The company will likely need additional capital to further fund the development of, and seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.
The condensed consolidated financial statements are derived from NantKwest's and NantCell's respective historical consolidated financial statements for each period presented. Since the entities have been under common control for all periods presented, the condensed consolidated financial statements assume that the Merger took place at the beginning of the earliest period for which the condensed consolidated financial statements are presented. Accordingly, these financial statements should be read in conjunction with the audited Combined Consolidated Financial Statements and Notes thereto included in the Combined Consolidated Financial Statements of ImmunityBio, Inc. as of December 31, 2020 and December 31, 2019 (including NantCell, Inc.) filed as
Exhibit 99.2
to our Current Report on Form 8‑K/A filed with the SEC on April 22, 2021. Interim operating results are not necessarily indicative of operating results for the full year.
The condensed consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty of our ability to continue as a going concern. As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings (including but not limited to the offering, issuance and sale by us of up to a maximum aggregate offering of $
500.0
million of our common stock that may be issued and sold under an "at-the-market" sales agreement with Jefferies LLC (the "ATM")), and our potential ability to borrow from affiliated entities, will be sufficient to fund our operations through at least the next 12 months following the issuance date of the financial statements based primarily upon our Executive Chairman's intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of our product candidates in development, we may need additional funds to meet our needs sooner than planned.
Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements include the accounts of the company and its subsidiaries. All intercompany amounts have been eliminated. For consolidated entities where we have less than 100% of ownership, we record net loss attributable to noncontrolling interest on the condensed consolidated statements of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties.
We apply the variable interest model under ASC Topic 810,
Consolidation
, to any entity in which we hold an equity investment or to which we have the power to direct the entity's most significant economic activities and the ability to participate in the entity's economics. If the entity is within the scope of the variable interest model and meets the definition of a variable interest entity ("VIE"), we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.
11
Table of Contents
For entities we hold as an equity investment that are not consolidated under the VIE
m
odel, we consider whether our investment constitutes ownership of a majority of the voting interests in the entity and therefore should be considered for consolidation under the voting interest model.
Unconsolidated equity investments in the common stock or in-substance common stock of an entity under which we are able to exercise significant influence, but not control, are accounted for using the equity method. Our ability to exercise significant influence is generally indicated by ownership of
20
% to
50
% interest in the voting securities of the entity.
All other unconsolidated equity investments on which we are not able to exercise significant influence will be subsequently measured at fair value with unrealized holding gains and losses included in
interest and investment income, net
, on the condensed consolidated statements of operations. In the instance the equity investment does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC Topic 820,
Fair Value Measurement
("ASC 820"), we will apply the measurement alternative under ASC Topic 321,
Investments—Equity Securities
("ASC 321"), pursuant to which we will measure the investment at its cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.
Prior to March 31, 2021, we owned non-marketable equity securities that were accounted for using the measurement alternative under ASC 321 because the preferred stock held by us was not considered in-substance common stock and such preferred stock did not have a readily determinable fair value. All investments are reviewed for possible impairment on a regular basis. If an investment's fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an impairment indicator is present include: the investees' earnings performance and clinical trial performance, change in the investees' industry and geographic area in which it operates, offers to purchase or sell the security for a price less than the cost of the investment, issues that raise concerns about the investee's ability to continue as a going concern, and any other information that we may be aware of related to the investment. Factors considered in determining whether an observable price change has occurred include: the price at which the investee issues equity instruments similar to those of our investment and the rights and preferences of those equity instruments compared to ours.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12 months from the date of issuance of these financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.
Risks and Uncertainties
In March 2020, the World Health Organization declared the novel strain of coronavirus disease (SARS‑CoV‑2) a pandemic. To date, our operations have not been significantly disadvantaged by the pandemic. However, we cannot at this time predict the specific extent, duration, or full impact that this pandemic may have on our financial condition and results of operations, including ongoing and planned clinical trials. More specifically, the pandemic may result in prolonged impacts that we cannot predict at this time and we expect that such uncertainties will continue to exist for the foreseeable future. The impact of the pandemic on our financial performance will depend on future developments, including the duration and spread of the outbreak, impact of potential variants and the related governmental advisories and restrictions. These developments and the impact of the ongoing pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, our results may be adversely affected.
12
Table of Contents
Contingencies
We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.
Concentration of Credit Risk and Other Risks and Uncertainties
Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, marketable securities, and a convertible note receivable.
Our cash and cash equivalents are held by one major financial institution in the U.S., one in South Korea and one in Italy.
Product candidates developed by us will require approvals or clearances from the FDA or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.
Stock-Based Compensation
We account for stock-based compensation under the provisions of FASB ASC Topic 718,
Compensation—Stock Compensation
("ASC 718"). We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.
Basic and Diluted Net Loss per Share of Common Stock
Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.
For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.
The following table details those securities that have been excluded from the computation of potentially dilutive securities:
As of June 30,
2021
2020
(Unaudited)
Outstanding stock options
4,330,318
6,104,799
Outstanding RSUs
7,443,504
565,802
Outstanding related-party warrants
1,638,000
1,638,000
Total
13,411,822
8,308,601
Amounts in the table above reflect the common stock equivalents of the noted instruments, including awards issued under the NantKwest 2015 Equity Incentive Plan (the "2015 Plan"), the NantKwest 2014 Equity Incentive Plan (the "2014 Plan"), and awards issued under the NantCell, Inc. 2015 Stock Incentive Plan (the "NC 2015 Plan") that, in the case of June 30, 2021, were outstanding immediately prior to the Effective Time of the Merger and in the case of June 30, 2020 have been adjusted to include the combined NC 2015 Plan and NantCell warrants then outstanding (in both cases adjusted
using the Exchange Ratio of
0.8190
). See
Note 10
,
Stock-Based Compensation
, for further information.
13
Table of Contents
Recent Accounting Pronouncements
Application of New or Revised Accounting Standards – Not Yet Adopted
In June 2016, the FASB issued Accounting Standards Update ("ASU") 2016‑13,
Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
("ASU 2016-13"). The FASB subsequently issued amendments to ASU 2016‑13, which have the same effective date and transition dates as described below. The new guidance supersedes existing U.S. GAAP for measuring and recording of credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. For public business entities that meet the definition of an SEC filer, except entities that are eligible to be a smaller reporting company as defined by the SEC, the standard is effective for annual periods beginning after December 15, 2019, and interim periods therein. For all other entities, including us, the standard is effective for annual periods beginning after December 15, 2022, and interim periods therein. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. We continue to evaluate the impact that this new standard and its related amendments will have on our consolidated financial statements.
Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC during the three months ended June 30, 2021 did not, or are not expected to, have a material effect on our consolidated financial statements.
3.     Financial Statement Details
Prepaid expenses and other current assets
As of June 30, 2021 and December 31, 2020, prepaid expenses and other current assets consist of the following (in thousands):
June 30,
2021
December 31,
2020
(Unaudited)
Prepaid preclinical and clinical trial services – with
related party (Note 8)
$
1,760
$
4,626
Prepaid license fees
1,579
801
Prepaid services
1,356
1,294
Prepaid insurance
1,191
1,365
Prepaid rent
659
589
Insurance premium financing asset
627
1,421
Prepaid equipment maintenance
198
243
Prepaid supplies – with related party (Note 8)
103
143
Insurance claims receivable
—
2,518
Equipment deposits
—
66
Interest receivable
–
marketable debt securities
—
473
Other
283
110
Prepaid expenses and other current assets
$
7,756
$
13,649
We have reflected our right to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.
Our insurance claims receivable as of December 31, 2020 were the result of the recovery of legal costs, which had been previously charged in prior periods to s
elling, general and administrative expense,
on the condensed consolidated statements of operations.
14
Table of Contents
Property,
p
lant and
e
quipment,
n
et
As of June 30, 2021 and December 31, 2020, property, plant and equipment, net, consist of the following (in thousands):
June 30,
2021
December 31,
2020
(Unaudited)
Leasehold improvements
$
62,445
$
52,251
Equipment
45,443
34,738
Buildings
22,690
22,690
Construction in progress
4,030
1,333
Software
1,449
2,376
Furniture & fixtures
1,046
1,015
Gross property, plant and equipment
137,103
114,403
Less: Accumulated depreciation and amortization
48,080
41,862
Property, plant and equipment, net
$
89,023
$
72,541
Construction in progress at June 30, 2021 is related primarily to expansion of our pharmaceutical development and manufacturing facilities, including construction of a new filling suite at our leased facilities in El Segundo, California
.
For the three months ended June 30, 2021, costs totaling $
8.2
million were transferred from construction in progress to leasehold improvements as the construction was complete and the asset was ready for its intended use.
Depreciation and amortization expense related to property, plant and equipment totaled $
7.0
million and $
7.0
million for the six months ended June 30, 2021 and 2020, respectively.
Other assets
As of June 30, 2021 and December 31, 2020, other assets consist of the following (in thousands):
June 30,
2021
December 31,
2020
(Unaudited)
Prepaid insurance
$
3,220
$
—
Prepaid preclinical and clinical trial services – with
related party (Note 8)
911
92
Value-added tax (VAT) receivable
877
864
ERP system implementation costs
585
—
Security deposits
486
634
Restricted cash
179
179
Prepaid software license fees
110
455
Due from related party
55
51
Other
374
323
Other assets
$
6,797
$
2,598
Prepaid insurance consists of policies required by and associated with the Merger. Restricted cash is comprised of a certificate of deposit that serves as collateral for a letter of credit required by our landlord as a security deposit related to our facility in San Diego, California.
15
Table of Contents
Accrued
e
xpenses
and other liabilities
As of June 30, 2021 and December 31, 2020, accrued expenses and other liabilities consist of the following (in thousands):
June 30,
2021
December 31,
2020
(Unaudited)
Accrued dissenting shares (Note 7)
$
6,941
$
6,769
Accrued professional and service fees
6,575
7,668
Accrued preclinical and clinical trial costs
4,866
4,339
Accrued compensation
4,719
3,891
Accrued research and development costs
3,528
4,002
Accrued bonus
3,377
5,288
Accrued construction costs
2,894
—
Accrued contingent consideration payable
831
856
Accrued laboratory equipment, supplies and related services
779
641
Financing obligation – current portion
627
1,421
Deferred revenue
217
270
Accrued franchise, sales, use and property taxes
211
103
Accrued capital expenditures
—
337
Other
569
1,186
Accrued expenses and other liabilities
$
36,134
$
36,771
Interest and investment (loss) income, net
Interest and investment (loss) income, net consists of the following (in thousands):
Three Months Ended
June 30,
Six Months Ended
June 30,
2021
2020
2021
2020
(Unaudited)
(Unaudited)
Unrealized (losses) gains from equity securities
$
(
442
)
$
692
$
8,391
$
494
Interest income
112
341
451
663
Investment amortization expense, net
(
23
)
(
48
)
(
248
)
(
93
)
Realized gains on investments
176
1
173
—
Interest and investment (loss) income, net
$
(
177
)
$
986
$
8,767
$
1,064
Interest income includes interest from marketable securities, convertible notes receivable, other assets, and interest from bank deposits.
16
Table of Contents
4.     Financial Instruments
Investments in Marketable Debt Securities
As of June 30, 2021, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in thousands):
June 30, 2021
(Unaudited)
Weighted-
Average
Remaining
Contractual Life
(in years)
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Current:
Foreign bonds
0.7
$
244
$
—
$
—
$
244
Mutual funds
35
3
—
38
Current portion
279
3
—
282
Noncurrent:
Foreign bonds
5.4
761
61
—
822
Noncurrent portion
761
61
—
822
Total
$
1,040
$
64
$
—
$
1,104
As of December 31, 2020, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in thousands):
December 31, 2020
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Current:
Corporate debt securities
$
54,789
$
2
$
(
19
)
$
54,772
Mutual funds
35
2
—
37
Current portion
54,824
4
(
19
)
54,809
Noncurrent:
Foreign bonds
861
89
—
950
Noncurrent portion
861
89
—
950
Total
$
55,685
$
93
$
(
19
)
$
55,759
We do
no
t have debt securities classified as available-for-sale that were in an unrealized loss position as of June 30, 2021. Accumulated unrealized losses on debt securities that have been in a continuous loss position for less than 12 months and more than 12 months as of December 31, 2020 were as follows (in thousands):
December 31, 2020
Less than 12 months
More than 12 months
Estimated
Fair
Value
Gross
Unrealized
Losses
Estimated
Fair
Value
Gross
Unrealized
Losses
Corporate debt securities
$
42,762
$
(
19
)
$
—
$
—
Total
$
42,762
$
(
19
)
$
—
$
—
We evaluated our securities for other-than-temporary impairment, and we did
no
t recognize any other-than-temporary impairment losses for the six months ended June 30, 2021 and 2020.
Realized gains and losses on sales of available-for-sale debt securities were not significant for the six months ended June 30, 2021 and 2020.
17
Table of Contents
Marketable E
quity
S
ecurities
We held investments in marketable equity securities with readily determinable fair values of $
19.7
million and $
6.3
million as of June 30, 2021 and December 31, 2020, respectively. Unrealized gains recorded on these securities totaled $
8.4
million and $
0.5
million in
interest and investment (loss) income, net
, on the condensed consolidated statements of operations for the six months ended June 30, 2021 and 2020, respectively. We recorded a realized gain totaling $
0.2
million from sales of equity securities in
interest and investment (loss) income, net
, on the condensed consolidated statements of operations for the six months ended June 30, 2021.
5.     Fair Value Measurements
Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.
The three tiers are defined as follows:
•
Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level 1 assets consist of bank deposits, money market funds, and marketable equity securities.
•
Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level 2 assets consist of corporate debt securities including commercial paper, government-sponsored securities and corporate bonds, as well as foreign municipal securities.
•
Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.
Recurring Valuations
Financial assets and liabilities measured at fair value on a recurring basis are summarized below as of June 30, 2021 and December 31, 2020 (in thousands):
Fair Value Measurements at June 30, 2021
(Unaudited)
Total
Level 1
Level 2
Level 3
Assets:
Current:
Cash and cash equivalents
$
83,958
$
83,958
$
—
$
—
Equity securities
19,688
(1)
19,688
—
—
Foreign bonds
244
244
—
—
Mutual funds
38
38
—
—
Noncurrent:
Foreign bonds
822
822
—
—
Total assets measured at fair value
$
104,750
$
104,750
$
—
$
—
Liabilities:
Contingent consideration obligations
$
(
854
)
(2)
$
—
$
—
$
(
854
)
18
Table of Contents
Fair Value Measurements at December 31, 2020
Total
Level 1
Level 2
Level 3
Assets:
Current:
Cash and cash equivalents
$
34,915
$
34,915
$
—
$
—
Corporate debt securities
54,772
—
54,772
—
Equity securities
6,337
6,337
—
—
Mutual funds
37
37
—
—
Noncurrent:
Foreign bonds
950
950
—
—
Total assets measured at fair value
$
97,011
$
42,239
$
54,772
$
—
Liabilities:
Contingent consideration obligations
$
(
972
)
(2)
$
—
$
—
$
(
972
)
(1)
Our equity securities include a $
17.7
million investment in Viracta Therapeutics, Inc. ("Viracta"), a clinical stage drug development company with whom we have an exclusive worldwide license to develop and commercialize one of their proprietary drug candidates. In February 2021, Viracta merged with Sunesis Pharmaceuticals, Inc. ("Sunesis"), a public company. In connection with this transaction, our preferred stock investment in Viracta was converted into
1,562,604
shares of Viracta common stock effective February 25, 2021.
Prior to the acquisition by Sunesis, we accounted for our investment in Viracta
by applying the measurement alternative under ASC 321. As of December 31, 2020, the carrying value of our investment in Viracta, which was reflected in
non-marketable equity investment
, on the condensed combined consolidated balance sheets, was $
7.8
million.
(2)
Contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period until the related contingencies are resolved. The fair value measurements of these obligations are based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level 3 measurement within the fair value hierarchy) and are reviewed periodically by management. See
Note 7
,
Commitments and Contingencies,
for additional information.
Changes in the carrying amount of contingent consideration obligations were as follows (in thousands):
Six Months Ended
June 30,
2021
2020
(Unaudited)
Fair value, beginning of period
$
(
972
)
$
(
1,725
)
Net change in fair value
118
457
Fair value, end of period
$
(
854
)
$
(
1,268
)
Non-recurring Valuations
Non-financial assets and liabilities are recognized at fair value subsequent to initial recognition when they are deemed to be other-than-temporarily impaired. There were no material non-financial assets and liabilities deemed to be other-than-temporarily impaired and measured at fair value on a non-recurring basis for the six months ended June 30, 2021 and 2020.
6.     Collaboration and License Agreements
Collaboration Agreements
National Cancer Institute
In May 2015, Etubics Corporation ("Etubics") entered into a Cooperative Research and Development Agreement ("CRADA") with the U.S. Department of Health and Human Services as represented by the National Cancer Institute ("NCI") of the National Institutes of Health ("NIH") to collaborate on the preclinical and clinical development of an adenovirus technology expressing tumor-associated antigens for cancer immunotherapy. In January 2016, we acquired all of the outstanding equity interests in Etubics and Etubics became a wholly-owned subsidiary.
19
Table of Contents
Effective January 2018, we assumed the CRADA and it was amended to cover a collaboration for the preclinical and clinical development
of our proprietary yeast-based T
armogens expressing tumor-associated antigens and proprietary adenovirus technology expressing tumor-associated antigens for cancer immunotherapy. Pursuant to the CRADA,
the
N
IH
provides scientific staff and other support necessary to conduct research and related activities as described in the CRADA
.
During the term of the CRADA, we are required to make annual payments of $
0.6
million to the NIH for support of research activities. We made payments of $
0.6
million in each of the six months ended June 30, 2021 and 2020, respectively, and recorded $
0.3
million in
research and development expense
, on the condensed consolidated statements of operations for the six months ended June 30, 2021 and 2020. The CRADA expires in May 2023.
In February 2018, we entered into an amendment to a CRADA with the NIH that was originally executed between the NIH and Amgen, Inc. ("Amgen") in May 2012 and subsequently assigned by Amgen to the company effective as of December 17, 2015. The research goal of this CRADA, as amended, is for the non-clinical and clinical development of ganitumab, our licensed monoclonal antibody targeting insulin-like growth factor one receptor, to evaluate its safety and efficacy in patients with hematological malignancies and solid tumors. The CRADA has a five-year term commencing on February 20, 2018 and expiring on February 20, 2023.
During the term of the agreement, we are required to make minimum annual payments of $
0.2
million to the NIH for support of research activities and additional payments for the clinical trials based on the scope and phase of the clinical trials. Unpaid research and development expense was estimated at $
0.5
million and $
0.6
million as of June 30, 2021 and December 31, 2020, respectively.
In February 2021, we entered into a CRADA with the NIH to conduct collaborative analysis of human clinical trial samples from clinical trials utilizing our proprietary recombinant NK cells and/or monoclonal antibodies ("mAbs") for preclinical development in monotherapy and in combination immunotherapies. The CRADA has a two-year term commencing on February 22, 2021 and expiring on February 22, 2023. During the term of the agreement, we are required to provide $
0.1
million per year to the NIH for support of the research activities. We made a payment of $
0.1
million during the six months ended June 30, 2021.
All CRADA agreements may be terminated at any time upon the mutual written consent of the company and the NIH. Either party may unilaterally terminate either of the CRADAs at any time by providing written notice to the other party at least 60 days before the desired termination date.
Pursuant to the terms of the CRADAs, we have an option to elect to negotiate an exclusive or non-exclusive commercialization license to any inventions discovered in the performance of either of the CRADAs, whether solely by an NIH employee or jointly with a company employee for which a patent application has been filed. The parties jointly own any inventions and materials that are jointly produced by employees of both parties in the course of performing activities under the CRADAs.
License Agreements
Infectious Disease Research Institute
In May 2021, we entered into license agreements with the Infectious Disease Research Institute ("IDRI"), pursuant to which we received licenses to certain of their platforms and formulations relevant to our product portfolio. Under the licenses, we were obligated to pay one-time, non-creditable, non-refundable upfront cash payments totaling $
2.0
million that we recorded in
research and development expense
, on the condensed consolidated statements of operations for the six months ended June 30, 2021. In addition, we will owe IDRI milestone payments based on the achievement of certain development and regulatory milestones and royalties on net sales of licensed products.
No
milestone fees were incurred for the six months ended June 30, 2021. In connection with the license agreements, we also entered into a Sponsored Research Agreement ("SRA") with IDRI pursuant to which we will fund continued research of at least $
2
million per year, payable in four equal quarterly installments each year until May 2024, or such year of earlier termination. For the six months ended June 30, 2021, we recorded $
0.2
million in
research and development expense
, on the condensed consolidated statements of operations related to the SRA.
20
Table of Contents
iosBio Ltd. Exclusive License Agreement
In August 2020, we executed an exclusive license agreement with iosBio Ltd., formerly Stabilitech Biopharma Ltd. ("iosBio"), pursuant to which we and our affiliates will receive an exclusive, worldwide license to certain of iosBio's intellectual property rights relating to the SARS-CoV-2 and successor vaccine candidates. In return, we are required to pay mid-to-high single-digit royalties on net sales of the resulting licensed products. Concurrently we entered into a non-exclusive license agreement with iosBio, which grants iosBio and its affiliates a non-exclusive, worldwide license for the intellectual property and technology relating to our adenovirus constructs for the prevention and treatment of shingles and other infectious disease targets to be mutually agreed by the parties in good faith. As of June 30, 2021 and December 31, 2020, we accrued $
0.2
million and $
0.5
million payable, respectively, to iosBio for costs of supplies and reimbursable costs related to the clinical trial activities initiated by iosBio.
7.     Commitments and Contingencies
Contingent Consideration Related to Business Combinations
VivaBioCell, S.p.A.
On April 10, 2015, NantWorks, LLC ("NantWorks"), a related party, acquired a
100
% interest in VivaBioCell, S.p.A. ("VivaBioCell") through its wholly-owned subsidiary, VBC Holdings, LLC, ("VBC Holdings") for $
0.7
million, less working capital adjustments. On June 15, 2015, NantWorks contributed its equity interest in VBC Holdings to the company, in exchange for cash consideration equal to its cost basis in the investment. VivaBioCell develops bioreactors and products based on cell culture and tissue engineering in Italy. In connection with this transaction, we are obligated to pay the former owners up to $
3.7
million upon the achievement of certain sales milestones relating to scaffold technology and certain clinical and regulatory milestones relating to the GMP-in-a-Box technology. The fair value of the contingent consideration obligation decreased $
0.1
million during the six months ended June 30, 2021 to $
0.8
million.
Altor BioScience Corporation
In connection with our July 2017 acquisition of Altor BioScience Corporation ("Altor"), we issued contingent value rights ("CVRs") under which we agreed to pay the prior stockholders of Altor approximately $
304.0
million upon successful approval of the Biologics License Application ("BLA") or foreign equivalent, for Anktiva by December 31, 2022 and approximately $
304.0
million upon the first calendar year before December 31, 2026 in which worldwide net sales of Anktiva exceed $
1.0
billion (with amounts payable in cash or shares of our common stock or a combination thereof). Dr. Soon-Shiong and his related party hold approximately $
279.5
million in the aggregate of CVRs and they have both irrevocably agreed to receive shares of the company's common stock in satisfaction of their CVRs. As the transaction was recorded as an asset acquisition, future CVR payments will be recorded when the corresponding events are probable of achievement or the consideration becomes payable.
Litigation
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. We are aware of complaints that have been filed regarding the Merger, but we have not been served with any of such complaints. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
Altor BioScience, LLC Litigation
In 2017, NantCell announced it had entered into a definitive merger agreement to acquire Altor BioScience Corporation. An action captioned Gray v. Soon-Shiong, et al. was filed in Delaware Chancery Court by plaintiffs Clayland Boyden Gray ("Gray") and Adam R. Waldman. The plaintiffs, two minority stockholders, asserted claims against the company and other defendants for (1) breach of fiduciary duty and (2) aiding and abetting breach of fiduciary duty and filed a motion to enjoin the merger. The court denied the motion and permitted the merger to close.
Subsequent to the close of the merger, in 2017 the plaintiffs (joined by two additional minority stockholders, Barbara Sturm Waldman and Douglas E. Henderson ("Henderson")) filed a second amended complaint, asserting claims for (1) appraisal; (2) quasi-appraisal; (3) breach of fiduciary duty; and (4) aiding and abetting breach of fiduciary duty. The defendants moved to dismiss the second amended complaint, raising grounds that included a "standstill" agreement under which defendants maintained that Gray and Adam R. Waldman and Barbara Strum Waldman (the "Waldmans") agreed not to bring the lawsuit.
21
Table of Contents
In
a
second
action, Dyad Pharmaceutical Corporation, or Dyad, filed a petition
in Delaware Chancery Court
for appraisal in connection with the merger. Respondent moved to dismiss the appraisal petition
in
2018, arguing in part that the petition was barred by the same "standstill" agreement.
In
2018, the court heard oral arguments on the motions to dismiss in both consolidated cases and converted the motions to dismiss into motions for summary judgment with regard to the "standstill" agreement argument, or the Converted Motions.
The court issued an oral ruling in 2019 that dismissed certain claims and dismissed Altor BioScience from the action. The following claims remain: (a) the appraisal claims by all plaintiffs and Dyad (against Altor BioScience, LLC), and (b) Henderson's claims for breach of fiduciary duty and aiding and abetting breach of fiduciary duty.
In 2019, the court issued a written order implementing its ruling on the Converted Motions (the "Implementing Order"). In the Implementing Order, the court confirmed that all fiduciary duty claims brought by Gray, both individually and as trustee of the Gordon Gray Trust f/b/o C. Boyden Gray, were dismissed. Gray and the Waldmans filed answers denying the counterclaims and asserting defenses. The plaintiffs moved for leave to file a third amended complaint to add two former Altor stockholders as plaintiffs and a fiduciary duty claim on behalf of a purported class of former Altor stockholders, which the defendants opposed.
In 2020, the court granted the plaintiffs' motion, and the plaintiffs filed a third amended complaint. In 2020, the defendants answered the third amended complaint and asserted counter claims against the plaintiffs. The defendants are seeking damages for attorneys' fees and costs incurred as a result of these breaches. The plaintiffs filed an answer denying the counterclaims and asserting defenses. The trial has been set to commence in October 2021, but trial is likely to be continued until the second half of 2022.
The shares of these former Altor stockholders met the definition of dissenting shares under the merger agreement and were not entitled to receive any portion of the merger consideration at the closing date. However, these dissenting shares will automatically be converted to receive the portion of the merger consideration they were entitled to, on the later of the closing date or when the stockholder withdraws or loses the right to demand appraisal rights. Payment for dissenting shares will be on the same terms and conditions originally stated in the merger agreement.
As of June 30, 2021 and December 31, 2020, we had accrued $
6.9
million and $
6.8
million related to these obligations, respectively. The accrued amount represents the estimated low-end of the range of currently estimated payout amounts in accordance with ASC Topic 450,
Contingencies
, after considering the reasonable outcomes for settling the dissenting stockholder dispute along with any accrued statutory interest. We cannot reasonably estimate a range of loss or likelihood of loss beyond the amounts recorded for dissenting shares as of June 30, 2021, as the dissenting stockholders have not yet provided a quantified value of their claim and, therefore, an upper end of the range of loss cannot be determined. Discovery is ongoing, and class certification motions relating to the putative class have not yet been filed or decided. We reassess the reasonableness of the recorded amount at each reporting period. We believe the claims lack merit and intend to continue defending the case vigorously.
Sorrento Therapeutics, Inc. Litigation
Sorrento Therapeutics, Inc. ("Sorrento"), derivatively on behalf of NANTibody, LLC ("NANTibody"), filed an action in the Superior Court of California, Los Angeles County (the "Superior Court") against the company, Dr. Soon-Shiong and Charles Kim. The action alleged that the defendants improperly caused NANTibody to acquire IgDraSol, Inc. from our affiliate NantPharma, LLC ("NantPharma") and sought to have the transaction undone and the purchase amount returned to NANTibody. In 2019, we filed a demurrer to several causes of action alleged in the Superior Court action, and Sorrento filed an amended complaint, eliminating Mr. Kim as a defendant and dropping the causes of action we had challenged in our demurrer.
Sorrento filed a related arbitration proceeding, the Cynviloq arbitration, against Dr. Soon-Shiong and NantPharma; the company is not named in the Cynviloq arbitration. In 2020, the Superior Court granted Dr. Soon-Shiong's request for a preliminary injunction barring Sorrento from pursuing claims against him in the Cynviloq arbitration. Sorrento then filed the claims it had previously asserted in arbitration against Dr. Soon-Shiong in the Superior Court, and at Sorrento's request, the arbitrator entered an order dismissing Sorrento's claims against Dr. Soon-Shiong in the Cynviloq arbitration. The hearing in the Cynviloq arbitration commenced in June 2021, and is scheduled to continue with breaks until at least September 2021.
Also in 2019, the company and Dr. Soon-Shiong filed cross-claims in the Superior Court action against Sorrento and its Chief Executive Officer Henry Ji, asserting claims for fraud, breach of contract, breach of the covenant of good faith and fair dealing, tortious interference with contract, unjust enrichment, and declaratory relief. Our claims allege that Dr. Ji and Sorrento breached the terms of an exclusive license agreement between the company and Sorrento related to Sorrento's antibody library and that Sorrento did not perform its obligations under the exclusive license agreement. The Superior Court ruled that the company's claims should be pursued in arbitration and that Dr. Soon-Shiong's claims could be pursued in Superior Court.
22
Table of Contents
In
2019,
the company
, along with NANTibody, filed an arbitration against Sorrento and Dr.
Ji asserting
our
claims relating to the exclusive license agreement.
In
2020, Sorrento sent letters purporting to terminate the exclusive license agreement with the company, and an exclusive license agreement with NANTibody and demanding the return of its confidential information and transfer of all regulatory filings and related materials. As required pursuant to the exclusive license agreements, both parties must engage in good-faith negotiations before attempting to invoke any termination provision contained in the agreement. Notwithstanding such negotiations, Sorrento sent a letter purporting to terminate the exclusive license agreements, maintaining the negotiations did not reach a successful resolution. We believe we have cured any perceived breaches during the 90-day contractual cure period provided under the agreements.
Sorrento filed counterclaims against the company and NANTibody in the arbitration and requested leave to file a dispositive motion.
The hearings in the antibody arbitration commenced in April 2021 and
concluded in
early August 2021.
Post-hearing briefing will be followed by concluding arguments on November 10, 2021.
We intend to prosecute our claims, and to defend the claims asserted against us, vigorously. An estimate of the possible loss or range of loss cannot be made at this time.
Shenzhen Beike Biotechnology Corporation Litigation
In 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration, served by Shenzhen Beike Biotechnology Corporation ("Beike"). The arbitration relates to a license, development, and commercialization agreement that Altor Bioscience Corporation (succeeded by our wholly-owned subsidiary Altor BioScience, LLC ("Altor")) entered into with Beike in 2014, which agreement was amended and restated in 2017, pursuant to which Altor granted to Beike an exclusive license to use, research, develop and commercialize products based on Anktiva in China for human therapeutic uses. In the arbitration, Beike is asserting a claim for breach of contract under the license agreement. Among other things, Beike alleges that we failed to use commercially reasonable efforts to deliver to Beike materials and data related to Anktiva. Beike is seeking specific performance, or in the alternative, damages for the alleged breaches. On September 25, 2020, the parties entered into a standstill and tolling agreement under which, among other things, the parties affirmed they will perform certain of their obligations under the license agreement by specified dates and agreed that all deadlines in the arbitration are indefinitely extended. The standstill agreement may be terminated by any party on ten calendar days' notice, and upon termination, the parties will have the right to pursue claims arising from the license agreement in any appropriate tribunal. The parties have been asked to provide an update to the International Chamber of Commerce by August 31, 2021 of any further developments.
Given that this action remains at the pleading stage and no discovery has occurred, it remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the claims lack merit and intend to defend the case vigorously and that we may have counterclaims.
Fox Chase Litigation
On July 21, 2020, ImmunityBio filed a declaratory judgment lawsuit in the Superior Court for San Diego County, California, naming Fox Chase Cancer Center Foundation and Institute for Cancer Research as the defendants (hereafter collectively "Fox Chase"). This litigation relates to the license with Fox Chase and includes various intellectual property rights (the "2004 License"). Our initial court filing requested the Court to find that we have not breached material obligations under the 2004 License and that Fox Chase has not and cannot terminate the 2004 License. Fox Chase filed a Cross-Complaint raising a patent inventorship challenge and moved the case to federal court. On June 4, 2021, the federal court separated the parties' claims, and returned ImmunityBio's declaratory judgment claims back to the San Diego County court while retaining the patent inventorship challenge. While the litigation is in the early stage, its outcome cannot be predicted. We do not consider the 2004 License or the patent inventorship challenge to be material to our business.
Litigation Related to the Merger with ImmunityBio, Inc.
In connection with the Merger with
NantCell, Inc. (formerly known as ImmunityBio, Inc., a private company), a Delaware corporation, via a wholly-owned subsidiary of NantKwest (the "Merger Sub"),
seven complaints have been filed as individual actions in United States District Courts. Three complaints have been filed in the United States District Court for the District of Delaware against NantKwest and its directors and are captioned
Hargett v. NantKwest, Inc., et al.
, 1:21‑cv‑00197 (filed February 11, 2021) (the "Hargett Complaint"),
Franchi v. NantKwest, Inc., et al.
, 1:21‑cv‑00218 (filed February 16, 2021) (the "Franchi Complaint"), and
Gross v. NantKwest, Inc., et al.
, 1:21‑cv‑00223 (filed February 17, 2021) (the "Gross Complaint"). One complaint has been filed in the United States District Court for the Southern District of New York and is captioned
Leaman v. NantKwest, Inc., et al.
, 1:21‑cv‑01351 (filed February 16, 2021) (the "Leaman Complaint"). Two complaints have been filed in the United States District Court for the Southern District of California and are captioned
Weiss v. NantKwest, Inc., et al.
, 3:21‑cv‑00280 (filed February 16, 2021) (the "Weiss Complaint") and
Carlisle v. NantKwest, Inc., et al.
, 3:21‑cv‑00304 (filed February 19, 2021) (the "Carlisle Complaint").
23
Table of Contents
One complaint has been filed in the United States District Court for the Eastern District of New York and was captioned
Shenk v. NantKwest, Inc., et al.
, 1:21‑cv‑00871 (filed February 18, 2021) (the "Shenk Complaint," and collectively with the Hargett Complaint, the "Franchi Complaint," the Gross Complaint, the Leaman Complaint, the Weiss Complaint, and the Carlisle Complaint, the "Merger Actions"). The Shenk Complaint was voluntarily dismissed on March 10, 2021. The Franchi Complaint was voluntarily dismissed on May 6, 2021. The Leaman Complaint was voluntarily dismissed on May 7, 2021. The Hargett Complaint and the Gross Complaint were both voluntarily dismissed on May 18, 2021. The Hargett Complaint and the Gross Complaint also brought claims against ImmunityBio, and Merger Sub. The Merger Actions generally allege that the Definitive Proxy Statement filed with the SEC on February 2, 2021 misrepresents and/or omits certain purportedly material information relating to financial projections, analysis performed by the financial advisor to NantKwest's Special Committee, alleged past engagements of the Special Committee's financial advisor and industry consultant, and the terms of the engagement of such consultant. The Merger Actions assert violations of Sections 14(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 14a-9 promulgated thereunder against all defendants and violations of Section 20(a) of the Exchange Act against NantKwest's directors. The Merger Actions seek, among other things, an injunction enjoining the stockholder vote on the Merger and the consummation of the Merger unless and until certain additional information is disclosed to NantKwest's stockholders, costs of the action, including plaintiffs' attorneys' fees and experts' fees, and other relief the Court may deem just and proper. Neither the stockholder vote on the Merger nor the Merger were enjoined and occurred on March 8 and March 9, 2021, respectively. The company cannot predict the outcome of the Merger Actions. The company believes the Merger Actions are without merit and the company and the individual defendants intend to vigorously defend against the Merger Actions and any subsequently filed similar actions. If additional similar complaints are filed, absent new or significantly different allegations, the company will not necessarily disclose such additional filings.
Lease Arrangements
Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. We have leases in multiple facilities across the U.S. and Italy, including El Segundo, California (general corporate and administrative activities, research and development and regulatory from related parties); San Diego, California (research facility and office space); Culver City, California (research and manufacturing space from a related party); Torrance, California (a research facility from a related party); Miramar, Florida (clinical development); Seattle, Washington (research and development); Louisville, Colorado (research and development and manufacturing); Woburn, Massachusetts (research facility); and Udine and Tavangnacco, Italy (GMP-in-a-Box, research facility and office space). See
Note 8
,
Related-Party Agreements
, for further information.
Our leases generally have initial terms ranging from
two to ten years
and often include one or more options to renew. These renewal terms can extend the lease term from
one to five years
, and are included in the lease term when it is reasonably certain that we will exercise the option.
Information regarding our leases is as follows:
June 30,
2021
December 31,
2020
(Unaudited)
Weighted average remaining lease term
6.2
years
3.9
years
Weighted average discount rate
9
%
9
%
The components of lease expense consist of the following (in thousands):
Three Months Ended
June 30,
Six Months Ended
June 30,
2021
2020
2021
2020
(Unaudited)
(Unaudited)
Operating lease costs
$
1,717
$
1,624
$
3,864
$
3,406
Variable lease costs
517
726
1,183
1,574
Total lease costs
$
2,234
$
2,350
$
5,047
$
4,980
24
Table of Contents
Cash paid for amounts included in the measurement of lease liabilities is as follows (in thousands):
Six Months Ended
June 30,
2021
2020
(Unaudited)
Operating cash flows for operating leases
$
4,004
$
2,785
Future minimum lease payments as of June 30, 2021, including $
12.6
million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in thousands). Common area maintenance costs and taxes are not included in these payments.
Years ending December 31:
Operating
Leases
2021 (excluding the six months ended June 30, 2021)
$
834
2022
8,952
2023
7,288
2024
5,840
2025
5,467
Thereafter
15,729
Total future minimum lease payments
44,110
Less: Interest
12,564
Present value of operating lease liabilities
$
31,546
In February 2021, but effective on January 1, 2021, we entered into a lease agreement with 605 Nash, LLC, a related party, for a facility primarily used for pharmaceutical development and manufacturing purposes.
In May 2021, but effective on April 1, 2021, we entered into an amendment to our lease agreement with 605 Nash, LLC. See
Note 8
,
Related-Party Agreements
, for further information.
There have been no other material changes related to our existing lease agreements from those disclosed in Note 8 of the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio, Inc. as of December 31, 2020 and December 31, 2019 (including NantCell, Inc.) filed as
Exhibit 99.2
to our Current Report on Form 8‑K/A filed with the SEC on April 22, 2021.
Commitments
We did not enter into any significant contracts during the six months ended June 30, 2021, other than those disclosed in these condensed consolidated financial statements.
In addition, we are also a party to various contracts with contract research organizations and contract manufacturers that generally provide for termination on notice, with the exact amounts in the event of termination to be based on the timing of the termination and the terms of the agreement. There have been no material changes in unconditional purchase commitments from those disclosed in Note 8 of the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio, Inc. as of December 31, 2020 and December 31, 2019 (including NantCell, Inc.) filed as
Exhibit 99.2
to our Current Report on Form 8‑K/A filed with the SEC on April 22, 2021.
25
Table of Contents
8.     Related-Party Agreements
We conduct business with several affiliates under written agreements and informal arrangements.
Below is a summary of outstanding balances and a description of significant relationships (in thousands):
June 30,
2021
December 31,
2020
(Unaudited)
Due from related party–NantBio
$
1,294
$
1,294
Due from related party–NantOmics
591
591
Due from related parties–Various
162
118
Total due from related parties
$
2,047
$
2,003
Due to related party–NantWorks
$
12,925
$
10,650
Due to related party–Duley Road
2,427
2,787
Due to related party–NantBio
943
943
Due to related party–Immuno-Oncology Clinic
229
271
Due to related party–Various
187
187
Total due to related parties
$
16,711
$
14,838
Our Executive Chairman, and principal stockholder, founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new genetically modified NK cells for our product pipeline. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman.
NantWorks
Under the NantWorks shared services agreement executed in November 2015, but effective August 2015, NantWorks, a related party, provides corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy, and other support services. We are charged for the services at cost plus reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the employees providing the services. For the three months ended June 30, 2021 and 2020, we recorded $
1.2
million and $
2.4
million, respectively, in
selling, general and administrative expense
, and $
0.1
million and $
0.2
million, respectively, of expense reimbursements under this arrangement in
research and development expense
, on the condensed consolidated statements of operations. For the six months ended June 30, 2021 and 2020, we recorded $
3.0
million and $
3.9
million, respectively, in
selling, general and administrative expense
, and $
0.4
million and $
1.2
million, respectively, of expense reimbursements under this arrangement in
research and development expense
, on the condensed consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third-party vendors directly for our benefit, which have been reimbursed to NantWorks based on those vendors' invoiced amounts without markup by NantWorks.
As of June 30, 2021 and December 31, 2020, we owed NantWorks a net amount of $
12.9
million and $
10.7
million, respectively, for all agreements between the two affiliates, which is included in
due to related parties,
on the condensed consolidated balance sheets. We also recorded $
1.2
million and $
1.1
million of prepaid expenses for services that have been passed through to the company from NantWorks as of June 30, 2021 and December 31, 2020, respectively, which are included in
prepaid expenses and other current assets
, on the condensed consolidated balance sheets.
26
Table of Contents
In November 2015, we entered into a facility license agreement with NantWorks for approximately
9,500
square feet of office space in Culver City, California, which has been converted to a research and development laboratory and a current Good Manufacturing Practice ("cGMP") manufacturing facility. The initial license was effective from May 2015 through December 2020. The base rent for the initial lease term was $
47,000
per month, with annual increases of 3% beginning in January 2017. In September 2020, we amended this agreement to extend the term of this lease through December 31, 2021. Commencing January 1, 2021, the base rent increased by 3% to approximately $
54,500
per month. Subsequent to December 31, 2021, the lease term will automatically renew on a month-to-month basis, terminable by either party with at least 30 days' prior written notice to the other party. In addition, we have a one-time option to extend the lease term through December 31, 2022. If we exercise the option to extend the lease through December 31, 2022, or continue on a month-to-month basis, the base rent will increase by
3
% annually commencing on January 1 of each year. On the date of amendment, we recorded an increase of $
1.2
million in both
operating lease right-of-use assets
and
operating lease liabilities
, on the condensed consolidated balance sheets, reflecting our belief that we will extend the term of this lease through December 31, 2022. Lease expense for this facility totaling $
0.3
million and $
0.3
million for the six months ended June 30, 2021 and 2020, respectively, was recorded in
research and development expense
, on the condensed consolidated statements of operations.
Immuno-Oncology Clinic, Inc.
Beginning in 2017, we entered into multiple agreements with Immuno-Oncology Clinic, Inc. (the "Clinic") to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by an officer of the company and NantWorks manages the administrative operations of the Clinic. Prior to June 30, 2019, one of our officers was an investigator or sub-investigator for all of our trials conducted at the Clinic.
In July 2019, we entered into a new agreement with the Clinic (the "Clinic Agreement"), which became effective on July 1, 2019. The Clinic Agreement, as amended on March 31, 2020, covers clinical trial and research-related activities on a non-exclusive basis relating to our existing clinical trials, commenced prior to July 1, 2019, and prospective clinical trials and research projects. The Clinic Agreement also specifies certain services and related costs that are excluded from the Clinic Agreement. Prior to commencing any work under the Clinic Agreement, the parties have agreed to execute written work orders setting forth the terms and conditions related to specific services to be performed, including financial terms. For clinical trials that commenced prior to July 1, 2019, fees incurred for services performed after July 1, 2019 are covered under the Clinic Agreement and applied towards the below-mentioned prepayments. The Clinic Agreement allows for automatic renewal and additional extensions beyond the initial one-year term.
In consideration of the services to be performed under the Clinic Agreement, as amended on March 31, 2020, we agreed to make payments of up to $
7.5
million to the Clinic, of which $
3.75
million and $
1.88
million were paid in July 2019 and October 2019, respectively. As amended, a conditional payment of $
1.88
million shall be due and payable at such time, if any, that the payments made in July 2019 and October 2019 have been earned by the Clinic through the performance of services. On a quarterly basis, our prepayment is increased by a nominal interest credit computed in accordance with terms specified in the Clinic Agreement.
To the extent any portion of the prepayments remain unearned by the Clinic on the third anniversary of the Clinic Agreement, we may elect at our sole discretion either to (i) not extend the term of the Clinic Agreement and have the Clinic reimburse us for the total amount of any remaining unused portion of the prepayments, or (ii) extend the term of the Clinic Agreement for up to three additional one year periods, at which time the Clinic will reimburse us for the total amount of any remaining unused portion of the prepayments plus interest if reimbursement is not made within 60 days of expiration. The Clinic may terminate this agreement upon each anniversary date upon 60 days prior written notice and reimbursement in full to us of any outstanding unearned balance of the prepayments, provided that any such termination by the Clinic will not apply with respect to any work orders still in effect at the time of such termination.
We executed a clinical trial work order under the Clinic Agreement for an open-label, Phase I study of PD‑L1.t‑haNK for infusion in subjects with locally advanced or metastatic solid cancers. In July 2020, but effective on June 22, 2020, we and NantCell executed a clinical trial work order under our existing master agreement with the Clinic for an open-label, randomized, comparative Phase II study of NantCell's proprietary IL‑15 superagonist ("N‑803") and aldoxorubicin hydrochloride ("Aldoxorubicin") and our PD‑L1.t‑haNK with standard-of-care chemotherapy versus standard-of-care chemotherapy for first and second-line treatment of locally or advanced metastatic pancreatic cancer.
27
Table of Contents
In April 2021, ImmunityBio executed two work orders under an existing master agreement with
the Clinic. Under these work orders, the parties agreed that the
Clinic would serve as a site for the following multi-site clinical trials:
•
A Phase I study of the safety, reactogenicity, and immunogenicity of subcutaneously- and orally-administered supplemental spike & nucleocapsid-targeted COVID
‑
19 vaccine to enhance T cell-based immunogenicity in participants who have already received a vaccine authorized for emergency use; and
•
A Phase I study of the safety, reactogenicity, and immunogenicity of a supplemental spike & nucleocapsid-targeted COVID
‑
19 vaccine to enhance T cell-based immunogenicity in participants who have already received a vaccine authorized for emergency use.
Based on a review of our updated clinical trial programs post-Merger, we updated our estimates of the investigator fees for the clinical trials currently underway or planned at the Clinic. As certain programs costs are excluded from and certain services are subject to credit adjustments under the Clinic Agreement, we determined the expected future fees for services to be performed are less than the carrying value of the prepaid asset on the condensed consolidated balance sheets. As a result, we partially wrote down the value of our prepayments under the Clinic Agreement and recorded approximately $
1.9
million in
research and development expense
, on the condensed consolidated statements of operations for the three months ended June 30, 2021. In addition
, we reclassified $
0.9
million of prepaid assets from
prepaid expenses and other current assets
to
other assets,
on the condensed consolidated balance sheets
as of June 30, 2021 based on the additional time expected for them to be realized than initially estimated
.
For the three months ended June 30, 2021 and 2020, we incurred $
0.5
million and $
0.1
million in
research and development expense
, on the condensed consolidated statements of operations related to the Clinic Agreement. For the six months ended June 30, 2021 and 2020, we incurred $
0.8
million and $
0.2
million in
research and development expense
, on the condensed consolidated statements of operations related to the Clinic Agreement. As of June 30, 2021 and December 31, 2020, we owed the Clinic $
0.2
million and $
0.3
million, respectively, for services excluded from the Clinic Agreement. As of June 30, 2021 and December 31, 2020, we had prepaid balances related to the Clinic Agreement of $
2.7
million and $
4.7
million, respectively.
NantBio, Inc.
In March 2016, NantBio, Inc. ("NantBio") and the NCI entered into a cooperative research and development agreement. The initial five-year agreement covered NantBio and its affiliates, including us. Under the agreement, the parties collaborated on the preclinical and clinical development of proprietary recombinant natural killer cells and monoclonal antibodies in monotherapy and combination immunotherapies. In each of the contractual years under the agreement we paid $
0.6
million to the NCI as a payment for services under the agreement. We recognize expense related to this agreement ratably over a 12-month period for each funding year. We accrued $
0.2
million in
research and development expense
, on the condensed consolidated statements of operations related to this agreement for the six months ended June 30, 2021 and 2020. As of December 31, 2020, we recorded $
0.1
million in
prepaid expenses and other current assets
, on the condensed consolidated balance sheets related to this agreement.
In August 2018, we entered into a supply agreement with NantCancerStemCell, LLC ("NCSC"), a 60% owned subsidiary of NantBio (with the other 40% owned by Sorrento). Under this agreement, we agreed to supply VivaBioCell's proprietary GMP-in-a-Box bioreactors and related consumables, made according to specifications mutually agreed to with both companies. The agreement has an initial term of five years and renews automatically for successive one-year terms unless terminated by either party in the event of material default upon prior written notice of such default and the failure of the defaulting party to remedy the default within 30 days of the delivery of such notice, or upon 90 days' prior written notice by NCSC. We recognized revenue of $
0.3
million for the six months ended June 30, 2021. We recorded $
0.1
million and $
0.3
million of deferred revenue for bioreactors that were delivered but not installed as of June 30, 2021 and December 31, 2020, respectively. As of June 30, 2021 and December 31, 2020, we recorded $
0.9
million in
due to related parties
, on the condensed consolidated balance sheets related to this agreement.
In 2018, we entered into a shared service agreement, pursuant to which, we are charged for services at cost, without mark-up or profit for NantBio, but including reasonable allocations of employee benefits that relate to the employees providing the services. In April 2019, we agreed with NantBio to transfer certain NantBio employees and associated research and development projects, comprising the majority of NantBio's business, to the company. After the transfer, NantBio continued to make payments on our behalf for certain employee benefits and vendor costs related to the research and development projects that were transferred to the company. In addition, we settled certain employee bonuses and benefits that were accrued by NantBio for 2018. As of June 30, 2021 and December 31, 2020, we recorded a net receivable from NantBio of $
1.3
million, which included $
1.0
million for employee bonuses and $
0.3
million for vendor costs we paid on behalf of NantBio.
28
Table of Contents
NantOmics
In 2019, we made a strategic decision and transferred certain employees from NantOmics, LLC ("NantOmics"), a related party that is controlled by our Executive Chairman, to the company. After the transfer, we settled certain employee bonuses and benefits that were accrued by NantOmics for the year ended December 31, 2020 and recorded a $
0.6
million receivable from NantOmics as of June 30, 2021 and December 31, 2020.
605 Doug St, LLC
In September 2016, we entered into a lease agreement with 605 Doug St, LLC, an entity owned by our Executive Chairman, for approximately
24,250
square feet in El Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease runs from July 2016 through July 2023. We have the option to extend the lease for an additional
three-year
term through July 2026. The base rent is approximately $
72,385
per month, with annual increases of
3
% that began in July 2017. Lease expense of $
0.4
million for this facility for the six months ended June 30, 2021 and 2020, respectively, was recorded in
research and development expense
, on the condensed consolidated statements of operations. The prepaid rent for this lease was $
0.1
million, which was included in
prepaid expenses and other current assets
, and the security deposit for this lease was $
0.1
million, which was included in
other assets
, on the condensed consolidated balance sheets as of June 30, 2021.
Duley Road, LLC
In February 2017, Altor BioScience Corporation (succeeded by our wholly-owned subsidiary Altor BioScience, LLC), through its wholly-owned subsidiary, entered into a lease agreement with Duley Road, LLC ("Duley Road"), a related party that is indirectly controlled by our Executive Chairman, for approximately
12,000
square feet of office and cGMP manufacturing facility space in El Segundo, California. The lease term is from February 2017 through October 2024. We have the option to extend the initial term for
two
consecutive
five-year
periods through July 2034. The base rent is approximately $
40,700
per month, with annual increases of
3
% that began in November 2018. As of June 30, 2021 and December 31, 2020, we recorded rent payable to Duley Road of $
1.1
million and $
1.0
million, respectively. For the six months ended June 30, 2021 and 2020, we recorded rent expense of $
0.3
million and $
0.3
million, respectively, which is reflected in
research
and development expense
, on the condensed consolidated statements of operations.
Effective in January 2019, we entered into two lease agreements with Duley Road for a second building located in El Segundo, California. The first lease is for the first floor of the building with approximately
5,650
square feet. The lease has a seven-year term commencing in September 2019. The second lease is for the second floor of the building with approximately
6,488
square feet. The lease has a seven-year term commencing in July 2019. Both floors of the building are used for research and development and office space. We have options to extend the initial terms of both leases for
two
consecutive
five-year
periods through 2036. The base rent for the two leases is approximately $
35,800
per month that increases at a rate of
3
% per year.
As of June 30, 2021 and December 31, 2020, we recorded $
0.9
million and $
0.7
million of leasehold improvement payables, respectively, and $
0.4
million and $
1.1
million of lease-related payables to Duley Road, which were included in
due to related parties
, on the condensed consolidated balance sheets. For the six months ended June 30, 2021 and 2020, we recorded $
0.2
million and $
0.1
million of rent expense for the two leases, respectively, which was included in
research and development expense
, on the condensed consolidated statements of operations. The security deposits for the leases totaled $
0.1
million as of June 30, 2021, which were included in
other assets
, on the condensed consolidated balance sheets.
605 Nash, LLC
In February 2021, but effective on January 1, 2021, we entered into a lease agreement with 605 Nash, LLC, a related party, whereby we leased approximately
6,883
square feet (the "Initial Premises") in a two story mixed use building containing approximately 64,643 rentable square feet on 605-607 Nash Street in El Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease term commenced in January 2021 and expires in December 2027, and includes an option to extend the lease for
an
additional
three-year
term through December 2030. The base rent is approximately $
20,300
per month with an annual increase of
3
% on January 1 of each year during the initial term and, if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. We will receive a rent abatement for the first seven months, and a tenant improvement incentive of $
0.3
million from the landlord for
costs and expenses associated with the construction of tenant improvements for the Initial Premises.
29
Table of Contents
During the three months ended June 30, 2021, we completed the build out of certain facility space in connection with this lease and transferred costs totaling $
8.2
million from construction in progress to leasehold improvements. For
the three and six months ended June 30, 2021, we recorded rent expense of $
0.1
million, which is reflected in
research and development expense,
on the condensed consolidated statements of operations.
In May 2021, but effective on April 1, 2021, we entered into an amendment to our Initial Premises lease with 605 Nash, LLC. The amendment expanded the leased square feet by approximately
57,760
rentable square feet (the "Expansion Premises"). The lease term of the Expansion Premises commenced in April 2021 and expires in March 2028, whereby the company has the
option
to extend the initial term for
three years
. Per the terms of the amendment, the term of the Initial Premises lease was extended for an additional three months and now expires on March 31, 2028. Base rent for the Expansion Premises is approximately $
170,400
per month with annual increases of
3
% on April 1 of each year. We are responsible for the build out of the facility space and associated costs. The amended lease provides for a rent abatement for the first
seven month
s, and for a tenant improvement allowance of approximately $
2.6
million for costs and expenses related to improvements made by us to the Expansion Premises. During the three and six months ended June 30, 2021, we incurred
$
0.5
million of rent expense related to the Expansion Premises lease agreement. The security deposits for the leases total $
0.2
million as of June 30, 2021, which are included in
other assets
, on the condensed consolidated balance sheets.
Related-Party Notes Payable
As of June 30, 2021 and December 31, 2020, related-party notes payable consist of the following (in thousands):
Total Notes and Interest Payable
Note
Outstanding
Interest
June 30,
2021
December 31,
2020
Related-Party Notes Payable
Year
Advances
Rate
(Unaudited)
Nant Capital
(1)
2015
$
55,226
5.0
%
$
59,908
(2)
$
58,482
(2)
Nant Capital
(1)
2020
50,000
6.0
%
52,252
(3)
50,764
(3)
Nant Capital
(4)
2021
40,000
6.0
%
40,000
(4)
—
NantMobile
(1)
2019
55,000
3.0
%
57,502
(5)
56,660
(5)
NantWorks
(1)
2017
43,418
5.0
%
52,791
(6)
51,546
(6)
NCSC
(1)
2018
33,000
5.0
%
37,799
(7)
36,901
(7)
Total related-party notes payable
$
276,644
$
300,252
$
254,353
(1)
All outstanding advances and accrued and unpaid interest is due and payable on
September 30, 2025
. Interest on related-party notes payable is compounded annually. We may prepay the outstanding principal at any time without premium, penalty or the prior consent of the issuer. All outstanding amounts under the notes become due and payable upon certain bankruptcy and insolvency-related events. There are no equity or equity-linked convertible rights related to these promissory notes.
(2)
Accrued and unpaid interest on this note totaled $
4.7
million and $
3.3
million as of June 30, 2021 and December 31, 2020, respectively.
(3)
Accrued and unpaid interest on this note totaled $
2.3
million and $
0.8
million as of June 30, 2021 and December 31, 2020, respectively.
(4)
The outstanding principal is due and payable on
September 30, 2025
. Interest on this related-party note is compounded annually and payable quarterly commencing on June 30, 2021. We paid $
0.8
million in interest on this loan during the three months ended June 30, 2021. All outstanding amounts under the note become due and payable upon certain bankruptcy and insolvency-related events. There are no equity or equity-linked convertible rights related to this promissory note.
(5)
Accrued and unpaid interest on this note totaled $
2.5
million and $
1.7
million as of June 30, 2021 and December 31, 2020, respectively.
(6)
Accrued and unpaid interest on this note totaled $
9.4
million and $
8.1
million as of June 30, 2021 and December 31, 2020, respectively.
(7)
Accrued and unpaid interest on this note totaled $
4.8
million and $
3.9
million as of June 30, 2021 and December 31, 2020, respectively.
30
Table of Contents
9.     Stockholders' Deficit
Merger with NantCell
Under the terms of the Merger Agreement, at the Effective Time of the Merger, each share of NantCell common stock
, par value $0.001 per share,
issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive
0.8190
newly issued shares of common stock
, par value $
0.0001
per share, resulting in the issuance of approximately
273.7
million shares of Company Common Stock.
From and after the Effective Time, all of such NantCell shares ceased to be outstanding, were canceled and ceased to exist.
At the Effective Time, each share of our common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company.
Since the Merger has been accounted for as a transaction between entities under common control, the outstanding shares presented on the condensed consolidated financial statements assume that NantCell outstanding common stock was converted into shares of Company Common Stock for all periods presented, and in connection with the conversion, those shares of common stock have been recorded at the company's par value of $
0.0001
per share.
Stock Repurchases
No
shares of our common stock were repurchased during the six months ended June 30, 2021 and 2020 under the company's 2015 Share Repurchase Program. As of June 30, 2021, $
18.3
million remained authorized for repurchase under the program.
Common Stock Reserved for Future Issuance
As of June 30, 2021, a total of approximately
11.8
million shares of common stock were reserved for issuance,
including awards issued under the NC 2015 Plan that were outstanding immediately prior to the Effective Time of the Merger.
At the Effective Time, all outstanding equity awards granted under the NC 2015 Plan to purchase NantCell common stock were converted into equity awards to purchase shares of Company Common Stock (using the Exchange Ratio of
0.8190
), on the same terms and conditions as immediately prior to the Effective Time. As of June 30, 2021, there were approximately
6.8
million RSUs and
0.7
million stock options outstanding under the NC 2015 Plan, and there were
no
additional shares available for future grant.
Open Market Sale Agreement
On April 30, 2021, we entered into an Open Market Sale Agreement (the "Sale Agreement") with respect to an ATM offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $
500.0
million through our sales agent. We pay our sales agent a commission of up to
3.0
% of the gross sales proceeds of any shares of our common stock sold through them under the Sale Agreement, and also have provided them with customary indemnification and contribution rights.
During the three months ended June 30, 2021, we received net proceeds totaling $
94.9
million from the issuance of
6,420,441 shares
under the ATM, which
we expect to use for general corporate purposes, including to progress our clinical development programs, fund other research and development activities, for capital expenditures and to fund working capital. We may also use a portion of the net proceeds to license intellectual property or to make acquisitions or investments.
As of June 30, 2021, we had $
402.0
million available for future stock issuances under the ATM.
We are not obligated to sell any shares and may at any time suspend solicitation and offers under the Sale Agreement. The Sale Agreement may be terminated by us at any time given written notice to the sales agent for any reason or by the sales agent at any time by giving written notice to us for any reason or immediately under certain circumstances, and shall automatically terminate upon the issuance and sale of all of the shares.
31
Table of Contents
10.     Stock-Based Compensation
2015 Equity Incentive Plan
In July 2015, the company's board of directors adopted, and the company's stockholders approved, the 2015 Plan. Pursuant to the Merger, we assumed
7,121,110
RSUs (adjusted for the Exchange Ratio of
0.8190
) issued under NantCell's equity incentive plan. As of June 30, 2021, the 2015 Plan is the only equity plan available for grant of equity awards to employees, directors and consultants of the company. As of June 30, 2021, a total of approximately
5.9
million shares were available for future grant under the 2015 Plan.
Stock-based Compensation
The following table presents stock-based compensation included on the condensed consolidated statements of operations (in thousands):
Three Months Ended
June 30,
Six Months Ended
June 30,
2021
2020
2021
2020
(Unaudited)
(Unaudited)
Stock-based compensation expense:
Stock options
$
1,610
$
198
$
7,965
$
328
RSUs
16,253
124
25,196
474
$
17,863
$
322
$
33,161
$
802
Stock-based compensation expense in operating expenses:
Research and development
$
8,545
$
(
53
)
$
11,433
$
108
Selling, general and administrative
9,318
375
21,728
694
$
17,863
$
322
$
33,161
$
802
On March 18, 2021, the Board of Directors approved to modify certain non-qualified stock options that were assumed in the Merger and otherwise would have expired during a period when the grantees were legally restricted from exercising these awards. The expiration date of these options was extended to thirty (30) days following the effective date of Post-Effective Amendment No. 1 on Form S-3 to our Form S-4 Registration Statement. We recorded incremental stock-based compensation expense of approximately $
2.7
million for this stock option modification.
On March 29, 2021, in connection with the resignation of
two
former independent directors, the Board of Directors approved the acceleration of vesting of
83,333
shares of unvested stock options of the former directors on the date of their respective resignations. The modified options are exercisable for ninety (90) days after the date of the modification. We recorded incremental stock-based compensation expense of approximately $
2.3
million for this stock option modification.
The stock option modifications were measured as the excess of the fair value of the modified awards over the fair value of the original awards immediately before the modifications. The incremental stock-based compensation was recorded in
selling, general and administrative expense
, on the condensed consolidated statements of operations during the six months ended June 30, 2021.
Stock Options
The following table summarizes stock option activity and related information for the six months ended June 30, 2021:
Number of
Options
Weighted-
Average
Exercise
Price
Aggregate
Intrinsic
Value
(in thousands)
Weighted-
Average
Remaining
Contractual
Life
(in years)
Outstanding at December 31, 2020
4,996,284
$
9.96
$
29,746
4.7
Granted
1,069,940
$
21.38
Exercised
(
1,661,912
)
$
3.86
Expired/forfeited
(
73,994
)
$
5.22
Outstanding at June 30, 2021
4,330,318
$
15.25
$
19,012
5.7
Vested and exercisable at June 30, 2021
3,143,710
$
13.61
$
17,705
4.3
32
Table of Contents
On
February
5, 2021, the
compensation
committee
of
the
board
of
directors
of
the c
ompany
granted
Richard
Adcock,
our
c
hief
e
xecutive
o
fficer, a stock option award
(the
"
Option
Grant")
to
purchase
750,000
shares
of
our
common
stock
pursuant
to
our
2015 Plan.
The
Option
Grant
has
an
exercise
price
of $
23.72
per share,
the
closing
price
as
reported
on
the
Nasdaq
on
the
date
of
grant.
In
addition,
the
Option
Grant
shall
vest
according
to
the
following
vesting
schedule:
one-third
of
the
Option
Grant
(i.e.,
250,000 options)
shall
vest
in
equal
installments
on
each
of
the
first,
second,
and
third
anniversaries
of
the
date of
grant,
such
that
all
shares
shall
be
fully
vested
on
the
third anniversary
of
the
date of grant
,
subject
to
Mr.
Adcock
remaining
in
c
ontinuous
s
ervice
as
defined
in
the
2015
Plan
through
the
applicable
vesting
dates.
This
grant
of
equity
awards
to
Mr.
Adcock
was
made
in
connection
with
his
appointment
as
c
hief
e
xecutive
o
fficer
of
the
c
ompany,
which
was
effective
as
of
October
26, 2020,
and
was
modified
from
the
recommended
equity
grant
described
in
Mr.
Adcock's
offer
of
employment
as
of
that
date.
On May 3, 2021, the compensation committee of the board of directors of the company granted each of our newly-appointed independent directors a non-qualified stock option award to purchase
21,873
shares of our common stock pursuant to the 2015 Plan at an exercise price of $
17.24
per share, the closing price as reported on the Nasdaq on the date of grant.
The shares subject to the award will vest in three (3) equal installments on each of the first, second and third anniversary date of their appointment to the board of directors, such that the award will be fully vested on the third anniversary date in 2024, subject to the director continuing to be a service provider as defined in the 2015 Plan through the applicable vesting dates.
On June 10, 2021, the compensation committee of the board of directors of the company granted our Chairman and each of the independent members of our board of directors a non-qualified stock option award to purchase
26,064
shares of our common stock pursuant to the 2015 Plan at an exercise price of $
14.91
per share, the closing price as reported on the Nasdaq on the date of grant.
The shares subject to the award will vest 100% on the earlier to occur of June 10, 2022 or the date immediately preceding the 2022 annual meeting of stockholders, subject to the recipient continuing to be a service provider as defined in the 2015 Plan through the applicable vesting date.
These grants were made in connection with the re-election of our Executive Chairman and independent directors to the company's board of directors at the 2021 annual meeting of stockholders.
As of June 30, 2021, the unrecognized compensation cost related to outstanding stock options was $
16.2
million, which is expected to be recognized over a remaining weighted-average period of
2.4
years.
The total intrinsic value of stock options exercised during the six months ended June 30, 2021 was $
20.6
million. Cash proceeds received from stock option exercises during the six months ended June 30, 2021 was $
4.4
million.
As of December 31, 2020, a total of
4,345,497
vested and exercisable shares were outstanding.
The fair value of stock options issued was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:
Six Months Ended
June 30,
2021
(Unaudited)
Expected term (in years)
5.9
Risk-free interest rate
0.7
%
Expected volatility
101.0
%
Dividend yield
0.0
%
Weighted-average grant date fair value
$
16.80
The expected term was estimated using the average of the contractual term and the weighted-average vesting term of the options. The risk-free interest rate was based on the U.S. Treasury's rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The expected volatility was estimated based on the historical volatility of our common stock. The assumed dividend yield was based on our expectation of not paying dividends in the foreseeable future.
33
Table of Contents
Restricted Stock Units
The following table summarizes RSU activity during the six months ended June 30, 2021:
Number of
Units
Weighted-
Average
Grant Date
Fair Value
Nonvested balance at December 31, 2020
466,842
$
2.52
Granted
7,643,955
$
25.23
Vested
(
336,084
)
$
11.78
Forfeited/canceled
(
331,209
)
$
23.91
Nonvested balance at June 30, 2021
7,443,504
$
24.47
As of June 30, 2021, there was $
159.9
million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of
3.9
years.
We may grant RSUs to both employees and directors of the company and to employees of related parties that provide shared services to the company under our shared services agreement with NantWorks as discussed in
Note 8
,
Related-Party Agreements
.
On
February
5,
2021, the
compensation
committee
of
the
board
of
directors
of
the c
ompany
granted
Mr. Adcock
two
awards
totaling
400,000
RSUs
(each
an
"RSU
Award"
and
collectively,
the
"RSU
Awards")
of
our
common
stock
pursuant
to
the
2015
Plan.
The
RSU
Awards
are
comprised
of
two separate
awards,
one
settled
by
issuing
150,000
shares
of
our
common
stock
and
the
other
to
be
settled
by
issuing
250,000
shares
of
our
common
stock
upon
vesting.
The
first
RSU
Aw
a
rd
vested
immediately
on
the
date of grant
with
the
c
ompany
retaining
shares
equal
in
value
to
the
c
ompany's
tax
withholding
obligations. The
second
RSU
Aw
a
rd
will
vest
according
to
the
following
schedule:
one-third
(i.e.
83,333
)
of
the
shares
subject
to
the
RSU
Aw
a
rd
shall
vest
in
equal
annual
installments
on
each
of
the
first,
second
and
third anniversaries
of
the
date of grant
,
such
that
all
shares
shall
be
fully
vested
on
the
third anniversary
of
the
date of g
rant,
subject
to
Mr.
Adcock
remaining
in
c
ontinuous
s
ervice
as
defined
in
the
2015
Plan
through
the
applicable
vesting
dates.
This
grant
of
equity
awards
to
Mr.
Adcock
was
made
in
connection
with
his
appointment
as
c
hief
e
xecutive
o
fficer
of
the
c
ompany,
which
was
effective
as
of
October
26, 2020,
and
was
modified
from
the
recommended
equity
grant
described
in
Mr.
Adcock's
offer
of
employment
as
of
that
date.
On March 4, 2021, prior to the Merger, NantCell awarded
7,121,110
RSUs (adjusted for the Exchange Ratio of
0.8190
) to employees and consultants of NantCell and its affiliated companies, pursuant to the NC 2015 Plan. These RSU awards were subject to a performance condition in connection with a "Liquidity Event", defined as either (i) NantCell's registration of shares for issuance on a securities offering or (ii) the closing of a corporate transaction. In addition, the vesting of certain performance-based RSU grants accelerates upon obtaining approval by the FDA of a BLA or equivalent application for approval of Anktiva for use in the treatment of non-muscle-invasive bladder cancer. These performance-based RSUs are also subject to service conditions and are scheduled to cliff vest on the last date of each tranche as defined by the individual grant agreements. On March 9, 2021, we completed the Merger with NantCell, and the performance condition related to the Liquidity Event was met.
The fair value of the RSUs was estimated based on a third-party valuation as of the grant date of March 4, 2021 and was derived primarily from the estimated probabilities of the Merger close on March 9, 2021 and the other exit assumptions. Once the liquidity event related performance condition was met as of March 9, 2021 due to the Merger, compensation expense for these RSUs began to be recognized on a graded vesting attribution approach over the requisite service period for each participant, which ranges from
six-month
to seventy (70)-month vesting periods. During the six months ended June 30, 2021, we recorded approximately $
21.1
million of stock-based compensation expense related to these awards, of which approximately $
11.3
million was recorded in
research and development expense
and approximately $
9.8
million was recorded in
selling, general and administrative expense
, on the condensed consolidated statements of operations.
The RSUs awarded to employees and consultants of affiliated companies were accounted for as stock-based compensation in accordance with ASU 2018-07,
Compensation—Stock Compensation (Topic 718)
, as the compensation was in exchange for continued support or services expected to be provided to the company over the vesting periods under the NantWorks shared services agreement discussed in
Note 8
,
Related-Party Agreements
. We have evaluated the associated benefit of these awards to the affiliated companies under common control and determined that the benefit is limited to the retention of their employees. We estimated such benefit at the grant date fair value of $
4.0
million and recorded $
0.5
million of deemed dividends for the six months ended June 30, 2021 in
additional paid-in capital,
on the condensed consolidated balance sheets, with a corresponding credit to stock compensation expense.
34
Table of Contents
Warrants
In connection with the Merger, warrants issued to NantWorks, a related party, in connection with NantCell's acquisition of Altor were assumed by the company. After applying the Exchange Ratio at the Effective Time of the Merger, a total of
1,638,000
warrants with an exercise price of $
3.24
per share were outstanding as of June 30, 2021. The fair value of $
18.0
million assigned to the warrants will be recognized in equity upon achievement of a performance-based vesting condition
pertaining to building manufacturing capacity to support supply requirements for one of our product candidates
.
11.     Income Taxes
On March 9, 2021, the company completed the Merger with NantCell. The Merger is accounted for as a transaction between entities under common control, and is considered a nontaxable transaction for U.S. income tax purposes, as it is intended to qualify as a "reorganization" within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended.
The company is subject to taxation in the United States, various state, and foreign jurisdictions. Earnings from non-U.S. activities are subject to local country income tax. The company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter.
No
tax benefit was provided for losses incurred in the United States, Italy, and South Korea because those losses are offset by a full valuation allowance.
The difference between the federal statutory tax rate of
21
% and the company's
0
% tax rate is due to losses from which the company cannot benefit.
The company is no longer subject to income tax examination by the U.S. federal, state or local tax authorities for years ended December 31, 2015 or prior; however, its tax attributes, such as net operating loss ("NOL") carryforwards and tax credits, are still subject to examination in the year they are used.
35
Table of Contents
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Forward-Looking Statements
The following discussion and analysis should be read together with our condensed consolidated financial statements and the notes to those statements included elsewhere in this Quarterly Report on Form 10-Q. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act") that are based on our management's beliefs and assumptions and on information currently available to our management. The forward-looking statements are contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations. Forward-looking statements include, but are not limited to:
•
our ability to pioneer immunotherapy, harness the power of the innate immune system, implement precision cancer medicine and change the current paradigm of cancer care;
•
our ability to implement and support our COVID
‑
19 vaccine and therapeutic programs;
•
any impact of the coronavirus pandemic, or responses to the pandemic, on our business, clinical trials or personnel;
•
our expectations regarding the potential benefits of our strategy and technology;
•
our expectations regarding the operation of our product candidates and related benefits;
•
our ability to utilize multiple modes to induce cell death;
•
our beliefs regarding the benefits and perceived limitations of competing approaches, and the future of competing technologies and our industry;
•
details regarding our strategic vision and planned product candidate pipeline, including that we eventually plan to advance therapies for virally induced infectious diseases;
•
our beliefs regarding the success, cost and timing of our product candidate development activities and current and future clinical trials and studies, including study design;
•
our expectations regarding our ability to utilize the Phase I and II aNK and haNK clinical trials data to support the development of our product candidates, including our haNK, taNK, t‑haNK, MSC and M-ceNK product candidates;
•
our expectations regarding the development, application, commercialization, marketing, prospects and use generally of our product candidates, including Anktiva, hAd5 and aldoxorubicin;
•
the timing or likelihood of regulatory filings or other actions and related regulatory authority responses, including any planned investigational new drug ("IND"); Biologics License Application ("BLA"); or New Drug Application ("NDA") filings or pursuit of accelerated regulatory approval pathways or orphan drug status and Breakthrough Therapy designations;
•
our ability to implement an integrated discovery ecosystem and the operation of that planned ecosystem, including being able to regularly add neoepitopes and subsequently formulate new product candidates;
•
the ability and willingness of strategic collaborators, including certain affiliates of NantWorks, LLC ("NantWorks") to share our vision and effectively work with us to achieve our goals;
•
the ability and willingness of various third parties to engage in research and development activities involving our product candidates, and our ability to leverage those activities;
•
our ability to attract additional third-party collaborators;
•
our expectations regarding the ease of administration associated with our product candidates;
•
our expectations regarding the patient compatibility associated with our product candidates;
•
our beliefs regarding the potential markets for our product candidates and our ability to serve those markets;
•
our ability to produce an "off-the-shelf" therapy;
•
our beliefs regarding the potential manufacturing and distribution benefits associated with our product candidates, and our ability to scale up the production of our product candidates;
36
Table of Contents
•
our plans regarding our manufacturing facilit
ies
and our belief that our manufacturing is capable of being conducted in
‑house;
•
our belief in the potential of our antibody cytokine fusion protein, vaccine technology and NK-92 and M-ceNK cell therapy technology, and the fact that our business is based upon the success individually and collectively of our platforms;
•
our antibody cytokine fusion protein, vaccine technology and NK-92 and M-ceNK cell therapy technology along with other product candidate families, will require significant additional clinical testing;
•
even if we successfully develop and commercialize specific product candidates like our Anktiva or haNK and t‑hank, we may not be successful in developing and commercializing our other product candidates either alone or in combination with other therapeutic agents;
•
the ability to obtain and maintain regulatory approval of any of our product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product candidate;
•
our ability to commercialize any approved products;
•
the rate and degree of market acceptance of any approved products;
•
our ability to attract and retain key personnel;
•
the accuracy of our estimates regarding our future revenue, as well as our future operating expenses, capital requirements and needs for additional financing;
•
our ability to obtain funding for our operations, including funding necessary to complete further development and any commercialization of our product candidates;
•
our ability to obtain, maintain, protect and enforce intellectual property protection for our product candidates and technology and not infringe upon, misappropriate or otherwise violate the intellectual property of others;
•
the terms and conditions of licenses granted to us and our ability to license additional intellectual property relating to our product candidates and technology;
•
the impact on us, if any, if the contingent value rights ("CVRs") held by former Altor BioScience Corporation ("Altor") stockholders become due and payable in accordance with their terms; and
•
regulatory developments in the United States ("U.S.") and foreign countries.
Forward-looking statements include statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would," or similar expressions and the negatives of those terms. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in Part II, Item 1A. "Risk Factors" of this Quarterly Report
on Form 10-Q
. Given these uncertainties, you should not place undue reliance on these forward-looking statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date of this Quarterly Report
on Form 10-Q
.
Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You should read this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect.
37
Table of Contents
This
Quarterly Report
on Form 10-Q
contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this
Quarterly Report
on Form 10-Q
, including logos, artwork and other visual displays, may appear without the
®
or
TM
symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us
,
by any other companies.
In this Quarterly Report on Form 10-Q, "ImmunityBio," "the company," "the combined company," "we," "us," and "our" refer to ImmunityBio, Inc. and its subsidiaries.
Overview
We established ImmunityBio to advance next-generation immunotherapies and address unmet needs within oncology and infectious disease. Our platform is designed to overcome limitations of the current standards of T cell-based immunotherapies, including checkpoint inhibitors and CAR-T cells and is based on our four key modalities: (1) activating natural killer ("NK") and T cells using antibody cytokine fusion proteins, (2) activating tumoricidal macrophages using low-dose synthetic immunomodulators, (3) generating memory T cells using vaccine candidates developed with our second-generation adenovirus ("hAd5") technology, and (4) off-the-shelf natural killer cells from the NK-92 cell line and memory-like cytokine-enhanced natural killer cells ("M-ceNK") from allogenic and autologous donors.
We own a broad, clinical-stage immunotherapy pipeline, including an antibody cytokine fusion protein (an IL-15 superagonist ("N-803") known as Anktiva), an albumin-associated anthracycline synthetic immunomodulator (aldoxorubicin), second-generation adenovirus ("hAd5") and yeast vaccine technologies (targeting tumor-associated antigens and neoepitopes), off-the-shelf genetically engineered natural killer cell lines inducing cancer and virally infected cell death through a variety of concurrent mechanisms (including innate killing, antibody-mediated killing, and CAR-directed killing),
patient specific NK cell product for cancer that is an autologous memory cytokine enhanced NK cells ("M-ceNK"),
macrophage polarizing peptides, and bi-specific fusion proteins targeting CD20, PD-L1, TGF-
b
and IL-12. Our immunotherapy clinical pipeline consists of over 40 clinical trials in Phase 1, 2, or 3 development across 19 indications in solid and liquid cancers and infectious diseases. We have an expansive clinical-stage pipeline and intellectual property portfolio with 17 first-in-human assets in 25 Phase II to III clinical trials.
38
Table of Contents
In December 2019, the
U.S.
Food and Drug Administration
("
FDA
")
granted Breakthrough Therapy designation to Anktiva for bacillus Calmette-Guérin
("
BCG
")
unresponsive carcinoma in situ non-muscle invasive bladder cancer.
Based on patient reado
ut data that was submitted with
our application to obtain our Breakthrough Therapy designation, Anktiva achieved its primary endpoint of complete response
rate at any time in the ongoing registrational Phase
II / III
trial
.
Other indications currently
with
registration-
potential
studies include BCG unresponsive papillary bladder cancer, first- and second-line lung cancer, and metastatic pancreatic cancer.
The Merger
On December 21, 2020, we and NantCell, Inc. (formerly known as ImmunityBio, Inc., a private company) ("NantCell") entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which we and NantCell agreed to combine our businesses. The Merger Agreement provided that a wholly-owned subsidiary of the company would merge with and into NantCell (the "Merger"), with NantCell surviving the Merger as a wholly-owned subsidiary of the company.
On March 9, 2021, we completed the Merger pursuant to the terms of the Merger Agreement. Under the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of NantCell common stock
, par value
$
0.001
per share,
issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive
0.8190
(the "Exchange Ratio") newly
issued shares of common stock, par value
$
0.0001
per share, of the company ("Company Common Stock"), with cash paid in lieu of any fractional shares.
At the Effective Time, each share of the company's common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company. At the Effective Time, each outstanding option, warrant or restricted stock unit to purchase NantCell common stock was converted using the Exchange Ratio into an option, warrant or restricted stock unit, respectively, on the same terms and conditions immediately prior to the Effective Time, to purchase shares of Company Common Stock.
Immediately following the Effective Time, the former stockholders of NantCell held approximately 71.5% of the outstanding shares of Company Common Stock and the stockholders of the company as of immediately prior to the Merger held approximately 28.5%
of the outstanding shares of Company Common Stock. As a result of the Merger and immediately following the Effective Time, Dr. Patrick Soon-Shiong, our Executive Chairman, and his affiliates beneficially owned, in the aggregate, approximately 81.8% of the outstanding shares of Company Common Stock.
Following the consummation of the Merger, shares of the company's common stock were listed on the Nasdaq Global Select Market under the symbol "IBRX."
We incurred costs totaling $23.3 million in connection with the Merger, consisting of financial advisory, legal and other professional fees, of which $13.0 million was recorded during the six months ended June 30, 2021.
Accounting Treatment of the Merger
The Merger represents a business combination pursuant to Financial Accounting Standards Board Accounting Standards Codification Topic 805-50,
Mergers
, which is accounted for as a transaction between entities under common control as Dr. Soon‑Shiong
and his affiliates were the controlling stockholders of both the company and
NantCell for all of the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We have recast our prior
period financial statements to reflect the conveyance of NantCell's common shares as if the Merger had occurred as of the earliest date of the condensed consolidated financial statements presented in Item 1. "Financial Statements" of this Quarterly Report on Form 10-Q. All
material intercompany accounts and transactions have been eliminated in consolidation.
Coronavirus Pandemic
In March 2020, the World Health Organization declared the novel strain of coronavirus disease (SARS‑CoV‑2) a pandemic. To date, our operations have not been significantly disadvantaged by the pandemic. However, we cannot at this time predict the specific extent, duration, or full impact that this pandemic may have on our financial condition and results of operations, including ongoing and planned clinical trials. More specifically, the pandemic may result in prolonged impacts that we cannot predict at this time and we expect that such uncertainties will continue to exist for the foreseeable future. The impact of the pandemic on our financial performance will depend on future developments, including the duration and spread of the outbreak, impact of potential variants and the related governmental advisories and restrictions. These developments and the impact of the ongoing pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, our results may be adversely affected.
39
Table of Contents
Given the unprecedented and
continuously
evolving nature of the pandemic, the future impact of these changes and potential changes on
the
company are unknown at this time. To date, we have seen no material adverse impact
to our business from the
pandemic. We anticipate, however, that enrollment of patients in
certain
studies will likely take longer than forecasted in prior
Securities and Exchange Commission
("
SEC
")
filings and that our clinical trials may require additional time to complete which would in turn impact the timeline in which we were previously forecasting
BLA
submissions of our product candidates and subsequent revenue generation. These factors have been accounted for in the
company's
anticipated upcoming milestones. During any such delays in our clinical trials, we will continue to incur fixed costs such as selling, general and administrative expenses and operating expenses related to our laboratory,
Good Manufacturing Practice
("
GMP
")
manufacturing, and office facilities.
Many of our office-based employees have been working from home since mid-March 2020. Essential staffing levels for our research and development operations remain in place, including maintaining key personnel in our laboratory and GMP manufacturing facilities. It is likely that the pandemic and resulting mitigation efforts could have an impact in the future on our third-party suppliers who manufacture laboratory supplies required for our in-house manufacturing process, which in turn could have an impact on having sufficient clinical product supply available for our clinical trials. We have addressed this in part by ensuring that we have sufficient supplies on hand to weather interruptions in our supply chain.
There is significant uncertainty about the progression and ultimate impact of the pandemic on our business and operations. While the pandemic did not materially impact our results during the periods presented in this Quarterly Report on Form 10-Q, we anticipate that it could impact our business in the future due to factors such as fewer patients accessing treatment for cancer.
Operating Results
To date, we
have
generated
minimal
revenue
from
non-exclusive
license
a
g
reements
related
to our
cell
li
n
es,
the
sale
of
our
bioreactors
and
related consumables
and
grant
programs. We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. We have incurred net losses in each year since our inception and, as of June 30, 2021, we had an accumulated deficit of $1.8 billion. Our net losses attributable to ImmunityBio common stockholders were $167.9 million and $88.5 million for the six months ended June 30, 2021 and 2020, respectively. Substantially all of our net losses resulted principally from costs incurred in connection with our ongoing clinical trials and operations, our research and development programs, and from selling, general and administrative costs associated with our operations, including stock-based compensation expense.
As of June 30, 2021, we had 511 employees. Personnel of related companies who provide corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy and other support services under our shared services agreement with NantWorks are not included in this number. For additional information, see
Note 8
,
Related-Party Agreements,
of the "Notes to Unaudited Condensed Consolidated Financial Statements"
that appears
in Item 1. "Financial Statements" of this Quarterly Report
on Form 10-Q
. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, which may fluctuate significantly from quarter-to-quarter and year-to-year. See "—
Future Funding Requirements
" below for a discussion of our anticipated expenditures and sources of capital we expect to access to fund these expenditures.
Collaboration Agreements
We anticipate that strategic collaborations will become an integral part of our operations, providing opportunities to leverage our partners' expertise and capabilities to further expand the potential of our technologies and product candidates. We believe we are well positioned to become a leader in immunotherapy due to our broad and vertically integrated platform and through complementary strategic partnerships. We may also enter into supply arrangements for various investigational agents to be used in our clinical trials. See
Note 6
,
Collaboration and License Agreements
, of the "Notes to Unaudited Condensed Consolidated Financial Statements"
that appears
in Item 1. "Financial Statements" of
this Quarterly Report on Form 10-Q
for a more detailed discussion regarding our existing collaboration and license agreements.
40
Table of Contents
Agreements with Related Parties
We conduct business with several affiliates under written and informal arrangements. Our Executive Chairman, and principal stockholder, founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. We have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new immunotherapies for our product pipeline. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman.
As of June 30, 2021, we have outstanding promissory notes with certain entities affiliated with Dr. Soon-Shiong in an aggregate amount of $300.3 million, including accrued interest. The notes bear interest at a per annum rate ranging from 3.0% to 6.0%. As of June 30, 2021, the notes provide that all outstanding principal is due and payable on September 30, 2025, and accrued and unpaid interest is payable on either the maturity date or, with respect to one of the notes, on a quarterly basis beginning June 30, 2021. We may prepay the outstanding amount of any advance under such notes, together with accrued and unpaid interest, at any time, in whole or in part, without premium or penalty.
In May 2021, but effective on April 1, 2021, we entered into an amendment to our existing lease with 605 Nash, LLC. The amendment expanded the leased square feet by approximately 57,760 rentable square feet (the "Expansion Premises"). The lease term of the Expansion Premises commenced in April 2021 and expires in March 2028, whereby the company has the option to extend the initial term for three years. Per the terms of the amendment, the term of the lease that commenced in January 2021 was extended for an additional three months and now expires on March 31, 2028. Base rent for the Expansion Premises is approximately $170,400 per month with annual increases of 3% on April 1 of each year. We are responsible for the build out of the facility space and associated costs. The amended lease provides for a rent abatement for the first seven months, and for a tenant improvement allowance of approximately $2.6 million for costs and expenses related to improvements made by us to the Expansion Premises.
We entered into multiple agreements with Immuno-Oncology Clinic, Inc.
(the "Clinic")
to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by an officer of the company and NantWorks manages the administrative operations of the Clinic. B
ased on a review of our updated clinical trial programs post-Merger, we updated our estimates of the investigator fees for the clinical trials currently underway or planned at the Clinic. As certain programs costs are excluded from and certain services are subject to credit adjustments under the Clinic Agreement, we determined the expected future fees for services to be performed are less than the carrying value of the prepaid asset on the condensed consolidated balance sheets. As a result, we partially wrote down the value of our prepayments under the Clinic Agreement and recorded approximately $1.9 million in
research and development expense
, on the condensed consolidated statements of operations for the three months ended June 30, 2021. In addition, we reclassified $0.9 million of prepaid assets from
prepaid expenses and other current assets
to
other current assets
, on the condensed consolidated balance sheets as of June 30,
2021 based on the additional time expected for them to be realized than initially estimated.
See
Note 8
,
Related-Party Agreements
, of the "Notes to Unaudited Condensed Consolidated Financial Statements" that appears in Item 1. "Financial Statements" of this Quarterly Report on Form 10-Q for a more detailed discussion regarding our related party agreements.
41
Table of Contents
Components of our Results of Operations
Revenue
To date, we
have
generated
minimal
revenue
from
non-exclusive
license
a
g
reements
related
to our
cell
li
n
es,
the
sale
of
our
bioreactors
and
related consumables
and
grant
programs. We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. If we fail to complete the development of our product candidates in a timely manner or fail to obtain regulatory approval for them, we may never be able to generate substantial future revenue.
Operating Expenses
We generally classify our operating expenses into research and development, and selling, general and administrative expenses. Personnel costs, including salaries, benefits, bonuses, and stock-based compensation expense comprise a significant component of our research and development, and selling, general and administrative expense categories. We allocate expenses associated with our facilities and information technology costs between these two categories based on the nature of each cost.
Research and Development
Research and development expense consists of expenses incurred while performing research and development activities to discover and develop our technology and product candidates. This includes conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for product candidates. We recognize research and development expenses as they are incurred. Our research and development expense primarily consists of:
•
clinical trial and regulatory-related costs;
•
expenses incurred under agreements with investigative sites and consultants that conduct our clinical trials;
•
expenses incurred under collaborative agreements;
•
manufacturing and testing costs and related supplies and materials;
•
employee-related expenses, including salaries, benefits, travel and stock-based compensation; and
•
facility expenses dedicated to research and development.
We typically use our employee, consultant and infrastructure resources across our development programs. We track outsourced development costs by product candidate or development program, but we do not allocate personnel costs, other internal costs or external consultant costs to specific product candidates or development programs.
We expect our research and development expenses to continue to increase significantly for the foreseeable future as we advance our product candidates through clinical development, including the conduct of our ongoing and any future clinical trials. The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. The successful development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required to complete the remaining development of any product candidates. This is due to the numerous risks and uncertainties associated with the development of product candidates.
The costs of clinical trials may vary significantly over the life of a project owing to, but not limited to, the following:
•
per patient trial costs;
•
the number of sites included in the clinical trials;
•
the countries in which the clinical trials are conducted;
•
the length of time required to enroll eligible patients;
•
the number of patients that participate in the clinical trials;
•
the number of doses that patients receive;
•
the cost of comparative agents used in clinical trials;
•
the drop-out or discontinuation rates of patients;
•
potential additional safety monitoring or other studies requested by regulatory agencies;
42
Table of Contents
•
the duration of patient follow-up; and
•
the efficacy and safety profile of the product candidate.
We do not expect any of our product candidates to be commercially available for the foreseeable future, if ever.
Selling, General and Administrative
Selling, general and administrative expense consists primarily of salaries and personnel-related costs, including employee benefits and any stock-based compensation, for employees performing functions other than research and development. This includes personnel in executive, finance, human resources, information technology, legal, and administrative support functions. Other selling, general and administrative expenses include facility-related costs not otherwise allocated to research and development expense, professional fees for auditing, tax and legal services, advertising costs, expenses associated with strategic business transactions and business development efforts, obtaining and maintaining patents, consulting costs, royalties and licensing costs, and costs of our information systems.
We expect that our selling, general and administrative expenses will increase for the foreseeable future as we expand operations, build out information systems and increase our headcount to support continued research activities and the development of our clinical programs. We have incurred and expect that we will continue to incur in the future, additional costs associated with operating as a public company, including costs to comply with stock exchange listing and SEC requirements, future funding efforts, corporate governance, internal controls, investor relations, disclosure and similar requirements applicable to public companies. Additionally, if and when we believe that a regulatory approval of a product candidate appears likely, we expect to incur significant increases in our selling, general and administrative expenses relating to the sales and marketing of the approved product candidate.
Other Income and Expense
Other income and expense consists primarily of interest income, interest expense, unrealized gains and losses on investments in equity securities, realized gains and losses on both debt and equity securities, and gains and losses on foreign currency transactions.
Income Taxes
The company is subject to taxation in the United States, various state, and foreign jurisdictions. Earnings from non-U.S. activities are subject to local country income tax. To date, we have not been required to pay U.S. federal income taxes or foreign income taxes because of our or our subsidiaries' current and accumulated net operating losses.
43
Table of Contents
Results of Operations
Comparison of the three months ended June 30, 2021 and 2020
Three Months Ended
June 30,
2021
2020
$ Change
% Change
(Unaudited, $ in thousands)
Revenue
$
339
$
436
$
(97
)
(22
%)
Operating expenses:
Research and development (including amounts
with related parties)
53,800
33,005
20,795
63
%
Selling, general and administrative (including amounts
with related parties)
32,445
18,347
14,098
77
%
Total operating expenses
86,245
51,352
34,893
68
%
Loss from operations
(85,906
)
(50,916
)
(34,990
)
69
%
Other expense:
Interest and investment (expense) income, net
(177
)
986
(1,163
)
(118
%)
Interest expense (including amounts with related parties)
(3,577
)
(2,123
)
(1,454
)
68
%
Other income, net (including amounts
with related parties)
277
81
196
242
%
Total other expense
(3,477
)
(1,056
)
(2,421
)
229
%
Loss before income taxes and noncontrolling interests
(89,383
)
(51,972
)
(37,411
)
72
%
Income tax expense
(2
)
(45
)
43
(96
%)
Net loss
$
(89,385
)
$
(52,017
)
$
(37,368
)
72
%
Research and Development Expense
Research and development expense increased $20.8 million during the three months ended June 30, 2021, as compared to the three months ended June 30, 2020. The increase in research and development expense was primarily driven by an $11.2 million increase in compensation expense, including an $8.6 million increase in stock compensation expense due to new grants issued and a $2.6 million increase in personnel costs due to higher headcount to support our continued research and development efforts, a $3.4 million increase in clinical trial and regulatory expenses related to our Anktiva and COVID
‑
19 programs, including a $1.9 million expense associated with the write down of a prepaid asset with the Clinic, a $2.5 million increase in license and research agreement costs, primarily driven by new license agreements entered into in the second quarter of 2021, a $1.9 million increase in facilities expense, primarily related to the expansion of our manufacturing facility in El Segundo, California during 2021, and a $1.8 million increase in laboratory supply expenses and other research and development costs, primarily driven by higher expenses related to our COVID
‑
19 programs.
We expect our research and development expense to increase significantly for the foreseeable future as we advance our product candidates through clinical development and conduct our ongoing and planned clinical trials.
Selling, General and Administrative Expense
Selling, general and administrative expense increased $14.1 million during the three months ended June 30, 2021, as compared to the three months ended June 30, 2020.
The increase in selling, general and administrative expense was primarily attributable to $
9.8 million increase in compensation expense, including an $8.9 million increase in stock compensation expense driven by new grants and option modifications resulting in incremental stock-based compensation expense in 2021 and a $0.9 million increase personnel-related expenses, and a $6.2 million increase in legal expense, primarily due to ongoing litigation. These increases were partially offset by a $1.2 million decrease in shared services and travel costs, and a $0.7 million decrease in general liability insurance costs.
44
Table of Contents
Other
Expense
Other expense increased $2.4 million during the three months ended June 30, 2021, as compared to the three months ended June 30, 2020.
The increase in other expense was mainly due to a $1.4 million increase in interest expense driven higher related-party borrowings and a reduction in net unrealized gains of $1.2 million related to our equity securities, which were partially offset by a $0.2 million increase in other income.
Comparison of the six months ended June 30, 2021 and 2020
Six Months Ended
June 30,
2021
2020
$ Change
% Change
(Unaudited, $ in thousands)
Revenue
$
478
$
601
$
(123
)
(20
%)
Operating expenses:
Research and development (including amounts
with related parties)
94,928
60,379
34,549
57
%
Selling, general and administrative (including amounts
with related parties)
77,720
27,840
49,880
179
%
Total operating expenses
172,648
88,219
84,429
96
%
Loss from operations
(172,170
)
(87,618
)
(84,552
)
97
%
Other income (expense):
Interest and investment income, net
8,767
1,064
7,703
724
%
Interest expense (including amounts with related parties)
(6,745
)
(4,012
)
(2,733
)
68
%
Other income, net (including amounts
with related parties)
290
1,185
(895
)
(76
%)
Total other income (expense)
2,312
(1,763
)
4,075
(231
%)
Loss before income taxes and noncontrolling interests
(169,858
)
(89,381
)
(80,477
)
90
%
Income tax expense
(8
)
(63
)
55
(87
%)
Net loss
$
(169,866
)
$
(89,444
)
$
(80,422
)
90
%
Research and Development Expense
Research and development expense increased $34.5 million during the six months ended June 30, 2021, as compared to the six months ended June 30, 2020. The increase in research and development expense was primarily driven by a $15.3 million increase in compensation expense, including an $11.3 million increase in stock compensation expense due to new grants issued and a $4.0 million increase in the personnel costs due to higher headcount in support of our continued research and development efforts, a $5.1 million increase in clinical trial expenses and regulatory costs related to our Anktiva and COVID
‑
19 programs, including a $1.9 million expense associated with the write down of a prepaid asset with the Clinic, a $4.7 million increase in laboratory supply expenses and other preclinical research and development costs, a $4.5 million increase in manufacturing costs for contract manufacturing of clinical materials, a $2.8 million increase in facilities expense, primarily related to the expansion of our manufacturing facility in El Segundo, California during 2021, and a $2.1 million increase in license and collaboration costs, primarily driven by new license agreements entered in the second quarter of 2021.
We expect our research and development expense to increase significantly for the foreseeable future as we advance our product candidates through clinical development and conduct our ongoing and planned clinical trials.
45
Table of Contents
Selling, General and Administrative
Expense
Selling, general and administrative expense increased $49.9 million during the six months ended June 30, 2021, as compared to the six months ended June 30, 2020.
The increase in selling, general and administrative expense was primarily attributable to a
$22.4 million increase in compensation expense, including a $21.0 million increase in stock compensation expense driven by new grants issued and option modifications
resulting in incremental stock-based compensation expense in 2021
and a $1.4 million increase in personnel-related expenses due to higher headcount needed to support our business activities, a $24.3 million increase in financial advisory, legal, public company and other professional fees (including fees related to our Merger, which was announced in December 2020 and closed in March 2021), as well as higher costs associated with ongoing litigation, patent-related legal fees and other matters, and a $3.2 million increase in insurance costs, primarily due to higher directors' and officers' insurance renewal rates and increased insurance coverage.
Other Income and Expense
Other income increased $4.1 million during the six months ended June 30, 2021, as compared to the six months ended June 30, 2020.
The increase was mainly due a $7.7 million increase in unrealized gains from our equity investments, which were partially offset by a $2.7 million increase in interest expense driven primarily by higher related-party borrowings and a $0.9 million decrease in other income.
Liquidity and Capital Resources
Sources of Liquidity
Our principal sources of liquidity are our existing cash, cash equivalents, and marketable securities. We have historically invested our cash primarily in investment grade short- to intermediate-term corporate debt securities, commercial paper, government-sponsored securities, U.S. treasury securities, and foreign government bonds and classify these investments as available-for-sale. Certain of these investments are subject to general credit, liquidity and other market risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets.
As of June 30, 2021, we had cash and cash equivalents, and marketable securities of $104.8 million compared to $97.0 million as of December 31, 2020. On April 30, 2021, we entered into an Open Market Sale Agreement (the "Sale Agreement") with respect to an at-the-market (the "ATM") offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $500.0 million through our sales agent. For the three months ended June 30, 2021, we received net proceeds totaling $94.9 million from the issuance of 6,420,441 shares under the ATM, which
we expect to use for general corporate purposes, including to progress our clinical development programs, fund other research and development activities, for capital expenditures and to fund working capital. We may also use a portion of the net proceeds to license intellectual property or to make acquisitions or investments.
As of June 30, 2021, we had $402.0 million available for future stock issuances under the ATM.
In order to complete the development of our current product candidates, and implement our business plan, we will require substantial additional funding. Furthermore, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to raise even greater amounts of funds sooner if we choose to expand more rapidly than we presently anticipate. Moreover, our fixed expenses such as rent and other contractual commitments are substantial and are expected to increase in the future.
Uses of Liquidity
In addition to the cash used to fund our operating activities discussed in "
—Future Funding Requirements
" below, we will require cash to settle the following obligations:
As of June 30, 2021, we had related-party notes payable together with accrued interest thereon of $300.3 million compared to $254.4 million as of December 31, 2020. During the six months ended June 30, 2021, we received a $40.0 million advance pursuant to a related-party promissory note. Such notes bear interest at 3% to 6% per year and may be prepaid by us without penalty. The notes allow for additional advances as we may request with the consent of the applicable lender. With the exception of interest on the recent $40.0 million advance, all outstanding principal and accrued and unpaid interest on these notes are due and payable on September 30, 2025.
46
Table of Contents
In connection with our acquisition of Altor, we issued
CVRs
under which we have agreed to pay the prior stockholders of Altor approximately
$304.0 million
upon successful approval of the BLA or foreign equivalent for Anktiva by
December 31, 2022
and approximately
$304.0 million
upon the first calendar year prior to
December 31, 2026
in which worldwide net sales of Anktiva exceed
$1.0 billion
(with payments payable in cash or shares of our common stock or a combination thereof). Dr. Soon-Shiong and his related party hold approximately
$279.5 million
in the aggregate of CVRs and they have both irrevocably agreed to receive shares of common stock in satisfaction of their CVRs. We may need to seek additional sources of capital to satisfy the CVR obligations if they are achieved.
Cash Flows
The following table sets forth our primary sources and uses of cash for periods indicated:
Six Months Ended
June 30,
2021
2020
(Unaudited, in thousands)
Cash provided by (used in):
Operating activities
$
(130,064
)
$
(77,129
)
Investing activities
42,334
29,268
Financing activities
136,834
87,217
Effects of exchange rate changes on cash, cash equivalents,
and restricted cash
(61
)
5
Net change in cash, cash equivalents, and restricted cash
$
49,043
$
39,361
Operating Activities
For the six months ended June 30, 2021, net cash used in operating activities of $130.1 million consisted of a
net
l
oss
of $169.9 million and $0.4 million
of
cash used in net working capital changes, part
i
a
l
ly
offset by
$40.2 million
in
ad
j
us
t
ments
f
o
r
no
n
-cash
items.
A
d
justmen
t
s
f
or non
-
cash
i
tems
pr
i
mari
l
y
consisted
of $33.2 million
in
s
t
ock
compe
n
sati
o
n
expense, $7.0 million
in
depreciati
o
n
and
amo
r
tizati
o
n expense,
$6.2 million
in
non
-
cash
i
n
terest
related primarily to related party loans, $2.3 million
in
non
-
cash
l
e
ase
expense
related
to
operat
i
ng
lease
righ
t
-of-use assets,
and $0.2 million
in
a
m
or
t
iza
t
ion
of
net
premiums and discounts on
mar
k
e
t
a
b
le
debt
securi
t
ies, reduced
b
y
$8.4 million in
u
n
realized
gains
on
e
q
u
i
ty
secur
i
ties
dri
v
en pr
i
mari
l
y
by
an
i
ncrease
i
n
the
val
u
e
o
f
our
in
v
e
st
m
ents, $0.2 million in realized gains on sales of equity securities, and a $0.1 million change in the fair value of contingent consideration.
The
change
in
net
working
capi
t
al
co
n
sisted
pr
i
mari
l
y
of increases of $5.4 million in prepaid and other current assets and
$2.6 million
in each of accounts payable and related parties.
T
h
e increases
i
n
net
wo
r
king
ca
p
ital
were
p
a
r
tially
of
f
s
et
b
y
de
creases
of $4.2 million in other assets,
$3.8 million in
accrued expenses
and other liabilities and $3.0 million in o
p
e
r
ating
lease
liab
i
lities.
For the six months ended June 30, 2020, net cash used in operating activities of $77.1 million consisted of a
net
l
oss
of $89.4 million, partially offset by $11.9 million
i
n
adjustmen
t
s
f
or
non-cash
i
t
e
m
s and $0.4 million
of cash provided by net
w
o
rki
n
g
capital
changes.
Adjust
m
e
n
ts
for
non-cash items
p
r
ima
r
ily
consisted of
$7.0 million
in
dep
r
ec
i
a
t
ion
and
a
m
ort
i
za
t
ion,
$4.0 million
in
n
o
n-cash
inte
r
e
st items, $2.0 million
in non-cash
lease
ex
p
e
n
s
e
r
e
l
ated
to
o
p
e
r
ating
lease ri
g
ht-
o
f-
u
se
assets, and
$0.8 million
in
stock
co
m
pensa
t
ion
expense, partially offset by a $1.0 million change in deferred tax liability, a $0.5 million unrealized gain on equity securities and a $0.4 million change in the fair value of contingent consideration obligation.
The changes in net working capital consisted primarily of increases related to $10.2 million in accrued expenses and other liabilities and $2.3 million in accounts payable, partially offset by decreases related to $5.6 million in prepaid
expenses
and
other
current
assets, $4.7 million in due
to
related
parties
and
$1.8 million
in ope
r
a
t
ing
lease liabi
l
ities.
Investing Activities
For the six months ended June 30, 2021, net cash provided by investing activities was $42.3 million, which included cash inflows of $57.7 million
f
rom
matu
r
ities
and
sales
o
f
m
a
r
ketable
sec
u
rit
i
es
, partially offset
by $15.1 million
of p
urchases
of
p
r
opert
y
,
plant
and
equip
m
ent and $0.3 million of purchases of marketable debt securities.
Our
invest
m
e
n
ts
in
p
r
opert
y
,
plant
a
n
d
equip
m
ent
related
p
ri
m
a
r
ily
t
o
acquisiti
o
ns
of
equ
i
pment
w
hich
wi
l
l
be
used
f
o
r
the
m
anufactu
r
ing
o
f
our
p
r
oduct
cand
ida
te
s and expenditures related to the build out of our manufacturing facilities
.
47
Table of Contents
For the
six months ended June 30, 2020
, net cash
provided by
investing activities was
$29.3 million
, which included cash
inflows
of
$44.4 million
f
rom
matu
r
ities
and
sales
o
f
m
a
r
ketable
sec
u
rit
i
es
,
partially offset by
$14.8 million
of purchases of marketable debt securities
and
$0.3 million
of purchases of property, plant and equipment
.
Financing Activities
For the six months ended June 30, 2021, net cash provided by financing activities was $136.8 million, which consisted of $95.0 million in net proceeds
from the ATM offering
, $40.0 million in proceeds from issuances of
related
party notes and $4.4 million in proceeds from exercises of stock options. Net cash used in financing activities consisted of $2.6 million
related
t
o
net
share
settle
m
e
n
t
of
ves
t
ed
RSUs
for
pay
m
e
n
t
of
pay
r
oll
t
a
x withholding
.
For the six months ended June 30, 2020, net cash provided by financing activities was $87.2 million, which consisted primarily of $86.8 million in net proceeds from an equity offering.
Future Funding Requirements
To date, we have generated minimal revenue, and we have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. We do not expect to generate significant revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not know when, or if, this will occur. In addition, we expect our expenses to significantly increase in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our product candidates. We have also incurred and expect that we will continue to incur in the future additional costs associated with operating as a public company as well as costs related to future fundraising efforts. In addition, subject to obtaining regulatory approval of our product candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations. We expect that our expenses will increase substantially if and as we:
•
continue research and development, including preclinical and clinical development of our existing product candidates;
•
potentially seek regulatory approval for our product candidates;
•
seek to discover and develop additional product candidates;
•
establish a commercialization infrastructure and scale up our manufacturing and distribution capabilities to commercialize any of our product candidates for which we may obtain regulatory approval;
•
seek to comply with regulatory standards and laws;
•
maintain, leverage and expand our intellectual property portfolio;
•
hire clinical, manufacturing, scientific and other personnel to support our product candidates' development and future commercialization efforts;
•
add operational, financial and management information systems and personnel; and
•
incur additional legal, accounting and other expenses in operating as a public company.
As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings (including the ATM) and our potential ability to borrow from affiliated entities, will be sufficient to fund our operations through at least the next 12 months following the issuance date of the condensed consolidated financial statements based primarily upon our Executive Chairman's intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we may need additional funds to meet our needs sooner than planned.
48
Table of Contents
We
will
need
to obtain
a
dditional
financing
to fund
our
fut
u
re
o
p
erations,
including
completing
the
development
and
commercial
i
zation
of
our
product candidates.
C
hanging
cir
c
umstances
may
cause
us
to increase
our
spending
s
i
gnif
i
can
t
ly
faster
th
a
n
we curr
e
ntly
an
t
ic
ip
ate
and
we
may
n
eed
to
raise
additional
funds
sooner
than
we
presently
anticipate.
Moreover,
research and development and our operating costs and fixed
expenses
such
as
rent
and
other
contractual
co
m
mitm
e
nt
s
,
in
c
l
uding those
for
our
research
collaborat
i
ons,
are
subs
t
a
nt
i
a
l
and
are
e
xpec
t
ed
to
i
ncr
e
a
se
in
the
futur
e
.
Our
future
funding
requ
i
rements
will
depend
on
many
factors,
including,
but
not
limited
to:
•
progr
e
s
s,
t
i
ming,
number,
scope
a
nd
c
os
t
s
of
researching and developing our product candidates
and
our
on
g
oing,
plan
n
e
d
a
nd po
t
ent
i
al
c
lin
i
c
a
l
t
ria
l
s
;
•
t
ime
and
cost
of
regulatory
approvals;
•
our
ability
to
successfully
commercialize
any
product
candidates,
if
approved and the costs of such commercialization activities;
•
revenue
from
p
r
oduct
candidates
that
we
may
commercialize,
if
any,
i
n
cluding
the
selling
prices
for
su
c
h potential
products
and
the
availabi
l
ity
of
adequate
third-party
cover
a
ge
and
reimbursement
for
patients;
•
c
ost
of
building,
staffing
and
validating
our
own
manufacturing
facilities
in
t
he
Un
i
ted
Sta
t
es, including having a product candidate successfully manufactured consistent with FDA and European Medicines Agency regulations;
•
t
erms,
t
iming
and costs
of
our
current
and
any
pote
n
tial
future
collaborations,
business or product acquisitions,
CVRs,
m
i
lestones,
r
o
yalti
e
s,
l
i
c
e
n
s
i
n
g or
other
arrangements
that
we
have
established
or
may
establish;
•
t
ime
and
cost
necessary
to respond
to
technological,
regulatory,
po
l
itical
and
market
developments; and
•
c
osts
of
filing,
prosecuting,
maintaining,
defending
and
enforcing
any
patent
claims
a
n
d
other
intellectual
property
rights.
Unless
and
until
we
can
generate
a
suffic
i
ent
amount
of
reve
n
ues,
we
m
a
y
finance
f
uture
cash
needs
through
pu
b
lic
or
private
equity
offerings,
license agreements,
debt
financings,
col
l
abor
a
t
i
ons,
str
a
teg
i
c
al
l
ian
c
e
s
and
marketing
or
dis
t
ribution
arrangements.
However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms, or at all, including but not limited to the offering, issuance and sale by us of up to a maximum aggregate amount of
$500.0 million of our common stock that may be issued and sold under the ATM. See
Note 9
,
Stockholders' Deficit
, of the "Notes to Unaudited Condensed Consolidated Financial Statements" that appear in Item 1. "Financial Statements" of this Quarterly Report on Form 10-Q.
To
the
extent
that
we
raise
additional
c
a
pital
through
the
sale
of
equity
or
conver
t
ible
debt
securitie
s including through the ATM or other offerings
,
your
ownership
interest
will
be
diluted,
and
the terms
may
include
liquidation
or
other
preferences
that
adversely
affect
your
rights
as
a
stockholder.
The
incurrence
of
additional
indebtedness
would result
in
increased
fixed
payment
obligations
and
could
involve
certain
r
e
strictive
covenants,
such
as
limitations
on
o
u
r
abil
i
ty
to incur
additional
debt, li
m
it
a
tions
on our
a
bil
i
ty
to
a
c
qu
i
re
or
l
i
c
e
nse
i
n
t
e
l
le
c
tu
a
l
p
r
operty
rights
and
other
operating
r
e
strictions
that
could
adversely
impact
our
ability
to conduct
our
business.
If
we
raise
additional
funds
through
strategic
partnerships
a
nd alliances
and
licensing
arrangements
with
third
parti
e
s,
w
e
m
a
y have
to
relinquish
valuable
rights
to our technologies
or
product
candidates,
or
grant
licenses
on
terms
unfavorable
to us. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to delay or reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts. Our current license and collaboration agreements may also be terminated if we are unable to meet the payment obligations under those agreements. As a result, we may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.
Contractual Obligations, Commitments and Contingencies
Contractual Obligations and Commitments
See
Note 7
,
Commitments and Contingencies – Lease Arrangements
,
and
Note 8
,
Related-Party Agreements
, of the "Notes to Unaudited Condensed Consolidated Financial Statements"
that appear
in Item 1. "Financial Statements" of
this Quarterly Report on Form 10-Q.
49
Table of Contents
Contingencies
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business.
We are aware of complaints that have been filed regarding the Merger, but we have not been served with any of such complaints. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve.
Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
Off-Balance Sheet Arrangements
During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.
Critical Accounting Policies and Significant Judgments
In the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio, Inc. as of December 31, 2020 and December 31, 2019 (including NantCell, Inc.) filed as
Exhibit 99.2
and the Management's Discussion and Analysis of Financial Condition and Results of Operations of ImmunityBio, Inc. filed as
Exhibit 99.3
to our Current Report on Form 8-K/A filed with the SEC on April 22, 2021, we have disclosed those accounting policies that we consider to be significant in determining our results of operations and financial condition. There have been no material changes to those policies that we consider to be significant since the filing of our Current Report on Form 8-K/A on April 22, 2021. The accounting principles used in preparing our condensed consolidated financial statements conform in all material respects
with accounting principles generally accepted in the United States of America ("U.S. GAAP")
.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses for the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12 months from the date of issuance of these financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.
Stock-Based Compensation
We account for stock-based compensation under the provisions of FASB ASC Topic 718,
Compensation—Stock Compensation
("ASC 718"). We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.
Recent Accounting Pronouncements
Refer to
Note 2
,
Summary of Significant Accounting Policies
, of the "Notes to Unaudited Condensed Consolidated Financial Statements"
that appears
in Item 1. "Financial Statements" of
this Quarterly Report on Form 10-Q
for a discussion of recent accounting pronouncements or changes in accounting pronouncements that are of significance, or potential significance, to us.
50
Table of Contents
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
Financial market risks related to interest rates, equity investments, foreign currency exchange rates and inflation are described in the Combined Management's Discussion and Analysis of Financial Condition and Results of Operations of ImmunityBio, Inc. filed as
Exhibit 99.3
to
our Current Report on Form 8-K filed with the SEC on April 22, 2021, there have been no material changes to the financial market risks described at December 31, 2020. We do not currently anticipate any other near-term changes in the nature of our financial market risk exposures or in management's objectives and strategies with respect to managing such exposures.
ITEM 4. CONTROLS AND PROCEDURES.
Evaluation of Disclosure Controls and Procedures
Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives of ensuring that information we are required to disclose in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer ("CEO") and chief financial officer ("CFO"), as appropriate, to allow timely decisions regarding required disclosures, and is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. There is no assurance that our disclosure controls and procedures will operate effectively under all circumstances.
Management, with the participation of our CEO and CFO, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2021. The term "disclosure controls and procedures," as defined in Rule 13a-15(e) of the Exchange Act means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2021, our CEO and CFO have concluded that, as of June 30, 2021, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the fiscal quarter ended June 30, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. However, as a result of the Merger, our internal control over financial reporting may change. Our process for evaluating controls and procedures is continuous and encompasses constant improvement of the design and effectiveness of established controls and procedures and the remediation of any deficiencies, which may be identified during this process.
Inherent Limitations on Effectiveness of Controls
Management recognizes that a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
51
Table of Contents
PART II—OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. We are aware of complaints that have been filed regarding the Merger, but we have not been served with any of such complaints. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
See
Note 7
,
Commitments and Contingencies—Litigation
, of the "Notes to Unaudited Condensed Consolidated Financial Statements" included in Part I, Item 1. "Financial Statements" of this Quarterly Report on Form 10-Q for a discussion of legal matters.
52
Table of Contents
ITEM 1A. RISK FACTORS.
Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, any of which may be relevant to decisions regarding an investment in or ownership of our stock. The occurrence of any of these risks could have a significant adverse effect on our reputation, business, financial condition, results of operations, growth and ability to accomplish our strategic objectives. We have organized the description of these risks into groupings in an effort to enhance readability, but many of the risks interrelate or could be grouped or ordered in other ways, so no special significance should be attributed to the groupings or order below.
On
March 9, 2021,
we
completed
t
h
e
merger
with
ImmunityBio,
Inc
.
,
a
private
company
r
e
ferred
to below
as
"Imm
u
nityBio."
After
t
he
completion
of this
merger,
we
(formerly
known
as
NantK
w
est,
Inc.)
changed
our
name
to ImmunityBio, Inc.,
and
references
below
to
"the
c
ompan
y
,"
"the combined company,"
"we,"
"us,"
and "our"
refer
to
ImmunityBio, Inc. and its subsidiaries
.
Risk
Factor
Summary
R
i
sks
Relat
e
d
to Our
Limited Operating History,
F
inan
c
ial
Condition
and
Capital
R
e
qui
r
em
e
n
ts
•
W
e
will
need
additional
f
i
nancing
to
fund
our
operations
and
complete
the
dev
e
lopment
and
comme
r
cialization
of
our
various
pr
o
duct candidates,
and
if we
are
unable
to obtain
such
financing when needed, or on acceptable terms,
we
may
be
unable
to complete
the
dev
e
lopment
and
commercialization
o
f
our product
candidates.
Raising
addit
i
onal
capital
may
cause
dilution
to our
stockholders,
restrict
our
operat
i
ons
or
require
us
to
relinquish rights
to
our
technologies
or
product
candidates.
•
Our
debt
could
adversely
affect
our
cash
flows
and
limit
our
f
l
exib
i
li
t
y
to
ra
i
s
e
a
ddit
i
onal
c
a
pit
a
l.
•
Our
b
u
sinesses
may
not
be
integrated
succ
e
ssfully,
or
such
integration
may
be
more
d
i
fficult,
time
consuming
or
costly
than
ex
p
ected. Operating
costs,
customer
loss
and
business
disruption,
including
difficult
i
es
i
n m
a
int
a
in
i
ng
re
l
a
t
ionsh
i
ps
with
e
m
ploye
e
s
,
c
u
s
tom
e
r
s
, suppliers
or
vendors,
may
be
greater
than
expected
for the combined company
.
Revenues
may
be
lower
than
expec
t
ed for the combined company.
•
We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. W
e
have
a
history
of
operat
i
ng
losses,
and
we
expect
to continue
to
incur
losses
and
may
never
be
profitable, which together with our limited operating history, makes it difficult to assess our future viability.
•
We invest our cash on hand in various financial instruments, which are subject to risks that could adversely affect our business, results of operations, liquidity and financial condition
.
R
i
s
k
s Related
to
Our
Business and
I
n
d
u
stry
R
e
gulation
•
We will be substantially dependent on the success of our product candidates and cannot guarantee that these product candidates will successfully complete development, receive regulatory approval or be successfully commercialized.
•
W
e
may
develop
product
candidates
in combination
with
other
therapies,
which
exposes us
to
additional
risks.
•
Due to the significant resources required for the development of our product candidates, and depending on our ability to access capital, we must prioritize among many different opportunities. We may expend our limited resources on programs that do not yield successful product candidates as opposed to indications that may be more profitable or for which there is a greater likelihood of success
.
•
Our
clinical
trial
costs
may
be
higher
than
for
more
conventional
therapeutic
t
e
chnologies
or
drug
products.
•
Our
clinical
trials
may
f
a
il
to
demonst
r
ate
adequately
the
sa
f
e
ty
a
nd
efficacy
of
our
product
cand
i
dates,
which
would
prevent
o
r
delay regulatory
approval
and
co
m
mer
c
i
a
li
z
at
i
on.
•
Interim,
initial,
"top-line"
and
preliminary
data
from
our
clinical
tri
a
ls
that
we
announce
or
publi
s
h
from
time
to
time
may
c
hange
as
more patient
data
become
a
v
a
i
lab
l
e
and
a
re
sub
j
e
c
t
t
o audit
and
veri
f
ication
procedures
that
c
ould
re
s
ult in
m
a
t
e
rial
c
hang
e
s
in
the
final
data.
•
W
e
have
limited
experience
conducting
clinical
trials
and
have
r
e
lied
and
will
rely
on
third
p
a
rties
and
relat
e
d
parties
to c
o
nduct
many
of our
preclinical
studies
and
clin
i
cal
trials and to manufacture products.
Any
failure
by
a
third
party,
relat
e
d
party,
or
by
us
to
conduct
the
clinical
trials
according
to Good
Clinical
Practi
c
e
("GCP")
regulations,
and
in
a timely
manner
may
delay
or
prevent
our ability
to
seek
or
o
btain
re
g
ulato
r
y
a
p
p
r
o
val for
or
commercialization of our
product
candidates.
53
Table of Contents
•
Our
clinical
trials
may
not
be
initiated
or
completed
when
we
expec
t
,
or at all, they may take longer and cost more to complete than we project
and
we
may
be
required
to
conduct
additional
clinical
t
r
i
a
ls
or modify
current
or
future
cli
n
ical
trials
based
on
feedback
we
receive
from
the
United States ("U.S.") Food and Drug Administration ("
F
DA
")
.
•
We will be unable to commercialize our product candidates if our trials are not successful.
•
Even if one of our product candidates is approved and commercialized, we may not become profitable.
•
W
e
use
Immuno-Oncology
Clinic, Inc
. (the "Clinic")
,
a related
party,
in some
of
our
clinical
trials
which
may
expose
us
to
significant
regul
a
tory
risks.
If our
data
f
o
r
this
site
is
not
sufficiently
robust
or
if
there
are
any
data
integrity
i
s
sues, we
may
be
requ
i
red
to
repeat
such
studies
or
required
t
o
c
ontra
c
t
w
i
th o
t
her
cl
i
ni
c
al
tr
i
a
l
s
i
t
e
s,
and
our
clinical
developme
n
t
plans
will
be
significantly
delayed,
and
we
will
inc
u
r
additional
c
o
s
t
s.
•
If
we
encounter
delays or
difficulties
enr
o
lling
and/or maintaining
patients
in our
clinical
trials,
our
clinical
devel
o
pment
activities
and
receipt
of
ne
c
essary
marketing approvals
could
be
delayed
or
otherwise
adversely
affected.
•
Our
prod
u
ct
candidates
may
cause
undesirable
side
effects
or
h
a
ve
other
properties
that
could
halt
their
clinical
development,
prev
e
nt
t
heir regulatory
approval,
limit
the
i
r
c
omm
e
rc
i
a
l
pot
e
nti
a
l
or result
i
n
significant
negative
consequences.
•
T
he
manufacture
of
our
product
c
a
ndidates
is
complex,
and
we
may
encounter
difficulties
in p
r
o
duction,
particularly
with
resp
e
c
t
t
o process
development,
quali
t
y
control,
or
scaling-up
of
our
m
a
nufacturing
capabili
t
ies.
If
we
or
our
related
parties,
or
any
of
our
third-party manufacturers
encounter
such
d
i
fficulties,
our
ability
to provide
adequate
supply
of
our
product
candidates
for
clinical
trials
or
our
p
roducts
for patients,
if
approved,
could
be
delayed
or
stoppe
d
,
or
we
may
be
unable
to maintain
a
commerc
i
ally
viable
cost
structure.
•
Cell-based therapies and biologics rely on the availability of reagents, specialized equipment and other specialty materials, which may not be available to us on acceptable terms or at all. For some of these reagents, equipment and materials, we rely or may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products, if approved.
•
Our
efforts
to develop,
manufacture
a
n
d
market
COVID‑19
therapeutics
will
require
additional
personnel
who
w
i
ll
require training,
which
may cause
some
of
our
employees
to
reallocate
t
h
e
i
r
t
i
me
from other
duties
which
could
in turn
cause
delays
in clinical
supply
of
our
other
product candidates
or
trials.
•
Our
ability
to use
net
operating
losses
and
research
and
development
credits
to
offset
future
t
axable
income
may
be
subject
to
c
e
rtain
l
im
i
tat
i
ons.
•
Changes
in
tax
law
could
adv
e
r
s
e
ly
affe
c
t
o
u
r
b
u
sin
e
ss
and financial
co
n
dition. Negative or unexpected tax consequences could adversely affect our results of operations.
•
Our
transfer
pricing
poli
c
ies
may
be
subject
to
challenge
by
the
Internal Revenue Service ("IRS") or other
taxing
a
u
thorities.
•
We could be subje
c
t
to
additional income tax liabilities and to
examinations
of
our
tax
returns by
t
h
e
IRS
and
other
domestic
a
n
d
foreign
tax authorities.
An
adverse
out
c
ome
of
any
such
audit
or
examination
by
the
IRS
or other
tax
authority
cou
l
d
have
a
material
adver
s
e
eff
e
ct
on o
u
r op
e
rating
results and finan
c
ial
condit
i
on.
•
Our projections regarding the market opportunities for our product candidates may not be accurate, and the actual market for our products, if approved, may be smaller than we estimate.
•
Because our current product candidates represent, and our other potential product candidates will represent novel approaches to the treatment of disease, there are many uncertainties regarding the development, market acceptance, third-party reimbursement coverage and the commercial potential of our product candidates.
•
If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
•
We will face significant competition from other biotechnology and pharmaceutical companies and from non-profit institutions.
•
Public opinion and scrutiny of immunotherapy approaches may impact public perception of us and our product candidates, which may adversely affect our ability to conduct our business and implement our business plans.
54
Table of Contents
•
We may seek orphan drug status or Fast Track or Breakthrough Therapy designations or other designation for one or more of our product candidates, but even if any such designation or status is granted, it may
not
lead to faster development or a faster regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval and we may be unable to maintain any benefits associated with such designations or status, including market exclusivity.
•
As a condition of approval, the FDA may require that we implement various post-marketing requirements and conduct post-marketing studies, any of which would require a substantial investment of time, effort, and money, and which may limit our commercial prospects.
•
W
e
have
never
commercial
i
zed
a
product
candidate
before,
and
we
may
lack
the
necessary
exper
t
ise,
personnel
and
resources
to successfully
commercia
l
ize
any
products
on
our
o
w
n
or
together
with
suitable
collaborators. We may be unable to establish effective marketing and sales capabilities or enter into agreements with third parties or related parties to market and sell our product candidates, if they are approved, and as a result, we may be unable generate product revenues.
•
We expect to rely on third parties to perform many essential services for any products that we commercialize, including services related to distribution, government price reporting, customer service, accounts receivable management, cash collection and adverse event reporting. If these third parties fail to perform as expected or to comply with legal and regulatory requirements, our ability to commercialize our current or future product candidates will be significantly impacted and we may be subject to regulatory sanctions.
•
If our product candidates do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.
•
We
will
need
to obtain
FDA
approval
of
a
n
y proposed
branded
product
names,
and
any
f
a
ilure
or
delay
associated
with
such
approval
may
adversely affect
o
u
r
b
u
s
i
n
e
s
s
.
•
Our
i
n
te
r
n
al
c
omputer
s
y
s
t
ems,
or
those
used
by
our
contract research organizations ("
CROs"), contract manufacturing organizations ("C
M
Os"),
c
li
n
i
c
al
s
i
t
e
s
or other
contractors
or
consultants,
m
a
y
fail
or suffer s
e
c
u
rity
b
r
ea
c
h
e
s.
•
Our business could be adversely affected by the effects of health epidemics, pandemics or contagious diseases, including the recent COVID 19 pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations.
•
We have formed, and may in the future form or seek, strategic alliances or enter into collaborations with third parties or additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements. If we fail to enter into such strategic alliances, collaborations or licensing arrangement, or such strategic alliances, collaborations or licensing arrangements are not successful, we may not be able to capitalize on the market potential of our product candidates.
•
If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.
•
We will be heavily dependent on our senior management, particularly Dr. Soon-Shiong, our Executive Chairman, and a loss of a member of our senior management team in the future, even if only temporary, could harm our business.
•
We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.
•
If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.
•
We may
b
e
come
i
n
v
olv
e
d
i
n securit
i
es
l
it
i
gation
or
stockholder
derivative
l
it
i
gation
i
n conn
e
c
t
ion
wi
t
h
our
recent
merger,
and
this
could divert
the
attention
of
our
ma
n
agement
and
harm
our
bus
i
n
e
s
s
,
and i
n
s
u
rance
c
ov
e
rage
may
not
be
s
u
ffi
c
ie
n
t
to
cov
e
r
all
r
e
l
ated
costs
and damages.
•
A variety
of
risks
associated
with
mar
k
eting
our
product
candidates
int
e
rnationally
could
materially
adversely
affect
our
bus
i
ness.
55
Table of Contents
Risks
Related
to
Government
Regulation
•
We may be unable to obtain U.S. or foreign
regulatory
approval
and,
as a result
,
be unable
to commercialize
our product
candidates
. We are,
and
if
we
receive
regulatory
app
r
oval
of
our
product
candidates, will continue to be subject to ongoing extensive regulation, regulatory obligations and continued regulatory review, which may result in significant additional expense.
•
Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
•
If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business.
•
Results
for
any
patient
who
r
e
ceives
compassionate
use
access
to
our
product
candidates
should
not
be
viewed
as
representative
of
how
the product
candidate
will
perform
in
a
well-controlled
clinical
trial,
and
cannot
be
used
to establish
safety
or
efficacy
for
regulatory
approval.
•
Our
GMP
-
in-a-Box
will
be
regulated
by
the
FDA
as
a medical
device,
and
regulatory
compliance
for
m
e
dical
devices
is
expensive, complex
and
uncertain,
and
a
failure
to
com
p
ly
could
lead
to enf
o
r
c
e
m
ent
a
c
tions
aga
i
nst
us and
other
negative
consequences
for
our business.
•
We will be subject to governmental export and import controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws.
•
We
are subject
to
U.S.
and for
e
ign
anti-corruption
and
anti-money
l
aundering
l
aws with
r
e
sp
e
c
t
to
our
o
p
erations
and
non-compl
i
an
c
e
with
such laws
can subj
e
c
t
us
to
c
riminal
an
d
/
or
civil
liabi
l
ity
and harm our business.
•
Our failure to comply with state, national and/or international data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.
•
If we, or any third party contract manufacturers or suppliers that we engage, fail to comply with environmental, health, and safety laws and regulations, including regulations governing the handling, storage or disposal of hazardous materials, we could become subject to fines or penalties or incur costs that could harm our business.
•
Disruptions at the FDA, the Securities and Exchange Commission ("SEC") and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
•
If we
fail
to
comp
l
y
with
f
e
deral
and s
t
ate
healthcare
and promotional
laws,
including
fraud
and ab
u
se
and
information
privacy
and
security
laws, we
could
face
substantial
penalties
and
o
u
r busines
s
, fi
n
an
c
ial
c
onditio
n
,
r
e
sults of operations,
and
prospects
could
be
adversely
affe
c
ted.
•
Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.
•
We may face difficulties from changes to current regulations and future legislation.
•
Go
v
e
r
n
m
e
n
ts
o
u
tside
t
h
e
Un
i
ted
S
t
ates
tend
t
o
i
mpose
s
t
r
i
ct
pri
c
e
co
n
trols,
whi
c
h
may
ad
v
e
r
s
e
ly
aff
e
ct
our r
e
v
e
n
u
e
s
,
if
an
y
.
•
Our
employees,
independent
contractors,
consultants,
commercial
partners, principal investigators, CROs, suppliers
and
vendors
may
engage
in
misconduct
or
other
improper
ac
t
i
v
it
i
es, in
c
luding
non
c
omp
l
ian
c
e
with
r
e
gu
la
tory
standards
a
n
d
requirements.
56
Table of Contents
R
i
s
k
s R
e
lat
e
d
to I
n
te
l
le
c
tual
P
r
o
p
er
t
y
•
If
we
are
unable
to obtain,
maintain,
p
r
o
t
ect
and
enforce
p
a
tent
protection
and
other
propri
e
tary
rights
for
our
product
cand
i
dates
and technologies,
we
may
not
be
able
to compete
effectively
or
operate
profitably and our
ab
i
l
i
ty
t
o pr
e
vent our
competitors
from
comme
r
cializing
sim
i
lar
or
identical
technology
and
product
candidates
would
be
a
d
v
e
rsely
affected.
•
If any of our owned or in-licensed patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively.
W
e
or our licensors, collaborators, or any future strategic partners may become subject to third party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation
to
protect
or
enforce
our
patents
or
o
t
her
intellectual
property
or
the
patents
or
other
intellectual
property of
our
licenso
r
s,
all of
which
c
o
uld
be
expensive,
time-consuming
a
nd
unsuccessful, may delay or prevent the development and commercialization of our product
candidates, or may put our patents and other proprietary rights at risk.
•
T
he
use
of
our
technology
a
n
d
p
r
oduct
candidates
could
potentially
conflict
with
the
rights
of
others, and
third-party
claims
of
i
nt
e
ll
e
ctu
a
l property
infringement,
misa
p
p
r
o
p
r
iation
or
other
violation
against
us,
our licensors
or
our
collaborators
may
prevent
or
delay
the development
and
commercialization
of our
product
candidat
e
s
and
technologies.
•
Obtaining
and
maintaining
our
patent
pro
t
ection
depends
on
compliance
with
various
p
r
ocedural,
document
submission,
fee
payment,
and other
requirements
imposed
by
government
patent
agencies,
and
our
patent
protection
could
be
r
e
duced
or
eliminated
for
non-compl
i
an
c
e with
t
h
ese
r
e
quirements.
•
Changes
in
United
States
patent
law
could
diminish
the
value
of patents
in general,
t
h
e
r
e
by
i
m
pairing
our
ability
to
protect
our product
candidates.
•
Our
rights
to
develop
and
comme
r
cialize
our
product
cand
i
dates
and
technologies
are
s
u
b
j
ec
t
,
in
part,
to
the
t
e
r
m
s
and condit
i
o
ns
of
l
i
c
e
n
s
es granted
to
us
by
others.
•
If
we
fail
to
comp
l
y
with
our
obl
i
gations
i
n t
h
e
agr
e
em
e
n
t
s
u
n
der
wh
i
c
h
we
l
i
c
e
n
s
e
i
n
tellectual
property
r
i
ghts
from
third
par
t
ies
or otherwise experience
disruptions
to our
business
r
e
lat
i
o
n
s
h
ips
with
o
u
r lic
e
n
s
ors,
we may be required to pay damages and
we
co
u
l
d lo
s
e
l
ic
e
n
s
e
righ
t
s
t
h
at
are
important
to our
b
u
s
i
n
e
s
s
.
•
We have
l
i
mi
t
e
d
for
e
ign
int
e
l
l
ec
t
ual
proper
t
y rights
and
may
not
be
able
to
protect
o
u
r intellectual
property
rights t
h
roug
h
out
the
world.
•
We
may
be
subject
to claims
that
our employees,
consultants or i
n
depende
n
t
co
n
trac
t
ors
h
ave
wro
n
gfully
used
or
disclosed
trade
s
e
cr
e
ts
or
oth
e
r confident
i
al
i
n
forma
t
ion
of
third
parti
e
s
or
claims
asserti
n
g
ownership
of
what
we
regard
as
our
own
intellectual
property.
•
We may
not
be
able
to
li
c
ense
or
acquire
new
or
necessary
i
n
tellectual
property
rights
or
t
e
chnology
from
t
h
i
r
d
pa
r
ti
e
s.
•
If we
do
not
ob
t
ain
pa
t
ent
t
e
rm
ext
e
nsion
and
data
exclusivity
for
any
product ca
n
didat
e
s
we
may
d
e
v
e
lop,
our
business
may
be
m
at
e
r
i
ally
harmed.
•
We
may
be
subject
to claims
challenging
the
inv
e
n
t
orship
of
our
patents
a
n
d
oth
e
r
int
e
ll
e
c
t
ual
propert
y
.
•
If
we
are
unable
to protect
t
h
e
confidentiality
of
o
u
r t
r
ade
s
e
c
r
ets,
o
u
r business and
co
m
pe
t
it
i
ve
pos
i
t
i
on
wou
l
d
be
h
ar
m
ed.
•
If
our trademarks
and
trade
names
are
not
ad
e
quately
protected,
t
h
en
we
may
not
be
able
to build
name
recognition
in our
marke
t
s
of
interest
and o
u
r busi
n
e
ss
may
be
adversely
affected.
•
Intellectual
pr
o
perty
rights
do
not
necessarily
address all
potential
threats.
57
Table of Contents
Risks
Related
to
Our
Common Stock
•
Dr.
Patrick
Soon-Shiong,
o
ur
E
xecutive
C
hairman
a
nd our
principal
stockholder,
has
significant
interests
in
other
companies
which
may
conflict wi
t
h
our int
e
rests.
•
Dr.
Soon-Shiong,
th
r
o
u
gh
his
voting
c
ontrol
of
the
company,
has the ability
to
con
t
rol
actions
that
re
q
uire stockholder
approval.
•
T
he
market
price
of
our
common
stock
has
b
e
en
and
may
continue
to be
volatile,
and
inves
t
ors
may
have
difficulty
selling
their
shar
e
s.
•
Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
•
W
e
have
incurred
and
will
continue
to
incur
costs
as
a
result
of
operating
as
a public
company
and
our
management
has
been
and
w
i
ll
be required
to
devote
substantial
time
to compliance
initiatives
and
corporate
governance
p
r
actices,
including
maintaining
an
eff
ec
tive
sys
t
em of
internal
control
over
financial
r
e
porting.
•
If a restatement of our financial statements were to occur, our stockholders' confidence in the company's financial reporting in the future may be affected, which could in turn have a material adverse effect on our business and stock price.
•
We have not paid cash dividends in the past and do not expect to pay dividends in the future. Any return on investment may be limited to the value of our common stock.
•
Because we are relying on the exemptions from corporate governance requirements as a result of being a "controlled company" within the meaning of the Nasdaq listing standards, you do not have the same protections afforded to stockholders of companies that are subject to such requirements.
•
We are a "smaller reporting company," and the reduced disclosure requirements applicable to smaller reporting companies could make our common stock less attractive to investors.
•
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.
•
We are not subject to the provisions of Section 203 of the Delaware General Corporation Law ("DGCL"), which could negatively affect your investment.
•
Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.
•
Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.
58
Table of Contents
Risks Related to Our
Limited Operating History,
Financial Condition and Capital Requirements
We
will
need
ad
d
iti
o
nal
financing
to fund
our
operations
and
compl
e
te
the
de
v
e
lop
m
ent
and com
m
e
r
cialization
of
our
various
pro
d
u
c
t candidat
e
s
, and
if we
are
unable
to obtain
such
financi
n
g when needed, or on acceptable terms,
we
may
be
u
n
able
t
o co
m
ple
t
e
t
h
e
dev
e
lopment
and
commercia
l
ization
of
our
produ
c
t ca
n
didat
e
s.
The development of biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our
operations
have
consumed
sub
s
tantial
amounts
of
cash
since
inception.
A
sign
i
fic
a
nt
p
o
r
tion of
our
funding
had
been
in the
form
of
promissory
notes
r
e
presenting
$300.3 million
in
i
ndebtedness, including interest thereon,
as
of
June 30, 2021
held
by
entities
affiliated with
Dr. Soon-Shiong with
a
maturity
date
of
September 30, 2025.
As of June 30, 2021, we
held
cash,
cash
equiv
a
lents
and
ma
r
k
etable
securities
totaling $104.8 million
.
We
will
need
to obtain
a
dditional
financing
to fund
our
fut
u
re
o
p
erations,
including
completing
the
development
and
commercial
i
zation
of
our
product candidates.
C
hanging
cir
c
umstances
may
cause
us
to increase
our
spending
s
i
gnif
i
can
t
ly
faster
th
a
n
we curr
e
ntly
an
t
ic
ip
ate
and
we
may
n
eed
to
raise
additional
funds
sooner
than
we
presently
anticipate.
Moreover,
research and development and our operating costs and fixed
expenses
such
as
rent
and
other
contractual
co
m
mitm
e
nt
s
,
in
c
l
uding those
for
our
research
collaborat
i
ons,
are
subs
t
a
nt
i
a
l
and
are
e
xpec
t
ed
to
i
ncr
e
a
se
in
the
futur
e
.
Our
future
funding
requ
i
rements
will
depend
on
many
factors,
including,
but
not
limited
to:
•
progr
e
s
s,
t
i
ming,
number,
scope
a
nd
c
os
t
s
of
researching and developing our product candidates
and
our
on
g
oing,
plan
n
e
d
a
nd po
t
ent
i
al
c
lin
i
c
a
l
t
ria
l
s
;
•
t
ime
and
cost
of
regulatory
approvals;
•
our
ability
to
successfully
commercialize
any
product
candidates,
if
approved and the costs of such commercialization activities;
•
revenue
from
p
r
oduct
candidates
that
we
may
commercialize,
if
any,
i
n
cluding
the
selling
prices
for
su
c
h potential
products
and
the
availabi
l
ity
of
adequate
third-party
cover
a
ge
and
reimbursement
for
patients;
•
c
ost
of
building,
staffing
and
validating
our
own
manufacturing
facilities
in
t
he
Un
i
ted
Sta
t
es, including having a product candidate successfully manufactured consistent with FDA and European Medicines Agency regulations;
•
t
erms,
t
iming
and costs
of
our
current
and
any
pote
n
tial
future
collaborations,
business or product acquisitions
,
contingent
value
rights
("CVRs"),
m
i
lestones,
r
o
yalti
e
s,
l
i
c
e
n
s
i
n
g or
other
arrangements
that
we
have
established
or
may
establish;
•
t
ime
and
cost
necessary
to respond
to
technological,
regulatory,
po
l
itical
and
market
developments; and
•
c
osts
of
filing,
prosecuting,
maintaining,
defending
and
enforcing
any
patent
claims
a
n
d
other
intellectual
property
rights.
Unless
and
until
we
can
generate
a
suffic
i
ent
amount
of
reve
n
ues,
we
m
a
y
finance
f
uture
cash
needs
through
pu
b
lic
or
private
equity
offerings,
license agreements,
debt
financings,
col
l
abor
a
t
i
ons,
str
a
teg
i
c
al
l
ian
c
e
s
and
marketing
or
dis
t
ribution
arrangements.
However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms, or at all, including but not limited to the offering, issuance and sale by us of up to a maximum aggregate amount of $500.0 million of our common stock that may be issued and sold under an "at-the-market" sales agreement with Jefferies LLC (the "ATM").
To
the
extent
that
we
raise
additional
c
a
pital
through
the
sale
of
equity
or
conver
t
ible
debt
securitie
s including through the ATM or other offerings
,
your
ownership
interest
will
be
diluted,
and
the terms
may
include
liquidation
or
other
preferences
that
adversely
affect
your
rights
as
a
stockholder.
The
incurrence
of
additional
indebtedness
would result
in
increased
fixed
payment
obligations
and
could
involve
certain
r
e
strictive
covenants,
such
as
limitations
on
o
u
r
abil
i
ty
to incur
additional
debt, li
m
it
a
tions
on our
a
bil
i
ty
to
a
c
qu
i
re
or
l
i
c
e
nse
i
n
t
e
l
le
c
tu
a
l
p
r
operty
rights
and
other
operating
r
e
strictions
that
could
adversely
impact
our
ability
to conduct
our
business.
If
we
raise
additional
funds
through
strategic
partnerships
a
nd alliances
and
licensing
arrangements
with
third
parti
e
s,
w
e
m
a
y have
to
relinquish
valuable
rights
to our technologies
or
product
candidates,
or
grant
licenses
on
terms
unfavorable
to us. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to delay or reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts. Our current license and collaboration agreements may also be terminated if we are unable to meet the payment obligations under those agreements. As a result, we may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.
59
Table of Contents
Our
debt
could
adversely
affect
o
u
r cash
flows
and limit
our flexib
i
li
t
y
t
o raise addit
i
onal
c
apita
l
.
We
have
a significant
amount
of
debt
and
m
a
y
need
to incur
additional
debt
to
support
our
growth.
As
of
June 30, 2021
,
our in
debtedness
was $300.3 million,
consisting
of
related
-
party
promissory
notes and interest thereon,
all
held
by
ent
i
ties
affiliated
w
ith
Dr. Soon-Shiong, w
i
th
a
m
a
t
urity
date of
September 30, 2025.
Our
substantial
amount
of
debt
could
have
important
consequences
and
could:
•
require
us
to dedicate
a
substantial
portion
of
our
cash
and
c
a
sh
equivalents
to
make
interest
and
p
r
incipal
payments
on
our
d
ebt,
reducing the
availability
of
our
cash
and
cash
equivalents
and
c
a
sh
flow
from
operations
to fund
future
capital
expenditures,
working
c
a
pit
a
l, execution
of
our
strategy
and
other
general
corporate
requirements;
•
i
ncrease
o
ur
cost
of
borrowing
and
even
limit
our
ability
to
access
additional
debt
to fund
future
growth;
•
i
ncrease
o
ur
vulnerability
to
general
adverse
economic
a
nd
industry
conditions
and
adverse
c
h
anges
in governm
e
ntal
regulation
s
;
•
l
imit
our
flexibility
in
planning
for,
or reacting
to,
changes
in
our
business
and
industry,
which
may
place
us
at a disadvantage compared
with
our
competitors;
and
•
l
imit
our
ability
to borrow
additional
fund
s
, even
when
necessary
to
m
a
intain
adequate
liquidity,
w
h
ich
would
also
limit
our
a
bi
l
ity
to further
expand
our
business.
The
occurrence
of
any
of
the
foregoing
facto
r
s
could
have
a
material
adverse
effect
on
our
business,
results
of
o
perations
and
financial
condition.
We
may
also
need
to refinance
a
portion
of
our
outstanding
debt
as
it mat
u
res.
We
may
not
be
able
to refina
n
c
e
existing
debt
or the
terms
of
any refinanci
n
g
may
not
be
as
f
a
vorable
as
the
terms
of
our
existing
debt.
F
u
rthermore,
if
prevailing
int
e
rest
rates
or
other
fact
o
rs
at the
time
of
refinancing result
in
higher
interest
rates
upon
refinancing,
then
the
interest
expense
relating
to
that
refinanced
ind
e
btedness
would
inc
re
a
s
e
.
The
s
e
risks
could materially
adversely
a
ffect
our
financial
condition,
cash
flows
and
results
of
ope
r
a
tions.
O
u
r b
u
s
i
n
e
s
s
es
may
not
be
i
n
t
e
gra
t
ed
s
u
c
c
essfu
l
ly,
or su
c
h integrat
i
on
m
a
y
be
more
difficult,
time
consuming
or
cos
t
ly
than
exp
e
c
t
ed.
Operat
i
n
g costs,
customer
loss
and
busin
e
ss
disruption,
including
d
i
ffi
c
u
l
ti
e
s
in
m
aintaining
re
l
ationsh
i
ps
with
employe
e
s
,
c
u
stom
e
rs,
s
uppliers
or
vendors, may
be
greater
than
e
xp
e
cted
for the combined company
.
R
ev
e
n
u
es
may
be
low
e
r
t
h
an
exp
e
ct
e
d for the combined company.
The
co
m
bina
t
ion
of two
busin
e
s
s
e
s
is
c
ompl
e
x,
costly
and
time-consuming
and
may
divert
significant
managem
e
nt
attention
and
re
s
ources
to
c
o
mbining o
u
r
prior
businesses.
This
process
may
dis
r
upt
our
businesses.
The
failure
to
meet
the
challenges
involved
in
combining
the
two
businesses
and
to rea
l
i
z
e
t
he
ant
i
c
i
p
a
t
e
d
b
e
nefi
t
s
of
t
he
merg
e
r
c
ould
cause
an
i
n
terruption
of,
or
a
loss
of
mom
e
n
t
um
i
n, the
a
c
tiv
i
ti
e
s
of the
combined
company
and
could adversely
affect
the
results
of operations
of
the
combined
comp
a
ny.
Our ability to realize the anticipated benefits of the merger will depend, to a large extent, on our ability to integrate our businesses in a manner that facilitates growth opportunities and achieves the projected synergies identified by each company without adversely affecting current revenues and investments in future growth. The
overall
combination
of
our
b
usines
s
es may
a
l
s
o
r
e
sult
in m
a
t
e
rial
un
a
nti
c
ipa
t
ed problems,
expenses,
li
a
bilities,
competitive
responses,
and
loss
of
customer
and
other
business
relationships.
The
difficulties
of
combining
the o
p
erations
of
the
companies
include,
among
others:
•
t
he
diversion
of
management
attention
to
integration
matters;
•
d
i
fficu
l
ti
e
s
in
in
t
e
gra
t
ing
operations
and
systems,
including
intellectual
property
and
communications
syste
m
s,
a
dmin
i
s
t
ra
t
ive
and information
technology
infrastruc
t
ure
and
financial
reporting
and
internal
control
systems;
•
c
hallenges
in
conforming
standards,
controls,
procedu
r
es
and
accounting
and
o
t
her
policies,
business
cultures
and
compensation
struc
t
ures between
the
two
companies;
•
difficulties
in
integrating
employees
and
attracting
and
r
e
taining
key
personnel,
including
talent;
•
difficulties
in
achiev
i
ng
anticipated
cost
savings,
synergies,
accretion targets,
business
opportunit
i
es,
financing
plans
and
growth
prospects from
the
combination;
•
difficulties
in
managing
the
exp
a
nded
operations
of
a
significantly
l
a
rger
and
more
complex
company;
•
c
onting
e
nt
li
a
bil
i
ti
e
s
th
a
t
are
l
a
rger
than
exp
e
ct
e
d;
and
•
potential
unknown
liabili
t
ies,
adverse
cons
e
quences
and
unforeseen
increased
exp
e
nses
ass
o
ciated
with
the
merger.
60
Table of Contents
Many
of
these
factors
are
outside
of
our
c
ontrol,
and
any
one
of
them
could
result
in lower
revenues,
higher
costs
and
diversi
o
n
of
management
time
and energy,
which
could
materially
i
m
pact
the
b
usiness,
financial
cond
i
tion
and
results
of
operations
of the
combined
company.
In
a
ddit
i
on,
even
if
the o
p
erations
of
our
businesses
are
integrated
su
c
c
e
s
sful
l
y,
the
full
ben
e
fits
of
the
m
e
r
g
er
may
not
be
real
i
zed,
i
nc
l
ud
i
ng,
a
m
ong
others,
the
synergies
or growth
opportunities
that
are
expected.
These
b
e
nefits
may
not
be
achieved
within
the
anticipated
time
frame
or
at
all.
Furthe
r
,
additional
unanticipated costs
may
be
incurred
in
the
integration
of our
businesses.
All
of
these
factors
cou
l
d
negatively
impact
the
company's operations and/or the
price
of
the
company's
common stock
.
As a
result,
it
cannot
be
assured
that
the
combination
of
our
businesses
will
result
in
the
re
a
l
i
za
t
ion
of
the
full ben
e
fits
e
xpe
c
ted
from
the
m
e
rger
w
i
thin
the
a
nti
c
ipa
t
ed
ti
m
e
fram
e
s
or
a
t
al
l
.
A
c
cord
i
ngly,
hold
e
rs
of
t
he
combined
comp
a
ny's
common
stock
may
experie
n
ce
a
loss
a
s
a
res
u
lt
of a
de
c
line
in the
m
a
rket
pri
c
e
of
s
uch
common
sto
c
k.
In
addition,
a dec
l
ine
in
the
m
a
rket
pri
c
e
of
the combined company's
com
m
on
stock
could
adversely
affect
the
c
o
mpany's
ability
to issue
a
d
d
i
t
i
on
a
l
s
e
cur
i
ti
e
s
and
to
obta
i
n
additio
n
al
financing
in
the
future.
We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale.
We have a history of operating losses, and we expect to continue to incur losses and may never be profitable,
which together with our limited operating history, makes it difficult to assess our future viability.
We are a clinical stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects, and now that the merger has been completed, we have a much broader portfolio of product candidates at various stages of development. None of our products have been approved for commercial sale and we have not generated any revenue from product sales, although we have generated revenues from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables and grant programs.
In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry, including in connection with
obtaining marketing approvals, manufacturing a commercial-scale product or arranging for a third party to do so on our behalf or conducting sales and marketing
activities necessary for successful product commercialization
.
Because of the numerous risks and uncertainties associated with our product development efforts, we are unable to predict when we may become profitable, if at all.
Since the commencement of our operations, we have incurred significant losses in each year and, as of June 30, 2021 we had an accumulated deficit of $1.8 billion. We expect to continue to
incur
significant
expenses as
we
seek to expand our business, including in connection with conducting research and development across multiple therapeutic areas, participating in clinical trial activities, continuing to acquire or in-license technologies, maintaining, protecting and expanding our intellectual property, seeking regulatory approvals, increasing our manufacturing capabilities and, upon successful receipt of FDA approval, commercializing our products. Moreover, we do not expect to have significant product sales or revenue for the foreseeable future.
If
our
resea
r
ch
and
development
efforts
are successful,
we
may
also
face
the
risks
a
ssociated
with
the
shift
from
development
to
commercialization
of
new products based
on innovative technologies
.
Our ability to achieve profitability is dependent upon obtaining regulatory approvals for our product candidates and successfully commercializing our product candidates alone or with third parties. However, our operations may not be profitable even if one or more of our product candidates under development are successfully developed and produced and thereafter commercialized. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis. As a result, it may be more difficult for you to assess our future viability than it could be if we had a longer operating history.
We
inv
e
st
our cash on hand in
various
finan
c
ial
ins
t
rum
e
n
t
s
which
are sub
j
ect
t
o ris
k
s
that
could
adversely
affect
our
busines
s
, r
e
sul
t
s
of op
e
rations,
l
iquidi
t
y
and finan
c
ial
condi
t
ion.
We
invest
our
cash
in a variety
of
financi
a
l
instruments,
principally
c
o
mmercial
paper,
corporate
debt
securities
and
foreign
g
overnment
bonds.
All
of these
inv
e
s
t
men
t
s
are
subj
e
c
t
to
cr
e
dit,
li
quidity,
market
and
interest
r
a
te
ris
k
. Such
risks, in
c
luding
the
failure
or
severe
financial
distress
of
the
financial institutions
that
hold
our
cash,
cash
equiv
a
lents
and
investments,
may
result
in
a
loss
of
liquid
i
ty,
impairment
to
our
investments,
realization
of substantial future
losses,
or
a
complete
l
o
ss
of
the
investments
in the
long-term,
which
may
have
a material
adverse
effect
on
our
business,
results
of o
p
erations, liquidity
and
financi
a
l
condition.
In
order
to manage
t
h
e
risk
to
our investments,
we
maintain
an
investment
policy
that,
among
other
things,
limits
the amount
that
we
may
invest
in
any
one
issue
or
any
single
issuer
and
re
q
uires
us
to
only
i
n
v
e
st
in high
credit
quali
t
y
secur
i
ti
e
s
to
preserve
liqu
i
d
i
ty.
61
Table of Contents
R
i
s
k
s R
e
lated
to
O
u
r
Business a
n
d
I
n
d
u
st
r
y
We will be substantially dependent on the success of our product candidates and cannot guarantee that these product candidates will successfully complete development, receive regulatory approval or be successfully commercialized.
Other than our proprietary GMP-in-a-Box bioreactors for which we have received nominal revenue to date, we currently have no products approved for commercial sale or for which regulatory approval to market has been sought. We have invested a significant portion of our efforts and financial resources in the development of our main product candidates, Anktiva, aldoxorubicin and human adenovirus serotype 5 ("hAd5") vaccine candidates, some or all of which are used in combination with our natural killer cells. Our product candidates will require additional clinical and non-clinical development, regulatory approval, commercial manufacturing arrangements, establishment of a commercial organization, significant marketing efforts, and further investment before we can generate any revenues from product sales. We expect to invest heavily in these product candidates as well as in our other existing product candidates and in any future product candidates that we may develop. Our business and our ability to generate revenues in the future substantially depends on the successful development, regulatory approval and commercialization of such product candidates, each of which may never occur. Our product candidates will be susceptible to the risks of failure inherent at any stage of product development, including the appearance of unexpected adverse events or failure to achieve primary endpoints in clinical trials. Furthermore, we cannot assure you that we will meet our timelines for current or future clinical trials, which may be delayed or not completed for a number of reasons. Additionally, our ability to generate revenues from our combination therapy products will also depend on the availability of the other therapies with which our products are intended to be used. We currently generate no meaningful revenues from the sale of any product candidates, and we may never be able to develop or commercialize a product.
We
may
develop
product
can
d
idates
in
combination
with
other
therapies,
w
h
ich
exposes
us
to additional
risks.
We may develop product candidates in combination with one or more other therapies. We are studying Anktiva therapy along with other product candidates, such as aldoxorubicin and hAd5 product candidates. The development of product candidates for use in combination with another product may present challenges. The FDA may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. To the extent that we do not have rights to already approved products, this may require us to work with another company to satisfy such a requirement. It is possible that the results of these trials could show that any positive results are attributable to the already approved product. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. Following product approval, the FDA may require that products used in conjunction with each other be cross labeled for combined use. If the therapies we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially.
We
also
may
evaluate
product
candid
a
tes
in combination
with
one
or
more
the
r
a
p
ies
that
have
not
yet
been
approved
for
marketing
by
the FDA
or
comparable
foreign
regulatory
authorities.
We
will
not
be
able
to market
and
sell
any
product
candid
a
te
in c
o
mb
i
nat
i
on
with
an u
n
approved
therapy
if that
unapproved
therapy
does
not
ultimately
obtain
marketing
approval.
In
addition,
unapproved
therapies
f
ace
the
same
risks described
with
respect
to our
product
candidates
currently
in development
and
clinical
trials,
including
the
potential
for
serious
adverse
effects,
delays
in
c
l
ini
c
al
t
ria
l
s
and
la
c
k
o
f
FDA approval.
If
the
FDA
or comparable
foreign
regulatory
authorities
do
not
approve
or
revoke
t
h
eir
approval
of these other therapies,
or
if
safety,
efficacy,
quality,
manufacturing
or supply
issues
arise
with,
the
therapies
we
choo
s
e
to
evaluate
in combination
with
any of
our
product
candidates,
we
may
be
unable
to obtain
approval
of or
m
a
rket
such
comb
i
nat
i
on
t
herapy.
62
Table of Contents
Due to the significant resources required for the development of our product candidates, and depending on our ability to access capital, we must prioritize among many different opportunities.
W
e may expend our limited resources on programs that do not yield successful product candidates as opposed to indications that may be more profitable or for which there is a greater likelihood of success.
We do not have sufficient resources to pursue development of all or even a substantial portion of the potential opportunities that we believe will be afforded to us by our product candidates. Because we have limited resources and access to capital to fund our operations, our management must make significant prioritization decisions as to which product candidates and indications to pursue and how much of our resources to allocate to each. Our management must also evaluate the benefits of developing in-licensed or jointly owned technologies, which in some circumstances we may be contractually obligated to pursue, relative to developing other product candidates, indications or programs. Our management has broad discretion to suspend, scale down, or discontinue any or all of these development efforts, or to initiate new programs to treat other diseases. If we select and commit resources to opportunities that we are unable to successfully develop, or we forego more promising opportunities, our business, financial condition and results of operations will be adversely affected.
Our
c
l
inical
t
r
i
al
c
osts may
be
higher
t
h
an
for mo
r
e
co
n
v
e
n
tional
therapeutic
techno
l
ogies
or
drug
products.
Because our product candidates include, and we expect our future product candidates to include, candidates based on advanced therapy technologies, we expect that they will require extensive research and development and have substantial manufacturing costs. In addition, costs to treat patients and to treat potential side effects that may result from our product candidates can be significant. Some clinical trial sites may not bill, or obtain coverage from Medicare, Medicaid, or other third-party payors for some or all of these costs for patients enrolled in our clinical trials, and clinical trial sites outside of the United States may not reimburse for costs typically covered by third-party payors in the United States, and as a result we may be required by those trial sites to pay such costs. Accordingly, our clinical trial costs are likely to be significantly higher per patient than those of more conventional therapeutic technologies or drug products.
Our c
l
inical
t
r
i
als
may
fa
i
l
to d
e
mons
t
r
a
t
e
adequately
the
safety
and
e
fficacy
of
our
product
cand
i
dates,
which
would
prevent
o
r
d
e
lay
regulatory a
p
proval
and
com
m
ercia
l
ization.
The clinical trials of our product candidates as well as the manufacturing and marketing of our product candidates will be subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective. Because most of our product candidates will be subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. The risk/benefit profile required for product licensure will vary depending on these factors and may include not only the ability to show tumor shrinkage, but also adequate duration of response, a delay in the progression of the disease, and/or an improvement in survival. For example, response rates from the use of our product candidates may not be sufficient to obtain regulatory approval unless we can also show an adequate duration of response. Regulatory authorities may ultimately disagree with our chosen endpoints or may find that our studies or study results do not support product approval. Preclinical studies may reveal unfavorable product candidate characteristics, including safety concerns. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials.
There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.
63
Table of Contents
In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. Moreover, should there be a flaw in a clinical trial or cross-site variation that are not properly addressed, it may not become apparent until the clinical trial is well advanced or until data from different sites become available. For example, our current clinical trials are, and we expect our clinical trials to be, conducted at multiple sites in different geographies, with different levels of experience and expertise by medical professionals, and these professionals may make mistakes or introduce site-specific variation that could have an impact on clinical trials by disqualifying patients or impacting patient ability to continue in a study or on the clinical data. Further, because we currently plan to test our product candidates for use with other oncology products, the design, implementation and interpretation of the clinical trials necessary for marketing approval may be more complex than if we were developing our product candidates alone.
In addition, even if such trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.
We have reported preliminary results for clinical trials of our product candidates, including Anktiva. These preliminary results, which include assessments of efficacy, are subject to substantial risk of change due to small sample sizes and may change as patients are evaluated or as additional patients are enrolled in these clinical trials. These outcomes may be unfavorable, deviate from our earlier reports, and/or delay or prevent regulatory approval or commercialization of our product candidates, including candidates for which we have reported preliminary efficacy results.
Further, certain of our hypotheses regarding the potential benefits of our product candidates compared to alternative therapies and treatments are based on cross-trial comparisons of results that were not derived from head-to-head clinical trials. Such clinical trial data may not be directly comparable due to differences in study protocols, conditions and patient populations. Accordingly, these cross-trial comparisons may not be reliable predictors of the relative efficacy or other benefits of our product candidates compared to other product candidates that may have been approved previously.
We do not have data on possible harmful long-term effects of our product candidates and do not expect to have this data in the near future. As a result, our ability to generate clinical safety and effectiveness data sufficient to support submission of a marketing application or commercialization of our product candidates is uncertain and is subject to significant risk.
Int
e
r
i
m,
ini
t
ial,
"top-
l
in
e
"
and
preliminary
data
from our
c
lini
c
al
trials
that
we
ann
oun
ce
or p
u
blish
from
ti
m
e
to
t
ime
m
ay
c
h
ange
as
more
patient d
a
ta become
available
and
are
sub
j
ect
to audit
and
verification
p
r
ocedures
that
could
result
in
mat
e
r
i
al
ch
anges
in the
final
d
ata.
From time to time, we may publicly disclose preliminary, interim or top-line data from our preclinical studies and clinical trials, which are based on preliminary analyses of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. We also may make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.
In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.
64
Table of Contents
We
h
ave
l
i
mi
t
e
d
experi
e
n
c
e
co
n
du
c
t
i
ng
cl
i
nical
trials
and
have
relied
and
will
rely
on
third
parties
and
related
parties
to co
n
duct
many
of
our pr
e
c
l
i
n
i
cal
stud
i
e
s
and
c
l
i
n
i
c
al
trials
and to manufacture products
.
Any
failure
by
a third
part
y
,
r
e
l
a
t
e
d
part
y
,
or by
us to
c
onduct
t
h
e
c
lini
c
al
t
r
i
als
a
ccording
to
GCP regulations,
and
in a
timely
manner
,
may
delay
or prevent
our
ab
i
lity
to
seek
o
r
obtain
regulatory
approval
for
or
commercialization of
our
product
candidates.
Large-scale clinical trials require significant financial and management resources. We expect to be heavily reliant on third and related parties, including medical institutions, academic institutions, clinical investigators or CROs to conduct, supervise or monitor some or all aspects of our clinical trials, and in some cases, CMOs to manufacture products. We have entered into agreements with the Clinic, a related party, to continue to conduct and oversee certain of our clinical trials. Our CROs, the Clinic and other third parties must communicate and coordinate with one another in order for our trials to be successful. We have a limited history of conducting clinical trials and have no experience as a company in filing and supporting the applications necessary to gain marketing approvals. Our relative lack of experience conducting clinical trials may contribute to our planned clinical trials not beginning or completing on time, if at all. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities and clinical trial sites by, applicable regulatory authorities.
Relying on third-party clinical investigators, CROs or CMOs may force us to encounter delays and challenges that are outside of our control. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable trial protocol and legal, regulatory and scientific standards, and our reliance on CROs, clinical trial sites, and other third parties does not relieve us of these responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial and for ensuring that our preclinical studies are conducted in accordance with Good Laboratory Practice ("GLP") regulations, as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us and the third parties upon which we intend to rely for conducting our clinical trials to comply with GCP for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic inspections (including pre-approval inspections once a Biologics License Application ("BLA") or New Drug Application ("NDA") is filed with the FDA) of trial sponsors, clinical investigators, trial sites and certain third parties including CMOs. If we, our CROs, clinical trial sites, or other third parties fail to comply with applicable GCP or other regulatory requirements, we or they may be subject to enforcement or other legal actions, the clinical data generated in our clinical trials may be deemed unreliable and have to be repeated, and our submission of marketing applications may be delayed or the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations.
Our clinical trials will need to be conducted with product candidates and materials that were produced under current Good Manufacturing Practices ("cGMP") and/or Good Tissue Practice regulations, which are enforced by regulatory authorities. Our failure to comply or our CMOs' failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We may not be able to demonstrate sufficient comparability between products manufactured at different facilities to allow for inclusion of the clinical results from patients treated with products from these different facilities, in our product registrations. We also are required to register certain clinical trials and post the results of certain completed clinical trials on a government sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so could result in enforcement actions and adverse publicity.
We rely on third parties to manufacture, package, label and ship some of our product candidates for the clinical trials that we conduct. Any performance failure on the part of these third parties could delay clinical development or marketing approval of our product candidates or commercialization of our product candidates, if approved, producing additional losses and depriving us of potential product revenues.
65
Table of Contents
Our CROs,
the
Clinic,
clinical trial sites and other third parties may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting clinical trials or other therapeutic development activities that could harm our competitive position. In addition, these third parties are not our employees, and except for remedies available to us under our agreements with them, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and preclinical programs. If these third parties
conducting our clinical trials
(i)
do not successfully carry out their contractual duties,
(ii)
do not
meet expected deadlines
, (iii)
experience work stoppages, (iv)
do not
conduct our clinical trials in accordance with regulatory requirements or our stated protocols,
(v)
need to be replaced
, (vi) experience financial hardships
or (vi)
terminate their agreements with us
or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our
clinical
trial protocols,
GCP or other
regulatory requirements or for other reasons, our trials may need to be repeated, extended, delayed or terminated, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates, we will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates or we or they may be subject to regulatory enforcement actions.
Additionally,
we may need to conduct additional clinical trials or enter into new arrangements with alternative CROs, clinical investigators or other third parties. We may be unable to enter into arrangements with alternative CROs on commercially reasonable terms, or at all.
Switching or adding additional contractors involves additional cost and time and requires management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays could occur, which could compromise our ability to meet our desired development timelines.
Furthermore, if any of the third parties conducting our clinical trials experience any financial hardships due to difficulties relating to the operation of their business, if could damage our business, financial condition, results of operations and prospects.
In addition, if an agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay
the
continued development of our product candidates utilizing the collaborator's technology or intellectual property or require us to stop development of those product candidates completely.
As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. To the extent we are unable to successfully identify and manage the performance of third-party service providers in the future, our business may be materially and adversely affected.
Our reliance on third and related parties can also present intellectual property-related risks. For example, collaborators may not properly obtain, maintain, enforce or defend intellectual property or proprietary rights relating to our product candidates or technology or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property-related proceedings, including proceedings challenging the scope, ownership, validity and enforceability of our intellectual property. Collaborators may also own or co-own intellectual property covering our product candidates or technology that results from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates or technology. Collaborators may also gain access to our trade secrets or formulations and impact our ability to commercialize proprietary technology. We may also need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us.
We also anticipate that part of our strategy for pursuing the wide range of indications potentially addressed by Anktiva will involve further investigator-initiated clinical trials. While these trials generally provide us with valuable clinical data that can inform our future development strategy, we generally have less control over not only the conduct but also the design of these clinical trials. Third-party investigators may design clinical trials involving our product candidates with clinical endpoints that are more difficult to achieve or in other ways that increase the risk of negative clinical trial results compared to clinical trials we may design on our own. Negative results from investigator-initiated clinical trials, regardless of how the clinical trial was designed or conducted, could have a material adverse effect on our business and the perception of our product candidates.
Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services.
66
Table of Contents
Our c
l
inical
t
r
i
als
may
not
be
init
i
ated
or
c
ompl
e
t
e
d
w
h
en we
e
xpect,
or at all, they may take longer and cost more to complete than we project
and
we
may
be
required
to
conduct
addit
i
onal
c
lini
c
al
t
r
i
als
or modify
current or
future
clinical
trials
based
on
feedback
we
receive
from
the
FDA.
We cannot guarantee that any current or future clinical trials will be conducted as planned or completed on schedule, if at all, or that any of our product candidates will receive regulatory approval. A failure of one or more clinical trials can occur at any stage of the clinical trial process, other events may cause us to temporarily or permanently stop a clinical trial, and our future clinical trials may not be successful. We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to:
•
regulators
or
Institutional
Review
Boards
("IRBs") may
(i)
not
authorize
us
or
our inv
e
s
t
iga
t
ors
to
com
m
ence
a
c
lin
i
c
a
l
t
ri
a
l,
co
n
duct
a
c
lin
i
c
a
l
t
ri
a
l
a
t
a
prosp
e
ct
i
ve
tri
a
l
s
i
te,
or a
m
end
t
ri
a
l
pro
t
oco
l
s,
or
(ii)
r
e
quire
that
we
modify
or
amend
our
c
l
ini
c
al trial
protocols;
•
delays
in reaching, or a failure to reach,
a consensus
with
regulatory
authorities
on
t
rial
design or e
l
igib
i
li
t
y
c
r
it
e
ria
for
p
a
t
i
ent
enro
l
lm
e
nt;
•
t
he
FDA
or
comparable
foreign
regulatory
authorities
may
(i)
disagree
with
our
intended
indications, or
o
ur
interpre
t
ation
of
data from
preclinical
studies
and
clinical
trials, (ii) find
that
a product
candidate's
benefits do not outweigh
its
safety
risks, (iii) not
a
cc
e
pt
data
from
t
r
ia
l
s
w
i
th
cl
i
nic
a
l
tri
a
l
s
i
tes
in for
e
ign
cou
n
tr
i
e
s, (iv) fail to approve or subsequently find fault with the manufacturing processes or our manufacturing facilities for clinical and future commercial supplies or (v) take longer than we anticipate when making a decision on our product candidates;
•
t
he
FDA may
not
allow
us
to use
the
cli
n
ical
trial
data
from
a
research
institution
to support
an
investigational
new
drug ("IN
D
")
application
if
we cannot
demonstrate
the
comparability
of
our
product
candidates
with
the
product
candidate
used
by
the relevant
research
instit
u
tion
in its
c
lin
i
c
a
l
t
ri
a
ls;
•
d
e
lays
in or fa
i
lure
to
re
a
c
h
an
agre
e
m
e
nt
on a
c
c
e
ptab
l
e
ter
m
s
w
i
th
prosp
e
ct
i
ve
CROs and
c
l
i
nic
a
l
tri
a
l
s
i
tes,
the
t
e
rms of which
can
be subject
to
extensive
negotiation
and
may
vary
significantly
among
different
CROs and
c
linical
trial
sites;
•
i
mposition
of
a
temporary
or
permanent
clinical
hold, such as the clinical hold on the Phase II/III clinical trial for our hAd5 COVID-19 vaccine candidate pending modifications to the protocol and FDA's review of additional information, including of immunogenicity and safety data from the Phase I portion of the study;
•
delays
in adding
new
investigators
or c
l
ini
c
al
tr
i
a
l
s
i
t
e
s,
or w
i
thdr
a
w
a
l
of
c
l
ini
c
al
tr
i
a
l
sit
e
s
from
a
tr
i
a
l, including scheduling conflicts with participating clinicians and clinical institutions;
•
difficulties in identifying and enrolling patients who meet trial eligibility criteria and who remain in the study until its conclusion;
•
f
a
ilure
by our
CROs, cl
i
ni
c
al
tr
i
a
l
s
i
t
e
s
or
patients,
or
other
third
parties,
or
us
t
o
a
dhere
to
c
l
ini
c
al
tr
i
a
l
requ
i
re
m
e
nts,
including
regulatory, contractual
or
pro
t
ocol
requirements;
•
failure
to perform
in accordance
with
the
GCP
requiremen
t
s,
or
applicable
regulatory
guidelines
in
other
countries;
•
occurrence
of
adverse
events
associated
with
the
product
can
d
idate
that
a
r
e
viewed
to
outweigh
its
potential
benefits;
•
c
hanges
in
regulatory
requireme
n
t
s
and
guid
a
nce
that
r
e
quire
amending
or
submitting
n
e
w
clinical
protocols
to regulatory
auth
o
ri
t
ies
and IRBs,
and
which
may
cause
delays
in
our
development
programs,
or
chan
g
e
s
to
regulatory
review
times;
•
t
here
may
be
regulatory
qu
e
stions
or
disagreements
regarding
interpretations
of
data
and
resul
t
s,
or
new
information
may
emerge regarding
our
p
r
o
duct
candidates;
•
c
hanges
in
the
standard
of
care
on
which
a
clinical
development
plan
was
based,
which
may
require
new
or
additional
trials;
•
the availability of financial resources to commence and complete the planned trials
;
•
ambiguous or negative interim results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials, or preclinical studies, or abandon product development programs;
•
obtaining sufficient supply of therapies that may be used in combination with our molecular agents or as comparative agents in clinical trials or i
nterruption
of,
or
delays
in
receiving,
supplies
of
our
product
candidates
or
other
drugs
or components
of
our
therapies
due
to
staffing shortages,
production
slowdowns or
stoppages
and
disruptions
in
delivery
systems;
67
Table of Contents
•
e
arly
results
from
our
clinical
trials
of
our
product
candidates
may
be
negatively
affected
by
changes
in
e
fficacy
measures
such
as
overall response
rate
and
duration
of
re
s
ponse
as
more
patients
are
enrolled
in our
clinical
trials
or
as new
cohorts
of
our
clinical
t
ria
l
s
are
t
e
sted, and
overall
response
rate
and
duration
of
response
may
be
negat
i
vely
a
f
fected
by
the
inclusion
of
unconfirmed
res
p
onses
in
pre
l
iminary results
that
we
report
if
such
r
e
sponses are
not
later
confirmed;
•
we
may
not
be
able
to demonst
r
ate
that
a product
candidate
provides
an
a
d
vantage
over
current
standards
of
care
or
current
or
future competitive
therapies
in
developme
n
t;
•
t
here
may
be
changes
to the
therapeutics
or
their
regulatory
s
t
atus
which
we
are
administering
in
combination
with
our
product
candidates;
•
transfer
of
our
manufacturing
processes
to
our
CMOs
or
other
larger-scale facilities
operated
by
a
CMO
or
by
us
and
delays
or
failure
by our
CMOs
or
us
to
commence,
make
any
necessary
changes
to
or complete such
manufacturing
process;
•
our
use
of
different
manufactur
i
ng
processes
within
our
clinical
tri
a
l
s
,
and
any
eff
e
cts
that
may
result
from
the
use
of
diff
e
rent
processes on the
c
l
ini
c
al
d
a
ta
th
a
t
we have
r
e
ported
and
will
report
in the
future;
•
delays
in manufacturing,
testing,
releasing,
validatin
g
,
or
importing/exporting
sufficient
sta
b
le
quantities
of
our
product
c
a
ndidates
for
use in
clini
ca
l
tri
a
ls
or the
in
a
bili
t
y
to
do any
of
the
foregoing,
including
as
a result
of any
qua
l
ity
issu
e
s associ
a
t
e
d
wi
t
h
the
contract manufacturer; and
•
delays
and
additional
costs
associated
with
business
disruption
s
,
new
regulatory
requirements,
social
distancing
and
other
re
s
tri
c
tions imposed
b
y
governmental
or
regulatory
agenc
i
es
and
clinical
trial
sites
due
to the
C
OVID
‑
19
pandemic,
which
may
include
enroll
m
ent d
e
lays
or
f
a
ilur
e
s
to
follow
tri
a
l
protoco
l
s.
Collaborations
with other entities
may
be
subject
to additional
delays
bec
a
use
of
the
management of the
trials,
contract
negotiations,
the
need
to obtain
agreement
from
multiple
par
t
ies
and
the
necessity
of
obtaining
additional
approvals
for ther
a
peut
i
cs
used in
the
co
m
bina
t
ion
tri
a
ls.
Th
e
se
c
o
m
bin
a
tion
ther
a
pi
e
s
w
i
ll
requ
i
re
additional
testing
and
clinical
trials
will
require
additional
FDA regulatory
approval
and
will
increase
our
future
costs.
Any inab
i
li
t
y
t
o suc
c
essfu
l
ly
c
omp
l
e
te
pr
e
c
l
i
ni
c
a
l
and
cl
i
ni
c
al
development
could
result
in
addit
i
onal
costs
to
us, slow down our product development and approval process
or
impair
o
u
r
ability
to
commence product sales and
generate revenues.
In
addition,
if we
m
a
ke
manufacturing
changes
to our
product
candidates,
we
m
a
y
be
required
to,
or
we
may
elect
to,
conduct
additional
trials to bridge
our
modified
product
candidates
to
earlier
versions.
These
changes
may
require
FDA
approval
or
no
t
ification
and
may
not have
their
desired effect.
The
FDA
may
also
not
acc
e
pt
data
from
prior
versions
of
the
product
to
support
an
application,
delaying
our
clinical
t
r
ials
or
programs
or nec
e
ssi
t
a
t
ing
a
ddit
i
onal
c
l
ini
c
al
tr
i
a
l
s
or
pr
e
c
l
i
ni
c
a
l
s
t
udi
e
s
.
We
may
find
that
this
change
has
unintended
con
s
equences
that
necessitates
additional development
and
manufacturing
work,
additional
clinical
and
precl
i
nical
studies,
or
that
results
in
refusal
to file
or
non-app
r
oval
of
a BLA
and/or
NDA.
Clinical
trial
delays
could
shorten
any
p
e
riods
during
which
our
product
candidates
have
patent
protecti
o
n
and
may
allow
our
c
o
mpetitors
to bring products to market
before
we
do,
which
c
ould
impair
our
ability
to
successfully
commercialize
our
product
candidates
and
may
h
a
rm
our
business and results
of
operati
o
ns. If we fail to commence or complete, or experience delays in, any of our planned clinical trials, our stock price and our ability to conduct our business as currently planned could be harmed.
We wi
l
l
be
u
n
able
to
co
m
merc
ia
lize
our
product
candidat
e
s
if
our trials
a
r
e
not
s
u
c
ce
ssf
u
l
.
Our research and development programs are each at an early stage and our current product candidates are in the early stages of development. We currently have ongoing clinical trials to evaluate our product candidates. We must demonstrate our product candidates' safety and efficacy in humans through extensive clinical testing. Success in early clinical trials does not ensure that large-scale clinical trials will be successful, nor does it predict final results. We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent commercialization of our product candidates, including but not limited to the following:
•
s
a
fety
a
nd
e
ffic
a
cy
re
s
ults
in various
human
clinical
trials
reported
in scientific
and
medic
a
l
literature
may
not
be
indicat
i
ve
of res
u
lts
we obtain
in
our
clinical
trials;
•
a
fter
re
v
i
ewing
test
res
u
lts,
we
or
our
collaborators
may
a
b
andon
projects
that
we
might
previously
have
believed
to be
promising;
•
we, our
collaborators
or
regulators
may
sus
p
e
nd
or
t
e
r
m
ina
t
e
cl
i
nic
a
l
tri
a
ls
i
f
t
he p
a
rticipating
subjects
or
patients
are
be
i
ng
exposed
to unacceptable
health
risks;
68
Table of Contents
•
t
he
standard
of
care
may
change
as
the
result
of
new
tech
n
ology
or
therapies
in
our
target
clinical
i
ndicatio
n
s,
precluding
r
e
gulatory approval
or
limited
commercial
use
if
approved;
•
t
he
effects
our
potential
products
have
may
not
be
the
desired
effects
or
may
include
undesirab
l
e
side
effects
or
other
chara
c
teristi
c
s
that precl
u
de
regulatory
approval
or
limit
their
commercial
use
if approved;
•
m
anufacturers
may
not
meet
the necessary
standa
r
ds
for
the
production
of
the
p
r
oduct
candidates
or
may
not
be
able
to supply
t
he
product candidates
in
a
sufficient
quantity;
and
•
regulatory
authorities
may
find
that
our
clinical
trial
design
or
conduct
does
not
meet
the
applicable
approval
requirements.
Clinical testing is very expensive, can take many years and the outcome is uncertain. It could take as much as 12 months or more before we learn the results from any clinical trial using Anktiva, aldoxorubicin, adenovirus and yeast technologies or other therapy. The data collected from our clinical trials may not be sufficient to support approval by the FDA of our Anktiva product candidate for the treatment of bladder cancer or of other therapies, including our hAd5 COVID‑19 vaccine candidate. Anktiva and many of our other product candidates have only been tested in a small number of patients. Results from these clinical trials may not necessarily be indicative of the safety and tolerability or efficacy of our product candidates as we expand into larger clinical trials. The clinical trials for our product candidates under development may not be completed on schedule and the FDA may not ultimately approve any of our product candidates for commercial sale. We may not ultimately be able to provide the FDA with substantial clinical evidence to support a claim of safety, purity and potency sufficient to enable the FDA to approve our product candidate for any indication. This may be because later clinical trials fail to reproduce favorable data obtained in earlier clinical trials, because the FDA disagrees with how we interpret the data from these clinical trials or because the FDA does not accept these therapeutic effects as valid endpoints in pivotal clinical trials necessary for market approval. If we fail to adequately demonstrate the safety and efficacy of any product candidate under development, we may not receive regulatory approval for those product candidates, which would prevent us from generating revenues or achieving profitability.
Even
if one of our
product
candidates
is
approved
and commercialized,
we
may
not
become
profitable.
If approved for marketing by applicable regulatory authorities, our ability to generate revenues from our product candidates will depend on our ability to:
•
price our product candidates competitively such that third-party and government reimbursement leads to broad product adoption;
•
prepare a broad network of clinical sites for administration of our product;
•
create market demand for our product candidates through our own marketing and sales activities, and any other arrangements to promote these product candidates that we may otherwise establish;
•
receive regulatory approval for the targeted patient population(s) and claims that are necessary or desirable for successful marketing;
•
manufacture product candidates through CMOs or in our own, or our affiliates', manufacturing facilities in sufficient quantities and at acceptable quality and manufacturing cost to meet commercial demand at launch and thereafter;
•
establish and maintain agreements with wholesalers, distributors, pharmacies, and group purchasing organizations on commercially reasonable terms;
•
obtain, maintain, protect and enforce patent and other intellectual property protection and regulatory exclusivity for our product candidates;
•
successfully commercialize any of our product candidates that receive regulatory approval;
•
maintain compliance with applicable laws, regulations, and guidance specific to commercialization including interactions with health care professionals, patient advocacy groups, and communication of health care economic information to payors and formularies;
•
achieve market acceptance of our product candidates by patients, the medical community, and third-party payors;
•
achieve appropriate reimbursement for our product candidates;
69
Table of Contents
•
maintain a distribution and logistics network capable of product storage within our specifications and regulatory guidelines, and further capable of timely product delivery to commercial clinical sites;
•
effectively compete with other therapies or competitors; and
•
following launch, assure that our product will be used as directed and that additional unexpected safety risks will not arise.
Even if the FDA approves Anktiva for certain indications, and even if we obtain significant market share for it, because the potential target population may be small, we may never achieve profitability without obtaining regulatory approval for additional indications. The FDA often approves new therapies initially only for use in patients with relapsed or refractory metastatic disease, which may limit our patient population.
Additionally, we may not be able to obtain the labeling claims necessary or desirable for the promotion of our product candidates.
Additionally,
in connection
with
the
merger
with
ImmunityBio,
we
assum
e
d
the
obligation
to
issue
CVRs
to
the
former
stockholde
r
s
of
Al
t
or BioScience
Corporation
(succeeded
by
Altor
B
i
oScience LLC) ("Altor")
in
connection
with
the
acquisit
i
on
of
Altor.
These
CVRs
b
e
come
payable
u
p
on the
attainment
of certa
i
n
regulatory
and
sales
milestones
related
to Anktiva.
The
former
Altor
stockholders
have
t
h
e
ability
to
choose
to receive
these payments
either
in cas
h
,
in an
equivalent
value
of
our
common
stock
or
in a combination
of
both
cash
and
stock
at t
h
e
time
such
payments
are
due, except
that
Dr.
S
o
on-Shiong
and
his
related
party,
as
prior
stockholders
of
Altor,
have
irrevocably
elected
to
receive
all
pay
m
ents
in
re
s
pe
c
t
of th
e
ir CVRs
in the
form
of
our
common
stock.
Such
CVR
payments
to
Dr.
Soon-Shiong
and
his
related
party
aggregate
to approximately $279.5 million.
We
may,
however,
still
be
requi
r
e
d
to pay
the
other
prior
Altor
stockholders
up
to
$164.2 million
for
the
CVRs
r
e
lating
to
the
regulatory milestone
and
up
to $164.2 million for
the
CVRs relating
to
the
sales
milestone
should
they
cho
o
se
to
have
the
s
e
CVRs
paid
in
c
ash instead
of
common stock.
If
this
were
to occur,
we
may
need
to seek
additional
sources
of
capital,
and
we
may
not
be
able
to a
c
hieve
profitability
or p
o
sitive
cash
flow.
We
plan
to
collaborate
with
governmen
t
al,
academic
and
corporate
pa
r
tners,
including
affili
a
tes,
to
improve
and
develop
Anktiva, hAd5
and
other
therapies
for
new
indications
for
use
in combinat
i
on
with
other
therapies
and
to
imp
r
o
v
e
and
develop
other prod
u
ct
candidates,
which
may
e
xpose
us
to
additional
risks,
or
we may
not
realize
the
benefits
of
such
collaborations.
We use the Clinic, a related party, in some of our clinical trials which may expose us to significant regulatory risks. If our data for this site is not sufficiently robust or if there are any data integrity issues, we may be required to repeat such studies or required to contract with other clinical trial sites, and our clinical development plans will be significantly delayed, and we will incur additional costs.
The Clinic has conducted, is currently conducting, and in the future may conduct, clinical trials involving our product candidates. The Clinic is a related party as it is owned by an officer of the company and additionally, NantWorks, LLC ("NantWorks") manages the administrative operations of the Clinic. Prior to June 30, 2019, one of the company's officers was an investigator or sub-investigator for certain of the company's trials conducted at the Clinic. NantWorks, which is wholly owned by our Executive Chairman, Dr. Soon‑Shiong, provides certain administrative services (and has loaned money) to the Clinic. Under certain circumstances, we may be required to report some of these relationships to the FDA. Relying on a related party clinical site to develop data that is used as the basis to support regulatory approval can expose us to significant regulatory risks. The FDA may conclude that a financial relationship between us, the Clinic and/or a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. If any data integrity, or regulatory non-compliance issues occur during the study, we may not be able to use the data for our regulatory approval. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of regulatory approval of one or more of our product candidates.
70
Table of Contents
If we encounter
delays or
difficulties enrolling
and/or maintaining
patients in our clinical trials, our clinical development activities and receipt of necessary marketing approvals could be delayed or otherwise adversely affected.
The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We may experience difficulties or delays in patient enrollment and retention in our clinical trials for a variety of reasons, including:
•
the size and nature of the patient population;
•
the severity of the disease under investigation;
•
the patient eligibility criteria defined in the protocol;
•
the proximity of patients to trial sites;
•
our ability to recruit clinical trial investigators with the appropriate competencies and experience;
•
the efforts to facilitate timely enrollment in clinical trials and the effectiveness of recruiting publicity;
•
the patient referral practices of physicians;
•
patients that enroll in our studies may misrepresent their eligibility or may otherwise not comply with the clinical trial protocol or clinical investigators may enroll patients who do not meet the enrollment criteria, resulting in the need to drop such patients from the study or clinical trial, increase the needed enrollment size for the study or clinical trial or extend the study's or clinical trial's duration;
•
clinicians' and patients' perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating;
•
amendments to our clinical protocols, including amendments we have made to further define the patient population to be studied;
•
ability to obtain and maintain patient consents;
•
the impact of the current COVID‑19 pandemic or other material adverse events, which may affect the conduct of a clinical trial, including by slowing potential enrollment or reducing the number of eligible patients for clinical trials; and
•
the risk that patients enrolled in clinical trials will not complete a clinical trial, return for post-treatment follow-up, or follow the required study procedures.
In addition, we expect that our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Because the number of qualified clinical investigators is limited, we may need to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer and/or viral disease treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and approved immunotherapies that have established safety and efficacy profiles, rather than enroll patients in any future clinical trial.
Even if we are able to enroll a sufficient number of patients in our clinical trials, delays in patient enrollment or small population size may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.
71
Table of Contents
Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.
Results of our trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. Combination immunotherapy that includes our current product candidates may be associated with more frequent adverse events or additional adverse events. Undesirable side effects or unacceptable toxicities caused by our product candidates could cause us, IRBs, Drug Safety Monitoring Boards, the FDA or comparable foreign regulatory authorities to interrupt, delay or halt clinical trials or order our clinical trials to be placed on clinical hold, and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities for any or all targeted indications. The FDA or comparable foreign regulatory authorities may also require additional data, clinical studies, or preclinical studies should unacceptable toxicities arise. We may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk/benefit perspective. Toxicities associated with our clinical trials and product candidates may also negatively impact our ability to conduct clinical trials using tumor-infiltrating lymphocyte therapy in larger patient populations, such as in patients that have not yet been treated with other therapies or have not yet progressed on other therapies. Even if we were to receive product approval, such approval could be contingent on inclusion of unfavorable information in our product labeling, such as limitations on the indicated uses for which the products may be marketed or distributed, a label with significant safety warnings, including boxed warnings, contraindications, and precautions, a label without statements necessary or desirable for successful commercialization, or requirements for costly post marketing testing and surveillance, or other requirements, including a Risk Evaluation and Mitigation Strategy ("REMS") to monitor the safety or efficacy of the products, and in turn prevent us from commercializing and generating revenues from the sale of our current or future product candidates. In addition, these serious adverse effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from our product candidates are not normally encountered in the general patient population and by medical personnel. Any of these occurrences may materially harm our business, financial condition and prospects.
The manufacture of our product candidates is complex, and we may encounter difficulties in production, particularly with respect to process development, quality control, or scaling-up of our manufacturing capabilities. If we or our related parties, or any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.
The manufacture of our product candidates involves complex processes, especially for our biologics, vectors and cell therapy product candidates, which are complex, highly regulated and subject to multiple risks. As a result of the complexities, the cost to manufacture biologics, vectors and cell therapies is generally higher than traditional small molecule chemical compounds, and the manufacturing process is less reliable and is more difficult to reproduce. The manufacture of cell therapy products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel and compliance with strictly enforced federal, state, local and foreign regulations. We may also find that the manufacture of our product candidates is more difficult than anticipated, resulting in an inability to produce a sufficient amount of our product candidates for our clinical trials or, if approved, commercial supply. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. Currently, our product candidates are manufactured using processes developed or modified by us, our affiliates or by our third-party research institution collaborators that we may not utilize for more advanced clinical trials or commercialization.
Currently we manufacture our product candidates or we may use third-party CMOs or some of our related parties to manufacture our product candidates. Our product candidates may compete with other products and product candidates for access to manufacturing facilities. Moreover, because of the complexity and novelty of our manufacturing process, there are only a limited number of manufacturers that operate under cGMP regulations and that are both capable of manufacturing our product candidates for us and willing to do so. If our CMOs should cease manufacturing for us, we would experience delays in obtaining sufficient quantities of our product candidates for clinical trials and, if approved, commercial supply. Further, our CMOs may breach, terminate, or not renew our agreements with them. If we were to need to find alternative manufacturing facilities it may take us significant time to find a replacement, if we are able to find a replacement at all and it would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. The commercial terms of any new arrangement could be less favorable than our existing arrangements and the expenses relating to the transfer of necessary technology and processes could be significant.
72
Table of Contents
Reliance on third-party manufacturers entails exposure to risks to which we would not be subject if we manufactured the product candidate ourselves, including:
•
inability to negotiate manufacturing and quality agreements with third parties under commercially reasonable terms;
•
reduced day-to-day control over the manufacturing process for our product candidates as a result of using third-party manufacturers for all aspects of manufacturing activities;
•
reduced control over the protection of our trade secrets, know-how and other proprietary information from misappropriation or inadvertent disclosure or from being used in such a way as to expose us to potential litigation;
•
termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that may be costly or damaging to us or result in delays in the development or commercialization of our product candidates; and
•
disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier.
Moreover, any problems or delays we or our CMOs experience in preparing for commercial scale manufacturing of a product candidate may result in a delay in the FDA approval of the product candidate or may impair our ability to manufacture commercial quantities or such quantities at an acceptable cost, which could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates and could adversely affect our business. Furthermore, if we or our CMOs fail to deliver the required commercial quantities of our product candidates on a timely basis and at reasonable costs, we would likely be unable to meet demand for our products and we would lose potential revenues. We may ultimately be unable to reduce the cost of goods for our product candidates to levels that will allow for an attractive return on investment if and when those product candidates are commercialized.
In addition, the manufacturing process and facilities for any products that we may develop are subject to FDA and foreign regulatory authority approval processes, and we or our CMOs will need to meet all applicable FDA and foreign regulatory authority requirements, including cGMP, on an ongoing basis. The cGMP requirements include quality control, quality assurance and the maintenance of records and documentation. The FDA and other regulatory authorities enforce these requirements through facility inspections. Manufacturing facilities must submit to pre-approval inspections by the FDA that will be conducted after we submit our marketing applications, including our BLAs and NDAs, to the FDA. Manufacturers are also subject to continuing FDA and other regulatory authority inspections following marketing approval. Further, we and our third-party CMOs must supply all necessary chemistry, manufacturing and quality control documentation in support of a BLA or NDA on a timely basis. Our or our CMOs' manufacturing facilities may be unable to comply with our specifications, cGMP, and with other FDA, state, and foreign regulatory requirements, and there is no guarantee that we or our CMOs will be able to successfully pass all aspects of a pre-approval inspection by the FDA or other foreign regulatory authorities.
Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of product candidates that may not be detectable in final product testing. If microbial, viral, environmental or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination which could delay clinical trials and adversely harm our business. If we or our CMOs are unable to reliably produce products to specifications acceptable to the FDA or other regulatory authorities, or in accordance with the strict regulatory requirements, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Deviations from manufacturing requirements may further require remedial measures that may be costly and/or time-consuming for us or a third party to implement and may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.
As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenues.
73
Table of Contents
To the extent we use CMOs, we are ultimately responsible for the manufacture of our products, if approved, and product candidates. A failure to comply with these requirements may result in regulatory enforcement actions against our manufacturers or us, including fines and civil and criminal penalties, which could result in imprisonment, suspension or restrictions of production, injunctions, delay or denial of product approval or supplements to approved products, clinical holds or termination of clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the biologic, refusal to permit the import or export of the products, product seizure, detention, or recall, operating restrictions, suits under the federal civil False Claims
Act ("
FCA
"), co
rporate integrity agreements, consent decrees, or withdrawal of product approval.
Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have a material adverse effect on our business, financial condition, results of operations and growth prospects.
Cell-based therapies and biologics rely on the availability of reagents, specialized equipment and other specialty materials, which may not be available to us on acceptable terms or at all. For some of these reagents, equipment and materials, we rely or may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products, if approved.
Manufacturing our product candidates will require many reagents, which are substances used in our manufacturing processes to bring about chemical or biological reactions, and other specialty materials and equipment, some of which are manufactured or supplied by small companies with limited resources and experience to support commercial biologics production. For some of these reagents, equipment and materials used in the manufacture of our product candidates, we rely, and we may in the future rely, on sole source vendors or a limited number of vendors. Some of these suppliers may not have the capacity to support clinical trials and commercial products manufactured under cGMP by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. We also do not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key materials and equipment to support clinical or commercial manufacturing. An inability to continue to source product from any of these suppliers, which could be due to a number of issues, including regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business.
As we seek to develop and scale our manufacturing process, we expect that we will need to obtain rights to and supplies of certain materials and equipment to be used as part of that process. We may not be able to obtain rights to such materials on commercially reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect on our business. Even if we are able to alter our process so as to use other materials or equipment, such a change may lead to a delay in our clinical development and/or commercialization plans. If such a change occurs for a product candidate that is already in clinical testing, the change may require us to perform both ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials.
Our
efforts
to develop,
manufacture
a
n
d
market
COVID‑19
therapeutics
will
require
additional
personnel
who
w
i
ll
require training,
which
may cause
some
of
our
employees
to
reallocate
t
h
e
i
r
t
i
me
from other
duties
which
could
in turn
cause
delays
in clinical
supply
of
our
other
product candidates
or
trials.
We
have
been
planning
for
the
development
of
COVID
‑
19-related
p
r
oduct
candidates.
We
have
repurposed
some
of
our
personnel
overseeing
q
u
ality, clinical
operations
and
manufacturing
of
our
oncology
product
cand
i
dates
to
support
our
COVID
‑
19
e
fforts and
we
plan
to
hire
a
ddit
i
onal
s
t
aff
to support
the
COVID
‑
19
efforts,
which
will
increase
our
expenses.
If
our
personnel
fail
to
remain
focused
on
our
o
n
cology
or
oth
e
r
infectious
disease drug
candidates
or, if
the
services
of
employees
that
may
have
shifted
to the
COV
I
D
‑
19
efforts
are
not
adequately
covered
by
o
t
her
em
p
l
oyees,
or
if
new personnel
that
we
plan
to hire
to support
the
COVID
‑
19
effor
t
s
require
extensive
training,
our
current
oncology
ope
r
a
tions
may
be
adversely
impacted.
74
Table of Contents
Our
ability
to use
net
operating
losses
and
research
and
development
credits
to
offset
future
t
axable
income
may
be
subject
to
c
e
rtain
l
im
i
tat
i
ons
In
general,
under
Sections
382
and
383
of
the
Internal Revenue
Code
("Code"),
a
corporation
that
undergoes
an
"ow
n
ership
change"
is
subject
to limitatio
n
s
on its
a
bi
l
ity
to
utilize its
pre-change
net
operating
losses
or
tax
credits
("
NOLs")
or
cr
e
dits,
to
offset
future
t
a
xab
l
e
inco
m
e
or
t
a
xes.
For
th
e
s
e
pu
r
poses,
an
ownership
change generally
occurs
where
the
aggregate
stock
ownership
of
one
or
mo
r
e
s
t
ockholders
or
groups
of
stockho
l
ders
who
owns at least 5%
of
a corporation's stock
increases
its
ownership
by
mo
r
e
than
50 percentage
points
over
its
l
o
west
ownership
percentage
with
i
n
a
spe
c
ifi
e
d
t
e
sting
period.
We
have
not conducted
a complete
study
to assess
whether
a
change
of
control
has
occurred
or
whether
there
h
a
ve
been
multiple
chan
g
e
s
of
control
since
inception d
u
e
to the
significant
complexity
and
cost
associated
with
such
a
study.
If
we
have
e
xperienced
a
change
of control,
as
defined
by
Section 382,
at
any time since
inception
(inc
l
udi
n
g
as
a result
of
the
merger),
utilization
of
the
net
operating
loss carryforwards
or
research
and
development
tax
credit carryforwards
would
be
subject
to
an
a
nnual
limitation
under
Section 382. Any
limitation
may
r
e
sult
in
expiration
of
a portion
o
f
the
net
operating
loss carryforwards
or
research
and
development
tax
credit
carryforwards
before
utilization.
I
n
addition,
our
NOLs
or
credits
may
also
be
impaired
under
state law.
Acc
o
rdingly,
we
m
a
y
not
be
able
to utilize
a
material
portion
of
our
NOLs
or
credits.
Since
we
will
need
to
raise
s
ubstantial
ad
d
i
ti
o
nal
funding
to finance
our
operations,
we
may
e
xperience
further
ownership
chan
g
e
s
in
the
futur
e
,
some
of which
may
be
outside
of
our
contr
o
l.
L
i
mi
t
s
on
our abi
l
ity
to
use our
pre-change
NOLs
or
credits
to offset
U.S. federal
taxable
income
could
potentially result
in
increased
future
tax
liability
to
us
if we
earn
net
taxable
income
in
t
h
e
future.
In
addition,
under
the
legislation
commonly
referred
to
as
the
Tax Cuts
and
Jobs
Act
of
2017 ("TCJA"),
as
modified
by
the
Co
r
o
n
a
virus Aid,
Relief,
and
E
c
onomic
Security
Act
("
CARES
Act"),
t
h
e
amount
of
NOLs generated
in
taxable
periods
beginning
after
December 31, 2017,
that
we
are
permitted
to
deduct
in
any
taxable
year
beginning
after
December 31, 2020 is
limited
to 80% of
our
taxable
income
in such
year,
where
t
a
xable
income
is
determined
wi
t
hout
regard
to
the
NOL
deduction
it
s
e
lf.
The
TCJA
a
llo
w
s p
o
st-2017
unused
NOLs
to
be
car
r
ied
forward
indefi
n
itely.
Similar
rul
e
s
may
apply
under
state
tax
laws.
Changes
in
tax
law
could
adv
e
r
s
e
ly
affe
c
t
o
u
r
b
u
sin
e
ss
and financial
co
n
dition. Negative or unexpected tax consequences could adversely affect our results of operations.
New tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our domestic and international business operations, and our business and financial performance. The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us and our stockholders. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, the TCJA significantly reformed the Code. We have generally accounted for such changes in accordance with our understanding of the TCJA and guidance available as of the date of this filing as described in more detail in our condensed consolidated financial statements. Additionally, on March 27, 2020, the CARES Act was enacted, which, among other things, suspends the 80% limitation on the deduction for net operating losses in taxable years beginning before January 1, 2021, permits a 5-year carryback of net operating losses arising in taxable years beginning after December 31, 2017 and before January 1, 2021, and generally caps the limitation on the deduction for net interest expense at 50% of adjusted taxable income for taxable years beginning in 2019 and 2020. It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof. In addition, adverse changes in the financial outlook of our operations or further changes in tax laws or regulations could lead to changes in our valuation allowances against deferred tax assets on our consolidated balance sheets, which could materially affect our results of operations.
Our
transfer
pricing
poli
c
ies
may
be
subject
to
challenge
by
the
IRS or other
taxing
a
u
thorities.
Our
intercompany
relationships
are
subject
to complex
trans
f
er
pricing
regulations
administered
by
taxing
authorities
in vario
u
s
juri
s
di
c
tions.
The relevant taxing
authorities
may
disa
g
r
ee
with
our
deter
m
ina
t
ions
a
s
to
the
va
l
ue
of
a
s
se
t
s
sold
or
acquired
or
income
and
expe
n
ses
a
ttr
i
butab
l
e
to
sp
e
c
if
i
c jurisdictions.
If
such
a
disagreement
were
to
occur,
and
our
position
were
not
sustain
e
d,
we
could
b
e
required
to
pay
additional
taxes,
interest
and penalties,
which
could
result
in
one-time
tax
charges,
high
e
r
effective
tax
rates,
reduced
cash
flows,
and
lower
overall
profitability
of
our
operations.
We bel
i
eve
th
a
t
our
fin
a
nc
i
a
l
s
t
a
t
em
e
nts
r
e
fle
c
t
ad
e
quate
r
e
s
e
rves
to cover
such
a
contingency,
but
there
can
be
no
assurances
in that
regard.
75
Table of Contents
We
could be
subje
c
t
to
additional income tax liabilities and to
examinations
of
our
tax
returns by
t
h
e
IRS
and
other
domestic
a
n
d
foreign
tax authorities.
An
adverse
out
c
ome
of
any
such
audit
or
examination
by
the
IRS
or other
tax
authority
cou
l
d
have
a
material
adver
s
e
eff
e
ct
on o
u
r op
e
rating
results and finan
c
ial
condit
i
on.
We are a U.S.-based company subject to tax in the U.S. and certain foreign tax jurisdictions. Significant judgment is required in determining our global provision for income taxes, deferred tax assets or liabilities, and in evaluating our tax positions on a worldwide basis. We
may
become
subject
to
regular
review
and
audit
by
the
IRS
a
nd
other
tax
authorities
in
various
domestic
and
foreign
jurisdi
c
tions.
As a
resul
t
,
we may in
the
future
r
e
ce
i
ve
ass
e
ssm
e
nts
i
n
m
u
l
t
i
ple
jurisdi
c
t
i
ons
on
various
tax-related
assert
i
ons.
Taxing
authorities
may
in
t
h
e
future
challenge
our
tax p
o
sitions
and
methodologies
on
var
i
ous
matters,
including
our
posit
i
ons
r
e
garding
the
collection
of
sales
and
use
taxes,
the
d
e
termination
and
payment
of
value
added
taxes
and
the
jurisdictions
in
which
we
are
subject
to
t
a
xes, which
could
e
xpose us
to additional
taxes.
We
regularly
assess
the
likelihood
of
adverse
outcomes
result
i
ng
from
future
tax
e
x
aminations
to
determine
the
a
d
equacy
of
our
provision
for
income
taxes.
These
assessments
can
require considerable
estimates
and judgments.
The
calculation
of
our tax
liabilities
involv
e
s
dealing
with
uncertainties
in
the
applic
a
tion
of
complex
tax
laws and
regulations
in a variety
of
jurisdictions.
While we believe our tax positions are consistent with the tax laws in the jurisdictions in which we conduct our business, there
can
be
no
assurance
that
our
tax
positions
and
m
e
thodologies
or
calculati
o
n
of
our
tax
liabilities
are accurate
or
that
the
outcomes
f
r
o
m
ongoing
and
future
tax
examinations
will
not
have
an
adverse
eff
e
ct
on
our
operati
n
g
results
and
financial
condition.
Our
projections
regarding
the
market
opportu
n
ities
for our product
candidates
may
not
be
accurate,
and the
actual
market
for
o
u
r
products, if a
p
proved,
may
be
small
e
r
t
h
a
n
w
e
e
s
t
ima
t
e
.
We
do
not
have
verifia
b
le
data regarding
the
potential
size
of
the
commercial
ma
r
kets
for
our
current
product
c
andidates
or
any
future prod
u
ct
candidates.
Since
our
c
u
rrent
product
candidates
and
any
future
product
candidates
will
represent
novel
approaches
to
t
reating
various conditions,
it
may
be
difficult,
in any
eve
n
t,
to accurately
estimate
the
potential
revenues
from
these
product
candidates.
Ac
c
ordingly,
we
may
spend sig
n
ificant
capital
trying
to
obtain
approval
for
product
candidates
that
have
an
uncertain
commercial
market.
Our
projections
of
addressable patient populations that may
benefit
from
treatme
n
t
with
our
product
cand
i
dates
are
based
on
our
beliefs
and
estimates. These
estimates
have
been
derived
from
a v
a
riety
of
sources,
including
scientific
lite
r
ature,
surve
y
s
of
clinics,
patient
foun
d
ations,
or
mar
k
et
r
e
s
e
ar
c
h
by third
parties,
and
may
prove
to
be
incorrec
t
.
Further,
new studies
or
a
pprovals
of
new
therapeutics
m
a
y
change
t
he
e
sti
m
at
e
d
in
cidence
or
prevalence
of these
diseases.
The
number
of
patients
may
turn
out
to be
lower
than
expected.
Add
i
tionally,
the
potentia
l
ly
addressable
patie
n
t
population
for
our prod
u
ct
candidates
may
be
limited
or
may
not
be
amenable
to treatment
with
our
p
r
o
d
uct
candidates
and
may
also
be
limited
by
t
h
e
cost
of
our tre
a
tm
e
nts
a
nd
t
he r
e
i
m
burs
e
ment
of those
tre
a
t
m
ent
costs
by thi
r
d-party
payors.
Even
if
we
obtain
significant
market
share
for
our product
candidat
e
s,
because
the
p
o
t
e
nt
i
a
l
t
a
rg
e
t p
o
pulations
may
be
s
m
all,
we
may
never
achie
v
e
profitability
without
obtaining
regulatory
approval
f
o
r
additional
indications.
Because
our
current
product
candidates
r
e
present,
and
o
u
r other
potential
product
candidates
w
i
ll
represent
novel
approaches
to
the
treat
m
ent
of dis
e
ase,
t
h
ere
are
many
un
certa
i
n
t
ies
r
e
gard
i
ng
t
h
e
dev
e
lop
m
e
n
t,
market
acceptance,
third-party
reimbursement
coverage
and t
h
e
co
m
merc
i
al p
o
tential
of
our
product
candidates.
Human
immunotherapy
products
are
a
new
category
of
therapeutics.
B
e
cause
this
is
a
relatively
new
and
expanding
area
of
novel
therapeutic int
e
rv
e
nt
i
on
s
,
th
e
re
a
re
m
a
ny
un
ce
rt
a
inti
e
s
r
e
l
a
ted
to de
v
e
lopment,
marke
t
ing,
reimbursement
and
the
co
m
me
r
ci
a
l
poten
t
ial
for
o
ur
product
candidates. There
can
be
no
assurance
as
to
the
length
of
the
trial
period,
the
number
of
patients
t
h
e
FDA will
requ
i
re
to
be
e
nrol
l
ed
i
n
t
he
tri
a
ls
i
n order
to
est
a
blish the
safety,
efficacy,
purity
and
potency
of
immunotherapy
p
r
o
ducts,
or
that
the
data
g
e
nerated
in these
trials
will
be
accepta
b
le
to
the
FDA
to support marketing
approval.
The
FDA
may
t
a
ke
longer
than
usual
to
come
to a decision
on
any
BLA
and/
o
r
NDA
that
we
submit
and
may
ultimately
det
e
rmine that
there
is not
en
o
ugh
data,
information,
or
exper
i
ence
with
our
product
candidates
to
support
an
approval
decision.
The
FDA
may
also
require
that
we conduct
additional
post-marketing
studies
or
implement
risk
management
programs,
such
as
REMS,
until
more
experience
with
our
p
roduct
candidates is obtained.
Finall
y
,
after
i
n
creased
usage,
we
may
find
that
our
product
candidates
do
not
have
the
i
n
tended
effect,
do
not
w
o
rk
with
other
combinati
o
n therapies
or
have
unanticipated
side
eff
e
c
t
s,
pot
e
nt
i
al
l
y
j
e
opard
i
z
ing
in
i
ti
a
l
or
continuing
regulatory
approval
and
commercial
prospects.
76
Table of Contents
There
is
no
assurance
that
the
approaches
offered
by
our
product
candidates
will
gain
broad
acceptance
among
docto
r
s
or
patients
or
that
governmental agencies
or
third-party
medical
insurers
will
be
willing
to provide
reimbursement
coverage
for
our
p
r
oposed
product
candidates.
The
ma
r
ket
for
any
prod
u
cts
that
we
successfully
develop
will
also
depend
on
the
cost
of
the
product.
We
d
o
not
yet
have
sufficient
information
to
r
e
l
i
ably
est
i
ma
t
e
wh
a
t it
will cost to
commercially
manu
f
acture
our
current
produ
c
t
candidates,
and
the
actual
cost
to
manufacture
these
products
could
materially
and
adversely
affect
the commercial
viability
of
the
s
e
products.
Our
goal
is to reduce
the
cost
of
manufacturing
and
providing
our
therapies.
However, u
n
less we
can
reduce
those
costs
to
an
acceptable
amount,
we
may
never
be
able
to
develop
a commercial
l
y
viable
product.
If we
do
not
succes
s
fully
develop
and commercialize
products
based
upon
our
approach
or
find
suit
a
ble
and
economical
sources
for
materials
used
in
the
production
of our
potential
products, we
will
not
become
profitable,
which
would
materially
and
adver
s
ely
affect
the
value
of
our
com
m
on
stock.
Our
Anktiva
therapies
and
our
o
t
her therapies
may
be
provided
to
pat
i
ents
in
combination
with
other
agents
provided
by
third
parties
or
our
affiliates.
The
cost
of such
co
m
bina
t
ion
t
her
a
py may
inc
r
ease
the
ov
e
rall
c
ost
of
therapy
and
may
result
in
issues
regarding
t
h
e
allocation
of
reimbursements
between
our
thera
p
y
and
the
other
agents, all
of
which
may
affect
our
ability
to
o
b
tain
reimbursement
coverage
for
the
combi
n
ation
therapy
from
governmental
or
private
t
hird-party
medical insu
r
e
rs.
If
product
liability
law
s
uits
are brought
against
u
s
,
we
may
incur
substanti
a
l liabilities
and may
be
r
e
quired
to
limit
commer
c
ialization
of
our product
candidates.
We
face
an
inherent
risk
of
product
liability
as
a result
of
the
clinical
development,
testing
and manufacturing
of
o
ur
product
candidates
and
will
face
an
e
v
en
gre
a
ter
risk
i
f we commercialize
any
products.
For
example,
we
may
be
sued
if
our
product
candidates
cause
or
are
perceived
to
cause
injury
or
are
found
to be
otherwise u
n
suitable
during
clinical
tes
t
i
n
g,
manufacturing,
marketing
or sale.
Any
such
product
liability
claims
may
include
allegations
of
defects
in manufacturing,
defects
in design,
a
failure
to
warn
of
dange
r
s
inherent
in
the
product,
negligence,
strict
lia
b
ility
or
a
brea
c
h
of
warranties.
Claims
could also
be
asse
r
ted
under
state
consumer
pro
t
ection
acts.
Large
judgements
have
b
een
awarded
in c
l
ass
action
lawsuits
based
o
n ther
a
peu
t
ics
that
h
a
d u
n
anticipated
side
effec
t
s.
If
we
cannot
successfu
l
ly
defend
ourselves
against
product
lia
b
ility
claims,
we
may
incur
substant
i
al
l
i
ab
i
li
t
ies
or
be
required to limit
commercia
l
ization
of
our
product
candidates.
Even
successful
defense
w
ould
require
significant
financial
and
management
resources.
Regardless of
the
merits
or
eventual
ou
t
com
e
,
li
a
bil
i
ty
cl
a
ims
may
result
in
a regulatory investigation of the safety and effectiveness of our products, our third-party manufacturer's manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, including limitations on the approved indications for which our product candidates may be used or suspension or withdrawal of approvals, decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management's time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price.
Our
inability
to obtain
sufficient
product
l
i
ability
insurance
at
an
acceptable
cost
to protect
again
s
t
potential
product
liab
i
lity
claims
could
prevent
or inhibit
the
commercialization
of
products
we
may
develop,
alone
or
with
corporate
c
o
llaborators.
Our
insurance
policies
may
also
have
various exclusions,
and
we
may
be
subject
to product
liability
claims
for
which
we
have
no
cove
r
a
ge.
While
we
have
obta
i
ned
clinical
t
rial
insurance
for
our cl
i
ni
c
al
tr
i
a
ls,
we may
have
to
pay
am
o
unts
awarded
by
a
court
or
negotiated
in a
set
t
l
e
ment
th
a
t
exceed
our
coverage
li
m
it
a
tions
or th
a
t
are
not covered
by
our
insurance,
and
we
may
not
have,
or
be
able
to
ob
t
ain,
sufficient
c
a
pital
to pay
such
amounts.
Even
if
our
agreem
e
nts
w
i
th
a
ny
future corporate
collaborators
entitle
us
to
indem
n
ifi
c
a
t
ion
a
ga
i
nst
losses, such
i
ndemn
i
fi
c
a
t
ion
may
not
be
a
v
ail
a
ble
or
adequate
should
any
claim
arise.
77
Table of Contents
We wi
l
l
face
signifi
c
ant
c
ompe
t
it
i
on
from
other
biotech
n
ology
and
pharmaceutical
companies
and
from
non-prof
i
t ins
t
itut
i
ons.
Competition in the field of cancer and viral infectious disease therapy is intense and is accentuated by the rapid pace of technological development. Based on the breadth and depth of our platforms, we believe our competitors include large pharmaceutical and biotechnology companies, and specialized pharmaceutical and biotechnology firms acting either independently or together with other such companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research in the U.S. and Europe are also potential competitors and may seek patent protection or may establish collaborative arrangements for competitive products or programs. These competitors have developed, may develop and are developing product candidates and processes competitive with our product candidates. Research and discoveries by others may result in breakthroughs which may render our product candidates obsolete even before they generate any revenues. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are developing product candidates. Many of our competitors have several therapeutic products that have already been developed, approved and successfully commercialized, or are in the process of obtaining regulatory approval for their therapeutic products in the United States and internationally. Many of our potential competitors have substantially greater research and development capabilities and scientific, regulatory, manufacturing, marketing, sales, financial, managerial, and human resources and experience than we do. Our competitors may be more successful than us in obtaining regulatory approval for their treatments and products, often more rapidly than we may obtain approval for ours, and achieving widespread market acceptance and a strong market position, rendering our treatments obsolete or non-competitive, possibly even before we are able to enter the market. Accelerated merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. Early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.
Our
competitors
may:
•
develop
safe
r
,
more
convenient
or more
effective
immunothe
r
a
pies
and
other
therapeutic
products;
•
develop
therapies
that
are
less
expensive
or
have
better
reimbursement
from
private
or
public
payors;
•
reach
the
market
more
rapid
l
y,
reducing
the
potential
sales
of
our
product
candidates;
or
•
e
stablish
superior
proprietary
positions.
Even if we obtain regulatory approval for our product candidates, the availability and price of our competitors' products could limit the demand and the price we are able to charge for our therapies. The level of generic competition and the availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products.
A large
number
of
compa
n
ies,
government
agenc
i
es
and
academic
centers
around
t
h
e
world
are
developing
COVID
‑
1
9
vaccines,
and many
of
t
hese
ent
i
ti
e
s
are
i
n more
advanced
stages
of
development
than
we
are,
including
some
that
have
started
P
hase II
and/or
III
clinical
trials
or have already
obtained
emergency
regulato
r
y
approval
in
the United States and internationally
.
Even
if our
COVID
‑
19
vaccine
candidate
is
ultimately
approved
for
m
arketing,
the
value of
our
op
p
o
r
tunity
will be
adversely
impacted
by
other
COVID
‑
19
vaccines
that have obtained emergency regulatory approval, obtain full regulatory approval,
or
demonstrate
better
efficacy
or
sa
f
e
ty
than
our COVID
‑
19 vaccine
candidate.
We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from other methods of treatment to our product, or if physicians switch to other new therapies, drugs or biologic products or choose to reserve our product candidates for use in limited circumstances. We may be adversely impacted if any of these competitors gain market share as a result of new technologies, commercialization strategies or otherwise.
78
Table of Contents
Pu
b
l
ic
opinion
and
s
c
rutiny
of
immunotherapy
app
r
oaches
may
impact
public
per
c
eption
of
us
and
our
product
candi
d
ates,
which
may ad
v
e
rsely
aff
e
ct
our abil
i
ty
to
condu
c
t
our
business
and
implement
our
business
plans.
We
use
r
e
latively
novel
technologies
in
v
olving
the
Anktiva,
a
ldoxorubicin,
hAd5
and
yeast
technologies
and
cell-based
therapies
and
o
ur
natural
killer cell
platform
utilizes
a
relatively
novel
technology
involv
i
ng
the
genetic
modification
of
human
cells
and
util
i
zation
of
those
modified
cells
in
other individuals.
Public
pe
r
ception
may
be
influ
e
nced
by
claims,
such
as
claims
that
our
technologies
are
unsafe,
unethical
or
immo
r
al
and,
consequently,
our approach
may
not
gain
the
acceptance
of
the
public
or
the
medical
community.
Negative
public
react
i
on
to
cell-based
immunotherapy
in
general
could result
in
greater
government
regulation
a
nd
stricter
labeling
requirem
e
nts
of
immunotherapy
products,
including
our
product
candidates,
and could
cause
a
decrease
in
t
h
e
demand
for
any products
we
may
develop. Adverse
public
attitudes
may
adversely
impact
our ability
to
enro
l
l
patients in
c
lin
i
c
a
l trials.
Moreover,
our
success
will
depend
upon
physicians
specializing
in
the
treatment
of
those
dis
e
ases
that
our
p
r
o
duct
can
d
ida
t
es
t
a
rget
pr
e
s
c
ribing, and
their
patients
being
willing
to
receive
treatments
that
involve
the
use
of
our
product
candidates
in
lieu
of,
or
in
addit
i
on
to,
ex
i
s
t
ing
tre
a
tm
e
nts
t
hey are
already
familiar
with
and
f
or
which
greater
clinical
data
may
be
available.
More
restrictive
gove
r
n
ment
reg
u
lations
or
negative
public
o
p
inion
could have
an
adverse
effect
on
our
business
or financial
condition
and
may
del
a
y
or
impair
the
de
v
e
lopme
n
t
and
commercialization
of
our
product
candidates or
demand
for
any
products
we
may
develop.
Adverse
events
in
our
clinical
trial
s
,
even
if
not
ultimately
attributable
to our
p
r
oduct
candidates,
and
the resulting
publicity
could
result
in
increas
e
d
governmental
regulation,
unfavorable
pub
l
ic
perception,
potential
regulatory
del
a
ys
in
the
testing
or approval
of
our
potential
product
candidates,
stricter
labeling
requirements
for
those
product
candidates
that
are
approved
and
a decrease
in demand
for any
such
product
candidates.
We may seek orphan drug status or Fast Track or Breakthrough Therapy designations or other designation for one or more of our product candidates, but even if any such designation or status is granted, it may not lead to faster development or a faster regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval and we may be unable to maintain any benefits associated with such designations or status, including market exclusivity.
In 2012, the FDA established a Breakthrough Therapy designation, which is intended to expedite the development and review of products that treat serious or life-threatening conditions. We have received, and may seek in the future, Fast Track or Breakthrough Therapy designation for current or future product candidates. Receipt of a designation to facilitate product candidate development is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for a designation, the FDA may disagree. In any event, the receipt of such a designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and does not assure ultimate marketing approval by the FDA. In addition, the FDA may later decide that the product candidates no longer meet the designation conditions.
Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition or for which there is no reasonable expectation that the cost of developing and making available the drug or biologic will be recovered from sales in the U.S. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA to market the same drug or biologic for the same indication for seven years, except in limited circumstances. We may seek orphan drug status for one or more of our product candidates, but exclusive marketing rights in the U.S. may be lost if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.
As
a condition
of
approval,
the
FDA m
a
y
re
q
u
ire
that
we
implement
var
i
ous
post-marketing
requirements
and
conduct
post-marketi
n
g
studies,
any of
which
would
require
a
substantial
investment
of
time,
effort,
and
money,
and
which
may
l
im
i
t
our
c
omm
e
rcial
prospects.
As a condition of biologic licensing, the FDA is authorized to require that sponsors of approved BLAs implement various post-market requirements, including REMS and Phase IV trials. For example, in connection with FDA approval of another company's drug, the FDA required significant post-marketing commitments, including a Phase IV trial, revalidation of a test method, and a substantial REMS program that included, among other requirements, the certification of hospitals and their associated clinics that dispensed the drug, including the implementation of a training program and limited distribution only to certified hospitals and their associated clinics. If we receive approval of our product candidates, the FDA may determine that similar or additional or more burdensome post-approval requirements are necessary to ensure that our product candidates are safe, pure and potent. To the extent that we are required to establish and implement any post-approval requirements, we will likely need to invest a significant amount of time, effort and money. Such post-approval requirements may also limit the commercial prospects of our product candidates.
79
Table of Contents
We have never commercialized a product candidate before, and we may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.
We may be unable to establish effective marketing and sales capabilities or enter into agreements with third parties or related parties to market and sell our product candidates, if they are approved, and as a result, we may be unable to generate product revenues.
We have little to no prior experience in, and currently do not have a commercial infrastructure for, the marketing, sale and distribution of biopharmaceutical products. To achieve commercial success for the product candidates, which we may license to others, we will rely on the assistance and guidance of those collaborators. For product candidates for which we retain commercialization rights and marketing approval, if approved, in order to commercialize our product candidates, we must build our marketing, sales and distribution capabilities, including a comprehensive healthcare compliance program, or arrange with third parties to perform these services, which will take time and require significant financial expenditures and could delay any product launch and we may not be successful in doing so. There are significant risks involved with building and managing a commercial infrastructure. We, or our collaborators, will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train, manage and retain medical affairs, marketing, sales and commercial support personnel. Recruiting, training and retaining a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have incurred these commercialization expenses prematurely or unnecessarily. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In the event we are unable to develop a commercial infrastructure, we may not be able to commercialize our current or future product candidates, which would limit our ability to generate product revenues. Even if we are able to effectively establish a sales force and develop a marketing and sales infrastructure, our sales force and marketing teams may not be successful in commercializing our current or future product candidates. To the extent we rely on third parties to commercialize any products for which we obtain regulatory approval, we would have less control over their sales efforts and could be held liable if they failed to comply with applicable legal or regulatory requirements.
Factors that may inhibit our efforts to commercialize our current or future product candidates and generate product revenues include:
•
if the COVID‑19 pandemic continues or reoccurs it may negatively impact our ability to establish commercial operations, educate and interact with healthcare professionals, and successfully launch our product on a timely basis;
•
the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe our current or future product candidates;
•
our inability to effectively oversee a geographically dispersed sales and marketing team;
•
the costs and time associated with the initial and ongoing training of sales and marketing personnel on legal and regulatory compliance matters and monitoring their actions;
•
an inability to secure adequate coverage and reimbursement by government and private health plans;
•
the clinical indications for which the products are approved and the claims that we may make for the products;
•
limitations or warnings, including distribution or use restrictions, contained in the products' approved labeling;
•
any distribution and use restrictions imposed by the FDA or to which we agree as part of a mandatory REMS or voluntary risk management plan;
•
liability for sales or marketing personnel who fail to comply with the applicable legal and regulatory requirements;
•
the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and
•
unforeseen costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales organization.
80
Table of Contents
We expect to rely on third parties to perform many essential services for any products that we commercialize, including services related to distribution, government price reporting, customer service, accounts receivable management, cash collection and adverse event reporting. If these third parties fail to perform as expected or to comply with legal and regulatory requirements, our ability to commercialize our current or future product candidates will be significantly impacted and we may be subject to regulatory sanctions.
We expect to retain third-party service providers to perform a variety of functions related to the sale of our current or future product candidates, key aspects of which will be out of our direct control. These service providers may provide key services related to distribution, customer service, accounts receivable management, and cash collection. If we retain a service provider, we would substantially rely on it as well as other third-party providers that perform services for us, including entrusting our inventories of products to their care and handling. If these third-party service providers fail to comply with applicable laws and regulations, fail to meet expected deadlines or otherwise do not carry out their contractual duties to us, or encounter physical or natural damage at their facilities, our ability to deliver product to meet commercial demand would be significantly impaired and we may be subject to regulatory enforcement action.
In addition, we may engage in the future with third parties to perform various other services for us relating to adverse event reporting, safety database management, fulfillment of requests for medical information regarding our product candidates and related services. If the quality or accuracy of the data maintained by these service providers is insufficient, or these third parties otherwise fail to comply with regulatory requirements related to adverse event reporting, we could be subject to regulatory sanctions.
Additionally, we may contract in the future with a third party to calculate and report pricing information mandated by various government programs. If a third party fails to timely report or adjust prices as required or errs in calculating government pricing information from transactional data in our financial records, it could impact our discount and rebate liability, and potentially subject us to regulatory sanctions or FCA lawsuits.
If
our product
candidates
do
not
achieve
b
r
oad
market
acceptance,
the
rev
e
nues
that
we
generate
from their
sales
will
be
limit
e
d.
We have not commercialized a product candidate for any indication. Even if our product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors and others in the medical community. If any product candidate for which we obtain regulatory approval does not gain an adequate level of market acceptance, we may not generate significant product revenues or become profitable. Market acceptance of our product candidates by the medical community, patients and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians are often reluctant to switch their patients, and patients may be reluctant to switch from, existing therapies even when new and potentially more effective or safer treatments enter the market. Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. Even if the medical community accepts that our product candidates are safe and effective for their approved indications, physicians and patients may not immediately be receptive to such product candidates and may be slow to adopt them as an accepted treatment of the approved indications. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market acceptance of any of our product candidates will depend on a number of factors, including:
•
the continued safety and efficacy of our product candidates;
•
the prevalence and severity of adverse events associated with such product candidates;
•
the clinical indications for which the products are approved and the approved claims that we may make for the products;
•
limitations or warnings contained in the product's FDA-approved labeling, including potential limitations or warnings for such products that may be more restrictive than other competitive products or distribution and use restrictions imposed by the FDA with respect to such product candidates or to which we agree as part of a mandatory REMS or voluntary risk management plan;
•
changes in the standard of care for the targeted indications for such product candidates;
•
the relative difficulty of administration of such product candidates;
•
our ability to offer such product candidates for sale at competitive prices, including the cost of treatment versus economic and clinical benefit in relation to alternative treatments or therapies;
•
the availability of adequate coverage or reimbursement by third parties, such as insurance companies and other healthcare payors, and by government healthcare programs, including Medicare and Medicaid;
81
Table of Contents
•
the extent and strength of our marketing and distribution of such product candidates;
•
the safety, efficacy and other potential advantages over, and availability of, alternative treatments already used or that may later be approved for any of our intended indications;
•
the timing of market introduction of such product candidates, as well as competitive products;
•
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
•
the extent and strength of our third-party manufacturer and supplier support;
•
adverse publicity about the product or favorable publicity about competitive products; and
•
potential product liability claims.
If any product candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects.
Our
product
candidates
may
face
c
o
mpetition
sooner
than
anticipated.
The
enactment
of
the
Biologics
Price
Competition
and
Innovation
A
c
t
of
2009
("BPCIA")
created
an
abbre
v
iated
p
a
thway
for
the
a
p
proval
of
biosimilar and
inte
r
c
hangeable
biological
products.
The
abbreviated
regulatory
pathway
establi
s
hes
legal
authority
for
the
FDA
to
review
and
approve
biosimilar biologics,
including
the
possible
d
e
signation
of
a
biosimilar
as
"in
t
erchangeable"
based
on
its
sim
i
lar
i
ty
to
a
n
e
xisting
brand
product.
Under
the
BPCIA, the
FDA cannot
make
an
approval
of
an
a
pplication
for
a biosimilar
product
effective
until
12 years
after
t
h
e
original
branded
product was approved under a BLA.
Certain
changes,
ho
w
ever,
and
supplements
to an
app
r
oved
BLA,
and
subsequent applications
fil
e
d
by
the
same
spons
o
r,
manufacturer, li
c
ensor,
pred
e
cessor
i
n in
t
e
r
e
st
or
other
related
entity
do
not
qualify
for
the
12-year
exclusivity
period.
Our
product
candidates
may
qualify
for
the
BPCIA's
12-year
period
of
exclusivity.
Howev
e
r,
the
r
e
is
a
risk
that
the
FDA
will
n
o
t consider
our
p
r
od
u
ct candidates
to
be
reference
products
for
competing
products,
p
o
ten
t
ially
creating
the
opport
u
nity
f
o
r bi
o
similar
competition
sooner
th
a
n
a
nti
c
ipa
t
ed. Additionally,
this
pe
r
iod
of
regulatory
exclusivity
does
not
b
l
ock
companies
pursu
i
ng
regulatory
approval
via
their
own
tradit
i
onal
BLA,
rather
than
via the
abbreviated
pathway.
Changes
may
also
b
e
made
to
this
exclusivity
period
as
a
result
of
future
legis
l
ation
as
there
have
b
e
en
ongoing
efforts
to reduce
the
period
of
exclusivity.
Even
if
we
receive
a period
of
BPCIA
exclusivity
for
our
first
licensed
product,
if
subse
q
ue
n
t
products
do
not
include
a modification
to the
structure
of
the
produ
c
t
that
impacts
safety,
purity,
or
potency,
we
may
not
receive
a
dditional
periods
of
exclusivity
for
those prod
u
cts.
Moreover,
the
extent
to which
a
biosimilar,
once
approv
e
d,
will
be
substituted
for
a
ny one
of
our
refere
n
c
e
product
candidates
in a way
that
is similar
to traditional
generic
substitution
for
non-biological
products
is not
y
e
t
clear,
and
will
dep
e
nd
on
a
number
of
marke
t
place
and
regulatory
factors that
are
still
developing.
Medicare
Part
B encourages
use
of
biosimilars
by
paying
the
provider
the
sa
m
e
perc
e
nt
a
ge
of
the
r
e
f
e
rence
product
average sale
price
as
a mark-up,
regardless
of
whi
c
h
product
is reimbursed.
It is
also
possible
that
payors
w
ill give
rei
m
bursement
pr
e
feren
c
e
to
biosim
i
lars
even o
v
er
reference
biologics
abs
e
nt
a
de
t
e
rm
i
na
t
ion
of
interchangeability.
For
our
small
molecular
product
candidates,
if
qualified,
the
regulatory exclusivity
period
is less
than
for
our
biologic
product
candidates. The
Federal Food,
Drug,
and
Cosmetic
Act
("FDCA") provides
a
five-year
period
of
non-patent
marketing
exclusivity
within
the
United
States
to
the
first
applicant to
gain
approval
of
an
NDA
for
a drug
where the
FDA
has
not
previously
approved
any
other
new
drug
containing
the
same
active
molecule
or
ion
respons
i
ble
for
the
action
of the
drug
substance.
During the
e
x
clusivity
period,
the
FDA
may
not
a
c
cept
for rev
i
ew
a
n abbr
e
vi
a
ted
new
drug
application
or
a 505(b)(2)
NDA submitted
by
another
company
for
a
generic
version
of
such
drug
where
the
applica
n
t
does
not
own
or
have
a legal
right
of
refe
re
n
c
e
to
a
ll
th
e
da
ta required
for
approval.
However,
an
application
may
be
submitted
after
four
years
if it
c
ontains
a certification
of
patent
inva
l
idity
or
non-infringement. The
FDCA
also
provides
three
years
of
mar
k
eting
exclu
s
ivity
for
an NDA, 505(b
)
(2)
N
D
A
or
supplement
to
an
exi
s
ting
NDA if
new c
l
in
i
c
al
investigations,
other
than
bioav
a
ilability
studies,
that
were
c
onducted
or
sponsored
by
the
appli
c
ant
a
r
e
deemed
b
y
the
FDA
to
be
e
ss
e
nti
a
l
to
t
he approval
of
the
applicatio
n
,
f
or
example,
n
e
w
indications,
dosages
or
strengths
of
an
existing
drug.
As su
c
h, we m
a
y
f
a
ce
c
omp
e
tition
from
gene
r
ic versions
of
our
small
molecule
product
c
a
ndidates,
which
will
negative
l
y
impact
our
long-term
busi
n
ess
prospects
and
marketing
opportunities.
82
Table of Contents
We
will
need
to obtain
FDA
approval
of
a
n
y proposed
branded
product
names,
and
any
f
a
ilure
or
delay
associated
with
such
approval
may
adversely affect
o
u
r
b
u
s
i
n
e
s
s
.
Any name
we
intend
to use
for
our
product
c
a
ndidates
in the
United
States
will
require
approval
from
the
FDA
regardless
of
whether
we
have
secured
a formal
t
r
ademark
registration
from
the
U.S.
Patent
and
Trademark
Office ("USPTO").
The
FDA
typically
conducts
a
review
of
prop
o
sed
product
names,
including
an
e
v
aluation
of
the
pote
n
tial
for
confusion
with
other
product
names.
The
FDA
may
also
object
to
a product
n
a
me
if
it beli
e
v
e
s
the
name
i
n
appropriately
implies
medical
claims
or
contributes
to an
overstatement
of
e
fficacy.
If
the
FDA
objects
to
any
of
our
proposed
product
names,
we
may
be
required
to
adopt
alternative
names
for
our
product
candidates.
If
we
adopt
alternative
names,
we
would
lose
the
benefit
of
any
existing
tradema
r
k
applications
for
such
product
cand
i
date
and
may
be
required
to
expend
significant
a
dditional
resources
in
an
effort
t
o iden
t
ify
a
sui
t
ab
l
e prod
u
ct
name
that
would
qualify
under
applicable
trademark
laws,
not
infringe
or
other
w
ise
violate
the
existing
ri
g
hts
of
third
parties,
and
be
ac
c
ep
t
a
ble to the
FDA.
We
may
be
unable
to
build
a
successful
brand
identity
for
a new
product
name
in
a timely
manner
or
at all,
which
w
o
uld
li
m
it
our
a
bil
i
ty
to commercialize
our product
candidates.
Our
i
n
te
r
n
al
c
omputer
s
y
s
t
ems,
or
those
used
by
our
CROs, C
M
Os,
c
li
n
i
c
al
s
i
t
e
s
or other
contractors
or
consultants,
m
a
y
fail
or suffer s
e
c
u
rity
b
r
ea
c
h
e
s.
We
will
be
dependent
upon
inform
a
tion
technology
systems,
infrastruc
t
ure
and
data.
In
the
ordinary
course
of
our
business,
we
will
directly
or
indirectly col
l
ec
t
,
s
t
ore
and
transm
i
t
s
e
ns
i
tive
d
a
ta,
including
intellectual
property,
confidential
i
nforma
t
ion,
pre
c
l
i
nic
a
l
and
c
l
i
nic
a
l
tri
a
l
dat
a
,
proprie
t
a
ry
bus
i
ness information,
personal
data
and
personally
identifiable
health
information
of
our cl
i
nic
a
l
tri
a
l
sub
j
ec
t
s
and
employees,
in our
data
centers
and
on
our networks,
or
on
those
of
third
parties.
T
h
e
secure
processing,
ma
i
nten
a
nce
a
nd tr
a
ns
m
iss
i
on
of this
inform
a
tion
is
c
rit
i
c
a
l
to
our
operations.
The multitude
a
n
d
complexity
of
our
computer
systems
and
those
of
our
CROs, CMOs, clinical
sites
or
other
con
t
ractors
or
consultan
t
s
make
them inherently
vulnerable
to service
interruption
or
destruction,
mal
i
cious
intrusion
and
r
a
ndom
attack.
Data
privacy
or
security
b
reaches
by
third
parties, employees,
contractors
or
others
may
pose
a risk
that
sensiti
v
e
data,
including
our
intellectual
property,
trade
secrets
or
personal
information
of
our employees,
patients,
or
other
business
partn
e
rs
may
be
exposed
to
unaut
h
o
r
ized
persons
or
to
the
public.
Despite
the
implement
a
tion
of
security measures,
our
internal
computer
systems
and
those
of
our CROs,
C
M
Os, c
l
ini
c
al
sit
e
s
and
oth
e
r
c
ontractors
and
consultants
are
vulnerable
to failure
or damage
from
computer
viruses
and
other
mal
w
are,
employee
error,
unauthorized
a
n
d
authori
z
ed
a
c
c
e
ss
or oth
e
r
cybe
r
s
ecurity
attacks,
natural
disasters, terrorism,
war,
fire
and
telecommunication
and
electrical
failures.
Cyberattacks
are
increasing
in
their
f
r
equency,
sophistica
t
ion
and
intensity.
The techniques
used
by
cyber
crimina
l
s
change
frequently,
may
not
be
recognized
until
launched
and
can
originate
from
a
wide
variety
of
sources,
including o
u
tside
groups
such
as
external
service
p
r
oviders,
organized
crime
aff
i
liates,
terrorist
organizations
or
ho
s
tile
foreign
gove
r
nments
or
a
gen
c
ie
s
. Cy
b
e
rattacks
could
include
the
deployment
of
h
a
rmful
m
a
lwar
e
,
deni
a
l-of-serv
i
ce,
soc
i
al
engineering
and
other
means
to
affect
s
ervice
reliability
and thre
a
ten
da
t
a
confid
e
nti
a
l
i
ty,
in
t
e
gri
t
y
a
nd av
a
i
l
a
bi
l
ity.
W
hile
we
and
our
shared
services
partner,
NantWorks,
have
invested,
and
continue
to
invest,
in the
protection
of
our
data
and
information
technolo
g
y
infrastruc
t
ure,
there
can
be
no
assurance
that
our
efforts,
or
the
e
f
forts of
our
partners, vendors,
CROs,
CMOs,
clinical
sites
and
other
c
o
ntractors
and
co
n
sultants
will
prevent
service
inte
r
ruptions,
or
identify
brea
c
hes
in
our
or
their systems,
that
could
adversely
a
ffect
our
business
and
operations
and/or
result
in
the
loss
of cr
i
ti
c
al
or
s
e
nsi
t
ive
infor
m
a
t
io
n
,
which
could
result
in financial,
legal,
business
or
reputational
harm
to us.
In
addit
i
on,
our
liability
insurance
may
not
be
suf
f
icient
in
type
or
a
m
ount
to
cover
us
against
claims rel
a
t
e
d
to
s
e
cur
i
ty
b
r
ea
c
hes,
cyb
e
r
a
ttacks
and
other
related
breaches.
If
a
n
y
such
event
were
to occur
and
cause
interruptions
in our
operations,
it could
r
e
sult
in
a dis
r
u
ption
of
our
product
develop
m
ent
progra
m
s.
F
or
e
xa
m
p
l
e, the
loss
of
clinical
trial
data
from
completed
or
ongoing
clinical
trials
for
a product
candidate
could
r
e
sult
in
delays
in
our
regulatory
approval
efforts and
significantly
increase
our
costs
to r
e
cover
or
r
e
produce
the
data,
or
may
limit
our
ability
to effec
t
ively
execute
a
product
recall,
if
required.
To
the extent
that
a
n
y
disruption
or
security
breach
were
to
result
in a
loss
of
or
damage
to our
data
or
applications,
or
inappropriate
disclosure
of
personal, confid
e
nti
a
l
or
propri
e
t
a
ry
i
nforma
t
ion,
we could
in
c
ur
l
i
abi
l
ity
and
the
further
development
and commercialization
of
any
p
r
od
u
ct
candidates
could
b
e
dela
y
e
d.
Any such
event could
also
result
in
legal
claims
or
proceedings,
liability
under
laws
that
p
r
otect
t
h
e
privacy
of
personal
information
and
si
g
nificant
regulatory
penalties, and
damage
to our
reputation
and
a
loss
of
confidence
in
us
and
our
ability
to conduct
clinical
trials.
83
Table of Contents
O
u
r
b
u
s
i
n
e
s
s
c
o
u
l
d
be adversely affected by
t
h
e
eff
e
c
t
s
of
h
e
a
l
th
ep
i
de
m
i
c
s,
pandemics
or contagious diseases, including the
r
e
cent
COVID
‑
19
pandemic
,
in regio
n
s
w
h
e
r
e
w
e
o
r
t
h
i
r
d
parties
on
which
we
r
e
ly
ha
v
e
signif
i
c
ant man
u
fa
c
tu
r
i
n
g
faci
l
it
i
es,
co
n
c
e
n
t
ra
t
ions
of
c
lini
c
al
t
r
i
al
s
i
t
e
s
or
other
business
operations
.
Outbreaks of epidemic, pandemic or contagious diseases, such as the COVID
‑
19 pandemic, may significantly disrupt our operations and adversely affect our business, financial condition and results of operations. In March 2020, the World Health Organization
declared the outbreak of COVID
‑
19 as a pandemic as the novel coronavirus continues to spread throughout the world. The spread of this pandemic has caused significant volatility and uncertainty in the U.S. and international markets and has resulted in increased risks to our operations. The
COVI
D
‑
19
pandemic and any actions we have taken in response,
could materially
affect
our
operations,
including
at
our
headquarters
and
at
our
manufacturing
facilities,
which have been and may in the future be subject to state executive orders and shelter-in-place orders, and at our clinical trial sites, as well as the business or operations of our CROs, CMOs, clinical sites or other third parties with whom we conduct business. Any such epidemic or pandemic may heighten the risk that a significant portion of our workforce could suffer illness or otherwise not be permitted or be unable to work, and may require that certain of our employees work remotely, which heightens certain risks, including those related to cybersecurity and internal controls.
We are monitoring
a number
of
risks
related
to this
pandemic,
includi
n
g
the
following:
•
Financial
: We anticipate that the pandemic could have an adverse financial impact in the short-term and potentially beyond. We expect to continue spending on research and development during the ye
a
r-ended December
31, 2021 and beyond, and we could also have unexpected expenses related to the pandemic. The short-term continued expenses, as well as the overall uncertainty and disruption caused by the pandemic, will likely cause a delay in our ability to commercialize a product and adversely impact our financial results.
•
Manufacturing
: The pandemic has impacted, and may continue to impact, our manufacturing locations, including through the effects of facility closures, reductions in operating hours and other social distancing efforts. For example, if even a small number of our employees in our working clusters related to manufacturing, analytical, process development, or translational research, tested positive for COVID‑19, it would require us to temporarily close a number of our offices or manufacturing facilities and temporarily suspend operations in order to conduct a deep clean of the facilities in order to ensure the safety of our employees. Additionally, we cannot predict whether these conditions and concerns will continue or whether we will experience more significant or frequent disruptions in the future, including the complete closure of one or more of our facilities.
•
Supply Chain
: An extended duration of this pandemic could result in significant disruptions in our respective supply chains and distribution channels in the future. For example, quarantines, shelter-in-place and similar government orders, travel restrictions and health impacts of the COVID
‑
19 pandemic, could impact the availability or productivity of personnel at third-party laboratory supply manufacturers, distributors, freight carriers and other necessary components of our supply chain. In addition, there may be unfavorable changes in the availability or cost of raw materials, intermediates and other materials necessary for production, which may result in disruptions in our supply chain and adversely affect our ability to have
manufactured certain product candidates for clinical supply.
•
Clinical Trials
: This pandemic may adversely affect certain of our clinical trials, including our ability to initiate and complete our clinical trials within the anticipated timelines. Due to site and participant availability during the pandemic, new subject enrollment is expected to slow,
a
t
l
e
ast in the short-term, for most of our clinical trials. For ongoing trials, we have seen an increasing number of clinical trial sites imposing restrictions on patient visits to limit risks of possible COVID
‑
19 exposure, and we may experience issues with participant compliance with clinical trial protocols as a result of quarantines, travel restrictions and interruptions to healthcare services. The current pressures on medical systems and the prioritization of healthcare resources toward the COVID
‑
19 pandemic have also resulted in interruptions in data collection and submissions for certain clinical trials and delayed starts for certain planned studies. As a result, our anticipated filing and marketing timelines may be adversely impacted.
•
Overall Economic and Capital
Markets
Environmen
t
: The impact of the COVID
‑
19 pandemic could result in a prolonged recession or depression in the United
States or globally that could harm the banking system, limit demand for all products and services and cause other seen and unforeseen events and circumstances, all of which could negatively impact us. The continued spread of COVID
‑
19 has led to and could continue to lead to severe disruption and volatility in the United
States and global capital markets, which could result in a decline in stock price, increase our cost of capital and adversely affect our ability to access the capital markets in the future. In addition, trading prices on the public stock market have been highly volatile as a result of the COVID
‑
19 pandemic.
84
Table of Contents
•
Regulatory Reviews
: The operations of the FDA or other regulatory agencies may be adversely affected. In response to COVID
‑
19, federal, state and local governments are issuing new rules, regulations, orders and advisories on a regular basis. These government actions can impact us, our members and our suppliers. There is also the possibility that we may experience delays with obtaining approvals for our IND applications,
BLA
s
, and/or
NDA
s
.
We have formed, and may in the future form or seek, strategic alliances or enter into collaborations with third parties or additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.
If we fail to enter into such strategic alliances, collaborations or licensing arrangement, or such strategic alliances, collaborations or licensing arrangements are not successful, we may not be able to capitalize on the market potential of our product candidates.
We have formed, and may in the future form or seek, strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third and related parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. For example, we have entered into an agreement whereby Viracta Therapeutics, Inc. ("Viracta") granted to us exclusive world-wide rights to Viracta's Phase II drug candidate, VRx-3996, for use in combination with our platform of NK cell therapies. However, if Viracta fails to raise sufficient capital to complete their pivotal Phase II trial, if their trial is unsuccessful, or if our future clinical trial of NK cell therapy in combination with VRx-3996 fails, the value of the Viracta license would be adversely affected. We plan to collaborate with governmental, academic and corporate partners, including affiliates, to improve and develop Anktiva, hAd5 and other therapies for new indications for use in combination with other therapies and to improve and develop other product candidates, which may expose us to additional risks, or we may not realize the benefits of such collaborations.
Because some of our collaborations are conducted at outside laboratories, and we do not have complete control over how the studies are conducted or reported or over the manufacturing methods used to manufacture our Anktiva product candidate, the results of such studies, which we may use as the basis for our conclusions, projections or decisions with respect to our current or future product candidates, may be incorrect or unreliable, or may have a negative impact on us if the results of such studies are imputed to our product candidates or proposed indications, even if such imputation is improper. Additionally, we may use third-party data to analyze, reach conclusions or make predictions or decisions with respect to our product candidates that may be incomplete, inaccurate or otherwise unreliable.
Further, collaborations involving our product candidates will be subject to numerous risks, which may include the following:
•
collaborators, including their related or affiliated companies, may be entitled to receive exclusive rights for or involving our products;
•
collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration;
•
collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization of our product candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;
•
collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
•
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates;
•
a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution;
•
collaborators may not properly maintain, defend or enforce our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;
•
disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;
•
collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;
85
Table of Contents
•
if an agreement with any collaborator terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaborator's technology or intellectual property or require us to stop development of those product candidates completely; and
•
collaborators may own or co-own intellectual property covering our product candidates or technology that results from our collaborating with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property.
As a result, if we enter into collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. Additionally, exclusive rights that we may grant in connection with collaboration agreements may limit our ability to enter into new or additional collaboration agreements or strategic partnerships if we experience issues with existing collaborations. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenues or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.
Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy.
If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.
If conflicts arise between our corporate or academic collaborators or strategic partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Some of our existing academic collaborators and strategic partners are conducting multiple product development efforts. Such current or future collaborators or strategic partners could become our competitors in the future and could develop competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the development and commercialization of our product candidates. Competing product candidates, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of our collaborator's or partner's support for our product candidates.
For example, in May 2019, Sorrento Therapeutics, Inc. ("Sorrento") with which we jointly established a new entity called Immunotherapy NANTibody, LLC ("NANTibody") as a stand-alone biotechnology company, commenced litigation against us and certain of our officers and directors, alleging that we improperly caused NANTibody to acquire IgDraSol, Inc. and in January 2020 and April 2020, Sorrento sent letters purporting to terminate an exclusive license agreement with us and an exclusive license agreement with NANTibody. Additionally, in July 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration, served by Shenzhen Beike Biotechnology Co. Ltd. asserting breach of contract under our subsidiary Altor's license agreement with them. For more information regarding these disputes, see
Note 7
,
Commitments and Contingencies—Litigation
, of the "Notes to Unaudited Condensed Consolidated Financial Statements" that appear in Part 1. Item 1. "Financial Statements" of this Quarterly Report on Form 10‑Q. Any of these developments could harm our product development efforts.
86
Table of Contents
We
will
be
heavily
dependent
on our
senior
management,
particularly
Dr.
Soon-Shiong,
our
E
xecutive
C
hairman,
and
a
loss
of
a
member
of
our senior
manageme
n
t
t
e
a
m
in
t
h
e
fu
t
u
r
e
,
e
ven
if
only
temporary,
c
ould
harm
o
u
r busines
s
.
Our operations will be dependent upon the services of our executives and our employees who are engaged in research and development. If we lose the services of members of our senior management, particularly Dr. Soon-Shiong, for a short or an extended time, for any reason, we may not be able to find appropriate replacements on a timely basis, and our business, financial condition and results of operations could be materially adversely affected. Our existing operations and our future development depend to a significant extent upon the performance and active participation of certain key individuals, particularly Dr. Soon-Shiong, our Executive Chairman. Although Dr. Soon-Shiong focuses heavily on our matters and is highly active in our management, he does devote a significant amount of his time to a number of different endeavors and companies, including NantHealth, Inc., NantMedia Holdings, LLC (which operates the Los Angeles Times and the San Diego Union-Tribune) and NantWorks, which is a collection of multiple companies in the healthcare and technology space. The risks related to our dependence upon Dr. Soon-Shiong are particularly acute given his ownership percentage, the commercial and other relationships that we have with entities affiliated with him, his role in our company and his public reputation. We may also be dependent on additional funding from Dr. Soon-Shiong and his affiliates, which may not be available when needed and which he is under no obligation to provide.
To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided, and plan to continue providing, equity incentive awards that vest over time. The value to employees of equity incentive awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. We do not have employment agreements with our key employees and all of our employees are hired on an "at-will" basis, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain "key man" insurance policies on the lives of these individuals or the lives of any of our other employees.
We
will
need
to grow
the
size
and
capabili
t
ies
of
our
organization,
and
we
may
experie
n
ce
difficulties
in
managing
this
growth.
Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of their attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. In order to develop our business in accordance with our business plan, we will have to hire additional qualified personnel, including in the areas of research, manufacturing, clinical trials management, regulatory affairs, and sales and marketing. We are continuing our efforts to recruit and hire the necessary employees to support our planned operations in the near term. However, competition for qualified personnel in the biotechnology and pharmaceuticals industry is intense due to the limited number of individuals who possess the skills and experience required, and no assurance can be given that we will be able attract, hire, retain and motivate the highly skilled employees that we need, on acceptable terms or at all. Future growth will impose significant added responsibilities on members of management, including:
•
i
dentifying,
recruiting,
integrating,
mai
n
t
a
in
i
ng,
and
m
otiv
a
ting
additional
employees;
•
m
anaging
our
internal
develop
m
ent
efforts
effectively,
including
the
clinical
and
FDA rev
i
ew
process
for
our
product
candidat
e
s
,
wh
i
l
e complying
with
our
contractual
obligations
to
contractors
and
other
third
parties;
and
•
i
mproving
our
operational,
financial
and
management
controls,
re
p
o
r
ting
systems,
and
procedures.
We
currently
rely,
and
for
the
foreseeable
future
we exp
e
ct
to
re
l
y,
in substan
t
i
a
l
part
on
certain
independent
organizations,
advisors
and
c
onsultants
to provide
certain
services.
There
can
be
no
a
s
surance
that
the
services
of
these
indep
e
ndent
organizations,
a
dvisors and
consult
a
nts
will
continue
to
b
e ava
i
lab
l
e
to
us
on
a
t
i
me
l
y
b
a
s
i
s
when
n
e
e
d
ed,
or
that
we
can
find
q
ualified
replacemen
t
s on economically reasonable terms, or at all.
In
addition,
if we
are
unable
to
ef
f
ectively
manage
our o
u
tsourced
activities
or
if the
quality,
compliance
or
accuracy
of the
services
provided
by
c
o
nsultants
is compromised
for
any
reason,
our cl
i
nic
a
l
tri
a
ls may
be
extended,
delayed,
or
terminated,
and
we
may
not
be
able
to
obtain
regulato
r
y
approval
of
o
ur
product
candidates
or
otherwise
advance
our b
u
siness.
If
we
are
not
able
to effectively
expand
our
organization
by
hiring
new
employees
and
expanding
our
groups
of
consultants
and
contractors,
we
may
not be
able
to
su
cc
e
s
sfully
implem
e
nt
the
t
a
sks necessary
to further
develop
and
commercialize
our
p
r
oduct
candidates
and,
accordi
n
gl
y
,
may
not
achieve our
res
e
arch,
d
e
ve
l
opmen
t
,
and
c
om
m
erc
i
a
l
iz
a
tion
goals
on
a timely
b
a
s
i
s,
or
at
a
ll.
87
Table of Contents
If
we
engage
in
future
acquis
i
tions
or
strate
g
i
c
partne
r
ships,
this
may
increase
our capital
requirements,
dilute
our
stockhol
de
r
s
,
c
a
u
s
e
u
s
t
o
i
n
c
u
r debt
or
assume
contingent
liabilities,
and
subject
us to
oth
e
r
risk
s
.
We
may
evaluate
various
acqui
s
itions
and
strategic
par
t
nerships,
including
licensing
or
acqu
i
ring
complementary
products,
inte
l
lectual
property
rights, technologies,
or
business
e
s.
Any
potential
acquisition
or strategic
partnership
may
ent
a
il
numerous
risks,
including:
•
a
ssimilati
o
n
of
operation
s
,
intellectual
property
a
n
d
products
of
an
acquired
compa
n
y
or
p
r
oduct,
including
d
i
fficulties
associ
a
ted
with integrating
new
personnel;
•
t
he
diversion
of
our
managem
e
nt's
attention
from
our
existing
product
programs
a
nd initiatives
in pursuing
such
a
strategic
m
e
rger
or acquisition;
•
retention
of
key
employees,
the
loss
of
k
e
y
personnel,
and
uncert
a
inties
in our
ability
to
mai
n
tain
key
business
relationship
s
;
•
r
i
s
ks
a
nd un
c
er
t
a
in
t
ies
asso
c
ia
t
ed
w
i
th
t
h
e
other
pa
r
ty
to such
a
transaction,
inc
l
uding
the
prospects
of
that
party
and
their
existing
products or
product
candidates
and
regulatory
approvals;
and
•
our
inability
to generate
revenues
from
acquired
technology
and/or
products
sufficient
to meet
our
objectives
in
undertaking
t
he acquisition
or
even
to offset the associated
acquisition
and
maintenance
costs.
Depending
on
the
size
and
nat
u
r
e
of
future
strategic
acquisitions,
we may
acquire
assets
or
busine
s
ses
that
require
us
to
raise
a
ddit
i
onal
c
a
pit
a
l
or
to o
p
erate
or
manage
businesses
in which
we
have
limited
experience.
Mak
i
ng
larger
acquisitions
that
require
us
to
raise
additional
capital
to
fund
the acquisition
will
expo
s
e
us
to
the
risks
associated
with
capital
raising
activities.
Acquiring
and
t
h
ere
a
fter
operating
larger
new
busin
e
s
s
e
s
w
i
ll
a
l
so increase
our
management,
operat
i
ng
and
reporting
costs
and
burdens (including increased cash requirements).
In
addition,
if
we
undertake
acquisitions,
we
may
issue
di
l
utive
equity
s
e
curiti
e
s,
a
ssume or
incur
additional
debt
o
b
ligations or contingent liabilities,
incur
large
one-
t
ime
expenses
and
acquire
int
a
ngible
assets
that
co
u
l
d
res
u
lt
in significant
future
a
m
ort
i
za
t
ion
expense. Moreover,
we
may
not
be
able
to locate
suitable
acquisition
opportunities
and
this
inability
could
impair
our
ability
to
grow
o
r
ob
t
ain
a
c
c
e
ss
t
o technology
or
products
that
m
a
y
be
important
to
the
development
of
our
business.
We may
b
e
come
i
n
v
olv
e
d
i
n securit
i
es
l
it
i
gation
or
stockholder
derivative
l
it
i
gation
i
n conn
e
c
t
ion
wi
t
h
our recent merger,
and
this
could divert
the
attention
of
our
ma
n
agement
and
harm
our
bus
i
n
e
s
s
,
and i
n
s
u
rance
c
ov
e
rage
may
not
be
s
u
ffi
c
ie
n
t
to
cov
e
r
all
r
e
l
ated
costs
and damages.
Securities
litigation
o
r
stockho
l
der
derivative
litigation
frequently
follows
the
annou
n
cement
of
certain
significant
business
t
rans
a
c
tions,
such
as the
s
a
l
e of
a
business
division
or
announcement
of
a
bu
s
iness
combination
transaction.
We
are
involved
in
this
type
of
litigation
in c
o
n
nection
with
our recent
merger,
and
we
may
become
involved
in this
type
of
litigation
in the
future.
Litigation
often
is expensive
and
dive
rt
s
management's
attention and
reso
u
r
ces,
which
could
adversely
affect
our
business
and
the
combined
company.
A
v
ariety
of
r
i
s
ks associat
e
d
with
ma
r
keti
n
g
our
product
candidates
internationally
could
materially
adversely
affect
our
busi
n
e
ss.
We
plan
to
seek
regulatory
approval
of
our
product
candidates
outside
of
the
United
States
and,
accordingly,
we
expect
that
we will
be
subj
e
c
t
to additional
risks related
to operating
in foreign
countries
if we
ob
t
ain
the
necessary
approvals,
including:
•
differing
regulato
r
y
requirem
e
nts
in foreign
countries;
•
unexpected
changes
in
tariffs,
trade
b
a
rriers,
price
and exchange
controls
and
o
t
her
regulatory
requirements;
•
e
conomic
weakness,
including
inflation,
or
political
instability
in particular
fore
i
gn
economies
and
markets;
•
c
ompliance
with
tax,
employment,
immigration
and
labor
laws
for
employees
living
or
traveling
abroad;
•
foreign
taxes,
including
wi
t
hholding
of
payroll
taxes;
•
foreign
currency
fluctuations,
which
could
re
s
ult
in in
c
re
a
s
e
d
op
e
r
a
t
i
ng
expenses
and
reduced
revenues,
and
oth
e
r
obligations
incident
to doing
business
in an
o
t
her
count
r
y;
•
difficulties
sta
f
fing
and
managing
foreign
operations;
•
workforce
uncertainty
in
countries
where
labor
unrest
is more
common
than
in the
United
States;
•
differing
payor
reimbursement
regimes,
governm
e
ntal
payors
or
patient
self-pay
systems,
and
price
controls;
88
Table of Contents
•
potential
liability
under
the
Foreign
C
o
rrupt
Practices
Act
of
1977
("
FCP
A")
or
comparable
foreign
regulations;
•
c
hallenges
enforcing
our
contrac
t
ual
and
intellectual
property
rights,
especially
in
those
for
e
ign
countries
that
do
not
resp
e
ct
and
protect
i
nte
l
le
c
tu
a
l
p
r
op
e
rty
rights
to
t
he
s
a
me
ex
t
e
nt
as
the
Un
i
t
e
d
S
ta
t
es;
•
production
s
h
o
r
tages
resulting
from
any
events
affecting
raw
mat
e
rial
supply
or
manufact
u
ring
capabilities
abroad;
•
t
he
impact
of
public
health
epidemics
on
the
global
economy,
such
as
the
coronavirus
pandemic
currently
hav
i
ng
an
impact
throughout
the world;
and
•
business
interruptions
resulting
from
geo-po
l
itical
actions,
including
war
and
terrorism.
These
and
oth
e
r
risks
a
s
soc
i
at
e
d
wi
t
h
i
nter
n
ational
operations
may
material
l
y
adv
e
rsely
aff
e
ct
our
a
bi
l
ity
to
a
t
t
a
in
or
m
a
in
t
a
i
n
profitable
operations.
R
i
s
k
s R
e
lat
e
d
to Government
Regulation
We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates. We are, and if we receive regulatory approval of our product candidates, will continue to be subject to ongoing extensive regulation, regulatory obligations and continued regulatory review, which may result in significant additional expense.
Our product candidates are subject to extensive governmental regulations relating to, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs and therapeutic biologics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the United States and in many foreign jurisdictions before a new drug or therapeutic biologic can be marketed. Satisfaction of these and other regulatory requirements is costly, lengthy, time-consuming, uncertain and subject to unanticipated delays and can vary substantially based upon the type, complexity and novelty of the products involved. We will not be permitted to market or promote any of our product candidates without receiving regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates or regulatory approval that will allow us to successfully commercialize our product candidates. In addition, regulatory agencies may lack experience with our technologies and products, which may lengthen the regulatory review process, increase our development costs and delay or prevent their commercialization.
We have not previously submitted a BLA or NDA or similar marketing or drug approval application to the FDA or comparable foreign authorities, for any product candidate, which may impede our ability to obtain timely FDA approvals, if at all, and we cannot be certain that any of our current product candidates or any future product candidates will be successful in clinical trials or receive regulatory approval. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical studies, clinical trials or other research. The number and types of preclinical studies and clinical trials that will be required for regulatory approval also vary depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. Approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate's clinical development and may vary among jurisdictions and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.
Any delay in completing development or obtaining, or failing to obtain, required approvals would have a material and adverse effect on our ability to generate revenue from the particular product candidate for which we are developing and seeking approval. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, be subject to other regulatory enforcement action, and we may not achieve or sustain profitability.
89
Table of Contents
Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, however a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval policies, procedures and requirements may vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our product candidates is also subject to approval.
Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. If we fail to comply with the regulatory requirements in international markets and/or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.
If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business.
Any
regulatory
approvals
that
we
receive
for
our
product
candidates
will
requi
r
e
surveillance
to
monitor
the
safety
and
efficacy
of
the
product
ca
n
didate. The
FDA
may
also
require
a REMS
to app
r
ove
our
product
candidates,
which
could
entail
requirements
for
a medication
guide,
phy
s
i
c
ian
communication plans
or
addit
i
onal
elements
to ensure
safe
use,
such
as restricted
distribution
methods,
patient
regist
r
ies
and
other
risk
minimization
tools.
The
FDA
may
also
requi
r
e
post-approv
a
l
P
hase IV
trials.
Moreover,
the
F
DA and
comp
a
rable
foreign
regulatory
authorities
will
continue
to
closely
monitor
the
safety
profile
of
any
product
even
after
approval.
In
addition,
we,
o
ur
contractors,
and
o
u
r
collab
o
r
ators
are
and
will
remain
responsible
for
FDA
compliance,
including
requirem
e
nts
related
to
product design,
t
e
s
t
ing, clinical trials and preclinical studies approval,
manufacturing
processes
and
quality,
lab
e
ling,
packaging,
d
i
stribution,
adverse
event
and deviation
reporting,
storage,
advertising,
marketing,
promotion,
sale,
imp
o
r
t,
export,
sub
m
issions
of
safety
and
other
post-ma
r
keting
information
and reports
such
as
deviation
reports,
registration,
product
listing,
annual
user
fees,
and
reco
r
dkeeping
for
our
product
candidat
e
s.
We
and
any
of
o
u
r collaborators,
including
our
con
t
ract
manufacturers,
could
be
s
ubject
to
periodic
unannounced
ins
p
ections
by
the
FDA
to monitor
and
ensure compliance
with
regulatory
requ
i
rements.
Application
holders
must
further
notify
the
FDA,
and
depending
on
the
nature
of
the
c
h
ange,
obtain
FDA pre-approval
for
product
and
manufacturing
changes.
The
cost
of
compl
i
ance
with
post-approval
regulat
i
ons
may
have
a negative
effe
c
t
on
our
operating results
and
financial
condition.
If the FDA or comparable foreign regulatory authorities become aware of new safety information or previously unknown problems after approval of any of our product candidates, including: (i) adverse events of unanticipated severity or frequency, (ii) that the product is less effective than previously thought, (iii) problems with our third-party manufacturers or manufacturing processes, or (iv) failure to comply with regulatory requirements, or if we violate regulatory requirements at any stage, whether before or after marketing approval is obtained, we may face a number of regulatory consequences, including refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, modification of promotional materials or labeling (including required additional warnings), provision of corrective information, imposition of post-market requirements, including the need for additional testing or costly post-approval studies or post-market surveillance, imposition of distribution, manufacturing or other restrictions under a REMS, imposition of restrictions on a product's indicated uses, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, FDA debarment, injunctions, fines, consent decrees, corporate integrity agreements, debarment from receiving government contracts, exclusion from participation in federal and state healthcare programs, issuance of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information, restitution, disgorgement, or civil or criminal penalties, including fines and imprisonment, reputational harm and adverse publicity, among other adverse consequences. Any such restrictions could limit sales of the product. Any of these events could further have other material and adverse effects on our operations and business and could adversely impact our stock price and could significantly harm our business, financial condition, results of operations, and prospects.
90
Table of Contents
Results for any patient who receives compassionate use access to our product candidates should not be viewed as representative of how the product candidate will perform in a well-controlled clinical trial, and cannot be used to establish safety or efficacy for regulatory approval.
We often receive requests for compassionate use access to our investigational drugs by patients that do not meet the entry criteria for enrollment into our clinical trials. Generally, patients requesting compassionate use have no other treatment alternatives for life threatening conditions. We evaluate each compassionate use request on an individual basis, and in some cases grant access to our investigational product candidates outside of our sponsored clinical trials if a physician certifies that the patient receiving treatment is critically ill and does not meet the entry criteria for one of our open clinical trials. Individual patient results from compassionate use access may not be used to support submission of a regulatory application, may not support approval of a product candidate and should not be considered to be indicative of results from any on-going or future well-controlled clinical trial. Before we can seek regulatory approval for any of our product candidates, we must demonstrate in well-controlled clinical trials statistically significant evidence that the product candidate is both safe and effective for the indication we are seeking approval. The results of our compassionate use program may not be used to establish safety or efficacy or regulatory approval.
Our
GMP-in-a-Box
will
be
regulated
by
the
FDA
as
a
medical
device,
and
regulatory
com
p
liance
for
medical
devices
is expensive,
complex
and uncertain,
and
a
failure
to
com
p
ly
could
lead
to
enforcement
actions
against
us
and
o
t
her
negative
consequen
c
es for our busine
s
s.
The
FDA
a
nd si
m
il
a
r
a
genc
i
es
r
e
gula
t
e
med
i
c
a
l
devices. All of our potential medical device products and material modifications will be subject to extensive regulation and clearance or approval from the FDA and non-U.S. regulatory agencies prior to commercial sale and distribution as well as after clearance or approval. Complying
with
t
h
ese
regulations
is
costly,
time-consuming,
complex
and
u
ncertain.
For instance,
be
f
ore
a new
medical
device,
or
a
new
intended
use
for
an
existing
dev
i
ce
,
c
a
n
be
m
a
rketed
in
the
Unit
e
d
State
s
,
a
c
o
mpany
must
f
irst submit and
receive
either
510(k) clearance
or
pre-marketing
approval
from
the
F
D
A,
unless
an
exe
m
ption
applies.
FDA
regulations
and
regulations
of
similar
agencies
are
wide-ranging
and include,
among
other
things,
oversight
of:
•
product
design,
development,
manufacture
(including
su
p
plie
r
s)
and
testing;
•
l
aboratory
and
preclinical
s
t
udi
e
s
and
cl
i
nic
a
l
tri
a
ls;
•
product
safety
and
effectiveness;
•
product
labeling;
•
product
storage
and
shipping;
•
record
kee
p
ing;
•
pre-market
clearance
or
approval;
•
m
arketing,
adverti
s
ing
and
promotion;
•
product
sales
and distribution;
•
product
changes;
•
product
recalls;
and
•
post-market
surveillance
and
r
e
porting
of
deaths
o
r
serious
injuries
and
certain
malfunctions.
Medical
devices
regulated
by
the
FDA
are
subj
e
c
t
to
gen
e
ral
con
t
rols
whi
c
h
in
c
lud
e:
r
e
gistr
a
tion
w
i
th
the
FDA; list
i
ng
c
omm
e
rc
i
ally
distributed prod
u
cts
with
the
FDA; complying
with
cGMP
under
Quality
Systems
Regulations;
filing
reports
with
t
h
e
FDA
of
and
keeping
recor
d
s
r
e
l
a
tive
t
o certain
types
of
adverse
events
associated
with
devices
under
the
medical
device
repo
r
ting
regulation;
assuring
that
device
la
b
eling
complies
with
device labeling
requirements;
reporting
c
e
rtain
device
field
removals
and
corrections
to
the
FDA;
and
obtaining
pre-market
notification
510(k) clearance
for devices
prior
to
marketing.
Some
devices
known as
510(k)-exempt
d
e
vices
can
be
m
a
rketed
without
prior
marketing-clearance
or
a
p
proval
from
the FDA.
In
addition
to
the
general
controls,
some
Class II
medical
devices
a
re
also
sub
j
ect
t
o spe
c
ial
controls,
including
adherence
to a particular
guidance d
o
cument
and
compliance
with
the
performa
n
ce
standard.
Instead
of
obtaining
510(k) cle
a
rance,
most
Class
I
II
devices
are
subje
c
t
to
pre-m
a
rket approval
("
PMA").
91
Table of Contents
The
FDA
can
also
refuse
to clear
or
approve
pre-market
applications
for
any
medical
device
we
develop.
We may not be able to obtain the necessary clearances or approvals or may be unduly delayed in doing so, for any medical device products we develop, which could harm our business.
Furthermore, even if we are granted regulatory clearances or approvals for any medical device products, they may include significant limitations on the indicated uses for the product, which may limit the market for the product.
Any
enforcement
action
by
the
FDA
and
other comparable
non-U.S.
regulatory
agencies
c
ould
have
a material
adver
s
e
effect
on
our
business,
f
i
nancial
condit
i
on
and
results
of
operations.
Our
failure to comply
with
applicable
regulatory
requirements
could
result
in
enforcement
action
by
the
FDA
or
state
agencies,
which
may
i
n
clude
any
of
the following
a
c
tions:
•
un
t
it
l
ed
le
t
ters,
warn
i
ng
l
e
tt
e
rs,
fines,
in
j
unctions,
consent
dec
r
ees
and
civil
penalties;
•
un
a
nti
c
ip
a
ted
exp
e
nditur
e
s
to
address
or
defend
such
actions;
•
c
ustomer
notificatio
n
s
for
repair,
replacement
or
refunds;
•
recall,
detention
or
seizure
of
our
products;
•
operating
restrictions
or
partial
suspension
or
total
sh
u
t
down
of
p
r
o
duction;
•
refusing
or
delaying
our
requests
for
510(k)
clearance
or
PMA
approval
of
new
products
or
modified
products;
•
operating
r
e
s
t
ri
c
tions;
•
withdrawing
510(k) clearances
or
PMA approvals
that
h
a
ve
already
been
granted;
•
refusal
to
grant
export
approval
for
our
products;
or
•
c
riminal
prosecution.
If
a
n
y
of
these
events
were
to occur,
it
would
have
a
material
and
adverse
effect
on
our
business, financial
condition
and
res
u
lts
of
operatio
n
s.
The FDA also regulates the advertising and promotion of medical devices to ensure that the claims are consistent with their regulatory clearances or approvals, that there are adequate and reasonable data to substantiate the claims and that the promotional labeling and advertising is neither false nor misleading in any respect. If the FDA determines that any of our advertising or promotional claims are misleading, not substantiated or not permissible, we may be subject to enforcement actions, including warning letters, and we may be required to revise our promotional claims and make other corrections or restitutions. Failure to comply with applicable U.S. requirements regarding, for example, promoting, manufacturing, or labeling our medical device products, may subject us to a variety of administrative or judicial actions and sanctions, such as Form 483 observations, warning letters, untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. If any of our medical device products cause or contribute to a death or a serious injury or malfunction in certain ways, we will be required to report under applicable medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.
We
will
be
subject
to
governmental
export
and import
controls
that
could
impair
our
ability
to
compete
in international
markets
du
e to
l
i
c
e
n
s
i
n
g requirements
and
subject
u
s
to liability
if
we
are
n
ot in
c
omplian
c
e
with
applicable
laws.
Our
product
candidates
will
be
subject
to
export
control
and
import
laws
and
regulations,
including
the
U.S. Export
Administration
Regulations,
U.S. Cust
o
m
s
regulations
and
v
a
rious
economic
and
trade
s
a
nctions
regulations
administered
by
the
U.S. Treasury
Department's
Office
of
Foreign
Assets Co
n
t
rols.
Exports
of
our
product
candidates
and solutions
outside
of
the
United
States
must
be
made
in
compliance
with
these
laws
and
regulations.
If we f
a
il
to
comp
l
y
with
th
e
s
e
l
a
ws
and
regu
l
ations,
we
and
certain
of
our
employees
could
b
e
subject
to
substantial
civil
or
criminal
penalties,
including the
possible
loss of
export
or
import
privi
l
eges;
fines,
which
may
be
i
m
posed
on
us
and
responsible
employees
or
managers;
and,
i
n
e
x
tre
m
e
c
a
s
e
s
,
t
he incarceration
of
responsible
employees
or
managers.
In
addition,
changes
in
our
product
candidat
e
s
or
solutions
or
changes
in
applicable
export
or
import
laws
and
regulations
may
cr
e
a
t
e
d
e
l
a
ys
in
the introduction,
provision,
or sale
of
our
product
candidates
and
solutions
in
international
markets,
prevent
customers
from
using
o
u
r
product
candidates and
solutions
or,
in some
cases,
preve
n
t
the
export
or
import
of
our
product
candidates
and
solutions
to
certain
countries,
governments
or
persons altogether.
Any
limitations
on
our
ability
to
export,
provide,
or
sell
our
produ
c
t
candidates
and
solutions
could
adversely
affect
our
business, financial condition
and
results
of
operations.
92
Table of Contents
We
are subject
to
U.S.
and for
e
ign
anti-corruption
and
anti-money
l
aundering
l
aws with
r
e
sp
e
c
t
to
our
o
p
erations
and
non-compl
i
an
c
e
with
such laws
can subj
e
c
t
us
to
c
riminal
an
d
/
or
civil
liabi
l
ity
and harm our business.
We
are
subject
to
the
FCPA,
the
U
.
S.
domestic
bribery
sta
t
ute
contained
in 18 U.S.C. §201,
the
U.S.
T
r
avel
Act,
the
USA
PATRIOT
Act
and
possibly other
state
and
nation
a
l
anti-bribery
and
anti-money
laund
e
ring
laws
in
countries
in which
we
conduct
a
c
tivities.
Anti-corruption
laws
are
interpreted broadly
and
prohibit
companies
and
their
e
m
ployees,
agents,
third-party
in
t
e
rm
e
di
a
ries,
jo
i
nt
ventu
r
e
partners
and
collaborato
r
s
from
authorizing, promising,
offering
or
providing,
directly
or
indirectly,
improper
payments
or
benefits
to
recipients
in the
public
or
private
sector.
We
use CROs abroad
for
clinical
t
r
ials.
I
n
addition,
we
m
a
y
engage
third-party
intermediaries
to sell
our
product
candidates
and
solu
t
ions
abroad
once
we
enter
a
commercialization
phase
for
our
product
cand
i
dates
and/or
to
obtain
nec
e
ssary
permits,
licenses,
and
other
regulatory
approvals.
We
or
our
third-party intermediaries
may
have
direct
or
in
d
i
rect
interactions
with
o
fficials
and
employees
of
government
agencies
or
state-owned
or
a
ffi
l
i
a
ted
en
t
it
i
es.
We
c
a
n be
h
e
ld
li
a
ble
for the
corrupt
or other
i
l
leg
a
l
ac
t
ivi
t
ies
of
these
third-party
intermediarie
s
,
o
ur
employees,
representatives,
contractors,
partners
and agents,
even
if
we
do
not
explicitly
authori
z
e
or
have
actual
knowledge
of
such
activities.
We
have
adopted
an
anti-corruption
policy
, which
mandates
compliance
with
the
FCPA
and
other
anti
-
corruption
laws
applicable
to
our
business
throughout
the
world.
However,
the
r
e
can
be
no assurance
that
our
employees
and
third-par
t
y
in
t
e
rm
e
di
a
ries
w
i
ll
co
m
ply
wi
t
h
t
his
po
l
icy
or
such
anti-corruption
laws.
Non-compl
i
ance
wi
t
h
a
nti-corruption
and
anti-money
laundering
laws
could
subject
us to
whistleblower
compl
a
ints,
investigations,
sanctions,
settlements,
prosecution,
other
investigations,
or
other
en
f
orcement
actions.
If
such
actions
are
launched,
or
governm
e
ntal
or
o
t
her
sanctions
a
r
e
imposed,
or
if
we
do
not
prevail
in any p
o
ssible
civil
or
criminal
liti
g
ation,
our
business,
results
of
operations
and
financial
condition
could
be
mat
e
rially
harmed.
In
addition,
res
p
onding
to any ac
t
ion
w
i
ll
lik
e
ly
result
in
a
ma
t
e
r
i
al
l
y
sign
i
ficant
diversion
of
manag
e
me
n
t
's
attention
and
resources
and
significant
defense
and
compliance
costs
and other
professional
fees.
In
certa
i
n
cases,
enforcement
a
u
tho
r
ities
may
even
cause
us
to appoint
an
inde
p
e
ndent
compliance
monitor,
whi
c
h
c
a
n
result
in added
costs
and
administrative
burdens.
Our failure to comply with state, national and/or international data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.
There are numerous laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns, and some state privacy laws apply more broadly than the Health Insurance Portability and Accountability Act ("HIPAA") and associated regulations. For example, California recently enacted legislation—the California Consumer Privacy Act of 2018 ("CCPA")—which went into effect on January 1, 2020. The CCPA, among other things, creates new data privacy and security obligations for covered companies and provides new privacy rights to California consumers, including the right to opt out of certain disclosures of their information. The CCPA also provides for civil penalties as well as a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Although the law includes limited exceptions, including for certain information collected as part of clinical trials as specified in the law, it may regulate or impact our processing of personal information depending on the context. Additionally, a new privacy law, the California Privacy Rights Act ("CPRA"), was approved by California voters in November 2020. The CPRA significantly modified the CCPA, which may require us to modify our practices and policies and may further increase our compliance costs and potential liability. To the extent these state laws as well as other federal and state privacy laws, including new laws and changes in existing laws, apply to our business and operations, our compliance costs and potential liability with respect to personal information we collect could expose us to great liability and increase compliance costs.
There are also various laws and regulations in other jurisdictions relating to privacy and security. For example, European Union ("EU") member states and other foreign jurisdictions, including Switzerland, have adopted data protection laws and regulations which impose significant compliance obligations on us. The collection and use of health data in the EU is governed by the EU General Data Protection Regulation ("GDPR"). The GDPR, which is wide-ranging in scope and applies extraterritorially, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to such individuals, the security and confidentiality of the personal data, data breach notification, the adoption of appropriate privacy governance, including policies, procedures, training and audits, and the use of third-party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EU, including to the United States, provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to €20 million or up to 4% of the total worldwide annual global revenues of the noncompliant entity, whichever is greater. The GDPR requirements apply not only to third-party transactions, but also to transfers of information between us and our subsidiaries, including employee information.
93
Table of Contents
Complying with these numerous, complex and often changing regulations is expensive and difficult, and failure to comply with any privacy laws or data security laws or any security incident or breach involving the misappropriation, loss or other unauthorized processing, use or disclosure of sensitive or confidential patient, consumer or other personal information, whether by us, one of our CROs or business associates or another third party, could adversely affect our business, financial condition and results of operations, including but not limited to: investigation costs; material fines and penalties; compensatory, special, punitive and statutory damages; litigation; consent orders regarding our privacy and security practices; requirements that we provide notices, credit monitoring services and/or credit restoration services or other relevant services to impacted individuals; adverse actions against our licenses to do business; reputational damage; and injunctive relief. The recent implementation of the CCPA and GDPR has increased our responsibility and liability in relation to personal data that we process, including in clinical trials, and we may in the future be required to put in place additional mechanisms to ensure compliance with the CCPA, GDPR and other applicable laws and regulations, which could divert management's attention and increase our cost of doing business. In addition, new regulation or legislative actions regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the EU and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.
We cannot assure you that our CROs or other third-party service providers with access to our or our customers', suppliers', trial patients' and employees' personally identifiable and other sensitive or confidential information in relation to which we are responsible will not breach contractual obligations imposed by us, or that they will not experience data security breaches, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations and/or which could in turn adversely affect our business, results of operations and financial condition. We cannot assure you that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, use, storage and transmission of such information. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.
If we, or any third party contract manufacturers or suppliers that we engage, fail to comply with environmental, health, and safety laws and regulations, including regulations governing the handling, storage or disposal of hazardous materials, we could become subject to fines or penalties or incur costs that could harm our business.
We and any of our third-party manufacturers or suppliers will be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, manufacture, storage, treatment and disposal of hazardous materials and wastes. Our operations and research and development activities involve the controlled use of medical and hazardous materials, including chemicals, biological materials and infectious agents. Our operations also may produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. Although we believe that our procedures for using, storing and disposing of these materials comply with legally prescribed standards, we will not be able to eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.
Although we will maintain workers' compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain comprehensive insurance coverage for liabilities arising from medical or hazardous materials, environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.
In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. These current or future laws and regulations may impair our research, development, or production efforts, which could harm our business, prospects, financial condition or results of operations. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.
94
Table of Contents
Disruptions at
the FDA, the
SEC and other government agencies
caused by funding shortages or global health concerns
could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the FDA, SEC, and other government agencies on which our operations may rely is inherently fluid and unpredictable.
Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. In response to the COVID‑19 pandemic, in 2020, the FDA announced that it would postpone domestic and foreign routine surveillance inspections. Based on updated guidance issued in May 2021, the FDA continues to conduct "mission-critical" inspections on a case-by-case basis, or, where possible to do so safely, has resumed prioritized domestic inspections, such as pre-approval and surveillance inspections. While the FDA indicated that it will consider alternative methods for inspections and exercise discretion on a case-by-case basis to approve products based on a desk review, if a prolonged government shutdown occurs, or if the government experiences a protracted backlog of inspections and regulatory review, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns, delays, or prioritization policies could potentially impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.
If we
fail
to
comp
l
y
with
f
e
deral
and s
t
ate
healthcare
and promotional
laws,
including
fraud
and ab
u
se
and
information
privacy
and
security
laws, we
could
face
substantial
penalties
and
o
u
r busines
s
, fi
n
an
c
ial
c
onditio
n
,
r
e
sults of operations,
and
prospects
could
be
adversely
affe
c
ted.
As a biopharmaceutical
company,
we
are
sub
j
ect
to
many
federal
and
sta
t
e
healthcare
laws,
including
the
federal
Anti
-
Kickback
S
t
a
tut
e
("
AKS"),
t
he FCA, the civil monetary pen
a
lt
i
es
st
a
tut
e
,
the
Medicaid
Drug Rebate
s
t
atute
and
other
price
reporting
requirements,
the
federal
Physician
Payment Sunshine
Act,
the
Veter
a
ns
Health
Care
Act
of
1992,
HIP
A
A (as
amended
b
y
the
Health
Inf
o
rmation
Technology
for
Economics
and
C
l
ini
c
al
He
a
lth Act),
the
FCPA, the
Patient
Pro
t
ection
and
Affordable
Care
Act
of
2010 (as
amended
by
the
Health
Care
and Education
Reconcilia
t
ion
Act)
(
the "ACA")
and
similar
state
laws. Even
though
we
do
not
make
referrals
of healthcare
services
or
bill
directly
to M
e
dicare,
Medicaid,
or
other
third-party payors,
certain
fe
d
e
ral
and
sta
t
e
healthcare
laws
and
regulations
pertaining
to
fraud
and
abuse
and
patients'
rights
are
and
w
i
ll
be
applicable
to
our b
u
siness.
If
we
do
not
comply
with
all
app
l
icable
fraud
and
abuse
laws,
we
may
be
sub
j
ect
to
healthcare
fraud
and
abuse
enforc
e
ment
by both
the federal
government
and
the
states
in
which
we
conduct
our
business.
Laws
and
re
g
ulations
re
q
uire
c
a
lculation
and
reporting
of
compl
e
x
pricing
information
for
presc
r
iption
drugs,
and
compliance
will
require
us
to invest
in sig
n
ificant
resources
to
develop
a price
reporting
infrastructure
or
depend
on
third
parties
to
compute
and
report
our
drug
p
ricing.
Pricing
reported
to the Centers
for
Medicare
and
Med
i
caid
Services
("
CMS") must
be
certified.
Non
-
compliant
activiti
e
s
expose
us
to
FCA
risk
if t
he
y
re
s
u
l
t
in o
v
ercharging agencies,
underpaying
rebates
to age
n
cies,
or
causing
agencies
to
overpay
providers.
If
we
or
our
operations
are
found
to be
in
violation
of
any
fed
e
ral
o
r
state
healthcare
law,
or
any
other
gove
r
n
mental
regulations
that
apply
to us,
we
may be
subject
to
penalties,
including
civ
i
l,
c
r
im
i
nal,
a
nd
a
dministrative
pen
a
lties,
d
a
mag
e
s,
fin
e
s,
d
i
sgorgement,
debarment
from
government
contracts, refusal
of
orders
under
existing
contracts,
exclusion
from
participation
in
U.S. federal
or
state
hea
l
th
care
programs,
corpor
a
te
i
ntegr
i
ty
agre
e
m
e
nts
a
nd the
curtailment
or
restructuring
of
our
op
e
rations,
any
of
which
could
materially
adv
e
rsely
affect
our
ability
to operate
our
business
and
our
financial results.
If
any
of
the
physicians
or
other
healthcare
p
r
o
v
iders
or
entities
with
whom
we
expect
to do
bu
s
iness,
including
our
collaborators,
is found
not
to be
in
compliance
with
applicable
laws,
they
may
be
subject
to
criminal,
civil,
or
administrative
sanctions,
including
but
not
limited
to,
exclusions
from participation in
government
healt
h
care
programs,
which
could
also
materially
affect
our
business.
95
Table of Contents
In
particular,
if
we
are
found
to
have
impermissibly
promoted
any
of
our
product
candidates,
we
may
become
subject
to
significant
liability
and
government fines.
We,
and
any
of
our
collaborators,
must
comply
with
requirements
concerning
advertising
and
promotion
for
any
of
our
product
candidates
for
which
we
or
they
obtain
marketing
approval.
Pro
m
otional
communications
with
respe
c
t
t
o
t
her
a
peut
i
cs are
subject
to a variety
of
legal
and
regulatory
restrictions
and
continuing
review
by
the
FDA,
Department
of
Justice,
Department
of
Health
and
Human Services'
Office
of
Inspector
General,
state
attorneys
general,
members
of
Congress,
and
the
public.
When
the
FDA
or
comparable
foreign
regulatory authorities
issue
regulatory
approval
for
a
product
candidate,
the
regulato
r
y
approval
is
limited
to
t
hose
specific
uses
and
i
n
dications
for
which
a
product is approved.
If
we
are
not
able
to
obtain
FDA
approval
for
desired
uses
or
indications
for
our
produ
c
t
candidates,
we
may
not
m
arket
or
promote
our prod
u
ct
candidates
for
those
indic
a
tions
and
uses,
refe
r
red
to as off-label
uses,
and
our
busin
e
ss
may
be
adversely
affected.
While
physicians
may
c
h
oose
to
prescribe
produ
c
ts
for
uses
that
are
not
described
in
the
product's
labeling
and
for
uses
that
d
iffer
from
those
tested
in clinical trials
and
approved
by
the
regula
t
ory
authorities,
we
are
prohibited
from
m
a
rketing
and
promoting
the
products
for
indications
and
uses
that
are n
o
t specifically
approved
by
the
FDA.
These
off-label
uses
are
common
across
medical
specialties
and
may
c
onstitute
an
appropriate
tr
ea
t
m
e
nt
for
s
o
me pat
i
ents
in v
a
ri
e
d
c
i
rcu
m
s
t
anc
e
s.
Regulatory
authorities
in
the
United
States
generally
do
not
restrict
or
regulate
the
behavi
o
r
of
physicians
in
their choice
of
treatment
within
the
practice
of
medicine.
Regulatory
au
t
horities
do,
however,
restrict
communications
by
biopharmace
u
t
i
c
a
l
co
mp
a
n
i
e
s concerning
off-label
use. We further must be able to sufficiently substantiate any claims that we make for our product candidates including claims comparing our product candidates to other companies' products and must abide by the FDA's strict requirements regarding the content of promotion and advertising.
The
FDA and
ot
h
e
r
agencies
actively
enforce
the
laws
and
regulations
r
e
garding
product
promotion,
p
a
rticularly
those
prohibiting
the
promotion
of off-label
uses,
and
a company
t
h
at
is
found
to ha
v
e
imprope
r
ly
promoted
a
produ
c
t
may
be
subject
to
s
i
gnificant
sanctions.
The
fe
d
e
ral
government
has lev
i
ed
large
c
ivil
a
nd cr
i
min
a
l
fines
aga
i
nst
c
ompan
i
e
s
for a
l
leged
improper
promotion
and
has
en
j
oined
s
e
ver
a
l
comp
a
nies
from
engaging
in off-label promotio
n
.
The
FDA
has
also
requested
that
companies
enter
into
consent
decrees
or
permanent
injunctions
under
which
specified
promotional
conduct is changed
or
curtailed.
Thus,
we
and
any
of
our
collaborators
will
not
be
able
to
promote
any
products
we
develop
for
indicat
i
ons
or
uses
for
which
they
are
not
approved.
In
the
United
States,
engaging
in
the
imp
e
rmissible
promotion
of
our
products,
follow
i
ng
approval,
for
off-label
uses
can
also
subje
c
t
us to
false
c
l
ai
m
s and
other
litigation
under
f
e
deral
and
state
statutes,
inc
l
uding
fraud
and
abuse
and
consumer
protection
laws,
which
can
lead to civil and criminal penalties and
fines,
agreements
with
governmental
authori
t
ies
that
materially
restrict
the
manner
in
whi
c
h
we
promote
or
distr
i
bute
therapeutic
products and
do
business
through,
for
example,
corporate
integrity
agreements,
sus
p
ension
or
exclusion
f
rom participation
in
fede
r
a
l
and
s
t
ate
h
e
a
l
thc
a
re
programs,
and
debarment
from
gove
r
n
ment
c
o
ntracts
and
refusal
of
future
orders
under
existing
contracts.
These
false
claims
st
a
tut
e
s
in
c
lude
the
F
CA,
which
allows
any
individual
to bring
a l
a
wsuit
against
a
biopharmaceut
i
cal
company
on
behalf
of
t
h
e
fe
d
e
ral
government
alleging
submission
of
false
or fraudulent claims
or
causing
others
to pre
s
ent
such
false
or
fraudulent
claims,
for
p
a
yment
by
a federal
program
such
as
Medic
a
re
or
Medicaid.
If
the
g
o
vernment
decides
to intervene
a
nd pr
e
va
i
ls
in
the
l
a
wsu
i
t,
t
h
e
individual
will
share
in the
proceeds
from
any
fines
or
settl
e
me
n
t
funds. If the
g
o
vernment
declines
to
inte
r
v
ene,
the
individ
u
al
may
pursue
the
case
alone.
The
s
e
FCA lawsuits
a
ga
i
nst
m
a
nufacture
r
s
of
drugs
a
nd biologics
have
increased
significantly
in
volume
and
breadt
h
,
l
e
ading
to
s
e
ver
a
l
substan
t
i
a
l
c
ivil
a
nd criminal
settlements,
up
to $3.0 billi
o
n,
pertaining
to
c
e
rta
i
n
s
a
l
e
s
practices
and
promoting
off
-
label
u
ses.
In
addition,
FCA
lawsuits
may
e
x
pose
manufacturers
to
fol
l
ow-on
claims
by
private
payo
r
s
based
on
fraudulent
marketing
practices.
This growth in litigation
has
increased
the
risk
that
a biopharmaceutical
company
will have
to
defend
a
f
a
lse
claim
action,
pay
s
e
tt
l
em
e
nt
fines
or
r
e
s
t
itu
t
ion,
as
w
e
ll
as
c
rim
i
nal
and
c
i
vil
pen
a
lt
i
es,
agr
e
e
t
o
c
omply
with
burdensome
reporting
and
compliance
obligations,
and
be
exc
l
uded
from
M
e
d
i
c
a
re,
M
e
d
i
ca
i
d,
or
ot
h
e
r
federal
and
state
hea
l
thcare
programs.
If
we
or
our future
c
oll
a
bora
t
ors
do
not
law
f
ully
promote
our approved
products,
if any,
we
may
become
s
ubject
to
such
litigation
and,
if
we
do
not
successfully
defend
against
such
actions,
those
actions
may
have
a
material
adve
r
s
e
effect
on
our
bu
s
iness,
financial
condition,
resul
t
s
of
o
perations
and
prospects.
Although
an
effective
compliance
program
can
mitigate
the
risk
of
investigation
and
pro
s
ecution
for
violations
of
these
laws,
t
he
risks cannot
be
entirely eliminated.
Moreo
v
er,
achieving
and
sustaining
c
ompl
i
an
c
e
w
i
th
a
ppli
c
ab
l
e
feder
a
l
a
nd
state
fraud
laws
may
prove
costly. Any action
against
u
s
for violation
of
these
laws,
even
if
we
succ
e
ssfully
defend
against
it,
could
cause
us
to incur
significant
legal
expenses
and
div
e
rt
our
ma
n
a
gement's
attention
from
the
oper
a
tion
of
our
business.
96
Table of Contents
Coverage
and
reimbursement may
be
limited
or
unavai
l
able
in certain
market
segments
for
o
u
r
product
candidates,
which
could
ma
k
e
it difficult
for us to sell
our product
candidates
pro
f
itably.
In both domestic and foreign markets, sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. Regulatory authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability or that of our collaborators to sell our product candidates profitably. In addition, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Patients are unlikely to use our product candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Such third-party payors include government health programs such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. Obtaining coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenues from our product candidates.
Government authorities and third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers, or those of our collaborators, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. If reimbursement is not available, or is available only to limited levels, our product candidates may be competitively disadvantaged, and we, or our collaborators, may not be able to successfully commercialize our product candidates. Alternatively, securing favorable reimbursement terms may require us to compromise pricing and prevent us from realizing an adequate margin over cost. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor's determination that use of a product is:
•
a covered benefit under its health plan;
•
safe, effective and medically necessary;
•
appropriate for the specific patient;
•
cost-effective; and
•
neither experimental nor investigational.
In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Moreover, the factors noted above have continued to be the focus of policy and regulatory debate that has, thus far, shown the potential for movement towards permanent policy changes; this trend is likely to continue, and may result in more or less favorable impacts on pricing. The recent and ongoing series of congressional hearings relating to drug pricing has presented heightened attention to the biopharmaceutical industry, creating the potential for political and public pressure, while the potential for resulting legislative or policy changes presents uncertainty.
Prices paid for a drug also vary depending on the class of trade. Prices charged to government customers are subject to price controls, including ceilings, and private institutions obtain discounts through group purchasing organizations. Net prices for drugs may be further reduced by mandatory discounts or rebates required by government healthcare programs and demanded by private payors. It is also not uncommon for market conditions to warrant multiple discounts to different customers on the same unit, such as purchase discounts to institutional care providers and rebates to the health plans that pay them, which reduces the net realization on the original sale.
97
Table of Contents
In addition, federal programs impose penalties on manufacturers of drugs marketed under a
BLA
or
NDA
, in the form of mandatory additional rebates and/or discounts if commercial prices increase at a rate greater than the Consumer Price Index-Urban, and these rebates and/or discounts, which can be substantial, may impact our ability to raise commercial prices. Cost control initiatives could cause us, or our collaborators, to decrease, discount, or rebate a portion of the price we, or they, might establish for products, which could result in lower than anticipated product revenues. If the realized prices for our product candidates, if any, decrease or if governmental and other third-party payors do not provide adequate coverage or reimbursement, our prospects for revenues and profitability will suffer.
Even if we obtain coverage for a given product, the resulting approved reimbursement payment rates might not be high enough to allow us to establish or maintain a market share sufficient to realize a sufficient return on our or their investments or achieve or sustain profitability or may require co-payments that patients find unacceptably high. If payors subject our product candidates to maximum payment amounts or impose limitations that make it difficult to obtain reimbursement, providers may choose to use therapies which are less expensive when compared to our product candidates. Additionally, if payors require high copayments, beneficiaries may decline prescriptions and seek alternative therapies. We may need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any future products to the satisfaction of hospitals and other target customers and their third-party payors. Such studies might require us to commit a significant amount of management time and financial and other resources. Our future products might not ultimately be considered cost-effective. Adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.
We, and our collaborators, cannot be sure that coverage will be available for any product candidate that we, or they, commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products, and our overall financial condition.
There have been, and likely will continue to be, legislative and regulatory proposals at the federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:
•
the demand for our product candidates, if we obtain regulatory approval;
•
our ability to set a price that we believe is fair for our product candidates;
•
our ability to generate revenues and achieve or maintain profitability;
•
the level of taxes that we are required to pay; and
•
the availability of capital.
Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. A particular challenge for our product candidates arises from the fact that they will primarily be used in an inpatient setting. Inpatient reimbursement generally relies on stringent packaging rules that may mean that there is no separate payment for our product candidates. Additionally, data used to set the payment rates for inpatient admissions is usually several years old and would not take into account all of the additional therapy costs associated with the administration of our product candidates. If special rules are not created for reimbursement for immunotherapy treatments such as our product candidates, hospitals might not receive enough reimbursement to cover their costs of treatment, which will have a negative effect on their adoption of our product candidates.
98
Table of Contents
We may face difficulties from changes to current regulations and future legislation.
In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability, or the ability of our collaborators, to profitably sell any products for which we obtain marketing approval. We expect that current laws, as well as other federal and state healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria, increased regulatory burdens and operating costs, decreased revenues from our biopharmaceutical product candidates, decreased potential returns from our development efforts, and additional downward pressure on the price that we, or our collaborators, may receive for any approved products.
Since enactment of the ACA in 2010, in both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our product candidates profitably. These changes included aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, effective April 1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2030, with the exception of a temporary suspension implemented under various COVID‑19 relief legislation from May 1, 2020 through the end of 2021, unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 ("ATRA") was approved which, among other things, reduced Medicare payments to several providers, with primary focus on the hospital outpatient setting and ancillary services, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our product candidates, if approved, and accordingly, our financial operations.
Since its enactment, various portions of the ACA have been subject to judicial and constitutional challenges. Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts to repeal or replace certain aspects of the ACA. It is unclear how judicial decisions, future litigation, and healthcare measures promulgated by the Biden administration will impact the ACA and our business, financial condition and results of operations. Complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business.
Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenues, attain profitability or commercialize our product candidates.
Legislative
and
regulatory
proposals
may
also
be
made
to
expand
post-approval
requirements
and
restrict
s
a
les
and
promotional
a
ctivities
for
drugs.
We cannot
be
sure
whether
add
i
tional
legislati
v
e
changes
will
be
enacted,
or
whether
t
h
e
FDA
regulations,
guid
a
nce,
or
interpretations
will
be
changed,
or what
the
impact
of
such
c
h
anges
on
the
m
a
rketing
approvals
of
our
produ
c
t
candidates,
if
any,
may
b
e
.
In
addition,
increased
s
c
rutiny
by
Congress
of the
FDA's
approval
process
may
si
g
nificantly
delay
or
prevent
marketing
approval,
as
w
e
ll as
subject
us
to
more
stringent
prod
u
ct
labeling
and
post-marketing
testing
and
other
requirements.
In
addition,
there
ha
v
e
been
increasing legislative efforts and enforcement interest in the United States with respect to drug pricing practices, including Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, in 2020, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives, some of which resulted in lawsuits against the U.S Department of Health and Human Services challenging various aspects of the rules. In January 2021, the Biden administration issued a "regulatory freeze" memorandum that directs department and agency heads to review new or pending rules of the prior administration. The impact of these lawsuits as well as legislative, executive, and administrative actions of the Biden administration on us and the pharmaceutical industry as a whole remains unclear.
At
the
sta
t
e
level,
legislatures
have
increasingly
passed
legislation
and
implemented
regulations
designed
to
control p
h
armaceutical
and
biological
product
pricing,
including
price
or
patient
reimbursem
e
nt
constraints,
dis
c
ounts,
restrictions
on
certain
product
access
and marketing
cost
discl
o
sure
and
transparency
measures,
an
d
,
in
some
cases,
designed
to
encou
r
age
importation
from
other
countries
and
bulk
purc
h
asing
.
We
are
unable
to
predict
the
future
course
of
federal
or
state
healthcare
l
e
g
i
s
l
at
i
on
in
the
Uni
t
ed
States
directed
at broaden
i
ng
the
availability
of healthcare
and
containing
or
lowering
the cost of
h
e
a
l
thc
a
re.
T
he
ACA and
any
further
changes
in
t
h
e
law
or
regulatory
framewo
r
k
that
reduce
our revenues
or
increase
our
costs
could
also
have
a material
and
a
d
verse
effect
on
our
business,
financial
con
d
ition
and
results
o
f
operations.
99
Table of Contents
Go
v
e
r
n
m
e
n
ts
o
u
tside
t
h
e
Un
i
ted
S
t
ates
tend
t
o
i
mpose
s
t
r
i
ct
pri
c
e
co
n
trols,
whi
c
h
may
ad
v
e
r
s
e
ly
aff
e
ct
our r
e
v
e
n
u
e
s
,
if
an
y
.
In
international
markets,
reimbu
r
sement
and
health
care
pa
y
m
ent
systems
vary
significantly
by
country,
and
many
countries
have
i
ns
t
itu
t
e
d
price
ceilings
o
n
specific
products
and
therapies.
I
n
some
countries,
p
a
rticularly
the
countries
of
t
h
e
EU,
the
pricing
of
prescript
i
on
pharmaceuticals
is
subject
to
governmental
contr
o
l.
In
these
countries,
pricing
negotiations
with
governmental
authorities
can
take
considerable
time
aft
e
r
the
r
e
c
e
ipt
of
m
a
rk
e
ting approval
for
a
product. To obtain coverage
and
reimbursement
or
pricing
approval
in s
o
me
countries,
we
may
be
required
to conduct
a
c
l
ini
c
al
tr
i
a
l
th
a
t compares
the
cost-effectiveness
of
our
product
candidate
to other
avail
a
ble
therapies.
There
can
be
no
assurance
that
our
prod
u
ct
candidates
will
be considered
cost-effective
by
third-party
payors,
that
an
adequate
level
of reimbursement
will
be
ava
i
lable,
or
that
the
third-
p
arty
payors'
reimbursement p
o
licies
will
not
adversely
affect
our
ability
to sell
our
product
c
a
ndidates
pro
f
itably.
If
r
e
imbu
r
sement
of
our
product
cand
i
dates
is unavailable
or limited in scope or amount,
or
if
pricing
is
set
at unsatis
f
actory
l
e
vels,
our
business
c
ould
be
harmed,
possibly
materially.
Our
employees,
independent
contractors,
consultants,
commercial
partners, principal investigators, CROs, suppliers
and
vendors
may
engage
in
misconduct
or
other
improper
ac
t
i
v
it
i
es, in
c
luding
non
c
omp
l
ian
c
e
with
r
e
gu
la
tory
standards
a
n
d
requirements.
We
are
exposed
to the
risk
of
employee
fraud
or
other
illegal
activity
by
our
employee
s
,
independent
contractors,
consultants,
commercial
partners, principal investigators, CROs, suppliers
and vendors.
Misconduct
by
these
parties
could
inc
l
ude
intentional,
reckless
and/or
negli
g
ent
conduct
that
fails
to:
comply
with
t
h
e
laws of the
F
DA and other similar
foreign
regulatory
bodies,
provide
true,
complete
and accurate
information
to the
FDA
and
other
similar
foreign
r
egulatory
bodies,
comply with
manufacturing
standards
we
have
established,
comply
with
h
e
alt
h
care
fraud
and
abuse
laws
in
the
Un
i
t
e
d
S
ta
t
es
a
nd si
m
il
a
r
foreign
f
r
audulent misconduct
laws,
or
report
f
i
nancial
i
n
f
ormation
or
data
accu
r
ately
or
to disclose
unauthorized
activities
to
us.
I
f
we
obtain
FDA
approval
of
any
of
our prod
u
ct
candidates
and
begin
comm
e
rcializing
those
product
candidates
in the
United
States, our
potential
exposure
under
such
l
aws will
in
c
re
a
se sig
n
ificantly,
and o
u
r
costs
associated
with
compliance
with
such
laws
are
also
likely
to
increase.
In
particular,
the
promotion,
sales and
marketing
of
healthcare
items
and
services,
as
well
as
certain
business
a
r
rangements
in the
healthcare
industry,
are
subje
c
t
t
o
extensive laws designed to prevent
fraud,
kickb
a
cks,
self-dealing
and
other
abusive
pra
c
ti
c
es.
Th
e
s
e
l
a
ws
and
regulations
may
restrict
or
prohibit
a
wide
range
of pricing, discounting,
mar
k
eting
and
promotion,
structuring
and
commission(s),
certain
customer
incentive
programs
and
other
bu
s
iness
arrangements generally.
Activities
subject
to these
laws
also
involve
the
improper
use
of
information
obta
i
ned
in
the
course
of
patient
rec
r
uit
m
ent
for
c
l
i
nic
a
l
tri
a
ls.
It is
not
always
possible
to identify
a
nd deter
misconduct
or
other
imp
r
oper
activities
by
our
employ
e
es
or
third
parties
that
we
engage
for
our
business o
p
erations and
the precautions
we
take
to
detect
and
prevent
inappropriate
conduct
may
not
be
e
ffective
in
cont
r
o
lli
n
g
unknown
or
unmanaged
risks or
losses
or
in protecting
us
from
governmental
investigations
or
other
actions
or
lawsuits
stemming
from
a failure
to comply
with
such
laws
or regulations.
If
any such
actions
are
instituted
against
us,
a
nd we
are
not
successful
in defending
oursel
v
es
or
asserting
our rights,
those
actions
could
have
a si
g
nificant impact
on
our
business,
including
the
imposit
i
on
of civil,
criminal
and
administrative
penalties,
d
a
mages,
disgorgement,
monetary
fines,
possible exclusion
from
participation
in Medicare,
Medicaid
and
other
fed
e
ral
healthcare
programs,
contr
a
ctual
damages,
reputational
ha
r
m,
diminished
profits and
future
earnings,
compliance
agreeme
n
ts,
withdrawal
of
product
approvals,
and
c
u
rtailme
n
t
of
our oper
a
tions,
among
other
th
i
ngs,
any of which could adversely affect
our
ability
to oper
a
te
our
business
and
our
results
of
operations.
In
addition,
the
approval
and
commer
c
ialization
of
any
of
our prod
u
ct
candidates
outside
the
United
States
will
also
likely
subject
us
to
foreign
equivalents
of the
healthcare
laws
mention
e
d
above,
among
other foreign
laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs.
100
Table of Contents
R
i
s
k
s R
e
lat
e
d
to I
n
te
l
le
c
tual
P
r
o
p
er
t
y
If
we
are
unable
to obtain,
mai
n
tain,
protect
and
enfor
c
e
patent
protection
and
other
proprietary
rights for
our
product
candi
d
ates
and technologies, we
may
n
ot be
able
to
c
omp
e
t
e
e
ffectively
or
oper
a
te profitably and our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected.
Our success is dependent in large part on our obtaining, maintaining, protecting and enforcing patents and other proprietary rights in the United States and other countries with respect to our product candidates and technology and on our ability to avoid infringing the intellectual property and other proprietary rights of others. Certain of our intellectual property rights are licensed from other entities, and as such the preparation and prosecution of any such patents and patent applications was not performed by us or under our control. Furthermore, patent law relating to the scope of claims in the biotechnology field in which we operate is still evolving and, consequently, patent positions in our industry may not be as strong as in other more well-established fields. The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved and has been the subject of much litigation in recent years. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. As a result, the issuance, scope, validity, enforceability, or commercial value of our patent rights remain highly uncertain.
Any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing therapeutics and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, any of our issued or granted patents will not later be found to be invalid or unenforceable, or any issued or granted patents will include claims sufficiently broad to cover our product candidates and technology, or to provide meaningful protection from our competitors. Our owned or in-licensed pending and future patent applications may not result in patents being issued which protect our Anktiva, hAd5, aldoxorubicin or other product candidates or other technologies or which effectively prevent others from commercializing competitive technologies and product candidates.
Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or in-license may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether our Anktiva, hAd5 or other product candidates or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and growth prospects.
The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and it is uncertain how much protection, if any, will be provided by our patents, including if they are challenged in the courts or patent offices or in other proceedings, such as re-examinations or oppositions, which may be brought in the United States or foreign jurisdictions to challenge the validity of a patent. A third party may challenge the validity or enforceability of a patent after its issuance. It is possible that a competitor may successfully challenge our patents or that a challenge will result in limiting their coverage. Moreover, it is possible that competitors may infringe our patents or successfully avoid the patented technology through design innovation. To stop these activities, we may need to file a lawsuit.
We or our licensors may be subject to a third-party preissuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant and
inter partes
review, or interference proceedings or other similar proceedings challenging our owned or licensed patent rights. Should third parties file patent applications, or be issued patents claiming technology also used or claimed by our licensor(s) or by us in any future patent application, we, or one of our licensors, may be required to participate in interference proceedings in the USPTO to determine priority of invention for those patents or patent applications that are subject to the first-to-invent law in the United States, or may be required to participate in derivation proceedings in the USPTO for those patents or patent applications that are subject to the first-inventor-to-file law in the United States. We may be required to participate in such interference or derivation proceedings involving our issued patents and pending applications. We may also be required to participate in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or our licensor's priority of invention or other features of patentability with respect to our owned or in-licensed patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our Anktiva, hAd5 or other product candidates and other technologies. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our owned or in-licensed patent rights, allow third parties to commercialize our Anktiva, hAd5 or other product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.
101
Table of Contents
If we or our collaborators are unsuccessful in any such proceeding or other priority or inventorship dispute,
w
e may be required to cease using the technology or to
obtain and maintain
license rights from prevailing third parties
,
including parties involved in any such interference proceedings or other priority or inventorship disputes. A prevailing party in that case may not offer us a license on commercially acceptable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products.
Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.
In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.
Some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. In addition, certain of our licensors co-own the patents and patent applications we in-license with other third parties with whom we do not have a direct relationship. Our exclusive rights to certain of these patents and patent applications are dependent, in part, on inter-institutional or other operating agreements between the joint owners of such patents and patent applications, who are not parties to our license agreements. If our licensors do not have exclusive control of the grant of licenses under any such third-party co-owners' interest in such patents or patent applications or we are otherwise unable to secure such exclusive rights, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and growth prospects.
If
any of
our owned
or in-lice
n
sed
patent
applications
do
not issue
as
patents
in any
jurisdi
c
tion,
we
may
not
be
able
to
compete
e
f
fec
t
i
v
el
y
.
Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties. The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in any of our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.
102
Table of Contents
We
or our licensors, collaborators, or any future strategic partners
may be
come subject to third
party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation
to protect or enforce our patents or other intellectual property or the patents or other intellectual property of our licensors,
all of
which could be expensive, time-consuming and unsuccessful
, may delay or prevent the development and commercialization of our product candidates, or may put our patents and other proprietary rights at risk
.
Competitors and other third parties may infringe, misappropriate or otherwise violate our patents or other intellectual property or the patents or other intellectual property of our licensors. In addition, our patents or the patents of our licensors also may become involved in inventorship, priority or validity disputes. To counter infringement or other unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming, even if we were successful in stopping the violation of our patent rights.
If we or one of our licensors initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or other technologies, the defendant could counterclaim that the patent is invalid and/or unenforceable or that we infringe their patents. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or other applicable body, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review,
inter partes
review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings).
With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our licensor, our or our licensor's patent counsel and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business, financial condition, results of operations and prospects.
The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources, including our scientists and management, from our business.
An adverse result in any litigation or defense proceeding could put one or more of our owned or licensed patents at risk of being invalidated, held unenforceable, or interpreted narrowly, and could put our patent applications at risk of not issuing. Such proceedings could result in revocation or cancellation of, or amendment to, our patents in such a way that they no longer cover our product candidates or technologies. If the outcome of litigation is adverse to us, third parties may be able to use our patented invention without payment to us. In addition, in an infringement proceeding, there is a risk that a court may decide that one or more of our patents is not valid or is unenforceable and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of our patents were upheld, a court would refuse to stop the other party on the grounds that its activities are not covered by, that is, do not infringe, our patents. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.
In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be better able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.
103
Table of Contents
T
h
e
u
se
of
o
u
r t
e
c
h
no
l
ogy
a
n
d
product
candidates
could
pote
n
t
ia
l
ly
confli
c
t
with
the
rights of
others,
and
third-party
claims
of
intellectual
property in
f
r
ingement,
misappropriat
i
on
or
other
violation
against
us,
our
licensors
or
our
collaborators
may
prevent
or
delay
the
deve
l
opment
and com
m
ercia
l
ization
of
our
product
candidates
a
n
d
technologies.
Our com
m
er
c
ial
suc
c
ess
dep
e
nds
in
part
on
ou
r
,
our
lice
n
sors'
and
our
collaborators'
ability
to avoid
infringing,
misappropriating
and
otherwise
violating the
patents
and
other
intellectu
a
l
property
rights
of
third
parties.
There
is
a
substantial
amount
of
complex
litiga
t
ion
involving
patents
and
other intellectual
property
rights
in
the
biopharmaceutic
a
l
industry.
Our
potential
competitors
or other
parties
may
have,
develop
or acquire
patent
or
other intellectual
property
rights
that
they
could
assert
again
s
t
us.
If
they
do
so,
then
we
may
be
required
to
alter
our
product
candidates,
pay
lic
e
nsing
fees
or cease
our
development
and
comme
r
cialization
activiti
e
s
with
respect
to the
applicable
product
candidates
or
technologies.
If
our
product
candidates conflict
with
patent
or
other
intellectual
property
rights
of
others,
such
parti
e
s
could
bring
legal
act
i
ons
against
us
or
our
collaborators,
licensees,
suppliers
or
customers,
claim
i
ng
damages
and
seeking
to enjoin
manufacturing,
use
and
marketing
of the
affected
products.
Although
we
have
conducted
fr
e
edom
-
to-operate
("
FTO")
analyses
of
the
patent
landscape
with
respect
to our
lead
product
candi
d
ates
and
continue
to u
n
dertake
FTO
analyses
of
our
manufacturing
processes,
our
Anktiva
product
candidate,
and
contemplated
future
processes
and
pr
o
ducts,
because
patent applications
do
not
p
ublish
for
18 months,
and
because
the
claims
o
f
patent
applicat
i
ons
can
change
ov
e
r
ti
m
e,
no F
T
O
analysis
can
be
considered
exhaustive.
We
may
not
be
aware
of
patents
that
have
already
been
issued
and
that
a
competitor
or
other
third
party
m
i
ght
a
s
sert
are
infringed
by
our
c
u
r
rent
or
future
product
c
a
ndidates
or
technologies.
It
is also
possible
that
we
could
be
found
to have
infringed
patents
owned
by
third
parties
of
which
we
are
aware,
but
which
we
do
not
believe
are
relevant
to our
product
candidates
or
technologies.
In
addition,
because
patent
applications
can
take
many
years
to
i
s
su
e
,
th
e
re
m
a
y
be
curr
e
ntly
pending
patent
a
ppli
c
a
t
ions
th
a
t
may
l
a
ter
result
i
n issued
p
atents
that
our
product candidates
or
technologies
may
i
n
f
r
inge.
Furthermore,
patent
and
other
intellectu
a
l
property
rights
in
biotechnology
remains
an
evolving
area
with
many risks
and
uncertainties.
As
such,
we
may
not
be
able
to ensure
that
we
can
market
our
product
candidates
without
conflict
with
the
rights
of
others.
If
intellectual
property-related
leg
a
l
ac
t
ions
a
s
s
e
r
t
ed
aga
i
nst
us
a
re
su
c
c
e
s
sful,
i
n
a
ddit
i
on
to
any
pot
e
nti
a
l
l
i
a
bil
i
ty
for
d
amages
(including
treble
damages
and
attorneys'
fees
for
willful
i
n
fringement),
we
could
be
enjoined
from,
or required
to obtain
a
license
to
continue,
manufacturing,
promoting
the
use
of
or
marketing
the
affected
p
r
o
d
ucts.
We
may
n
ot prevail
in any
legal
a
c
tion
and
a
required
license
under
the
applicable
patent
or
other
int
e
ll
e
ctu
a
l proper
t
y m
a
y
not
be
available
on
acceptable
terms
or
at
a
ll.
E
ven
if we were
a
ble
to
obta
i
n
a
l
i
c
e
ns
e
,
it
cou
l
d
be
non-exclusive,
thereby
giving
our
competitors
and
other
t
h
ird
parties
access
to
the
same
technologies
licensed
to
us,
and
it could
require
us
to make
substantial
licensing
and
royalty
payments.
We
also
cou
l
d
be
required
to redesign
our
infringing
p
r
o
ducts,
which
may
be
impossible
or
require
substantial
time
and
monetary
expenditure.
Defense
of
i
n
f
ringement
claims,
regardless
of
their
merit,
wou
l
d
involve
substantial
litigation
expense
and
would
be
a
substan
t
ial
diversion
of management
and
other
employee
re
s
ources
from
our
business, and
may
i
m
pact
our
reputation.
Some
of our
competitors
may
be
able
to
su
s
t
a
in
the
c
osts of
litigation
or
administrative
proceedings
more
effectively
than
we
can
because
of
greater
fin
a
ncial
resources.
In
addition,
t
here
could
be
public announcements
of
the
results
of
hearings,
m
o
tions,
or
other
interim
proceedings
or
dev
e
lopments,
and
if securities
analysts
or investors
per
c
e
i
v
e
th
e
s
e results
to be
negative,
it
could
have
a
substantial
adve
r
s
e
effect
on
the
price
of
our
common
s
t
ock.
The
occurrence
of
any
of
t
he
foregoing
could
have
a material
adve
r
s
e
effect
on
our
bu
s
iness,
financial
condition,
resul
t
s
of
o
perations
and
prospects.
Obtaining
and
maintaining
our
patent
prote
c
tion
depends
on
compliance
with
various
procedural,
do
c
ument
submission,
fee
paymen
t
,
and other requirements
imposed
by
govern
m
ent
patent
agencies,
and
our
patent
protection
could
be
red
u
ced
or eliminated
for non-compliance
with
th
e
se
r
e
qu
i
r
e
m
e
n
t
s.
Periodic
maintenance
fees,
renewal
fees,
annuity
fees,
and
various
other
government
fees
on
pat
e
nts
and
patent
applications
are
due
to
be
p
a
id
to
t
he USPTO and
foreign
patent
agencies
in several
stages
over
the
lifetime
of
a
patent.
The
USPTO
and
various
fore
i
gn
governmental
pat
e
nt
agen
c
i
e
s require
compliance
with
sever
a
l
procedural,
documentary,
fee
payment
and
other
similar
provisions
during
the
pat
e
nt
application
p
r
ocess.
In
certain circumstances,
we
rely
on
our
licensors
to pay
these
fees
and
take
the
ne
c
e
ss
a
ry
ac
t
ions
t
o co
m
ply
w
i
th
t
hese
requi
r
e
m
e
nts.
Wh
i
le
an
inadvertent
lapse can
in
many
cases
be
cured
by
payment
of
a late
f
e
e
or by
o
t
her
me
a
ns
in
a
c
cord
a
n
c
e
with
the
app
l
ic
a
ble
rul
e
s,
there
a
re
s
i
tua
t
ions
in
which n
o
ncompliance
can
result
in ab
a
ndonment
or
lapse
of
the
patent
or
patent
applica
t
ion,
resulting
in partial
or
complete
loss
of
patent
rights
in the
relevant jurisdiction.
Noncompliance
e
v
ents
that
cou
l
d
result
in abandonment
or
lapse
of
a
patent
or
patent
applica
t
ion
inclu
d
e,
but
are
not
limited
to,
failure
to respond
to
official
actions
within
prescribed
time
limits,
non-payment
of
fees
and
failure
to properly
legalize
and
submit
formal
documents.
In
such
an event,
our
competitors
might
be
able
to e
n
ter
the
market
with
similar
or
identical
products
or
technology,
which
would
have
a mat
e
rial
a
dverse
imp
a
ct on
our
business, financial
condition,
results
of
operations
and
prospects.
104
Table of Contents
Changes
in
United
States
patent
law
could
diminish
the
value
of patents
in general,
t
h
e
r
e
by
i
m
pairing
our
ability
to
protect
our product
candidates.
As
is
the
case
with
other
i
m
munotherapy
and
biopharmaceutical
companies,
our
success
is dependent
on
intellec
t
ual
property,
particularly
patents. Obtaining
and
enforcing
patents
in the
b
i
opharmaceutical
industry
invol
v
e
both
technological
and
legal
complexity,
and
is ther
e
fore
costly,
time-consuming
and
inherently
uncertain.
In
a
ddit
i
on,
the
Unit
e
d
S
t
a
tes
h
a
s
r
e
cen
t
ly
ena
c
ted
and
is currently
implementing
wide-ranging
patent
reform legislation.
Assuming
that
other
requir
e
m
e
nts
for pat
e
nt
a
bil
i
ty
a
re
m
e
t,
prior
to
M
a
rch 2013,
i
n
t
he
Un
i
ted
S
t
at
e
s,
the
first
t
o
invent
the
claimed
invention
was
entitled
to t
h
e
p
a
t
e
nt,
while
outside
t
he
Un
i
ted
S
t
a
t
es,
the
first
to
file
a
p
a
tent
a
ppli
c
at
i
on
was
e
nt
i
tl
e
d
to
t
he
patent.
After
March 2013, u
n
der
the
Leahy-Smith
America
Inv
e
nts
Act
(
the
"
America
Invents
Act")
enacted
in September 2011,
the
United
States
transitioned
to a
first-to-file
system
in
which,
assuming
that
other
requir
e
men
t
s
for
p
a
t
e
ntab
i
li
t
y
a
re
m
e
t
,
the
first
inventor
to file
a
patent
application
w
i
ll
be
en
t
it
l
ed
t
o
t
he
p
a
t
e
nt
on an
invention
regardless
of
whether
a
third
party
was
the
first
to invent
the
claimed
inve
n
t
ion.
A
third
party
that
files
a
pat
e
nt
application
in the
USPTO after
March 2013,
but
before
us
could
the
r
efore
be
awarded
a patent
covering
an
invention
of
ours even
if we
had
made
the
inve
n
tion
before
it was
made by
such
third
party.
This
will
require
us
to be
co
g
nizant
of
the
time
from
invention
to
filing
of a
patent
application.
Since
patent
appli
ca
t
ions
in
the United
States
a
n
d
most
other
countries
a
r
e
con
f
idential
for
a
period
of
time
after
filing
or
until
issuance,
we
cannot
be
cert
a
in
that
we
or
our
licensors were the
first
to
either
file
any
patent
ap
p
l
ication
r
e
lated
to our
product
candidates
or
other
technologies
or
invent
any
of
t
he
inventions
c
l
aimed
in
our
or o
u
r
licensor's
patents
or
patent
applications.
The
Ame
r
ica
I
nvents
Act
also
includes
a
n
u
mber
of
significant
changes
that
affect
the
way patent applications
will
be
pro
s
e
c
ut
e
d
a
nd
a
l
so
m
a
y
a
ffect
patent
litig
a
t
i
on.
These
in
c
lude
a
l
lowing
thi
r
d-party
submission
of
p
r
ior
art
to the
USPTO during patent
p
r
osecution
and
additional
proced
u
r
es
to
attack
the
validity
of
a p
a
tent
by
USPTO-administered
post
-
g
r
ant
proceedings,
i
ncluding
post-grant review,
int
e
r
pa
r
t
e
s
review,
a
n
d
derivation
proceedings.
There
f
ore,
the
America
Invents
Act
and
its
imp
l
ementation
could
increase
the
uncertainties
and costs
surrounding
the
prosecution
of
our
owned
or
in-licensed
patent
appli
c
ations
and
the
enforcement
or
defense
of
our
owned
o
r
in-licensed
issued patents,
all
of
which
c
ould
have
a material
adverse
effect
on
our
business,
financial
condition,
res
u
lts
of
operations,
and
prosp
e
c
ts.
Additionally,
recent
U
.
S.
Supreme
Court
rulings
have
narr
o
wed
the
scope
of
patent
pro
t
ec
t
ion
ava
i
lab
l
e
in
cer
t
a
in
c
i
rcu
m
s
t
anc
e
s
and
weak
e
ned
the rights
of
patent
owners
in
cer
t
ain
situations.
I
n
addition
to
i
n
creasing
uncertainty
with
regard
to
our
ability
to obtain
pate
n
ts
in
the
futur
e
,
this comb
i
nat
i
on
of even
t
s
has
cre
a
t
e
d
unc
e
rt
a
inty
with
respe
c
t
t
o the
value
of
patents,
once
ob
t
ained. Depending
on
decisio
n
s
by
Congress,
the
federal courts,
and
the
USPTO,
t
h
e
laws
and
regulations
governing
patents
could
change
in unpredictable
ways
that
would
weaken
our
abi
l
ity
to
obtain
new patents
or
to
enforce
our
exist
i
ng
patents
and
patents
that
we
m
i
ght
obtain
in
the
fut
u
re.
While
we
do
not
believe
that
any
of
the
patents
ow
n
e
d or licensed
by
us
will
be
found
invalid
based
on
the
foregoing,
we
cannot
predict
how
future
decisions
by
Congress,
the
federal
c
o
urts
or
the
USPTO
may impact
the
value
of
our
patents.
Our
rights
to
develop
and
comme
r
cialize
our
product
cand
i
dates
and
technologies
are
s
u
b
j
ec
t
,
in
part,
to
the
t
e
r
m
s
and condit
i
o
ns
of
l
i
c
e
n
s
es granted
to
us
by
others.
We
will
rely
on
licenses
to cer
t
ain
patent
rights
and
proprietary
technology
from
third
parties
t
h
at
are
important
or
necessary
to the
developme
n
t
of aldoxorubicin
and
products
enabled
by
our
yeast,
inclu
d
ing
T
armogen,
technologies.
License
agreements
may
not
prov
i
de
exclusive
r
ights
to use
certain
licensed
i
n
tellectual
property
and
technology
in all
releva
n
t
fiel
d
s
of
use
and
in all territories
in
which
we
may
wish
to
dev
e
lop
or
commercialize
our
technology
and
produ
c
t
candidates
in the
f
uture.
As
a result,
we
may
not
be
able
to prevent
competitors
or
other
third
parties
from
developi
n
g
and
commercializing
competitive
products
that
a
l
so utilizes
technology
that
we
have in-l
i
cens
e
d.
In
addition,
subject
to
the
terms
of
any
s
u
ch
license
agreements,
we
do
n
ot have
the
right
to
control
the
preparation,
filing,
prosecution
and
maintenance, and
we
may
not
have
the
right
to
control
the
enforcement,
and
defense
of
patents
and
patent
appli
c
ations
covering
the
technology
that
we l
i
cense
from third
parties.
We
cannot
be
cer
t
ain
that
our
in-licensed
or
out
-
licensed
patents
and
patent
applications
that
are
controlled
by
our
licensors
or
licensees will
be
prepa
r
ed,
filed,
prosecuted,
maintained,
enforced,
a
n
d
defended
in
a manner
con
s
istent
with
the
best
interests
of
our
b
usiness.
If
our
licensors
or li
c
e
ns
e
es
f
a
il
to
pros
e
c
ut
e
,
m
a
int
a
in,
e
nforce,
and
defend
such
patents,
or
lose
rig
h
ts
to
those
patents
or
patent
application
s
,
the
rights
we
have
licensed may
be
reduced
or
eliminated,
our
right
to
develop
and
commercialize
A
nktiva
and
any
of
our product
candidates
that
are
subject
of
such
licensed
rights could
be
adversely
affec
t
ed,
and
we
may
not
be
able
to prevent
competitors
from
making,
using
and
s
e
lling
competing
products.
I
n
addition,
even
where we
have
the
right
to
control
patent
prosecution
of
patents
and
patent
applications
we have
licensed
to and
from
third
parties,
we
may
still
be
adversely affected
or
prejudiced
by
actions
or
inact
i
o
ns
of
our
licensees,
our
licensors
and
the
i
r
counsel
that
took
place
prior
to the
date
upon
which
we
assumed control
over
patent
prosecution.
105
Table of Contents
Furthermore,
our
owned
and
in-li
c
ensed
patents
may
be
su
b
j
ect
to
a reservation
of
rights
by
one
or
more
third
parties.
For
example,
certain
of
our in-licensed
intellectual
property
was
funded
in part
by
the
U.S.
government.
As a
res
u
lt,
t
h
e
U.S.
government
m
a
y
have
certain
rig
h
t
s
to
s
u
c
h
in
t
e
l
l
e
c
tu
al
property.
When
new
technologies
are
deve
l
oped
with
U.S.
government
f
unding,
the
U.S.
gover
n
ment
generally
obtains
certain
righ
t
s
in
any
resulting patents,
including
a non-exclusive
license
au
t
horizing
the
U.S.
gover
n
ment
to
use
the
invention
or
to
have
others
use the
invention
on
its
behalf.
The U.S.
government's
righ
t
s
may
also
permit
it to
disclose
the
funded
inventions
and
technology
to third
parties
and
to exercise
m
arch-in
rights
to
use
or allow
third
parties
to use
the
technology
we
have
licensed
that
was
developed
using
U.S.
government
funding.
The
U.S.
government
may
ex
e
rcise
i
t
s march-in
rights
if it determines
that
action
is
necessary
because
we fail
to achieve
practical
a
pplication
of
the
government-funded
technology,
or
because ac
t
ion
is ne
c
e
ssary
to
a
ll
e
vi
a
te
he
a
lth
or
saf
e
ty
ne
e
ds,
t
o m
e
et
requirements
of
fed
e
ral
regulations,
or
to
give
preference
to
U.S.
industry.
In
addition,
our rights
in such
inventions
may
be
subject
to
certain
requirements
to
manufact
u
re
products
embodying
s
u
ch
inventions
in
the
Unit
e
d
Stat
e
s
in c
e
rt
a
in circumstances
if this
requir
e
ment
is not
waived.
Any
exercise
by
the
U.S.
government
of
such
rights
or
by
any
third
party
of
its
reserved
rights
could have
a
material
adverse
effect
on
our
competitive
positi
o
n,
business,
financial
cond
i
tion,
results
of
operations
and
growth
prosp
e
c
t
s
.
If
we
fail
to
comp
l
y
with
our
obl
i
gations
i
n t
h
e
agr
e
em
e
n
t
s
u
n
der
wh
i
c
h
we
l
i
c
e
n
s
e
i
n
tellectual
property
r
i
ghts
from
third
par
t
ies
or otherwise experience
disruptions
to our
business
r
e
lat
i
o
n
s
h
ips
with
o
u
r lic
e
n
s
ors,
we may be required to pay damages and
we
co
u
l
d lo
s
e
l
ic
e
n
s
e
righ
t
s
t
h
at
are
important
to our
b
u
s
i
n
e
s
s
.
We
have
en
t
e
r
e
d
in
t
o
l
ic
e
nse
a
gre
e
men
t
s
with
third
par
t
ies
and
may
need
to
obtain
additional
lice
n
ses
from
others
to advance
our
research
or
allow commercialization
of
our
product
c
a
ndidates.
It
is possible
that
we
may
be
unable
to
obtain
additional
licen
s
es
at a reasonable
cost
or
on
reasonable terms,
if at all.
In
that
event,
we may
be
r
e
quired
to expend
sign
i
ficant
time
and
resources
to redesign
our
technology,
product
candidates,
or
the methods
for
manufacturing
them
or
to
deve
l
op
or
license
replace
m
ent
technology,
all
of
which
may
not
be
feasible
on a
technical
or
commercial
basis. If
we
are
unable
to
do
so,
we
may
be
unable
to
develop
or
com
m
ercialize
the
aff
e
cted
product
candidates
or
continue
to utilize
our
existing
technology, which
could
harm
our
business, financial
condition,
results
of
operations
and
growth
prospects
significan
t
ly.
We
cannot
provide
any
assurances
that third-party
p
a
tents
do
not
exist
which
might
be
enforced
aga
i
nst
our
current
technology,
manufacturing
methods,
p
r
o
duct
candid
a
tes,
or
future
methods or
products
resulting
in either
an
injunct
i
on
prohibiting
our
man
u
f
acture
or
fut
u
r
e
sales,
or,
with
respect
to our
future
sale
s
,
an
obligation
on
our
part
to pay
royalties
and/or
other
forms
of
compensation
to third
parti
e
s,
which
could
be
significant.
In
addition,
each
of
our
license
agreements,
and
we
expect
our
future
agreements,
will
im
p
ose
various
development,
diligence,
c
ommercialization,
and other
obligatio
n
s
on
us.
Certain
of
our
license
agreements
also
r
e
quire
us
to
meet
development
ti
m
el
i
nes,
or
t
o
e
xerc
i
se
c
omm
er
cially
reasonable efforts to develop
and
commercialize
licensed
product
s
,
in
order
to
maintain
the
licenses.
In
spite
o
f
our
efforts,
our
licensors
mig
h
t
conclude
that
we
have ma
t
e
ri
a
l
l
y
bre
a
ch
e
d
our oblig
a
tions
und
e
r
such
l
i
c
e
nse
ag
r
ee
m
e
n
ts
a
nd
might
ther
e
fore
t
e
rmin
a
te
the
lic
e
nse
a
gr
e
ements,
th
e
reby
removing or limiting our ability to develop
and
com
m
ercialize
products
and
t
e
chnology
covered
by
these
license
agr
e
ements.
If
these
in-licenses
are
t
e
rmin
a
t
e
d,
or
if
the u
n
derlying
patents
fail
to provide
the
int
e
nded
exclusivity,
competitors
or
other
third
parties
would
have
t
h
e
freedom
to
seek
regulatory
approval
of, and to market,
products
identical
to
ours and
we
may
be
required
to
cease
our development
and
commerciali
z
ation
of
certain
of
our
product
candidates
or
of Anktiva.
Any
of
the
foregoing
could
have
a
material
adver
s
e
effect
on
our
comp
e
titive
position,
business,
financial
conditions,
results
of
o
p
erations
and growth
prospects.
106
Table of Contents
Moreover,
disputes
may
arise
regar
d
ing
intellectual
property
subject
to
a licensing
agr
e
ement,
including:
•
t
he
scope
of
rights
granted
un
d
er the
license
a
g
r
e
em
e
nt
and
o
t
her
int
e
rpre
t
a
t
i
on-re
l
a
t
e
d
i
s
sues;
•
t
he
extent
to which
our
technology
and
p
r
ocesses
infringe
on
intellectual
property
of
the
licensor
that
is not
subject
to
the
l
i
censing agr
e
em
e
nt;
•
t
he
sublicensing
of
patent
a
nd
other
rights
under
our
collaborative
development
relationships;
•
our
diligence
obligations
under
the
license
agreement
and
what
activ
i
ties
satisfy
those
diligence
obligations;
•
t
he
inventorship
a
n
d
ownership
of
inventions
and
know-how
resulting
from
the
joint
c
r
eati
o
n
or use of
intellect
u
a
l
property
by our licensors
and
us
a
nd
our
pa
r
tners;
and
•
t
he
priority
of
invent
i
on
of
patented
technology.
In
addition,
the
agreements
und
e
r
which
we
curre
n
t
ly
license
i
n
tellectual
property
or
technology
from
third
parties
are
complex,
and
certain
provisions in such agr
e
e
m
ents
m
a
y
be
susc
e
ptib
l
e
to
m
ult
i
ple
in
t
e
rpr
e
ta
t
i
ons.
The
resolution
of any
contract
interpretation
disagreement
that
may
arise
could narrow what
we
believe
to
be
the
scope
of
our
rights
to
the
relevant
i
n
tellectual
property
or
technology,
or
increase
what
we
b
elieve
to be
our
financial or
other
obligations
under
t
h
e
relevant
agreement,
either
of
which
could
have
a material
adverse
eff
e
ct
on
our
business,
financial
condition,
results
of o
p
erations
and
growth
prospects.
Moreover,
if disputes
over
intellectual
property
that
we
have
l
i
censed
prevent
or
impair
our
a
b
i
li
t
y
to
m
a
int
a
in
our current
l
ic
e
ns
i
ng
arrangements
on com
m
erc
i
a
l
ly
a
c
c
e
pt
a
ble
t
e
rms,
we
m
a
y
be
unable
to successfully
develop
and
commerci
a
li
z
e
the
aff
e
c
t
ed
p
r
odu
c
t
c
a
ndida
t
e
s,
wh
i
ch
could
have
a material
adve
r
s
e
effect
on
our
busi
n
ess,
financial
conditions,
results
of operations
and
growth
prospects.
We have
l
i
mi
t
e
d
for
e
ign
int
e
l
l
ec
t
ual
proper
t
y rights
and
may
not
be
able
to
protect
o
u
r intellectual
property
rights t
h
roug
h
out
the
world.
We
have
limited
int
e
llectual
property
rights
outside
the
United
States.
Filing,
prosecuting
and
def
e
nding
patents
on
product
c
a
ndidates
in all
countries throughout
the
world
would
be
prohibitively
expensive,
and
our
intellectual
property
rights
in some
countries
outside
the
Unit
e
d
S
t
a
tes
can
be
l
e
ss extensive
than
those
in
the
Uni
t
ed
States.
In
addition,
the
laws
of
some
foreign
countries
do
not
protect
int
e
llectual
property
rights
to
the
s
a
me
e
xt
e
nt
a
s feder
a
l
and
s
t
ate
l
a
ws
in
the
Unit
e
d
St
a
te
s
.
Consequently,
we
may
not
be
able
to p
r
event
third
parties
from
p
r
acticing
our
inv
e
ntions
in all
countries o
u
tside
the
United
States,
or
from
selling
or importing
products
made
using
our
inventions
in and
into
t
h
e
United
States
or other jurisdictions. Competitors may
use
our
technologies
in
jurisdictions
where
we
have
not
obtained
patent
protection
to
develop
their
own
products
and
further,
may export
otherwise
in
f
ringing
products
to territories
w
h
ere
we
have
patent
protection,
but
enforcement
is
not
as
strong
as
that
i
n
the
Unit
e
d
Stat
e
s.
The
s
e prod
u
cts
may
compete
with
our
product
candid
a
tes
and
our
patents
or
other
intellectual
property
rights
may
not
be
effective
or
suff
i
ci
e
nt
to pr
e
vent
th
e
m from
c
omp
e
ting.
Many
companies
ha
v
e
encountered
significant
problems
in protecting
and
defending
intellectual
property
rights
in foreign
juris
d
ictions.
The legal systems
of
certain
countries,
particularly
certain
developing
c
ount
r
ies,
do
not
favor
the
enforcement
of
patents,
trade
secrets
and
other
intellectual
property
protection,
parti
c
ularly
those
relating
to
biopharma
c
eutical
p
r
o
d
ucts,
whi
c
h
could
make
it
diffic
u
lt
for
us
to
stop
the
infringement
of
our
patents
or
marketing
of
competing
products
in
vio
l
ation
of
our
proprietary
rights
generally.
Proceedings
to
enforce
our
patent
rights
i
n foreign
jurisdictions could
result
in
substantial
costs
and
divert
our
efforts
and
attention
from
other
aspects
of
our
business,
could
put
our
patents
at
risk
of
being
invalidated or
interpreted
narrowly
and
our
patent
appli
c
ations
at risk
of
not
issuing
and
could
provoke
third
parties
to assert
claims
ag
a
inst
us.
We
may
not
prevail in
a
ny
l
a
wsu
i
ts
t
h
a
t
we
i
nit
i
at
e
,
and
the
damages
or
other
r
e
medies
awa
r
ded,
if any,
may
not
be
c
o
m
m
er
c
ia
l
ly
me
a
ningful.
A
c
cordingly,
our
e
f
forts to enforce
our
intellectual
property
rights
around
the
world
may
be
inadequate
to
obtain
a significant
commercial
advantage
from
the
intellectual
property that
we
develop
or
license.
Many
countries
have
compulsory
licensing
laws
under
which
a
patent
owner
may
be
compelled
to
grant
licenses
to
third
parties.
I
n
addition,
many countries
limit
the
enforceabili
t
y
of
patents
against
government
agencies
or
gov
e
rnment
contractors.
In
these
countries,
the
patent
owner
may
have li
m
it
e
d
r
e
med
i
es,
wh
i
c
h
could
materially
diminish
the
value
of such
patent.
If
we
or
any
of
our
licensors
is
forced
to
grant
a
l
i
c
e
nse
to
th
i
rd
pa
r
ti
e
s
w
i
th respect
to any
patents
relevant
to
our
business,
our
competi
t
ive
position
may
be
impaired,
and
our
business,
financial
conditi
o
n,
results
of
operations
and prospects
may
be
a
dversely
affected.
107
Table of Contents
We
may
be
subject
to claims
that
our employees,
consultants or i
n
depende
n
t
co
n
trac
t
ors
h
ave
wro
n
gfully
used
or
disclosed
trade
s
e
cr
e
ts
or
oth
e
r confident
i
al
i
n
forma
t
ion
of
third
parti
e
s
or
claims
asserti
n
g
ownership
of
what
we
regard
as
our
own
intellectual
property.
We
have
r
e
c
e
ived
conf
i
dent
i
al
and
proprietary
information
from
third
parties
and
their
employees
and
con
t
ractors.
In
addition,
we
plan
to employ
and contract
with
individuals
who
were
previously
e
m
ployed
at other
biotechnology
or
pharmaceutical
companies.
We
may
be
subject
to
c
la
i
ms
t
hat
we
or o
u
r
employees,
consultants
or
ind
e
pendent
contractors
have
inadver
t
ently
or
otherwise
used
or
disclosed
the
trade
secrets
or
o
t
her
confidential information
of
these
third
parties
o
r
our
emp
l
oyees'
former
e
m
ployers.
Litigation
may
be
necessary
to defend
against
or
pursue
these
c
l
ai
m
s
.
E
ven
if we are
succ
e
ssful
in
resolv
i
ng
th
e
s
e
c
l
a
ims,
l
i
tig
a
tion
cou
l
d
result
in
sub
s
t
a
nti
a
l
c
ost
and
be
a
distraction
to
our
management
and
employees.
In
addition,
while
it
is our poli
c
y
to require
our
empl
o
yees,
c
onsultants
and
independ
e
nt
contractors
who
m
a
y
be
involved
in
the
conception
or development
of
intellectual
prop
e
rty
to execute
agreements
assigning
such
intell
e
ctual
property
to
us,
we
may
be
unsuccessful
i
n
executing
such
an agreement
with
each
party
who,
in
fact,
conceives
or
develops
intellectual
property
that
we
regard
as
our
own.
The
assignment
o
f
intellectual
property rights
may
not
be
self-executing,
or
t
h
e
a
s
s
i
gn
m
e
nt
agr
e
e
m
ents
may
be
bre
a
ched,
a
nd we
may
be
forced
to bring
claims
against
t
h
ird
parties,
or
defend claims
that
they
may
bring
against
us,
to
determine
the
ownership
of
wh
a
t
we r
e
gard
as
our int
e
ll
e
ctual
property.
Any
of
the
f
o
r
e
going
could
have
a material
adve
r
s
e
effect
on
our
bu
s
iness,
financial
condition,
resul
t
s
of
o
perations,
and
prospects.
We may
not
be
able
to
li
c
ense
or
acquire
new
or
necessary
i
n
tellectual
property
rights
or
t
e
chnology
from
t
h
i
r
d
pa
r
ti
e
s.
An
element
of
our
intellectual
property
s
t
rategy
is to
license
intel
l
ectual
property
rights
and
t
echnologies
from
third
parties
and/or
our
a
f
filiates.
Other parties,
including
our
competitors
or
our
affiliates,
may
have
p
a
tents
and
have
filed
and
are
l
i
kely
filing
pat
e
nt
applications
potentially
relevant
to our b
u
siness.
In
order
to avoid
infringing
these
patents,
we
may
find
it
necessary
or
prud
e
nt
to
obtain
licenses
to
such
patents
f
r
om
such
parties.
In
addition, w
i
th r
e
sp
e
c
t
to
any
pa
t
e
nts
we
c
o-own
w
i
th
other
parties, including
our
affiliates, we
may
require
l
i
c
e
nses
to
such
co-owners'
in
terest
to such
patents. The
licensing
or
acquisition
of
intellectual
property
rights
is
a
competitive
area,
and other
mo
r
e
established
companies
may
pursue
strategies
to license or
acquire
third-party
intellect
u
al
property
rights
that
we
may
consider
attract
i
ve
or
necessary.
These
established
companies
may
have
a competitive advantage
over
us due
t
o
t
heir
siz
e
,
c
a
pit
a
l
r
es
ources
and
greater
clinical
development
and
commercial
i
z
a
tion
c
a
p
a
bi
l
it
i
es.
In addition,
companies
that
perceive
us
to
be
a competitor
may
be
unwilling
to
assign
or
license
rights
to us.
We
also
may
be unable
to
license
or
acquire
third
party
intelle
c
tual
property
rights
on terms that
would
allow
us
to make
an
approp
r
iate
return
on
our
inv
e
stment
or
at all.
No
assurance
can
be
given
that
we
will
be
succ
e
s
s
ful
in licensing any additional
rights
or
technologies
from
t
h
ird
parties
and/or
our
af
f
iliates.
Our
inability
to l
i
cense
the
rights
and
techno
l
ogies
that we have identified, or
th
a
t
we
m
a
y
i
n
t
he
future
id
e
ntify,
c
ould
have
a
material
a
dverse
impact
on
our
ability
to
c
o
mplete
the
development
of
our
product
candidates
or
to develop
additional
product
c
a
ndidates.
Even
if we
were
able
to obtain
a
lice
n
se,
it could
be
non-exclu
s
ive,
thereby
giving
our competitors
and
other
third parties
access
to
the
same
technologies
licensed
to
us,
and
it could
require
us
to make
substantial
licensing
and
royalty
payments.
Failure
to
obtain
any
necessary
rights
or
licenses
may
detriment
a
lly
af
f
ect
our
planned
development
of
o
u
r
current
or
future
additional
product
candidates
and
could
increase
the
cost,
and
extend
the
timelines
associated
with
our
development,
of
such
other
products,
and
we
may
have
to abandon
development
of
the
relevant program
or
product
candidate.
Any
of the
foregoing
could
have
a
material
adverse
e
ffect
on
our
business,
financial
co
n
dition,
results
of o
p
erations
and
prospects.
If we
do
not
ob
t
ain
pa
t
ent
t
e
rm
ext
e
nsion
and
data
exclusivity
for
any
product ca
n
didat
e
s
we
may
d
e
v
e
lop,
our
business
may
be
m
at
e
r
i
ally
harmed.
Depending
upon
the
timing,
duration
and
specifi
c
s
of
any
FDA
marketing
approval
of
any
product
candidates
we may
develop,
one
o
r
more
of
our owned
or
in-licensed
U.S. patents
may
be
eligible
for
limited
patent
term
extension
under
the
D
r
u
g
Price
Competition
and
Patent
Term
Restoration
Act of 1984
(
the
"
Hatch-Wa
x
m
an
Act").
The
Hatch-Waxman
Act
permits
a
patent
term
extension
of
up
to five years
as
compensation
for
patent
te
r
m
lost d
u
r
ing the
FDA reg
u
latory
review
p
r
o
c
ess.
A
patent
term
extension
cannot
extend
the
remaining
term
of
a
patent
beyond
a
total
o
f
14 years
from
the
date
of
product
approval,
only
one
patent
may
be
extended
and
only
tho
s
e
claims
covering
the
approved
drug,
a
method
for
using
it,
or
a method
for manufacturing
it may
be
extended.
Similar
e
x
tensions
as
compensation
for
patent
term
lost
during
r
e
gulatory
re
v
i
ew
processes are
also
a
va
i
lab
l
e
in certain
foreign
countries
and
territories,
such
as
in
Europe
under
a
Supplementary
Patent
Certificate.
Howev
e
r,
we
may
not
be
g
ranted
an
extension
in the
United
States
and/or
foreign
countries
and
territories
because
of,
for
example,
failing
to
exercise
due
diligence
during
t
h
e
testing
phase
or
regulatory review
process,
failing
to
apply
within
applicable
d
e
adlines,
failing
to
apply
prior
to
e
xpiration
of
relevant
patents,
or
otherwise
fa
i
ling
to
s
a
tisfy applicable
requirements.
Mor
e
over,
the
a
ppli
c
ab
l
e
ti
m
e
period
or
the
scope
of
patent
protect
i
on
afforded
could
be
less
than
we
request.
If
we
are
unable to obtain
patent
term
extension
or
the
term
of
any
such
extension
is
shorter
t
h
an
what
we
request,
our
competitors
may
obtain
approval
of
competing prod
u
cts
following
our
patent
e
x
piration,
and
our
busine
s
s,
financial
condition,
results
of
operations
and
growth
prospects
co
u
ld
be
m
a
t
e
ri
a
lly
harm
e
d.
108
Table of Contents
We
may
be
subject
to claims
challenging
the
inv
e
n
t
orship
of
our
patents
a
n
d
oth
e
r
int
e
ll
e
c
t
ual
propert
y
.
We
or
our
licensors
may
be
subject
to
claims
that
fo
r
mer
employees,
collaborators
or
o
t
her
third
par
t
ies
h
a
ve
an
int
e
rest
in our
owned
or
in-licensed patents,
trade
secrets,
or
other
intellectual
property
as
an
inventor
or
co-inv
e
ntor.
For example,
we
or
our
licensors
may
ha
v
e
inventorship
disputes
a
r
ise from
conflicting
obligations
of emplo
y
ees,
consult
a
nts
or
others
who
are
involved
in
developing
our
product
candidates. Litigation
may
be
necessary
to
defend
against
these
and
other
c
l
aims
challenging
inventorship
or our
or
our
licensors'
ownership
of
our
owned
or in-licensed
patents,
trade
secrets
or
oth
e
r
intellectual
property.
If
we
or
our
licensors
fail
in
defending
any
such
claims,
in
addition
to p
a
ying
monetary dam
a
ges,
we
m
a
y
lose
v
a
lu
a
ble
in
t
e
l
l
ec
t
ual
prope
r
ty
rights,
such
as
exclusive
ownership
of,
or
right
to
use,
valuable
in
t
e
l
l
e
c
tual property.
Even
if
we
are
successful
in
defending
against
such
claims,
litigation
could
r
e
sult
in
sub
s
t
a
nti
a
l
c
osts and
be
a distraction
to
management
and
other
employees.
Any
of
the
foregoing
could
have
a material
adverse
e
ffect
on
our
b
usin
e
ss,
financial
condition, results
of
operati
o
ns
and
growth
prospects.
On September 10, 2020, a legal complaint was filed in a California court where Institute for Cancer Research (d/b/a Fox Chase Cancer Center) argued that it has a co-ownership interest in U.S. Patent No. 10,456,420 and its underlying U.S. Patent Application No. 15/529,848, as well as in certain related patent applications or issued patents that include claimed subject matter allegedly invented by one of the claimant's employees. On September 30, 2020, we filed motion with the court asking that the complaint be dismissed. We disagree that this claim for co-ownership has merit and intend to vigorously defend our position. All of the existing named inventors have assigned their rights in this patent to us. We will continue to have an undivided interest in the entire patent even if claimant succeeds in this suit. However, litigating this matter could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
If
we
are
unable
to protect
t
h
e
confidentiality
of
o
u
r t
r
ade
s
e
c
r
ets,
o
u
r business and
co
m
pe
t
it
i
ve
pos
i
t
i
on
wou
l
d
be
h
ar
m
ed.
In
addition
to
seeking
patents
for
Anktiva,
hAd5
and
yeast
te
c
hn
o
logies
and
other
p
r
oduct
candidates
and
technologies,
we
a
lso
r
e
ly
on tr
a
de
s
e
cr
e
ts and
confidentiality
agreements
to
p
r
otect
o
u
r
unpatented
know-how,
technology,
and
other
proprietary
information
and
to mainta
i
n
our
c
omp
e
ti
t
ive p
o
sition.
Trade
secrets
and
know-how
can
be
difficult
to
protect.
We
expect
our
trade
secrets
and
know-how
to
over
time
be
dis
s
e
m
ina
t
ed
w
i
thin
the industry
through
independent
deve
l
opment,
the
publication
of
journ
a
l
articles
des
c
ribing
the
methodology,
and
the
movement
of
p
ersonnel
from academic
to
industry
s
c
ientific
positions.
We
seek
to
protect
these
trade
secrets
a
nd other
proprietary
technology,
in
part,
by entering
into
nondisclosure
and
confidentia
l
i
t
y
agr
e
e
m
ents
w
i
th
parties
who have
access
to them,
such
as
our
employees,
corporate
collaborators,
outs
i
de
s
c
ien
t
ific
c
oll
a
borators,
CROs,
CMOs,
consultants, advisors,
and
other
th
i
rd
par
t
i
e
s.
W
e
also
ent
e
r
i
nto
c
onfid
e
nti
a
li
t
y
and
invention
or
pat
e
nt
a
s
sign
m
ent
agr
e
e
m
ents
with
our
employees
and
consultants
as
well
as
t
r
ain
our
employees
not
to bring
or
use
proprietary
information
or
t
e
chnology
from
former
employers
to
us
or
in their
w
o
r
k,
and
remind
former
empl
o
yees
when they
leave
t
h
eir
employment
of
their
confidentiality
obli
g
ations.
We
cannot
guarantee
that
we
have
e
nt
e
red
into
su
c
h agreements
with
each
party
that
may
have
or
have
had
access
to our
trade
secrets
or
proprietary
technology
and
processes.
Despite
our
efforts,
any
of these
par
t
ies
may bre
a
ch
the
agr
e
em
e
nts
a
nd disclose
our
proprietary
i
n
formation,
including
our
trade
secrets,
and
we
may
not
be able
to
obtain
adequate
rem
e
dies
for
such bre
a
ches.
Enfor
c
ing
a
cl
a
im
th
a
t
a p
a
rty
il
l
e
g
ally
disclosed
or
misappropriated
a
t
rade
secr
e
t
is
d
i
fficu
l
t,
expensive,
and
time-consuming,
and
the
outcome
is
unpredictable.
In
addition,
some
c
ourts inside
and
outside
the
Uni
t
ed
States
are
less
willing
or u
n
willing
to
protect
trade
secrets.
If
any
of
our
trade
secrets
w
e
re to be
lawfully
obtained
o
r
independently
developed
by
a c
o
mpetitor
or
other
third party,
we
would
have
no
rig
h
t
to prevent
them
from
using
that
technology
or
information
to
compete
with
us.
If
any
of
our
t
r
ade
secr
e
ts
were
t
o be disclosed
to
or
independently
developed
by
a competitor
or
other
third
party,
our
com
p
etitive
p
osition
would
be
materially
and
adversely
harmed.
If
our trademarks
and
trade
names
are
not
ad
e
quately
protected,
t
h
en
we
may
not
be
able
to build
name
recognition
in our
marke
t
s
of
interest
and o
u
r busi
n
e
ss
may
be
adversely
affected.
Our
registered
or
unregistered
trademarks
or
t
r
ade
names
may
be
challenged,
infringed,
circumvented
or
dec
l
ared
generic
or
det
e
rmined
to be
infringing on
other
marks.
We
may
not
be
able
to pro
t
e
c
t
our righ
t
s
to
these
tr
a
dem
a
rks
a
nd
tr
a
de
names,
which
we
need
to build
name
reco
g
nition
among p
o
tential
partners
or
customers
in our
markets
of
interest.
At
times,
competitors
or
other
t
h
ird
parties
may
adopt
trade
names
or
tr
a
de
m
arks
sim
i
l
a
r
to o
u
r
s
,
t
h
ereby
im
p
e
ding
our
ability
to build
brand
identity
and
possibly
leading
to
mar
k
et
confusion.
In
addition,
there
could
be
potential
trade
name
or tradema
r
k
infringement
claims
brought
by
owners of
other
registered
t
r
ademarks
or
trademarks
that
incorporate
variations
of
our
registered
or u
n
r
e
gistered
trademarks
or
trade
names.
Over
the
long
term,
if we
are
unable
to
e
s
tablish
n
a
me
recognition
based
on
our
tradem
a
rks
and
trade
names, th
e
n
w
e
m
a
y
not
be
able
to
c
om
p
ete
eff
e
ctively
and
our
business
may
be
adversely
aff
e
cted.
Our efforts
to enforce
or
protect
o
u
r
proprietary
rights related
to
trademarks,
trade
sec
r
ets,
domain
names,
copyrights
or other
intellectual
property
m
a
y
be
ineffective
and
could
resu
l
t
in substan
t
i
a
l
c
os
t
s
and diversion
of
resources
and
could
adversely
affect
our
business, financial
condition,
r
e
sults
of
operations
and
growth
prospect
s
.
109
Table of Contents
Intellectual
pr
o
perty
rights
do
not
necessarily
address all
potential
threats.
The
degree
of
future
protection
afforded
by
our
intellectual
property
rights
is
uncertain
because
intellectual
property
rights
have
limitations
and
may
not adequately
protect
our
business
or
permit
us
to
m
a
i
nta
i
n
our comp
e
ti
t
ive
advantage.
For
example:
•
others
may
be
able
to
make
p
r
o
ducts
t
h
at
are
similar
to our
product
candidates
or utilize
similar
technology
but
that
are
not
covered
by
the claims
of
the
patents
that
we
license
or
may
own;
•
we, or
our
current
or
future
licensors
or
collaborators,
might
not
have
been
the
first
to
make
the
inven
t
ions
covered
by
the
i
ssued patent
or pending
patent
appl
i
cation
that
we
license
or
own
now
or
in the
future;
•
we, or
our
current
or
future
licensors
or
collaborators,
might
not
have
been
the
first
to
file
p
a
tent
a
pplications
covering
c
e
rtain
of
our
or their
inventions;
•
others
may
independently
deve
l
op
similar
or
alternati
v
e
technologies
or
duplicate
any
of our
technologies
without
infringing
our
ow
n
e
d or
l
i
c
en
s
e
d
in
t
e
l
l
e
c
tual
property
rights;
•
i
t is
possible
that
our
current
or
future
pending
owned
or
licensed
patent
applications
will
not
le
a
d
t
o issued pat
e
nts;
•
i
ssued
patents
that
we
hold
r
ights
to may
be
held
invalid
or
unenforceable,
including
as
a
result
of
legal
challenges
by
our
c
ompetitors
or other
third
parties;
•
our
competitors
or
other
third
pa
r
ties
m
i
ght
conduct
research
and
development
activities
in countries
where
we
do not
have
pa
t
ent
rights and
then
use
the
information
learned
from
s
u
ch
activities
to
develop
competitive
products
for
sale
in
our
major
commercial
mark
e
t
s;
•
we
may
not
develop
additional
proprietary
technologies
that
are
patenta
b
le;
•
t
he
patents
of
others
m
a
y
harm
our
business;
and
•
we
may
choose
not
to
file
a patent
in order
to
maintain
certain
trade
secrets
or
know-how,
and
a
third
party
may
subsequently
file
a
p
a
tent covering
such
intellectual
property.
Should
any
of
these
events
occur,
they
could
have
a material
adverse
ef
f
ect
on
our
business,
financial
condition,
results
of
operations
a
n
d
growth prospects.
Risks
Related
to
Our
Common Stock
Dr. Soon-Shiong,
o
u
r
E
xecutive
C
hairman and our principal stockholder, h
a
s signifi
c
ant interests
in
oth
e
r
c
ompanies
w
h
i
c
h
may
c
onfli
c
t
w
i
th
our i
n
t
e
r
e
sts.
Our Executive
C
hairma
n
, Dr. Soon-Shiong, is the founder of NantWorks. The various NantWorks companies are currently exploring opportunities in the immunotherapy,
oncology, infectious disease and inflammatory disease fields. In particular, we have agreements with a number of related parties that provide services, technology and equipment for use in their efforts to develop their product pipelines. Dr. Soon-Shiong holds a controlling interest, either directly or indirectly, in these entities. Consequently, Dr. Soon-Shiong's interests may not be aligned with our other stockholders and he may from time to time be incentivized to take certain actions that benefit his other interests and that our other stockholders do not view as being in their interest as investors in our company. In addition, other companies affiliated with Dr. Soon-Shiong may compete with us for business opportunities or, in the future, develop products that are competitive with ours (including products in other therapeutic fields which we may target in the future). Moreover, even if they do not directly relate to us, actions taken by Dr. Soon-Shiong and the companies with which he is involved could impact us.
We are also pursuing supply arrangements for various investigational agents controlled by affiliates to be used in their clinical trials. If Dr. Soon-Shiong w
e
re to cease his affiliation with us or NantWorks, these entities may be unwilling to continue these relationships with us on commercially reasonable terms, or at all, and as a result may impede our ability to control the supply chain for our combination therapies. These collaboration agreements do not typically specify how sales will be apportioned between the parties upon successful commercialization of the product. As a result, we cannot guarantee that we will receive a percentage of the revenues that is at least proportional to the costs that we will incur in commercializing the product candidate.
110
Table of Contents
We
have
entered into
sh
a
red
s
e
rvic
e
s
agr
e
e
m
ents
with NantWorks, pursuant to which NantWorks and its affiliates provide corporate, general and administrative and other support services to us
.
If Dr.
Soon-Shiong was to cease his affiliation with us or with NantWorks, we may be unable to establish or maintain this relationship with NantWorks on a commercially reasonable basis, if at all. As a result, we could experience a lack of business continuity due to loss of historical and institutional knowledge and a lack of familiarity of new employees and/or new service providers with business processes, operating requirements, policies and procedures, and we may incur additional costs as new employees and/or service providers gain necessary experience. In addition, the loss of the services of NantWorks might significantly delay or prevent the development of our
product
ca
n
didates
or achievement of other business objectives by diverting management's attention to transition matters and identification of suitable replacements, if any, and could have a material adverse effect on our business and results of operations.
Dr.
Soon-Shiong,
through
his
voti
n
g
co
n
t
r
ol
of
t
h
e
compan
y
,
has the ability
to
control
actions
that
req
u
ire
stockholder a
p
proval.
Dr. Soon-Shiong,
through
his
direct
and
indi
r
ect
ownership
of
the
company's
common
stock,
has
voting
control
of
the
company.
As of
June 30, 2021
,
Dr. So
o
n
-
S
hiong
and
certain
of
his
af
f
iliates
beneficially
own
approximately 80.3%
of
the
company's
common
stock
outstanding.
A
dditionally,
an
affilia
t
e
of Dr. Soon-Shiong holds
a
warrant
to
pur
c
ha
s
e
an
additional 1,638,000 shares
of
the
comp
a
ny's
common
stock
that
will
become
exercisable
if certain
perfor
m
ance
conditions
are
satisfie
d
.
Dr. Soon-Shiong and his related party also
h
old
approximately $279.5 million in the aggregate of
C
V
Rs
iss
u
ed
to the
fo
r
mer
s
t
ockholders
of
Altor
in connection
with
NantCell
's
acquisition
of
Altor.
I
f the
u
n
derlying
conditions
for
payment
are
met,
the
CVRs
become
paya
b
l
e
in
cash
or
shares
of
the company's
common
stock
or
any
combination
as the
holder
elects. Dr. Soon-Shiong
and his related party
have
irrevocably agreed
to receive
shares
of
the company's
common
stock
in satisfaction
of their
CVRs.
Dr. Soon-Shiong is
in a position
to con
t
rol
the
outcome
of
corporate
actions
that
require,
or
may
be
accomplished
by,
sto
c
kholder
approval, including
amending
the
bylaws
of
the
company,
the
elect
i
on
or
removal
of
directors
and
transactions
involving
a change
of
control.
Dr. Soon-Shiong's
controlling
ownership
could
limit
the
a
b
ility
of
the
remaining
stockholders
of
the
company
to
influence
corporate
m
a
t
t
ers,
and
the interests
of
Dr. Soon-Shiong
may
not
coincide
with
the
company's
interests
or
the
int
e
rests
of
its
remaining
stockholders.
In
a
ddit
i
on,
ent
i
ti
e
s affiliated
with
Dr. Soon-Shiong
hold
p
r
o
m
issory
notes
representing
$300.3 million
in
indebtedness, including interest thereon,
of
the company
as
of
June 30, 2021
.
In addition, pursuant to the Nominating Agreement between us and Cambridge Equities, LP ("Cambridge"), an entity that Dr. Soon-Shiong controls, Cambridge has the ability to designate one director to be nominated for election to our board of directors for as long as Cambridge continues to hold at least 20% of the issued and outstanding shares of our common stock. Dr. Soon-Shiong was selected by Cambridge to hold this board seat. Dr. Soon-Shiong and his affiliates will therefore have significant influence over management and significant control over matters requiring stockholder approval, including the annual election of directors and significant corporate transactions, such as a merger or other sale of our company or its assets, for the foreseeable future. This control will limit stockholders' ability to influence corporate matters and, as a result, we may take actions that our stockholders do not view as beneficial. As a result, the market price of our common stock could be adversely affected.
The market price of our common stock has been and may continue to be volatile, and investors may have difficulty selling their shares.
Although our common stock is listed on the Nasdaq Global Select Market, the market for our shares has demonstrated varying levels of trading activity. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.
The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price of our common stock has been and may continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including:
•
the commencement, enrollment or results of the planned clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;
•
any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority's review of such filings, including without limitation the FDA's issuance of a "refusal to file" letter or a request for additional information;
•
adverse results or delays in clinical trials;
111
Table of Contents
•
our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;
•
adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;
•
changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;
•
our failure to commercialize our product candidates;
•
additions or departures of key scientific or management personnel;
•
unanticipated serious safety concerns related to the use of our product candidates;
•
announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments;
•
our ability to effectively manage our growth;
•
variations in our quarterly operating results;
•
our liquidity position and the amount and nature of any debt we may incur;
•
announcements that our revenue or income are below or that costs or losses are greater than analysts' expectations;
•
publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;
•
changes in the market valuations of similar companies;
•
sales of large blocks of our common stock;
•
fluctuations in stock market prices and volumes;
•
disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;
•
significant lawsuits, including patent or stockholder litigation;
•
the perception of our clinical trial results by retail investors, which investors may be subject to the influence of information provided by third party investor websites and independent authors distributing information on the internet;
•
general economic slowdowns;
•
coordinated actions by independent third-party actors to affect the price of certain stocks, coordinated via the Internet and otherwise; and
•
other factors described in this "
Risk Factors
" section.
In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company's securities. This type of litigation could result in substantial costs and a diversion of management's attention and resources, which would harm our business, operating results or financial condition.
Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. In addition, our Executive
Chairman, Dr. Soon-Shiong, and his affiliates cur
r
ently
beneficially own approximately 80.3% of our outstanding shares of common stock as of June 30, 2021. Sales of stock by Dr. Soon-Shiong and his affiliates could have an adverse effect on the trading price of our common stock.
Certain holders of our common stock are entitled to certain rights with respect to the registration of their shares under the Securities Act of 1933, as amended ("Securities Act"). Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by our affiliates as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have an adverse effect on the market price of our common stock.
112
Table of Contents
In addition, we expect that additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating
as
a public company. To raise capital, we may sell common stock,
including as part of t
he ATM
,
convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock,
including through the ATM,
convertible securities or other equity securities, investors may be materially diluted and new investors could gain rights, preferences and privileges senior to the holders of our
common
stock.
We have incurred and will continue to incur costs as a result of operating as a public company and our management has been and will be required to devote substantial time to compliance initiatives and corporate governance practices, including maintaining an effective system of internal control over financial reporting.
As a public company listed in the U.S., and increasingly after we no longer qual
i
fy
as
a
"smaller
reporting company," we have incurred and will continue to incur significant additional legal, accounting and other expenses as a result of operating as a public company. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002 ("Sarbanes Oxley") and regulations implemented by the SEC and Nasdaq, may increase legal and financial compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to create a larger finance function with additional personnel to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If, notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us, and our business may be harmed.
As a public company in the U.S., we are required, pursuant to Section 404 of Sarbanes-Oxley ("Section 404") to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. The controls and other procedures are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is disclosed accurately and is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. In
addition,
we
are
required
to disclose
any
material
weakn
e
sses
identified
by our management
in our
internal
control
over
financial
reporting,
and,
since
we
no
longer
qualify
as
a "
s
maller
reporting
company"
as of
fiscal year end 2021, we are required to provide a statement that our independent registered public accounting firm has issued an opinion on our internal control over financial reporting in our Annual Report on Form 10-K. We have initiated the process of engaging and coordinating with our independent registered public accounting firm to perform an audit of, and give an opinion on, our internal control over financial reporting for the annual period ending December 31, 2021. There can be no assurance that we will not discover deficiencies or a material weakness in our internal control over financial reporting or that our independent registered public accounting firm will agree with management's assessment of our internal control over financial reporting when they conduct such audit and deliver an opinion.
In the normal course of business our controls and procedures may become inadequate because of changes in conditions or the degree of compliance with these policies or procedures may deteriorate and material weaknesses in our internal control over financial reporting may be discovered. We may err in the design or operation of our controls, and all internal control systems, no matter how well designed and operated, can provide only reasonable assurance that the objectives of the control system are met. Because there are inherent limitations in all control systems, there can be no absolute assurance that all control issues have been or will be detected. If we are unable, or are perceived as unable, to produce reliable financial reports due to internal control deficiencies, investors could lose confidence in our reported financial information and operating results, which could result in a negative market reaction.
To fully comply with Section 404, we will need to retain additional employees to supplement our current finance staff, and we may not be able to do so in a timely manner, or at all. In addition, in the process of evaluating our internal control over financial reporting, we expect that certain of our internal control practices will need to be updated to comply with the requirements of Section 404 and the regulations promulgated thereunder, and we may not be able to do so on a timely basis, or at all. In the event that we are not able to demonstrate compliance with Section 404 in a timely manner, or are unable to produce timely or accurate financial statements, we may be subject to sanctions or investigations by regulatory authorities, such as the SEC or Nasdaq, and investors may lose confidence in our operating results and the price of our common stock could decline. Furthermore, if we are unable to certify that our internal control over financial reporting is effective and in compliance with Section 404, we may be subject to sanctions or investigations by regulatory authorities, such as the SEC or stock exchanges, and investors could lose confidence in the accuracy and completeness of our financial reports, which could hurt our business, the price of our common stock and our ability to access the capital markets.
113
Table of Contents
Operating as
a public company make
s
it more expensive for us to obtain director
s'
and officer
s'
liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors
,
or as members of senior management.
If a restatement of our financial statements were to occur, our stockholders' confidence in the company's financial reporting in the future may be affected, which could in turn have a material adverse effect on our business and stock price.
If any material weaknesses in our internal control over financial reporting are discovered or occur in the future, our consolidated financial statements may contain material misstatements, and we could be required to restate our financial results. In addition, if we are unable to successfully remediate any future material weaknesses in our internal controls or if we are unable to produce accurate and timely financial statements, our stock price may be adversely affected, and we may be unable to maintain compliance with applicable stock exchange listing requirements.
We have not paid cash dividends in the past and do not expect to pay dividends in the future. Any return on investment may be limited to the value of our common stock.
We have never paid cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future. The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting us at such time as the board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if our stock price appreciates.
Because we are relying on the exemptions from corporate governance requirements as a result of being a "controlled company" within the meaning of the Nasdaq listing standards, you do not have the same protections afforded to stockholders of companies that are subject to such requirements.
Our Executive
Chairman, Dr. Patrick Soon-Shiong, and entities affiliated with him, control a majority of our common stock. As a result, we are a "controlled company" within the meaning of the Nasdaq listing standards. Under these rules, a company of which more than 50% of the voting power is held by an individual, a group or another company is a "controlled company" and may elect not to comply with certain Nasdaq corporate governance requirements, including (1) the requirement that a majority of the board of directors consist of independent directors, and (2) the requirement that we have a nominating and corporate governance committee that is composed entirely of independent directors with a written charter addressing the committee's purpose and responsibilities. Accordingly, you do not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq corporate governance requirements. However, our board of directors is currently comprised of a majority of independent directors and we currently have a nominating and corporate governance committee and the majority of the members of such committee are independent directors.
We are a "smaller reporting company," and the reduced disclosure requirements applicable to smaller reporting companies could make our common stock less attractive to investors.
Although
we
no
longer
qualify
as
an
emerging
g
r
owth
company,
we
qualify
as
a "smaller
r
e
porting
company"
during
fiscal
year
2021,
which
allows
us to take
advantage
of
many
of
the
same
e
x
emptions
from
disclosu
r
e
requirements,
including
reduced
dis
c
losure
obligations
regard
i
ng
executive compensation
in
our
periodic
reports
and
proxy
statements.
These
exemptions
include:
•
being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced "Management's discussion and analysis of financial condition and results of operations" disclosure;
•
not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; and
•
reduced disclosure obligations regarding executive compensation.
Investors
may
find
our
common
stock
less
a
t
t
ra
c
tive
a
s
a
result
of our
re
l
i
a
nce
on
th
ese
exemptio
n
s.
If
some
investors
f
ind our
common
stock
less at
t
ra
c
tive
a
s
a
result,
t
here
m
a
y
be
a
l
e
ss
a
c
tive
tr
a
ding
mark
e
t
for our
common
stock
and
the
m
a
rket
price
of
o
u
r
common
stock
may
be
reduced
or
more v
o
l
a
til
e
.
114
Table of Contents
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.
The trading market for our common stock will depend on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts' cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.
We are not subject to the provisions of Section 203 of the DGCL, which could negatively affect your investment.
We elected in our amended and restated certificate of incorporation to not be subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a "business combination" with an "interested stockholder" for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A "business combination" includes a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder. An "interested stockholder" is a person who, together with affiliates and associates, owns (or, in certain cases, within three years prior, did own) 15% or more of the corporation's voting stock. Our decision not to be subject to Section 203 will allow, for example, our Executive
C
hairman (who, with members of his immediate family and entities affiliated with him, currently beneficially own, in the aggregate, approximately 80.3% of our common stock as of June 30, 2021) to transfer shares in excess of 15% of our voting stock to a third-party free of the restrictions imposed by Section 203. This may make us more vulnerable to takeovers that are completed without the approval of our board of directors and/or without giving us the ability to prohibit or delay such takeovers as effectively.
Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.
Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders. These provisions include:
•
a requirement that special meetings of stockholders be called only by the board of directors, the president or the chief executive officer;
•
advance notice requirements for stockholder proposals and nominations for election to our board of directors; and
•
the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.
These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.
Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.
Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. In addition, as permitted by Section 145 of the DGCL, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:
•
We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person's conduct was unlawful.
115
Table of Contents
•
We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.
•
We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.
•
We are not obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.
•
The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.
•
We may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.
To the extent that a claim for indemnification is brought by any of our directors or officers, it would reduce the amount of funds available for use in our business.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
(a) Recent Sales of Unregistered Securities
None.
(b) Issuer Purchases of Equity Securities
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.
ITEM 5. OTHER INFORMATION.
None.
116
Table of Contents
ITEM 6. EXHIBITS.
The documents listed below are incorporated by reference or are filed with this Quarterly Report, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S‑K).
Exhibit
Number
Description of Exhibit
2.1
Agreement and Plan of Merger, dated as of December 21, 2020, by and among ImmunityBio, Inc. (f/k/a NantKwest, Inc.), NantCell, Inc. (f/k/a ImmunityBio, Inc.) and Nectarine Merger Sub, Inc. (filed as Exhibit 2.1 to the company's Current Report on Form 8-K filed with the SEC on December 22, 2020).
3.1
Certificate of Amendment of Amended and Restated Certificate of Incorporation of ImmunityBio, Inc. (f/k/a NantKwest, Inc.) dated March 9, 2021 (filed as Exhibit 3.1 to the company's Form 8-K filed with the SEC on March 10, 2021).
3.2*
Amended and Restated Bylaws of ImmunityBio, Inc., effective as of March 10, 2021.
10.1*
First Amendment to Lease made and entered into as of May 28, 2021, but made effective as of April 1, 2021, by and between 605 Nash, LLC and ImmunityBio, Inc.
31.1*
Rule 13a-14(a) / 15(d)-14(a) Certification of Principal Executive Officer.
31.2*
Rule 13a-14(a) / 15(d)-14(a) Certification of Principal Financial Officer.
32.1**
Section 1350 Certification of Chief Executive Officer.
32.2**
Section 1350 Certification of Chief Financial Officer.
99.2
Combined Consolidated Financial Statements of ImmunityBio, Inc. as of December 31, 2020 and December 31, 2019 (including NantCell, Inc.) (filed as Exhibit 99.2 to the company's Current Report on Form 8-K/A filed with the SEC on April 22, 2021).
101.INS
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
101.SCH
Inline XBRL Taxonomy Extension Schema Document.
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB
Inline XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
*
Filed herewith.
**
The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of ImmunityBio, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report, irrespective of any general incorporation language contained in such filing.
117
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
IMMUNITYBIO, INC.
Date: August 12, 2021
By:
/s/ Richard Adcock
Richard Adcock
Chief Executive Officer
(Principal Executive Officer)
Date: August 12, 2021
By:
/s/ David C. Sachs
David C. Sachs
Chief Financial Officer
(Principal Financial and Accounting Officer)
118